1	Cholestyramine	Cholestyramine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	5	amod
4	cholestyramine	cholestyramine	NN	_	5	compound
5	administration	administration	NN	_	6	nsubj
6	decreased	decrease	VBD	_	1	dep
7	the	the	DT	_	9	det
8	mean	mean	NN	_	9	compound
9	AUC	auc	NN	_	6	dobj
10	of	of	IN	_	12	case
11	total	total	JJ	_	12	amod
12	ezetimibe	ezetimibe	NN	_	9	nmod
13	approximately	approximately	RB	_	14	advmod
14	55	55	CD	_	15	nummod
15	%	%	NN	_	6	nmod:npmod
16	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	incremental	incremental	JJ	_	3	amod
3	LDL	ldl	NN	_	15	nsubjpass
4	-	-	:	_	3	punct
5	C	c	NN	_	6	compound
6	reduction	reduction	NN	_	3	dep
7	due	due	JJ	_	3	amod
8	to	to	TO	_	9	mark
9	adding	add	VBG	_	7	advcl
10	ezetimibe	ezetimibe	NN	_	9	dobj
11	to	to	TO	_	12	case
12	cholestyramine	cholestyramine	NN	_	9	nmod
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	reduced	reduce	VBN	_	0	ROOT
16	by	by	IN	_	18	case
17	this	this	DT	_	18	det
18	interaction	interaction	NN	_	15	nmod
19	.	.	.	_	15	punct

1	Fibrates	fibrate	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	safety	safety	NN	_	15	nsubjpass
5	and	and	CC	_	4	cc
6	effectiveness	effectiveness	NN	_	4	conj
7	of	of	IN	_	8	case
8	ezetimibe	ezetimibe	NN	_	4	nmod
9	administered	administer	VBN	_	8	acl
10	with	with	IN	_	11	case
11	fibrates	fibrate	NNS	_	9	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	established	establish	VBN	_	1	dep
16	.	.	.	_	15	punct

1	Fibrates	fibrate	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	cholesterol	cholesterol	NN	_	5	compound
5	excretion	excretion	NN	_	3	dobj
6	into	into	IN	_	8	case
7	the	the	DT	_	8	det
8	bile	bile	NN	_	3	nmod
9	,	,	,	_	3	punct
10	leading	lead	VBG	_	3	advcl
11	to	to	TO	_	12	case
12	cholelithiasis	cholelithiasis	NN	_	10	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	preclinical	preclinical	JJ	_	4	amod
4	study	study	NN	_	9	nmod
5	in	in	IN	_	6	case
6	dogs	dog	NNS	_	4	nmod
7	,	,	,	_	9	punct
8	ezetimibe	ezetimibe	NN	_	9	nsubj
9	increased	increase	VBD	_	0	ROOT
10	cholesterol	cholesterol	NN	_	9	dobj
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	gallbladder	gallbladder	NN	_	14	compound
14	bile	bile	NN	_	9	nmod
15	.	.	.	_	9	punct

1	Co	Co	NNP	_	16	nsubjpass
2	-	-	:	_	1	punct
3	administration	administration	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	ZETIA	zetia	NN	_	3	nmod
6	with	with	IN	_	7	case
7	fibrates	fibrate	NNS	_	3	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	recommended	recommend	VBN	_	16	csubjpass
11	until	until	IN	_	12	case
12	use	use	NN	_	10	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	is	be	VBZ	_	16	auxpass
16	studied	study	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Fenofibrate	fenofibrate	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	11	nmod
7	,	,	,	_	11	punct
8	concomitant	concomitant	JJ	_	10	amod
9	fenofibrate	fenofibrate	NN	_	10	compound
10	administration	administration	NN	_	11	nsubj
11	increased	increase	VBD	_	1	dep
12	total	total	JJ	_	14	amod
13	ezetimibe	ezetimibe	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	approximately	approximately	RB	_	16	advmod
16	1.5	1.5	CD	_	11	nmod
17	-	-	:	_	16	punct
18	fold	fold	NN	_	16	dep
19	.	.	.	_	1	punct

1	Gemfibrozil	Gemfibrozil	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	11	nmod
7	,	,	,	_	11	punct
8	concomitant	concomitant	JJ	_	10	amod
9	gemfibrozil	gemfibrozil	NN	_	10	compound
10	administration	administration	NN	_	11	nsubj
11	increased	increase	VBD	_	1	dep
12	total	total	JJ	_	14	amod
13	ezetimibe	ezetimibe	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	approximately	approximately	RB	_	16	advmod
16	1.7	1.7	CD	_	11	nmod:npmod
17	-	-	:	_	16	punct
18	fold	fold	NN	_	16	dep
19	.	.	.	_	1	punct

1	HMG	hmg	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	CoA	coa	NN	_	5	compound
4	reductase	reductase	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	1	dep
6	:	:	:	_	1	punct
7	No	no	DT	_	11	neg
8	clinically	clinically	RB	_	9	advmod
9	significant	significant	JJ	_	11	amod
10	pharmacokinetic	pharmacokinetic	JJ	_	11	amod
11	interactions	interaction	NNS	_	13	nsubjpass
12	were	be	VBD	_	13	auxpass
13	seen	see	VBN	_	1	dep
14	when	when	WRB	_	17	advmod
15	ezetimibe	ezetimibe	NN	_	17	nsubj
16	was	be	VBD	_	17	cop
17	co	co	SYM	_	13	advcl
18	-	-	:	_	13	punct
19	administered	administer	VBN	_	13	dep
20	with	with	IN	_	21	case
21	atorvastatin	atorvastatin	NN	_	19	nmod
22	,	,	,	_	21	punct
23	simvastatin	simvastatin	NN	_	21	conj
24	,	,	,	_	21	punct
25	pravastatin	pravastatin	NN	_	21	conj
26	,	,	,	_	21	punct
27	lovastatin	lovastatin	NN	_	21	conj
28	,	,	,	_	21	punct
29	or	or	CC	_	21	cc
30	fluvastatin	fluvastatin	NN	_	21	conj
31	.	.	.	_	1	punct

1	Cyclosporine	cyclosporine	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	6	det
4	total	total	JJ	_	6	amod
5	ezetimibe	ezetimibe	NN	_	6	compound
6	level	level	NN	_	7	nsubj
7	increased	increase	VBD	_	1	dep
8	12	12	CD	_	10	nummod
9	-	-	:	_	10	punct
10	fold	fold	NN	_	7	dobj
11	in	in	IN	_	15	case
12	one	one	CD	_	15	nummod
13	renal	renal	JJ	_	15	amod
14	transplant	transplant	NN	_	15	compound
15	patient	patient	NN	_	7	nmod
16	receiving	receive	VBG	_	15	acl
17	multiple	multiple	JJ	_	18	amod
18	medications	medication	NNS	_	16	dobj
19	,	,	,	_	18	punct
20	including	include	VBG	_	21	case
21	cyclosporine	cyclosporine	NN	_	18	nmod
22	.	.	.	_	1	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	who	who	WP	_	3	nsubj
3	take	take	VBP	_	1	acl:relcl
4	both	both	DT	_	5	cc:preconj
5	ezetimibe	ezetimibe	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	cyclosporine	cyclosporine	NN	_	5	conj
8	should	should	MD	_	11	aux
9	be	be	VB	_	11	auxpass
10	carefully	carefully	RB	_	11	advmod
11	monitored	monitor	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Carcinogenesis	carcinogenesis	NN	_	18	nsubjpass
2	,	,	,	_	1	punct
3	Mutagenesis	mutagenesis	NN	_	1	conj
4	,	,	,	_	1	punct
5	Impairment	impairment	NN	_	1	appos
6	of	of	IN	_	8	case
7	Fertility	fertility	NN	_	8	compound
8	A	a	NN	_	5	nmod
9	104	104	CD	_	8	nummod
10	-	-	:	_	5	punct
11	week	week	NN	_	14	compound
12	dietary	dietary	JJ	_	14	amod
13	carcinogenicity	carcinogenicity	NN	_	14	compound
14	study	study	NN	_	5	dep
15	with	with	IN	_	16	case
16	ezetimibe	ezetimibe	NN	_	14	nmod
17	was	be	VBD	_	18	auxpass
18	conducted	conduct	VBN	_	0	ROOT
19	in	in	IN	_	20	case
20	rats	rat	NNS	_	43	nmod
21	at	at	IN	_	22	case
22	doses	dose	NNS	_	20	nmod
23	up	up	RB	_	25	advmod
24	to	to	TO	_	25	dep
25	1500	1500	CD	_	26	nummod
26	mg	mg	NN	_	22	dep
27	/	/	:	_	20	punct
28	kg	kg	NN	_	20	dep
29	/	/	:	_	20	punct
30	day	day	NN	_	32	compound
31	(	(	CD	_	32	nummod
32	males	male	NNS	_	43	nsubj
33	)	)	CD	_	36	nummod
34	and	and	CC	_	33	cc
35	500	500	CD	_	33	conj
36	mg	mg	NN	_	32	dep
37	/	/	:	_	36	punct
38	kg	kg	NN	_	36	dep
39	/	/	:	_	36	punct
40	day	day	NN	_	42	compound
41	(	(	CD	_	42	nummod
42	females	female	NNS	_	36	dep
43	)	)	VBP	_	18	ccomp
44	(	(	CD	_	45	compound
45	~	~	CD	_	47	dep
46	20	20	CD	_	47	compound
47	times	time	NNS	_	50	dep
48	the	the	DT	_	50	det
49	human	human	JJ	_	50	amod
50	exposure	exposure	NN	_	43	dobj
51	at	at	IN	_	53	case
52	10	10	CD	_	53	nummod
53	mg	mg	NN	_	43	nmod
54	daily	daily	JJ	_	53	advmod
55	based	base	VBN	_	53	acl
56	on	on	IN	_	57	case
57	AUC0	auc0	NN	_	55	nmod
58	-	-	:	_	43	punct
59	24hr	24hr	NN	_	43	dobj
60	for	for	IN	_	63	case
61	total	total	JJ	_	63	amod
62	ezetimibe	ezetimibe	NN	_	63	compound
63	)	)	NN	_	59	nmod
64	.	.	.	_	18	punct

1	A	a	DT	_	7	det
2	104	104	CD	_	7	nummod
3	-	-	:	_	7	punct
4	week	week	NN	_	7	compound
5	dietary	dietary	JJ	_	7	amod
6	carcinogenicity	carcinogenicity	NN	_	7	compound
7	study	study	NN	_	12	nsubjpass
8	with	with	IN	_	9	case
9	ezetimibe	ezetimibe	NN	_	7	nmod
10	was	be	VBD	_	12	auxpass
11	also	also	RB	_	12	advmod
12	conducted	conduct	VBN	_	0	ROOT
13	in	in	IN	_	14	case
14	mice	mouse	NNS	_	12	nmod
15	at	at	IN	_	16	case
16	doses	dose	NNS	_	12	nmod
17	up	up	RB	_	19	advmod
18	to	to	TO	_	19	dep
19	500	500	CD	_	20	nummod
20	mg	mg	NN	_	16	dep
21	/	/	:	_	16	punct
22	kg	kg	NN	_	16	dep
23	/	/	:	_	16	punct
24	day	day	NN	_	27	compound
25	(	(	CD	_	26	compound
26	>150	>150	CD	_	27	nummod
27	times	time	NNS	_	30	nummod
28	the	the	DT	_	30	det
29	human	human	JJ	_	30	amod
30	exposure	exposure	NN	_	16	dep
31	at	at	IN	_	33	case
32	10	10	CD	_	33	nummod
33	mg	mg	NN	_	30	nmod
34	daily	daily	JJ	_	30	advmod
35	based	base	VBN	_	37	case
36	on	on	IN	_	37	case
37	AUC0	auc0	NN	_	34	advcl
38	-	-	:	_	37	punct
39	24hr	24hr	NN	_	37	dep
40	for	for	IN	_	43	case
41	total	total	JJ	_	43	amod
42	ezetimibe	ezetimibe	NN	_	43	compound
43	)	)	NN	_	39	nmod
44	.	.	.	_	12	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	6	neg
4	statistically	statistically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	increases	increase	NNS	_	2	nsubj
7	in	in	IN	_	9	case
8	tumor	tumor	NN	_	9	compound
9	incidences	incidence	NNS	_	6	nmod
10	in	in	IN	_	11	case
11	drug	drug	NN	_	9	nmod
12	-	-	:	_	6	punct
13	treated	treat	VBN	_	14	amod
14	rats	rat	NNS	_	6	dep
15	or	or	CC	_	14	cc
16	mice	mouse	NNS	_	14	conj
17	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	evidence	evidence	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	mutagenicity	mutagenicity	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	6	advmod
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	microbial	microbial	JJ	_	12	amod
12	mutagenicity	mutagenicity	NN	_	6	nmod
13	(	(	CD	_	16	nummod
14	Ames	Ames	NNP	_	16	compound
15	)	)	CD	_	16	nummod
16	test	test	NN	_	12	dep
17	with	with	IN	_	19	case
18	Salmonella	salmonella	FW	_	19	compound
19	typhimurium	typhimurium	FW	_	16	nmod
20	and	and	CC	_	19	cc
21	Escherichia	escherichia	FW	_	22	compound
22	coli	coli	FW	_	19	conj
23	with	with	IN	_	27	nmod
24	or	or	CC	_	23	cc
25	without	without	IN	_	23	conj
26	metabolic	metabolic	JJ	_	27	amod
27	activation	activation	NN	_	16	nmod
28	.	.	.	_	6	punct

1	No	no	DT	_	2	neg
2	evidence	evidence	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	clastogenicity	clastogenicity	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	6	advmod
9	in	in	IN	_	13	case
10	a	a	DT	_	13	det
11	chromosomal	chromosomal	JJ	_	13	amod
12	aberration	aberration	NN	_	13	compound
13	assay	assay	NN	_	6	nmod
14	in	in	IN	_	18	case
15	human	human	JJ	_	18	amod
16	peripheral	peripheral	JJ	_	18	amod
17	blood	blood	NN	_	18	compound
18	lymphocytes	lymphocyte	NNS	_	13	nmod
19	with	with	IN	_	23	nmod
20	or	or	CC	_	19	cc
21	without	without	IN	_	19	conj
22	metabolic	metabolic	JJ	_	23	amod
23	activation	activation	NN	_	18	nmod
24	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	5	nmod
3	,	,	,	_	5	punct
4	there	there	EX	_	5	expl
5	was	be	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	evidence	evidence	NN	_	5	nsubj
8	of	of	IN	_	9	case
9	genotoxicity	genotoxicity	NN	_	7	nmod
10	in	in	IN	_	16	case
11	the	the	DT	_	16	det
12	in	in	FW	_	16	amod
13	vivo	vivo	FW	_	12	dep
14	mouse	mouse	NN	_	16	compound
15	micronucleus	micronucleus	NN	_	16	compound
16	test	test	NN	_	7	nmod
17	.	.	.	_	5	punct

1	In	in	IN	_	7	case
2	oral	oral	JJ	_	7	amod
3	(	(	NN	_	7	compound
4	gavage	gavage	NN	_	7	compound
5	)	)	NN	_	7	compound
6	fertility	fertility	NN	_	7	compound
7	studies	study	NNS	_	15	nmod
8	of	of	IN	_	9	case
9	ezetimibe	ezetimibe	NN	_	7	nmod
10	conducted	conduct	VBN	_	9	acl
11	in	in	IN	_	12	case
12	rats	rat	NNS	_	10	nmod
13	,	,	,	_	15	punct
14	there	there	EX	_	15	expl
15	was	be	VBD	_	0	ROOT
16	no	no	DT	_	17	neg
17	evidence	evidence	NN	_	15	nsubj
18	of	of	IN	_	20	case
19	reproductive	reproductive	JJ	_	20	amod
20	toxicity	toxicity	NN	_	17	nmod
21	at	at	IN	_	22	case
22	doses	dose	NNS	_	20	nmod
23	up	up	RB	_	25	advmod
24	to	to	TO	_	25	dep
25	1000	1000	CD	_	26	nummod
26	mg	mg	NN	_	22	dep
27	/	/	:	_	20	punct
28	kg	kg	NN	_	30	compound
29	/	/	:	_	30	punct
30	day	day	NN	_	36	nsubj
31	in	in	IN	_	35	case
32	male	male	JJ	_	35	amod
33	or	or	CC	_	32	cc
34	female	female	JJ	_	32	conj
35	rats	rat	NNS	_	30	nmod
36	(	(	VBP	_	20	acl:relcl
37	~	~	NN	_	39	compound
38	7	7	CD	_	39	compound
39	times	time	NNS	_	36	dobj
40	the	the	DT	_	42	det
41	human	human	JJ	_	42	amod
42	exposure	exposure	NN	_	39	dep
43	at	at	IN	_	45	case
44	10	10	CD	_	45	nummod
45	mg	mg	NN	_	42	nmod
46	daily	daily	JJ	_	42	advmod
47	based	base	VBN	_	49	case
48	on	on	IN	_	49	case
49	AUC0	auc0	NN	_	46	advcl
50	-	-	:	_	49	punct
51	24hr	24hr	NN	_	49	dep
52	for	for	IN	_	55	case
53	total	total	JJ	_	55	amod
54	ezetimibe	ezetimibe	NN	_	55	compound
55	)	)	NN	_	51	nmod
56	.	.	.	_	15	punct

1	Pregnancy	Pregnancy	NNP	_	3	compound
2	Pregnancy	Pregnancy	NNP	_	3	compound
3	Category	Category	NNP	_	0	ROOT
4	:	:	:	_	3	punct
5	C	c	NN	_	3	dep
6	There	there	EX	_	7	expl
7	are	be	VBP	_	5	acl:relcl
8	no	no	DT	_	9	neg
9	adequate	adequate	JJ	_	7	nsubj
10	and	and	CC	_	9	cc
11	well	well	RB	_	9	advmod
12	-	-	:	_	9	punct
13	controlled	controlled	JJ	_	14	amod
14	studies	study	NNS	_	9	dep
15	of	of	IN	_	16	case
16	ezetimibe	ezetimibe	NN	_	14	nmod
17	in	in	IN	_	19	case
18	pregnant	pregnant	JJ	_	19	amod
19	women	woman	NNS	_	14	nmod
20	.	.	.	_	3	punct

1	Ezetimibe	ezetimibe	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	during	during	IN	_	6	case
6	pregnancy	pregnancy	NN	_	4	nmod
7	only	only	RB	_	12	advmod
8	if	if	IN	_	12	mark
9	the	the	DT	_	11	det
10	potential	potential	JJ	_	11	amod
11	benefit	benefit	NN	_	12	nsubj
12	justifies	justify	VBZ	_	4	advcl
13	the	the	DT	_	14	det
14	risk	risk	NN	_	12	dobj
15	to	to	TO	_	17	case
16	the	the	DT	_	17	det
17	fetus	fetus	NN	_	12	nmod
18	.	.	.	_	4	punct

1	In	in	IN	_	6	case
2	oral	oral	JJ	_	6	amod
3	(	(	NN	_	6	compound
4	gavage	gavage	NN	_	6	compound
5	)	)	NN	_	6	compound
6	embryo	embryo	NN	_	0	ROOT
7	-	-	:	_	10	punct
8	fetal	fetal	JJ	_	10	amod
9	development	development	NN	_	10	compound
10	studies	study	NNS	_	6	dep
11	of	of	IN	_	12	case
12	ezetimibe	ezetimibe	NN	_	10	nmod
13	conducted	conduct	VBN	_	12	acl
14	in	in	IN	_	15	case
15	rats	rat	NNS	_	13	nmod
16	and	and	CC	_	15	cc
17	rabbits	rabbit	NNS	_	15	conj
18	during	during	IN	_	19	case
19	organogenesis	organogenesis	NN	_	13	nmod
20	,	,	,	_	10	punct
21	there	there	EX	_	22	expl
22	was	be	VBD	_	10	acl:relcl
23	no	no	DT	_	24	neg
24	evidence	evidence	NN	_	22	nsubj
25	of	of	IN	_	27	case
26	embryolethal	embryolethal	JJ	_	27	amod
27	effects	effect	NNS	_	24	nmod
28	at	at	IN	_	30	case
29	the	the	DT	_	30	det
30	doses	dose	NNS	_	27	nmod
31	tested	test	VBN	_	30	acl
32	(	(	RB	_	33	advmod
33	250	250	CD	_	31	dobj
34	,	,	,	_	33	punct
35	500	500	CD	_	33	conj
36	,	,	,	_	33	punct
37	1000	1000	CD	_	38	nummod
38	mg	mg	NN	_	33	conj
39	/	/	:	_	33	punct
40	kg	kg	NN	_	42	compound
41	/	/	:	_	42	punct
42	day	day	NN	_	33	dep
43	)	)	CD	_	42	nummod
44	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	rats	rat	NNS	_	11	nmod
3	,	,	,	_	11	punct
4	increased	increase	VBD	_	5	amod
5	incidences	incidence	NNS	_	11	nsubj
6	of	of	IN	_	10	case
7	common	common	JJ	_	10	amod
8	fetal	fetal	JJ	_	10	amod
9	skeletal	skeletal	JJ	_	10	amod
10	findings	finding	NNS	_	5	nmod
11	(	(	VBP	_	0	ROOT
12	extra	extra	JJ	_	13	amod
13	pair	pair	NN	_	23	nsubj
14	of	of	IN	_	16	case
15	thoracic	thoracic	JJ	_	16	amod
16	ribs	rib	NNS	_	13	nmod
17	,	,	,	_	16	punct
18	unossified	unossified	JJ	_	21	amod
19	cervical	cervical	JJ	_	21	amod
20	vertebral	vertebral	JJ	_	21	amod
21	centra	centra	NNS	_	16	appos
22	,	,	,	_	16	punct
23	shortened	shorten	VBD	_	11	ccomp
24	ribs	rib	NNS	_	23	dobj
25	)	)	CD	_	24	nummod
26	were	be	VBD	_	27	auxpass
27	observed	observe	VBN	_	11	dep
28	at	at	IN	_	30	case
29	1000	1000	CD	_	30	nummod
30	mg	mg	NN	_	27	nmod
31	/	/	:	_	30	punct
32	kg	kg	NN	_	30	dep
33	/	/	:	_	30	punct
34	day	day	NN	_	36	compound
35	(	(	CD	_	36	nummod
36	~	~	NN	_	30	dep
37	10	10	CD	_	38	compound
38	times	time	NNS	_	41	nummod
39	the	the	DT	_	41	det
40	human	human	JJ	_	41	amod
41	exposure	exposure	NN	_	36	dep
42	at	at	IN	_	44	case
43	10	10	CD	_	44	nummod
44	mg	mg	NN	_	41	nmod
45	daily	daily	JJ	_	44	advmod
46	based	base	VBN	_	41	acl
47	on	on	IN	_	48	case
48	AUC0	auc0	NN	_	46	nmod
49	-	-	:	_	48	punct
50	24hr	24hr	NN	_	48	dep
51	for	for	IN	_	54	case
52	total	total	JJ	_	54	amod
53	ezetimibe	ezetimibe	NN	_	54	compound
54	)	)	NN	_	50	nmod
55	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	rabbits	rabbit	NNS	_	15	nmod
3	treated	treat	VBN	_	2	acl
4	with	with	IN	_	5	case
5	ezetimibe	ezetimibe	NN	_	3	nmod
6	,	,	,	_	15	punct
7	an	a	DT	_	9	det
8	increased	increase	VBN	_	9	amod
9	incidence	incidence	NN	_	15	nsubjpass
10	of	of	IN	_	13	case
11	extra	extra	JJ	_	13	amod
12	thoracic	thoracic	JJ	_	13	amod
13	ribs	rib	NNS	_	9	nmod
14	was	be	VBD	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	at	at	IN	_	18	case
17	1000	1000	CD	_	18	nummod
18	mg	mg	NN	_	15	nmod
19	/	/	:	_	18	punct
20	kg	kg	NN	_	18	dep
21	/	/	:	_	18	punct
22	day	day	NN	_	25	compound
23	(	(	CD	_	24	compound
24	150	150	CD	_	25	nummod
25	times	time	NNS	_	28	nummod
26	the	the	DT	_	28	det
27	human	human	JJ	_	28	amod
28	exposure	exposure	NN	_	18	dep
29	at	at	IN	_	31	case
30	10	10	CD	_	31	nummod
31	mg	mg	NN	_	28	nmod
32	daily	daily	JJ	_	28	advmod
33	based	base	VBN	_	35	case
34	on	on	IN	_	35	case
35	AUC0	auc0	NN	_	32	advcl
36	-	-	:	_	35	punct
37	24hr	24hr	NN	_	35	dep
38	for	for	IN	_	41	case
39	total	total	JJ	_	41	amod
40	ezetimibe	ezetimibe	NN	_	41	compound
41	)	)	NN	_	37	nmod
42	.	.	.	_	15	punct

1	Ezetimibe	ezetimibe	NN	_	2	nsubj
2	crossed	cross	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	placenta	placenta	NN	_	2	dobj
5	when	when	WRB	_	11	advmod
6	pregnant	pregnant	JJ	_	7	amod
7	rats	rat	NNS	_	11	nsubjpass
8	and	and	CC	_	7	cc
9	rabbits	rabbit	NNS	_	7	conj
10	were	be	VBD	_	11	auxpass
11	given	give	VBN	_	2	advcl
12	multiple	multiple	JJ	_	14	amod
13	oral	oral	JJ	_	14	amod
14	doses	dose	NNS	_	11	dobj
15	.	.	.	_	2	punct

1	Multiple	multiple	JJ	_	3	amod
2	dose	dose	NN	_	3	compound
3	studies	study	NNS	_	0	ROOT
4	of	of	IN	_	5	case
5	ezetimibe	ezetimibe	NN	_	3	nmod
6	given	give	VBN	_	5	acl
7	in	in	IN	_	8	case
8	combination	combination	NN	_	6	nmod
9	with	with	IN	_	10	case
10	HMG	hmg	NN	_	8	nmod
11	-	-	:	_	10	punct
12	CoA	coa	NN	_	14	compound
13	reductase	reductase	NN	_	14	compound
14	inhibitors	inhibitor	NNS	_	10	dep
15	(	(	VBP	_	10	dep
16	statins	statin	NNS	_	15	dobj
17	)	)	RB	_	16	advmod
18	in	in	IN	_	19	case
19	rats	rat	NNS	_	16	nmod
20	and	and	CC	_	19	cc
21	rabbits	rabbit	NNS	_	19	conj
22	during	during	IN	_	24	case
23	organogenesis	organogenesis	NN	_	24	compound
24	result	result	NN	_	15	nmod
25	in	in	IN	_	27	case
26	higher	higher	JJR	_	27	amod
27	ezetimibe	ezetimibe	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	statin	statin	NN	_	30	compound
30	exposures	exposure	NNS	_	27	conj
31	.	.	.	_	3	punct

1	Reproductive	Reproductive	NNP	_	2	compound
2	findings	finding	NNS	_	3	nsubj
3	occur	occur	VBP	_	0	ROOT
4	at	at	IN	_	6	case
5	lower	lower	JJR	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	in	in	IN	_	9	case
8	combination	combination	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	compared	compare	VBN	_	12	case
11	to	to	TO	_	12	case
12	monotherapy	monotherapy	NN	_	3	advcl
13	.	.	.	_	3	punct

1	All	all	DT	_	8	dep
2	HMG	hmg	NN	_	8	dep
3	-	-	:	_	8	punct
4	CoA	coa	NN	_	6	compound
5	reductase	reductase	NN	_	6	compound
6	inhibitors	inhibitor	NNS	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	in	in	IN	_	13	case
10	pregnant	pregnant	JJ	_	13	amod
11	and	and	CC	_	10	cc
12	nursing	nursing	NN	_	10	conj
13	women	woman	NNS	_	8	nmod
14	.	.	.	_	8	punct

1	When	when	WRB	_	4	advmod
2	ZETIA	ZETIA	NNP	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	19	advcl
5	with	with	IN	_	11	case
6	an	a	DT	_	11	det
7	HMG	hmg	NN	_	11	compound
8	-	-	:	_	11	punct
9	CoA	coa	NN	_	11	compound
10	reductase	reductase	NN	_	11	compound
11	inhibitor	inhibitor	NN	_	4	nmod
12	in	in	IN	_	14	case
13	a	a	DT	_	14	det
14	woman	woman	NN	_	4	nmod
15	of	of	IN	_	17	case
16	childbearing	childbearing	JJ	_	17	amod
17	potential	potential	NN	_	14	nmod
18	,	,	,	_	19	punct
19	refer	refer	VBP	_	0	ROOT
20	to	to	TO	_	23	case
21	the	the	DT	_	23	det
22	pregnancy	pregnancy	NN	_	23	compound
23	category	category	NN	_	19	nmod
24	and	and	CC	_	23	cc
25	package	package	NN	_	26	compound
26	labeling	labeling	NN	_	23	conj
27	for	for	IN	_	33	case
28	the	the	DT	_	33	det
29	HMG	hmg	NN	_	33	compound
30	-	-	:	_	33	punct
31	CoA	coa	NN	_	33	compound
32	reductase	reductase	NN	_	33	compound
33	inhibitor	inhibitor	NN	_	19	nmod
34	.	.	.	_	19	punct

1	Labor	labor	NN	_	16	nsubj
2	and	and	CC	_	1	cc
3	Delivery	delivery	NN	_	1	conj
4	The	the	DT	_	5	det
5	effects	effect	NNS	_	1	dep
6	of	of	IN	_	7	case
7	ZETIA	zetia	NN	_	5	nmod
8	on	on	IN	_	9	case
9	labor	labor	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	delivery	delivery	NN	_	9	conj
12	in	in	IN	_	14	case
13	pregnant	pregnant	JJ	_	14	amod
14	women	woman	NNS	_	9	nmod
15	are	be	VBP	_	16	cop
16	unknown	unknown	JJ	_	0	ROOT
17	.	.	.	_	16	punct

1	Nursing	Nursing	NNP	_	2	compound
2	Mothers	Mothers	NNP	_	17	nsubj
3	In	in	IN	_	5	case
4	rat	rat	NN	_	5	compound
5	studies	study	NNS	_	2	nmod
6	,	,	,	_	2	punct
7	exposure	exposure	NN	_	2	appos
8	to	to	TO	_	10	case
9	total	total	JJ	_	10	amod
10	ezetimibe	ezetimibe	NN	_	7	nmod
11	in	in	IN	_	13	case
12	nursing	nursing	NN	_	13	compound
13	pups	pup	NNS	_	10	nmod
14	was	be	VBD	_	17	cop
15	up	up	RB	_	17	advmod
16	to	to	TO	_	17	case
17	half	half	NN	_	0	ROOT
18	of	of	IN	_	19	case
19	that	that	DT	_	17	nmod
20	observed	observe	VBN	_	19	acl
21	in	in	IN	_	23	case
22	maternal	maternal	JJ	_	23	amod
23	plasma	plasma	NN	_	20	nmod
24	.	.	.	_	17	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	whether	whether	IN	_	8	mark
6	ezetimibe	ezetimibe	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	excreted	excrete	VBN	_	4	ccomp
9	into	into	IN	_	12	case
10	human	human	JJ	_	12	amod
11	breast	breast	NN	_	12	compound
12	milk	milk	NN	_	8	nmod
13	;	;	:	_	4	punct

1	therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	ZETIA	zetia	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	nursing	nursing	NN	_	10	compound
10	mothers	mother	NNS	_	7	nmod
11	unless	unless	IN	_	15	mark
12	the	the	DT	_	14	det
13	potential	potential	JJ	_	14	amod
14	benefit	benefit	NN	_	15	nsubj
15	justifies	justify	VBZ	_	7	advcl
16	the	the	DT	_	18	det
17	potential	potential	JJ	_	18	amod
18	risk	risk	NN	_	15	dobj
19	to	to	TO	_	21	case
20	the	the	DT	_	21	det
21	infant	infant	NN	_	18	nmod
22	.	.	.	_	7	punct

1	Pediatric	Pediatric	NNP	_	4	compound
2	Use	Use	NNP	_	4	compound
3	The	The	NNP	_	4	compound
4	pharmacokinetics	pharmacokinetic	NNS	_	9	nsubj
5	of	of	IN	_	6	case
6	ZETIA	ZETIA	NNP	_	4	nmod
7	in	in	IN	_	8	case
8	adolescents	adolescent	NNS	_	4	nmod
9	(	(	VBP	_	0	ROOT
10	10	10	CD	_	12	compound
11	to	to	TO	_	12	dep
12	18	18	CD	_	13	nummod
13	years	year	NNS	_	9	dobj
14	)	)	RB	_	17	advmod
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	shown	show	VBN	_	13	acl
18	to	to	TO	_	20	mark
19	be	be	VB	_	20	cop
20	similar	similar	JJ	_	17	xcomp
21	to	to	TO	_	22	case
22	that	that	DT	_	20	nmod
23	in	in	IN	_	24	case
24	adults	adult	NNS	_	22	nmod
25	.	.	.	_	9	punct

1	Treatment	treatment	NN	_	2	compound
2	experience	experience	NN	_	10	nsubjpass
3	with	with	IN	_	4	case
4	ZETIA	zetia	NN	_	2	nmod
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	pediatric	pediatric	JJ	_	8	amod
8	population	population	NN	_	2	nmod
9	is	be	VBZ	_	10	auxpass
10	limited	limit	VBN	_	0	ROOT
11	to	to	TO	_	13	case
12	4	4	CD	_	13	nummod
13	patients	patient	NNS	_	10	nmod
14	(	(	IN	_	19	case
15	9	9	CD	_	17	compound
16	to	to	TO	_	17	dep
17	17	17	CD	_	18	nummod
18	years	year	NNS	_	19	nmod:npmod
19	)	)	RB	_	13	acl
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	sitosterolemia	sitosterolemia	NN	_	23	compound
23	study	study	NN	_	19	nmod
24	and	and	CC	_	13	cc
25	5	5	CD	_	26	nummod
26	patients	patient	NNS	_	13	conj
27	(	(	IN	_	32	case
28	11	11	CD	_	30	compound
29	to	to	TO	_	30	dep
30	17	17	CD	_	31	nummod
31	years	year	NNS	_	32	nmod:npmod
32	)	)	RB	_	26	nmod
33	in	in	IN	_	36	case
34	the	the	DT	_	36	det
35	HoFH	hofh	NN	_	36	compound
36	study	study	NN	_	32	nmod
37	.	.	.	_	10	punct

1	Treatment	treatment	NN	_	6	nsubj
2	with	with	IN	_	3	case
3	ZETIA	zetia	NN	_	1	nmod
4	in	in	IN	_	5	case
5	children	child	NNS	_	1	nmod
6	(	(	VBP	_	0	ROOT
7	&lt	&lt	VBN	_	6	xcomp
8	;	;	:	_	6	punct
9	10	10	CD	_	10	nummod
10	years	year	NNS	_	14	nsubjpass
11	)	)	CD	_	10	nummod
12	is	be	VBZ	_	14	auxpass
13	not	not	RB	_	14	neg
14	recommended	recommend	VBN	_	6	parataxis
15	.	.	.	_	6	punct

1	Geriatric	Geriatric	NNP	_	2	compound
2	Use	Use	NNP	_	0	ROOT
3	Of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	patients	patient	NNS	_	2	nmod
6	who	who	WP	_	7	nsubj
7	received	receive	VBD	_	5	acl:relcl
8	ZETIA	ZETIA	NNP	_	7	dobj
9	in	in	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	studies	study	NNS	_	7	nmod
12	,	,	,	_	2	punct
13	948	948	CD	_	15	nsubj
14	were	be	VBD	_	15	cop
15	65	65	CD	_	2	acl:relcl
16	and	and	CC	_	15	cc
17	older	older	JJR	_	15	conj
18	(	(	CD	_	15	dep
19	this	this	DT	_	20	nsubj
20	included	include	VBD	_	18	acl:relcl
21	206	206	CD	_	20	dobj
22	who	who	WP	_	24	nsubj
23	were	be	VBD	_	24	cop
24	75	75	CD	_	21	acl:relcl
25	and	and	CC	_	24	cc
26	older	older	JJR	_	24	conj
27	)	)	NN	_	24	dep
28	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effectiveness	effectiveness	NN	_	8	nsubj
3	and	and	CC	_	2	cc
4	safety	safety	NN	_	2	conj
5	of	of	IN	_	6	case
6	ZETIA	ZETIA	NNP	_	2	nmod
7	were	be	VBD	_	8	cop
8	similar	similar	JJ	_	0	ROOT
9	between	between	IN	_	11	case
10	these	these	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	and	and	CC	_	11	cc
13	younger	younger	JJR	_	14	amod
14	subjects	subject	NNS	_	11	conj
15	.	.	.	_	8	punct

1	Greater	Greater	NNP	_	2	compound
2	sensitivity	sensitivity	NN	_	9	nsubjpass
3	of	of	IN	_	6	case
4	some	some	DT	_	6	det
5	older	older	JJR	_	6	amod
6	individuals	individual	NNS	_	2	nmod
7	cannot	cannot	VBP	_	9	aux
8	be	be	VB	_	9	auxpass
9	ruled	rule	VBN	_	0	ROOT
10	out	out	RP	_	9	compound:prt
11	.	.	.	_	9	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	Guanethidine	guanethidine	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Although	although	IN	_	10	mark
6	minoxidil	minoxidil	NN	_	10	nsubj
7	does	do	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	itself	itself	PRP	_	10	nsubj
10	cause	cause	VB	_	19	advcl
11	orthostatic	orthostatic	JJ	_	12	amod
12	hypotension	hypotension	NN	_	10	dobj
13	,	,	,	_	19	punct
14	its	its	PRP$	_	15	nmod:poss
15	administration	administration	NN	_	19	nsubj
16	to	to	TO	_	17	case
17	patients	patient	NNS	_	15	nmod
18	already	already	RB	_	19	advmod
19	receiving	receive	VBG	_	1	dep
20	guanethidine	guanethidine	NN	_	19	dobj
21	can	can	MD	_	22	aux
22	result	result	VB	_	19	dep
23	in	in	IN	_	26	case
24	profound	profound	JJ	_	26	amod
25	orthostatic	orthostatic	JJ	_	26	amod
26	effects	effect	NNS	_	22	nmod
27	.	.	.	_	1	punct

1	If	if	IN	_	8	mark
2	at	at	IN	_	5	case
3	all	all	DT	_	5	det
4	possible	possible	JJ	_	5	amod
5	guanethidine	guanethidine	NN	_	8	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	discontinued	discontinue	VBN	_	0	ROOT
9	well	well	RB	_	8	advmod
10	before	before	IN	_	13	mark
11	minoxidil	minoxidil	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	begun	begin	VBN	_	8	advcl
14	.	.	.	_	8	punct

1	Where	where	WRB	_	5	advmod
2	this	this	DT	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	possible	possible	JJ	_	11	advcl
6	,	,	,	_	11	punct
7	minoxidil	minoxidil	NN	_	8	compound
8	therapy	therapy	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	started	start	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	hospital	hospital	NN	_	11	nmod
15	and	and	CC	_	11	cc
16	the	the	DT	_	17	det
17	patient	patient	NN	_	19	nsubj
18	should	should	MD	_	19	aux
19	remain	remain	VB	_	11	conj
20	institutionalized	institutionalized	JJ	_	19	xcomp
21	until	until	IN	_	28	mark
22	severe	severe	JJ	_	24	amod
23	orthostatic	orthostatic	JJ	_	24	amod
24	effects	effect	NNS	_	28	nsubj
25	are	be	VBP	_	28	cop
26	no	no	RB	_	27	neg
27	longer	longer	RB	_	28	advmod
28	present	present	JJ	_	19	advcl
29	or	or	CC	_	28	cc
30	the	the	DT	_	31	det
31	patient	patient	NN	_	33	nsubj
32	has	have	VBZ	_	33	aux
33	learned	learn	VBN	_	28	conj
34	to	to	TO	_	35	mark
35	avoid	avoid	VB	_	33	xcomp
36	activities	activity	NNS	_	35	dobj
37	that	that	WDT	_	38	nsubj
38	provoke	provoke	VBP	_	36	acl:relcl
39	them	they	PRP	_	38	dobj
40	.	.	.	_	11	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	0	ROOT
4	in	in	IN	_	5	case
5	which	which	WDT	_	10	nmod
6	34	34	CD	_	8	nummod
7	different	different	JJ	_	8	amod
8	drugs	drug	NNS	_	10	nsubjpass
9	were	be	VBD	_	10	auxpass
10	tested	test	VBN	_	3	acl:relcl
11	,	,	,	_	3	punct
12	therapeutically	therapeutically	RB	_	13	advmod
13	relevant	relevant	JJ	_	14	amod
14	concentrations	concentration	NNS	_	11	root
15	of	of	IN	_	16	case
16	tolbutamide	tolbutamide	NN	_	14	nmod
17	,	,	,	_	16	punct
18	sodium	sodium	NN	_	19	compound
19	salicylate	salicylate	NN	_	16	conj
20	and	and	CC	_	16	cc
21	sulfamethizole	sulfamethizole	NN	_	23	compound
22	displaced	displaced	JJ	_	23	amod
23	protein	protein	NN	_	16	conj
24	-	-	:	_	14	punct
25	bound	bind	VBN	_	26	amod
26	teniposide	teniposide	NN	_	14	dep
27	in	in	IN	_	30	case
28	fresh	fresh	JJ	_	30	amod
29	human	human	JJ	_	30	amod
30	serum	serum	NN	_	26	nmod
31	to	to	TO	_	36	case
32	a	a	DT	_	36	det
33	small	small	JJ	_	36	amod
34	but	but	CC	_	33	cc
35	significant	significant	JJ	_	33	conj
36	extent	extent	NN	_	26	nmod
37	.	.	.	_	14	punct

1	Because	because	IN	_	6	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	6	det
4	extremely	extremely	RB	_	5	advmod
5	high	high	JJ	_	6	amod
6	binding	binding	NN	_	19	nmod
7	of	of	IN	_	8	case
8	teniposide	teniposide	NN	_	6	nmod
9	to	to	TO	_	11	case
10	plasma	plasma	NN	_	11	compound
11	proteins	protein	NNS	_	6	nmod
12	,	,	,	_	19	punct
13	these	these	DT	_	15	det
14	small	small	JJ	_	15	amod
15	decreases	decrease	NNS	_	19	nsubj
16	in	in	IN	_	17	case
17	binding	binding	NN	_	15	nmod
18	could	could	MD	_	19	aux
19	cause	cause	VB	_	0	ROOT
20	substantial	substantial	JJ	_	21	amod
21	increases	increase	NNS	_	19	dobj
22	in	in	IN	_	25	case
23	free	free	JJ	_	25	amod
24	drug	drug	NN	_	25	compound
25	levels	level	NNS	_	21	nmod
26	in	in	IN	_	27	case
27	plasma	plasma	NN	_	25	nmod
28	which	which	WDT	_	30	nsubj
29	could	could	MD	_	30	aux
30	result	result	VB	_	21	acl:relcl
31	in	in	IN	_	32	case
32	potentiation	potentiation	NN	_	30	nmod
33	of	of	IN	_	35	case
34	drug	drug	NN	_	35	compound
35	toxicity	toxicity	NN	_	32	nmod
36	.	.	.	_	19	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	8	mark
8	administering	administer	VBG	_	6	advcl
9	VUMON	VUMON	NNP	_	12	compound
10	(	(	CD	_	12	nummod
11	teniposide	teniposide	NN	_	12	compound
12	injection	injection	NN	_	8	dobj
13	)	)	CD	_	12	nummod
14	to	to	TO	_	15	case
15	patients	patient	NNS	_	8	nmod
16	receiving	receive	VBG	_	15	acl
17	these	these	DT	_	19	det
18	other	other	JJ	_	19	amod
19	agents	agent	NNS	_	16	dobj
20	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	change	change	NN	_	2	nsubj
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	plasma	plasma	NN	_	8	compound
8	kinetics	kinetics	NNS	_	2	nmod
9	of	of	IN	_	10	case
10	teniposide	teniposide	NN	_	8	nmod
11	when	when	WRB	_	12	advmod
12	coadministered	coadminister	VBN	_	2	advcl
13	with	with	IN	_	14	case
14	methotrexate	methotrexate	NN	_	12	nmod
15	.	.	.	_	2	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	5	det
4	plasma	plasma	NN	_	5	compound
5	clearance	clearance	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	methotrexate	methotrexate	NN	_	5	nmod
8	was	be	VBD	_	10	auxpass
9	slightly	slightly	RB	_	10	advmod
10	increased	increase	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	An	a	DT	_	2	det
2	increase	increase	NN	_	9	nsubjpass
3	in	in	IN	_	5	case
4	intracellular	intracellular	JJ	_	5	amod
5	levels	level	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	methotrexate	methotrexate	NN	_	5	nmod
8	was	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	in	in	FW	_	11	compound
11	vitro	vitro	FW	_	9	advmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	presence	presence	NN	_	9	nmod
15	of	of	IN	_	16	case
16	teniposide	teniposide	NN	_	14	nmod
17	.	.	.	_	9	punct

1	Salicylates	salicylate	NNS	_	2	nsubj
2	antagonize	antagonize	VBP	_	0	ROOT
3	the	the	DT	_	5	det
4	uricosuric	uricosuric	JJ	_	5	amod
5	action	action	NN	_	2	dobj
6	of	of	IN	_	8	case
7	.	.	.	_	8	punct
8	drugs	drug	NNS	_	5	nmod
9	used	use	VBN	_	8	acl
10	to	to	TO	_	11	mark
11	treat	treat	VB	_	9	xcomp
12	gout	gout	NN	_	11	dobj
13	.	.	.	_	2	punct

1	ASPIRIN	aspirin	NN	_	7	nsubj
2	AND	and	CC	_	1	cc
3	OTHER	other	JJ	_	5	amod
4	SALICYLATE	salicylate	NN	_	5	compound
5	DRUGS	drug	NNS	_	1	conj
6	WILL	will	MD	_	7	aux
7	BE	be	VB	_	0	ROOT
8	ADDITIVE	ADDITIVE	NNP	_	7	dobj
9	TO	to	TO	_	15	case
10	DISALCID	DISALCID	NNP	_	15	compound
11	AND	and	CC	_	10	cc
12	MAY	MAY	NNP	_	10	conj
13	INCREASE	INCREASE	NNP	_	15	compound
14	PLASMA	PLASMA	NNP	_	15	compound
15	CONCENTRATIONS	CONCENTRATIONS	NNPS	_	8	nmod
16	OF	of	IN	_	18	case
17	SALICYLIC	SALICYLIC	NNP	_	18	compound
18	ACID	ACID	NNP	_	8	nmod
19	TO	to	TO	_	21	case
20	TOXIC	TOXIC	NNP	_	21	compound
21	LEVELS	LEVELS	NNP	_	8	nmod
22	.	.	.	_	7	punct

1	Drugs	drug	NNS	_	9	nsubj
2	and	and	CC	_	1	cc
3	foods	food	NNS	_	1	conj
4	that	that	WDT	_	5	nsubj
5	raise	raise	VBP	_	1	acl:relcl
6	urine	urine	NN	_	7	compound
7	pH	ph	NN	_	5	dobj
8	will	will	MD	_	9	aux
9	increase	increase	VB	_	0	ROOT
10	renal	renal	JJ	_	11	amod
11	clearance	clearance	NN	_	9	dobj
12	and	and	CC	_	11	cc
13	urinary	urinary	JJ	_	14	amod
14	excretion	excretion	NN	_	11	conj
15	of	of	IN	_	17	case
16	salicylic	salicylic	JJ	_	17	amod
17	acid	acid	NN	_	11	nmod
18	,	,	,	_	9	punct
19	thus	thus	RB	_	20	advmod
20	lowering	lower	VBG	_	9	advcl
21	plasma	plasma	NN	_	22	compound
22	levels	level	NNS	_	20	dobj
23	;	;	:	_	9	punct

1	acidifying	acidify	VBG	_	2	amod
2	drugs	drug	NNS	_	6	nsubj
3	or	or	CC	_	2	cc
4	foods	food	NNS	_	2	conj
5	will	will	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	urinary	urinary	JJ	_	8	amod
8	excretion	excretion	NN	_	6	dobj
9	and	and	CC	_	8	cc
10	increase	increase	NN	_	12	compound
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	8	conj
13	.	.	.	_	6	punct

1	Salicylates	salicylate	NNS	_	8	nsubj
2	given	give	VBN	_	1	acl
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	6	case
5	anticoagulant	anticoagulant	JJ	_	6	amod
6	drugs	drug	NNS	_	2	nmod
7	may	may	MD	_	8	aux
8	predispose	predispose	VB	_	0	ROOT
9	to	to	TO	_	11	case
10	systemic	systemic	JJ	_	11	amod
11	bleeding	bleeding	NN	_	8	nmod
12	.	.	.	_	8	punct

1	Salicylates	salicylate	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypoglycemic	hypoglycemic	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	10	case
8	oral	oral	JJ	_	10	amod
9	antidiabetic	antidiabetic	JJ	_	10	amod
10	drugs	drug	NNS	_	6	nmod
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	sulfonylurea	sulfonylurea	NN	_	14	compound
14	class	class	NN	_	10	nmod
15	.	.	.	_	3	punct

1	Salicylate	salicylate	NN	_	2	nsubj
2	competes	compete	VBZ	_	0	ROOT
3	with	with	IN	_	5	case
4	a	a	DT	_	5	det
5	number	number	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	for	for	IN	_	11	case
9	protein	protein	NN	_	11	compound
10	binding	binding	NN	_	11	compound
11	sites	site	NNS	_	7	nmod
12	,	,	,	_	5	punct
13	notably	notably	RB	_	14	advmod
14	penicillin	penicillin	NN	_	5	appos
15	,	,	,	_	14	punct
16	thiopental	thiopental	JJ	_	14	conj
17	,	,	,	_	14	punct
18	thyroxine	thyroxine	NN	_	14	conj
19	,	,	,	_	14	punct
20	triiodothyronine	triiodothyronine	NN	_	14	conj
21	,	,	,	_	14	punct
22	phenytoin	phenytoin	NN	_	14	conj
23	,	,	,	_	14	punct
24	sulfinpyrazone	sulfinpyrazone	NN	_	14	conj
25	,	,	,	_	14	punct
26	naproxen	naproxen	NN	_	14	conj
27	,	,	,	_	14	punct
28	warfarin	warfarin	NN	_	14	conj
29	,	,	,	_	14	punct
30	methotrexate	methotrexate	NN	_	14	conj
31	,	,	,	_	14	punct
32	and	and	CC	_	14	cc
33	possibly	possibly	RB	_	34	advmod
34	corticosteroids	corticosteroid	NNS	_	14	conj
35	.	.	.	_	2	punct

1	Drug	drug	NN	_	6	compound
2	/	/	:	_	6	punct
3	Laboratory	Laboratory	NNP	_	6	compound
4	Test	Test	NNP	_	6	compound
5	Interactions	interaction	NNS	_	6	compound
6	Salicylate	Salicylate	NNP	_	7	nsubj
7	competes	compete	VBZ	_	0	ROOT
8	with	with	IN	_	10	case
9	thyroid	thyroid	NN	_	10	compound
10	hormone	hormone	NN	_	7	nmod
11	for	for	IN	_	12	case
12	binding	bind	VBG	_	7	nmod
13	to	to	TO	_	15	case
14	plasma	plasma	NN	_	15	compound
15	proteins	protein	NNS	_	12	nmod
16	,	,	,	_	15	punct
17	which	which	WDT	_	20	nsubjpass
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	reflected	reflect	VBN	_	15	acl:relcl
21	in	in	IN	_	26	case
22	a	a	DT	_	26	det
23	depressed	depressed	JJ	_	26	amod
24	plasma	plasma	NN	_	26	compound
25	T4	t4	NN	_	26	compound
26	value	value	NN	_	20	nmod
27	in	in	IN	_	29	case
28	some	some	DT	_	29	det
29	patients	patient	NNS	_	26	nmod
30	;	;	:	_	7	punct

1	thyroid	thyroid	NN	_	2	compound
2	function	function	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	basal	basal	JJ	_	5	amod
5	metabolism	metabolism	NN	_	2	conj
6	are	be	VBP	_	7	cop
7	unaffected	unaffected	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	elderly	elderly	JJ	_	3	amod
3	patients	patient	NNS	_	21	nmod
4	concurrently	concurrently	RB	_	5	advmod
5	receiving	receive	VBG	_	3	acl
6	certain	certain	JJ	_	7	amod
7	diuretics	diuretic	NNS	_	5	dobj
8	,	,	,	_	21	punct
9	primarily	primarily	RB	_	10	advmod
10	thiazides	thiazide	NNS	_	21	nsubjpass
11	,	,	,	_	10	punct
12	an	a	DT	_	14	det
13	increased	increase	VBN	_	14	amod
14	incidence	incidence	NN	_	10	appos
15	of	of	IN	_	16	case
16	thrombopenia	thrombopenia	NN	_	14	nmod
17	with	with	IN	_	18	case
18	purpura	purpura	NN	_	14	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	8	mark
6	sulfamethoxazole	sulfamethoxazole	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	prolong	prolong	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	8	dobj
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	who	who	WP	_	16	nsubj
15	are	be	VBP	_	16	aux
16	receiving	receive	VBG	_	13	acl:relcl
17	the	the	DT	_	19	det
18	anticoagulant	anticoagulant	JJ	_	19	amod
19	warfarin	warfarin	NN	_	16	dobj
20	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	kept	keep	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	mind	mind	NN	_	5	nmod
8	when	when	WRB	_	11	advmod
9	Gantanol	Gantanol	NNP	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	given	give	VBN	_	5	advcl
12	to	to	TO	_	13	case
13	patients	patient	NNS	_	11	nmod
14	already	already	RB	_	17	advmod
15	on	on	IN	_	17	case
16	anticoagulant	anticoagulant	JJ	_	17	amod
17	therapy	therapy	NN	_	11	nmod
18	,	,	,	_	5	punct
19	and	and	CC	_	5	cc
20	the	the	DT	_	22	det
21	coagulation	coagulation	NN	_	22	compound
22	time	time	NN	_	25	nsubjpass
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	reassessed	reassess	VBN	_	5	conj
26	.	.	.	_	5	punct

1	Sulfamethoxazole	Sulfamethoxazole	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	inhibit	inhibit	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	3	dobj
7	of	of	IN	_	8	case
8	phenytoin	phenytoin	NN	_	6	nmod
9	.	.	.	_	3	punct

1	At	at	IN	_	6	case
2	a	a	DT	_	6	det
3	1.6	1.6	CD	_	6	nummod
4	-	-	:	_	6	punct
5	g	g	NN	_	6	compound
6	dose	dose	NN	_	9	nmod
7	,	,	,	_	9	punct
8	sulfamethoxazole	sulfamethoxazole	NN	_	9	nsubj
9	produced	produce	VBD	_	0	ROOT
10	a	a	DT	_	14	det
11	slight	slight	JJ	_	14	amod
12	but	but	CC	_	11	cc
13	significant	significant	JJ	_	11	conj
14	increase	increase	NN	_	9	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	half	half	NN	_	14	nmod
18	-	-	:	_	17	punct
19	life	life	NN	_	17	dep
20	of	of	IN	_	21	case
21	phenytoin	phenytoin	NN	_	19	nmod
22	but	but	CC	_	9	cc
23	did	do	VBD	_	25	aux
24	not	not	RB	_	25	neg
25	produce	produce	VB	_	9	conj
26	a	a	DT	_	28	det
27	corresponding	corresponding	JJ	_	28	amod
28	decrease	decrease	NN	_	25	dobj
29	in	in	IN	_	33	case
30	the	the	DT	_	33	det
31	metabolic	metabolic	JJ	_	33	amod
32	clearance	clearance	NN	_	33	compound
33	rate	rate	NN	_	28	nmod
34	.	.	.	_	9	punct

1	When	when	WRB	_	2	advmod
2	administering	administer	VBG	_	10	advcl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	concurrently	concurrently	RB	_	2	advmod
6	,	,	,	_	10	punct
7	one	one	CD	_	10	nsubj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	cop
10	alert	alert	JJ	_	0	ROOT
11	for	for	IN	_	15	case
12	possible	possible	JJ	_	15	amod
13	excessive	excessive	JJ	_	15	amod
14	phenytoin	phenytoin	NN	_	15	compound
15	effect	effect	NN	_	10	nmod
16	.	.	.	_	10	punct

1	Sulfonamides	sulfonamide	NNS	_	4	nsubj
2	can	can	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	displace	displace	VB	_	0	ROOT
5	methotrexate	methotrexate	NN	_	4	dobj
6	from	from	IN	_	8	case
7	plasma	plasma	NN	_	8	compound
8	protein	protein	NN	_	4	nmod
9	-	-	:	_	4	punct
10	binding	bind	VBG	_	11	amod
11	sites	site	NNS	_	4	dobj
12	,	,	,	_	11	punct
13	thus	thus	RB	_	14	advmod
14	increasing	increase	VBG	_	11	acl
15	free	free	JJ	_	17	amod
16	methotrexate	methotrexate	NN	_	17	compound
17	concentrations	concentration	NNS	_	14	dobj
18	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	presence	presence	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	sulfamethoxazole	sulfamethoxazole	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	interfere	interfere	VB	_	0	ROOT
7	with	with	IN	_	13	case
8	the	the	DT	_	13	det
9	Jaff	Jaff	NNP	_	13	compound
10	alkaline	alkaline	NN	_	13	compound
11	picrate	picrate	NN	_	13	compound
12	reaction	reaction	NN	_	13	compound
13	assay	assay	NN	_	6	nmod
14	for	for	IN	_	15	case
15	creatinine	creatinine	NN	_	13	nmod
16	,	,	,	_	6	punct
17	resulting	result	VBG	_	6	advcl
18	in	in	IN	_	19	case
19	overestimations	overestimation	NNS	_	17	nmod
20	of	of	IN	_	23	case
21	about	about	IN	_	22	advmod
22	10	10	CD	_	23	nummod
23	%	%	NN	_	19	nmod
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	range	range	NN	_	17	nmod
27	of	of	IN	_	29	case
28	normal	normal	JJ	_	29	amod
29	values	value	NNS	_	26	nmod
30	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubj
4	listed	list	VBN	_	3	acl
5	below	below	RB	_	4	advmod
6	are	be	VBP	_	9	cop
7	potentially	potentially	RB	_	9	advmod
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Mutual	mutual	JJ	_	2	amod
2	inhibition	inhibition	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	metabolism	metabolism	NN	_	2	nmod
5	occurs	occur	VBZ	_	0	ROOT
6	with	with	IN	_	8	case
7	concurrent	concurrent	JJ	_	8	amod
8	use	use	NN	_	5	nmod
9	of	of	IN	_	10	case
10	cyclosporin	cyclosporin	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	methylprednisolone	methylprednisolone	NN	_	10	conj
13	;	;	:	_	5	punct

1	therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	possible	possible	JJ	_	0	ROOT
6	that	that	IN	_	20	mark
7	adverse	adverse	JJ	_	8	amod
8	events	event	NNS	_	20	nsubj
9	associated	associate	VBN	_	8	acl
10	with	with	IN	_	13	case
11	the	the	DT	_	13	det
12	individual	individual	JJ	_	13	amod
13	use	use	NN	_	9	nmod
14	of	of	IN	_	16	case
15	either	either	CC	_	16	det
16	drug	drug	NN	_	13	nmod
17	may	may	MD	_	20	aux
18	be	be	VB	_	20	cop
19	more	more	RBR	_	20	advmod
20	apt	apt	JJ	_	5	ccomp
21	to	to	TO	_	22	mark
22	occur	occur	VB	_	20	xcomp
23	.	.	.	_	5	punct

1	convulsions	convulsion	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	concurrent	concurrent	JJ	_	7	amod
7	use	use	NN	_	4	nmod
8	of	of	IN	_	9	case
9	methylprednisolone	methylprednisolone	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	cyclosporin	cyclosporin	NN	_	9	conj
12	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	15	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	hepatic	hepatic	JJ	_	5	amod
5	enzymes	enzyme	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	phenobarbital	phenobarbital	NN	_	5	nmod
9	,	,	,	_	8	punct
10	phenytoin	phenytoin	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	rifampin	rifampin	NN	_	8	conj
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	clearance	clearance	NN	_	15	dobj
18	of	of	IN	_	19	case
19	methylprednisolone	methylprednisolone	NN	_	17	nmod
20	and	and	CC	_	15	cc
21	may	may	MD	_	22	aux
22	require	require	VB	_	15	conj
23	increased	increase	VBN	_	22	ccomp
24	in	in	IN	_	26	case
25	methylprednisolone	methylprednisolone	NN	_	26	compound
26	dose	dose	NN	_	23	nmod
27	to	to	TO	_	28	mark
28	achieve	achieve	VB	_	23	xcomp
29	the	the	DT	_	31	det
30	desired	desire	VBN	_	31	amod
31	response	response	NN	_	28	dobj
32	.	.	.	_	15	punct

1	Drugs	drug	NNS	_	8	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	troleandomycin	troleandomycin	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	ketoconazole	ketoconazole	NN	_	4	conj
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	methylprednisolone	methylprednisolone	NN	_	10	nmod
13	and	and	CC	_	8	cc
14	thus	thus	RB	_	15	advmod
15	decrease	decrease	VB	_	8	conj
16	its	its	PRP$	_	17	nmod:poss
17	clearance	clearance	NN	_	15	dobj
18	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	methylprednisolone	methylprednisolone	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	titrated	titrate	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	avoid	avoid	VB	_	9	xcomp
12	steroid	steroid	NN	_	13	compound
13	toxicity	toxicity	NN	_	11	dobj
14	.	.	.	_	9	punct

1	Methylprednisolone	methylprednisolone	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	clearance	clearance	NN	_	3	dobj
6	of	of	IN	_	10	case
7	chronic	chronic	JJ	_	10	amod
8	high	high	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	aspirin	aspirin	NN	_	5	nmod
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	decreased	decrease	VBN	_	8	amod
6	salicylate	salicylate	NN	_	8	compound
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	3	nmod
9	or	or	CC	_	3	cc
10	increase	increase	VB	_	3	conj
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	salicylate	salicylate	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	when	when	WRB	_	19	advmod
17	methylprednisolone	methylprednisolone	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	withdrawn	withdraw	VBN	_	10	advcl
20	.	.	.	_	3	punct

1	Aspirin	aspirin	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	conjunction	conjunction	NN	_	4	nmod
8	with	with	IN	_	9	case
9	corticosteroids	corticosteroid	NNS	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	suffering	suffer	VBG	_	11	acl
13	from	from	IN	_	14	case
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	12	nmod
15	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	methylprednisolone	methylprednisolone	NN	_	2	nmod
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	anticoagulants	anticoagulant	NNS	_	2	nmod
8	is	be	VBZ	_	9	cop
9	variable	variable	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	reports	report	NNS	_	2	nsubj
4	of	of	IN	_	10	case
5	enhanced	enhance	VBN	_	10	amod
6	as	as	RB	_	5	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	diminished	diminished	JJ	_	5	conj
10	effects	effect	NNS	_	3	nmod
11	of	of	IN	_	12	case
12	anticoagulant	anticoagulant	NN	_	10	nmod
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	2	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	corticosteroids	corticosteroid	NNS	_	14	nmod
18	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	coagulation	coagulation	NN	_	4	compound
4	indices	index	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	maintain	maintain	VB	_	7	xcomp
10	the	the	DT	_	13	det
11	desired	desire	VBN	_	13	amod
12	anticoagulant	anticoagulant	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	.	.	.	_	7	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	antibiotics	antibiotic	NNS	_	2	dobj
4	and	and	CC	_	3	cc
5	sulfonamides	sulfonamide	NNS	_	3	conj
6	generally	generally	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	treated	treat	VBN	_	0	ROOT
11	with	with	IN	_	13	case
12	ganglion	ganglion	NN	_	13	compound
13	blockers	blocker	NNS	_	10	nmod
14	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	action	action	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	Mecamylamine	mecamylamine	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	potentiated	potentiate	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	anesthesia	anesthesia	NN	_	7	nmod
10	,	,	,	_	9	punct
11	other	other	JJ	_	13	amod
12	antihypertensive	antihypertensive	JJ	_	13	amod
13	drugs	drug	NNS	_	9	conj
14	and	and	CC	_	9	cc
15	alcohol	alcohol	NN	_	9	conj
16	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	25	nmod
4	,	,	,	_	25	punct
5	the	the	DT	_	7	det
6	concurrent	concurrent	JJ	_	7	amod
7	administration	administration	NN	_	25	nsubjpass
8	of	of	IN	_	12	case
9	the	the	DT	_	12	det
10	ASMANEX	ASMANEX	NNP	_	12	compound
11	TWISTHALER	twisthaler	NN	_	12	compound
12	inhaler	inhaler	NN	_	7	nmod
13	and	and	CC	_	12	cc
14	other	other	JJ	_	15	amod
15	drugs	drug	NNS	_	12	conj
16	commonly	commonly	RB	_	17	advmod
17	used	use	VBN	_	12	acl
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	treatment	treatment	NN	_	17	nmod
21	of	of	IN	_	22	case
22	asthma	asthma	NN	_	20	nmod
23	was	be	VBD	_	25	auxpass
24	not	not	RB	_	25	neg
25	associated	associate	VBN	_	0	ROOT
26	with	with	IN	_	30	case
27	any	any	DT	_	30	det
28	unusual	unusual	JJ	_	30	amod
29	adverse	adverse	JJ	_	30	amod
30	events	event	NNS	_	25	nmod
31	.	.	.	_	25	punct

1	However	however	RB	_	14	advmod
2	,	,	,	_	14	punct
3	ketoconazole	ketoconazole	NN	_	14	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	potent	potent	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	3A4	3a4	NN	_	7	nmod
12	,	,	,	_	3	punct
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	plasma	plasma	NN	_	16	compound
16	levels	level	NNS	_	14	dobj
17	of	of	IN	_	19	case
18	mometasone	mometasone	NN	_	19	compound
19	furoate	furoate	NN	_	16	nmod
20	during	during	IN	_	22	case
21	concomitant	concomitant	JJ	_	22	amod
22	dosing	dosing	NN	_	14	nmod
23	.	.	.	_	14	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	13	nsubjpass
6	between	between	IN	_	7	case
7	Neulasta	Neulasta	NNP	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	performed	perform	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Drugs	drug	NNS	_	6	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	lithium	lithium	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	potentiate	potentiate	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	release	release	NN	_	6	dobj
9	of	of	IN	_	10	case
10	neutrophils	neutrophil	NNS	_	8	nmod
11	;	;	:	_	6	punct

1	patients	patient	NNS	_	7	nsubj
2	receiving	receive	VBG	_	1	acl
3	lithium	lithium	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	Neulasta	neulasta	NN	_	3	conj
6	should	should	MD	_	7	aux
7	have	have	VB	_	0	ROOT
8	more	more	RBR	_	9	advmod
9	frequent	frequent	JJ	_	10	amod
10	monitoring	monitoring	NN	_	7	dobj
11	of	of	IN	_	13	case
12	neutrophil	neutrophil	NN	_	13	compound
13	counts	count	NNS	_	10	nmod
14	.	.	.	_	7	punct

1	Anticoagulants	Anticoagulants	NNPS	_	3	compound
2	Anabolic	Anabolic	NNP	_	3	compound
3	steroids	steroid	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	sensitivity	sensitivity	NN	_	5	dobj
7	to	to	TO	_	9	case
8	oral	oral	JJ	_	9	amod
9	anticoagulants	anticoagulant	NNS	_	6	nmod
10	.	.	.	_	5	punct

1	Dosage	dosage	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	anticoagulant	anticoagulant	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	to	to	TO	_	9	mark
8	be	be	VB	_	9	auxpass
9	decreased	decrease	VBN	_	6	xcomp
10	in	in	IN	_	13	mark
11	order	order	NN	_	10	mwe
12	to	to	TO	_	13	mark
13	maintain	maintain	VB	_	9	advcl
14	desired	desire	VBN	_	16	amod
15	prothrombin	prothrombin	NN	_	16	compound
16	time	time	NN	_	13	dobj
17	.	.	.	_	6	punct

1	Patients	patient	NNS	_	6	nsubj
2	receiving	receive	VBG	_	1	acl
3	oral	oral	JJ	_	5	amod
4	anticoagulant	anticoagulant	JJ	_	5	amod
5	therapy	therapy	NN	_	2	dobj
6	require	require	VBP	_	0	ROOT
7	close	close	JJ	_	8	amod
8	monitoring	monitoring	NN	_	6	dobj
9	,	,	,	_	8	punct
10	especially	especially	RB	_	15	advmod
11	when	when	WRB	_	15	advmod
12	anabolic	anabolic	JJ	_	13	amod
13	steroids	steroid	NNS	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	started	start	VBN	_	8	acl
16	or	or	CC	_	15	cc
17	stopped	stop	VBN	_	15	conj
18	.	.	.	_	6	punct

1	Warfarin	Warfarin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	A	A	NNP	_	5	compound
4	multidose	multidose	JJ	_	5	amod
5	study	study	NN	_	25	nsubj
6	of	of	IN	_	7	case
7	oxandrolone	oxandrolone	NN	_	5	nmod
8	,	,	,	_	5	punct
9	given	give	VBN	_	5	acl
10	as	as	IN	_	15	case
11	5	5	CD	_	14	compound
12	or	or	CC	_	11	cc
13	10	10	CD	_	11	conj
14	mg	mg	NN	_	15	amod
15	BID	BID	NNP	_	9	nmod
16	in	in	IN	_	19	case
17	15	15	CD	_	19	nummod
18	healthy	healthy	JJ	_	19	amod
19	subjects	subject	NNS	_	9	nmod
20	concurrently	concurrently	RB	_	21	advmod
21	treated	treat	VBN	_	19	acl
22	with	with	IN	_	23	case
23	warfarin	warfarin	NN	_	21	nmod
24	,	,	,	_	5	punct
25	resulted	result	VBD	_	1	dep
26	in	in	IN	_	29	case
27	a	a	DT	_	29	det
28	mean	mean	JJ	_	29	amod
29	increase	increase	NN	_	25	nmod
30	in	in	IN	_	31	case
31	S	s	NN	_	29	nmod
32	-	-	:	_	29	punct
33	warfarin	warfarin	NN	_	34	compound
34	half	half	NN	_	29	dep
35	-	-	:	_	34	punct
36	life	life	NN	_	34	dep
37	from	from	IN	_	41	case
38	26	26	CD	_	40	compound
39	to	to	TO	_	40	dep
40	48	48	CD	_	41	nummod
41	hours	hour	NNS	_	36	nmod
42	and	and	CC	_	41	cc
43	AUC	auc	NN	_	41	conj
44	from	from	IN	_	48	case
45	4.55	4.55	CD	_	47	compound
46	to	to	TO	_	47	dep
47	12.08	12.08	CD	_	48	nummod
48	ng	ng	NN	_	52	nmod
49	*	*	SYM	_	50	dep
50	hr	hr	NN	_	52	dep
51	/	/	:	_	52	punct
52	mL	ml	NN	_	34	nmod
53	:	:	:	_	29	punct
54	similar	similar	JJ	_	55	amod
55	increases	increase	NNS	_	29	dep
56	in	in	IN	_	57	case
57	R	r	NN	_	55	nmod
58	-	-	:	_	55	punct
59	warfarin	warfarin	NN	_	60	compound
60	half	half	NN	_	67	nsubjpass
61	-	-	:	_	60	punct
62	life	life	NN	_	60	dep
63	and	and	CC	_	62	cc
64	AUC	auc	NN	_	62	conj
65	were	be	VBD	_	67	auxpass
66	also	also	RB	_	67	advmod
67	detected	detect	VBN	_	55	dep
68	.	.	.	_	1	punct

1	Microscopic	microscopic	JJ	_	2	amod
2	hematuria	hematuria	NN	_	18	nsubjpass
3	(	(	CD	_	4	compound
4	9	9	CD	_	2	nummod
5	/	/	:	_	2	punct
6	15	15	CD	_	7	nummod
7	)	)	NN	_	2	dep
8	and	and	CC	_	7	cc
9	gingival	gingival	JJ	_	11	amod
10	bleeding	bleeding	NN	_	11	compound
11	(	(	NN	_	7	conj
12	1	1	CD	_	11	nummod
13	/	/	:	_	11	punct
14	15	15	CD	_	15	compound
15	)	)	CD	_	11	nummod
16	were	be	VBD	_	18	auxpass
17	also	also	RB	_	18	advmod
18	observed	observe	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	A	a	DT	_	5	det
2	5.5	5.5	CD	_	5	nummod
3	-	-	:	_	5	punct
4	fold	fold	JJ	_	5	amod
5	decrease	decrease	NN	_	34	nsubj
6	in	in	IN	_	10	case
7	the	the	DT	_	10	det
8	mean	mean	NN	_	10	compound
9	warfarin	warfarin	NN	_	10	compound
10	dose	dose	NN	_	5	nmod
11	from	from	IN	_	13	case
12	6.13	6.13	CD	_	13	nummod
13	mg	mg	NN	_	5	nmod
14	/	/	:	_	5	punct
15	day	day	NN	_	5	dep
16	to	to	TO	_	18	case
17	1.13	1.13	CD	_	18	nummod
18	mg	mg	NN	_	15	nmod
19	/	/	:	_	5	punct
20	day	day	NN	_	27	nmod:tmod
21	(	(	CD	_	20	nummod
22	approximately	approximately	RB	_	23	advmod
23	80	80	CD	_	27	nummod
24	-	-	:	_	27	punct
25	85	85	CD	_	26	compound
26	%	%	NN	_	27	amod
27	reduction	reduction	NN	_	5	dep
28	of	of	IN	_	31	case
29	warfarin	warfarin	NN	_	31	compound
30	dose	dose	NN	_	31	compound
31	)	)	NN	_	27	nmod
32	,	,	,	_	5	punct
33	was	be	VBD	_	34	cop
34	necessary	necessary	JJ	_	0	ROOT
35	to	to	TO	_	36	mark
36	maintain	maintain	VB	_	34	xcomp
37	a	a	DT	_	39	det
38	target	target	NN	_	39	compound
39	INR	inr	NN	_	36	dobj
40	of	of	IN	_	41	case
41	1.5	1.5	CD	_	39	nmod
42	.	.	.	_	34	punct

1	When	when	WRB	_	5	advmod
2	oxandrolone	oxandrolone	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	initiated	initiate	VBN	_	25	advcl
6	in	in	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	already	already	RB	_	10	advmod
10	receiving	receive	VBG	_	8	acl
11	treatment	treatment	NN	_	10	dobj
12	with	with	IN	_	13	case
13	warfarin	warfarin	NN	_	10	nmod
14	,	,	,	_	25	punct
15	the	the	DT	_	16	det
16	INR	inr	NN	_	25	nsubjpass
17	or	or	CC	_	16	cc
18	prothrombin	prothrombin	NN	_	19	compound
19	time	time	NN	_	16	conj
20	(	(	CD	_	22	nummod
21	PT	pt	NN	_	22	compound
22	)	)	NN	_	19	dep
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	monitored	monitor	VBN	_	0	ROOT
26	closely	closely	RB	_	25	advmod
27	and	and	CC	_	25	cc
28	the	the	DT	_	29	det
29	dose	dose	NN	_	44	nsubjpass
30	of	of	IN	_	31	case
31	warfarin	warfarin	NN	_	29	nmod
32	adjusted	adjust	VBN	_	29	acl
33	as	as	RB	_	34	advmod
34	necessary	necessary	JJ	_	32	xcomp
35	until	until	IN	_	39	case
36	a	a	DT	_	39	det
37	stable	stable	JJ	_	39	amod
38	target	target	NN	_	39	compound
39	INR	inr	NN	_	34	nmod
40	or	or	CC	_	39	cc
41	PT	pt	NN	_	39	conj
42	has	have	VBZ	_	44	aux
43	been	be	VBN	_	44	auxpass
44	achieved	achieve	VBN	_	25	conj
45	.	.	.	_	25	punct

1	Furthermore	furthermore	RB	_	26	advmod
2	,	,	,	_	26	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	26	nmod
5	receiving	receive	VBG	_	4	acl
6	both	both	CC	_	7	cc:preconj
7	drugs	drug	NNS	_	5	dobj
8	,	,	,	_	26	punct
9	careful	careful	JJ	_	10	amod
10	monitoring	monitoring	NN	_	26	nsubjpass
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	INR	inr	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	PT	pt	NN	_	13	conj
16	,	,	,	_	10	punct
17	and	and	CC	_	10	cc
18	adjustment	adjustment	NN	_	10	conj
19	of	of	IN	_	22	case
20	the	the	DT	_	22	det
21	warfarin	warfarin	NN	_	22	compound
22	dosage	dosage	NN	_	18	nmod
23	if	if	IN	_	24	mark
24	indicated	indicate	VBN	_	10	dep
25	are	be	VBP	_	26	auxpass
26	recommended	recommend	VBN	_	0	ROOT
27	when	when	WRB	_	32	advmod
28	the	the	DT	_	30	det
29	oxandrolone	oxandrolone	NN	_	30	compound
30	dose	dose	NN	_	32	nsubjpass
31	is	be	VBZ	_	32	auxpass
32	changed	change	VBN	_	26	advcl
33	or	or	CC	_	32	cc
34	discontinued	discontinue	VBN	_	32	conj
35	.	.	.	_	26	punct

1	Patients	patient	NNS	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	be	be	VB	_	5	auxpass
4	closely	closely	RB	_	5	advmod
5	monitored	monitor	VBN	_	0	ROOT
6	for	for	IN	_	7	case
7	signs	sign	NNS	_	5	nmod
8	and	and	CC	_	7	cc
9	symptoms	symptom	NNS	_	7	conj
10	of	of	IN	_	12	case
11	occult	occult	NN	_	12	compound
12	bleeding	bleeding	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Oral	oral	JJ	_	3	amod
2	hypoglycemic	hypoglycemic	JJ	_	3	amod
3	agents	agent	NNS	_	0	ROOT
4	Oxandrolone	Oxandrolone	NNP	_	6	nsubj
5	may	may	MD	_	6	aux
6	inhibit	inhibit	VB	_	3	acl:relcl
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	6	dobj
9	of	of	IN	_	12	case
10	oral	oral	JJ	_	12	amod
11	hypoglycemic	hypoglycemic	JJ	_	12	amod
12	agents	agent	NNS	_	8	nmod
13	.	.	.	_	3	punct

1	Adrenal	adrenal	JJ	_	2	amod
2	steroids	steroid	NNS	_	19	nsubj
3	or	or	CC	_	2	cc
4	ACTH	acth	NN	_	2	conj
5	In	in	IN	_	6	case
6	patients	patient	NNS	_	2	nmod
7	with	with	IN	_	8	case
8	edema	edema	NN	_	6	nmod
9	,	,	,	_	2	punct
10	concomitant	concomitant	JJ	_	11	amod
11	administration	administration	NN	_	2	appos
12	with	with	IN	_	15	case
13	adrenal	adrenal	JJ	_	15	amod
14	cortical	cortical	JJ	_	15	amod
15	steroids	steroid	NNS	_	11	nmod
16	or	or	CC	_	15	cc
17	ACTH	acth	NN	_	15	conj
18	may	may	MD	_	19	aux
19	increase	increase	VB	_	0	ROOT
20	the	the	DT	_	21	det
21	edema	edema	NN	_	19	dobj
22	.	.	.	_	19	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	test	test	NN	_	5	compound
5	interactions	interaction	NNS	_	0	ROOT
6	Anabolic	anabolic	JJ	_	7	amod
7	steroids	steroid	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	decrease	decrease	VB	_	5	acl:relcl
10	levels	level	NNS	_	9	dobj
11	of	of	IN	_	12	case
12	thyroxine	thyroxine	NN	_	10	nmod
13	-	-	:	_	9	punct
14	binding	bind	VBG	_	9	dep
15	globulin	globulin	NN	_	14	dobj
16	,	,	,	_	14	punct
17	resulting	result	VBG	_	14	conj
18	in	in	IN	_	23	case
19	decreased	decrease	VBN	_	23	amod
20	total	total	JJ	_	23	amod
21	T4	t4	NN	_	23	compound
22	serum	serum	NN	_	23	compound
23	levels	level	NNS	_	17	nmod
24	and	and	CC	_	14	cc
25	increased	increase	VBD	_	27	amod
26	resin	resin	NN	_	27	compound
27	uptake	uptake	NN	_	14	conj
28	of	of	IN	_	29	case
29	T3	t3	NN	_	27	nmod
30	and	and	CC	_	29	cc
31	T4	t4	NN	_	29	conj
32	.	.	.	_	5	punct

1	Free	Free	NNP	_	4	compound
2	thyroid	thyroid	NN	_	4	compound
3	hormone	hormone	NN	_	4	compound
4	levels	level	NNS	_	5	nsubj
5	remain	remain	VBP	_	0	ROOT
6	unchanged	unchanged	JJ	_	5	xcomp
7	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	13	nmod
3	,	,	,	_	13	punct
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	13	nsubj
6	in	in	IN	_	7	case
7	PBI	pbi	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	radioactive	radioactive	JJ	_	11	amod
10	iodine	iodine	NN	_	11	compound
11	uptake	uptake	NN	_	7	conj
12	may	may	MD	_	13	aux
13	occur	occur	VB	_	0	ROOT
14	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	agents	agent	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	certain	certain	JJ	_	7	amod
7	actions	action	NNS	_	5	dobj
8	or	or	CC	_	7	cc
9	side	side	JJ	_	10	amod
10	effects	effect	NNS	_	7	conj
11	of	of	IN	_	13	case
12	anticholinergic	anticholinergic	JJ	_	13	amod
13	drugs	drug	NNS	_	10	nmod
14	:	:	:	_	5	punct
15	amantadine	amantadine	NN	_	5	dep
16	,	,	,	_	15	punct
17	antiarrhythmic	antiarrhythmic	JJ	_	18	amod
18	agents	agent	NNS	_	15	appos
19	of	of	IN	_	22	case
20	class	class	NN	_	22	compound
21	I	i	CD	_	22	nummod
22	(	(	CD	_	18	nmod
23	e	e	LS	_	18	dep
24	.	.	.	_	23	punct
25	g	g	NN	_	23	dep
26	.	.	.	_	25	punct
27	,	,	,	_	25	punct
28	quinidine	quinidine	NN	_	29	compound
29	)	)	NN	_	25	conj
30	,	,	,	_	25	punct
31	antihistamines	antihistamine	NNS	_	25	conj
32	,	,	,	_	25	punct
33	antipsychotic	antipsychotic	JJ	_	34	amod
34	agents	agent	NNS	_	35	nsubj
35	(	(	VBP	_	25	acl:relcl
36	e	e	LS	_	35	dobj
37	.	.	.	_	36	punct
38	g	g	NN	_	36	dep
39	.	.	.	_	38	punct
40	,	,	,	_	38	punct
41	phenothiazines	phenothiazine	NNS	_	42	nsubj
42	)	)	VBP	_	38	dep
43	,	,	,	_	42	punct
44	benzodiazepines	benzodiazepine	NNS	_	42	conj
45	,	,	,	_	42	punct
46	MAO	mao	NN	_	47	compound
47	inhibitors	inhibitor	NNS	_	42	conj
48	,	,	,	_	42	punct
49	narcotic	narcotic	JJ	_	50	amod
50	analgesics	analgesic	NNS	_	51	nsubj
51	(	(	VBP	_	42	ccomp
52	e	e	LS	_	51	dobj
53	.	.	.	_	52	punct
54	g	g	NN	_	52	dep
55	.	.	.	_	54	punct
56	,	,	,	_	54	punct
57	meperidine	meperidine	NN	_	58	compound
58	)	)	NN	_	54	conj
59	,	,	,	_	54	punct
60	nitrates	nitrate	NNS	_	54	conj
61	and	and	CC	_	54	cc
62	nitrites	nitrite	NNS	_	54	conj
63	,	,	,	_	54	punct
64	sympathomimetic	sympathomimetic	JJ	_	65	amod
65	agents	agent	NNS	_	54	conj
66	,	,	,	_	54	punct
67	tricyclic	tricyclic	JJ	_	68	amod
68	antidepressants	antidepressant	NNS	_	54	conj
69	,	,	,	_	54	punct
70	and	and	CC	_	54	cc
71	other	other	JJ	_	72	amod
72	drugs	drug	NNS	_	73	nsubj
73	having	have	VBG	_	54	conj
74	anticholinergic	anticholinergic	JJ	_	75	amod
75	activity	activity	NN	_	73	dobj
76	.	.	.	_	5	punct

1	Anticholinergics	anticholinergic	NNS	_	2	nsubj
2	antagonize	antagonize	VBP	_	0	ROOT
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	7	case
6	antiglaucoma	antiglaucoma	NN	_	7	compound
7	agents	agent	NNS	_	4	nmod
8	.	.	.	_	2	punct

1	Anticholinergic	anticholinergic	JJ	_	2	amod
2	drugs	drug	NNS	_	12	nsubj
3	in	in	IN	_	5	case
4	the	the	DT	_	5	det
5	presence	presence	NN	_	2	nmod
6	of	of	IN	_	9	case
7	increased	increase	VBN	_	9	amod
8	intraocular	intraocular	JJ	_	9	amod
9	pressure	pressure	NN	_	5	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	hazardous	hazardous	JJ	_	0	ROOT
13	when	when	WRB	_	14	advmod
14	taken	take	VBN	_	12	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	agents	agent	NNS	_	14	nmod
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	corticosteroids	corticosteroid	NNS	_	17	nmod
21	.	.	.	_	12	punct

1	Anticholinergic	anticholinergic	JJ	_	2	amod
2	agents	agent	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	affect	affect	VB	_	0	ROOT
5	gastrointestinal	gastrointestinal	JJ	_	6	amod
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	9	case
8	various	various	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	such	such	JJ	_	14	mark
12	as	as	IN	_	11	mwe
13	slowly	slowly	RB	_	14	advmod
14	dissolving	dissolve	VBG	_	9	acl
15	dosage	dosage	JJ	_	16	amod
16	forms	form	NNS	_	14	dobj
17	of	of	IN	_	18	case
18	digoxin	digoxin	NN	_	16	nmod
19	;	;	:	_	4	punct

1	increased	increase	VBN	_	4	amod
2	serum	serum	NN	_	4	compound
3	digoxin	digoxin	NN	_	4	compound
4	concentrations	concentration	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	.	.	.	_	6	punct

1	Anticholinergic	anticholinergic	JJ	_	2	amod
2	drugs	drug	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	antagonize	antagonize	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	that	that	WDT	_	10	nsubj
10	alter	alter	VBP	_	8	acl:relcl
11	gastrointestinal	gastrointestinal	JJ	_	12	amod
12	motility	motility	NN	_	10	dobj
13	,	,	,	_	12	punct
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	metoclopramide	metoclopramide	NN	_	12	nmod
17	.	.	.	_	4	punct

1	Because	because	IN	_	4	mark
2	antacids	antacid	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	interfere	interfere	VB	_	19	advcl
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	4	nmod
8	of	of	IN	_	10	case
9	anticholinergic	anticholinergic	JJ	_	10	amod
10	agents	agent	NNS	_	7	nmod
11	,	,	,	_	19	punct
12	simultaneous	simultaneous	JJ	_	13	amod
13	use	use	NN	_	19	nsubjpass
14	of	of	IN	_	16	case
15	these	these	DT	_	16	det
16	drugs	drug	NNS	_	13	nmod
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	avoided	avoid	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	The	the	DT	_	3	det
2	inhibiting	inhibiting	JJ	_	3	amod
3	effects	effect	NNS	_	13	nsubjpass
4	of	of	IN	_	6	case
5	anticholinergic	anticholinergic	JJ	_	6	amod
6	drugs	drug	NNS	_	3	nmod
7	on	on	IN	_	11	case
8	gastric	gastric	JJ	_	11	amod
9	hydrochloric	hydrochloric	JJ	_	11	amod
10	acid	acid	NN	_	11	compound
11	secretion	secretion	NN	_	3	nmod
12	are	be	VBP	_	13	auxpass
13	antagonized	antagonize	VBN	_	0	ROOT
14	by	by	IN	_	15	case
15	agents	agent	NNS	_	13	nmod
16	used	use	VBN	_	15	acl
17	to	to	TO	_	18	mark
18	treat	treat	VB	_	16	xcomp
19	achlorhydria	achlorhydria	NN	_	18	dobj
20	and	and	CC	_	19	cc
21	those	those	DT	_	19	conj
22	used	use	VBN	_	21	acl
23	to	to	TO	_	24	mark
24	test	test	VB	_	22	xcomp
25	gastric	gastric	JJ	_	26	amod
26	secretion	secretion	NN	_	24	dobj
27	.	.	.	_	13	punct

1	Since	since	IN	_	7	mark
2	Celontin	Celontin	NNP	_	5	compound
3	(	(	CD	_	5	nummod
4	methsuximide	methsuximide	NN	_	5	compound
5	)	)	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	interact	interact	VB	_	24	advcl
8	with	with	IN	_	12	case
9	concurrently	concurrently	RB	_	10	advmod
10	administered	administer	VBN	_	12	amod
11	antiepileptic	antiepileptic	JJ	_	12	amod
12	drugs	drug	NNS	_	7	nmod
13	,	,	,	_	24	punct
14	periodic	periodic	JJ	_	17	amod
15	serum	serum	NN	_	17	compound
16	level	level	NN	_	17	compound
17	determinations	determination	NNS	_	24	nsubj
18	of	of	IN	_	20	case
19	these	these	DT	_	20	det
20	drugs	drug	NNS	_	17	nmod
21	may	may	MD	_	24	aux
22	be	be	VB	_	24	cop
23	necessary	necessary	JJ	_	24	amod
24	(	(	NN	_	28	nsubj
25	eg	eg	FW	_	26	compound
26	methsuximide	methsuximide	FW	_	24	advmod
27	may	may	MD	_	28	aux
28	increase	increase	VB	_	0	ROOT
29	the	the	DT	_	31	det
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	28	dobj
32	of	of	IN	_	33	case
33	phenytoin	phenytoin	NN	_	31	nmod
34	and	and	CC	_	33	cc
35	phenobarbital	phenobarbital	JJ	_	36	amod
36	)	)	NN	_	33	conj
37	.	.	.	_	28	punct

1	Diuretics	diuretic	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Furosemide	furosemide	NN	_	14	nsubj
4	and	and	CC	_	3	cc
5	probably	probably	RB	_	8	advmod
6	other	other	JJ	_	8	amod
7	loop	loop	NN	_	8	compound
8	diuretics	diuretic	NNS	_	3	conj
9	given	give	VBN	_	3	acl
10	concomitantly	concomitantly	RB	_	9	advmod
11	with	with	IN	_	12	case
12	metolazone	metolazone	NN	_	9	nmod
13	can	can	MD	_	14	aux
14	cause	cause	VB	_	1	appos
15	unusually	unusually	RB	_	16	advmod
16	large	large	JJ	_	19	amod
17	or	or	CC	_	16	cc
18	prolonged	prolonged	JJ	_	16	conj
19	losses	loss	NNS	_	14	dobj
20	of	of	IN	_	21	case
21	fluid	fluid	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	electrolytes	electrolyte	NNS	_	21	conj
24	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	Antihypertensives	antihypertensive	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	When	when	WRB	_	8	advmod
5	MYKROX	MYKROX	NNP	_	6	compound
6	Tablets	tablet	NNS	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	17	advcl
9	with	with	IN	_	12	case
10	other	other	JJ	_	12	amod
11	antihypertensive	antihypertensive	JJ	_	12	amod
12	drugs	drug	NNS	_	8	nmod
13	,	,	,	_	17	punct
14	care	care	NN	_	17	nsubjpass
15	must	must	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	taken	take	VBN	_	2	dep
18	,	,	,	_	17	punct
19	especially	especially	RB	_	22	advmod
20	during	during	IN	_	22	case
21	initial	initial	JJ	_	22	amod
22	therapy	therapy	NN	_	17	nmod
23	.	.	.	_	2	punct

1	Dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	8	nsubj
3	of	of	IN	_	5	case
4	other	other	JJ	_	5	amod
5	antihypertensives	antihypertensive	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	necessary	necessary	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	Alcohol	alcohol	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	Barbiturates	Barbiturates	NNP	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	Narcotics	Narcotics	NNP	_	1	conj
7	:	:	:	_	1	punct
8	The	the	DT	_	10	det
9	hypotensive	hypotensive	JJ	_	10	amod
10	effects	effect	NNS	_	16	nsubjpass
11	of	of	IN	_	13	case
12	these	these	DT	_	13	det
13	drugs	drug	NNS	_	10	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	potentiated	potentiate	VBN	_	1	dep
17	by	by	IN	_	20	case
18	the	the	DT	_	20	det
19	volume	volume	NN	_	20	compound
20	contraction	contraction	NN	_	16	nmod
21	that	that	WDT	_	24	nsubjpass
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	associated	associate	VBN	_	20	acl:relcl
25	with	with	IN	_	27	case
26	metolazone	metolazone	NN	_	27	compound
27	therapy	therapy	NN	_	24	nmod
28	.	.	.	_	1	punct

1	Digitalis	digitalis	NN	_	2	compound
2	Glycosides	glycoside	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Diuretic	diuretic	JJ	_	7	amod
5	-	-	:	_	7	punct
6	induced	induce	VBN	_	7	amod
7	hypokalemia	hypokalemia	NN	_	9	nsubj
8	can	can	MD	_	9	aux
9	increase	increase	VB	_	2	dep
10	the	the	DT	_	11	det
11	sensitivity	sensitivity	NN	_	9	dobj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	myocardium	myocardium	NN	_	11	nmod
15	to	to	TO	_	16	case
16	digitalis	digitalis	NN	_	11	nmod
17	.	.	.	_	2	punct

1	Serious	serious	JJ	_	2	amod
2	arrhythmias	arrhythmia	NNS	_	4	nsubj
3	can	can	MD	_	4	aux
4	result	result	VB	_	0	ROOT
5	.	.	.	_	4	punct

1	Corticosteroids	corticosteroid	NNS	_	0	ROOT
2	or	or	CC	_	1	cc
3	ACTH	acth	NN	_	1	conj
4	:	:	:	_	1	punct
5	May	May	NNP	_	6	nsubj
6	increase	increase	VB	_	1	dep
7	the	the	DT	_	8	det
8	risk	risk	NN	_	6	dobj
9	of	of	IN	_	10	case
10	hypokalemia	hypokalemia	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	increase	increase	NN	_	13	compound
13	salt	salt	NN	_	10	conj
14	and	and	CC	_	10	cc
15	water	water	NN	_	16	compound
16	retention	retention	NN	_	10	conj
17	.	.	.	_	1	punct

1	Lithium	lithium	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Serum	serum	NN	_	5	compound
4	lithium	lithium	NN	_	5	compound
5	levels	level	NNS	_	7	nsubj
6	may	may	MD	_	7	aux
7	increase	increase	VB	_	1	parataxis
8	.	.	.	_	1	punct

1	Curariform	Curariform	NNP	_	2	compound
2	Drugs	Drugs	NNPS	_	0	ROOT
3	:	:	:	_	2	punct
4	Diuretic	diuretic	JJ	_	7	amod
5	-	-	:	_	7	punct
6	induced	induce	VBN	_	7	amod
7	hypokalemia	hypokalemia	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	enhance	enhance	VB	_	2	dep
10	neuromuscular	neuromuscular	JJ	_	12	amod
11	blocking	blocking	NN	_	12	compound
12	effects	effect	NNS	_	16	nsubj
13	of	of	IN	_	15	case
14	curariform	curariform	NN	_	15	compound
15	drugs	drug	NNS	_	12	nmod
16	(	(	VBP	_	9	ccomp
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	tubocurarine	tubocurarine	NN	_	28	nmod
20	)	)	CD	_	19	nummod
21	the	the	DT	_	24	det
22	most	most	RBS	_	23	advmod
23	serious	serious	JJ	_	24	amod
24	effect	effect	NN	_	28	nsubj
25	would	would	MD	_	28	aux
26	be	be	VB	_	28	cop
27	respiratory	respiratory	JJ	_	28	amod
28	depression	depression	NN	_	16	ccomp
29	which	which	WDT	_	31	nsubj
30	could	could	MD	_	31	aux
31	proceed	proceed	VB	_	28	acl:relcl
32	to	to	TO	_	33	case
33	apnea	apnea	NN	_	31	nmod
34	.	.	.	_	2	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	cop
6	advisable	advisable	JJ	_	0	ROOT
7	to	to	TO	_	8	mark
8	discontinue	discontinue	VB	_	6	xcomp
9	MYKROX	MYKROX	NNP	_	10	compound
10	Tablets	Tablets	NNPS	_	8	dobj
11	three	three	CD	_	12	nummod
12	days	day	NNS	_	8	nmod
13	before	before	IN	_	12	case
14	elective	elective	JJ	_	15	amod
15	surgery	surgery	NN	_	12	dep
16	.	.	.	_	6	punct

1	Salicylates	salicylate	NNS	_	0	ROOT
2	and	and	CC	_	1	cc
3	Other	other	JJ	_	4	amod
4	Non	Non	NNP	_	1	conj
5	-	-	:	_	1	punct
6	Steroidal	steroidal	JJ	_	7	amod
7	Anti	anti	NN	_	1	dep
8	-	-	:	_	7	punct
9	Inflammatory	inflammatory	JJ	_	10	amod
10	Drugs	drug	NNS	_	7	dep
11	:	:	:	_	1	punct
12	May	May	NNP	_	13	nsubj
13	decrease	decrease	VB	_	1	dep
14	the	the	DT	_	16	det
15	antihypertensive	antihypertensive	JJ	_	16	amod
16	effects	effect	NNS	_	13	dobj
17	of	of	IN	_	19	case
18	MYKROX	MYKROX	NNP	_	19	compound
19	Tablets	Tablets	NNPS	_	16	nmod
20	.	.	.	_	1	punct

1	Sympathomimetics	sympathomimetic	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Metolazone	metolazone	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	decrease	decrease	VB	_	1	dep
6	arterial	arterial	JJ	_	7	amod
7	responsiveness	responsiveness	NN	_	5	dobj
8	to	to	TO	_	9	case
9	norepinephrine	norepinephrine	NN	_	7	nmod
10	,	,	,	_	5	punct
11	but	but	CC	_	5	cc
12	this	this	DT	_	13	det
13	diminution	diminution	NN	_	16	nsubj
14	is	be	VBZ	_	16	cop
15	not	not	RB	_	16	neg
16	sufficient	sufficient	JJ	_	5	conj
17	to	to	TO	_	18	mark
18	preclude	preclude	VB	_	16	xcomp
19	effectiveness	effectiveness	NN	_	18	dobj
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	pressor	pressor	NN	_	23	compound
23	agent	agent	NN	_	19	nmod
24	for	for	IN	_	26	case
25	therapeutic	therapeutic	JJ	_	26	amod
26	use	use	NN	_	18	nmod
27	.	.	.	_	1	punct

1	Methenamine	Methenamine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Efficacy	Efficacy	NNP	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	decreased	decrease	VBN	_	1	dep
7	due	due	JJ	_	11	case
8	to	to	TO	_	11	case
9	urinary	urinary	JJ	_	11	amod
10	alkalizing	alkalize	VBG	_	11	amod
11	effect	effect	NN	_	6	advcl
12	of	of	IN	_	13	case
13	metolazone	metolazone	NN	_	11	nmod
14	.	.	.	_	1	punct

1	Anticoagulants	Anticoagulants	NNPS	_	0	ROOT
2	:	:	:	_	1	punct
3	Metolazone	Metolazone	NNP	_	15	nsubj
4	,	,	,	_	3	punct
5	as	as	RB	_	3	cc
6	well	well	RB	_	5	mwe
7	as	as	IN	_	5	mwe
8	other	other	JJ	_	9	amod
9	thiazide	thiazide	NN	_	3	conj
10	-	-	:	_	9	punct
11	like	like	IN	_	12	case
12	diuretics	diuretic	NNS	_	9	nmod
13	,	,	,	_	3	punct
14	may	may	MD	_	15	aux
15	affect	affect	VB	_	1	dep
16	the	the	DT	_	18	det
17	hypoprothrombinemic	hypoprothrombinemic	JJ	_	18	amod
18	response	response	NN	_	15	dobj
19	to	to	TO	_	20	case
20	anticoagulants	anticoagulant	NNS	_	18	nmod
21	;	;	:	_	15	punct

1	dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	necessary	necessary	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Coadministration	Coadministration	NNP	_	6	nsubj
2	of	of	IN	_	3	case
3	TRITEC	TRITEC	NNP	_	1	nmod
4	with	with	IN	_	5	case
5	clarithromycin	clarithromycin	NN	_	1	nmod
6	resulted	result	VBD	_	0	ROOT
7	in	in	IN	_	11	case
8	increased	increase	VBN	_	11	amod
9	plasma	plasma	NN	_	11	compound
10	ranitidine	ranitidine	NN	_	11	compound
11	concentrations	concentration	NNS	_	6	nmod
12	(	(	VBP	_	6	dep
13	57	57	CD	_	14	nummod
14	%	%	NN	_	12	dobj
15	)	)	CD	_	14	nummod
16	,	,	,	_	12	punct
17	increased	increase	VBN	_	21	amod
18	plasma	plasma	NN	_	21	compound
19	bismuth	bismuth	NN	_	21	compound
20	trough	trough	NN	_	21	compound
21	concentrations	concentration	NNS	_	22	nsubj
22	(	(	VBP	_	12	conj
23	48	48	CD	_	24	nummod
24	%	%	NN	_	22	dobj
25	)	)	CD	_	24	nummod
26	,	,	,	_	12	punct
27	and	and	CC	_	12	cc
28	increased	increase	VBD	_	12	conj
29	14	14	CD	_	31	nummod
30	-	-	:	_	31	punct
31	hydroxy	hydroxy	NN	_	28	dobj
32	-	-	:	_	31	punct
33	clarithromycin	clarithromycin	NN	_	35	compound
34	plasma	plasma	NN	_	35	compound
35	concentrations	concentration	NNS	_	36	nsubj
36	(	(	VBP	_	31	dep
37	31	31	CD	_	38	nummod
38	%	%	NN	_	36	dobj
39	)	)	CD	_	38	nummod
40	.	.	.	_	6	punct

1	Coadministration	coadministration	NN	_	4	nsubj
2	with	with	IN	_	3	case
3	aspirin	aspirin	NN	_	1	nmod
4	results	result	VBZ	_	0	ROOT
5	in	in	IN	_	8	case
6	a	a	DT	_	8	det
7	slight	slight	JJ	_	8	amod
8	decrease	decrease	NN	_	4	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	rate	rate	NN	_	8	nmod
12	of	of	IN	_	14	case
13	salicylate	salicylate	NN	_	14	compound
14	absorption	absorption	NN	_	11	nmod
15	that	that	WDT	_	18	nsubj
16	is	be	VBZ	_	18	cop
17	clinically	clinically	RB	_	18	advmod
18	unimportant	unimportant	JJ	_	11	acl:relcl
19	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	0	ROOT
2	with	with	IN	_	5	case
3	a	a	DT	_	5	det
4	high	high	JJ	_	5	amod
5	dose	dose	NN	_	1	nmod
6	of	of	IN	_	12	case
7	antacid	antacid	NN	_	12	compound
8	(	(	NN	_	12	compound
9	170	170	CD	_	12	nummod
10	mEq	meq	NN	_	12	compound
11	)	)	CD	_	12	nummod
12	results	result	NNS	_	5	nmod
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	28	28	CD	_	16	compound
16	%	%	NN	_	17	amod
17	decrease	decrease	NN	_	1	nmod
18	in	in	IN	_	20	case
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	17	nmod
21	of	of	IN	_	22	case
22	ranitidine	ranitidine	NN	_	20	nmod
23	and	and	CC	_	1	cc
24	may	may	MD	_	25	aux
25	decrease	decrease	VB	_	1	conj
26	plasma	plasma	NN	_	27	compound
27	concentrations	concentration	NNS	_	25	dobj
28	of	of	IN	_	29	case
29	bismuth	bismuth	NN	_	27	nmod
30	from	from	IN	_	31	case
31	TRITEC	TRITEC	NNP	_	25	nmod
32	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	clinically	clinically	RB	_	5	advmod
5	insignificant	insignificant	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	For	for	IN	_	2	case
2	information	information	NN	_	10	nmod
3	on	on	IN	_	5	case
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	2	nmod
6	associated	associate	VBN	_	5	acl
7	with	with	IN	_	8	case
8	ranitidine	ranitidine	NN	_	6	nmod
9	,	,	,	_	10	punct
10	refer	refer	VBP	_	0	ROOT
11	to	to	TO	_	15	case
12	the	the	DT	_	15	det
13	ZANTAC	ZANTAC	NNP	_	15	compound
14	package	package	NN	_	15	compound
15	insert	insert	NN	_	10	nmod
16	.	.	.	_	10	punct

1	Ropivacaine	ropivacaine	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	other	other	JJ	_	12	amod
11	local	local	JJ	_	12	amod
12	anesthetics	anesthetic	NNS	_	9	dobj
13	or	or	CC	_	12	cc
14	agents	agent	NNS	_	12	conj
15	structurally	structurally	RB	_	16	advmod
16	related	related	JJ	_	8	amod
17	to	to	TO	_	18	case
18	amide	amide	NN	_	16	nmod
19	-	-	:	_	18	punct
20	type	type	NN	_	22	compound
21	local	local	JJ	_	22	amod
22	anesthetics	anesthetic	NNS	_	18	dep
23	,	,	,	_	4	punct
24	since	since	IN	_	32	mark
25	the	the	DT	_	27	det
26	toxic	toxic	JJ	_	27	amod
27	effects	effect	NNS	_	32	nsubj
28	of	of	IN	_	30	case
29	these	these	DT	_	30	det
30	drugs	drug	NNS	_	27	nmod
31	are	be	VBP	_	32	cop
32	additive	additive	JJ	_	4	advcl
33	.	.	.	_	4	punct

1	Cytochrome	cytochrome	NN	_	2	compound
2	P4501A2	p4501a2	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	involved	involve	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	formation	formation	NN	_	4	nmod
8	of	of	IN	_	12	case
9	3	3	LS	_	12	dep
10	-	-	:	_	12	punct
11	hydroxy	hydroxy	NN	_	12	compound
12	ropivacaine	ropivacaine	NN	_	7	nmod
13	,	,	,	_	12	punct
14	the	the	DT	_	16	det
15	major	major	JJ	_	16	amod
16	metabolite	metabolite	NN	_	12	appos
17	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vivo	vivo	FW	_	10	advmod
3	,	,	,	_	10	punct
4	the	the	DT	_	6	det
5	plasma	plasma	NN	_	6	compound
6	clearance	clearance	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	ropivacaine	ropivacaine	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	by	by	IN	_	13	case
12	70	70	CD	_	13	nummod
13	%	%	NN	_	10	nmod
14	during	during	IN	_	15	case
15	coadministration	coadministration	NN	_	10	nmod
16	of	of	IN	_	17	case
17	fluvoxamine	fluvoxamine	NN	_	15	nmod
18	(	(	CD	_	19	compound
19	25	25	CD	_	17	nummod
20	mg	mg	NN	_	21	compound
21	bid	bid	NN	_	17	dep
22	for	for	IN	_	24	case
23	2	2	CD	_	24	nummod
24	days	day	NNS	_	10	nmod
25	)	)	RB	_	24	advmod
26	,	,	,	_	10	punct
27	a	a	DT	_	32	det
28	selective	selective	JJ	_	32	amod
29	and	and	CC	_	28	cc
30	potent	potent	JJ	_	28	conj
31	CYP1A2	cyp1a2	NN	_	32	compound
32	inhibitor	inhibitor	NN	_	10	nmod:npmod
33	.	.	.	_	10	punct

1	Thus	thus	RB	_	20	advmod
2	strong	strong	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	20	nsubj
4	of	of	IN	_	6	case
5	cytochrome	cytochrome	NN	_	6	compound
6	P4501A2	p4501a2	NN	_	3	nmod
7	,	,	,	_	3	punct
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	fluvoxamine	fluvoxamine	NN	_	3	nmod
11	,	,	,	_	3	punct
12	given	give	VBN	_	3	acl
13	concomitantly	concomitantly	RB	_	12	advmod
14	during	during	IN	_	15	case
15	administration	administration	NN	_	12	nmod
16	of	of	IN	_	17	case
17	Ropivacaine	Ropivacaine	NNP	_	15	nmod
18	,	,	,	_	3	punct
19	can	can	MD	_	20	aux
20	interact	interact	VB	_	0	ROOT
21	with	with	IN	_	23	mark
22	Ropivacaine	ropivacaine	JJ	_	23	amod
23	leading	lead	VBG	_	20	advcl
24	to	to	TO	_	28	case
25	increased	increase	VBN	_	28	amod
26	ropivacaine	ropivacaine	NN	_	28	compound
27	plasma	plasma	NN	_	28	compound
28	levels	level	NNS	_	23	nmod
29	.	.	.	_	20	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	9	advmod
6	CYP1A2	cyp1a2	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	coadministered	coadminister	VBN	_	4	advcl
10	.	.	.	_	4	punct

1	Possible	possible	JJ	_	2	amod
2	interactions	interaction	NNS	_	21	nsubj
3	with	with	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	known	know	VBN	_	4	acl
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	metabolized	metabolize	VBN	_	5	xcomp
9	by	by	IN	_	10	case
10	CYP1A2	cyp1a2	NN	_	8	nmod
11	via	via	IN	_	13	case
12	competitive	competitive	JJ	_	13	amod
13	inhibition	inhibition	NN	_	8	nmod
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	theophylline	theophylline	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	imipramine	imipramine	NN	_	16	conj
19	may	may	MD	_	21	aux
20	also	also	RB	_	21	advmod
21	occur	occur	VB	_	0	ROOT
22	.	.	.	_	21	punct

1	Coadministration	coadministration	NN	_	28	nsubj
2	of	of	IN	_	7	case
3	a	a	DT	_	7	det
4	selective	selective	JJ	_	7	amod
5	and	and	CC	_	4	cc
6	potent	potent	JJ	_	4	conj
7	inhibitor	inhibitor	NN	_	1	nmod
8	of	of	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	,	,	,	_	7	punct
11	ketoconazole	ketoconazole	NN	_	15	compound
12	(	(	NN	_	15	compound
13	100	100	CD	_	14	compound
14	mg	mg	NN	_	15	amod
15	bid	bid	NN	_	7	conj
16	for	for	IN	_	18	case
17	2	2	CD	_	18	nummod
18	days	day	NNS	_	15	nmod
19	with	with	IN	_	21	case
20	ropivacaine	ropivacaine	NN	_	21	compound
21	infusion	infusion	NN	_	18	nmod
22	administered	administer	VBN	_	24	amod
23	1	1	CD	_	24	nummod
24	hour	hour	NN	_	21	dep
25	after	after	IN	_	27	case
26	ketoconazole	ketoconazole	NN	_	27	compound
27	)	)	NN	_	15	nmod
28	caused	cause	VBD	_	0	ROOT
29	a	a	DT	_	32	det
30	15	15	CD	_	31	compound
31	%	%	NN	_	32	amod
32	reduction	reduction	NN	_	28	dobj
33	in	in	IN	_	38	case
34	in	in	IN	_	38	case
35	-	-	:	_	38	punct
36	vivo	vivo	FW	_	38	compound
37	plasma	plasma	NN	_	38	compound
38	clearance	clearance	NN	_	32	nmod
39	of	of	IN	_	40	case
40	ropivacaine	ropivacaine	NN	_	38	nmod
41	.	.	.	_	28	punct

1	Additives	additive	NNS	_	4	nsubj
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	cop
4	incompatible	incompatible	JJ	_	0	ROOT
5	;	;	:	_	4	punct

1	norepinephrine	norepinephrine	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	dobutamine	dobutamine	NN	_	1	conj
4	are	be	VBP	_	5	cop
5	incompatible	incompatible	JJ	_	0	ROOT
6	with	with	IN	_	9	case
7	sodium	sodium	NN	_	9	compound
8	bicarbonate	bicarbonate	NN	_	9	compound
9	solution	solution	NN	_	5	nmod
10	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	sodium	sodium	NN	_	5	compound
5	bicarbonate	bicarbonate	NN	_	2	nmod
6	to	to	TO	_	8	case
7	parenteral	parenteral	JJ	_	8	amod
8	solutions	solution	NNS	_	2	nmod
9	containing	contain	VBG	_	8	acl
10	calcium	calcium	NN	_	9	dobj
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	avoided	avoid	VBN	_	0	ROOT
14	,	,	,	_	13	punct
15	except	except	IN	_	21	mark
16	where	where	WRB	_	21	advmod
17	compatibility	compatibility	NN	_	21	nsubjpass
18	has	have	VBZ	_	21	aux
19	been	be	VBN	_	21	auxpass
20	previously	previously	RB	_	21	advmod
21	established	establish	VBN	_	13	advcl
22	.	.	.	_	13	punct

1	Precipitation	precipitation	NN	_	5	nsubj
2	or	or	CC	_	1	cc
3	haze	haze	NN	_	1	conj
4	may	may	MD	_	5	aux
5	result	result	VB	_	0	ROOT
6	from	from	IN	_	8	case
7	sodium	sodium	NN	_	8	compound
8	bicarbonate	bicarbonate	NN	_	5	nmod
9	-	-	:	_	8	punct
10	calcium	calcium	NN	_	11	compound
11	admixtures	admixture	NNS	_	8	dep
12	.	.	.	_	5	punct

1	NOTE	note	VB	_	0	ROOT
2	:	:	:	_	1	punct
3	Do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	use	use	VB	_	1	dep
6	the	the	DT	_	7	det
7	injection	injection	NN	_	5	dobj
8	if	if	IN	_	10	mark
9	it	it	PRP	_	10	nsubj
10	contains	contain	VBZ	_	5	advcl
11	precipitate	precipitate	NN	_	10	dobj
12	.	.	.	_	1	punct

1	Additives	additive	NNS	_	4	nsubj
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	cop
4	incompatible	incompatible	JJ	_	0	ROOT
5	.	.	.	_	4	punct

1	Consult	consult	VB	_	6	dep
2	with	with	IN	_	3	case
3	pharmacist	pharmacist	NN	_	1	nmod
4	,	,	,	_	6	punct
5	if	if	IN	_	6	mark
6	available	available	JJ	_	0	ROOT
7	.	.	.	_	6	punct

1	When	when	WRB	_	5	advmod
2	introducing	introduce	VBG	_	5	advcl
3	additives	additive	NNS	_	2	dobj
4	,	,	,	_	5	punct
5	use	use	VBP	_	0	ROOT
6	aseptic	aseptic	JJ	_	7	amod
7	technique	technique	NN	_	5	dobj
8	,	,	,	_	5	punct
9	mix	mix	NN	_	8	root
10	thoroughly	thoroughly	RB	_	9	advmod
11	and	and	CC	_	9	cc
12	do	do	VB	_	14	aux
13	not	not	RB	_	14	neg
14	store	store	NN	_	9	conj
15	.	.	.	_	9	punct

1	Drug	drug	NN	_	5	compound
2	-	-	:	_	5	punct
3	Drug	drug	NN	_	5	compound
4	Interactions	interaction	NNS	_	5	compound
5	Effect	effect	NN	_	0	ROOT
6	of	of	IN	_	11	case
7	Exelon	Exelon	NNP	_	11	compound
8	(	(	CD	_	11	nummod
9	rivastigmine	rivastigmine	NN	_	11	compound
10	tartrate	tartrate	JJ	_	11	amod
11	)	)	NN	_	5	nmod
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	Metabolism	metabolism	NN	_	5	nmod
15	of	of	IN	_	17	case
16	Other	other	JJ	_	17	amod
17	Drugs	drug	NNS	_	14	nmod
18	:	:	:	_	5	punct
19	Rivastigmine	rivastigmine	NN	_	22	nsubjpass
20	is	be	VBZ	_	22	auxpass
21	primarily	primarily	RB	_	22	advmod
22	metabolized	metabolize	VBN	_	5	dep
23	through	through	IN	_	24	case
24	hydrolysis	hydrolysis	NN	_	22	nmod
25	by	by	IN	_	26	case
26	esterases	esterase	NNS	_	22	nmod
27	.	.	.	_	5	punct

1	Minimal	minimal	JJ	_	2	amod
2	metabolism	metabolism	NN	_	3	nsubj
3	occurs	occur	VBZ	_	0	ROOT
4	via	via	IN	_	9	case
5	the	the	DT	_	9	det
6	major	major	JJ	_	9	amod
7	cytochrome	cytochrome	NN	_	9	compound
8	P450	p450	NN	_	9	compound
9	isoenzymes	isoenzyme	NNS	_	3	nmod
10	.	.	.	_	3	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	20	advcl
6	,	,	,	_	20	punct
7	no	no	DT	_	10	neg
8	pharmacokinetic	pharmacokinetic	JJ	_	10	amod
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	20	nsubjpass
11	with	with	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	metabolized	metabolize	VBN	_	12	acl
14	by	by	IN	_	18	case
15	the	the	DT	_	18	det
16	following	follow	VBG	_	18	amod
17	isoenzyme	isoenzyme	NN	_	18	compound
18	systems	system	NNS	_	13	nmod
19	are	be	VBP	_	20	auxpass
20	expected	expect	VBN	_	0	ROOT
21	:	:	:	_	20	punct
22	CYP1A2	cyp1a2	NN	_	20	dep
23	,	,	,	_	22	punct
24	CYP2D6	cyp2d6	NN	_	22	conj
25	,	,	,	_	22	punct
26	CYP3A4	cyp3a4	NN	_	22	appos
27	/	/	:	_	26	punct
28	5	5	CD	_	27	root
29	,	,	,	_	28	punct
30	CYP2E1	cyp2e1	NN	_	29	root
31	,	,	,	_	30	punct
32	CYP2C9	cyp2c9	NN	_	31	root
33	,	,	,	_	32	punct
34	CYP2C8	cyp2c8	NN	_	32	conj
35	,	,	,	_	32	punct
36	or	or	CC	_	32	cc
37	CYP2C19	cyp2c19	NN	_	32	conj
38	.	.	.	_	32	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	between	between	IN	_	7	case
7	rivastigmine	rivastigmine	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	digoxin	digoxin	NN	_	7	conj
10	,	,	,	_	7	punct
11	warfarin	warfarin	NN	_	7	conj
12	,	,	,	_	7	punct
13	diazepam	diazepam	NN	_	7	conj
14	,	,	,	_	7	punct
15	or	or	CC	_	7	cc
16	fluoxetine	fluoxetine	NN	_	7	conj
17	in	in	IN	_	18	case
18	studies	study	NNS	_	5	nmod
19	in	in	IN	_	21	case
20	healthy	healthy	JJ	_	21	amod
21	volunteers	volunteer	NNS	_	18	nmod
22	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	elevation	elevation	NN	_	11	nsubjpass
3	of	of	IN	_	5	case
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	2	nmod
6	induced	induce	VBN	_	5	acl
7	by	by	IN	_	8	case
8	warfarin	warfarin	NN	_	6	nmod
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	affected	affect	VBN	_	0	ROOT
12	by	by	IN	_	13	case
13	administration	administration	NN	_	11	nmod
14	of	of	IN	_	15	case
15	Exelon	Exelon	NNP	_	13	nmod
16	.	.	.	_	11	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	1	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	Metabolism	metabolism	NN	_	1	nmod
8	of	of	IN	_	9	case
9	Exelon	Exelon	NNP	_	7	nmod
10	:	:	:	_	1	punct
11	Drugs	drug	NNS	_	20	nsubjpass
12	that	that	WDT	_	13	nsubj
13	induce	induce	VBP	_	11	acl:relcl
14	or	or	CC	_	13	cc
15	inhibit	inhibit	VBP	_	13	conj
16	CYP450	cyp450	NN	_	17	compound
17	metabolism	metabolism	NN	_	13	dobj
18	are	be	VBP	_	20	auxpass
19	not	not	RB	_	20	neg
20	expected	expect	VBN	_	1	dep
21	to	to	TO	_	22	mark
22	alter	alter	VB	_	20	xcomp
23	the	the	DT	_	24	det
24	metabolism	metabolism	NN	_	22	dobj
25	of	of	IN	_	26	case
26	rivastigmine	rivastigmine	NN	_	24	nmod
27	.	.	.	_	20	punct

1	Single	single	JJ	_	4	amod
2	dose	dose	NN	_	4	compound
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	studies	study	NNS	_	5	nsubj
5	demonstrated	demonstrate	VBD	_	0	ROOT
6	that	that	IN	_	14	mark
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	14	nsubjpass
9	of	of	IN	_	10	case
10	rivastigmine	rivastigmine	NN	_	8	nmod
11	is	be	VBZ	_	14	auxpass
12	not	not	RB	_	14	neg
13	significantly	significantly	RB	_	14	advmod
14	affected	affect	VBN	_	5	ccomp
15	by	by	IN	_	17	case
16	concurrent	concurrent	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	digoxin	digoxin	NN	_	17	nmod
20	,	,	,	_	19	punct
21	warfarin	warfarin	NN	_	19	conj
22	,	,	,	_	19	punct
23	diazepam	diazepam	NN	_	19	conj
24	,	,	,	_	19	punct
25	or	or	CC	_	19	cc
26	fluoxetine	fluoxetine	NN	_	19	conj
27	.	.	.	_	5	punct

1	Population	Population	NNP	_	3	compound
2	PK	pk	NN	_	3	compound
3	analysis	analysis	NN	_	10	nsubj
4	with	with	IN	_	6	case
5	a	a	DT	_	6	det
6	database	database	NN	_	3	nmod
7	of	of	IN	_	9	case
8	625	625	CD	_	9	nummod
9	patients	patient	NNS	_	6	nmod
10	showed	show	VBD	_	0	ROOT
11	that	that	IN	_	18	mark
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	18	nsubjpass
14	of	of	IN	_	15	case
15	rivastigmine	rivastigmine	NN	_	13	nmod
16	were	be	VBD	_	18	auxpass
17	not	not	RB	_	18	neg
18	influenced	influence	VBN	_	10	ccomp
19	by	by	IN	_	22	case
20	commonly	commonly	RB	_	21	advmod
21	prescribed	prescribe	VBN	_	22	amod
22	medications	medication	NNS	_	18	nmod
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	antacids	antacid	NNS	_	22	nmod
26	(	(	CD	_	27	nummod
27	n	n	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	77	77	CD	_	30	nummod
30	)	)	NN	_	28	dep
31	,	,	,	_	18	punct
32	antihypertensives	antihypertensive	NNS	_	33	nsubj
33	(	(	VBP	_	18	parataxis
34	n	n	NN	_	35	nsubj
35	=	=	JJ	_	33	xcomp
36	72	72	CD	_	37	nummod
37	)	)	NN	_	42	nsubj
38	,	,	,	_	37	punct
39	calcium	calcium	NN	_	41	compound
40	channel	channel	NN	_	41	compound
41	blockers	blocker	NNS	_	37	appos
42	(	(	VBP	_	35	ccomp
43	n	n	NN	_	44	nsubj
44	=	=	JJ	_	42	ccomp
45	75	75	CD	_	46	nummod
46	)	)	NN	_	44	dobj
47	,	,	,	_	18	punct
48	antidiabetics	antidiabetic	NNS	_	49	nsubj
49	(	(	VBP	_	18	parataxis
50	n	n	NN	_	51	nsubj
51	=	=	JJ	_	49	ccomp
52	21	21	CD	_	53	nummod
53	)	)	NN	_	51	dobj
54	,	,	,	_	53	punct
55	nonsteroidal	nonsteroidal	JJ	_	59	amod
56	anti	anti	JJ	_	59	amod
57	-	-	:	_	59	punct
58	inflammatory	inflammatory	JJ	_	59	amod
59	drugs	drug	NNS	_	60	nsubj
60	(	(	VBP	_	53	acl:relcl
61	n	n	NN	_	62	nsubj
62	=	=	JJ	_	60	ccomp
63	79	79	CD	_	64	nummod
64	)	)	NN	_	62	dobj
65	,	,	,	_	18	punct
66	estrogens	estrogen	NNS	_	67	nsubj
67	(	(	VBP	_	18	parataxis
68	n	n	NN	_	69	nsubj
69	=	=	JJ	_	67	xcomp
70	70	70	CD	_	71	nummod
71	)	)	NN	_	75	nsubj
72	,	,	,	_	71	punct
73	salicylate	salicylate	NN	_	74	compound
74	analgesics	analgesic	NNS	_	71	appos
75	(	(	VBP	_	69	ccomp
76	n	n	NN	_	77	nsubj
77	=	=	JJ	_	75	xcomp
78	177	177	CD	_	79	nummod
79	)	)	NN	_	90	nsubj
80	,	,	,	_	79	punct
81	antianginals	antianginals	JJ	_	83	amod
82	(	(	NN	_	83	compound
83	n	n	NN	_	84	nsubj
84	=	=	JJ	_	79	dep
85	35	35	CD	_	86	nummod
86	)	)	NN	_	84	dobj
87	,	,	,	_	79	punct
88	and	and	CC	_	79	cc
89	antihistamines	antihistamine	NNS	_	79	conj
90	(	(	VBP	_	77	ccomp
91	n	n	NN	_	92	nsubj
92	=	=	JJ	_	90	ccomp
93	15	15	CD	_	94	nummod
94	)	)	NN	_	92	dobj
95	.	.	.	_	10	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	Anticholinergics	Anticholinergics	NNPS	_	1	nmod
4	:	:	:	_	1	punct
5	Because	because	IN	_	8	case
6	of	of	IN	_	5	mwe
7	their	they	PRP$	_	8	nmod:poss
8	mechanism	mechanism	NN	_	14	nmod
9	of	of	IN	_	10	case
10	action	action	NN	_	8	nmod
11	,	,	,	_	8	punct
12	cholinesterase	cholinesterase	NN	_	13	compound
13	inhibitors	inhibitor	NNS	_	14	nsubj
14	have	have	VBP	_	1	parataxis
15	the	the	DT	_	16	det
16	potential	potential	JJ	_	14	dobj
17	to	to	TO	_	18	mark
18	interfere	interfere	VB	_	16	acl
19	with	with	IN	_	21	case
20	the	the	DT	_	21	det
21	activity	activity	NN	_	18	nmod
22	of	of	IN	_	24	case
23	anticholinergic	anticholinergic	JJ	_	24	amod
24	medications	medication	NNS	_	21	nmod
25	.	.	.	_	1	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	Cholinomimetics	cholinomimetic	NNS	_	1	nmod
4	and	and	CC	_	3	cc
5	Other	other	JJ	_	7	amod
6	Cholinesterase	Cholinesterase	NNP	_	7	compound
7	Inhibitors	inhibitor	NNS	_	3	conj
8	:	:	:	_	1	punct
9	A	a	DT	_	11	det
10	synergistic	synergistic	JJ	_	11	amod
11	effect	effect	NN	_	14	nsubjpass
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	expected	expect	VBN	_	1	parataxis
15	when	when	WRB	_	19	advmod
16	cholinesterase	cholinesterase	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	19	nsubjpass
18	are	be	VBP	_	19	auxpass
19	given	give	VBN	_	14	advcl
20	concurrently	concurrently	RB	_	19	advmod
21	with	with	IN	_	22	case
22	succinylcholine	succinylcholine	NN	_	19	nmod
23	,	,	,	_	22	punct
24	similar	similar	JJ	_	27	amod
25	neuromuscular	neuromuscular	JJ	_	27	amod
26	blocking	block	VBG	_	27	amod
27	agents	agent	NNS	_	22	conj
28	or	or	CC	_	22	cc
29	cholinergic	cholinergic	JJ	_	30	amod
30	agonists	agonist	NNS	_	22	conj
31	such	such	JJ	_	33	case
32	as	as	IN	_	31	mwe
33	bethanechol	bethanechol	NN	_	30	nmod
34	.	.	.	_	1	punct

1	ACE	ace	NN	_	3	compound
2	inhibitors	inhibitor	NNS	_	3	compound
3	Reports	report	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	NSAIDs	nsaid	NNS	_	8	nsubj
7	may	may	MD	_	8	aux
8	diminish	diminish	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	antihypertensive	antihypertensive	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	angiotensin	angiotensin	NN	_	11	nmod
14	-	-	:	_	8	punct
15	converting	convert	VBG	_	8	dep
16	enzyme	enzyme	NN	_	20	compound
17	(	(	CD	_	20	nummod
18	ACE	ace	NN	_	20	compound
19	)	)	NN	_	20	compound
20	inhibitors	inhibitor	NNS	_	15	dobj
21	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	NSAIDs	nsaid	NNS	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	14	case
13	ACE	ace	NN	_	14	compound
14	inhibitors	inhibitor	NNS	_	9	nmod
15	.	.	.	_	5	punct

1	Aspirin	aspirin	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	15	nsubj
5	of	of	IN	_	6	case
6	aspirin	aspirin	NN	_	4	nmod
7	(	(	CD	_	8	compound
8	1000	1000	CD	_	6	nummod
9	mg	mg	NN	_	10	compound
10	TID	tid	NN	_	6	dep
11	)	)	CD	_	6	nummod
12	to	to	TO	_	14	case
13	healthy	healthy	JJ	_	14	amod
14	volunteers	volunteer	NNS	_	4	nmod
15	tended	tend	VBD	_	1	dep
16	to	to	TO	_	17	mark
17	increase	increase	VB	_	15	xcomp
18	the	the	DT	_	17	dobj
19	AUC	auc	NN	_	18	amod
20	(	(	CD	_	21	compound
21	10	10	CD	_	22	nummod
22	%	%	NN	_	19	dep
23	)	)	CD	_	22	nummod
24	and	and	CC	_	22	cc
25	Cmax	Cmax	NNP	_	22	conj
26	(	(	CD	_	27	compound
27	24	24	CD	_	28	nummod
28	%	%	NN	_	25	dep
29	)	)	CD	_	28	nummod
30	of	of	IN	_	31	case
31	meloxicam	meloxicam	NN	_	28	nmod
32	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	;	;	:	_	9	punct

1	however	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	as	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	NSAIDs	nsaid	NNS	_	17	nmod
7	,	,	,	_	17	punct
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	meloxicam	meloxicam	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	aspirin	aspirin	NN	_	11	conj
14	is	be	VBZ	_	17	auxpass
15	not	not	RB	_	17	neg
16	generally	generally	RB	_	17	advmod
17	recommended	recommend	VBN	_	0	ROOT
18	because	because	IN	_	21	case
19	of	of	IN	_	18	mwe
20	the	the	DT	_	21	det
21	potential	potential	NN	_	17	nmod
22	for	for	IN	_	25	case
23	increased	increase	VBN	_	25	amod
24	adverse	adverse	JJ	_	25	amod
25	effects	effect	NNS	_	21	nmod
26	.	.	.	_	17	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	11	nsubj
3	of	of	IN	_	7	case
4	low	low	JJ	_	7	amod
5	-	-	:	_	7	punct
6	dose	dose	NN	_	7	compound
7	aspirin	aspirin	NN	_	2	nmod
8	with	with	IN	_	9	case
9	MOBIC	mobic	NN	_	2	nmod
10	may	may	MD	_	11	aux
11	result	result	VB	_	0	ROOT
12	in	in	IN	_	15	case
13	an	a	DT	_	15	det
14	increased	increase	VBN	_	15	amod
15	rate	rate	NN	_	11	nmod
16	of	of	IN	_	18	case
17	GI	gi	NN	_	18	compound
18	ulceration	ulceration	NN	_	15	nmod
19	or	or	CC	_	18	cc
20	other	other	JJ	_	21	amod
21	complications	complication	NNS	_	18	conj
22	,	,	,	_	15	punct
23	compared	compare	VBN	_	25	case
24	to	to	TO	_	25	case
25	use	use	VB	_	15	acl
26	of	of	IN	_	27	case
27	MOBIC	mobic	NN	_	25	nmod
28	alone	alone	RB	_	27	advmod
29	.	.	.	_	11	punct

1	MOBIC	MOBIC	NNP	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	not	not	RB	_	5	neg
4	a	a	DT	_	5	det
5	substitute	substitute	NN	_	0	ROOT
6	for	for	IN	_	7	case
7	aspirin	aspirin	NN	_	5	nmod
8	for	for	IN	_	10	case
9	cardiovascular	cardiovascular	JJ	_	10	amod
10	prophylaxis	prophylaxis	NN	_	5	nmod
11	.	.	.	_	5	punct

1	Cholestyramine	Cholestyramine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Pretreatment	pretreatment	NN	_	10	nsubj
4	for	for	IN	_	6	case
5	four	four	CD	_	6	nummod
6	days	day	NNS	_	3	nmod
7	with	with	IN	_	8	case
8	cholestyramine	cholestyramine	NN	_	3	nmod
9	significantly	significantly	RB	_	10	advmod
10	increased	increase	VBD	_	1	dep
11	the	the	DT	_	12	det
12	clearance	clearance	NN	_	10	dobj
13	of	of	IN	_	14	case
14	meloxicam	meloxicam	NN	_	12	nmod
15	by	by	IN	_	17	case
16	50	50	CD	_	17	nummod
17	%	%	NN	_	10	nmod
18	.	.	.	_	1	punct

1	This	this	DT	_	2	nsubj
2	resulted	result	VBD	_	0	ROOT
3	in	in	IN	_	5	case
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	2	nmod
6	in	in	IN	_	7	case
7	t1	t1	NN	_	5	nmod
8	/	/	:	_	7	punct
9	2	2	CD	_	7	nummod
10	,	,	,	_	7	punct
11	from	from	IN	_	13	case
12	19.2	19.2	CD	_	13	nummod
13	hours	hour	NNS	_	7	nmod
14	to	to	TO	_	16	case
15	12.5	12.5	CD	_	16	nummod
16	hours	hour	NNS	_	13	nmod
17	,	,	,	_	7	punct
18	and	and	CC	_	7	cc
19	a	a	DT	_	22	det
20	35	35	CD	_	21	compound
21	%	%	NN	_	22	amod
22	reduction	reduction	NN	_	7	conj
23	in	in	IN	_	24	case
24	AUC	auc	NN	_	22	nmod
25	.	.	.	_	2	punct

1	This	this	DT	_	2	nsubj
2	suggests	suggest	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	existence	existence	NN	_	2	dobj
5	of	of	IN	_	8	case
6	a	a	DT	_	8	det
7	recirculation	recirculation	NN	_	8	compound
8	pathway	pathway	NN	_	4	nmod
9	for	for	IN	_	10	case
10	meloxicam	meloxicam	NN	_	8	nmod
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	gastrointestinal	gastrointestinal	JJ	_	14	amod
14	tract	tract	NN	_	8	nmod
15	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	10	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	established	establish	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Cimetidine	Cimetidine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	12	nsubj
5	of	of	IN	_	9	case
6	200	200	CD	_	7	compound
7	mg	mg	NN	_	9	amod
8	cimetidine	cimetidine	NN	_	9	compound
9	QID	qid	NN	_	4	nmod
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	alter	alter	VB	_	1	dep
13	the	the	DT	_	17	det
14	single	single	JJ	_	17	amod
15	-	-	:	_	17	punct
16	dose	dose	NN	_	17	compound
17	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
18	of	of	IN	_	21	case
19	30	30	CD	_	21	nummod
20	mg	mg	NN	_	21	compound
21	meloxicam	meloxicam	NN	_	17	nmod
22	.	.	.	_	1	punct

1	Digoxin	Digoxin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Meloxicam	Meloxicam	NNP	_	5	compound
4	15	15	CD	_	5	nummod
5	mg	mg	NN	_	13	nsubj
6	once	once	RB	_	7	advmod
7	daily	daily	RB	_	5	advmod
8	for	for	IN	_	10	case
9	7	7	CD	_	10	nummod
10	days	day	NNS	_	5	nmod
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	alter	alter	VB	_	1	dep
14	the	the	DT	_	17	det
15	plasma	plasma	NN	_	17	compound
16	concentration	concentration	NN	_	17	compound
17	profile	profile	NN	_	13	dobj
18	of	of	IN	_	19	case
19	digoxin	digoxin	NN	_	17	nmod
20	after	after	IN	_	24	case
21	b	b	SYM	_	24	dep
22	-	-	:	_	24	punct
23	acetyldigoxin	acetyldigoxin	NN	_	24	compound
24	administration	administration	NN	_	13	nmod
25	for	for	IN	_	27	case
26	7	7	CD	_	27	nummod
27	days	day	NNS	_	13	nmod
28	at	at	IN	_	30	case
29	clinical	clinical	JJ	_	30	amod
30	doses	dose	NNS	_	13	nmod
31	.	.	.	_	1	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	testing	testing	NN	_	4	nsubj
4	found	find	VBD	_	0	ROOT
5	no	no	DT	_	9	neg
6	protein	protein	NN	_	9	compound
7	binding	binding	NN	_	9	compound
8	drug	drug	NN	_	9	compound
9	interaction	interaction	NN	_	4	dobj
10	between	between	IN	_	11	case
11	digoxin	digoxin	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	meloxicam	meloxicam	NN	_	11	conj
14	.	.	.	_	4	punct

1	Furosemide	Furosemide	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	15	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	post	post	NN	_	12	compound
10	-	-	:	_	12	punct
11	marketing	marketing	NN	_	12	compound
12	observations	observation	NNS	_	4	conj
13	,	,	,	_	4	punct
14	have	have	VBP	_	15	aux
15	shown	show	VBN	_	1	dep
16	that	that	IN	_	19	mark
17	NSAIDs	nsaid	NNS	_	19	nsubj
18	can	can	MD	_	19	aux
19	reduce	reduce	VB	_	15	ccomp
20	the	the	DT	_	22	det
21	natriuretic	natriuretic	JJ	_	22	amod
22	effect	effect	NN	_	19	dobj
23	of	of	IN	_	24	case
24	furosemide	furosemide	NN	_	22	nmod
25	and	and	CC	_	24	cc
26	thiazide	thiazide	JJ	_	27	amod
27	diuretics	diuretic	NNS	_	24	conj
28	in	in	IN	_	30	case
29	some	some	DT	_	30	det
30	patients	patient	NNS	_	22	nmod
31	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	Studies	study	NNS	_	9	nsubj
2	with	with	IN	_	4	case
3	furosemide	furosemide	NN	_	4	compound
4	agents	agent	NNS	_	1	nmod
5	and	and	CC	_	4	cc
6	meloxicam	meloxicam	NN	_	4	conj
7	have	have	VBP	_	9	aux
8	not	not	RB	_	9	neg
9	demonstrated	demonstrate	VBN	_	0	ROOT
10	a	a	DT	_	11	det
11	reduction	reduction	NN	_	9	dobj
12	in	in	IN	_	14	case
13	natriuretic	natriuretic	JJ	_	14	amod
14	effect	effect	NN	_	11	nmod
15	.	.	.	_	9	punct

1	Furosemide	Furosemide	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	single	single	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	multiple	multiple	JJ	_	3	conj
6	dose	dose	NN	_	7	compound
7	pharmacodynamics	pharmacodynamic	NNS	_	12	nsubjpass
8	and	and	CC	_	7	cc
9	pharmacokinetics	pharmacokinetic	NNS	_	7	conj
10	are	be	VBP	_	12	auxpass
11	not	not	RB	_	12	neg
12	affected	affect	VBN	_	1	dep
13	by	by	IN	_	15	case
14	multiple	multiple	JJ	_	15	amod
15	doses	dose	NNS	_	12	nmod
16	of	of	IN	_	17	case
17	meloxicam	meloxicam	NN	_	15	nmod
18	.	.	.	_	1	punct

1	Nevertheless	nevertheless	RB	_	14	advmod
2	,	,	,	_	14	punct
3	during	during	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	therapy	therapy	NN	_	14	nmod
6	with	with	IN	_	7	case
7	furosemide	furosemide	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	MOBIC	mobic	NN	_	7	conj
10	,	,	,	_	14	punct
11	patients	patient	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	closely	closely	RB	_	14	advmod
16	for	for	IN	_	17	case
17	signs	sign	NNS	_	14	nmod
18	of	of	IN	_	21	case
19	declining	decline	VBG	_	21	amod
20	renal	renal	JJ	_	21	amod
21	function	function	NN	_	17	nmod
22	,	,	,	_	14	punct
23	as	as	RB	_	14	cc
24	well	well	RB	_	23	mwe
25	as	as	IN	_	23	mwe
26	to	to	TO	_	27	mark
27	assure	assure	VB	_	14	conj
28	diuretic	diuretic	JJ	_	29	amod
29	efficacy	efficacy	NN	_	27	dobj
30	.	.	.	_	14	punct

1	Lithium	lithium	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	9	nmod
6	,	,	,	_	9	punct
7	NSAIDs	nsaid	NNS	_	9	nsubj
8	have	have	VBP	_	9	aux
9	produced	produce	VBN	_	1	appos
10	an	a	DT	_	11	det
11	elevation	elevation	NN	_	9	dobj
12	of	of	IN	_	15	case
13	plasma	plasma	NN	_	15	compound
14	lithium	lithium	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	and	and	CC	_	11	cc
17	a	a	DT	_	18	det
18	reduction	reduction	NN	_	11	conj
19	in	in	IN	_	22	case
20	renal	renal	JJ	_	22	amod
21	lithium	lithium	NN	_	22	compound
22	clearance	clearance	NN	_	18	nmod
23	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	9	nmod
4	conducted	conduct	VBN	_	3	acl
5	in	in	IN	_	7	case
6	healthy	healthy	JJ	_	7	amod
7	subjects	subject	NNS	_	4	nmod
8	,	,	,	_	9	punct
9	mean	mean	VB	_	0	ROOT
10	pre	pre	JJ	_	14	amod
11	-	-	:	_	14	punct
12	dose	dose	NN	_	14	compound
13	lithium	lithium	NN	_	14	compound
14	concentration	concentration	NN	_	18	nsubjpass
15	and	and	CC	_	14	cc
16	AUC	auc	NN	_	14	conj
17	were	be	VBD	_	18	auxpass
18	increased	increase	VBN	_	9	ccomp
19	by	by	IN	_	21	case
20	21	21	CD	_	21	nummod
21	%	%	NN	_	18	nmod
22	in	in	IN	_	23	case
23	subjects	subject	NNS	_	18	nmod
24	receiving	receive	VBG	_	23	acl
25	lithium	lithium	NN	_	26	compound
26	doses	dose	NNS	_	24	dobj
27	ranging	range	VBG	_	26	acl
28	from	from	IN	_	29	case
29	804	804	CD	_	27	nmod
30	to	to	TO	_	31	dep
31	1072	1072	CD	_	29	nmod
32	mg	mg	NN	_	33	compound
33	BID	BID	NNP	_	31	dobj
34	with	with	IN	_	38	case
35	meloxicam	meloxicam	NN	_	38	compound
36	15	15	CD	_	37	compound
37	mg	mg	NN	_	38	amod
38	QD	qd	NN	_	33	nmod
39	as	as	IN	_	40	mark
40	compared	compare	VBN	_	18	advcl
41	to	to	TO	_	42	case
42	subjects	subject	NNS	_	40	nmod
43	receiving	receive	VBG	_	42	acl
44	lithium	lithium	NN	_	43	dobj
45	alone	alone	RB	_	43	advmod
46	.	.	.	_	9	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	by	by	IN	_	13	case
13	MOBIC	MOBIC	NNP	_	7	nmod
14	.	.	.	_	5	punct

1	Patients	patient	NNS	_	8	nsubjpass
2	on	on	IN	_	4	case
3	lithium	lithium	NN	_	4	compound
4	treatment	treatment	NN	_	1	nmod
5	should	should	MD	_	8	aux
6	be	be	VB	_	8	auxpass
7	closely	closely	RB	_	8	advmod
8	monitored	monitor	VBN	_	0	ROOT
9	when	when	WRB	_	12	advmod
10	MOBIC	MOBIC	NNP	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	introduced	introduce	VBN	_	8	advcl
13	or	or	CC	_	12	cc
14	withdrawn	withdraw	VBN	_	12	conj
15	.	.	.	_	8	punct

1	Methotrexate	Methotrexate	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	A	A	NNP	_	4	compound
4	study	study	NN	_	13	nmod:tmod
5	in	in	IN	_	10	case
6	13	13	CD	_	10	nummod
7	rheumatoid	rheumatoid	JJ	_	10	amod
8	arthritis	arthritis	NN	_	10	compound
9	(	(	NN	_	10	compound
10	RA	ra	NN	_	13	nmod
11	)	)	CD	_	12	nummod
12	patients	patient	NNS	_	13	nsubj
13	evaluated	evaluate	VBD	_	1	appos
14	the	the	DT	_	15	det
15	effects	effect	NNS	_	13	dobj
16	of	of	IN	_	18	case
17	multiple	multiple	JJ	_	18	amod
18	doses	dose	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	meloxicam	meloxicam	NN	_	18	nmod
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	pharmacokinetics	pharmacokinetic	NNS	_	15	nmod
24	of	of	IN	_	25	case
25	methotrexate	methotrexate	NN	_	23	nmod
26	taken	take	VBN	_	23	acl
27	once	once	RB	_	28	advmod
28	weekly	weekly	RB	_	26	advmod
29	.	.	.	_	1	punct

1	Meloxicam	Meloxicam	NNP	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	have	have	VB	_	0	ROOT
5	a	a	DT	_	7	det
6	significant	significant	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	single	single	JJ	_	13	amod
13	doses	dose	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	methotrexate	methotrexate	NN	_	13	nmod
16	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	7	advmod
3	,	,	,	_	7	punct
4	methotrexate	methotrexate	NN	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	displace	displace	VB	_	0	ROOT
8	meloxicam	meloxicam	NN	_	7	dobj
9	from	from	IN	_	14	case
10	its	its	PRP$	_	14	nmod:poss
11	human	human	JJ	_	14	amod
12	serum	serum	NN	_	14	compound
13	binding	binding	NN	_	14	compound
14	sites	site	NNS	_	7	nmod
15	.	.	.	_	7	punct

1	Warfarin	Warfarin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Anticoagulant	anticoagulant	JJ	_	4	amod
4	activity	activity	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	1	dep
8	,	,	,	_	7	punct
9	particularly	particularly	RB	_	14	advmod
10	in	in	IN	_	14	case
11	the	the	DT	_	14	det
12	first	first	JJ	_	14	amod
13	few	few	JJ	_	14	amod
14	days	day	NNS	_	7	nmod
15	after	after	IN	_	16	mark
16	initiating	initiate	VBG	_	14	acl
17	or	or	CC	_	16	cc
18	changing	change	VBG	_	16	conj
19	MOBIC	mobic	NN	_	20	compound
20	therapy	therapy	NN	_	16	dobj
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	receiving	receive	VBG	_	22	acl
24	warfarin	warfarin	NN	_	23	dobj
25	or	or	CC	_	24	cc
26	similar	similar	JJ	_	24	conj
27	agents	agent	NNS	_	24	dep
28	,	,	,	_	7	punct
29	since	since	IN	_	36	mark
30	these	these	DT	_	31	det
31	patients	patient	NNS	_	36	nsubj
32	are	be	VBP	_	36	cop
33	at	at	IN	_	36	case
34	an	a	DT	_	36	det
35	increased	increase	VBN	_	36	amod
36	risk	risk	NN	_	7	advcl
37	of	of	IN	_	38	case
38	bleeding	bleeding	NN	_	36	nmod
39	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	meloxicam	meloxicam	NN	_	2	nmod
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	anticoagulant	anticoagulant	JJ	_	8	amod
8	effect	effect	NN	_	2	nmod
9	of	of	IN	_	10	case
10	warfarin	warfarin	NN	_	8	nmod
11	was	be	VBD	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	group	group	NN	_	12	nmod
16	of	of	IN	_	18	case
17	healthy	healthy	JJ	_	18	amod
18	subjects	subject	NNS	_	15	nmod
19	receiving	receive	VBG	_	18	acl
20	daily	daily	JJ	_	21	amod
21	doses	dose	NNS	_	19	dobj
22	of	of	IN	_	23	case
23	warfarin	warfarin	NN	_	21	nmod
24	that	that	WDT	_	25	nsubj
25	produced	produce	VBD	_	21	acl:relcl
26	an	a	DT	_	32	det
27	INR	inr	NN	_	32	compound
28	(	(	CD	_	32	nummod
29	International	International	NNP	_	32	compound
30	Normalized	Normalized	NNP	_	32	compound
31	Ratio	Ratio	NNP	_	32	compound
32	)	)	NN	_	25	dobj
33	between	between	IN	_	34	case
34	1.2	1.2	CD	_	32	nmod
35	and	and	CC	_	34	cc
36	1.8	1.8	CD	_	34	conj
37	.	.	.	_	12	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	subjects	subject	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	meloxicam	meloxicam	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	alter	alter	VB	_	0	ROOT
9	warfarin	warfarin	NN	_	10	compound
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	and	and	CC	_	10	cc
12	the	the	DT	_	15	det
13	average	average	JJ	_	15	amod
14	anticoagulant	anticoagulant	JJ	_	15	amod
15	effect	effect	NN	_	10	conj
16	of	of	IN	_	17	case
17	warfarin	warfarin	NN	_	15	nmod
18	as	as	IN	_	19	mark
19	determined	determine	VBN	_	8	advcl
20	by	by	IN	_	22	case
21	prothrombin	prothrombin	NN	_	22	compound
22	time	time	NN	_	19	nmod
23	.	.	.	_	8	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	one	one	CD	_	4	nummod
4	subject	subject	NN	_	5	nsubj
5	showed	show	VBD	_	0	ROOT
6	an	a	DT	_	7	det
7	increase	increase	NN	_	5	dobj
8	in	in	IN	_	9	case
9	INR	inr	NN	_	7	nmod
10	from	from	IN	_	11	case
11	1.5	1.5	CD	_	7	nmod
12	to	to	TO	_	13	case
13	2.1	2.1	CD	_	11	nmod
14	.	.	.	_	5	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	MOBIC	mobic	NN	_	6	dobj
8	with	with	IN	_	9	case
9	warfarin	warfarin	NN	_	6	nmod
10	since	since	IN	_	15	mark
11	patients	patient	NNS	_	15	nsubj
12	on	on	IN	_	13	case
13	warfarin	warfarin	NN	_	11	nmod
14	may	may	MD	_	15	aux
15	experience	experience	VB	_	6	advcl
16	changes	change	NNS	_	15	dobj
17	in	in	IN	_	18	case
18	INR	inr	NN	_	16	nmod
19	and	and	CC	_	16	cc
20	an	a	DT	_	22	det
21	increased	increase	VBN	_	22	amod
22	risk	risk	NN	_	16	conj
23	of	of	IN	_	24	mark
24	bleeding	bleed	VBG	_	22	acl
25	complications	complication	NNS	_	24	dobj
26	when	when	WRB	_	31	advmod
27	a	a	DT	_	29	det
28	new	new	JJ	_	29	amod
29	medication	medication	NN	_	31	nsubjpass
30	is	be	VBZ	_	31	auxpass
31	introduced	introduce	VBN	_	24	advcl
32	.	.	.	_	4	punct

1	Trimethoprim	Trimethoprim	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	inhibit	inhibit	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	3	dobj
7	of	of	IN	_	8	case
8	phenytoin	phenytoin	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Trimethoprim	Trimethoprim	NNP	_	10	nsubj
2	,	,	,	_	1	punct
3	given	give	VBN	_	1	acl
4	at	at	IN	_	8	case
5	a	a	DT	_	8	det
6	common	common	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	dosage	dosage	NN	_	3	nmod
9	,	,	,	_	1	punct
10	increased	increase	VBD	_	0	ROOT
11	the	the	DT	_	13	det
12	phenytoin	phenytoin	NN	_	13	compound
13	half	half	NN	_	10	dobj
14	-	-	:	_	13	punct
15	life	life	NN	_	13	conj
16	by	by	IN	_	18	case
17	51	51	CD	_	18	nummod
18	%	%	NN	_	15	nmod
19	and	and	CC	_	10	cc
20	decreased	decrease	VBD	_	10	conj
21	the	the	DT	_	25	det
22	phenytoin	phenytoin	NN	_	25	compound
23	metabolic	metabolic	JJ	_	25	amod
24	clearance	clearance	NN	_	25	compound
25	rate	rate	NN	_	20	dobj
26	by	by	IN	_	28	case
27	30	30	CD	_	28	nummod
28	%	%	NN	_	20	nmod
29	.	.	.	_	10	punct

1	When	when	WRB	_	2	advmod
2	administering	administer	VBG	_	10	advcl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	concurrently	concurrently	RB	_	2	advmod
6	,	,	,	_	10	punct
7	one	one	CD	_	10	nsubj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	cop
10	alert	alert	JJ	_	0	ROOT
11	for	for	IN	_	15	case
12	possible	possible	JJ	_	15	amod
13	excessive	excessive	JJ	_	15	amod
14	phenytoin	phenytoin	NN	_	15	compound
15	effect	effect	NN	_	10	nmod
16	.	.	.	_	10	punct

1	Excessive	excessive	JJ	_	3	amod
2	glucocorticoid	glucocorticoid	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubj
4	will	will	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	growth	growth	NN	_	5	dobj
8	-	-	:	_	5	punct
9	promoting	promote	VBG	_	5	advcl
10	effect	effect	NN	_	9	dobj
11	of	of	IN	_	13	case
12	human	human	JJ	_	13	amod
13	GH	gh	NN	_	10	nmod
14	.	.	.	_	5	punct

1	Patients	patient	NNS	_	6	nsubj
2	with	with	IN	_	4	case
3	ACTH	acth	NN	_	4	compound
4	deficiency	deficiency	NN	_	1	nmod
5	should	should	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	their	they	PRP$	_	11	nmod:poss
8	glucocorticoid	glucocorticoid	NN	_	11	compound
9	-	-	:	_	11	punct
10	replacement	replacement	NN	_	11	compound
11	dose	dose	NN	_	13	nsubj
12	carefully	carefully	RB	_	13	advmod
13	adjusted	adjust	VBN	_	6	ccomp
14	to	to	TO	_	15	mark
15	avoid	avoid	VB	_	13	xcomp
16	an	a	DT	_	18	det
17	inhibitory	inhibitory	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	on	on	IN	_	20	case
20	growth	growth	NN	_	18	nmod
21	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	17	nsubjpass
3	of	of	IN	_	4	case
4	Nutropin	Nutropin	NNP	_	2	nmod
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	2	nmod
7	with	with	IN	_	10	case
8	chronic	chronic	JJ	_	10	amod
9	renal	renal	JJ	_	10	amod
10	insufficiency	insufficiency	NN	_	6	nmod
11	receiving	receive	VBG	_	10	acl
12	glucocorticoid	glucocorticoid	NN	_	13	compound
13	therapy	therapy	NN	_	11	dobj
14	has	have	VBZ	_	17	aux
15	not	not	RB	_	17	neg
16	been	be	VBN	_	17	auxpass
17	evaluated	evaluate	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Concomitant	concomitant	JJ	_	3	amod
2	glucocorticoid	glucocorticoid	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	growth	growth	NN	_	5	dobj
8	-	-	:	_	5	punct
9	promoting	promote	VBG	_	5	advcl
10	effect	effect	NN	_	9	dobj
11	of	of	IN	_	12	case
12	Nutropin	Nutropin	NNP	_	10	nmod
13	.	.	.	_	5	punct

1	If	if	IN	_	5	mark
2	glucocorticoid	glucocorticoid	NN	_	3	compound
3	replacement	replacement	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	13	advcl
6	,	,	,	_	13	punct
7	the	the	DT	_	9	det
8	glucocorticoid	glucocorticoid	NN	_	9	compound
9	dose	dose	NN	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	carefully	carefully	RB	_	13	advmod
13	adjusted	adjust	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	12	nsubj
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	controlled	controlled	JJ	_	8	amod
8	studies	study	NNS	_	4	nmod
9	of	of	IN	_	10	case
10	Nutropin	Nutropin	NNP	_	8	nmod
11	s	be	VBZ	_	12	compound
12	interaction	interaction	NN	_	2	nsubj
13	with	with	IN	_	14	case
14	drugs	drug	NNS	_	12	nmod
15	commonly	commonly	RB	_	16	advmod
16	used	use	VBN	_	14	acl
17	in	in	IN	_	21	case
18	chronic	chronic	JJ	_	21	amod
19	renal	renal	JJ	_	21	amod
20	insufficiency	insufficiency	NN	_	21	compound
21	patients	patient	NNS	_	16	nmod
22	.	.	.	_	2	punct

1	Limited	limited	JJ	_	3	amod
2	published	publish	VBN	_	3	amod
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	GH	gh	NN	_	7	compound
7	treatment	treatment	NN	_	8	nsubj
8	increases	increase	VBZ	_	4	ccomp
9	cytochrome	cytochrome	NN	_	13	compound
10	P450	p450	NN	_	13	compound
11	(	(	CD	_	13	nummod
12	CP450	cp450	NN	_	13	compound
13	)	)	NN	_	14	nsubj
14	mediated	mediate	VBD	_	8	ccomp
15	antipyrine	antipyrine	JJ	_	16	amod
16	clearance	clearance	NN	_	14	dobj
17	in	in	IN	_	18	case
18	man	man	NN	_	14	nmod
19	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	GH	gh	NN	_	6	compound
6	administration	administration	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	alter	alter	VB	_	3	ccomp
9	the	the	DT	_	10	det
10	clearance	clearance	NN	_	21	nsubj
11	of	of	IN	_	12	case
12	compounds	compound	NNS	_	10	nmod
13	known	know	VBN	_	12	acl
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	metabolized	metabolize	VBN	_	13	xcomp
17	by	by	IN	_	20	case
18	CP450	cp450	NN	_	20	compound
19	liver	liver	NN	_	20	compound
20	enzymes	enzyme	NNS	_	16	nmod
21	(	(	VBP	_	8	ccomp
22	e	e	LS	_	21	dobj
23	.	.	.	_	22	punct
24	g	g	NN	_	22	dep
25	.	.	.	_	24	punct
26	,	,	,	_	24	punct
27	corticosteroids	corticosteroid	NNS	_	24	conj
28	,	,	,	_	24	punct
29	sex	sex	NN	_	30	compound
30	steroids	steroid	NNS	_	24	conj
31	,	,	,	_	24	punct
32	anticonvulsants	anticonvulsant	NNS	_	24	conj
33	,	,	,	_	24	punct
34	cyclosporin	cyclosporin	NN	_	35	compound
35	)	)	NN	_	24	conj
36	.	.	.	_	3	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	advisable	advisable	JJ	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	GH	gh	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	nmod
14	known	know	VBN	_	13	acl
15	to	to	TO	_	17	mark
16	be	be	VB	_	17	auxpass
17	metabolized	metabolize	VBN	_	14	xcomp
18	by	by	IN	_	21	case
19	CP450	cp450	NN	_	21	compound
20	liver	liver	NN	_	21	compound
21	enzymes	enzyme	NNS	_	17	nmod
22	.	.	.	_	4	punct

1	Methyprylon	Methyprylon	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	other	other	JJ	_	7	amod
6	addictive	addictive	JJ	_	7	amod
7	medications	medication	NNS	_	3	nmod
8	,	,	,	_	3	punct
9	in	in	IN	_	13	mark
10	that	that	IN	_	13	mark
11	it	it	PRP	_	13	nsubj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	3	advcl
14	the	the	DT	_	15	det
15	likelyhood	likelyhood	NN	_	13	dobj
16	of	of	IN	_	17	case
17	addiction	addiction	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	abuse	abuse	NN	_	17	conj
20	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	alcohol	alcohol	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	other	other	JJ	_	8	amod
7	CNS	cns	NN	_	8	compound
8	depression	depression	NN	_	4	conj
9	-	-	:	_	2	punct
10	producing	produce	VBG	_	2	acl
11	drugs	drug	NNS	_	10	dobj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	0	ROOT
14	the	the	DT	_	17	det
15	CNS	cns	NN	_	17	compound
16	depressant	depressant	NN	_	17	compound
17	effects	effect	NNS	_	13	dobj
18	of	of	IN	_	19	case
19	methyprylon	methyprylon	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	these	these	DT	_	23	det
22	other	other	JJ	_	23	amod
23	medications	medication	NNS	_	19	conj
24	.	.	.	_	13	punct

1	Barbiturates	barbiturate	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effectiveness	effectiveness	NN	_	3	dobj
6	of	of	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	contraceptives	contraceptive	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	certain	certain	JJ	_	11	amod
11	antibiotics	antibiotic	NNS	_	8	conj
12	,	,	,	_	8	punct
13	quinidine	quinidine	NN	_	8	conj
14	,	,	,	_	8	punct
15	theophylline	theophylline	NN	_	8	conj
16	,	,	,	_	8	punct
17	corticosteroids	corticosteroid	NNS	_	8	conj
18	,	,	,	_	8	punct
19	anticoagulants	anticoagulant	NNS	_	8	conj
20	,	,	,	_	8	punct
21	and	and	CC	_	8	cc
22	beta	beta	NN	_	23	compound
23	blockers	blocker	NNS	_	8	conj
24	.	.	.	_	3	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	NEXAVAR	nexavar	NN	_	5	dobj
7	with	with	IN	_	8	case
8	compounds	compound	NNS	_	5	nmod
9	that	that	WDT	_	11	nsubjpass
10	are	be	VBP	_	11	auxpass
11	metabolized	metabolize	VBN	_	8	acl:relcl
12	/	/	:	_	3	punct
13	eliminated	eliminate	VBN	_	3	dep
14	predominantly	predominantly	RB	_	13	advmod
15	by	by	IN	_	18	case
16	the	the	DT	_	18	det
17	UGT1A1	ugt1a1	NN	_	18	compound
18	pathway	pathway	NN	_	13	nmod
19	(	(	CD	_	18	nummod
20	e	e	LS	_	25	dep
21	.	.	.	_	20	punct
22	g	g	NN	_	25	compound
23	.	.	.	_	25	punct
24	irinotecan	irinotecan	NN	_	25	compound
25	)	)	NN	_	18	dep
26	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	treatment	treatment	NN	_	5	nsubj
3	with	with	IN	_	4	case
4	NEXAVAR	nexavar	NN	_	2	nmod
5	resulted	result	VBD	_	0	ROOT
6	in	in	IN	_	10	case
7	a	a	DT	_	10	det
8	21	21	CD	_	9	compound
9	%	%	NN	_	10	amod
10	increase	increase	NN	_	5	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	AUC	auc	NN	_	10	nmod
14	of	of	IN	_	15	case
15	doxorubicin	doxorubicin	NN	_	13	nmod
16	.	.	.	_	5	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	doxorubicin	doxorubicin	NN	_	5	dobj
7	with	with	IN	_	8	case
8	NEXAVAR	nexavar	NN	_	5	nmod
9	.	.	.	_	3	punct

1	Sorafenib	Sorafenib	NNP	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	CYP2B6	cyp2b6	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	CYP2C8	cyp2c8	NN	_	3	conj
6	in	in	FW	_	7	compound
7	vitro	vitro	FW	_	2	advmod
8	with	with	IN	_	10	case
9	Ki	ki	NN	_	10	compound
10	values	value	NNS	_	2	nmod
11	of	of	IN	_	12	case
12	6	6	CD	_	10	nmod
13	and	and	CC	_	12	cc
14	1	1	CD	_	12	conj
15	-	-	:	_	12	punct
16	2	2	CD	_	12	dep
17	?	?	.	_	2	punct
18	M	m	NN	_	2	dep
19	,	,	,	_	18	punct
20	respectively	respectively	RB	_	18	advmod
21	.	.	.	_	2	punct

1	Systemic	systemic	JJ	_	2	amod
2	exposure	exposure	NN	_	10	nsubjpass
3	to	to	TO	_	4	case
4	substrates	substrate	NNS	_	2	nmod
5	of	of	IN	_	6	case
6	CYP2B6	cyp2b6	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	CYP2C8	cyp2c8	NN	_	6	conj
9	is	be	VBZ	_	10	auxpass
10	expected	expect	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	increase	increase	VB	_	10	xcomp
13	when	when	WRB	_	16	advmod
14	co	co	SYM	_	16	dep
15	-	-	:	_	16	punct
16	administered	administer	VBN	_	12	advcl
17	with	with	IN	_	18	case
18	NEXAVAR	nexavar	NN	_	16	nmod
19	.	.	.	_	10	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	substrates	substrate	NNS	_	5	dobj
7	of	of	IN	_	8	case
8	CYP2B6	cyp2b6	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	CYP2C8	cyp2c8	NN	_	8	conj
11	with	with	IN	_	12	case
12	NEXAVAR	nexavar	NN	_	5	nmod
13	.	.	.	_	3	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	10	advcl
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	ProAmatine	ProAmatine	NNP	_	2	nmod
6	,	,	,	_	10	punct
7	cardiac	cardiac	JJ	_	8	amod
8	glycosides	glycoside	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	enhance	enhance	VB	_	0	ROOT
11	or	or	CC	_	10	cc
12	precipitate	precipitate	VB	_	10	conj
13	bradycardia	bradycardia	NN	_	10	dobj
14	,	,	,	_	13	punct
15	A	a	DT	_	17	compound
16	.	.	.	_	17	punct
17	V	V	NNP	_	13	appos
18	.	.	.	_	10	punct

1	block	block	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	arrhythmia	arrhythmia	NN	_	1	conj
4	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	that	that	WDT	_	6	nsubj
6	stimulate	stimulate	VBP	_	4	acl:relcl
7	alpha	alpha	NN	_	10	compound
8	-	-	:	_	10	punct
9	adrenergic	adrenergic	JJ	_	10	amod
10	receptors	receptor	NNS	_	6	dobj
11	(	(	VBP	_	0	ROOT
12	e	e	LS	_	11	dobj
13	.	.	.	_	12	punct
14	g	g	NN	_	12	dep
15	.	.	.	_	14	punct
16	,	,	,	_	14	punct
17	phenylephrine	phenylephrine	NN	_	26	compound
18	,	,	,	_	17	punct
19	pseudoephedrine	pseudoephedrine	NN	_	17	conj
20	,	,	,	_	17	punct
21	ephedrine	ephedrine	NN	_	17	conj
22	,	,	,	_	17	punct
23	phenylpropanolamine	phenylpropanolamine	NN	_	17	conj
24	or	or	CC	_	17	cc
25	dihydroergotamine	dihydroergotamine	NN	_	17	conj
26	)	)	NN	_	28	nsubj
27	may	may	MD	_	28	aux
28	enhance	enhance	VB	_	14	parataxis
29	or	or	CC	_	28	cc
30	potentiate	potentiate	VB	_	28	conj
31	the	the	DT	_	33	det
32	pressor	pressor	JJ	_	33	amod
33	effects	effect	NNS	_	28	dobj
34	of	of	IN	_	35	case
35	ProAmatine	ProAmatine	NNP	_	33	nmod
36	.	.	.	_	28	punct
37	Therefore	therefore	RB	_	28	advmod
38	,	,	,	_	28	punct
39	caution	caution	NN	_	42	nsubjpass
40	should	should	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	used	use	VBN	_	28	dep
43	when	when	WRB	_	46	advmod
44	ProAmatine	ProAmatine	NNP	_	46	nsubjpass
45	is	be	VBZ	_	46	auxpass
46	administered	administer	VBN	_	42	advcl
47	concomitantly	concomitantly	RB	_	46	advmod
48	with	with	IN	_	49	case
49	agents	agent	NNS	_	46	nmod
50	that	that	WDT	_	51	nsubj
51	cause	cause	VBP	_	49	acl:relcl
52	vasoconstriction	vasoconstriction	NN	_	51	dobj
53	.	.	.	_	11	punct

1	ProAmatine	ProAmatine	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	concomitantly	concomitantly	RB	_	8	advmod
8	treated	treat	VBN	_	6	acl
9	with	with	IN	_	10	case
10	salt	salt	NN	_	8	nmod
11	-	-	:	_	4	punct
12	retaining	retain	VBG	_	4	dep
13	steroid	steroid	NN	_	14	compound
14	therapy	therapy	NN	_	12	dobj
15	(	(	CD	_	14	nummod
16	i	i	LS	_	12	dep
17	.	.	.	_	16	punct
18	e	e	LS	_	16	dep
19	.	.	.	_	18	punct
20	,	,	,	_	18	punct
21	fludrocortisone	fludrocortisone	NN	_	23	compound
22	acetate	acetate	NN	_	23	compound
23	)	)	NN	_	18	dep
24	,	,	,	_	23	punct
25	with	with	IN	_	29	nmod
26	or	or	CC	_	25	cc
27	without	without	IN	_	25	conj
28	salt	salt	NN	_	29	compound
29	supplementation	supplementation	NN	_	23	nmod
30	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	potential	potential	NN	_	9	nsubjpass
3	for	for	IN	_	5	case
4	supine	supine	NN	_	5	compound
5	hypertension	hypertension	NN	_	2	nmod
6	should	should	MD	_	9	aux
7	be	be	VB	_	9	auxpass
8	carefully	carefully	RB	_	9	advmod
9	monitored	monitor	VBN	_	0	ROOT
10	in	in	IN	_	12	case
11	these	these	DT	_	12	det
12	patients	patient	NNS	_	9	nmod
13	and	and	CC	_	9	cc
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	minimized	minimize	VBN	_	9	conj
17	by	by	IN	_	19	mark
18	either	either	CC	_	19	cc:preconj
19	reducing	reduce	VBG	_	16	advcl
20	the	the	DT	_	21	det
21	dose	dose	NN	_	19	dobj
22	of	of	IN	_	24	case
23	fludrocortisone	fludrocortisone	NN	_	24	compound
24	acetate	acetate	NN	_	21	nmod
25	or	or	CC	_	19	cc
26	decreasing	decrease	VBG	_	19	conj
27	the	the	DT	_	29	det
28	salt	salt	NN	_	29	compound
29	intake	intake	NN	_	26	dobj
30	prior	prior	RB	_	26	advmod
31	to	to	TO	_	32	case
32	initiation	initiation	NN	_	30	nmod
33	of	of	IN	_	34	case
34	treatment	treatment	NN	_	32	nmod
35	with	with	IN	_	32	nmod
36	.	.	.	_	9	punct

1	ProAmatine	ProAmatine	NNP	_	19	dep
2	.	.	.	_	1	punct
3	Alpha	alpha	NN	_	7	compound
4	-	-	:	_	7	punct
5	adrenergic	adrenergic	JJ	_	7	amod
6	blocking	block	VBG	_	7	amod
7	agents	agent	NNS	_	19	nsubj
8	,	,	,	_	7	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	prazosin	prazosin	NN	_	7	nmod
12	,	,	,	_	11	punct
13	terazosin	terazosin	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	doxazosin	doxazosin	NN	_	11	conj
17	,	,	,	_	7	punct
18	can	can	MD	_	19	aux
19	antagonize	antagonize	VB	_	0	ROOT
20	the	the	DT	_	21	det
21	effects	effect	NNS	_	19	dobj
22	of	of	IN	_	23	case
23	ProAmatine	ProAmatine	NNP	_	21	nmod
24	.	.	.	_	19	punct
25	Potential	potential	JJ	_	19	dep
26	for	for	IN	_	28	case
27	Drug	drug	NN	_	28	compound
28	Interactions	interaction	NNS	_	25	nmod
29	:	:	:	_	19	punct
30	It	it	PRP	_	31	nsubj
31	appears	appear	VBZ	_	19	parataxis
32	possible	possible	JJ	_	31	xcomp
33	,	,	,	_	31	punct
34	although	although	IN	_	36	mark
35	there	there	EX	_	36	expl
36	is	be	VBZ	_	31	advcl
37	no	no	DT	_	40	neg
38	supporting	support	VBG	_	40	amod
39	experimental	experimental	JJ	_	40	amod
40	evidence	evidence	NN	_	36	nsubj
41	,	,	,	_	36	punct
42	that	that	IN	_	54	mark
43	the	the	DT	_	46	det
44	high	high	JJ	_	46	amod
45	renal	renal	JJ	_	46	amod
46	clearance	clearance	NN	_	54	nsubj
47	of	of	IN	_	49	case
48	desglymidodrine	desglymidodrine	JJ	_	49	amod
49	(	(	NN	_	46	nmod
50	a	a	DT	_	52	det
51	base	base	NN	_	52	compound
52	)	)	NN	_	49	dep
53	is	be	VBZ	_	54	cop
54	due	due	JJ	_	36	ccomp
55	to	to	TO	_	58	case
56	active	active	JJ	_	58	amod
57	tubular	tubular	JJ	_	58	amod
58	secretion	secretion	NN	_	54	nmod
59	by	by	IN	_	61	case
60	the	the	DT	_	61	det
61	base	base	NN	_	58	nmod
62	-	-	:	_	54	punct
63	secreting	secrete	VBG	_	64	amod
64	system	system	NN	_	54	dep
65	also	also	RB	_	66	advmod
66	responsible	responsible	JJ	_	64	amod
67	for	for	IN	_	69	case
68	the	the	DT	_	69	det
69	secretion	secretion	NN	_	66	nmod
70	of	of	IN	_	72	case
71	such	such	JJ	_	72	amod
72	drugs	drug	NNS	_	69	nmod
73	as	as	IN	_	74	case
74	metformin	metformin	NN	_	72	nmod
75	,	,	,	_	74	punct
76	cimetidine	cimetidine	NN	_	74	conj
77	,	,	,	_	74	punct
78	ranitidine	ranitidine	NN	_	74	conj
79	,	,	,	_	74	punct
80	procainamide	procainamide	NN	_	74	conj
81	,	,	,	_	74	punct
82	triamterene	triamterene	NN	_	74	conj
83	,	,	,	_	74	punct
84	flecainide	flecainide	NN	_	74	conj
85	,	,	,	_	74	punct
86	and	and	CC	_	74	cc
87	quinidine	quinidine	NN	_	74	conj
88	.	.	.	_	19	punct

1	Thus	thus	RB	_	6	advmod
2	there	there	EX	_	6	expl
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	a	a	DT	_	6	det
6	potential	potential	NN	_	0	ROOT
7	for	for	IN	_	11	case
8	drug	drug	NN	_	11	compound
9	-	-	:	_	11	punct
10	drug	drug	NN	_	11	compound
11	interactions	interaction	NNS	_	6	nmod
12	with	with	IN	_	14	case
13	these	these	DT	_	14	det
14	drugs	drug	NNS	_	11	nmod
15	.	.	.	_	6	punct

1	Thalidomide	Thalidomide	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	enhance	enhance	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	sedative	sedative	NN	_	9	compound
9	activity	activity	NN	_	6	dobj
10	of	of	IN	_	11	case
11	barbiturates	barbiturate	NNS	_	9	nmod
12	,	,	,	_	11	punct
13	alcohol	alcohol	NN	_	11	conj
14	,	,	,	_	11	punct
15	chlorpromazine	chlorpromazine	NN	_	11	conj
16	,	,	,	_	11	punct
17	and	and	CC	_	11	cc
18	reserpine	reserpine	NN	_	11	conj
19	.	.	.	_	4	punct

1	Peripheral	peripheral	JJ	_	2	amod
2	Neuropathy	neuropathy	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Medications	medication	NNS	_	14	nsubjpass
5	known	know	VBN	_	4	acl
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	associated	associate	VBN	_	5	xcomp
9	with	with	IN	_	11	case
10	peripheral	peripheral	JJ	_	11	amod
11	neuropathy	neuropathy	NN	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	used	use	VBN	_	2	appos
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	thalidomide	thalidomide	NN	_	19	dobj
21	.	.	.	_	2	punct

1	Oral	oral	JJ	_	2	amod
2	Contraceptives	contraceptive	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	7	case
5	10	10	CD	_	7	nummod
6	healthy	healthy	JJ	_	7	amod
7	women	woman	NNS	_	2	nmod
8	,	,	,	_	7	punct
9	the	the	DT	_	11	det
10	pharmacokinetic	pharmacokinetic	JJ	_	11	amod
11	profiles	profile	NNS	_	36	nsubjpass
12	of	of	IN	_	13	case
13	norethindrone	norethindrone	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	ethinyl	ethinyl	NN	_	16	compound
16	estradiol	estradiol	NN	_	13	conj
17	following	follow	VBG	_	18	case
18	administration	administration	NN	_	11	nmod
19	of	of	IN	_	22	case
20	a	a	DT	_	22	det
21	single	single	JJ	_	22	amod
22	dose	dose	NN	_	18	nmod
23	containing	contain	VBG	_	22	acl
24	1.0	1.0	CD	_	25	nummod
25	mg	mg	NN	_	23	dobj
26	of	of	IN	_	28	case
27	norethindrone	norethindrone	NN	_	28	compound
28	acetate	acetate	NN	_	25	nmod
29	and	and	CC	_	25	cc
30	75	75	CD	_	31	nummod
31	g	g	NN	_	25	conj
32	of	of	IN	_	34	case
33	ethinyl	ethinyl	NN	_	34	compound
34	estradiol	estradiol	NN	_	31	nmod
35	were	be	VBD	_	36	auxpass
36	studied	study	VBN	_	7	acl:relcl
37	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	were	be	VBD	_	4	cop
4	similar	similar	JJ	_	0	ROOT
5	with	with	IN	_	14	case
6	and	and	CC	_	14	cc
7	without	without	IN	_	8	case
8	coadministration	coadministration	NN	_	14	nmod
9	of	of	IN	_	12	case
10	thalidomide	thalidomide	NN	_	12	compound
11	200	200	CD	_	12	nummod
12	mg	mg	NN	_	8	nmod
13	/	/	:	_	14	punct
14	day	day	NN	_	4	nmod
15	to	to	TO	_	19	case
16	steady	steady	JJ	_	19	amod
17	-	-	:	_	19	punct
18	state	state	NN	_	19	compound
19	levels	level	NNS	_	14	nmod
20	.	.	.	_	4	punct

1	Important	important	JJ	_	2	amod
2	Non	non	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	Thalidomide	Thalidomide	NNP	_	7	compound
5	Drug	Drug	NNP	_	7	compound
6	Interactions	interaction	NNS	_	7	compound
7	Drugs	drug	NNS	_	2	dep
8	That	that	WDT	_	9	nsubj
9	Interfere	interfere	VBP	_	7	acl:relcl
10	with	with	IN	_	12	case
11	Hormonal	hormonal	JJ	_	12	amod
12	Contraceptives	contraceptive	NNS	_	9	nmod
13	:	:	:	_	2	punct
14	Concomitant	concomitant	JJ	_	15	amod
15	use	use	NN	_	2	dep
16	of	of	IN	_	17	case
17	HIV	hiv	NN	_	15	nmod
18	-	-	:	_	17	punct
19	protease	protease	NN	_	20	compound
20	inhibitors	inhibitor	NNS	_	17	dep
21	,	,	,	_	17	punct
22	griseofulvin	griseofulvin	NN	_	17	conj
23	,	,	,	_	17	punct
24	modafinil	modafinil	NN	_	17	conj
25	,	,	,	_	17	punct
26	penicillins	penicillin	NNS	_	17	conj
27	,	,	,	_	17	punct
28	rifampin	rifampin	NN	_	17	conj
29	,	,	,	_	17	punct
30	rifabutin	rifabutin	NN	_	17	conj
31	,	,	,	_	17	punct
32	phenytoin	phenytoin	NN	_	17	conj
33	,	,	,	_	17	punct
34	carbamazepine	carbamazepine	NN	_	17	conj
35	,	,	,	_	17	punct
36	or	or	CC	_	17	cc
37	certain	certain	JJ	_	39	amod
38	herbal	herbal	JJ	_	39	amod
39	supplements	supplement	NNS	_	17	conj
40	such	such	JJ	_	42	case
41	as	as	IN	_	40	mwe
42	St	St	NNP	_	39	nmod
43	.	.	.	_	2	punct

1	John	John	NNP	_	3	nmod:poss
2	'	'	POS	_	1	case
3	s	s	NNS	_	4	nsubj
4	Wort	wort	VBP	_	0	ROOT
5	with	with	IN	_	8	case
6	hormonal	hormonal	JJ	_	8	amod
7	contraceptive	contraceptive	JJ	_	8	amod
8	agents	agent	NNS	_	4	nmod
9	may	may	MD	_	10	aux
10	reduce	reduce	VB	_	4	dep
11	the	the	DT	_	12	det
12	effectiveness	effectiveness	NN	_	10	dobj
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	contraception	contraception	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	up	up	RB	_	19	advmod
18	to	to	TO	_	19	dep
19	one	one	CD	_	20	nummod
20	month	month	NN	_	12	conj
21	after	after	IN	_	20	case
22	discontinuation	discontinuation	NN	_	20	dep
23	of	of	IN	_	26	case
24	these	these	DT	_	26	det
25	concomitant	concomitant	JJ	_	26	amod
26	therapies	therapy	NNS	_	22	nmod
27	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	women	woman	NNS	_	14	nsubj
4	requiring	require	VBG	_	3	acl
5	treatment	treatment	NN	_	4	dobj
6	with	with	IN	_	7	case
7	one	one	CD	_	5	nmod
8	or	or	CC	_	7	cc
9	more	more	JJR	_	7	conj
10	of	of	IN	_	12	case
11	these	these	DT	_	12	det
12	drugs	drug	NNS	_	7	nmod
13	must	must	MD	_	14	aux
14	use	use	VB	_	0	ROOT
15	two	two	CD	_	21	nummod
16	OTHER	other	JJ	_	21	amod
17	effective	effective	JJ	_	21	amod
18	or	or	CC	_	17	cc
19	highly	highly	RB	_	20	advmod
20	effective	effective	JJ	_	17	conj
21	methods	method	NNS	_	14	dobj
22	of	of	IN	_	23	case
23	contraception	contraception	NN	_	21	nmod
24	or	or	CC	_	23	cc
25	abstain	abstain	NN	_	23	conj
26	from	from	IN	_	29	case
27	heterosexual	heterosexual	JJ	_	29	amod
28	sexual	sexual	JJ	_	29	amod
29	contact	contact	NN	_	14	nmod
30	while	while	IN	_	31	mark
31	taking	take	VBG	_	14	advcl
32	thalidomide	thalidomide	NN	_	31	dobj
33	.	.	.	_	14	punct

1	SKELAXIN	skelaxin	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	alcohol	alcohol	NN	_	5	nmod
8	,	,	,	_	7	punct
9	barbiturates	barbiturate	NNS	_	7	conj
10	and	and	CC	_	7	cc
11	other	other	JJ	_	13	amod
12	CNS	cns	NN	_	13	compound
13	depressants	depressant	NNS	_	7	conj
14	.	.	.	_	3	punct

1	MAO	mao	NN	_	2	compound
2	inhibitors	inhibitor	NNS	_	7	nsubj
3	and	and	CC	_	2	cc
4	beta	beta	NN	_	6	compound
5	adrenergic	adrenergic	JJ	_	6	amod
6	blockers	blocker	NNS	_	2	conj
7	increase	increase	VBP	_	0	ROOT
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	pseudoephedrine	pseudoephedrine	NN	_	9	nmod
12	.	.	.	_	7	punct

1	Sympathomimetics	sympathomimetic	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	reduce	reduce	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	antihypertensive	antihypertensive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	methyldopa	methyldopa	NN	_	6	nmod
9	,	,	,	_	8	punct
10	mecamylamine	mecamylamine	NN	_	8	conj
11	,	,	,	_	8	punct
12	reserpine	reserpine	NN	_	8	conj
13	and	and	CC	_	8	cc
14	veratrum	veratrum	NN	_	15	compound
15	alkaloids	alkaloid	NNS	_	8	conj
16	.	.	.	_	3	punct

1	Interactions	interaction	NNS	_	11	nsubjpass
2	between	between	IN	_	3	case
3	Leukine	Leukine	NNP	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	have	have	VBP	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	fully	fully	RB	_	11	advmod
11	evaluated	evaluate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Drugs	drug	NNS	_	19	nsubjpass
2	which	which	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	potentiate	potentiate	VB	_	1	acl:relcl
5	the	the	DT	_	7	det
6	myeloproliferative	myeloproliferative	JJ	_	7	amod
7	effects	effect	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	Leukine	Leukine	NNP	_	7	nmod
10	,	,	,	_	9	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	lithium	lithium	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	corticosteroids	corticosteroid	NNS	_	13	conj
16	,	,	,	_	9	punct
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	0	ROOT
20	with	with	IN	_	21	case
21	caution	caution	NN	_	19	nmod
22	.	.	.	_	19	punct

1	The	the	DT	_	4	det
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	binding	binding	NN	_	12	nsubj
5	of	of	IN	_	6	case
6	warfarin	warfarin	NN	_	4	nmod
7	to	to	TO	_	10	case
8	human	human	JJ	_	10	amod
9	plasma	plasma	NN	_	10	compound
10	proteins	protein	NNS	_	4	nmod
11	is	be	VBZ	_	12	aux
12	unaffected	unaffected	JJ	_	0	ROOT
13	by	by	IN	_	14	case
14	tolmetin	tolmetin	NN	_	12	nmod
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	tolmetin	tolmetin	NN	_	20	nsubj
18	does	do	VBZ	_	20	aux
19	not	not	RB	_	20	neg
20	alter	alter	VB	_	12	conj
21	the	the	DT	_	23	det
22	prothrombin	prothrombin	NN	_	23	compound
23	time	time	NN	_	20	dobj
24	of	of	IN	_	26	case
25	normal	normal	JJ	_	26	amod
26	volunteers	volunteer	NNS	_	23	nmod
27	.	.	.	_	12	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	increased	increase	VBD	_	5	amod
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	bleeding	bleeding	NN	_	5	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	on	on	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	TOLECTIN	tolectin	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	warfarin	warfarin	NN	_	18	compound
18	therapy	therapy	NN	_	15	conj
19	.	.	.	_	10	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	administering	administer	VBG	_	6	advcl
9	TOLECTIN	TOLECTIN	NNP	_	8	dobj
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	8	nmod
12	on	on	IN	_	13	case
13	anticoagulants	anticoagulant	NNS	_	11	nmod
14	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	adult	adult	JJ	_	4	amod
3	diabetic	diabetic	JJ	_	4	amod
4	patients	patient	NNS	_	13	nmod
5	under	under	IN	_	6	case
6	treatment	treatment	NN	_	4	nmod
7	with	with	IN	_	9	case
8	either	either	CC	_	9	cc:preconj
9	sulfonylureas	sulfonylureas	NN	_	6	nmod
10	or	or	CC	_	9	cc
11	insulin	insulin	NN	_	9	conj
12	there	there	EX	_	13	expl
13	is	be	VBZ	_	0	ROOT
14	no	no	DT	_	15	neg
15	change	change	NN	_	13	nsubj
16	in	in	IN	_	19	case
17	the	the	DT	_	19	det
18	clinical	clinical	JJ	_	19	amod
19	effects	effect	NNS	_	13	nmod
20	of	of	IN	_	22	case
21	either	either	CC	_	22	cc:preconj
22	TOLECTIN	tolectin	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	the	the	DT	_	26	det
25	hypoglycemic	hypoglycemic	JJ	_	26	amod
26	agents	agent	NNS	_	22	conj
27	.	.	.	_	13	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	TOLECTIN	tolectin	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	methotrexate	methotrexate	NN	_	8	nmod
12	.	.	.	_	4	punct

1	TOLECTIN	tolectin	NN	_	11	nsubjpass
2	and	and	CC	_	1	cc
3	other	other	JJ	_	8	amod
4	nonsteroidal	nonsteroidal	JJ	_	8	amod
5	anti	anti	JJ	_	8	amod
6	-	-	:	_	8	punct
7	inflammatory	inflammatory	JJ	_	8	amod
8	drugs	drug	NNS	_	1	conj
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	reduce	reduce	VB	_	11	xcomp
14	the	the	DT	_	16	det
15	tubular	tubular	JJ	_	16	amod
16	secretion	secretion	NN	_	13	dobj
17	of	of	IN	_	18	case
18	methotrexate	methotrexate	NN	_	16	nmod
19	in	in	IN	_	22	case
20	an	a	DT	_	22	det
21	animal	animal	NN	_	22	compound
22	model	model	NN	_	13	nmod
23	,	,	,	_	13	punct
24	possibly	possibly	RB	_	25	advmod
25	enhancing	enhance	VBG	_	13	advcl
26	the	the	DT	_	27	det
27	toxicity	toxicity	NN	_	25	dobj
28	of	of	IN	_	29	case
29	methotrexate	methotrexate	NN	_	27	nmod
30	.	.	.	_	11	punct

1	Laboratory	Laboratory	NNP	_	2	compound
2	Tests	Tests	NNP	_	0	ROOT
3	Because	because	IN	_	11	mark
4	serious	serious	JJ	_	7	amod
5	GI	gi	NN	_	7	compound
6	tract	tract	NN	_	7	compound
7	ulceration	ulceration	NN	_	11	nsubj
8	and	and	CC	_	7	cc
9	bleeding	bleeding	NN	_	7	conj
10	can	can	MD	_	11	aux
11	occur	occur	VB	_	2	acl
12	without	without	IN	_	13	mark
13	warning	warn	VBG	_	11	advcl
14	symptoms	symptom	NNS	_	13	dobj
15	,	,	,	_	2	punct
16	physicians	physician	NNS	_	18	nsubj
17	should	should	MD	_	18	aux
18	follow	follow	VB	_	2	acl:relcl
19	chronically	chronically	RB	_	20	advmod
20	treated	treat	VBN	_	21	amod
21	patients	patient	NNS	_	18	dobj
22	for	for	IN	_	24	case
23	the	the	DT	_	24	det
24	signs	sign	NNS	_	21	nmod
25	and	and	CC	_	24	cc
26	symptoms	symptom	NNS	_	24	conj
27	of	of	IN	_	28	case
28	ulceration	ulceration	NN	_	24	nmod
29	and	and	CC	_	28	cc
30	bleeding	bleeding	NN	_	28	conj
31	and	and	CC	_	18	cc
32	should	should	MD	_	33	aux
33	inform	inform	VB	_	18	conj
34	them	they	PRP	_	33	dobj
35	of	of	IN	_	37	case
36	the	the	DT	_	37	det
37	importance	importance	NN	_	33	nmod
38	of	of	IN	_	39	case
39	this	this	DT	_	37	nmod
40	follow	follow	VBP	_	18	dep
41	-	-	:	_	40	punct
42	up	up	RP	_	40	compound:prt
43	.	.	.	_	2	punct

1	An	a	DT	_	2	det
2	inhibitor	inhibitor	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	CYP2C8	cyp2c8	NN	_	2	nmod
5	(	(	CD	_	4	nummod
6	such	such	JJ	_	9	case
7	as	as	IN	_	6	mwe
8	gemfibrozil	gemfibrozil	NN	_	9	compound
9	)	)	NN	_	4	nmod
10	may	may	MD	_	11	aux
11	increase	increase	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	AUC	auc	NN	_	11	dobj
14	of	of	IN	_	15	case
15	rosiglitazone	rosiglitazone	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	an	a	DT	_	18	det
18	inducer	inducer	NN	_	13	conj
19	of	of	IN	_	20	case
20	CYP2C8	cyp2c8	NN	_	18	nmod
21	(	(	CD	_	20	nummod
22	such	such	JJ	_	25	case
23	as	as	IN	_	22	mwe
24	rifampin	rifampin	NN	_	25	compound
25	)	)	NN	_	20	nmod
26	may	may	MD	_	27	aux
27	decrease	decrease	VB	_	11	dep
28	the	the	DT	_	29	det
29	AUC	auc	NN	_	27	dobj
30	of	of	IN	_	31	case
31	rosiglitazone	rosiglitazone	NN	_	29	nmod
32	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	if	if	IN	_	5	mark
4	an	a	DT	_	5	det
5	inhibitor	inhibitor	NN	_	12	nsubjpass
6	or	or	CC	_	5	cc
7	an	a	DT	_	8	det
8	inducer	inducer	NN	_	5	conj
9	of	of	IN	_	10	case
10	CYP2C8	cyp2c8	NN	_	5	nmod
11	is	be	VBZ	_	12	auxpass
12	started	start	VBN	_	0	ROOT
13	or	or	CC	_	12	cc
14	stopped	stop	VBN	_	12	conj
15	during	during	IN	_	16	case
16	treatment	treatment	NN	_	12	nmod
17	with	with	IN	_	18	case
18	rosiglitazone	rosiglitazone	NN	_	16	nmod
19	,	,	,	_	12	punct
20	changes	change	NNS	_	26	nsubjpass
21	in	in	IN	_	23	case
22	diabetes	diabetes	NN	_	23	compound
23	treatment	treatment	NN	_	20	nmod
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	needed	need	VBN	_	12	parataxis
27	based	base	VBN	_	26	dep
28	upon	upon	IN	_	30	case
29	clinical	clinical	JJ	_	30	amod
30	response	response	NN	_	27	nmod
31	.	.	.	_	12	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	properties	property	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	abacavir	abacavir	NN	_	2	nmod
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	altered	alter	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	the	the	DT	_	10	det
10	addition	addition	NN	_	7	nmod
11	of	of	IN	_	13	case
12	either	either	CC	_	13	cc:preconj
13	lamivudine	lamivudine	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	zidovudine	zidovudine	NN	_	13	conj
16	or	or	CC	_	13	cc
17	the	the	DT	_	18	det
18	combination	combination	NN	_	13	conj
19	of	of	IN	_	20	case
20	lamivudine	lamivudine	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	zidovudine	zidovudine	NN	_	20	conj
23	.	.	.	_	7	punct

1	No	no	DT	_	4	neg
2	clinically	clinically	RB	_	3	advmod
3	significant	significant	JJ	_	4	amod
4	changes	change	NNS	_	11	nsubjpass
5	to	to	TO	_	6	case
6	lamivudine	lamivudine	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	zidovudine	zidovudine	NN	_	9	compound
9	pharmacokinetics	pharmacokinetic	NNS	_	6	conj
10	were	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	following	follow	VBG	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	administration	administration	NN	_	11	nmod
15	of	of	IN	_	16	case
16	abacavir	abacavir	NN	_	14	nmod
17	.	.	.	_	11	punct

1	Abacavir	Abacavir	NNP	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	properties	property	NNS	_	2	nmod
9	of	of	IN	_	10	case
10	ethanol	ethanol	NN	_	8	nmod
11	.	.	.	_	2	punct

1	Ethanol	ethanol	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	elimination	elimination	NN	_	2	dobj
5	of	of	IN	_	6	case
6	abacavir	abacavir	NN	_	4	nmod
7	causing	cause	VBG	_	4	acl
8	an	a	DT	_	9	det
9	increase	increase	NN	_	7	dobj
10	in	in	IN	_	12	case
11	overall	overall	JJ	_	12	amod
12	exposure	exposure	NN	_	9	nmod
13	.	.	.	_	2	punct
14	The	the	DT	_	15	det
15	addition	addition	NN	_	18	nsubj
16	of	of	IN	_	17	case
17	methadone	methadone	NN	_	15	nmod
18	has	have	VBZ	_	2	parataxis
19	no	no	DT	_	22	neg
20	clinically	clinically	RB	_	21	advmod
21	significant	significant	JJ	_	22	amod
22	effect	effect	NN	_	18	dobj
23	on	on	IN	_	26	case
24	the	the	DT	_	26	det
25	pharmacokinetic	pharmacokinetic	JJ	_	26	amod
26	properties	property	NNS	_	18	nmod
27	of	of	IN	_	28	case
28	abacavir	abacavir	NN	_	26	nmod
29	.	.	.	_	2	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	0	ROOT
4	of	of	IN	_	6	case
5	11	11	CD	_	6	nummod
6	HIV	hiv	NN	_	3	nmod
7	-	-	:	_	6	punct
8	infected	infected	JJ	_	9	amod
9	patients	patient	NNS	_	6	dep
10	receiving	receive	VBG	_	9	acl
11	methadone	methadone	NN	_	10	dobj
12	-	-	:	_	9	punct
13	maintenance	maintenance	NN	_	14	compound
14	therapy	therapy	NN	_	41	nsubj
15	(	(	CD	_	17	nummod
16	40	40	CD	_	17	nummod
17	mg	mg	NN	_	14	dep
18	and	and	CC	_	17	cc
19	90	90	CD	_	20	nummod
20	mg	mg	NN	_	17	conj
21	daily	daily	JJ	_	22	amod
22	)	)	NN	_	14	dep
23	with	with	IN	_	25	case
24	600	600	CD	_	25	nummod
25	mg	mg	NN	_	22	nmod
26	of	of	IN	_	27	case
27	ZIAGEN	ZIAGEN	NNP	_	25	nmod
28	twice	twice	RB	_	30	advmod
29	daily	daily	RB	_	30	advmod
30	(	(	CD	_	36	nummod
31	twice	twice	RB	_	30	advmod
32	the	the	DT	_	36	det
33	currently	currently	RB	_	34	advmod
34	recommended	recommend	VBN	_	36	amod
35	dose	dose	NN	_	36	compound
36	)	)	NN	_	22	dep
37	,	,	,	_	14	punct
38	oral	oral	JJ	_	40	amod
39	methadone	methadone	NN	_	40	compound
40	clearance	clearance	NN	_	14	conj
41	increased	increase	VBD	_	9	dep
42	22	22	CD	_	43	nummod
43	%	%	NN	_	47	amod
44	(	(	CD	_	46	compound
45	90	90	CD	_	46	compound
46	%	%	NN	_	47	amod
47	CI	ci	NN	_	41	dobj
48	6	6	CD	_	52	compound
49	%	%	NN	_	52	dep
50	to	to	TO	_	52	dep
51	42	42	CD	_	52	compound
52	%	%	NN	_	47	dep
53	)	)	CD	_	52	nummod
54	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	alteration	alteration	NN	_	5	nsubj
3	will	will	MD	_	5	aux
4	not	not	RB	_	5	neg
5	result	result	VB	_	0	ROOT
6	in	in	IN	_	10	case
7	a	a	DT	_	10	det
8	methadone	methadone	NN	_	10	compound
9	dose	dose	NN	_	10	compound
10	modification	modification	NN	_	5	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	majority	majority	NN	_	10	nmod
14	of	of	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	;	;	:	_	5	punct

1	however	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	an	a	DT	_	6	det
4	increased	increase	VBN	_	6	amod
5	methadone	methadone	NN	_	6	compound
6	dose	dose	NN	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	small	small	JJ	_	13	amod
13	number	number	NN	_	9	nmod
14	of	of	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	.	.	.	_	9	punct

1	Other	other	JJ	_	5	amod
2	beta	beta	NN	_	5	compound
3	adrenergic	adrenergic	JJ	_	5	amod
4	aerosol	aerosol	NN	_	5	compound
5	bronchodilators	bronchodilator	NNS	_	9	nsubjpass
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	auxpass
9	used	use	VBN	_	0	ROOT
10	concomitantly	concomitantly	RB	_	9	advmod
11	with	with	IN	_	17	case
12	Alupent	alupent	JJ	_	17	amod
13	(	(	NN	_	17	compound
14	metaproterenol	metaproterenol	NN	_	17	compound
15	sulfate	sulfate	NN	_	17	compound
16	USP	usp	NN	_	17	compound
17	)	)	NN	_	9	nmod
18	because	because	IN	_	21	mark
19	they	they	PRP	_	21	nsubj
20	may	may	MD	_	21	aux
21	have	have	VB	_	9	advcl
22	additive	additive	JJ	_	23	amod
23	effects	effect	NNS	_	21	dobj
24	.	.	.	_	9	punct

1	Beta	beta	NN	_	3	compound
2	adrenergic	adrenergic	JJ	_	3	amod
3	agonists	agonist	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	administered	administer	VBN	_	34	csubjpass
7	with	with	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	to	to	TO	_	10	case
10	patients	patient	NNS	_	6	nmod
11	being	be	VBG	_	12	auxpass
12	treated	treat	VBN	_	10	acl
13	with	with	IN	_	16	case
14	monoamine	monoamine	NN	_	16	compound
15	oxidase	oxidase	NN	_	16	compound
16	inhibitors	inhibitor	NNS	_	12	nmod
17	or	or	CC	_	16	cc
18	tricyclic	tricyclic	JJ	_	19	amod
19	antidepressants	antidepressant	NNS	_	16	conj
20	,	,	,	_	6	punct
21	since	since	IN	_	23	case
22	the	the	DT	_	23	det
23	action	action	NN	_	6	nmod
24	of	of	IN	_	27	case
25	beta	beta	NN	_	27	compound
26	adrenergic	adrenergic	JJ	_	27	amod
27	agonists	agonist	NNS	_	23	nmod
28	on	on	IN	_	31	case
29	the	the	DT	_	31	det
30	vascular	vascular	JJ	_	31	amod
31	system	system	NN	_	23	nmod
32	may	may	MD	_	34	aux
33	be	be	VB	_	34	auxpass
34	potentiated	potentiate	VBN	_	0	ROOT
35	.	.	.	_	34	punct

1	A	a	DT	_	2	det
2	study	study	NN	_	6	nsubj
3	published	publish	VBN	_	2	acl
4	in	in	IN	_	5	case
5	2002	2002	CD	_	3	nmod
6	found	find	VBD	_	0	ROOT
7	that	that	IN	_	9	mark
8	vigabatrin	vigabatrin	NN	_	9	nsubj
9	causes	cause	VBZ	_	6	ccomp
10	a	a	DT	_	13	det
11	statistically	statistically	RB	_	12	advmod
12	significant	significant	JJ	_	13	amod
13	increase	increase	NN	_	9	dobj
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	clearance	clearance	NN	_	13	nmod
17	of	of	IN	_	18	case
18	carbamazepine	carbamazepine	NN	_	16	nmod
19	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	1984	1984	CD	_	13	nmod
3	,	,	,	_	13	punct
4	Drs	Drs	NNP	_	5	compound
5	Rimmer	Rimmer	NNP	_	13	nsubj
6	and	and	CC	_	5	cc
7	Richens	Richens	NNP	_	5	conj
8	at	at	IN	_	10	case
9	the	the	DT	_	10	det
10	University	University	NNP	_	5	nmod
11	of	of	IN	_	12	case
12	Wales	Wales	NNP	_	10	nmod
13	reported	report	VBD	_	0	ROOT
14	that	that	IN	_	19	mark
15	administering	administer	VBG	_	19	csubj
16	vigabatrin	vigabatrin	NN	_	15	dobj
17	with	with	IN	_	18	case
18	phenytoin	phenytoin	NN	_	15	nmod
19	lowered	lower	VBD	_	13	ccomp
20	the	the	DT	_	23	det
21	serum	serum	NN	_	23	compound
22	phenytoin	phenytoin	NN	_	23	compound
23	concentration	concentration	NN	_	19	dobj
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	23	nmod
26	with	with	IN	_	27	case
27	treatment	treatment	NN	_	25	nmod
28	-	-	:	_	19	punct
29	resistant	resistant	JJ	_	30	amod
30	epilepsy	epilepsy	NN	_	19	dep
31	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	concentration	concentration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	phenytoin	phenytoin	NN	_	2	nmod
5	falls	fall	VBZ	_	0	ROOT
6	to	to	TO	_	8	case
7	23	23	CD	_	8	nummod
8	%	%	NN	_	5	nmod
9	within	within	IN	_	11	case
10	five	five	CD	_	11	nummod
11	weeks	week	NNS	_	5	nmod
12	,	,	,	_	5	punct
13	according	accord	VBG	_	16	case
14	to	to	TO	_	13	mwe
15	an	a	DT	_	16	det
16	experiment	experiment	NN	_	5	nmod
17	published	publish	VBN	_	16	acl
18	in	in	IN	_	19	case
19	1989	1989	CD	_	17	nmod
20	by	by	IN	_	24	case
21	the	the	DT	_	24	det
22	same	same	JJ	_	24	amod
23	two	two	CD	_	24	nummod
24	scientists	scientist	NNS	_	17	nmod
25	that	that	WDT	_	26	nsubj
26	tried	try	VBD	_	24	acl:relcl
27	and	and	CC	_	26	cc
28	failed	fail	VBD	_	26	conj
29	to	to	TO	_	30	mark
30	elucidate	elucidate	VB	_	28	xcomp
31	the	the	DT	_	32	det
32	mechanism	mechanism	NN	_	30	dobj
33	behind	behind	IN	_	35	case
34	this	this	DT	_	35	det
35	interaction	interaction	NN	_	32	nmod
36	.	.	.	_	5	punct

1	Triprolidine	triprolidine	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	sedative	sedative	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	11	case
8	central	central	JJ	_	11	amod
9	nervous	nervous	JJ	_	11	amod
10	system	system	NN	_	11	compound
11	depressants	depressant	NNS	_	6	nmod
12	including	include	VBG	_	13	case
13	alcohol	alcohol	NN	_	11	nmod
14	,	,	,	_	13	punct
15	barbiturates	barbiturate	NNS	_	13	conj
16	,	,	,	_	13	punct
17	hypnotics	hypnotic	NNS	_	13	conj
18	,	,	,	_	13	punct
19	narcotic	narcotic	JJ	_	20	amod
20	analgesics	analgesic	NNS	_	13	conj
21	,	,	,	_	13	punct
22	sedatives	sedative	NNS	_	13	conj
23	,	,	,	_	13	punct
24	and	and	CC	_	13	cc
25	tranquillisers	tranquilliser	NNS	_	13	conj
26	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	15	nsubjpass
3	of	of	IN	_	5	case
4	anticholinergic	anticholinergic	JJ	_	5	amod
5	drugs	drug	NNS	_	2	nmod
6	,	,	,	_	5	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	atropine	atropine	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	tricyclic	tricyclic	JJ	_	12	amod
12	antidepressants	antidepressant	NNS	_	9	conj
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	enhanced	enhance	VBN	_	0	ROOT
16	by	by	IN	_	19	case
17	the	the	DT	_	19	det
18	concomitant	concomitant	JJ	_	19	amod
19	administration	administration	NN	_	15	nmod
20	of	of	IN	_	21	case
21	triprolidine	triprolidine	NN	_	19	nmod
22	.	.	.	_	15	punct

1	Triprolidine	triprolidine	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	effect	effect	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	metabolism	metabolism	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	liver	liver	NN	_	3	nmod
11	.	.	.	_	3	punct

1	Interactions	interaction	NNS	_	11	nsubjpass
2	between	between	IN	_	3	case
3	ZADAXIN	ZADAXIN	NNP	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	have	have	VBP	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	fully	fully	RB	_	11	advmod
11	evaluated	evaluate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	ZADAXIN	zadaxin	NN	_	8	compound
8	therapy	therapy	NN	_	6	dobj
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	14	case
12	other	other	JJ	_	14	amod
13	immunomodulating	immunomodulating	JJ	_	14	amod
14	drugs	drug	NNS	_	10	nmod
15	.	.	.	_	4	punct

1	ZADAXIN	zadaxin	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	mixed	mix	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	any	any	DT	_	9	det
8	other	other	JJ	_	9	amod
9	drug	drug	NN	_	5	nmod
10	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	Retavase	retavase	NN	_	2	nmod
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	cardioactive	cardioactive	JJ	_	8	amod
8	drugs	drug	NNS	_	2	nmod
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	29	nmod
3	to	to	TO	_	4	case
4	bleeding	bleeding	NN	_	2	nmod
5	associated	associate	VBN	_	4	acl
6	with	with	IN	_	7	case
7	heparin	heparin	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	vitamin	vitamin	NN	_	11	compound
10	K	k	NN	_	11	compound
11	antagonists	antagonist	NNS	_	7	conj
12	,	,	,	_	7	punct
13	drugs	drug	NNS	_	7	appos
14	that	that	WDT	_	15	nsubj
15	alter	alter	VBP	_	13	acl:relcl
16	platelet	platelet	NN	_	17	compound
17	function	function	NN	_	15	dobj
18	(	(	CD	_	17	dep
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	aspirin	aspirin	NN	_	18	nmod
22	,	,	,	_	21	punct
23	dipyridamole	dipyridamole	NN	_	21	conj
24	,	,	,	_	21	punct
25	and	and	CC	_	21	cc
26	abciximab	abciximab	NN	_	27	compound
27	)	)	NN	_	21	conj
28	may	may	MD	_	29	aux
29	increase	increase	VB	_	0	ROOT
30	the	the	DT	_	31	det
31	risk	risk	NN	_	29	dobj
32	of	of	IN	_	33	case
33	bleeding	bleed	VBG	_	31	nmod
34	if	if	IN	_	35	mark
35	administered	administer	VBN	_	29	advcl
36	prior	prior	RB	_	41	advmod
37	to	to	TO	_	41	nmod
38	or	or	CC	_	37	cc
39	after	after	IN	_	37	conj
40	Retavase	retavase	NN	_	41	compound
41	therapy	therapy	NN	_	35	nmod
42	.	.	.	_	29	punct

1	The	the	DT	_	2	det
2	occurrence	occurrence	NN	_	17	nsubjpass
3	of	of	IN	_	4	case
4	stupor	stupor	NN	_	2	nmod
5	,	,	,	_	4	punct
6	muscular	muscular	JJ	_	7	amod
7	rigidity	rigidity	NN	_	4	conj
8	,	,	,	_	4	punct
9	severe	severe	JJ	_	10	amod
10	agitation	agitation	NN	_	4	conj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	elevated	elevated	JJ	_	14	amod
14	temperature	temperature	NN	_	4	conj
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	0	ROOT
18	in	in	IN	_	20	case
19	some	some	DT	_	20	det
20	patients	patient	NNS	_	17	nmod
21	receiving	receive	VBG	_	20	acl
22	the	the	DT	_	23	det
23	combination	combination	NN	_	21	dobj
24	of	of	IN	_	25	case
25	selegiline	selegiline	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	meperidine	meperidine	NN	_	25	conj
28	.	.	.	_	17	punct

1	Symptoms	symptom	NNS	_	3	nsubj
2	usually	usually	RB	_	3	advmod
3	resolve	resolve	VBP	_	0	ROOT
4	over	over	IN	_	5	case
5	days	day	NNS	_	3	nmod
6	when	when	WRB	_	10	advmod
7	the	the	DT	_	8	det
8	combination	combination	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	discontinued	discontinue	VBN	_	5	acl:relcl
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	typical	typical	JJ	_	0	ROOT
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	of	of	IN	_	8	case
8	meperidine	meperidine	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	MAOIs	maoi	NNS	_	8	conj
11	.	.	.	_	3	punct

1	Other	other	JJ	_	3	amod
2	serious	serious	JJ	_	3	amod
3	reactions	reaction	NNS	_	4	nsubj
4	(	(	VBP	_	0	ROOT
5	including	include	VBG	_	7	case
6	severe	severe	JJ	_	7	amod
7	agitation	agitation	NN	_	4	nmod
8	,	,	,	_	7	punct
9	hallucinations	hallucination	NNS	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	death	death	NN	_	7	conj
13	)	)	CD	_	12	nummod
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	reported	report	VBN	_	4	dep
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	this	this	DT	_	21	det
21	combination	combination	NN	_	19	dobj
22	.	.	.	_	4	punct

1	Severe	severe	JJ	_	2	amod
2	toxicity	toxicity	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	the	the	DT	_	11	det
11	combination	combination	NN	_	9	dobj
12	of	of	IN	_	14	case
13	tricyclic	tricyclic	JJ	_	14	amod
14	antidepressants	antidepressant	NNS	_	11	nmod
15	and	and	CC	_	14	cc
16	ELDEPRYL	eldepryl	NN	_	14	conj
17	and	and	CC	_	16	cc
18	selective	selective	JJ	_	21	amod
19	serotonin	serotonin	NN	_	21	compound
20	reuptake	reuptake	NN	_	21	compound
21	inhibitors	inhibitor	NNS	_	16	conj
22	and	and	CC	_	16	cc
23	ELDEPRYL	eldepryl	NN	_	16	conj
24	.	.	.	_	6	punct

1	One	one	CD	_	2	nummod
2	case	case	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	hypertensive	hypertensive	JJ	_	5	amod
5	crisis	crisis	NN	_	2	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	a	a	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	taking	take	VBG	_	11	acl
13	the	the	DT	_	15	det
14	recommended	recommend	VBN	_	15	amod
15	doses	dose	NNS	_	12	dobj
16	of	of	IN	_	17	case
17	selegiline	selegiline	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	a	a	DT	_	24	det
20	sympathomimetic	sympathomimetic	JJ	_	24	amod
21	medication	medication	NN	_	24	compound
22	(	(	NN	_	24	compound
23	ephedrine	ephedrine	NN	_	24	compound
24	)	)	NN	_	17	conj
25	.	.	.	_	8	punct

1	When	when	WRB	_	6	advmod
2	atropine	atropine	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	pralidoxime	pralidoxime	NN	_	2	conj
5	are	be	VBP	_	6	auxpass
6	used	use	VBN	_	28	advcl
7	together	together	RB	_	6	advmod
8	,	,	,	_	28	punct
9	the	the	DT	_	10	det
10	signs	sign	NNS	_	28	nsubj
11	of	of	IN	_	14	case
12	atropinization	atropinization	NN	_	14	compound
13	(	(	CD	_	14	nummod
14	flushing	flushing	NN	_	10	nmod
15	,	,	,	_	14	punct
16	mydriasis	mydriasis	NN	_	14	conj
17	,	,	,	_	14	punct
18	tachycardia	tachycardia	NN	_	14	conj
19	,	,	,	_	14	punct
20	dryness	dryness	NN	_	14	appos
21	of	of	IN	_	26	case
22	the	the	DT	_	26	det
23	mouth	mouth	NN	_	26	compound
24	and	and	CC	_	23	cc
25	nose	nose	NN	_	23	conj
26	)	)	NN	_	20	nmod
27	may	may	MD	_	28	aux
28	occur	occur	VB	_	0	ROOT
29	earlier	earlier	JJR	_	28	advmod
30	than	than	IN	_	33	mark
31	might	might	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	expected	expect	VBN	_	29	advcl
34	when	when	WRB	_	37	advmod
35	atropine	atropine	NN	_	37	nsubjpass
36	is	be	VBZ	_	37	auxpass
37	used	use	VBN	_	33	advcl
38	alone	alone	RB	_	37	advmod
39	.	.	.	_	28	punct

1	This	this	DT	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	especially	especially	RB	_	4	advmod
4	true	true	JJ	_	0	ROOT
5	if	if	IN	_	13	mark
6	the	the	DT	_	8	det
7	total	total	JJ	_	8	amod
8	dose	dose	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	atropine	atropine	NN	_	8	nmod
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	cop
13	large	large	JJ	_	4	advcl
14	and	and	CC	_	13	cc
15	the	the	DT	_	16	det
16	administration	administration	NN	_	21	nsubjpass
17	of	of	IN	_	18	case
18	pralidoxime	pralidoxime	NN	_	16	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	delayed	delay	VBN	_	13	conj
22	.	.	.	_	4	punct

1	2	2	LS	_	0	ROOT
2	-	-	:	_	1	punct
3	4	4	CD	_	6	nummod
4	The	the	DT	_	6	det
5	following	follow	VBG	_	6	amod
6	precautions	precaution	NNS	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	kept	keep	VBN	_	1	dep
10	in	in	IN	_	11	case
11	mind	mind	NN	_	9	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	treatment	treatment	NN	_	9	nmod
15	of	of	IN	_	17	case
16	anticholinesterase	anticholinesterase	JJ	_	17	amod
17	poisoning	poisoning	NN	_	14	nmod
18	,	,	,	_	9	punct
19	although	although	IN	_	23	mark
20	they	they	PRP	_	23	nsubj
21	do	do	VBP	_	23	aux
22	not	not	RB	_	23	neg
23	bear	bear	VB	_	9	advcl
24	directly	directly	RB	_	23	advmod
25	on	on	IN	_	27	case
26	the	the	DT	_	27	det
27	use	use	NN	_	23	nmod
28	of	of	IN	_	29	case
29	pralidoxime	pralidoxime	NN	_	27	nmod
30	:	:	:	_	9	punct
31	since	since	IN	_	34	mark
32	barbiturates	barbiturate	NNS	_	34	nsubjpass
33	are	be	VBP	_	34	auxpass
34	potentiated	potentiate	VBN	_	42	advcl
35	by	by	IN	_	37	case
36	the	the	DT	_	37	det
37	anticholinesterases	anticholinesterase	NNS	_	34	nmod
38	,	,	,	_	42	punct
39	they	they	PRP	_	42	nsubjpass
40	should	should	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	used	use	VBN	_	9	parataxis
43	cautiously	cautiously	RB	_	42	advmod
44	in	in	IN	_	46	case
45	the	the	DT	_	46	det
46	treatment	treatment	NN	_	42	nmod
47	of	of	IN	_	48	case
48	convulsions	convulsion	NNS	_	46	nmod
49	;	;	:	_	1	punct

1	morphine	morphine	NN	_	18	nsubjpass
2	,	,	,	_	1	punct
3	theophylline	theophylline	NN	_	1	conj
4	,	,	,	_	1	punct
5	aminophylline	aminophylline	NN	_	1	conj
6	,	,	,	_	1	punct
7	succinylcholine	succinylcholine	NN	_	1	conj
8	,	,	,	_	1	punct
9	reserpine	reserpine	NN	_	1	conj
10	,	,	,	_	1	punct
11	and	and	CC	_	1	cc
12	phenothiazine	phenothiazine	NN	_	15	compound
13	-	-	:	_	15	punct
14	type	type	NN	_	15	compound
15	tranquilizers	tranquilizer	NNS	_	1	conj
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	avoided	avoid	VBN	_	0	ROOT
19	in	in	IN	_	20	case
20	patients	patient	NNS	_	18	nmod
21	with	with	IN	_	23	case
22	organophosphate	organophosphate	NN	_	23	compound
23	poisoning	poisoning	NN	_	20	nmod
24	.	.	.	_	18	punct

1	No	no	DT	_	2	neg
2	drug	drug	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	conducted	conduct	VBN	_	2	dep
10	with	with	IN	_	11	case
11	depo	depo	NN	_	9	nmod
12	-	-	:	_	11	punct
13	subQ	subq	NN	_	14	compound
14	provera	provera	NN	_	11	dep
15	104	104	CD	_	14	nummod
16	.	.	.	_	2	punct

1	Aminoglutethimide	Aminoglutethimide	NNP	_	2	nsubj
2	administered	administer	VBN	_	12	csubj
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	depo	depo	NN	_	2	nmod
6	-	-	:	_	5	punct
7	subQ	subq	NN	_	8	compound
8	provera	provera	NN	_	5	dep
9	104	104	CD	_	8	nummod
10	may	may	MD	_	12	aux
11	significantly	significantly	RB	_	12	advmod
12	decrease	decrease	VB	_	0	ROOT
13	the	the	DT	_	15	det
14	serum	serum	NN	_	15	compound
15	concentrations	concentration	NNS	_	12	dobj
16	of	of	IN	_	17	case
17	MPA	MPA	NNP	_	15	nmod
18	.	.	.	_	12	punct

1	Laboratory	laboratory	NN	_	2	compound
2	Tests	test	NNS	_	0	ROOT
3	The	the	DT	_	4	det
4	pathologist	pathologist	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	advised	advise	VBN	_	2	acl:relcl
8	of	of	IN	_	10	case
9	progestin	progestin	NN	_	10	compound
10	therapy	therapy	NN	_	7	nmod
11	when	when	WRB	_	15	advmod
12	relevant	relevant	JJ	_	13	amod
13	specimens	specimen	NNS	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	submitted	submit	VBN	_	7	advcl
16	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	informed	inform	VBN	_	0	ROOT
6	that	that	IN	_	19	mark
7	certain	certain	JJ	_	12	amod
8	endocrine	endocrine	JJ	_	12	amod
9	and	and	CC	_	8	cc
10	liver	liver	NN	_	8	conj
11	function	function	NN	_	12	compound
12	tests	test	NNS	_	19	nsubjpass
13	,	,	,	_	12	punct
14	and	and	CC	_	12	cc
15	blood	blood	NN	_	16	compound
16	components	component	NNS	_	12	conj
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	affected	affect	VBN	_	5	ccomp
20	by	by	IN	_	22	case
21	progestin	progestin	NN	_	22	compound
22	therapy	therapy	NN	_	19	nmod
23	:	:	:	_	5	punct
24	(	(	CD	_	27	nummod
25	a	a	DT	_	27	det
26	)	)	NN	_	27	compound
27	Plasma	plasma	NN	_	33	nsubjpass
28	and	and	CC	_	27	cc
29	urinary	urinary	JJ	_	31	amod
30	steroid	steroid	NN	_	31	compound
31	levels	level	NNS	_	27	conj
32	are	be	VBP	_	33	auxpass
33	decreased	decrease	VBN	_	5	parataxis
34	(	(	NN	_	37	compound
35	e	e	LS	_	37	dep
36	.	.	.	_	35	punct
37	g	g	NN	_	33	dobj
38	.	.	.	_	33	punct
39	,	,	,	_	33	punct
40	progesterone	progesterone	NN	_	33	dobj
41	,	,	,	_	40	punct
42	estradiol	estradiol	NN	_	40	conj
43	,	,	,	_	40	punct
44	pregnanediol	pregnanediol	NN	_	40	conj
45	,	,	,	_	40	punct
46	testosterone	testosterone	NN	_	40	conj
47	,	,	,	_	40	punct
48	cortisol	cortisol	NN	_	49	compound
49	)	)	NN	_	40	conj
50	.	.	.	_	5	punct

1	(	(	NN	_	4	compound
2	b	b	NN	_	4	compound
3	)	)	CD	_	4	nummod
4	Plasma	plasma	NN	_	10	nsubjpass
5	and	and	CC	_	4	cc
6	urinary	urinary	JJ	_	8	amod
7	gonadotropin	gonadotropin	NN	_	8	compound
8	levels	level	NNS	_	4	conj
9	are	be	VBP	_	10	auxpass
10	decreased	decrease	VBN	_	0	ROOT
11	(	(	NN	_	14	compound
12	e	e	LS	_	14	dep
13	.	.	.	_	12	punct
14	g	g	NN	_	10	dobj
15	.	.	.	_	10	punct
16	,	,	,	_	10	punct
17	LH	LH	NNP	_	10	dobj
18	,	,	,	_	17	punct
19	FSH	FSH	NNP	_	17	appos
20	)	)	CD	_	19	nummod
21	.	.	.	_	10	punct

1	(	(	NN	_	5	compound
2	c	c	NN	_	5	compound
3	)	)	CD	_	5	nummod
4	SHBG	shbg	NN	_	5	compound
5	concentrations	concentration	NNS	_	7	nsubjpass
6	are	be	VBP	_	7	auxpass
7	decreased	decrease	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	(	(	NN	_	4	compound
2	d	d	NN	_	4	compound
3	)	)	CD	_	4	nummod
4	T3	t3	NN	_	0	ROOT
5	-	-	:	_	4	punct
6	uptake	uptake	NN	_	7	compound
7	values	value	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	decrease	decrease	VB	_	4	dep
10	.	.	.	_	4	punct

1	(	(	NN	_	3	dep
2	e	e	SYM	_	3	dep
3	)	)	CD	_	8	dep
4	There	there	EX	_	8	expl
5	may	may	MD	_	8	aux
6	be	be	VB	_	8	cop
7	small	small	JJ	_	8	amod
8	changes	change	NNS	_	0	ROOT
9	in	in	IN	_	11	case
10	coagulation	coagulation	NN	_	11	compound
11	factors	factor	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	(	(	NN	_	4	compound
2	f	f	SYM	_	4	dep
3	)	)	CD	_	4	nummod
4	Sulfobromophthalein	sulfobromophthalein	NN	_	13	nsubjpass
5	and	and	CC	_	4	cc
6	other	other	JJ	_	10	amod
7	liver	liver	NN	_	10	compound
8	function	function	NN	_	10	compound
9	test	test	NN	_	10	compound
10	values	value	NNS	_	4	conj
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	increased	increase	VBN	_	0	ROOT
14	slightly	slightly	RB	_	13	advmod
15	.	.	.	_	13	punct

1	(	(	CD	_	2	nummod
2	g	g	NN	_	8	nsubj
3	)	)	CD	_	2	nummod
4	There	there	EX	_	8	expl
5	may	may	MD	_	8	aux
6	be	be	VB	_	8	cop
7	small	small	JJ	_	8	amod
8	changes	change	NNS	_	0	ROOT
9	in	in	IN	_	11	case
10	lipid	lipid	NN	_	11	compound
11	profiles	profile	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	38	nmod
4	of	of	IN	_	5	case
5	TOBI	TOBI	NNP	_	3	nmod
6	,	,	,	_	38	punct
7	patients	patient	NNS	_	38	nsubj
8	taking	take	VBG	_	7	acl
9	TOBI	TOBI	NNP	_	8	dobj
10	concomitantly	concomitantly	RB	_	8	advmod
11	with	with	IN	_	13	case
12	dornase	dornase	NN	_	13	compound
13	alfa	alfa	NN	_	8	nmod
14	(	(	CD	_	15	nummod
15	PULMOZYME	PULMOZYME	NNP	_	26	nsubj
16	,	,	,	_	15	punct
17	Genentech	Genentech	NNP	_	18	compound
18	)	)	NNP	_	15	appos
19	,	,	,	_	15	punct
20	(	(	CD	_	21	nummod
21	beta	beta	NN	_	24	compound
22	)	)	SYM	_	24	dep
23	-	-	:	_	24	punct
24	agonists	agonist	NNS	_	15	appos
25	,	,	,	_	15	punct
26	inhaled	inhale	VBD	_	13	acl:relcl
27	corticosteroids	corticosteroid	NNS	_	26	dobj
28	,	,	,	_	7	punct
29	other	other	JJ	_	33	amod
30	anti	anti	JJ	_	33	amod
31	-	-	:	_	33	punct
32	pseudomonal	pseudomonal	JJ	_	33	amod
33	antibiotics	antibiotic	NNS	_	7	conj
34	,	,	,	_	7	punct
35	or	or	CC	_	7	cc
36	parenteral	parenteral	JJ	_	37	amod
37	aminoglycosides	aminoglycoside	NNS	_	7	conj
38	demonstrated	demonstrate	VBD	_	0	ROOT
39	adverse	adverse	JJ	_	41	amod
40	experience	experience	NN	_	41	compound
41	profiles	profile	NNS	_	38	dobj
42	similar	similar	JJ	_	41	amod
43	to	to	TO	_	46	case
44	the	the	DT	_	46	det
45	study	study	NN	_	46	compound
46	population	population	NN	_	42	nmod
47	as	as	IN	_	49	case
48	a	a	DT	_	49	det
49	whole	whole	NN	_	46	nmod
50	.	.	.	_	38	punct

1	Concurrent	concurrent	JJ	_	19	nsubjpass
2	and	and	CC	_	1	cc
3	/	/	:	_	6	punct
4	or	or	CC	_	6	cc
5	sequential	sequential	JJ	_	6	amod
6	use	use	NN	_	1	conj
7	of	of	IN	_	8	case
8	TOBI	tobi	NN	_	6	nmod
9	with	with	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	8	nmod
12	with	with	IN	_	16	case
13	neurotoxic	neurotoxic	JJ	_	16	amod
14	or	or	CC	_	13	cc
15	ototoxic	ototoxic	JJ	_	13	conj
16	potential	potential	NN	_	6	nmod
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	avoided	avoid	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Some	some	DT	_	2	det
2	diuretics	diuretic	NNS	_	4	nsubj
3	can	can	MD	_	4	aux
4	enhance	enhance	VB	_	0	ROOT
5	aminoglycoside	aminoglycoside	NN	_	6	compound
6	toxicity	toxicity	NN	_	4	dobj
7	by	by	IN	_	8	mark
8	altering	alter	VBG	_	4	advcl
9	antibiotic	antibiotic	JJ	_	10	amod
10	concentrations	concentration	NNS	_	8	dobj
11	in	in	IN	_	12	case
12	serum	serum	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	tissue	tissue	NN	_	12	conj
15	.	.	.	_	4	punct

1	TOBI	TOBI	NNP	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	9	case
8	ethacrynic	ethacrynic	JJ	_	9	amod
9	acid	acid	NN	_	5	nmod
10	,	,	,	_	9	punct
11	furosemide	furosemide	NN	_	9	conj
12	,	,	,	_	9	punct
13	urea	urea	NN	_	9	conj
14	,	,	,	_	9	punct
15	or	or	CC	_	9	cc
16	mannitol	mannitol	NN	_	9	conj
17	.	.	.	_	5	punct

1	DRUG	drug	NN	_	2	compound
2	INTERACTIONS	interaction	NNS	_	0	ROOT
3	There	there	EX	_	4	expl
4	are	be	VBP	_	2	acl:relcl
5	no	no	RB	_	6	neg
6	known	know	VBN	_	10	amod
7	drug	drug	NN	_	10	compound
8	/	/	:	_	10	punct
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	21	nsubjpass
11	with	with	IN	_	14	case
12	oral	oral	JJ	_	14	amod
13	ALKERAN	ALKERAN	NNP	_	14	compound
14	Vaccinations	Vaccinations	NNPS	_	10	nmod
15	with	with	IN	_	18	case
16	live	live	JJ	_	18	amod
17	organism	organism	NN	_	18	compound
18	vaccines	vaccine	NNS	_	10	nmod
19	are	be	VBP	_	21	auxpass
20	not	not	RB	_	21	neg
21	recommended	recommend	VBN	_	4	ccomp
22	in	in	IN	_	24	case
23	immunocompromised	immunocompromised	JJ	_	24	amod
24	individuals	individual	NNS	_	35	nmod
25	Nalidixic	nalidixic	JJ	_	26	amod
26	acid	acid	NN	_	35	nsubj
27	together	together	RB	_	26	advmod
28	with	with	IN	_	33	case
29	high	high	JJ	_	33	amod
30	-	-	:	_	33	punct
31	dose	dose	NN	_	33	compound
32	intravenous	intravenous	JJ	_	33	amod
33	melphalan	melphalan	NN	_	26	nmod
34	has	have	VBZ	_	35	aux
35	caused	cause	VBN	_	21	ccomp
36	deaths	death	NNS	_	35	dobj
37	in	in	IN	_	38	case
38	children	child	NNS	_	36	nmod
39	due	due	JJ	_	35	advmod
40	to	to	TO	_	42	case
41	haemorrhagic	haemorrhagic	JJ	_	42	amod
42	enterocolitis	enterocolitis	NN	_	39	nmod
43	.	.	.	_	2	punct

1	Impaired	impaired	JJ	_	3	amod
2	renal	renal	JJ	_	3	amod
3	function	function	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	described	describe	VBN	_	0	ROOT
7	in	in	IN	_	11	case
8	bone	bone	NN	_	11	compound
9	marrow	marrow	NN	_	11	compound
10	transplant	transplant	NN	_	11	compound
11	patients	patient	NNS	_	6	nmod
12	who	who	WP	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	conditioned	condition	VBN	_	11	acl:relcl
15	with	with	IN	_	20	case
16	high	high	JJ	_	20	amod
17	-	-	:	_	20	punct
18	dose	dose	NN	_	20	compound
19	intravenous	intravenous	JJ	_	20	amod
20	melphalan	melphalan	NN	_	14	nmod
21	and	and	CC	_	20	cc
22	who	who	WP	_	24	nsubj
23	subsequently	subsequently	RB	_	24	advmod
24	received	receive	VBD	_	20	conj
25	cyclosporin	cyclosporin	NN	_	24	dobj
26	to	to	TO	_	27	mark
27	prevent	prevent	VB	_	24	advcl
28	graft	graft	NN	_	27	dobj
29	-	-	:	_	28	punct
30	versus	versus	CC	_	28	cc
31	-	-	:	_	28	punct
32	host	host	NN	_	33	compound
33	disease	disease	NN	_	28	dep

1	Pilocarpine	pilocarpine	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	4	nmod
9	taking	take	VBG	_	8	acl
10	beta	beta	NN	_	12	compound
11	adrenergic	adrenergic	JJ	_	12	amod
12	antagonists	antagonist	NNS	_	9	dobj
13	because	because	IN	_	16	case
14	of	of	IN	_	13	mwe
15	the	the	DT	_	16	det
16	possibility	possibility	NN	_	4	nmod
17	of	of	IN	_	19	case
18	conduction	conduction	NN	_	19	compound
19	disturbances	disturbance	NNS	_	16	nmod
20	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	11	nsubjpass
2	with	with	IN	_	4	case
3	parasympathomimetic	parasympathomimetic	JJ	_	4	amod
4	effects	effect	NNS	_	1	nmod
5	administered	administer	VBN	_	4	acl
6	concurrently	concurrently	RB	_	5	advmod
7	with	with	IN	_	8	case
8	pilocarpine	pilocarpine	NN	_	5	nmod
9	would	would	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	result	result	VB	_	11	xcomp
14	in	in	IN	_	17	case
15	additive	additive	JJ	_	17	amod
16	pharmacologic	pharmacologic	JJ	_	17	amod
17	effects	effect	NNS	_	13	nmod
18	.	.	.	_	11	punct

1	Pilocarpine	pilocarpine	NN	_	3	nsubj
2	might	might	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	anticholinergic	anticholinergic	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	used	use	VBN	_	8	acl
10	concomitantly	concomitantly	RB	_	9	advmod
11	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	when	when	WRB	_	11	advmod
7	anticholinergic	anticholinergic	JJ	_	8	amod
8	properties	property	NNS	_	11	nsubj
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	aux
11	contributing	contribute	VBG	_	5	advcl
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	therapeutic	therapeutic	JJ	_	15	amod
15	effect	effect	NN	_	11	nmod
16	of	of	IN	_	19	case
17	concomitant	concomitant	JJ	_	19	amod
18	medication	medication	NN	_	19	compound
19	(	(	NN	_	15	nmod
20	e	e	LS	_	22	dep
21	.	.	.	_	20	punct
22	g	g	NN	_	15	dep
23	.	.	.	_	22	punct
24	,	,	,	_	22	punct
25	atropine	atropine	NN	_	22	conj
26	,	,	,	_	22	punct
27	inhaled	inhale	VBN	_	29	amod
28	ipratropium	ipratropium	NN	_	29	compound
29	)	)	NN	_	22	appos
30	.	.	.	_	5	punct

1	While	while	IN	_	9	mark
2	no	no	DT	_	6	neg
3	formal	formal	JJ	_	6	amod
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	performed	perform	VBN	_	16	advcl
10	,	,	,	_	16	punct
11	the	the	DT	_	14	det
12	following	follow	VBG	_	14	amod
13	concomitant	concomitant	JJ	_	14	amod
14	drugs	drug	NNS	_	16	nsubjpass
15	were	be	VBD	_	16	auxpass
16	used	use	VBN	_	0	ROOT
17	in	in	IN	_	21	case
18	at	at	IN	_	19	case
19	least	least	JJS	_	20	nmod:npmod
20	10	10	CD	_	21	nummod
21	%	%	NN	_	16	nmod
22	of	of	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	in	in	IN	_	25	case
25	either	either	CC	_	23	nmod
26	or	or	CC	_	25	cc
27	both	both	DT	_	28	det
28	Sj	sj	NN	_	25	conj
29	grens	gren	VBZ	_	16	dep
30	efficacy	efficacy	NN	_	31	compound
31	studies	study	NNS	_	29	dobj
32	:	:	:	_	29	punct
33	acetylsalicylic	acetylsalicylic	JJ	_	34	amod
34	acid	acid	NN	_	29	dep
35	,	,	,	_	34	punct
36	artificial	artificial	JJ	_	37	amod
37	tears	tear	NNS	_	34	conj
38	,	,	,	_	34	punct
39	calcium	calcium	NN	_	34	conj
40	,	,	,	_	34	punct
41	conjugated	conjugate	VBN	_	42	amod
42	estrogens	estrogen	NNS	_	34	conj
43	,	,	,	_	34	punct
44	hydroxychloroquine	hydroxychloroquine	NN	_	45	compound
45	sulfate	sulfate	NN	_	34	conj
46	,	,	,	_	34	punct
47	ibuprofen	ibuprofen	NN	_	34	conj
48	,	,	,	_	34	punct
49	levothyroxine	levothyroxine	NN	_	50	compound
50	sodium	sodium	NN	_	34	conj
51	,	,	,	_	34	punct
52	medroxyprogesterone	medroxyprogesterone	NN	_	53	compound
53	acetate	acetate	NN	_	34	conj
54	,	,	,	_	34	punct
55	methotrexate	methotrexate	NN	_	34	conj
56	,	,	,	_	34	punct
57	multivitamins	multivitamin	NNS	_	34	conj
58	,	,	,	_	34	punct
59	naproxen	naproxen	NN	_	34	conj
60	,	,	,	_	34	punct
61	omeprazole	omeprazole	NN	_	34	conj
62	,	,	,	_	34	punct
63	paracetamol	paracetamol	NNP	_	34	conj
64	,	,	,	_	34	punct
65	and	and	CC	_	34	cc
66	prednisone	prednisone	NN	_	34	conj
67	.	.	.	_	16	punct

1	The	the	DT	_	4	det
2	induction	induction	NN	_	4	compound
3	dose	dose	NN	_	4	compound
4	requirements	requirement	NNS	_	11	nsubjpass
5	of	of	IN	_	8	case
6	DIPRIVAN	DIPRIVAN	NNP	_	8	compound
7	Injectable	Injectable	NNP	_	8	compound
8	Emulsion	Emulsion	NNP	_	4	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reduced	reduce	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	with	with	IN	_	15	case
15	intramuscular	intramuscular	JJ	_	13	nmod
16	or	or	CC	_	15	cc
17	intravenous	intravenous	JJ	_	15	conj
18	premedication	premedication	NN	_	15	dep
19	,	,	,	_	11	punct
20	particularly	particularly	RB	_	22	advmod
21	with	with	IN	_	22	case
22	narcotics	narcotic	NNS	_	11	nmod
23	(	(	CD	_	26	nummod
24	eg	eg	FW	_	26	compound
25	,	,	,	_	26	punct
26	morphine	morphine	NN	_	22	dep
27	,	,	,	_	26	punct
28	meperidine	meperidine	NN	_	26	conj
29	,	,	,	_	26	punct
30	and	and	CC	_	26	cc
31	fentanyl	fentanyl	NN	_	26	conj
32	,	,	,	_	31	punct
33	etc	etc	FW	_	31	dep
34	.	.	.	_	11	punct
35	)	)	SYM	_	11	punct

1	and	and	CC	_	7	cc
2	combinations	combination	NNS	_	7	nsubj
3	of	of	IN	_	4	case
4	opioids	opioid	NNS	_	2	nmod
5	and	and	CC	_	4	cc
6	sedatives	sedative	NNS	_	4	conj
7	(	(	VBP	_	0	ROOT
8	eg	eg	FW	_	19	compound
9	,	,	,	_	10	punct
10	benzodiazepines	benzodiazepine	NNS	_	19	dep
11	,	,	,	_	10	punct
12	barbiturates	barbiturate	NNS	_	10	conj
13	,	,	,	_	10	punct
14	chloral	chloral	JJ	_	15	amod
15	hydrate	hydrate	NN	_	10	conj
16	,	,	,	_	10	punct
17	droperidol	droperidol	NN	_	10	conj
18	,	,	,	_	10	punct
19	etc	etc	FW	_	7	advmod
20	.	.	.	_	7	punct
21	)	)	NN	_	7	dep
22	.	.	.	_	7	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	the	the	DT	_	9	det
6	anesthetic	anesthetic	NN	_	9	amod
7	or	or	CC	_	6	cc
8	sedative	sedative	JJ	_	6	conj
9	effects	effect	NNS	_	4	dobj
10	of	of	IN	_	13	case
11	DIPRIVAN	DIPRIVAN	NNP	_	13	compound
12	Injectable	Injectable	NNP	_	13	compound
13	Emulsion	Emulsion	NNP	_	9	nmod
14	and	and	CC	_	4	cc
15	may	may	MD	_	17	aux
16	also	also	RB	_	17	advmod
17	result	result	VB	_	4	conj
18	in	in	IN	_	21	case
19	more	more	RBR	_	20	advmod
20	pronounced	pronounced	JJ	_	21	amod
21	decreases	decrease	NNS	_	17	nmod
22	in	in	IN	_	21	amod
23	systolic	systolic	JJ	_	22	dep
24	,	,	,	_	23	punct
25	diastolic	diastolic	JJ	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	mean	mean	VB	_	23	conj
29	arterial	arterial	JJ	_	30	amod
30	pressures	pressure	NNS	_	28	dobj
31	and	and	CC	_	30	cc
32	cardiac	cardiac	JJ	_	33	amod
33	output	output	NN	_	30	conj
34	.	.	.	_	4	punct

1	During	during	IN	_	2	case
2	maintenance	maintenance	NN	_	17	nmod
3	of	of	IN	_	4	case
4	anesthesia	anesthesia	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	sedation	sedation	NN	_	4	conj
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	rate	rate	NN	_	17	nsubjpass
10	of	of	IN	_	14	case
11	DIPRIVAN	DIPRIVAN	NNP	_	14	compound
12	Injectable	Injectable	NNP	_	14	compound
13	Emulsion	Emulsion	NNP	_	14	compound
14	administration	administration	NN	_	9	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	adjusted	adjust	VBN	_	0	ROOT
18	according	accord	VBG	_	22	case
19	to	to	TO	_	18	mwe
20	the	the	DT	_	22	det
21	desired	desire	VBN	_	22	amod
22	level	level	NN	_	17	nmod
23	of	of	IN	_	24	case
24	anesthesia	anesthesia	NN	_	22	nmod
25	or	or	CC	_	24	cc
26	sedation	sedation	NN	_	24	conj
27	and	and	CC	_	17	cc
28	may	may	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	reduced	reduce	VBN	_	17	conj
31	in	in	IN	_	37	case
32	the	the	DT	_	37	dep
33	presence	presence	NN	_	37	dep
34	of	of	IN	_	37	case
35	supplemental	supplemental	JJ	_	37	amod
36	analgesic	analgesic	JJ	_	37	amod
37	agents	agent	NNS	_	30	nmod
38	(	(	VBP	_	30	xcomp
39	eg	eg	FW	_	38	dobj
40	,	,	,	_	39	punct
41	nitrous	nitrous	JJ	_	42	amod
42	oxide	oxide	NN	_	39	conj
43	or	or	CC	_	39	cc
44	opioids	opioid	NNS	_	39	conj
45	)	)	CD	_	44	nummod
46	.	.	.	_	17	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	7	case
5	potent	potent	JJ	_	7	amod
6	inhalational	inhalational	JJ	_	7	amod
7	agents	agent	NNS	_	3	nmod
8	(	(	VBP	_	28	csubjpass
9	eg	eg	FW	_	8	dobj
10	,	,	,	_	9	punct
11	isoflurane	isoflurane	NN	_	9	conj
12	,	,	,	_	9	punct
13	enflurane	enflurane	NN	_	9	conj
14	,	,	,	_	9	punct
15	and	and	CC	_	9	cc
16	halothane	halothane	NN	_	17	compound
17	)	)	NN	_	9	conj
18	during	during	IN	_	19	case
19	maintenance	maintenance	NN	_	8	nmod
20	with	with	IN	_	23	case
21	DIPRIVAN	DIPRIVAN	NNP	_	23	compound
22	Injectable	Injectable	NNP	_	23	compound
23	Emulsion	Emulsion	NNP	_	19	nmod
24	has	have	VBZ	_	28	aux
25	not	not	RB	_	28	neg
26	been	be	VBN	_	28	auxpass
27	extensively	extensively	RB	_	28	advmod
28	evaluated	evaluate	VBN	_	0	ROOT
29	.	.	.	_	28	punct

1	These	these	DT	_	3	det
2	inhalational	inhalational	JJ	_	3	amod
3	agents	agent	NNS	_	7	nsubjpass
4	can	can	MD	_	7	aux
5	also	also	RB	_	7	advmod
6	be	be	VB	_	7	auxpass
7	expected	expect	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	increase	increase	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	anesthetic	anesthetic	NN	_	9	dobj
12	or	or	CC	_	11	cc
13	sedative	sedative	NN	_	11	conj
14	and	and	CC	_	11	cc
15	cardiorespiratory	cardiorespiratory	JJ	_	16	amod
16	effects	effect	NNS	_	11	conj
17	of	of	IN	_	20	case
18	DIPRIVAN	DIPRIVAN	NNP	_	20	compound
19	Injectable	Injectable	NNP	_	20	compound
20	Emulsion	Emulsion	NNP	_	11	nmod
21	.	.	.	_	7	punct

1	DIPRIVAN	DIPRIVAN	NNP	_	3	compound
2	Injectable	Injectable	NNP	_	3	compound
3	Emulsion	Emulsion	NNP	_	6	nsubj
4	does	do	VBZ	_	6	aux
5	not	not	RB	_	6	neg
6	cause	cause	VB	_	0	ROOT
7	a	a	DT	_	10	det
8	clinically	clinically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	change	change	NN	_	6	dobj
11	in	in	IN	_	12	case
12	onset	onset	NN	_	10	nmod
13	,	,	,	_	12	punct
14	intensity	intensity	NN	_	12	conj
15	,	,	,	_	12	punct
16	or	or	CC	_	12	cc
17	duration	duration	NN	_	12	conj
18	of	of	IN	_	19	case
19	action	action	NN	_	17	nmod
20	of	of	IN	_	26	case
21	the	the	DT	_	26	det
22	commonly	commonly	RB	_	23	advmod
23	used	use	VBN	_	26	amod
24	neuromuscular	neuromuscular	JJ	_	26	amod
25	blocking	block	VBG	_	26	compound
26	agents	agent	NNS	_	19	nmod
27	(	(	CD	_	30	nummod
28	eg	eg	FW	_	30	compound
29	,	,	,	_	30	punct
30	succinylcholine	succinylcholine	NN	_	26	dep
31	and	and	CC	_	30	cc
32	nondepolarizing	nondepolarizing	JJ	_	34	amod
33	muscle	muscle	NN	_	34	compound
34	relaxants	relaxant	NNS	_	30	conj
35	)	)	VBP	_	6	dep
36	.	.	.	_	6	punct

1	No	no	DT	_	4	neg
2	significant	significant	JJ	_	4	amod
3	adverse	adverse	JJ	_	4	amod
4	interactions	interaction	NNS	_	37	nsubjpass
5	with	with	IN	_	8	case
6	commonly	commonly	RB	_	7	advmod
7	used	use	VBN	_	8	amod
8	premedications	premedication	NNS	_	4	nmod
9	or	or	CC	_	8	cc
10	drugs	drug	NNS	_	8	conj
11	used	use	VBN	_	4	acl
12	during	during	IN	_	13	case
13	anesthesia	anesthesia	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	sedation	sedation	NN	_	13	conj
16	(	(	CD	_	15	nummod
17	including	include	VBG	_	19	case
18	a	a	DT	_	19	det
19	range	range	NN	_	11	nmod
20	of	of	IN	_	22	case
21	muscle	muscle	NN	_	22	compound
22	relaxants	relaxant	NNS	_	19	nmod
23	,	,	,	_	22	punct
24	inhalational	inhalational	JJ	_	25	amod
25	agents	agent	NNS	_	22	conj
26	,	,	,	_	22	punct
27	analgesic	analgesic	JJ	_	28	amod
28	agents	agent	NNS	_	22	conj
29	,	,	,	_	22	punct
30	and	and	CC	_	22	cc
31	local	local	JJ	_	33	amod
32	anesthetic	anesthetic	JJ	_	33	amod
33	agents	agent	NNS	_	22	conj
34	)	)	RB	_	37	advmod
35	have	have	VBP	_	37	aux
36	been	be	VBN	_	37	auxpass
37	observed	observe	VBN	_	0	ROOT
38	.	.	.	_	37	punct

1	Oral	oral	JJ	_	2	amod
2	metronidazole	metronidazole	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	potentiate	potentiate	VB	_	5	xcomp
8	the	the	DT	_	10	det
9	anticoagulant	anticoagulant	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	coumarin	coumarin	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	warfarin	warfarin	NN	_	12	conj
15	,	,	,	_	7	punct
16	resulting	result	VBG	_	7	advcl
17	in	in	IN	_	19	case
18	a	a	DT	_	19	det
19	prolongation	prolongation	NN	_	16	nmod
20	of	of	IN	_	22	case
21	prothrombin	prothrombin	NN	_	22	compound
22	time	time	NN	_	19	nmod
23	.	.	.	_	5	punct

1	Drug	drug	NN	_	2	compound
2	interactions	interaction	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	kept	keep	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	mind	mind	NN	_	5	nmod
8	when	when	WRB	_	18	advmod
9	METROGEL	METROGEL	NNP	_	13	compound
10	(	(	CD	_	13	nummod
11	metronidazole	metronidazole	NN	_	13	compound
12	gel	gel	NN	_	13	compound
13	)	)	NN	_	18	nsubjpass
14	,	,	,	_	13	punct
15	1	1	CD	_	16	nummod
16	%	%	NN	_	13	appos
17	is	be	VBZ	_	18	auxpass
18	prescribed	prescribe	VBN	_	5	advcl
19	for	for	IN	_	20	case
20	patients	patient	NNS	_	18	nmod
21	who	who	WP	_	23	nsubj
22	are	be	VBP	_	23	aux
23	receiving	receive	VBG	_	20	acl:relcl
24	anticoagulant	anticoagulant	JJ	_	25	amod
25	treatment	treatment	NN	_	23	dobj
26	,	,	,	_	5	punct
27	although	although	IN	_	31	mark
28	they	they	PRP	_	31	nsubj
29	are	be	VBP	_	31	cop
30	less	less	RBR	_	31	advmod
31	likely	likely	JJ	_	5	advcl
32	to	to	TO	_	33	mark
33	occur	occur	VB	_	31	xcomp
34	with	with	IN	_	37	case
35	topical	topical	JJ	_	37	amod
36	metronidazole	metronidazole	NN	_	37	compound
37	administration	administration	NN	_	33	nmod
38	because	because	IN	_	41	case
39	of	of	IN	_	38	mwe
40	low	low	JJ	_	41	amod
41	absorption	absorption	NN	_	31	nmod
42	.	.	.	_	5	punct

1	Methazolamide	methazolamide	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	on	on	IN	_	11	case
10	steroid	steroid	NN	_	11	compound
11	therapy	therapy	NN	_	8	nmod
12	because	because	IN	_	15	case
13	of	of	IN	_	12	mwe
14	the	the	DT	_	15	det
15	potential	potential	NN	_	4	nmod
16	for	for	IN	_	17	mark
17	developing	develop	VBG	_	15	acl
18	hypokalemia	hypokalemia	NN	_	17	dobj
19	.	.	.	_	4	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	for	for	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	receiving	receive	VBG	_	5	acl
7	high	high	JJ	_	10	amod
8	-	-	:	_	10	punct
9	dose	dose	NN	_	10	compound
10	aspirin	aspirin	NN	_	6	dobj
11	and	and	CC	_	10	cc
12	methazolamide	methazolamide	NN	_	10	conj
13	concomitantly	concomitantly	RB	_	10	advmod
14	,	,	,	_	3	punct
15	as	as	IN	_	16	case
16	anorexia	anorexia	NN	_	3	nmod
17	,	,	,	_	16	punct
18	tachypnea	tachypnea	NN	_	16	conj
19	,	,	,	_	16	punct
20	lethargy	lethargy	NN	_	16	conj
21	,	,	,	_	16	punct
22	coma	coma	NN	_	16	conj
23	and	and	CC	_	16	cc
24	death	death	NN	_	16	conj
25	have	have	VBP	_	27	aux
26	been	be	VBN	_	27	auxpass
27	reported	report	VBN	_	3	dep
28	with	with	IN	_	30	case
29	concomitant	concomitant	JJ	_	30	amod
30	use	use	NN	_	27	nmod
31	of	of	IN	_	35	case
32	high	high	JJ	_	35	amod
33	-	-	:	_	35	punct
34	dose	dose	NN	_	35	compound
35	aspirin	aspirin	NN	_	30	nmod
36	and	and	CC	_	35	cc
37	carbonic	carbonic	JJ	_	39	amod
38	anhydrase	anhydrase	NN	_	39	compound
39	inhibitors	inhibitor	NNS	_	35	conj
40	.	.	.	_	3	punct

1	Pyrimethamine	pyrimethamine	NN	_	4	nsubjpass
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	sulfonamides	sulfonamide	NNS	_	4	nmod
7	,	,	,	_	6	punct
8	quinine	quinine	NN	_	6	conj
9	and	and	CC	_	6	cc
10	other	other	JJ	_	11	amod
11	antimalarials	antimalarial	NNS	_	6	conj
12	,	,	,	_	4	punct
13	and	and	CC	_	4	cc
14	with	with	IN	_	16	case
15	other	other	JJ	_	16	amod
16	antibiotics	antibiotic	NNS	_	4	conj
17	.	.	.	_	4	punct

1	If	if	IN	_	6	mark
2	signs	sign	NNS	_	6	nsubj
3	of	of	IN	_	5	case
4	folate	folate	NN	_	5	compound
5	deficiency	deficiency	NN	_	2	nmod
6	develop	develop	VB	_	11	advcl
7	,	,	,	_	11	punct
8	pyrimethamine	pyrimethamine	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	discontinued	discontinue	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Folinic	folinic	JJ	_	5	amod
2	acid	acid	NN	_	5	compound
3	(	(	NN	_	5	compound
4	leucovorin	leucovorin	NN	_	5	compound
5	)	)	NN	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	0	ROOT
9	until	until	IN	_	13	mark
10	normal	normal	JJ	_	11	amod
11	hematopoiesis	hematopoiesis	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	restored	restore	VBN	_	8	advcl
14	.	.	.	_	8	punct

1	Mild	mild	JJ	_	2	amod
2	hepatotoxicity	hepatotoxicity	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	some	some	DT	_	8	det
8	patients	patient	NNS	_	5	nmod
9	when	when	WRB	_	14	advmod
10	lorazepam	lorazepam	NN	_	14	nsubjpass
11	and	and	CC	_	10	cc
12	pyrimethamine	pyrimethamine	NN	_	10	conj
13	were	be	VBD	_	14	auxpass
14	administered	administer	VBN	_	5	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	.	.	.	_	5	punct

1	Due	due	JJ	_	4	case
2	to	to	TO	_	4	case
3	its	its	PRP$	_	4	nmod:poss
4	effects	effect	NNS	_	0	ROOT
5	on	on	IN	_	7	case
6	gastric	gastric	JJ	_	7	amod
7	emptying	emptying	NN	_	4	nmod
8	,	,	,	_	7	punct
9	SYMLIN	symlin	NN	_	10	compound
10	therapy	therapy	NN	_	7	appos
11	should	should	MD	_	14	aux
12	not	not	RB	_	14	neg
13	be	be	VB	_	14	auxpass
14	considered	consider	VBN	_	4	acl
15	for	for	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	taking	take	VBG	_	16	acl
18	drugs	drug	NNS	_	17	dobj
19	that	that	WDT	_	20	nsubj
20	alter	alter	VBP	_	18	acl:relcl
21	gastrointestinal	gastrointestinal	JJ	_	23	amod
22	motility	motility	NN	_	23	compound
23	(	(	NN	_	20	dobj
24	e	e	LS	_	14	xcomp
25	.	.	.	_	24	punct
26	g	g	NN	_	24	dep
27	.	.	.	_	26	punct
28	,	,	,	_	26	punct
29	anticholinergic	anticholinergic	JJ	_	30	amod
30	agents	agent	NNS	_	26	appos
31	such	such	JJ	_	34	case
32	as	as	IN	_	31	mwe
33	atropine	atropine	NN	_	34	compound
34	)	)	NN	_	30	nmod
35	and	and	CC	_	34	cc
36	agents	agent	NNS	_	34	conj
37	that	that	WDT	_	38	nsubj
38	slow	slow	VBP	_	30	acl:relcl
39	the	the	DT	_	41	det
40	intestinal	intestinal	JJ	_	41	amod
41	absorption	absorption	NN	_	38	dobj
42	of	of	IN	_	43	case
43	nutrients	nutrient	NNS	_	41	nmod
44	(	(	CD	_	43	nummod
45	e	e	LS	_	30	dep
46	.	.	.	_	45	punct
47	g	g	NN	_	45	dep
48	.	.	.	_	47	punct
49	,	,	,	_	47	punct
50	alpha	alpha	NN	_	52	compound
51	glucosidase	glucosidase	NN	_	52	compound
52	inhibitors	inhibitor	NNS	_	53	compound
53	)	)	NN	_	47	appos
54	.	.	.	_	4	punct

1	Patients	patient	NNS	_	8	nsubjpass
2	using	use	VBG	_	1	acl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	studied	study	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	trials	trial	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	SYMLIN	SYMLIN	NNP	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	potential	potential	JJ	_	2	dobj
5	to	to	TO	_	6	mark
6	delay	delay	VB	_	4	acl
7	the	the	DT	_	8	det
8	absorption	absorption	NN	_	6	dobj
9	of	of	IN	_	13	case
10	concomitantly	concomitantly	RB	_	11	advmod
11	administered	administer	VBN	_	13	amod
12	oral	oral	JJ	_	13	amod
13	medications	medication	NNS	_	8	nmod
14	.	.	.	_	2	punct

1	When	when	WRB	_	14	advmod
2	the	the	DT	_	4	det
3	rapid	rapid	JJ	_	4	amod
4	onset	onset	NN	_	14	nsubj
5	of	of	IN	_	10	case
6	a	a	DT	_	10	det
7	concomitant	concomitant	JJ	_	10	amod
8	orally	orally	RB	_	9	advmod
9	administered	administer	VBN	_	10	amod
10	agent	agent	NN	_	4	nmod
11	is	be	VBZ	_	14	cop
12	a	a	DT	_	14	det
13	critical	critical	JJ	_	14	amod
14	determinant	determinant	NN	_	27	advcl
15	of	of	IN	_	16	case
16	effectiveness	effectiveness	NN	_	14	nmod
17	(	(	CD	_	16	nummod
18	such	such	JJ	_	21	case
19	as	as	IN	_	18	mwe
20	analgesics	analgesics	NN	_	21	compound
21	)	)	NN	_	16	nmod
22	,	,	,	_	27	punct
23	the	the	DT	_	24	det
24	agent	agent	NN	_	27	nsubjpass
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	administered	administer	VBN	_	0	ROOT
28	at	at	IN	_	29	case
29	least	least	JJS	_	30	nmod:npmod
30	1	1	CD	_	31	nummod
31	hour	hour	NN	_	27	dobj
32	prior	prior	RB	_	27	advmod
33	to	to	TO	_	36	case
34	or	or	CC	_	33	cc
35	2	2	CD	_	33	conj
36	hours	hour	NNS	_	32	nmod
37	after	after	IN	_	39	case
38	SYMLIN	SYMLIN	NNP	_	39	compound
39	injection	injection	NN	_	36	nmod
40	.	.	.	_	27	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	the	the	DT	_	7	det
6	concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	14	nsubj
8	of	of	IN	_	9	case
9	sulfonylureas	sulfonylurea	NNS	_	7	nmod
10	or	or	CC	_	9	cc
11	biguanides	biguanide	NNS	_	9	conj
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	alter	alter	VB	_	0	ROOT
15	the	the	DT	_	18	det
16	adverse	adverse	JJ	_	18	amod
17	event	event	NN	_	18	compound
18	profile	profile	NN	_	14	dobj
19	of	of	IN	_	20	case
20	SYMLIN	SYMLIN	NNP	_	18	nmod
21	.	.	.	_	14	punct

1	No	no	DT	_	4	neg
2	formal	formal	JJ	_	4	amod
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	assess	assess	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	effect	effect	NN	_	9	dobj
12	of	of	IN	_	13	case
13	SYMLIN	SYMLIN	NNP	_	11	nmod
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	kinetics	kinetics	NNS	_	11	nmod
17	of	of	IN	_	20	case
18	oral	oral	JJ	_	20	amod
19	antidiabetic	antidiabetic	JJ	_	20	amod
20	agents	agent	NNS	_	16	nmod
21	.	.	.	_	7	punct

1	Mixing	mix	VBG	_	11	csubjpass
2	SYMLIN	SYMLIN	NNP	_	1	dobj
3	and	and	CC	_	2	cc
4	Insulin	insulin	NN	_	2	conj
5	The	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	parameters	parameter	NNS	_	2	dep
8	of	of	IN	_	9	case
9	SYMLIN	SYMLIN	NNP	_	7	nmod
10	were	be	VBD	_	11	auxpass
11	altered	alter	VBN	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	mixed	mix	VBN	_	11	advcl
14	with	with	IN	_	24	case
15	regular	regular	JJ	_	24	amod
16	,	,	,	_	15	punct
17	NPH	nph	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	70	70	CD	_	15	conj
21	/	/	:	_	24	punct
22	30	30	CD	_	24	nummod
23	premixed	premixed	JJ	_	24	amod
24	formulations	formulation	NNS	_	13	nmod
25	of	of	IN	_	28	case
26	recombinant	recombinant	JJ	_	28	amod
27	human	human	JJ	_	28	amod
28	insulin	insulin	NN	_	24	nmod
29	immediately	immediately	RB	_	30	advmod
30	prior	prior	RB	_	13	advmod
31	to	to	TO	_	32	case
32	injection	injection	NN	_	30	nmod
33	.	.	.	_	11	punct

1	Thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	SYMLIN	SYMLIN	NNP	_	9	nsubj
4	and	and	CC	_	3	cc
5	insulin	insulin	NN	_	3	conj
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	cop
9	mixed	mixed	JJ	_	0	ROOT
10	and	and	CC	_	9	cc
11	must	must	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	administered	administer	VBN	_	9	conj
14	separately	separately	RB	_	13	advmod
15	.	.	.	_	9	punct

1	Since	since	IN	_	5	mark
2	MEXITIL	mexitil	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	a	a	DT	_	5	det
5	substrate	substrate	NN	_	26	advcl
6	for	for	IN	_	9	case
7	the	the	DT	_	9	det
8	metabolic	metabolic	JJ	_	9	amod
9	pathways	pathway	NNS	_	5	nmod
10	involving	involve	VBG	_	9	acl
11	CYP2D6	cyp2d6	NN	_	14	compound
12	and	and	CC	_	11	cc
13	CYP1A2	cyp1a2	NN	_	11	conj
14	enzymes	enzyme	NNS	_	10	dobj
15	,	,	,	_	14	punct
16	inhibition	inhibition	NN	_	14	conj
17	or	or	CC	_	14	cc
18	induction	induction	NN	_	14	conj
19	of	of	IN	_	20	case
20	either	either	DT	_	18	nmod
21	of	of	IN	_	23	case
22	these	these	DT	_	23	det
23	enzymes	enzyme	NNS	_	20	nmod
24	would	would	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	expected	expect	VBN	_	0	ROOT
27	to	to	TO	_	28	mark
28	alter	alter	VB	_	26	xcomp
29	mexiletine	mexiletine	JJ	_	31	amod
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	28	dobj
32	.	.	.	_	26	punct

1	In	in	IN	_	9	case
2	a	a	DT	_	9	det
3	formal	formal	JJ	_	9	amod
4	,	,	,	_	3	punct
5	single	single	JJ	_	3	dep
6	-	-	:	_	3	punct
7	dose	dose	NN	_	9	compound
8	interaction	interaction	NN	_	9	compound
9	study	study	NN	_	15	nmod
10	(	(	CD	_	11	nummod
11	n	n	NN	_	15	nsubj
12	=	=	JJ	_	11	amod
13	6	6	CD	_	14	nummod
14	males	male	NNS	_	12	dep
15	)	)	VBP	_	0	ROOT
16	the	the	DT	_	17	det
17	clearance	clearance	NN	_	21	nsubjpass
18	of	of	IN	_	19	case
19	mexiletine	mexiletine	NN	_	17	nmod
20	was	be	VBD	_	21	auxpass
21	decreased	decrease	VBN	_	15	ccomp
22	by	by	IN	_	24	case
23	38	38	CD	_	24	nummod
24	%	%	NN	_	21	nmod
25	following	follow	VBG	_	27	case
26	the	the	DT	_	27	det
27	coadministration	coadministration	NN	_	21	nmod
28	of	of	IN	_	29	case
29	fluvoxamine	fluvoxamine	NN	_	27	nmod
30	,	,	,	_	29	punct
31	an	a	DT	_	32	det
32	inhibitor	inhibitor	NN	_	29	appos
33	of	of	IN	_	34	case
34	CYP1A2	cyp1a2	NN	_	32	nmod
35	.	.	.	_	15	punct

1	In	in	IN	_	4	case
2	another	another	DT	_	4	det
3	formal	formal	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	(	(	NN	_	6	compound
6	n	n	NN	_	7	nsubj
7	=	=	JJ	_	0	ROOT
8	8	8	CD	_	9	nummod
9	extensive	extensive	JJ	_	25	nsubj
10	and	and	CC	_	9	cc
11	n	n	NN	_	9	conj
12	=	=	JJ	_	9	dep
13	7	7	CD	_	15	nummod
14	poor	poor	JJ	_	15	amod
15	metabolizers	metabolizer	NNS	_	12	dobj
16	of	of	IN	_	18	case
17	CYP2D6	cyp2d6	NN	_	18	compound
18	)	)	NN	_	15	nmod
19	,	,	,	_	15	punct
20	coadministration	coadministration	NN	_	15	appos
21	of	of	IN	_	22	case
22	propafenone	propafenone	NN	_	20	nmod
23	did	do	VBD	_	25	aux
24	not	not	RB	_	25	neg
25	alter	alter	VB	_	7	ccomp
26	the	the	DT	_	27	det
27	kinetics	kinetics	NNS	_	25	dobj
28	of	of	IN	_	29	case
29	mexiletine	mexiletine	NN	_	27	nmod
30	in	in	IN	_	35	case
31	the	the	DT	_	35	det
32	poor	poor	JJ	_	35	amod
33	CYP2D6	cyp2d6	NN	_	35	compound
34	metabolizer	metabolizer	NN	_	35	compound
35	group	group	NN	_	25	nmod
36	.	.	.	_	7	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	5	det
4	metabolic	metabolic	JJ	_	5	amod
5	clearance	clearance	NN	_	2	root
6	of	of	IN	_	7	case
7	mexiletine	mexiletine	NN	_	5	nmod
8	in	in	IN	_	12	case
9	the	the	DT	_	12	det
10	extensive	extensive	JJ	_	12	amod
11	metabolizer	metabolizer	NN	_	12	compound
12	phenotype	phenotype	NN	_	5	nmod
13	decreased	decrease	VBN	_	12	acl
14	by	by	IN	_	17	case
15	about	about	RB	_	16	advmod
16	70	70	CD	_	17	nummod
17	%	%	NN	_	13	nmod
18	making	make	VBG	_	12	acl
19	the	the	DT	_	24	det
20	poor	poor	JJ	_	24	amod
21	and	and	CC	_	20	cc
22	extensive	extensive	JJ	_	20	conj
23	metabolizer	metabolizer	NN	_	24	compound
24	groups	group	NNS	_	25	nsubj
25	indistinguishable	indistinguishable	JJ	_	18	xcomp
26	.	.	.	_	5	punct

1	In	in	IN	_	6	case
2	this	this	DT	_	6	det
3	crossover	crossover	NN	_	6	compound
4	steady	steady	JJ	_	6	amod
5	state	state	NN	_	6	compound
6	study	study	NN	_	13	nmod
7	,	,	,	_	13	punct
8	the	the	DT	_	9	det
9	pharmacokinetics	pharmacokinetic	NNS	_	13	nsubj
10	of	of	IN	_	11	case
11	propafenone	propafenone	NN	_	9	nmod
12	were	be	VBD	_	13	cop
13	unaffected	unaffected	JJ	_	0	ROOT
14	in	in	IN	_	16	case
15	either	either	CC	_	16	det
16	phenotype	phenotype	NN	_	13	nmod
17	by	by	IN	_	19	case
18	the	the	DT	_	19	det
19	coadministration	coadministration	NN	_	13	nmod
20	of	of	IN	_	21	case
21	mexiletine	mexiletine	NN	_	19	nmod
22	.	.	.	_	13	punct

1	Addition	addition	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	mexiletine	mexiletine	NN	_	1	nmod
4	to	to	TO	_	5	case
5	propafenone	propafenone	NN	_	1	nmod
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	lead	lead	VB	_	0	ROOT
9	to	to	TO	_	13	case
10	further	further	JJ	_	13	amod
11	electrocardiographic	electrocardiographic	JJ	_	13	amod
12	parameters	parameter	NNS	_	13	compound
13	changes	change	NNS	_	8	nmod
14	of	of	IN	_	15	case
15	QRS	QRS	NNP	_	13	nmod
16	,	,	,	_	15	punct
17	QTc	QTc	NNP	_	15	conj
18	,	,	,	_	15	punct
19	RR	RR	NNP	_	15	conj
20	,	,	,	_	15	punct
21	and	and	CC	_	15	cc
22	PR	pr	NN	_	23	compound
23	intervals	interval	NNS	_	15	conj
24	than	than	IN	_	25	case
25	propafenone	propafenone	NN	_	13	nmod
26	alone	alone	RB	_	25	advmod
27	.	.	.	_	8	punct

1	When	when	WRB	_	13	advmod
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	13	nsubjpass
4	of	of	IN	_	5	case
5	either	either	DT	_	3	nmod
6	of	of	IN	_	9	case
7	these	these	DT	_	9	det
8	two	two	CD	_	9	nummod
9	drugs	drug	NNS	_	5	nmod
10	with	with	IN	_	11	case
11	mexiletine	mexiletine	NN	_	3	nmod
12	is	be	VBZ	_	13	auxpass
13	initiated	initiate	VBN	_	22	advcl
14	,	,	,	_	22	punct
15	the	the	DT	_	16	det
16	dose	dose	NN	_	22	nsubjpass
17	of	of	IN	_	18	case
18	mexiletine	mexiletine	NN	_	16	nmod
19	should	should	MD	_	22	aux
20	be	be	VB	_	22	auxpass
21	slowly	slowly	RB	_	22	advmod
22	titrated	titrate	VBN	_	0	ROOT
23	to	to	TO	_	25	case
24	desired	desire	VBN	_	25	amod
25	effect	effect	NN	_	22	nmod
26	.	.	.	_	22	punct

1	In	in	IN	_	7	case
2	a	a	DT	_	7	det
3	large	large	JJ	_	7	amod
4	compassionate	compassionate	JJ	_	7	amod
5	use	use	NN	_	7	compound
6	program	program	NN	_	7	compound
7	Mexitil	Mexitil	NNP	_	10	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	used	use	VBN	_	0	ROOT
11	concurrently	concurrently	RB	_	10	advmod
12	with	with	IN	_	15	case
13	commonly	commonly	RB	_	14	advmod
14	employed	employ	VBN	_	15	amod
15	antianginal	antianginal	JJ	_	10	nmod
16	,	,	,	_	15	punct
17	antihypertensive	antihypertensive	JJ	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	anticoagulant	anticoagulant	JJ	_	21	amod
21	drugs	drug	NNS	_	15	conj
22	without	without	IN	_	24	case
23	observed	observe	VBN	_	24	amod
24	interactions	interaction	NNS	_	10	nmod
25	.	.	.	_	10	punct

1	A	a	DT	_	2	det
2	variety	variety	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	antiarrhythmics	antiarrhythmic	NNS	_	2	nmod
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	quinidine	quinidine	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	propranolol	propranolol	NN	_	7	conj
10	were	be	VBD	_	12	auxpass
11	also	also	RB	_	12	advmod
12	added	add	VBN	_	0	ROOT
13	,	,	,	_	12	punct
14	sometimes	sometimes	RB	_	12	advmod
15	with	with	IN	_	17	case
16	improved	improve	VBN	_	17	amod
17	control	control	NN	_	14	nmod
18	of	of	IN	_	20	case
19	ventricular	ventricular	JJ	_	20	amod
20	ectopy	ectopy	NN	_	17	nmod
21	.	.	.	_	12	punct

1	When	when	WRB	_	15	advmod
2	phenytoin	phenytoin	NN	_	15	nsubjpass
3	or	or	CC	_	2	cc
4	other	other	JJ	_	7	amod
5	hepatic	hepatic	JJ	_	7	amod
6	enzyme	enzyme	NN	_	7	compound
7	inducers	inducer	NNS	_	2	conj
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	rifampin	rifampin	NN	_	2	nmod
11	and	and	CC	_	10	cc
12	phenobarbital	phenobarbital	NN	_	10	conj
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	taken	take	VBN	_	20	advcl
16	concurrently	concurrently	RB	_	15	advmod
17	with	with	IN	_	18	case
18	Mexitil	mexitil	NN	_	15	nmod
19	,	,	,	_	20	punct
20	lowered	lower	VBD	_	0	ROOT
21	Mexitil	Mexitil	NNP	_	23	compound
22	plasma	plasma	NN	_	23	compound
23	levels	level	NNS	_	26	nsubjpass
24	have	have	VBP	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reported	report	VBN	_	20	ccomp
27	.	.	.	_	20	punct

1	Monitoring	monitoring	NN	_	7	nsubjpass
2	of	of	IN	_	5	case
3	Mexitil	Mexitil	NNP	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	levels	level	NNS	_	1	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	during	during	IN	_	11	case
9	such	such	JJ	_	11	amod
10	concurrent	concurrent	JJ	_	11	amod
11	use	use	NN	_	7	nmod
12	to	to	TO	_	13	mark
13	avoid	avoid	VB	_	11	acl
14	ineffective	ineffective	JJ	_	15	amod
15	therapy	therapy	NN	_	13	dobj
16	.	.	.	_	7	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	formal	formal	JJ	_	4	amod
4	study	study	NN	_	8	nmod
5	,	,	,	_	8	punct
6	benzodiazepines	benzodiazepine	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	shown	show	VBN	_	0	ROOT
9	not	not	RB	_	11	neg
10	to	to	TO	_	11	mark
11	affect	affect	VB	_	8	xcomp
12	Mexitil	Mexitil	NNP	_	14	compound
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	.	.	.	_	8	punct

1	ECG	ecg	NN	_	2	compound
2	intervals	interval	NNS	_	3	nsubj
3	(	(	VBP	_	0	ROOT
4	PR	pr	NN	_	13	nsubjpass
5	,	,	,	_	4	punct
6	QRS	QRS	NNP	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	QT	QT	NNP	_	4	conj
10	)	)	CD	_	9	nummod
11	were	be	VBD	_	13	auxpass
12	not	not	RB	_	13	neg
13	affected	affect	VBN	_	3	ccomp
14	by	by	IN	_	16	case
15	concurrent	concurrent	JJ	_	16	amod
16	Mexitil	mexitil	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	digoxin	digoxin	NN	_	16	conj
19	,	,	,	_	16	punct
20	diuretics	diuretic	NNS	_	16	conj
21	,	,	,	_	16	punct
22	or	or	CC	_	16	cc
23	propranolol	propranolol	NN	_	16	conj
24	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	cimetidine	cimetidine	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	Mexitil	mexitil	NN	_	4	conj
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	increase	increase	VB	_	9	ccomp
12	,	,	,	_	11	punct
13	decrease	decrease	VB	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	leave	leave	VB	_	11	conj
17	unchanged	unchanged	JJ	_	20	amod
18	Mexitil	Mexitil	NNP	_	20	compound
19	plasma	plasma	NN	_	20	compound
20	levels	level	NNS	_	16	dobj
21	;	;	:	_	9	punct

1	therefore	therefore	RB	_	5	advmod
2	patients	patient	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	followed	follow	VBN	_	0	ROOT
6	carefully	carefully	RB	_	5	advmod
7	during	during	IN	_	9	case
8	concurrent	concurrent	JJ	_	9	amod
9	therapy	therapy	NN	_	5	nmod
10	.	.	.	_	5	punct

1	Mexitil	mexitil	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	alter	alter	VB	_	0	ROOT
5	serum	serum	NN	_	7	compound
6	digoxin	digoxin	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	but	but	CC	_	7	cc
9	magnesium	magnesium	NN	_	12	compound
10	-	-	:	_	12	punct
11	aluminum	aluminum	NN	_	12	compound
12	hydroxide	hydroxide	NN	_	7	conj
13	,	,	,	_	4	punct
14	when	when	WRB	_	15	advmod
15	used	use	VBN	_	4	advcl
16	to	to	TO	_	17	mark
17	treat	treat	VB	_	15	xcomp
18	gastrointestinal	gastrointestinal	JJ	_	19	amod
19	symptoms	symptom	NNS	_	17	dobj
20	due	due	JJ	_	17	advmod
21	to	to	TO	_	22	case
22	Mexitil	Mexitil	NNP	_	20	nmod
23	,	,	,	_	4	punct
24	has	have	VBZ	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reported	report	VBN	_	4	parataxis
27	to	to	TO	_	31	case
28	lower	lower	JJR	_	31	amod
29	serum	serum	NN	_	31	compound
30	digoxin	digoxin	NN	_	31	compound
31	levels	level	NNS	_	26	nmod
32	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	Mexitil	Mexitil	NNP	_	2	nmod
5	and	and	CC	_	4	cc
6	theophylline	theophylline	NN	_	4	conj
7	may	may	MD	_	8	aux
8	lead	lead	VB	_	0	ROOT
9	to	to	TO	_	13	case
10	increased	increase	VBN	_	13	amod
11	plasma	plasma	NN	_	13	compound
12	theophylline	theophylline	NN	_	13	compound
13	levels	level	NNS	_	8	nmod
14	.	.	.	_	8	punct

1	One	one	CD	_	3	nummod
2	controlled	controlled	JJ	_	3	amod
3	study	study	NN	_	8	nsubj
4	in	in	IN	_	7	case
5	eight	eight	CD	_	7	nummod
6	normal	normal	JJ	_	7	amod
7	subjects	subject	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	a	a	DT	_	15	det
10	72	72	CD	_	11	compound
11	%	%	NN	_	15	amod
12	mean	mean	JJ	_	15	amod
13	increase	increase	NN	_	15	compound
14	(	(	NN	_	15	compound
15	range	range	NN	_	8	dobj
16	35	35	CD	_	15	nummod
17	-	-	:	_	15	punct
18	136	136	CD	_	19	nummod
19	%	%	NN	_	15	dep
20	)	)	CD	_	19	nummod
21	in	in	IN	_	24	case
22	plasma	plasma	NN	_	24	compound
23	theophylline	theophylline	NN	_	24	compound
24	levels	level	NNS	_	19	nmod
25	.	.	.	_	8	punct

1	This	this	DT	_	2	det
2	increase	increase	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	at	at	IN	_	9	case
6	the	the	DT	_	9	det
7	first	first	JJ	_	9	amod
8	test	test	NN	_	9	compound
9	point	point	NN	_	4	nmod
10	which	which	WDT	_	14	nsubj
11	was	be	VBD	_	14	cop
12	the	the	DT	_	14	det
13	second	second	JJ	_	14	amod
14	day	day	NN	_	9	acl:relcl
15	after	after	IN	_	16	mark
16	starting	start	VBG	_	14	acl
17	Mexitil	Mexitil	NNP	_	22	advmod
18	.	.	.	_	22	punct
19	Theophylline	Theophylline	NNP	_	21	compound
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	22	nsubj
22	returned	return	VBD	_	16	ccomp
23	to	to	TO	_	24	case
24	pre	pre	JJ	_	22	nmod
25	-	-	:	_	4	punct
26	Mexitil	mexitil	NN	_	27	compound
27	values	value	NNS	_	50	nsubjpass
28	within	within	IN	_	30	case
29	48	48	CD	_	30	nummod
30	hours	hour	NNS	_	27	nmod
31	after	after	IN	_	32	mark
32	discontinuing	discontinue	VBG	_	27	acl
33	Mexitil	Mexitil	NNP	_	32	dobj
34	.	.	.	_	27	punct
35	If	if	IN	_	39	mark
36	Mexitil	mexitil	NN	_	39	nsubj
37	and	and	CC	_	36	cc
38	theophylline	theophylline	NN	_	36	conj
39	are	be	VBP	_	50	advcl
40	to	to	TO	_	42	mark
41	be	be	VB	_	42	auxpass
42	used	use	VBN	_	39	xcomp
43	concurrently	concurrently	RB	_	42	advmod
44	,	,	,	_	50	punct
45	theophylline	theophylline	NN	_	47	compound
46	blood	blood	NN	_	47	compound
47	levels	level	NNS	_	50	nsubjpass
48	should	should	MD	_	50	aux
49	be	be	VB	_	50	auxpass
50	monitored	monitor	VBN	_	4	parataxis
51	,	,	,	_	50	punct
52	particularly	particularly	RB	_	58	advmod
53	when	when	WRB	_	58	advmod
54	the	the	DT	_	56	det
55	Mexitil	Mexitil	NNP	_	56	compound
56	dose	dose	NN	_	58	nsubjpass
57	is	be	VBZ	_	58	auxpass
58	changed	change	VBN	_	50	advcl
59	.	.	.	_	4	punct

1	An	a	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	adjustment	adjustment	NN	_	9	nsubjpass
4	in	in	IN	_	6	case
5	theophylline	theophylline	NN	_	6	compound
6	dose	dose	NN	_	3	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Additionally	additionally	RB	_	20	advmod
2	,	,	,	_	20	punct
3	in	in	IN	_	6	case
4	one	one	CD	_	6	nummod
5	controlled	controlled	JJ	_	6	amod
6	study	study	NN	_	20	nmod
7	in	in	IN	_	10	case
8	five	five	CD	_	10	nummod
9	normal	normal	JJ	_	10	amod
10	subjects	subject	NNS	_	6	nmod
11	and	and	CC	_	10	cc
12	seven	seven	CD	_	13	nummod
13	patients	patient	NNS	_	10	conj
14	,	,	,	_	20	punct
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	20	nsubjpass
17	of	of	IN	_	18	case
18	caffeine	caffeine	NN	_	16	nmod
19	was	be	VBD	_	20	auxpass
20	decreased	decrease	VBN	_	0	ROOT
21	50	50	CD	_	22	nummod
22	%	%	NN	_	20	dobj
23	following	follow	VBG	_	25	case
24	the	the	DT	_	25	det
25	administration	administration	NN	_	20	nmod
26	of	of	IN	_	27	case
27	Mexitil	Mexitil	NNP	_	25	nmod
28	.	.	.	_	20	punct

1	Anticoagulants	Anticoagulants	NNPS	_	2	nsubj
2	(	(	VBP	_	0	ROOT
3	oral	oral	JJ	_	4	amod
4	)	)	NN	_	2	dobj
5	:	:	:	_	4	punct
6	The	the	DT	_	7	det
7	activity	activity	NN	_	13	nsubjpass
8	of	of	IN	_	10	case
9	oral	oral	JJ	_	10	amod
10	anticoagulants	anticoagulant	NNS	_	7	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	potentiated	potentiate	VBN	_	4	appos
14	by	by	IN	_	17	case
15	anti	anti	JJ	_	17	amod
16	-	-	:	_	17	punct
17	vitamin	vitamin	NN	_	13	nmod
18	-	-	:	_	17	punct
19	K	k	NN	_	20	compound
20	activity	activity	NN	_	17	dep
21	attributed	attribute	VBN	_	20	acl
22	to	to	TO	_	23	case
23	methimazole	methimazole	NN	_	21	nmod
24	.	.	.	_	2	punct

1	-	-	:	_	0	ROOT
2	adrenergic	adrenergic	JJ	_	4	amod
3	blocking	block	VBG	_	4	amod
4	agents	agent	NNS	_	1	root
5	:	:	:	_	4	punct
6	Hyperthyroidism	hyperthyroidism	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	cause	cause	VB	_	4	dep
9	an	a	DT	_	11	det
10	increased	increase	VBN	_	11	amod
11	clearance	clearance	NN	_	8	dobj
12	of	of	IN	_	14	case
13	beta	beta	NN	_	14	compound
14	ratio	ratio	NN	_	11	nmod
15	.	.	.	_	4	punct

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	reduction	reduction	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	beta	beta	NN	_	3	nmod
6	-	-	:	_	3	punct
7	adrenergic	adrenergic	JJ	_	8	amod
8	blockers	blocker	NNS	_	11	nsubjpass
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	needed	need	VBN	_	3	dep
12	when	when	WRB	_	16	advmod
13	a	a	DT	_	15	det
14	hyperthyroid	hyperthyroid	JJ	_	15	amod
15	patient	patient	NN	_	16	nsubj
16	becomes	become	VBZ	_	11	advcl
17	euthyroid	euthyroid	JJ	_	16	xcomp
18	.	.	.	_	3	punct

1	Digitalis	digitalis	NN	_	2	compound
2	glycosides	glycoside	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Serum	serum	NN	_	6	compound
5	digitalis	digitalis	NN	_	6	compound
6	levels	level	NNS	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	increased	increase	VBN	_	2	parataxis
10	when	when	WRB	_	19	advmod
11	hyperthyroid	hyperthyroid	JJ	_	12	amod
12	patients	patient	NNS	_	19	nsubj
13	on	on	IN	_	18	case
14	a	a	DT	_	18	det
15	stable	stable	JJ	_	18	amod
16	digitalis	digitalis	NN	_	18	compound
17	glycoside	glycoside	NN	_	18	compound
18	regimen	regimen	NNS	_	12	nmod
19	become	become	VBP	_	9	advcl
20	euthyroid	euthyroid	JJ	_	19	xcomp
21	;	;	:	_	2	punct

1	reduced	reduce	VBN	_	2	amod
2	dosage	dosage	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	digitalis	digitalis	NN	_	5	compound
5	glycosides	glycoside	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	required	require	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Theophylline	Theophylline	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Theophylline	theophylline	NN	_	4	compound
4	clearance	clearance	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	1	parataxis
7	when	when	WRB	_	15	advmod
8	hyperthyroid	hyperthyroid	JJ	_	9	amod
9	patients	patient	NNS	_	15	nsubj
10	on	on	IN	_	14	case
11	a	a	DT	_	14	det
12	stable	stable	JJ	_	14	amod
13	theophylline	theophylline	NN	_	14	compound
14	regimen	regimen	NNS	_	9	nmod
15	become	become	VBP	_	6	advcl
16	euthyroid	euthyroid	JJ	_	15	xcomp
17	;	;	:	_	1	punct

1	a	a	DT	_	3	det
2	reduced	reduce	VBN	_	3	amod
3	dose	dose	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	theophylline	theophylline	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	needed	need	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Other	other	JJ	_	8	amod
2	short	short	JJ	_	8	amod
3	-	-	:	_	8	punct
4	acting	act	VBG	_	8	amod
5	beta	beta	NN	_	8	compound
6	adrenergic	adrenergic	JJ	_	8	amod
7	aerosol	aerosol	NN	_	8	compound
8	bronchodilators	bronchodilator	NNS	_	12	nsubjpass
9	should	should	MD	_	12	aux
10	not	not	RB	_	12	neg
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	0	ROOT
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	16	case
15	MAXAIR	maxair	NN	_	16	compound
16	AUTOHALER	autohaler	NN	_	12	nmod
17	because	because	IN	_	20	mark
18	they	they	PRP	_	20	nsubj
19	may	may	MD	_	20	aux
20	have	have	VB	_	12	advcl
21	additive	additive	JJ	_	22	amod
22	effects	effect	NNS	_	20	dobj
23	.	.	.	_	12	punct

1	Some	some	DT	_	2	det
2	anticonvulsants	anticonvulsant	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	Mephenytoin	mephenytoin	NN	_	4	nmod
7	.	.	.	_	4	punct

1	They	they	PRP	_	4	nsubj
2	can	can	MD	_	4	aux
3	either	either	RB	_	4	advmod
4	increase	increase	VB	_	0	ROOT
5	or	or	CC	_	4	cc
6	decrease	decrease	VB	_	4	conj
7	the	the	DT	_	8	det
8	effect	effect	NN	_	4	dobj
9	of	of	IN	_	10	case
10	Mephenytoin	Mephenytoin	NNP	_	8	nmod
11	.	.	.	_	4	punct

1	Those	those	DT	_	2	det
2	anticonvulsants	anticonvulsant	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	divalproex	divalproex	NN	_	5	compound
5	sodium	sodium	NN	_	3	dobj
6	,	,	,	_	5	punct
7	valproic	valproic	JJ	_	8	amod
8	acid	acid	NN	_	5	conj
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	phenobarbital	phenobarbital	NN	_	5	conj
12	.	.	.	_	3	punct

1	Mephenytoin	Mephenytoin	NNP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	which	which	WDT	_	12	nsubj
12	include	include	VBP	_	9	acl:relcl
13	some	some	DT	_	15	det
14	steroid	steroid	NN	_	15	compound
15	medications	medication	NNS	_	12	dobj
16	,	,	,	_	15	punct
17	warfarin	warfarin	NN	_	15	conj
18	,	,	,	_	15	punct
19	certain	certain	JJ	_	21	amod
20	heart	heart	NN	_	21	compound
21	medicines	medicine	NNS	_	15	conj
22	,	,	,	_	15	punct
23	birth	birth	NN	_	25	compound
24	control	control	NN	_	25	compound
25	pills	pill	NNS	_	15	conj
26	,	,	,	_	15	punct
27	anti	anti	JJ	_	30	amod
28	-	-	:	_	30	punct
29	infective	infective	JJ	_	30	amod
30	medicines	medicine	NNS	_	15	conj
31	,	,	,	_	15	punct
32	furosemide	furosemide	NN	_	15	conj
33	and	and	CC	_	15	cc
34	theophylline	theophylline	NN	_	15	conj
35	Please	please	UH	_	36	discourse
36	note	note	VB	_	4	xcomp
37	that	that	IN	_	40	mark
38	Mephenytoin	Mephenytoin	NNP	_	40	nsubj
39	may	may	MD	_	40	aux
40	interact	interact	VB	_	36	ccomp
41	with	with	IN	_	43	case
42	other	other	JJ	_	43	amod
43	drugs	drug	NNS	_	40	nmod
44	that	that	WDT	_	47	nsubjpass
45	are	be	VBP	_	47	auxpass
46	not	not	RB	_	47	neg
47	listed	list	VBN	_	43	acl:relcl
48	here	here	RB	_	47	advmod
49	.	.	.	_	4	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	7	case
3	Other	other	JJ	_	7	amod
4	Central	Central	NNP	_	7	compound
5	Nervous	Nervous	NNP	_	7	compound
6	System	System	NNP	_	7	compound
7	Depressants	Depressants	NNPS	_	1	nmod
8	:	:	:	_	1	punct
9	The	the	DT	_	11	det
10	depressant	depressant	NN	_	11	compound
11	effects	effect	NNS	_	15	nsubjpass
12	of	of	IN	_	13	case
13	morphine	morphine	NN	_	11	nmod
14	are	be	VBP	_	15	auxpass
15	potentiated	potentiate	VBN	_	1	dep
16	by	by	IN	_	18	case
17	the	the	DT	_	18	det
18	presence	presence	NN	_	15	nmod
19	of	of	IN	_	22	case
20	other	other	JJ	_	22	amod
21	CNS	cns	NN	_	22	compound
22	depressants	depressant	NNS	_	18	nmod
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	alcohol	alcohol	NN	_	22	nmod
26	,	,	,	_	25	punct
27	sedatives	sedative	NNS	_	25	conj
28	,	,	,	_	25	punct
29	antihistaminics	antihistaminic	NNS	_	25	conj
30	,	,	,	_	25	punct
31	or	or	CC	_	25	cc
32	psychotropic	psychotropic	JJ	_	33	amod
33	drugs	drug	NNS	_	25	conj
34	.	.	.	_	15	punct

1	Use	use	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	neuroleptics	neuroleptic	NNS	_	1	nmod
4	in	in	IN	_	5	case
5	conjunction	conjunction	NN	_	1	nmod
6	with	with	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	morphine	morphine	NN	_	5	nmod
9	may	may	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	respiratory	respiratory	JJ	_	15	amod
15	depression	depression	NN	_	12	nmod
16	,	,	,	_	15	punct
17	hypotension	hypotension	NN	_	15	conj
18	and	and	CC	_	15	cc
19	profound	profound	JJ	_	20	amod
20	sedation	sedation	NN	_	15	conj
21	or	or	CC	_	20	cc
22	coma	coma	NN	_	20	conj
23	.	.	.	_	10	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	4	case
3	Mixed	Mixed	NNP	_	4	compound
4	Agonist	agonist	NN	_	1	nmod
5	/	/	:	_	4	punct
6	Antagonist	Antagonist	NNP	_	8	compound
7	Opioid	Opioid	NNP	_	8	compound
8	Analgesics	Analgesics	NNPS	_	4	dep
9	:	:	:	_	4	punct
10	Agonist	agonist	NN	_	14	dep
11	/	/	:	_	14	punct
12	antagonist	antagonist	NN	_	13	compound
13	analgesics	analgesic	NNS	_	14	nsubj
14	(	(	VBP	_	4	dep
15	i	i	LS	_	14	dep
16	.	.	.	_	15	punct
17	e	e	LS	_	15	dep
18	.	.	.	_	17	punct
19	,	,	,	_	17	punct
20	pentazocine	pentazocine	NN	_	32	nsubjpass
21	,	,	,	_	20	punct
22	nalbuphine	nalbuphine	NN	_	20	conj
23	,	,	,	_	20	punct
24	butorphanol	butorphanol	NN	_	20	conj
25	,	,	,	_	20	punct
26	or	or	CC	_	20	cc
27	buprenorphine	buprenorphine	NN	_	28	compound
28	)	)	NN	_	20	conj
29	should	should	MD	_	32	aux
30	NOT	not	RB	_	32	advmod
31	be	be	VB	_	32	auxpass
32	administered	administer	VBN	_	17	parataxis
33	to	to	TO	_	34	case
34	patients	patient	NNS	_	32	nmod
35	who	who	WP	_	37	nsubj
36	have	have	VBP	_	37	aux
37	received	receive	VBN	_	34	acl:relcl
38	or	or	CC	_	37	cc
39	are	be	VBP	_	40	aux
40	receiving	receive	VBG	_	37	conj
41	a	a	DT	_	42	det
42	course	course	NN	_	37	dobj
43	of	of	IN	_	44	case
44	therapy	therapy	NN	_	42	nmod
45	with	with	IN	_	49	case
46	a	a	DT	_	49	det
47	proof	proof	NN	_	49	compound
48	opioid	opioid	NN	_	49	compound
49	agonist	agonist	NN	_	37	nmod
50	analgesic	analgesic	JJ	_	49	amod
51	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	patients	patient	NNS	_	11	nmod
4	,	,	,	_	11	punct
5	the	the	DT	_	7	det
6	mixed	mixed	JJ	_	7	amod
7	agonist	agonist	NN	_	11	nsubj
8	/	/	:	_	9	punct
9	antagonist	antagonist	NN	_	11	nsubj
10	may	may	MD	_	11	aux
11	alter	alter	VB	_	0	ROOT
12	the	the	DT	_	14	det
13	analgesic	analgesic	JJ	_	14	amod
14	effect	effect	NN	_	11	dobj
15	or	or	CC	_	11	cc
16	may	may	MD	_	17	aux
17	precipitate	precipitate	VB	_	11	conj
18	withdrawal	withdrawal	NN	_	19	compound
19	symptoms	symptom	NNS	_	17	dobj
20	.	.	.	_	11	punct

1	Ritalin	Ritalin	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypotensive	hypotensive	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	8	case
8	guanethidine	guanethidine	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Use	Use	NNP	_	0	ROOT
2	cautiously	cautiously	RB	_	5	advmod
3	with	with	IN	_	5	case
4	pressor	pressor	NN	_	5	compound
5	agents	agent	NNS	_	1	nmod
6	.	.	.	_	1	punct

1	Human	human	JJ	_	3	amod
2	pharmacologic	pharmacologic	JJ	_	3	amod
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	17	ccomp
6	that	that	IN	_	9	mark
7	Ritalin	Ritalin	NNP	_	9	nsubj
8	may	may	MD	_	9	aux
9	inhibit	inhibit	VB	_	5	ccomp
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	14	case
13	coumarin	coumarin	NN	_	14	compound
14	anticoagulants	anticoagulant	NNS	_	11	nmod
15	,	,	,	_	17	punct
16	anticonvulsants	anticonvulsant	NNS	_	17	nsubj
17	(	(	VBP	_	0	ROOT
18	phenobarbital	phenobarbital	NN	_	30	nsubj
19	,	,	,	_	18	punct
20	diphenylhydantoin	diphenylhydantoin	NN	_	18	conj
21	,	,	,	_	18	punct
22	primidone	primidone	NN	_	23	compound
23	)	)	NN	_	18	conj
24	,	,	,	_	18	punct
25	phenylbutazone	phenylbutazone	NN	_	18	conj
26	,	,	,	_	18	punct
27	and	and	CC	_	18	cc
28	tricyclic	tricyclic	JJ	_	29	amod
29	drugs	drug	NNS	_	18	conj
30	(	(	VBP	_	17	ccomp
31	imipramine	imipramine	NN	_	30	dobj
32	,	,	,	_	31	punct
33	clomipramine	clomipramine	NN	_	31	conj
34	,	,	,	_	31	punct
35	desipramine	desipramine	NN	_	36	compound
36	)	)	NN	_	31	conj
37	.	.	.	_	17	punct

1	Downward	downward	JJ	_	3	amod
2	dosage	dosage	NN	_	3	compound
3	adjustments	adjustment	NNS	_	9	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	when	when	WRB	_	11	advmod
11	given	give	VBN	_	9	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	Ritalin	ritalin	NN	_	11	nmod
15	.	.	.	_	9	punct

1	Serious	serious	JJ	_	3	amod
2	adverse	adverse	JJ	_	3	amod
3	events	event	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	use	use	NN	_	6	nmod
10	with	with	IN	_	11	case
11	clonidine	clonidine	NN	_	9	nmod
12	,	,	,	_	6	punct
13	although	although	IN	_	21	mark
14	no	no	DT	_	15	neg
15	causality	causality	NN	_	21	nsubjpass
16	for	for	IN	_	18	case
17	the	the	DT	_	18	det
18	combination	combination	NN	_	15	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	established	establish	VBN	_	6	advcl
22	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	safety	safety	NN	_	22	nsubjpass
3	of	of	IN	_	4	mark
4	using	use	VBG	_	2	acl
5	methylphenidate	methylphenidate	NN	_	4	dobj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	4	nmod
8	with	with	IN	_	9	case
9	clonidine	clonidine	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	other	other	JJ	_	17	amod
12	centrally	centrally	RB	_	13	advmod
13	acting	act	VBG	_	17	amod
14	alpha	alpha	NN	_	17	compound
15	-	-	:	_	17	punct
16	2	2	CD	_	17	nummod
17	agonists	agonist	NNS	_	9	conj
18	has	have	VBZ	_	22	aux
19	not	not	RB	_	22	neg
20	been	be	VBN	_	22	auxpass
21	systemically	systemically	RB	_	22	advmod
22	evaluated	evaluate	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	Co	Co	NNP	_	0	ROOT
2	-	-	:	_	1	punct
3	administration	administration	NN	_	16	dep
4	of	of	IN	_	5	case
5	SUTENT	sutent	JJ	_	3	nmod
6	with	with	IN	_	8	case
7	strong	strong	JJ	_	8	amod
8	inhibitors	inhibitor	NNS	_	3	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	CYP3A4	cyp3a4	NN	_	12	compound
12	family	family	NN	_	8	nmod
13	(	(	CD	_	12	nummod
14	e	e	LS	_	16	dep
15	.	.	.	_	14	punct
16	g	g	NN	_	1	dep
17	.	.	.	_	1	punct
18	,	,	,	_	1	punct
19	ketoconazole	ketoconazole	NN	_	42	nsubj
20	,	,	,	_	19	punct
21	itraconazole	itraconazole	NN	_	19	conj
22	,	,	,	_	19	punct
23	clarithromycin	clarithromycin	NN	_	19	conj
24	,	,	,	_	19	punct
25	atazanavir	atazanavir	NN	_	19	conj
26	,	,	,	_	19	punct
27	indinavir	indinavir	NN	_	19	conj
28	,	,	,	_	19	punct
29	nefazodone	nefazodone	NN	_	19	conj
30	,	,	,	_	19	punct
31	nelfinavir	nelfinavir	NN	_	19	conj
32	,	,	,	_	19	punct
33	ritonavir	ritonavir	NN	_	19	conj
34	,	,	,	_	19	punct
35	saquinavir	saquinavir	NN	_	19	conj
36	,	,	,	_	19	punct
37	telithromycin	telithromycin	NN	_	19	conj
38	,	,	,	_	19	punct
39	voriconizole	voriconizole	NN	_	40	compound
40	)	)	NN	_	19	conj
41	may	may	MD	_	42	aux
42	increases	increase	NNS	_	1	acl:relcl
43	sunitinib	sunitinib	JJ	_	44	amod
44	concentrations	concentration	NNS	_	42	dobj
45	.	.	.	_	1	punct

1	Grapefruit	grapefruit	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	increase	increase	VB	_	0	ROOT
5	plasma	plasma	NN	_	6	compound
6	concentrations	concentration	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	SUTENT	SUTENT	NNP	_	6	nmod
9	.	.	.	_	4	punct

1	Co	Co	NNP	_	0	ROOT
2	-	-	:	_	1	punct
3	administration	administration	NN	_	15	dep
4	of	of	IN	_	5	case
5	SUTENT	sutent	JJ	_	3	nmod
6	with	with	IN	_	7	case
7	inducers	inducer	NNS	_	3	nmod
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	CYP3A4	cyp3a4	NN	_	11	compound
11	family	family	NN	_	7	nmod
12	(	(	CD	_	11	nummod
13	e	e	LS	_	15	dep
14	.	.	.	_	13	punct
15	g	g	NN	_	1	dep
16	.	.	.	_	1	punct
17	,	,	,	_	1	punct
18	dexamethasone	dexamethasone	NN	_	36	compound
19	,	,	,	_	18	punct
20	phenytoin	phenytoin	NN	_	18	conj
21	,	,	,	_	18	punct
22	carbamazepine	carbamazepine	NN	_	18	conj
23	,	,	,	_	18	punct
24	rifampin	rifampin	NN	_	18	conj
25	,	,	,	_	18	punct
26	rifabutin	rifabutin	NN	_	18	conj
27	,	,	,	_	18	punct
28	rifapentin	rifapentin	NN	_	18	conj
29	,	,	,	_	18	punct
30	phenobarbital	phenobarbital	NN	_	18	conj
31	,	,	,	_	18	punct
32	St	St	NNP	_	18	conj
33	.	.	.	_	18	punct
34	Johns	Johns	NNP	_	36	compound
35	Wort	Wort	NNP	_	36	compound
36	)	)	NN	_	38	nsubj
37	may	may	MD	_	38	aux
38	decrease	decrease	VB	_	1	dep
39	sunitinib	sunitinib	JJ	_	40	amod
40	concentrations	concentration	NNS	_	38	dobj
41	.	.	.	_	1	punct

1	St	St	NNP	_	0	ROOT
2	.	.	.	_	1	punct

1	Johns	Johns	NNP	_	2	compound
2	Wort	Wort	NNP	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	0	ROOT
5	SUTENT	SUTENT	NNP	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	unpredictably	unpredictably	RB	_	4	advmod
9	.	.	.	_	4	punct

1	Patients	patient	NNS	_	6	nsubj
2	receiving	receive	VBG	_	1	acl
3	SUTENT	SUTENT	NNP	_	2	dobj
4	should	should	MD	_	6	aux
5	not	not	RB	_	6	neg
6	take	take	VB	_	0	ROOT
7	St	St	NNP	_	6	dobj
8	.	.	.	_	6	punct

1	Johns	Johns	NNP	_	2	compound
2	Wort	Wort	NNP	_	0	ROOT
3	concomitantly	concomitantly	RB	_	2	advmod
4	.	.	.	_	2	punct

1	SUTENT	SUTENT	NNP	_	3	compound
2	dose	dose	NN	_	3	compound
3	modification	modification	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	using	use	VBG	_	7	acl
9	concomitant	concomitant	JJ	_	11	amod
10	CYP3A4	cyp3a4	NN	_	11	compound
11	inhibitors	inhibitor	NNS	_	8	dobj
12	or	or	CC	_	11	cc
13	inducers	inducer	NNS	_	11	conj
14	.	.	.	_	5	punct

1	Diuretics	diuretic	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Excessive	excessive	JJ	_	4	amod
4	reductions	reduction	NNS	_	9	nsubj
5	in	in	IN	_	7	case
6	blood	blood	NN	_	7	compound
7	pressure	pressure	NN	_	4	nmod
8	may	may	MD	_	9	aux
9	occur	occur	VB	_	1	dep
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	14	case
13	diuretic	diuretic	JJ	_	14	amod
14	therapy	therapy	NN	_	11	nmod
15	when	when	WRB	_	19	advmod
16	ACE	ace	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	19	nsubjpass
18	are	be	VBP	_	19	auxpass
19	started	start	VBN	_	9	advcl
20	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	UNIVASC	UNIVASC	NNP	_	5	nmod
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	minimized	minimize	VBN	_	0	ROOT
11	by	by	IN	_	12	mark
12	discontinuing	discontinue	VBG	_	10	advcl
13	diuretic	diuretic	JJ	_	14	amod
14	therapy	therapy	NN	_	12	dobj
15	for	for	IN	_	17	case
16	several	several	JJ	_	17	amod
17	days	day	NNS	_	12	nmod
18	or	or	CC	_	12	cc
19	cautiously	cautiously	RB	_	20	advmod
20	increasing	increase	VBG	_	12	conj
21	salt	salt	NN	_	22	compound
22	intake	intake	NN	_	20	dobj
23	before	before	IN	_	24	case
24	initiation	initiation	NN	_	20	nmod
25	of	of	IN	_	26	case
26	treatment	treatment	NN	_	24	nmod
27	with	with	IN	_	28	case
28	UNIVASC	UNIVASC	NNP	_	26	nmod
29	.	.	.	_	10	punct
30	If	if	IN	_	34	mark
31	this	this	DT	_	34	nsubj
32	is	be	VBZ	_	34	cop
33	not	not	RB	_	34	neg
34	possible	possible	JJ	_	43	advcl
35	,	,	,	_	43	punct
36	the	the	DT	_	38	det
37	starting	start	VBG	_	38	amod
38	dose	dose	NN	_	43	nsubjpass
39	of	of	IN	_	40	case
40	moexpril	moexpril	NN	_	38	nmod
41	should	should	MD	_	43	aux
42	be	be	VB	_	43	auxpass
43	reduced	reduce	VBN	_	10	parataxis
44	..	..	IN	_	43	dep

1	Potassium	potassium	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	Potassium	potassium	NN	_	2	conj
5	-	-	:	_	2	punct
6	Sparing	spare	VBG	_	7	amod
7	Diuretics	diuretic	NNS	_	2	dep
8	:	:	:	_	7	punct
9	UNIVASC	UNIVASC	NNP	_	11	nsubj
10	can	can	MD	_	11	aux
11	increase	increase	VB	_	7	dep
12	serum	serum	NN	_	13	compound
13	potassium	potassium	NN	_	11	dobj
14	because	because	IN	_	16	mark
15	it	it	PRP	_	16	nsubj
16	decreases	decrease	VBZ	_	11	advcl
17	aldosterone	aldosterone	NN	_	18	compound
18	secretion	secretion	NN	_	16	dobj
19	.	.	.	_	2	punct

1	Use	use	NN	_	22	nsubj
2	of	of	IN	_	3	case
3	potassium	potassium	NN	_	1	nmod
4	-	-	:	_	1	punct
5	sparing	spare	VBG	_	1	dep
6	diuretics	diuretic	NNS	_	8	compound
7	(	(	CD	_	8	nummod
8	spironolactone	spironolactone	NN	_	5	dobj
9	,	,	,	_	8	punct
10	triamterene	triamterene	NN	_	8	appos
11	,	,	,	_	8	punct
12	amiloride	amiloride	NN	_	13	compound
13	)	)	NN	_	8	appos
14	or	or	CC	_	13	cc
15	potassium	potassium	NN	_	16	compound
16	supplements	supplement	NNS	_	13	conj
17	concomitantly	concomitantly	RB	_	13	advmod
18	with	with	IN	_	20	case
19	ACE	ace	NN	_	20	compound
20	inhibitors	inhibitor	NNS	_	17	nmod
21	can	can	MD	_	22	aux
22	increase	increase	VB	_	0	ROOT
23	the	the	DT	_	24	det
24	risk	risk	NN	_	22	dobj
25	of	of	IN	_	26	case
26	hyperkalemia	hyperkalemia	NN	_	24	nmod
27	.	.	.	_	22	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	27	csubjpass
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	the	the	DT	_	20	det
20	patient	patient	NN	_	24	nmod:poss
21	'	'	POS	_	20	case
22	s	s	NNS	_	24	compound
23	serum	serum	NN	_	24	compound
24	potassium	potassium	NN	_	17	conj
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	monitored	monitor	VBN	_	0	ROOT
28	.	.	.	_	27	punct

1	Oral	oral	JJ	_	2	amod
2	Anticoagulants	Anticoagulants	NNPS	_	0	ROOT
3	:	:	:	_	2	punct
4	Interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubj
6	with	with	IN	_	7	case
7	warfarin	warfarin	NN	_	5	nmod
8	failed	fail	VBD	_	2	dep
9	to	to	TO	_	10	mark
10	identify	identify	VB	_	8	xcomp
11	any	any	DT	_	14	det
12	clinically	clinically	RB	_	13	advmod
13	important	important	JJ	_	14	amod
14	effect	effect	NN	_	10	dobj
15	on	on	IN	_	18	case
16	the	the	DT	_	18	det
17	serum	serum	NN	_	18	compound
18	concentrations	concentration	NNS	_	14	nmod
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	anticoagulant	anticoagulant	JJ	_	18	nmod
22	or	or	CC	_	21	cc
23	on	on	IN	_	26	case
24	its	its	PRP$	_	26	nmod:poss
25	anticoagulant	anticoagulant	JJ	_	26	amod
26	effect	effect	NN	_	21	conj
27	.	.	.	_	2	punct

1	Lithium	lithium	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	6	amod
4	serum	serum	NN	_	6	compound
5	lithium	lithium	NN	_	6	compound
6	levels	level	NNS	_	14	nsubjpass
7	and	and	CC	_	6	cc
8	symptoms	symptom	NNS	_	6	conj
9	of	of	IN	_	11	case
10	lithium	lithium	NN	_	11	compound
11	toxicity	toxicity	NN	_	8	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	1	appos
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	ACE	ace	NN	_	19	compound
19	inhibitors	inhibitor	NNS	_	17	dobj
20	during	during	IN	_	21	case
21	therapy	therapy	NN	_	17	nmod
22	with	with	IN	_	23	case
23	lithium	lithium	NN	_	21	nmod
24	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	frequent	frequent	JJ	_	11	amod
11	monitoring	monitoring	NN	_	17	nsubjpass
12	of	of	IN	_	15	case
13	serum	serum	NN	_	15	compound
14	lithium	lithium	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	is	be	VBZ	_	17	auxpass
17	recommended	recommend	VBN	_	5	conj
18	.	.	.	_	5	punct

1	If	if	IN	_	6	mark
2	a	a	DT	_	3	det
3	diuretic	diuretic	JJ	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	also	also	RB	_	6	advmod
6	used	use	VBN	_	15	advcl
7	,	,	,	_	15	punct
8	the	the	DT	_	9	det
9	risk	risk	NN	_	15	nsubjpass
10	of	of	IN	_	12	case
11	lithium	lithium	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	increased	increase	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Other	other	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	No	no	DT	_	8	neg
5	clinically	clinically	RB	_	6	advmod
6	important	important	JJ	_	8	amod
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	interactions	interaction	NNS	_	9	nsubj
9	occurred	occur	VBD	_	2	dep
10	when	when	WRB	_	13	advmod
11	UNIVASC	UNIVASC	NNP	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	concomitantly	concomitantly	RB	_	13	advmod
15	with	with	IN	_	16	case
16	hydrochlorothiazide	hydrochlorothiazide	NN	_	13	nmod
17	,	,	,	_	16	punct
18	digoxin	digoxin	NN	_	16	conj
19	,	,	,	_	16	punct
20	or	or	CC	_	16	cc
21	cimetidine	cimetidine	NN	_	16	conj
22	.	.	.	_	2	punct

1	UNIVASC	UNIVASC	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	trials	trial	NNS	_	4	nmod
8	concomitantly	concomitantly	RB	_	10	advmod
9	with	with	IN	_	10	case
10	calcium	calcium	NN	_	7	nmod
11	-	-	:	_	10	punct
12	channel	channel	NN	_	15	compound
13	-	-	:	_	15	punct
14	blocking	block	VBG	_	15	amod
15	agents	agent	NNS	_	10	dep
16	,	,	,	_	15	punct
17	diuretics	diuretic	NNS	_	15	conj
18	,	,	,	_	15	punct
19	H2	h2	NN	_	20	compound
20	blockers	blocker	NNS	_	15	conj
21	,	,	,	_	15	punct
22	digoxin	digoxin	NN	_	15	conj
23	,	,	,	_	15	punct
24	oral	oral	JJ	_	26	amod
25	hypoglycemic	hypoglycemic	JJ	_	26	amod
26	agents	agent	NNS	_	15	conj
27	,	,	,	_	15	punct
28	and	and	CC	_	15	cc
29	cholesterol	cholesterol	NN	_	32	compound
30	-	-	:	_	32	punct
31	lowering	lower	VBG	_	32	amod
32	agents	agent	NNS	_	15	conj
33	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	of	of	IN	_	9	case
6	clinically	clinically	RB	_	7	advmod
7	important	important	JJ	_	9	amod
8	adverse	adverse	JJ	_	9	amod
9	interactions	interaction	NNS	_	4	nmod
10	.	.	.	_	2	punct

1	ALIMTA	ALIMTA	NNP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	primarily	primarily	RB	_	4	advmod
4	eliminated	eliminate	VBN	_	0	ROOT
5	unchanged	unchanged	JJ	_	4	xcomp
6	renally	renally	RB	_	4	advmod
7	as	as	IN	_	9	case
8	a	a	DT	_	9	det
9	result	result	NN	_	4	nmod
10	of	of	IN	_	12	case
11	glomerular	glomerular	JJ	_	12	amod
12	filtration	filtration	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	tubular	tubular	JJ	_	15	amod
15	secretion	secretion	NN	_	12	conj
16	.	.	.	_	4	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	5	case
4	nephrotoxic	nephrotoxic	JJ	_	5	amod
5	drugs	drug	NNS	_	2	nmod
6	could	could	MD	_	7	aux
7	result	result	VB	_	0	ROOT
8	in	in	IN	_	10	case
9	delayed	delay	VBN	_	10	amod
10	clearance	clearance	NN	_	7	nmod
11	of	of	IN	_	12	case
12	ALIMTA	ALIMTA	NNP	_	10	nmod
13	.	.	.	_	7	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	20	dep
3	of	of	IN	_	4	case
4	substances	substance	NNS	_	2	nmod
5	that	that	WDT	_	9	nsubjpass
6	are	be	VBP	_	9	auxpass
7	also	also	RB	_	9	advmod
8	tubularly	tubularly	RB	_	9	advmod
9	secreted	secrete	VBN	_	4	acl:relcl
10	(	(	NN	_	13	compound
11	e	e	LS	_	13	dep
12	.	.	.	_	11	punct
13	g	g	NN	_	9	dobj
14	.	.	.	_	2	punct
15	,	,	,	_	20	punct
16	probenecid	probenecid	NN	_	17	compound
17	)	)	NN	_	20	nsubj
18	could	could	MD	_	20	aux
19	potentially	potentially	RB	_	20	advmod
20	result	result	VB	_	0	ROOT
21	in	in	IN	_	23	case
22	delayed	delay	VBN	_	23	amod
23	clearance	clearance	NN	_	20	nmod
24	of	of	IN	_	25	case
25	ALIMTA	ALIMTA	NNP	_	23	nmod
26	.	.	.	_	20	punct

1	Although	although	IN	_	10	mark
2	ibuprofen	ibuprofen	NN	_	7	compound
3	(	(	NN	_	7	compound
4	400	400	CD	_	7	nummod
5	mg	mg	NN	_	7	compound
6	qid	qid	NN	_	7	compound
7	)	)	NN	_	10	nsubjpass
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	31	advcl
11	with	with	IN	_	12	case
12	ALIMTA	alimta	NN	_	10	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	with	with	IN	_	18	case
16	normal	normal	JJ	_	18	amod
17	renal	renal	JJ	_	18	amod
18	function	function	NN	_	14	nmod
19	(	(	CD	_	21	nummod
20	creatinine	creatinine	NN	_	21	compound
21	clearance	clearance	NN	_	18	dep
22	80	80	CD	_	23	nummod
23	mL	ml	NN	_	21	dep
24	/	/	:	_	23	punct
25	min	min	NN	_	26	compound
26	)	)	NN	_	23	dep
27	,	,	,	_	31	punct
28	caution	caution	NN	_	31	nsubjpass
29	should	should	MD	_	31	aux
30	be	be	VB	_	31	auxpass
31	used	use	VBN	_	0	ROOT
32	when	when	WRB	_	33	advmod
33	administering	administer	VBG	_	31	advcl
34	ibuprofen	ibuprofen	NN	_	33	dobj
35	concurrently	concurrently	RB	_	34	advmod
36	with	with	IN	_	37	case
37	ALIMTA	alimta	NN	_	33	nmod
38	to	to	TO	_	39	case
39	patients	patient	NNS	_	37	nmod
40	with	with	IN	_	41	case
41	mild	mild	JJ	_	39	nmod
42	to	to	TO	_	45	case
43	moderate	moderate	JJ	_	45	amod
44	renal	renal	JJ	_	45	amod
45	insufficiency	insufficiency	NN	_	41	nmod
46	(	(	CD	_	48	nummod
47	creatinine	creatinine	NN	_	48	compound
48	clearance	clearance	NN	_	45	dep
49	from	from	IN	_	53	case
50	45	45	CD	_	52	compound
51	to	to	TO	_	52	dep
52	79	79	CD	_	53	nummod
53	mL	ml	NN	_	48	nmod
54	/	/	:	_	48	punct
55	min	min	NN	_	56	compound
56	)	)	NN	_	48	dep
57	.	.	.	_	31	punct

1	Patients	patient	NNS	_	9	nsubj
2	with	with	IN	_	3	case
3	mild	mild	JJ	_	1	nmod
4	to	to	TO	_	7	case
5	moderate	moderate	JJ	_	7	amod
6	renal	renal	JJ	_	7	amod
7	insufficiency	insufficiency	NN	_	3	nmod
8	should	should	MD	_	9	aux
9	avoid	avoid	VB	_	0	ROOT
10	taking	take	VBG	_	9	xcomp
11	NSAIDs	nsaid	NNS	_	10	dobj
12	with	with	IN	_	15	case
13	short	short	JJ	_	15	amod
14	elimination	elimination	NN	_	15	compound
15	half	half	NN	_	10	nmod
16	-	-	:	_	15	punct
17	lives	life	NNS	_	15	dep
18	for	for	IN	_	20	case
19	a	a	DT	_	20	det
20	period	period	NN	_	10	nmod
21	of	of	IN	_	23	case
22	2	2	CD	_	23	nummod
23	days	day	NNS	_	20	nmod
24	before	before	RB	_	20	advmod
25	,	,	,	_	9	punct
26	the	the	DT	_	27	det
27	day	day	NN	_	25	root
28	of	of	IN	_	27	acl
29	,	,	,	_	27	punct
30	and	and	CC	_	27	cc
31	2	2	CD	_	32	nummod
32	days	day	NNS	_	27	conj
33	following	follow	VBG	_	34	case
34	administration	administration	NN	_	32	nmod
35	of	of	IN	_	36	case
36	ALIMTA	ALIMTA	NNP	_	34	nmod
37	.	.	.	_	27	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	absence	absence	NN	_	25	nmod
4	of	of	IN	_	5	case
5	data	datum	NNS	_	3	nmod
6	regarding	regard	VBG	_	8	case
7	potential	potential	JJ	_	8	amod
8	interaction	interaction	NN	_	5	nmod
9	between	between	IN	_	10	case
10	ALIMTA	ALIMTA	NNP	_	8	nmod
11	and	and	CC	_	10	cc
12	NSAIDs	nsaid	NNS	_	10	conj
13	with	with	IN	_	15	case
14	longer	longer	JJR	_	15	amod
15	half	half	NN	_	8	nmod
16	-	-	:	_	15	punct
17	lives	life	NNS	_	15	dep
18	,	,	,	_	25	punct
19	all	all	DT	_	20	det
20	patients	patient	NNS	_	25	nsubj
21	taking	take	VBG	_	20	acl
22	these	these	DT	_	23	det
23	NSAIDs	nsaid	NNS	_	21	dobj
24	should	should	MD	_	25	aux
25	interrupt	interrupt	VB	_	0	ROOT
26	dosing	dosing	NN	_	25	dobj
27	for	for	IN	_	31	case
28	at	at	IN	_	29	case
29	least	least	JJS	_	30	nmod:npmod
30	5	5	CD	_	31	nummod
31	days	day	NNS	_	25	nmod
32	before	before	RB	_	31	advmod
33	,	,	,	_	25	punct
34	the	the	DT	_	35	det
35	day	day	NN	_	33	root
36	of	of	IN	_	35	acl
37	,	,	,	_	35	punct
38	and	and	CC	_	35	cc
39	2	2	CD	_	40	nummod
40	days	day	NNS	_	35	conj
41	following	follow	VBG	_	43	case
42	ALIMTA	ALIMTA	NNP	_	43	compound
43	administration	administration	NN	_	40	nmod
44	.	.	.	_	35	punct

1	If	if	IN	_	8	mark
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	an	a	DT	_	6	det
6	NSAID	nsaid	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	necessary	necessary	JJ	_	13	advcl
9	,	,	,	_	13	punct
10	patients	patient	NNS	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	closely	closely	RB	_	13	advmod
15	for	for	IN	_	16	case
16	toxicity	toxicity	NN	_	13	nmod
17	,	,	,	_	13	punct
18	especially	especially	RB	_	19	advmod
19	myelosuppression	myelosuppression	NN	_	13	dobj
20	,	,	,	_	19	punct
21	renal	renal	JJ	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	gastrointestinal	gastrointestinal	JJ	_	25	amod
25	toxicity	toxicity	NN	_	19	conj
26	.	.	.	_	13	punct

1	Drug	drug	NN	_	6	compound
2	/	/	:	_	6	punct
3	Laboratory	Laboratory	NNP	_	6	compound
4	Test	Test	NNP	_	6	compound
5	Interactions	interaction	NNS	_	6	compound
6	None	none	NN	_	0	ROOT
7	known	know	VBN	_	6	acl
8	.	.	.	_	6	punct

1	Prothrombin	Prothrombin	NNP	_	2	compound
2	time	time	NN	_	10	nsubjpass
3	or	or	CC	_	2	cc
4	other	other	JJ	_	7	amod
5	suitable	suitable	JJ	_	7	amod
6	anticoagulation	anticoagulation	JJ	_	7	amod
7	test	test	NN	_	2	conj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	0	ROOT
11	if	if	IN	_	14	mark
12	tigecycline	tigecycline	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	administered	administer	VBN	_	10	advcl
15	with	with	IN	_	16	case
16	warfarin	warfarin	NN	_	14	nmod
17	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	10	nsubj
3	of	of	IN	_	5	case
4	antibacterial	antibacterial	JJ	_	5	amod
5	drugs	drug	NNS	_	2	nmod
6	with	with	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	contraceptives	contraceptive	NNS	_	2	nmod
9	may	may	MD	_	10	aux
10	render	render	VB	_	0	ROOT
11	oral	oral	JJ	_	12	amod
12	contraceptives	contraceptive	NNS	_	14	nsubj
13	less	less	RBR	_	14	advmod
14	effective	effective	JJ	_	10	xcomp
15	.	.	.	_	10	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	There	there	EX	_	7	expl
7	are	be	VBP	_	5	acl:relcl
8	no	no	DT	_	10	neg
9	reported	report	VBN	_	10	amod
10	drug	drug	NN	_	7	nsubj
11	-	-	:	_	10	punct
12	laboratory	laboratory	NN	_	14	compound
13	test	test	NN	_	14	compound
14	interactions	interaction	NNS	_	10	dep
15	.	.	.	_	5	punct

1	Melatonin	melatonin	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	drugs	drug	NNS	_	3	nmod
8	:	:	:	_	7	punct
9	aspirin	aspirin	NN	_	13	nsubj
10	and	and	CC	_	9	cc
11	other	other	JJ	_	12	amod
12	NSAIDs	nsaid	NNS	_	9	conj
13	(	(	VBP	_	7	dep
14	may	may	MD	_	15	aux
15	lower	lower	VB	_	13	ccomp
16	melatonin	melatonin	NN	_	17	compound
17	levels	level	NNS	_	18	nsubj
18	)	)	VBP	_	15	ccomp
19	,	,	,	_	13	punct
20	fluvoxamine	fluvoxamine	VBP	_	27	csubjpass
21	(	(	CD	_	22	nummod
22	bioavailability	bioavailability	NN	_	20	dobj
23	of	of	IN	_	25	case
24	oral	oral	JJ	_	25	amod
25	melatonin	melatonin	NN	_	22	nmod
26	is	be	VBZ	_	27	auxpass
27	increased	increase	VBN	_	13	dep
28	with	with	IN	_	30	case
29	coadministration	coadministration	NN	_	30	compound
30	)	)	NN	_	27	nmod
31	,	,	,	_	30	punct
32	beta	beta	NN	_	33	compound
33	blockers	blocker	NNS	_	30	appos
34	(	(	VBP	_	36	nsubj
35	may	may	MD	_	36	aux
36	decrease	decrease	VB	_	13	parataxis
37	melatonin	melatonin	NN	_	38	compound
38	levels	level	NNS	_	39	nsubj
39	)	)	VBP	_	36	ccomp
40	,	,	,	_	13	punct
41	fluoxetine	fluoxetine	VBP	_	13	conj
42	(	(	CD	_	43	nummod
43	reports	report	NNS	_	41	dobj
44	of	of	IN	_	46	case
45	psychotic	psychotic	JJ	_	46	amod
46	episodes	episode	NNS	_	43	nmod
47	when	when	WRB	_	48	advmod
48	coadministered	coadminister	VBN	_	41	advcl
49	)	)	RB	_	48	advmod
50	,	,	,	_	13	punct
51	progestin	progestin	NN	_	53	compound
52	(	(	NN	_	53	compound
53	coadministration	coadministration	NN	_	59	nsubj
54	of	of	IN	_	55	case
55	melatonin	melatonin	NN	_	53	nmod
56	with	with	IN	_	57	case
57	progestin	progestin	NN	_	53	nmod
58	can	can	MD	_	59	aux
59	inhibit	inhibit	VB	_	13	parataxis
60	ovarian	ovarian	JJ	_	61	amod
61	function	function	NN	_	59	dobj
62	in	in	IN	_	63	case
63	women	woman	NNS	_	61	nmod
64	)	)	VBP	_	59	dep
65	,	,	,	_	64	punct
66	benzodiazepenes	benzodiazepene	NNS	_	64	conj
67	and	and	CC	_	64	cc
68	other	other	JJ	_	70	amod
69	sedating	sedating	JJ	_	70	amod
70	drugs	drug	NNS	_	64	conj
71	(	(	VBP	_	73	nsubj
72	may	may	MD	_	73	aux
73	result	result	VB	_	64	ccomp
74	in	in	IN	_	76	case
75	additive	additive	JJ	_	76	amod
76	sedation	sedation	NN	_	73	nmod
77	and	and	CC	_	76	cc
78	an	a	DT	_	80	det
79	increased	increase	VBN	_	80	amod
80	incidence	incidence	NN	_	76	conj
81	of	of	IN	_	83	case
82	adverse	adverse	JJ	_	83	amod
83	effects	effect	NNS	_	80	nmod
84	)	)	VBP	_	95	nsubj
85	,	,	,	_	84	punct
86	and	and	CC	_	84	cc
87	corticosteroids	corticosteroid	NNS	_	88	nsubj
88	(	(	VBP	_	84	conj
89	coadministration	coadministration	NN	_	88	dobj
90	of	of	IN	_	91	case
91	melatonin	melatonin	NN	_	89	nmod
92	and	and	CC	_	91	cc
93	corticosteroids	corticosteroid	NNS	_	91	conj
94	may	may	MD	_	95	aux
95	interfere	interfere	VB	_	73	ccomp
96	with	with	IN	_	98	case
97	the	the	DT	_	98	det
98	efficacy	efficacy	NN	_	95	nmod
99	of	of	IN	_	101	case
100	the	the	DT	_	101	det
101	corticosteroids	corticosteroid	NNS	_	98	nmod
102	)	)	VBP	_	98	acl
103	.	.	.	_	3	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	with	with	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	that	that	IN	_	13	mark
10	terbinafine	terbinafine	NN	_	13	nsubj
11	does	do	VBZ	_	13	aux
12	not	not	RB	_	13	neg
13	inhibit	inhibit	VB	_	8	ccomp
14	the	the	DT	_	15	det
15	metabolism	metabolism	NN	_	13	dobj
16	of	of	IN	_	17	case
17	tolbutamide	tolbutamide	NN	_	15	nmod
18	,	,	,	_	17	punct
19	ethinylestradiol	ethinylestradiol	NN	_	17	conj
20	,	,	,	_	17	punct
21	ethoxycoumarin	ethoxycoumarin	NN	_	17	conj
22	,	,	,	_	17	punct
23	and	and	CC	_	17	cc
24	cyclosporine	cyclosporine	NN	_	17	conj
25	.	.	.	_	8	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	6	nsubj
4	have	have	VBP	_	6	aux
5	also	also	RB	_	6	advmod
6	shown	show	VBN	_	0	ROOT
7	that	that	IN	_	9	mark
8	terbinafine	terbinafine	NN	_	9	nsubj
9	inhibits	inhibit	VBZ	_	6	ccomp
10	CYP2D6	cyp2d6	NN	_	9	dobj
11	-	-	:	_	10	punct
12	mediated	mediate	VBN	_	13	amod
13	metabolism	metabolism	NN	_	10	dep
14	.	.	.	_	6	punct

1	This	this	DT	_	6	nsubj
2	may	may	MD	_	6	aux
3	be	be	VB	_	6	cop
4	of	of	IN	_	6	case
5	clinical	clinical	JJ	_	6	amod
6	relevance	relevance	NN	_	0	ROOT
7	for	for	IN	_	8	case
8	compounds	compound	NNS	_	6	nmod
9	predominantly	predominantly	RB	_	10	advmod
10	metabolized	metabolize	VBN	_	8	acl
11	by	by	IN	_	13	case
12	this	this	DT	_	13	det
13	enzyme	enzyme	NN	_	10	nmod
14	,	,	,	_	8	punct
15	such	such	JJ	_	18	case
16	as	as	IN	_	15	mwe
17	tricyclic	tricyclic	JJ	_	18	amod
18	antidepressants	antidepressant	NNS	_	8	nmod
19	,	,	,	_	18	punct
20	-	-	:	_	18	punct
21	blockers	blocker	NNS	_	18	dep
22	,	,	,	_	18	punct
23	selective	selective	JJ	_	26	amod
24	serotonin	serotonin	NN	_	26	compound
25	reuptake	reuptake	NN	_	26	compound
26	inhibitors	inhibitor	NNS	_	18	conj
27	(	(	VBN	_	28	amod
28	SSRIs	ssri	NNS	_	29	nsubj
29	)	)	VBP	_	26	acl:relcl
30	,	,	,	_	18	punct
31	and	and	CC	_	18	cc
32	monoamine	monoamine	NN	_	34	compound
33	oxidase	oxidase	NN	_	34	compound
34	inhibitors	inhibitor	NNS	_	18	conj
35	(	(	VBP	_	41	dep
36	MAO	mao	SYM	_	41	dep
37	-	-	:	_	41	punct
38	Is	be	VBZ	_	41	cop
39	)	)	CD	_	41	nummod
40	Type	type	NN	_	41	compound
41	B	b	NN	_	6	dep
42	,	,	,	_	41	punct
43	if	if	IN	_	45	mark
44	they	they	PRP	_	45	nsubj
45	have	have	VBP	_	41	advcl
46	a	a	DT	_	49	det
47	narrow	narrow	JJ	_	49	amod
48	therapeutic	therapeutic	JJ	_	49	amod
49	window	window	NN	_	45	dobj
50	.	.	.	_	6	punct

1	In	in	FW	_	3	amod
2	vivo	vivo	FW	_	1	dep
3	drug	drug	NN	_	13	nsubj
4	-	-	:	_	3	punct
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	3	dep
8	conducted	conduct	VBN	_	7	acl
9	in	in	IN	_	12	case
10	normal	normal	JJ	_	12	amod
11	volunteer	volunteer	NN	_	12	compound
12	subjects	subject	NNS	_	8	nmod
13	showed	show	VBD	_	0	ROOT
14	that	that	IN	_	18	mark
15	terbinafine	terbinafine	NN	_	18	nsubj
16	does	do	VBZ	_	18	aux
17	not	not	RB	_	18	neg
18	affect	affect	VB	_	13	ccomp
19	the	the	DT	_	20	det
20	clearance	clearance	NN	_	18	dobj
21	of	of	IN	_	22	case
22	antipyrine	antipyrine	NN	_	20	nmod
23	or	or	CC	_	22	cc
24	digoxin	digoxin	NN	_	22	conj
25	.	.	.	_	13	punct

1	Terbinafine	terbinafine	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	clearance	clearance	NN	_	2	dobj
5	of	of	IN	_	6	case
6	caffeine	caffeine	NN	_	4	nmod
7	by	by	IN	_	9	case
8	19	19	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	.	.	.	_	2	punct

1	Terbinafine	terbinafine	NN	_	2	nsubj
2	increases	increase	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	clearance	clearance	NN	_	2	dobj
5	of	of	IN	_	6	case
6	cyclosporine	cyclosporine	NN	_	4	nmod
7	by	by	IN	_	9	case
8	15	15	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	.	.	.	_	2	punct

1	There	there	EX	_	5	expl
2	have	have	VBP	_	5	aux
3	been	be	VBN	_	5	cop
4	spontaneous	spontaneous	JJ	_	5	amod
5	reports	report	NNS	_	0	ROOT
6	of	of	IN	_	7	case
7	increase	increase	NN	_	5	nmod
8	or	or	CC	_	5	cc
9	decrease	decrease	VB	_	5	conj
10	in	in	IN	_	12	case
11	prothrombin	prothrombin	NN	_	12	compound
12	times	time	NNS	_	9	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	concomitantly	concomitantly	RB	_	16	advmod
16	taking	take	VBG	_	14	acl
17	oral	oral	JJ	_	18	amod
18	terbinafine	terbinafine	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	warfarin	warfarin	NN	_	18	conj
21	,	,	,	_	5	punct
22	however	however	RB	_	5	advmod
23	,	,	,	_	5	punct
24	a	a	DT	_	26	det
25	causal	causal	JJ	_	26	amod
26	relationship	relationship	NN	_	36	nsubjpass
27	between	between	IN	_	29	case
28	LAMISIL	LAMISIL	NNP	_	29	compound
29	Tablets	Tablets	NNPS	_	26	nmod
30	and	and	CC	_	29	cc
31	these	these	DT	_	32	det
32	changes	change	NNS	_	29	conj
33	has	have	VBZ	_	36	aux
34	not	not	RB	_	36	neg
35	been	be	VBN	_	36	auxpass
36	established	establish	VBN	_	5	dep
37	.	.	.	_	5	punct

1	Terbinafine	terbinafine	JJ	_	2	amod
2	clearance	clearance	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	increased	increase	VBN	_	25	dep
5	100	100	CD	_	6	nummod
6	%	%	NN	_	4	dobj
7	by	by	IN	_	8	case
8	rifampin	rifampin	NN	_	4	nmod
9	,	,	,	_	8	punct
10	a	a	DT	_	13	det
11	CyP450	cyp450	NN	_	13	compound
12	enzyme	enzyme	NN	_	13	compound
13	inducer	inducer	NN	_	8	appos
14	,	,	,	_	4	punct
15	and	and	CC	_	4	cc
16	decreased	decrease	VBD	_	4	conj
17	33	33	CD	_	18	nummod
18	%	%	NN	_	16	dobj
19	by	by	IN	_	20	case
20	cimetidine	cimetidine	NN	_	16	nmod
21	,	,	,	_	25	punct
22	a	a	DT	_	25	det
23	CyP450	cyp450	NN	_	25	compound
24	enzyme	enzyme	NN	_	25	compound
25	inhibitor	inhibitor	NN	_	0	ROOT
26	.	.	.	_	25	punct

1	Terbinafine	terbinafine	JJ	_	2	amod
2	clearance	clearance	NN	_	4	nsubj
3	is	be	VBZ	_	4	aux
4	unaffected	unaffected	JJ	_	0	ROOT
5	by	by	IN	_	6	case
6	cyclosporine	cyclosporine	NN	_	4	nmod
7	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	information	information	NN	_	2	nsubj
5	available	available	JJ	_	4	amod
6	from	from	IN	_	8	case
7	adequate	adequate	JJ	_	8	amod
8	drug	drug	NN	_	5	nmod
9	-	-	:	_	8	punct
10	drug	drug	NN	_	12	compound
11	interaction	interaction	NN	_	12	compound
12	studies	study	NNS	_	8	dep
13	with	with	IN	_	16	case
14	the	the	DT	_	16	det
15	following	follow	VBG	_	16	amod
16	classes	class	NNS	_	12	nmod
17	of	of	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	:	:	:	_	2	punct
20	oral	oral	JJ	_	21	amod
21	contraceptives	contraceptive	NNS	_	2	dep
22	,	,	,	_	21	punct
23	hormone	hormone	NN	_	25	compound
24	replacement	replacement	NN	_	25	compound
25	therapies	therapy	NNS	_	21	conj
26	,	,	,	_	21	punct
27	hypoglycemics	hypoglycemic	NNS	_	21	conj
28	,	,	,	_	21	punct
29	theophyllines	theophylline	NNS	_	21	conj
30	,	,	,	_	21	punct
31	phenytoins	phenytoin	NNS	_	21	conj
32	,	,	,	_	21	punct
33	thiazide	thiazide	JJ	_	34	amod
34	diuretics	diuretic	NNS	_	21	conj
35	,	,	,	_	21	punct
36	beta	beta	NN	_	37	compound
37	blockers	blocker	NNS	_	21	conj
38	,	,	,	_	21	punct
39	and	and	CC	_	21	cc
40	calcium	calcium	NN	_	42	compound
41	channel	channel	NN	_	42	compound
42	blockers	blocker	NNS	_	21	conj
43	.	.	.	_	2	punct

1	ZANOSAR	zanosar	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	demonstrate	demonstrate	VB	_	0	ROOT
4	additive	additive	JJ	_	5	amod
5	toxicity	toxicity	NN	_	3	dobj
6	when	when	WRB	_	7	advmod
7	used	use	VBN	_	5	acl:relcl
8	in	in	IN	_	9	case
9	combination	combination	NN	_	7	nmod
10	with	with	IN	_	13	case
11	other	other	JJ	_	13	amod
12	cytotoxic	cytotoxic	JJ	_	13	amod
13	drugs	drug	NNS	_	9	nmod
14	.	.	.	_	3	punct

1	Streptozocin	Streptozocin	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	prolong	prolong	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	elimination	elimination	NN	_	6	dobj
9	half	half	NN	_	11	dep
10	-	-	:	_	11	punct
11	life	life	NN	_	8	dep
12	of	of	IN	_	13	case
13	doxorubicin	doxorubicin	NN	_	11	nmod
14	and	and	CC	_	4	cc
15	may	may	MD	_	16	aux
16	lead	lead	VB	_	4	conj
17	to	to	TO	_	21	case
18	severe	severe	JJ	_	21	amod
19	bone	bone	NN	_	21	compound
20	marrow	marrow	NN	_	21	compound
21	suppression	suppression	NN	_	16	nmod
22	;	;	:	_	4	punct

1	a	a	DT	_	2	det
2	reduction	reduction	NN	_	9	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	doxorubicin	doxorubicin	NN	_	6	compound
6	dosage	dosage	NN	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	receiving	receive	VBG	_	11	acl
13	ZANOSAR	zanosar	NN	_	12	dobj
14	concurrently	concurrently	RB	_	12	advmod
15	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	streptozocin	streptozocin	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	phenytoin	phenytoin	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	one	one	CD	_	13	nummod
13	case	case	NN	_	10	nmod
14	to	to	TO	_	15	mark
15	result	result	VB	_	10	xcomp
16	in	in	IN	_	19	case
17	reduced	reduce	VBN	_	19	amod
18	streptozocin	streptozocin	NN	_	19	compound
19	cytotoxicity	cytotoxicity	NN	_	15	nmod
20	.	.	.	_	10	punct

1	Cholestyramine	Cholestyramine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Cholestyramine	Cholestyramine	NNP	_	4	nsubj
4	causes	cause	VBZ	_	1	dep
5	a	a	DT	_	8	det
6	60	60	CD	_	7	compound
7	%	%	NN	_	8	amod
8	reduction	reduction	NN	_	4	dobj
9	in	in	IN	_	14	case
10	the	the	DT	_	14	det
11	absorption	absorption	NN	_	14	amod
12	and	and	CC	_	11	cc
13	enterohepatic	enterohepatic	JJ	_	11	conj
14	cycling	cycling	NN	_	8	nmod
15	of	of	IN	_	16	case
16	raloxifene	raloxifene	NN	_	14	nmod
17	and	and	CC	_	4	cc
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	coadministered	coadminister	VBN	_	4	conj
22	with	with	IN	_	23	case
23	EVISTA	evista	NN	_	21	nmod
24	.	.	.	_	1	punct

1	Warfarin	Warfarin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	coadministration	coadministration	NN	_	12	nsubjpass
5	of	of	IN	_	6	case
6	EVISTA	EVISTA	NNP	_	4	nmod
7	and	and	CC	_	6	cc
8	warfarin	warfarin	NN	_	6	conj
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	assessed	assess	VBN	_	1	appos
13	under	under	IN	_	15	case
14	chronic	chronic	JJ	_	15	amod
15	conditions	condition	NNS	_	12	nmod
16	.	.	.	_	1	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	10	10	CD	_	4	nummod
4	%	%	NN	_	5	nsubj
5	decreases	decrease	VBZ	_	0	ROOT
6	in	in	IN	_	8	case
7	prothrombin	prothrombin	NN	_	8	compound
8	time	time	NN	_	5	nmod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	observed	observe	VBN	_	5	ccomp
12	in	in	IN	_	16	case
13	single	single	JJ	_	16	amod
14	-	-	:	_	16	punct
15	dose	dose	NN	_	16	compound
16	studies	study	NNS	_	11	nmod
17	.	.	.	_	5	punct

1	If	if	IN	_	4	mark
2	EVISTA	EVISTA	NNP	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	given	give	VBN	_	13	advcl
5	concurrently	concurrently	RB	_	4	advmod
6	with	with	IN	_	7	case
7	warfarin	warfarin	NN	_	4	nmod
8	,	,	,	_	13	punct
9	prothrombin	prothrombin	NN	_	10	compound
10	time	time	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Other	other	JJ	_	3	amod
2	Highly	Highly	NNP	_	3	compound
3	Protein	protein	NN	_	0	ROOT
4	-	-	:	_	3	punct
5	Bound	bind	VBN	_	6	amod
6	Drugs	drug	NNS	_	3	dep
7	:	:	:	_	3	punct
8	Raloxifene	raloxifene	NN	_	14	nsubjpass
9	is	be	VBZ	_	14	auxpass
10	more	more	JJR	_	12	advmod
11	than	than	IN	_	10	mwe
12	95	95	CD	_	13	nummod
13	%	%	NN	_	14	dep
14	bound	bind	VBD	_	3	dep
15	to	to	TO	_	17	case
16	plasma	plasma	NN	_	17	compound
17	proteins	protein	NNS	_	14	nmod
18	.	.	.	_	3	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	7	advmod
3	,	,	,	_	7	punct
4	raloxifene	raloxifene	NN	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	affect	affect	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	binding	binding	NN	_	7	dobj
10	of	of	IN	_	11	case
11	warfarin	warfarin	NN	_	9	nmod
12	,	,	,	_	11	punct
13	phenytoin	phenytoin	NN	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	tamoxifen	tamoxifen	NN	_	11	conj
17	.	.	.	_	7	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	EVISTA	EVISTA	NNP	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	coadministered	coadminister	VBN	_	4	advcl
9	with	with	IN	_	12	case
10	other	other	JJ	_	12	amod
11	highly	highly	RB	_	12	advmod
12	protein	protein	NN	_	8	nmod
13	-	-	:	_	12	punct
14	bound	bind	VBN	_	15	amod
15	drugs	drug	NNS	_	12	dep
16	,	,	,	_	12	punct
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	clofibrate	clofibrate	NN	_	12	nmod
20	,	,	,	_	19	punct
21	indomethacin	indomethacin	NN	_	19	conj
22	,	,	,	_	19	punct
23	naproxen	naproxen	NN	_	19	conj
24	,	,	,	_	19	punct
25	ibuprofen	ibuprofen	NN	_	19	conj
26	,	,	,	_	19	punct
27	diazepam	diazepam	NN	_	19	conj
28	,	,	,	_	19	punct
29	and	and	CC	_	19	cc
30	diazoxide	diazoxide	NN	_	19	conj
31	.	.	.	_	4	punct

1	See	see	VB	_	0	ROOT
2	also	also	RB	_	3	advmod
3	CLINICAL	clinical	JJ	_	4	amod
4	PHARMACOLOGY	pharmacology	NN	_	1	dobj
5	,	,	,	_	4	punct
6	Drug	drug	NN	_	9	compound
7	-	-	:	_	9	punct
8	Drug	drug	NN	_	9	compound
9	Interactions	interaction	NNS	_	4	appos

1	Sulfamethizole	Sulfamethizole	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	barbiturates	barbiturate	NNS	_	5	nmod
8	,	,	,	_	7	punct
9	tolbutamide	tolbutamide	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	uricosurics	uricosuric	NNS	_	7	conj
13	.	.	.	_	3	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	thiazides	thiazide	NNS	_	4	nmod
7	(	(	RB	_	8	advmod
8	increased	increase	VBD	_	10	amod
9	thrombocytopenia	thrombocytopenia	NN	_	10	compound
10	)	)	NN	_	4	dobj
11	,	,	,	_	10	punct
12	cyclosporine	cyclosporine	NN	_	13	compound
13	(	(	NN	_	14	nsubj
14	increased	increase	VBD	_	10	acl:relcl
15	nephrotoxicity	nephrotoxicity	NN	_	16	compound
16	)	)	NN	_	14	dobj
17	,	,	,	_	10	punct
18	sulfonylurea	sulfonylurea	NN	_	19	compound
19	agents	agent	NNS	_	20	nsubj
20	(	(	VBP	_	10	acl:relcl
21	increased	increase	VBN	_	24	amod
22	hypoglycemic	hypoglycemic	JJ	_	24	amod
23	response	response	NN	_	24	compound
24	)	)	NN	_	28	nsubj
25	,	,	,	_	24	punct
26	warfarin	warfarin	NN	_	27	compound
27	(	(	NN	_	24	appos
28	increased	increase	VBD	_	20	ccomp
29	anticoagulant	anticoagulant	JJ	_	31	amod
30	effect	effect	NN	_	31	compound
31	)	)	NN	_	28	dobj
32	,	,	,	_	31	punct
33	methotrexate	methotrexate	NN	_	34	compound
34	(	(	NN	_	35	nsubj
35	decreased	decrease	VBD	_	31	acl:relcl
36	renal	renal	JJ	_	37	amod
37	excretion	excretion	NN	_	35	dobj
38	of	of	IN	_	40	case
39	methotrexate	methotrexate	NN	_	40	compound
40	)	)	NN	_	37	nmod
41	,	,	,	_	40	punct
42	phenytoin	phenytoin	NN	_	43	compound
43	(	(	NN	_	40	appos
44	decreased	decrease	VBD	_	4	xcomp
45	hepatic	hepatic	JJ	_	46	amod
46	clearance	clearance	NN	_	44	dobj
47	of	of	IN	_	49	case
48	phenytoin	phenytoin	NN	_	49	compound
49	)	)	NN	_	46	nmod
50	.	.	.	_	4	punct

1	Dopamine	dopamine	NN	_	2	compound
2	antagonists	antagonist	NNS	_	8	nsubj
3	,	,	,	_	2	punct
4	such	such	JJ	_	7	case
5	as	as	IN	_	4	mwe
6	the	the	DT	_	7	det
7	neuroleptics	neuroleptic	NNS	_	2	nmod
8	(	(	VBP	_	0	ROOT
9	phenothiazines	phenothiazine	NNS	_	26	nsubj
10	,	,	,	_	9	punct
11	butyrophenones	butyrophenone	NNS	_	9	conj
12	,	,	,	_	9	punct
13	thioxanthines	thioxanthine	NNS	_	9	conj
14	)	)	CD	_	13	dep
15	or	or	CC	_	14	cc
16	metoclopramide	metoclopramide	NN	_	14	conj
17	,	,	,	_	9	punct
18	ordinarily	ordinarily	RB	_	22	advmod
19	should	should	MD	_	22	aux
20	not	not	RB	_	22	neg
21	be	be	VB	_	22	auxpass
22	administered	administer	VBN	_	9	acl
23	concurrently	concurrently	RB	_	22	advmod
24	with	with	IN	_	25	case
25	Permax	Permax	NNP	_	22	nmod
26	(	(	VBD	_	8	ccomp
27	a	a	DT	_	30	det
28	dopamine	dopamine	NN	_	30	compound
29	agonist	agonist	NN	_	30	compound
30	)	)	NN	_	26	dobj
31	;	;	:	_	8	punct

1	these	these	DT	_	2	det
2	agents	agent	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	diminish	diminish	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effectiveness	effectiveness	NN	_	4	dobj
7	of	of	IN	_	8	case
8	Permax	Permax	NNP	_	6	nmod
9	.	.	.	_	4	punct

1	Because	because	IN	_	8	mark
2	pergolide	pergolide	NN	_	3	compound
3	mesylate	mesylate	NN	_	8	nsubjpass
4	is	be	VBZ	_	8	auxpass
5	approximately	approximately	RB	_	6	advmod
6	90	90	CD	_	7	nummod
7	%	%	NN	_	8	nsubjpass
8	bound	bind	VBD	_	16	advcl
9	to	to	TO	_	11	case
10	plasma	plasma	NN	_	11	compound
11	proteins	protein	NNS	_	8	nmod
12	,	,	,	_	16	punct
13	caution	caution	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	exercised	exercise	VBN	_	0	ROOT
17	if	if	IN	_	21	mark
18	pergolide	pergolide	NN	_	19	compound
19	mesylate	mesylate	NN	_	21	nsubjpass
20	is	be	VBZ	_	21	auxpass
21	coadministered	coadminister	VBN	_	16	advcl
22	with	with	IN	_	24	case
23	other	other	JJ	_	24	amod
24	drugs	drug	NNS	_	21	nmod
25	known	know	VBN	_	24	acl
26	to	to	TO	_	27	mark
27	affect	affect	VB	_	25	xcomp
28	protein	protein	NN	_	29	compound
29	binding	binding	NN	_	27	dobj
30	.	.	.	_	16	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Women	woman	NNS	_	9	nsubj
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	contraceptives	contraceptive	NNS	_	4	nmod
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	2	dep
10	a	a	DT	_	12	det
11	significant	significant	JJ	_	12	amod
12	increase	increase	NN	_	9	dobj
13	in	in	IN	_	17	case
14	plasma	plasma	NN	_	17	compound
15	vitamin	vitamin	NN	_	17	compound
16	A	a	NN	_	17	compound
17	levels	level	NNS	_	12	nmod
18	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	9	nsubjpass
3	of	of	IN	_	4	case
4	metoclopramide	metoclopramide	NN	_	2	nmod
5	on	on	IN	_	7	case
6	gastrointestinal	gastrointestinal	JJ	_	7	amod
7	motility	motility	NN	_	2	nmod
8	are	be	VBP	_	9	auxpass
9	antagonized	antagonize	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	anticholinergic	anticholinergic	JJ	_	12	amod
12	drugs	drug	NNS	_	9	nmod
13	and	and	CC	_	12	cc
14	narcotic	narcotic	JJ	_	15	amod
15	analgesics	analgesic	NNS	_	12	conj
16	.	.	.	_	9	punct

1	Additive	additive	JJ	_	3	amod
2	sedative	sedative	JJ	_	3	amod
3	effects	effect	NNS	_	5	nsubj
4	can	can	MD	_	5	aux
5	occur	occur	VB	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	metoclopramide	metoclopramide	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	given	give	VBN	_	5	advcl
10	with	with	IN	_	11	case
11	alcohol	alcohol	NN	_	9	nmod
12	,	,	,	_	11	punct
13	sedatives	sedative	NNS	_	11	conj
14	,	,	,	_	11	punct
15	hypnotics	hypnotic	NNS	_	11	conj
16	,	,	,	_	11	punct
17	narcotics	narcotic	NNS	_	11	conj
18	,	,	,	_	11	punct
19	or	or	CC	_	11	cc
20	tranquilizers	tranquilizer	NNS	_	11	conj
21	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	finding	finding	NN	_	0	ROOT
3	that	that	IN	_	12	mark
4	metoclopramide	metoclopramide	NN	_	6	compound
5	releases	release	NNS	_	6	compound
6	catecholamines	catecholamine	NNS	_	12	nsubj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	essential	essential	JJ	_	11	amod
11	hypertension	hypertension	NN	_	8	nmod
12	suggests	suggest	VBZ	_	2	ccomp
13	that	that	IN	_	17	mark
14	it	it	PRP	_	17	nsubjpass
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	used	use	VBN	_	12	ccomp
18	cautiously	cautiously	RB	_	17	advmod
19	,	,	,	_	17	punct
20	if	if	IN	_	22	mark
21	at	at	IN	_	22	case
22	all	all	DT	_	17	advcl
23	,	,	,	_	17	punct
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	17	nmod
26	receiving	receive	VBG	_	25	acl
27	monoamine	monoamine	NN	_	31	compound
28	oxi	oxi	SYM	_	31	dep
29	-	-	:	_	31	punct
30	dase	dase	NN	_	31	compound
31	inhibitors	inhibitor	NNS	_	26	dobj
32	.	.	.	_	2	punct

1	Absorption	absorption	NN	_	9	nsubjpass
2	of	of	IN	_	3	case
3	drugs	drug	NNS	_	1	nmod
4	from	from	IN	_	6	case
5	the	the	DT	_	6	det
6	stomach	stomach	NN	_	1	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	diminished	diminish	VBN	_	0	ROOT
10	(	(	CD	_	13	nummod
11	e	e	LS	_	13	dep
12	.	.	.	_	11	punct
13	g	g	NN	_	9	dobj
14	.	.	.	_	9	punct
15	,	,	,	_	9	punct
16	digoxin	digoxin	NN	_	17	compound
17	)	)	NN	_	15	root
18	by	by	IN	_	19	case
19	metoclopramide	metoclopramide	NN	_	17	nmod
20	,	,	,	_	17	punct
21	whereas	whereas	IN	_	38	mark
22	the	the	DT	_	23	det
23	rate	rate	NN	_	38	nsubjpass
24	and	and	CC	_	23	cc
25	/	/	:	_	27	punct
26	or	or	CC	_	27	cc
27	extent	extent	NN	_	23	conj
28	of	of	IN	_	29	case
29	absorption	absorption	NN	_	27	nmod
30	of	of	IN	_	31	case
31	drugs	drug	NNS	_	29	nmod
32	from	from	IN	_	35	case
33	the	the	DT	_	35	det
34	small	small	JJ	_	35	amod
35	bowel	bowel	NN	_	31	nmod
36	may	may	MD	_	38	aux
37	be	be	VB	_	38	auxpass
38	increased	increase	VBN	_	20	root
39	(	(	RB	_	40	advmod
40	e	e	LS	_	38	nmod
41	.	.	.	_	40	punct
42	g	g	NN	_	40	dep
43	.	.	.	_	42	punct
44	,	,	,	_	42	punct
45	acetaminophen	acetaminophen	NN	_	42	dep
46	,	,	,	_	45	punct
47	tetracycline	tetracycline	NN	_	45	conj
48	,	,	,	_	45	punct
49	levodopa	levodopa	NN	_	45	conj
50	,	,	,	_	45	punct
51	ethanol	ethanol	NN	_	45	conj
52	,	,	,	_	45	punct
53	cyclosporine	cyclosporine	NN	_	54	compound
54	)	)	NN	_	45	conj
55	.	.	.	_	38	punct

1	Gastroparesis	Gastroparesis	NNP	_	5	compound
2	(	(	CD	_	5	nummod
3	gastric	gastric	JJ	_	5	amod
4	stasis	stasis	NN	_	5	compound
5	)	)	NN	_	8	nsubj
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	responsible	responsible	JJ	_	0	ROOT
9	for	for	IN	_	12	case
10	poor	poor	JJ	_	12	amod
11	diabetic	diabetic	JJ	_	12	amod
12	control	control	NN	_	8	nmod
13	in	in	IN	_	15	case
14	some	some	DT	_	15	det
15	patients	patient	NNS	_	12	nmod
16	.	.	.	_	8	punct

1	Exogenously	exogenously	RB	_	2	advmod
2	administered	administer	VBN	_	3	amod
3	insulin	insulin	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	begin	begin	VB	_	0	ROOT
6	to	to	TO	_	7	mark
7	act	act	VB	_	5	xcomp
8	before	before	IN	_	11	mark
9	food	food	NN	_	11	nsubj
10	has	have	VBZ	_	11	aux
11	left	leave	VBN	_	7	advcl
12	the	the	DT	_	13	det
13	stomach	stomach	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	lead	lead	VB	_	11	conj
16	to	to	TO	_	17	case
17	hypoglycemia	hypoglycemia	NN	_	15	nmod
18	.	.	.	_	5	punct

1	Because	because	IN	_	7	mark
2	the	the	DT	_	3	det
3	action	action	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	metoclopramide	metoclopramide	NN	_	3	nmod
6	will	will	MD	_	7	aux
7	influence	influence	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	delivery	delivery	NN	_	7	dobj
10	of	of	IN	_	11	case
11	food	food	NN	_	9	nmod
12	to	to	TO	_	14	case
13	the	the	DT	_	14	det
14	intestines	intestine	NNS	_	9	nmod
15	and	and	CC	_	7	cc
16	thus	thus	RB	_	29	advmod
17	the	the	DT	_	18	det
18	rate	rate	NN	_	29	nsubj
19	of	of	IN	_	20	case
20	absorption	absorption	NN	_	18	nmod
21	,	,	,	_	18	punct
22	insulin	insulin	NN	_	23	compound
23	dosage	dosage	NN	_	18	appos
24	or	or	CC	_	23	cc
25	timing	timing	NN	_	23	conj
26	of	of	IN	_	27	case
27	dosage	dosage	NN	_	23	nmod
28	may	may	MD	_	29	aux
29	require	require	VB	_	7	conj
30	adjustment	adjustment	NN	_	29	dobj
31	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubj
4	listed	list	VBN	_	3	acl
5	below	below	RB	_	4	advmod
6	are	be	VBP	_	9	cop
7	potentially	potentially	RB	_	9	advmod
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Drugs	drug	NNS	_	14	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	hepatic	hepatic	JJ	_	5	amod
5	enzymes	enzyme	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	phenobarbital	phenobarbital	NN	_	5	nmod
9	,	,	,	_	8	punct
10	phenytoin	phenytoin	NN	_	8	conj
11	and	and	CC	_	8	cc
12	rifampin	rifampin	NN	_	8	conj
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	14	dobj
17	of	of	IN	_	18	case
18	corticosteroids	corticosteroid	NNS	_	16	nmod
19	and	and	CC	_	14	cc
20	may	may	MD	_	21	aux
21	require	require	VB	_	14	conj
22	increases	increase	NNS	_	21	dobj
23	in	in	IN	_	25	case
24	corticosteroid	corticosteroid	NN	_	25	compound
25	dose	dose	NN	_	22	nmod
26	to	to	TO	_	27	mark
27	achieve	achieve	VB	_	21	xcomp
28	the	the	DT	_	30	det
29	desired	desire	VBN	_	30	amod
30	response	response	NN	_	27	dobj
31	.	.	.	_	14	punct

1	Drugs	drug	NNS	_	8	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	troleandomycin	troleandomycin	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	ketoconazole	ketoconazole	NN	_	4	conj
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	corticosteroids	corticosteroid	NNS	_	10	nmod
13	and	and	CC	_	8	cc
14	thus	thus	RB	_	15	advmod
15	decrease	decrease	VB	_	8	conj
16	their	they	PRP$	_	17	nmod:poss
17	clearance	clearance	NN	_	15	dobj
18	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	corticosteroid	corticosteroid	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	titrated	titrate	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	avoid	avoid	VB	_	9	xcomp
12	steroid	steroid	NN	_	13	compound
13	toxicity	toxicity	NN	_	11	dobj
14	.	.	.	_	9	punct

1	Corticosteroids	corticosteroid	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	clearance	clearance	NN	_	3	dobj
6	of	of	IN	_	10	case
7	chronic	chronic	JJ	_	10	amod
8	high	high	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	aspirin	aspirin	NN	_	5	nmod
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	decreased	decrease	VBN	_	8	amod
6	salicylate	salicylate	NN	_	8	compound
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	3	nmod
9	or	or	CC	_	3	cc
10	increase	increase	VB	_	3	conj
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	salicylate	salicylate	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	when	when	WRB	_	19	advmod
17	corticosteroid	corticosteroid	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	withdrawn	withdraw	VBN	_	10	advcl
20	.	.	.	_	3	punct

1	Aspirin	aspirin	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	conjunction	conjunction	NN	_	4	nmod
8	with	with	IN	_	9	case
9	corticosteroids	corticosteroid	NNS	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	suffering	suffer	VBG	_	11	acl
13	from	from	IN	_	14	case
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	12	nmod
15	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	corticosteroids	corticosteroid	NNS	_	2	nmod
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	anticoagulants	anticoagulant	NNS	_	2	nmod
8	is	be	VBZ	_	9	cop
9	variable	variable	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	reports	report	NNS	_	2	nsubj
4	of	of	IN	_	10	case
5	enhanced	enhance	VBN	_	10	amod
6	as	as	RB	_	5	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	diminished	diminished	JJ	_	5	conj
10	effects	effect	NNS	_	3	nmod
11	of	of	IN	_	12	case
12	anticoagulants	anticoagulant	NNS	_	10	nmod
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	2	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	corticosteroids	corticosteroid	NNS	_	14	nmod
18	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	coagulation	coagulation	NN	_	4	compound
4	indices	index	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	maintain	maintain	VB	_	7	xcomp
10	the	the	DT	_	13	det
11	desired	desire	VBN	_	13	amod
12	anticoagulant	anticoagulant	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	.	.	.	_	7	punct

1	Co	Co	NNP	_	0	ROOT
2	-	-	:	_	1	punct
3	administration	administration	NN	_	1	dep
4	of	of	IN	_	8	case
5	oral	oral	JJ	_	8	amod
6	ketoconazole	ketoconazole	NN	_	8	compound
7	200	200	CD	_	8	nummod
8	mg	mg	NN	_	3	nmod
9	twice	twice	RB	_	11	advmod
10	daily	daily	RB	_	11	advmod
11	increased	increase	VBN	_	15	amod
12	retapamulin	retapamulin	NN	_	15	compound
13	geometric	geometric	JJ	_	15	amod
14	mean	mean	NN	_	15	compound
15	AUC	auc	NN	_	3	dep
16	(	(	CD	_	17	compound
17	0	0	CD	_	15	nummod
18	-	-	:	_	15	punct
19	24	24	CD	_	20	nummod
20	)	)	NN	_	15	dep
21	and	and	CC	_	20	cc
22	Cmax	cmax	NN	_	20	conj
23	by	by	IN	_	25	case
24	81	81	CD	_	25	nummod
25	%	%	NN	_	15	nmod
26	after	after	IN	_	28	case
27	topical	topical	JJ	_	28	amod
28	application	application	NN	_	15	nmod
29	of	of	IN	_	31	case
30	retapamulin	retapamulin	NN	_	31	compound
31	ointment	ointment	NN	_	28	nmod
32	,	,	,	_	15	punct
33	1	1	CD	_	34	nummod
34	%	%	NN	_	15	appos
35	on	on	IN	_	38	case
36	the	the	DT	_	38	det
37	abraded	abraded	JJ	_	38	amod
38	skin	skin	NN	_	34	nmod
39	of	of	IN	_	42	case
40	healthy	healthy	JJ	_	42	amod
41	adult	adult	JJ	_	42	amod
42	males	male	NNS	_	38	nmod
43	.	.	.	_	1	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	low	low	JJ	_	4	amod
4	systemic	systemic	JJ	_	5	amod
5	exposure	exposure	NN	_	19	nmod
6	to	to	TO	_	7	case
7	retapamulin	retapamulin	NN	_	5	nmod
8	following	follow	VBG	_	10	case
9	topical	topical	JJ	_	10	amod
10	application	application	NN	_	5	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	,	,	,	_	19	punct
14	dosage	dosage	NN	_	15	compound
15	adjustments	adjustment	NNS	_	19	nsubj
16	for	for	IN	_	17	case
17	retapamulin	retapamulin	NN	_	15	nmod
18	are	be	VBP	_	19	cop
19	unnecessary	unnecessary	JJ	_	0	ROOT
20	when	when	WRB	_	23	advmod
21	co	co	SYM	_	23	dep
22	-	-	:	_	23	punct
23	administered	administer	VBN	_	19	advcl
24	with	with	IN	_	26	case
25	CYP3A4	cyp3a4	NN	_	26	compound
26	inhibitors	inhibitor	NNS	_	23	nmod
27	,	,	,	_	26	punct
28	such	such	JJ	_	30	case
29	as	as	IN	_	28	mwe
30	ketoconazole	ketoconazole	NN	_	26	nmod
31	.	.	.	_	19	punct

1	Based	base	VBN	_	7	case
2	on	on	IN	_	7	case
3	in	in	FW	_	7	amod
4	vitro	vitro	FW	_	3	dep
5	P450	p450	NN	_	7	compound
6	inhibition	inhibition	NN	_	7	compound
7	studies	study	NNS	_	22	advcl
8	and	and	CC	_	7	cc
9	the	the	DT	_	12	det
10	low	low	JJ	_	12	amod
11	systemic	systemic	JJ	_	12	amod
12	exposure	exposure	NN	_	7	conj
13	observed	observe	VBN	_	12	acl
14	following	follow	VBG	_	16	case
15	topical	topical	JJ	_	16	amod
16	application	application	NN	_	13	nmod
17	of	of	IN	_	18	case
18	ALTABAX	ALTABAX	NNP	_	16	nmod
19	,	,	,	_	22	punct
20	retapamulin	retapamulin	NN	_	22	nsubj
21	is	be	VBZ	_	22	cop
22	unlikely	unlikely	JJ	_	0	ROOT
23	to	to	TO	_	24	mark
24	affect	affect	VB	_	22	xcomp
25	the	the	DT	_	26	det
26	metabolism	metabolism	NN	_	24	dobj
27	of	of	IN	_	30	case
28	other	other	JJ	_	30	amod
29	P450	p450	NN	_	30	compound
30	substrates	substrate	NNS	_	26	nmod
31	.	.	.	_	22	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	21	nsubjpass
3	of	of	IN	_	5	case
4	concurrent	concurrent	JJ	_	5	amod
5	application	application	NN	_	2	nmod
6	of	of	IN	_	7	case
7	ALTABAX	ALTABAX	NNP	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	11	amod
10	topical	topical	JJ	_	11	amod
11	products	product	NNS	_	7	conj
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	same	same	JJ	_	15	amod
15	area	area	NN	_	2	nmod
16	of	of	IN	_	17	case
17	skin	skin	NN	_	15	nmod
18	has	have	VBZ	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	studied	study	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	Methscopolamine	methscopolamine	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	8	case
5	antidepressants	antidepressant	NNS	_	8	compound
6	(	(	CD	_	8	nummod
7	tricyclic	tricyclic	JJ	_	8	amod
8	type	type	NN	_	3	nmod
9	)	)	CD	_	8	nummod
10	,	,	,	_	8	punct
11	MAO	mao	NN	_	12	compound
12	inhibitors	inhibitor	NNS	_	13	nsubj
13	(	(	VBP	_	8	acl:relcl
14	e	e	LS	_	13	dobj
15	.	.	.	_	14	punct
16	g	g	NN	_	14	dep
17	.	.	.	_	16	punct
18	,	,	,	_	16	punct
19	phenelzine	phenelzine	NN	_	16	appos
20	,	,	,	_	19	punct
21	linezolid	linezolid	NN	_	19	conj
22	,	,	,	_	19	punct
23	tranylcypromine	tranylcypromine	NN	_	19	conj
24	,	,	,	_	19	punct
25	isocarboxazid	isocarboxazid	NN	_	19	conj
26	,	,	,	_	19	punct
27	selegiline	selegiline	NN	_	19	conj
28	,	,	,	_	19	punct
29	furazolidone	furazolidone	NN	_	30	compound
30	)	)	NN	_	19	conj
31	,	,	,	_	19	punct
32	quinidine	quinidine	NN	_	19	conj
33	,	,	,	_	19	punct
34	amantadine	amantadine	NN	_	19	conj
35	,	,	,	_	19	punct
36	antihistamines	antihistamine	NNS	_	37	nsubj
37	(	(	VBP	_	19	acl:relcl
38	e	e	LS	_	37	dobj
39	.	.	.	_	38	punct
40	g	g	NN	_	38	dep
41	.	.	.	_	40	punct
42	,	,	,	_	40	punct
43	diphenhydramine	diphenhydramine	NN	_	44	compound
44	)	)	NN	_	40	conj
45	,	,	,	_	40	punct
46	other	other	JJ	_	47	amod
47	anticholinergics	anticholinergic	NNS	_	40	conj
48	,	,	,	_	40	punct
49	potassium	potassium	NN	_	51	compound
50	chloride	chloride	NN	_	51	compound
51	supplements	supplement	NNS	_	40	conj
52	,	,	,	_	40	punct
53	antacids	antacid	NNS	_	40	conj
54	,	,	,	_	40	punct
55	absorbent	absorbent	JJ	_	40	amod
56	-	-	:	_	40	punct
57	type	type	NN	_	58	nmod:npmod
58	anti	anti	JJ	_	40	dep
59	-	-	:	_	40	punct
60	diarrhea	diarrhea	NN	_	61	compound
61	medicines	medicine	NNS	_	62	nsubj
62	(	(	VBP	_	40	dep
63	e	e	LS	_	62	xcomp
64	.	.	.	_	63	punct
65	g	g	NN	_	63	dep
66	.	.	.	_	65	punct
67	,	,	,	_	65	punct
68	kaolin	kaolin	NN	_	71	compound
69	-	-	:	_	71	punct
70	pectin	pectin	NN	_	71	compound
71	)	)	NN	_	65	conj
72	,	,	,	_	65	punct
73	phenothiazines	phenothiazine	NNS	_	74	nsubj
74	(	(	VBP	_	65	acl:relcl
75	e	e	LS	_	74	dobj
76	.	.	.	_	75	punct
77	g	g	NN	_	75	dep
78	.	.	.	_	77	punct
79	,	,	,	_	77	punct
80	chlorpromazine	chlorpromazine	NN	_	77	conj
81	,	,	,	_	77	punct
82	promethazine	promethazine	NN	_	83	compound
83	)	)	NN	_	77	conj
84	.	.	.	_	3	punct

1	FELDENE	FELDENE	NNP	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	highly	highly	RB	_	5	advmod
4	protein	protein	NN	_	5	nmod:npmod
5	bound	bind	VBD	_	0	ROOT
6	,	,	,	_	5	punct
7	and	and	CC	_	5	cc
8	therefore	therefore	RB	_	12	advmod
9	,	,	,	_	12	punct
10	might	might	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	expected	expect	VBN	_	5	conj
13	to	to	TO	_	14	mark
14	displace	displace	VB	_	12	xcomp
15	other	other	JJ	_	16	amod
16	protein	protein	NN	_	14	dobj
17	-	-	:	_	16	punct
18	bound	bind	VBN	_	19	amod
19	drugs	drug	NNS	_	16	dep
20	.	.	.	_	5	punct

1	Although	although	IN	_	5	mark
2	this	this	DT	_	5	nsubj
3	has	have	VBZ	_	5	aux
4	not	not	RB	_	5	neg
5	occurred	occur	VBN	_	24	advcl
6	in	in	IN	_	9	case
7	in	in	FW	_	9	amod
8	vitro	vitro	FW	_	7	dep
9	studies	study	NNS	_	5	nmod
10	with	with	IN	_	11	case
11	coumarin	coumarin	NN	_	9	nmod
12	-	-	:	_	11	punct
13	type	type	NN	_	14	compound
14	anticoagulants	anticoagulant	NNS	_	11	dep
15	,	,	,	_	11	punct
16	interactions	interaction	NNS	_	11	appos
17	with	with	IN	_	18	case
18	coumarin	coumarin	NN	_	16	nmod
19	-	-	:	_	18	punct
20	type	type	NN	_	21	compound
21	anticoagulants	anticoagulant	NNS	_	18	dep
22	have	have	VBP	_	24	aux
23	been	be	VBN	_	24	auxpass
24	reported	report	VBN	_	0	ROOT
25	with	with	IN	_	26	case
26	FELDENE	feldene	NN	_	24	nmod
27	since	since	IN	_	28	case
28	marketing	marketing	NN	_	26	nmod
29	,	,	,	_	26	punct
30	therefore	therefore	RB	_	26	advmod
31	,	,	,	_	26	punct
32	physicians	physician	NNS	_	35	nsubj
33	should	should	MD	_	35	aux
34	closely	closely	RB	_	35	advmod
35	monitor	monitor	VB	_	26	dep
36	patients	patient	NNS	_	35	dobj
37	for	for	IN	_	39	case
38	a	a	DT	_	39	det
39	change	change	NN	_	35	nmod
40	in	in	IN	_	42	case
41	dosage	dosage	NN	_	42	compound
42	requirements	requirement	NNS	_	39	nmod
43	when	when	WRB	_	44	advmod
44	administering	administer	VBG	_	35	advcl
45	FELDENE	FELDENE	NNP	_	44	dobj
46	to	to	TO	_	47	case
47	patients	patient	NNS	_	44	nmod
48	on	on	IN	_	52	case
49	coumarin	coumarin	NN	_	52	compound
50	-	-	:	_	52	punct
51	type	type	NN	_	52	compound
52	anticoagulants	anticoagulant	NNS	_	47	nmod
53	and	and	CC	_	52	cc
54	other	other	JJ	_	56	amod
55	highly	highly	RB	_	56	advmod
56	protein	protein	NN	_	52	conj
57	-	-	:	_	35	punct
58	bound	bind	VBN	_	59	amod
59	drugs	drug	NNS	_	35	dobj
60	.	.	.	_	24	punct

1	Plasma	plasma	NN	_	2	compound
2	levels	level	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	piroxicam	piroxicam	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	depressed	depress	VBN	_	0	ROOT
7	to	to	TO	_	10	case
8	approximately	approximately	RB	_	9	advmod
9	80	80	CD	_	10	nummod
10	%	%	NN	_	6	nmod
11	of	of	IN	_	14	case
12	their	they	PRP$	_	14	nmod:poss
13	normal	normal	JJ	_	14	amod
14	values	value	NNS	_	10	nmod
15	when	when	WRB	_	18	advmod
16	FELDENE	FELDENE	NNP	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	administered	administer	VBN	_	6	advcl
19	in	in	IN	_	20	case
20	conjunction	conjunction	NN	_	18	nmod
21	with	with	IN	_	22	case
22	aspirin	aspirin	NN	_	20	nmod
23	(	(	CD	_	24	compound
24	3900	3900	CD	_	25	nummod
25	mg	mg	NN	_	22	dep
26	/	/	:	_	6	punct
27	day	day	NN	_	6	nmod:tmod
28	)	)	CD	_	27	nummod
29	,	,	,	_	6	punct
30	but	but	CC	_	6	cc
31	concomitant	concomitant	JJ	_	32	amod
32	administration	administration	NN	_	35	nsubj
33	of	of	IN	_	34	case
34	antacids	antacid	NNS	_	32	nmod
35	has	have	VBZ	_	6	conj
36	no	no	DT	_	37	neg
37	effect	effect	NN	_	35	dobj
38	on	on	IN	_	41	case
39	piroxicam	piroxicam	NN	_	41	compound
40	plasma	plasma	NN	_	41	compound
41	levels	level	NNS	_	35	nmod
42	.	.	.	_	6	punct
43	Nonsteroidal	nonsteroidal	JJ	_	47	amod
44	anti	anti	JJ	_	47	amod
45	-	-	:	_	47	punct
46	inflammatory	inflammatory	JJ	_	47	amod
47	agents	agent	NNS	_	54	nsubjpass
48	,	,	,	_	47	punct
49	including	include	VBG	_	50	case
50	FELDENE	FELDENE	NNP	_	47	nmod
51	,	,	,	_	47	punct
52	have	have	VBP	_	54	aux
53	been	be	VBN	_	54	auxpass
54	reported	report	VBN	_	6	parataxis
55	to	to	TO	_	56	mark
56	increase	increase	VB	_	54	xcomp
57	steady	steady	JJ	_	61	amod
58	state	state	NN	_	61	compound
59	plasma	plasma	NN	_	61	compound
60	lithium	lithium	NN	_	61	compound
61	levels	level	NNS	_	56	dobj
62	.	.	.	_	6	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	9	mark
5	plasma	plasma	NN	_	7	compound
6	lithium	lithium	NN	_	7	compound
7	levels	level	NNS	_	9	nsubjpass
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	3	ccomp
10	when	when	WRB	_	11	advmod
11	initiating	initiate	VBG	_	9	advcl
12	,	,	,	_	11	punct
13	adjusting	adjust	VBG	_	11	conj
14	and	and	CC	_	11	cc
15	discontinuing	discontinue	VBG	_	11	conj
16	FELDENE	FELDENE	NNP	_	15	dobj
17	.	.	.	_	3	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	7	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	,	,	,	_	7	punct
5	testolactone	testolactone	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	increase	increase	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	12	case
11	oral	oral	JJ	_	12	amod
12	anticoagulants	anticoagulant	NNS	_	9	nmod
13	;	;	:	_	7	punct

1	monitor	monitor	NN	_	5	compound
2	and	and	CC	_	1	cc
3	adjust	adjust	VBP	_	1	conj
4	anticoagulant	anticoagulant	JJ	_	5	amod
5	dosage	dosage	NN	_	0	ROOT
6	accordingly	accordingly	RB	_	5	advmod
7	.	.	.	_	5	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	Physiologic	physiologic	JJ	_	8	amod
8	effects	effect	NNS	_	12	nsubj
9	of	of	IN	_	10	case
10	testolactone	testolactone	NN	_	8	nmod
11	may	may	MD	_	12	aux
12	result	result	VB	_	5	dep
13	in	in	IN	_	16	case
14	decreased	decrease	VBN	_	16	amod
15	estradiol	estradiol	NN	_	16	compound
16	concentrations	concentration	NNS	_	12	nmod
17	with	with	IN	_	18	case
18	radioimmunoassays	radioimmunoassay	NNS	_	16	nmod
19	for	for	IN	_	20	case
20	estradiol	estradiol	NN	_	18	nmod
21	,	,	,	_	12	punct
22	increased	increase	VBN	_	25	amod
23	plasma	plasma	NN	_	25	compound
24	calcium	calcium	NN	_	25	compound
25	concentrations	concentration	NNS	_	12	dobj
26	,	,	,	_	12	punct
27	and	and	CC	_	12	cc
28	increased	increase	VBD	_	12	conj
29	24	24	CD	_	33	nummod
30	-	-	:	_	33	punct
31	hour	hour	NN	_	33	compound
32	urinary	urinary	JJ	_	33	amod
33	excretion	excretion	NN	_	28	dobj
34	of	of	IN	_	35	case
35	creatine	creatine	NN	_	33	nmod
36	and	and	CC	_	33	cc
37	17	17	CD	_	39	nummod
38	-	-	:	_	39	punct
39	ketosteroids	ketosteroid	NNS	_	33	conj
40	.	.	.	_	5	punct

1	Although	although	IN	_	8	mark
2	a	a	DT	_	4	det
3	causal	causal	JJ	_	4	amod
4	relationship	relationship	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	established	establish	VBN	_	13	advcl
9	,	,	,	_	13	punct
10	there	there	EX	_	13	expl
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	cop
13	reports	report	NNS	_	0	ROOT
14	of	of	IN	_	15	case
15	bleeding	bleeding	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	/	/	:	_	21	punct
18	or	or	CC	_	21	cc
19	prolonged	prolonged	JJ	_	21	amod
20	prothrombin	prothrombin	NN	_	21	compound
21	time	time	NN	_	15	conj
22	in	in	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	treated	treat	VBN	_	23	acl
25	with	with	IN	_	26	case
26	TRENTAL	trental	NN	_	24	nmod
27	with	with	IN	_	30	nmod
28	and	and	CC	_	27	cc
29	without	without	IN	_	27	conj
30	anticoagulants	anticoagulant	NNS	_	26	nmod
31	or	or	CC	_	30	cc
32	platelet	platelet	NN	_	34	compound
33	aggregation	aggregation	NN	_	34	compound
34	inhibitors	inhibitor	NNS	_	30	conj
35	.	.	.	_	13	punct

1	Patients	patient	NNS	_	5	nsubj
2	on	on	IN	_	3	case
3	Warfarin	Warfarin	NNP	_	1	nmod
4	should	should	MD	_	5	aux
5	have	have	VB	_	0	ROOT
6	more	more	RBR	_	7	advmod
7	frequent	frequent	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	of	of	IN	_	11	case
10	prothrombin	prothrombin	NN	_	11	compound
11	times	time	NNS	_	8	nmod
12	,	,	,	_	5	punct
13	while	while	IN	_	23	mark
14	patients	patient	NNS	_	23	nsubj
15	with	with	IN	_	18	case
16	other	other	JJ	_	18	amod
17	risk	risk	NN	_	18	compound
18	factors	factor	NNS	_	14	nmod
19	complicated	complicate	VBN	_	18	acl
20	by	by	IN	_	21	case
21	hemorrhage	hemorrhage	NN	_	19	nmod
22	(	(	CD	_	21	nummod
23	e	e	LS	_	5	advcl
24	.	.	.	_	5	punct
25	g	g	NN	_	35	nsubj
26	.	.	.	_	25	punct
27	,	,	,	_	25	punct
28	recent	recent	JJ	_	29	amod
29	surgery	surgery	NN	_	25	conj
30	,	,	,	_	25	punct
31	peptic	peptic	JJ	_	33	amod
32	ulceration	ulceration	NN	_	33	compound
33	)	)	NN	_	25	conj
34	should	should	MD	_	35	aux
35	have	have	VB	_	5	parataxis
36	periodic	periodic	JJ	_	37	amod
37	examinations	examination	NNS	_	35	dobj
38	for	for	IN	_	39	case
39	bleeding	bleed	VBG	_	37	nmod
40	including	include	VBG	_	41	case
41	hematocrit	hematocrit	NN	_	39	nmod
42	and	and	CC	_	41	cc
43	/	/	:	_	45	punct
44	or	or	CC	_	45	cc
45	hemoglobin	hemoglobin	NN	_	41	conj
46	.	.	.	_	5	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	10	nsubj
3	of	of	IN	_	4	case
4	TRENTAL	trental	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	theophylline	theophylline	NN	_	4	conj
7	-	-	:	_	2	punct
8	containing	contain	VBG	_	2	acl
9	drugs	drug	NNS	_	8	dobj
10	leads	lead	VBZ	_	0	ROOT
11	to	to	TO	_	14	case
12	increased	increase	VBN	_	14	amod
13	theophylline	theophylline	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	and	and	CC	_	14	cc
16	theophylline	theophylline	NN	_	17	compound
17	toxicity	toxicity	NN	_	14	conj
18	in	in	IN	_	20	case
19	some	some	DT	_	20	det
20	individuals	individual	NNS	_	14	nmod
21	.	.	.	_	10	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	be	be	VB	_	6	auxpass
5	closely	closely	RB	_	6	advmod
6	monitored	monitor	VBN	_	0	ROOT
7	for	for	IN	_	8	case
8	signs	sign	NNS	_	6	nmod
9	of	of	IN	_	10	case
10	toxicity	toxicity	NN	_	8	nmod
11	and	and	CC	_	6	cc
12	have	have	VBP	_	16	aux
13	their	they	PRP$	_	15	nmod:poss
14	theophylline	theophylline	NN	_	15	compound
15	dosage	dosage	NN	_	16	nsubj
16	adjusted	adjust	VBN	_	6	conj
17	as	as	RB	_	18	advmod
18	necessary	necessary	JJ	_	16	xcomp
19	.	.	.	_	6	punct

1	TRENTAL	TRENTAL	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	concurrently	concurrently	RB	_	4	advmod
6	with	with	IN	_	8	case
7	antihypertensive	antihypertensive	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	,	,	,	_	8	punct
10	beta	beta	NN	_	11	compound
11	blockers	blocker	NNS	_	8	conj
12	,	,	,	_	8	punct
13	digitalis	digitalis	NN	_	8	conj
14	,	,	,	_	8	punct
15	diuretics	diuretic	NNS	_	8	conj
16	,	,	,	_	8	punct
17	antidiabetic	antidiabetic	JJ	_	18	amod
18	agents	agent	NNS	_	8	conj
19	,	,	,	_	8	punct
20	and	and	CC	_	8	cc
21	antiarrhythmics	antiarrhythmic	NNS	_	8	conj
22	,	,	,	_	4	punct
23	without	without	IN	_	25	case
24	observed	observe	VBN	_	25	amod
25	problems	problem	NNS	_	4	nmod
26	.	.	.	_	4	punct

1	Small	small	JJ	_	2	amod
2	decreases	decrease	NNS	_	8	nsubjpass
3	in	in	IN	_	5	case
4	blood	blood	NN	_	5	compound
5	pressure	pressure	NN	_	2	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	some	some	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	treated	treat	VBN	_	11	acl
13	with	with	IN	_	14	case
14	TRENTAL	trental	NN	_	12	nmod
15	;	;	:	_	8	punct

1	periodic	periodic	JJ	_	5	amod
2	systemic	systemic	JJ	_	5	amod
3	blood	blood	NN	_	5	compound
4	pressure	pressure	NN	_	5	compound
5	monitoring	monitoring	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	for	for	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	concomitant	concomitant	JJ	_	13	amod
12	antihypertensive	antihypertensive	JJ	_	13	amod
13	therapy	therapy	NN	_	10	dobj
14	.	.	.	_	7	punct

1	If	if	IN	_	2	mark
2	indicated	indicate	VBN	_	11	advcl
3	,	,	,	_	11	punct
4	dosage	dosage	NN	_	11	nsubjpass
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	antihypertensive	antihypertensive	JJ	_	8	amod
8	agents	agent	NNS	_	4	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reduced	reduce	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	5	det
5	use	use	NN	_	32	nsubjpass
6	of	of	IN	_	12	case
7	ZEMURON	ZEMURON	NNP	_	12	compound
8	(	(	CD	_	12	nummod
9	rocuronium	rocuronium	NN	_	12	compound
10	bromide	bromide	NN	_	12	compound
11	)	)	CD	_	12	nummod
12	Injection	injection	NN	_	5	nmod
13	before	before	IN	_	14	case
14	succinylcholine	succinylcholine	NN	_	5	nmod
15	,	,	,	_	5	punct
16	for	for	IN	_	18	case
17	the	the	DT	_	18	det
18	purpose	purpose	NN	_	5	nmod
19	of	of	IN	_	20	mark
20	attenuating	attenuate	VBG	_	18	acl
21	some	some	DT	_	20	dobj
22	of	of	IN	_	25	case
23	the	the	DT	_	25	det
24	side	side	JJ	_	25	amod
25	effects	effect	NNS	_	21	nmod
26	of	of	IN	_	27	case
27	succinylcholine	succinylcholine	NN	_	25	nmod
28	,	,	,	_	5	punct
29	has	have	VBZ	_	32	aux
30	not	not	RB	_	32	neg
31	been	be	VBN	_	32	auxpass
32	studied	study	VBN	_	2	dep
33	.	.	.	_	32	punct

1	If	if	IN	_	4	mark
2	ZEMURON	ZEMURON	NNP	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	14	advcl
5	following	follow	VBG	_	6	case
6	administration	administration	NN	_	4	nmod
7	of	of	IN	_	8	case
8	succinylcholine	succinylcholine	NN	_	6	nmod
9	,	,	,	_	14	punct
10	it	it	PRP	_	14	nsubjpass
11	should	should	MD	_	14	aux
12	not	not	RB	_	14	neg
13	be	be	VB	_	14	auxpass
14	given	give	VBN	_	0	ROOT
15	until	until	IN	_	21	mark
16	recovery	recovery	NN	_	21	nsubjpass
17	from	from	IN	_	18	case
18	succinylcholine	succinylcholine	NN	_	16	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	observed	observe	VBN	_	14	advcl
22	.	.	.	_	14	punct

1	The	the	DT	_	3	det
2	median	median	JJ	_	3	amod
3	duration	duration	NN	_	34	nsubj
4	of	of	IN	_	5	case
5	action	action	NN	_	3	nmod
6	of	of	IN	_	9	case
7	ZEMURON	ZEMURON	NNP	_	9	compound
8	0.6	0.6	CD	_	9	nummod
9	mg	mg	NN	_	5	nmod
10	/	/	:	_	11	punct
11	kg	kg	NN	_	34	nsubj
12	administered	administer	VBN	_	11	acl
13	after	after	IN	_	16	case
14	a	a	DT	_	16	det
15	1	1	CD	_	16	nummod
16	mg	mg	NN	_	12	nmod
17	/	/	:	_	11	punct
18	kg	kg	NN	_	19	compound
19	dose	dose	NN	_	11	dep
20	of	of	IN	_	21	case
21	succinylcholine	succinylcholine	NN	_	19	nmod
22	when	when	WRB	_	25	advmod
23	T	t	NN	_	25	nsubj
24	1	1	CD	_	23	nummod
25	returned	return	VBD	_	19	acl:relcl
26	to	to	TO	_	28	case
27	75	75	CD	_	28	nummod
28	%	%	NN	_	25	nmod
29	of	of	IN	_	30	case
30	control	control	NN	_	28	nmod
31	was	be	VBD	_	34	cop
32	36	36	CD	_	33	nummod
33	minutes	minute	NNS	_	34	nmod:npmod
34	(	(	JJ	_	0	ROOT
35	range	range	NN	_	41	dep
36	14	14	CD	_	41	dep
37	-	-	:	_	41	punct
38	57	57	CD	_	41	dep
39	,	,	,	_	41	punct
40	n	n	NN	_	41	nsubj
41	=	=	JJ	_	34	xcomp
42	12	12	CD	_	43	nummod
43	)	)	CD	_	41	dobj
44	vs	vs	CC	_	41	dep
45	.	.	.	_	34	punct

1	28	28	CD	_	2	nummod
2	minutes	minute	NNS	_	3	nsubj
3	(	(	VBP	_	0	ROOT
4	17	17	CD	_	9	dep
5	-	-	:	_	9	punct
6	51	51	CD	_	9	dep
7	,	,	,	_	9	punct
8	n	n	NN	_	9	nsubj
9	=	=	JJ	_	3	xcomp
10	12	12	CD	_	11	nummod
11	)	)	NN	_	9	dobj
12	without	without	IN	_	13	case
13	succinylcholine	succinylcholine	NN	_	9	nmod
14	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	5	neg
4	controlled	controlled	JJ	_	5	amod
5	studies	study	NNS	_	2	nsubj
6	documenting	document	VBG	_	5	acl
7	the	the	DT	_	8	det
8	use	use	NN	_	6	dobj
9	of	of	IN	_	10	case
10	ZEMURON	zemuron	NN	_	8	nmod
11	before	before	IN	_	17	nmod
12	or	or	CC	_	11	cc
13	after	after	IN	_	11	conj
14	other	other	JJ	_	17	amod
15	nondepolarizing	nondepolarizing	JJ	_	17	amod
16	muscle	muscle	NN	_	17	compound
17	relaxants	relaxant	NNS	_	6	nmod
18	.	.	.	_	2	punct

1	Interactions	interaction	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	when	when	WRB	_	12	advmod
6	other	other	JJ	_	9	amod
7	nondepolarizing	nondepolarizing	JJ	_	9	amod
8	muscle	muscle	NN	_	9	compound
9	relaxants	relaxant	NNS	_	12	nsubjpass
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	administered	administer	VBN	_	4	advcl
13	in	in	IN	_	14	case
14	succession	succession	NN	_	12	nmod
15	.	.	.	_	4	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	None	none	NN	_	5	dep
8	known	know	VBN	_	7	acl
9	.	.	.	_	5	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	bacteriostatic	bacteriostatic	JJ	_	5	amod
5	antibiotics	antibiotic	NNS	_	2	nmod
6	(	(	VBP	_	0	ROOT
7	e	e	LS	_	17	dep
8	.	.	.	_	7	punct
9	g	g	NN	_	17	nsubj
10	.	.	.	_	9	punct
11	,	,	,	_	9	punct
12	erythromycin	erythromycin	NN	_	9	conj
13	,	,	,	_	9	punct
14	tetracycline	tetracycline	NN	_	15	compound
15	)	)	NN	_	9	conj
16	may	may	MD	_	17	aux
17	diminish	diminish	VB	_	6	ccomp
18	the	the	DT	_	20	det
19	bactericidal	bactericidal	JJ	_	20	amod
20	effects	effect	NNS	_	17	dobj
21	of	of	IN	_	22	case
22	penicillins	penicillin	NNS	_	20	nmod
23	by	by	IN	_	24	mark
24	slowing	slow	VBG	_	17	advcl
25	the	the	DT	_	26	det
26	rate	rate	NN	_	24	dobj
27	of	of	IN	_	29	case
28	bacterial	bacterial	JJ	_	29	amod
29	growth	growth	NN	_	26	nmod
30	.	.	.	_	6	punct

1	Bactericidal	bactericidal	JJ	_	2	amod
2	agents	agent	NNS	_	3	nsubj
3	work	work	VBP	_	0	ROOT
4	most	most	RBS	_	5	advmod
5	effectively	effectively	RB	_	3	advmod
6	against	against	IN	_	10	case
7	the	the	DT	_	10	det
8	immature	immature	JJ	_	10	amod
9	cell	cell	NN	_	10	compound
10	wall	wall	NN	_	3	nmod
11	of	of	IN	_	14	case
12	rapidly	rapidly	RB	_	13	advmod
13	proliferating	proliferate	VBG	_	14	amod
14	microorganisms	microorganism	NNS	_	10	nmod
15	.	.	.	_	3	punct

1	This	this	DT	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	in	in	FW	_	6	compound
6	vitro	vitro	FW	_	4	advmod
7	;	;	:	_	4	punct

1	however	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	the	the	DT	_	5	det
4	clinical	clinical	JJ	_	5	amod
5	significance	significance	NN	_	12	nsubjpass
6	of	of	IN	_	8	case
7	this	this	DT	_	8	det
8	interaction	interaction	NN	_	5	nmod
9	is	be	VBZ	_	12	auxpass
10	not	not	RB	_	12	neg
11	well	well	RB	_	12	advmod
12	documented	document	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	few	few	JJ	_	5	amod
4	clinical	clinical	JJ	_	5	amod
5	situations	situation	NNS	_	2	nsubj
6	in	in	IN	_	7	case
7	which	which	WDT	_	21	nmod
8	the	the	DT	_	10	det
9	concurrent	concurrent	JJ	_	10	amod
10	use	use	NN	_	21	nsubjpass
11	of	of	IN	_	13	case
12	''	''	''	_	13	punct
13	static	static	JJ	_	10	nmod
14	''	''	''	_	13	punct
15	and	and	CC	_	13	cc
16	''	''	''	_	13	punct
17	cidal	cidal	JJ	_	19	amod
18	''	''	''	_	19	punct
19	antibiotics	antibiotic	NNS	_	13	conj
20	are	be	VBP	_	21	auxpass
21	indicated	indicate	VBN	_	5	acl:relcl
22	.	.	.	_	2	punct

1	However	however	RB	_	26	advmod
2	,	,	,	_	26	punct
3	in	in	IN	_	5	case
4	selected	select	VBN	_	5	amod
5	circumstances	circumstance	NNS	_	26	nmod
6	in	in	IN	_	7	case
7	which	which	WDT	_	11	nmod
8	such	such	JJ	_	9	amod
9	therapy	therapy	NN	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	appropriate	appropriate	JJ	_	5	acl:relcl
12	,	,	,	_	11	punct
13	using	use	VBG	_	11	conj
14	adequate	adequate	JJ	_	15	amod
15	doses	dose	NNS	_	13	dobj
16	of	of	IN	_	18	case
17	antibacterial	antibacterial	JJ	_	18	amod
18	agents	agent	NNS	_	15	nmod
19	and	and	CC	_	11	cc
20	beginning	begin	VBG	_	22	amod
21	penicillin	penicillin	NN	_	22	compound
22	therapy	therapy	NN	_	11	conj
23	first	first	RB	_	22	advmod
24	,	,	,	_	26	punct
25	should	should	MD	_	26	aux
26	minimize	minimize	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	potential	potential	NN	_	26	dobj
29	for	for	IN	_	30	case
30	interaction	interaction	NN	_	28	nmod
31	.	.	.	_	26	punct

1	Penicillin	penicillin	NN	_	3	compound
2	blood	blood	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	prolonged	prolong	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	concurrent	concurrent	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	probenecid	probenecid	NN	_	9	nmod
12	which	which	WDT	_	13	nsubj
13	blocks	block	VBZ	_	9	acl:relcl
14	the	the	DT	_	17	det
15	renal	renal	JJ	_	17	amod
16	tubular	tubular	JJ	_	17	amod
17	secretion	secretion	NN	_	13	dobj
18	of	of	IN	_	19	case
19	penicillins	penicillin	NNS	_	17	nmod
20	.	.	.	_	6	punct

1	Displacement	displacement	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	penicillin	penicillin	NN	_	1	nmod
4	from	from	IN	_	8	case
5	plasma	plasma	NN	_	8	compound
6	protein	protein	NN	_	8	compound
7	binding	binding	NN	_	8	compound
8	sites	site	NNS	_	1	nmod
9	will	will	MD	_	10	aux
10	elevate	elevate	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	level	level	NN	_	10	dobj
13	of	of	IN	_	15	case
14	free	free	JJ	_	15	amod
15	penicillin	penicillin	NN	_	12	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	serum	serum	NN	_	12	nmod
19	.	.	.	_	10	punct

1	Catecholamine	catecholamine	NN	_	4	compound
2	-	-	:	_	4	punct
3	depleting	deplete	VBG	_	4	amod
4	drugs	drug	NNS	_	6	nsubj
5	(	(	CD	_	4	nummod
6	e	e	LS	_	0	ROOT
7	.	.	.	_	6	punct
8	g	g	NN	_	14	dep
9	.	.	.	_	8	punct
10	,	,	,	_	14	punct
11	reserpine	reserpine	NN	_	12	compound
12	)	)	NN	_	14	nsubj
13	may	may	MD	_	14	aux
14	have	have	VB	_	6	parataxis
15	an	a	DT	_	17	det
16	additive	additive	JJ	_	17	amod
17	effect	effect	NN	_	14	dobj
18	when	when	WRB	_	19	advmod
19	given	give	VBN	_	14	advcl
20	with	with	IN	_	21	case
21	beta	beta	NN	_	19	nmod
22	-	-	:	_	14	punct
23	blocking	block	VBG	_	14	xcomp
24	agents	agent	NNS	_	23	dobj
25	.	.	.	_	6	punct

1	Patients	patient	NNS	_	16	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	pindolol	pindolol	NN	_	2	dobj
4	plus	plus	CC	_	3	cc
5	a	a	DT	_	6	det
6	catecholamine	catecholamine	NN	_	3	conj
7	-	-	:	_	1	punct
8	depleting	deplete	VBG	_	16	csubjpass
9	agent	agent	NN	_	8	dobj
10	should	should	MD	_	16	aux
11	,	,	,	_	16	punct
12	therefore	therefore	RB	_	16	advmod
13	,	,	,	_	16	punct
14	be	be	VB	_	16	auxpass
15	closely	closely	RB	_	16	advmod
16	observed	observe	VBN	_	0	ROOT
17	for	for	IN	_	18	case
18	evidence	evidence	NN	_	16	nmod
19	of	of	IN	_	20	case
20	hypotension	hypotension	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	/	/	:	_	25	punct
23	or	or	CC	_	25	cc
24	marked	marked	JJ	_	25	amod
25	bradycardia	bradycardia	NN	_	20	conj
26	which	which	WDT	_	28	nsubj
27	may	may	MD	_	28	aux
28	produce	produce	VB	_	25	acl:relcl
29	vertigo	vertigo	NN	_	28	dobj
30	,	,	,	_	29	punct
31	syncope	syncope	NN	_	29	conj
32	,	,	,	_	29	punct
33	or	or	CC	_	29	cc
34	postural	postural	JJ	_	35	amod
35	hypotension	hypotension	NN	_	29	conj
36	.	.	.	_	16	punct

1	Pindolol	pindolol	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	a	a	DT	_	7	det
7	variety	variety	NN	_	4	nmod
8	of	of	IN	_	10	case
9	antihypertensive	antihypertensive	JJ	_	10	amod
10	agents	agent	NNS	_	7	nmod
11	,	,	,	_	10	punct
12	including	include	VBG	_	13	case
13	hydrochlorothiazide	hydrochlorothiazide	NN	_	10	nmod
14	,	,	,	_	13	punct
15	hydralazine	hydralazine	NN	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	guanethidine	guanethidine	NN	_	13	conj
19	without	without	IN	_	22	case
20	unexpected	unexpected	JJ	_	22	amod
21	adverse	adverse	JJ	_	22	amod
22	interactions	interaction	NNS	_	4	nmod
23	.	.	.	_	4	punct

1	Pindolol	pindolol	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	increase	increase	VB	_	4	xcomp
7	serum	serum	NN	_	9	compound
8	thioridazine	thioridazine	NN	_	9	compound
9	levels	level	NNS	_	6	dobj
10	when	when	WRB	_	14	advmod
11	both	both	DT	_	12	det
12	drugs	drug	NNS	_	14	nsubj
13	are	be	VBP	_	14	cop
14	co	co	SYM	_	6	advcl
15	-	-	:	_	14	punct
16	administered	administer	VBN	_	14	dep
17	.	.	.	_	4	punct

1	Pindolol	pindolol	NN	_	2	compound
2	levels	level	NNS	_	6	nsubjpass
3	may	may	MD	_	6	aux
4	also	also	RB	_	6	advmod
5	be	be	VB	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	this	this	DT	_	9	det
9	combination	combination	NN	_	6	nmod
10	.	.	.	_	6	punct

1	Risk	risk	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	anaphylactic	anaphylactic	JJ	_	4	amod
4	reaction	reaction	NN	_	1	nmod
5	:	:	:	_	1	punct
6	While	while	IN	_	7	mark
7	taking	take	VBG	_	27	advcl
8	beta	beta	NN	_	9	compound
9	blockers	blocker	NNS	_	7	dobj
10	,	,	,	_	27	punct
11	patients	patient	NNS	_	27	nsubj
12	with	with	IN	_	14	case
13	a	a	DT	_	14	det
14	history	history	NN	_	11	nmod
15	of	of	IN	_	18	case
16	severe	severe	JJ	_	18	amod
17	anaphylactic	anaphylactic	JJ	_	18	amod
18	reaction	reaction	NN	_	14	nmod
19	to	to	TO	_	21	case
20	a	a	DT	_	21	det
21	variety	variety	NN	_	18	nmod
22	of	of	IN	_	23	case
23	allergens	allergen	NNS	_	21	nmod
24	may	may	MD	_	27	aux
25	be	be	VB	_	27	cop
26	more	more	RBR	_	27	advmod
27	reactive	reactive	JJ	_	1	dep
28	to	to	TO	_	30	case
29	repeated	repeat	VBN	_	30	amod
30	challenge	challenge	NN	_	27	nmod
31	,	,	,	_	27	punct
32	either	either	CC	_	33	cc:preconj
33	accidental	accidental	JJ	_	27	dep
34	,	,	,	_	33	punct
35	diagnostic	diagnostic	JJ	_	33	conj
36	,	,	,	_	33	punct
37	or	or	CC	_	33	cc
38	therapeutic	therapeutic	JJ	_	33	conj
39	.	.	.	_	1	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	epinephrine	epinephrine	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	allergic	allergic	JJ	_	16	amod
16	reactions	reaction	NNS	_	14	dobj
17	.	.	.	_	5	punct

1	Although	although	IN	_	12	mark
2	specific	specific	JJ	_	3	amod
3	drug	drug	NN	_	12	nsubjpass
4	or	or	CC	_	3	cc
5	food	food	NN	_	6	compound
6	interactions	interaction	NNS	_	3	conj
7	with	with	IN	_	8	case
8	mifepristone	mifepristone	NN	_	3	nmod
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	28	advcl
13	,	,	,	_	28	punct
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	basis	basis	NN	_	28	nmod
17	of	of	IN	_	21	case
18	this	this	DT	_	21	det
19	drug	drug	NN	_	21	compound
20	s	s	NNS	_	21	compound
21	metabolism	metabolism	NN	_	16	nmod
22	by	by	IN	_	24	case
23	CYP	cyp	NN	_	24	compound
24	3A4	3a4	NN	_	16	nmod
25	,	,	,	_	28	punct
26	it	it	PRP	_	28	nsubj
27	is	be	VBZ	_	28	cop
28	possible	possible	JJ	_	0	ROOT
29	that	that	IN	_	40	mark
30	ketoconazole	ketoconazole	NN	_	40	nsubj
31	,	,	,	_	30	punct
32	itraconazole	itraconazole	NN	_	30	conj
33	,	,	,	_	30	punct
34	erythromycin	erythromycin	NN	_	30	conj
35	,	,	,	_	30	punct
36	and	and	CC	_	30	cc
37	grapefruit	grapefruit	NN	_	38	compound
38	juice	juice	NN	_	30	conj
39	may	may	MD	_	40	aux
40	inhibit	inhibit	VB	_	28	ccomp
41	its	its	PRP$	_	46	nmod:poss
42	metabolism	metabolism	NN	_	46	compound
43	(	(	CD	_	46	nummod
44	increasing	increase	VBG	_	46	amod
45	serum	serum	NN	_	46	compound
46	levels	level	NNS	_	40	dobj
47	of	of	IN	_	49	case
48	mifepristone	mifepristone	NN	_	49	compound
49	)	)	NN	_	46	nmod
50	.	.	.	_	28	punct

1	Furthermore	furthermore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	rifampin	rifampin	NN	_	5	dep
4	,	,	,	_	5	punct
5	dexamethasone	dexamethasone	NN	_	0	ROOT
6	,	,	,	_	5	punct
7	St	St	NNP	_	5	appos
8	.	.	.	_	5	punct

1	John	John	NNP	_	3	compound
2	s	be	VBZ	_	3	compound
3	Wort	Wort	NNP	_	8	nsubj
4	,	,	,	_	3	punct
5	and	and	CC	_	3	cc
6	certain	certain	JJ	_	7	amod
7	anticonvulsants	anticonvulsant	NNS	_	3	conj
8	(	(	VBP	_	0	ROOT
9	phenytoin	phenytoin	NN	_	16	nsubj
10	,	,	,	_	9	punct
11	phenobarbital	phenobarbital	NN	_	9	conj
12	,	,	,	_	9	punct
13	carbamazepine	carbamazepine	NN	_	14	compound
14	)	)	NN	_	9	conj
15	may	may	MD	_	16	aux
16	induce	induce	VB	_	8	ccomp
17	mifepristone	mifepristone	NN	_	18	compound
18	metabolism	metabolism	NN	_	20	nsubj
19	(	(	CD	_	18	nummod
20	lowering	lower	VBG	_	16	dep
21	serum	serum	NN	_	22	compound
22	levels	level	NNS	_	20	dobj
23	of	of	IN	_	25	case
24	mifepristone	mifepristone	NN	_	25	compound
25	)	)	NN	_	22	nmod
26	.	.	.	_	8	punct

1	Based	base	VBN	_	6	case
2	on	on	IN	_	6	case
3	in	in	FW	_	6	amod
4	vitro	vitro	FW	_	3	dep
5	inhibition	inhibition	NN	_	6	compound
6	information	information	NN	_	12	advcl
7	,	,	,	_	12	punct
8	coadministration	coadministration	NN	_	12	nsubj
9	of	of	IN	_	10	case
10	mifepristone	mifepristone	NN	_	8	nmod
11	may	may	MD	_	12	aux
12	lead	lead	VB	_	0	ROOT
13	to	to	TO	_	15	case
14	an	a	DT	_	15	det
15	increase	increase	NN	_	12	nmod
16	in	in	IN	_	18	case
17	serum	serum	NN	_	18	compound
18	levels	level	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	drugs	drug	NNS	_	18	nmod
21	that	that	WDT	_	25	nsubj
22	are	be	VBP	_	25	cop
23	CYP	cyp	NN	_	25	compound
24	3A4	3a4	NN	_	25	compound
25	substrates	substrate	NNS	_	20	acl:relcl
26	.	.	.	_	12	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	5	det
4	slow	slow	JJ	_	5	amod
5	elimination	elimination	NN	_	16	nmod
6	of	of	IN	_	7	case
7	mifepristone	mifepristone	NN	_	5	nmod
8	from	from	IN	_	10	case
9	the	the	DT	_	10	det
10	body	body	NN	_	5	nmod
11	,	,	,	_	16	punct
12	such	such	JJ	_	13	amod
13	interaction	interaction	NN	_	16	nsubjpass
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	for	for	IN	_	20	case
18	a	a	DT	_	20	det
19	prolonged	prolonged	JJ	_	20	amod
20	period	period	NN	_	16	nmod
21	after	after	IN	_	23	case
22	its	its	PRP$	_	23	nmod:poss
23	administration	administration	NN	_	20	nmod
24	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	mifepristone	mifepristone	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	with	with	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	that	that	WDT	_	17	nsubj
14	are	be	VBP	_	17	cop
15	CYP	cyp	NN	_	17	compound
16	3A4	3a4	NN	_	17	compound
17	substrates	substrate	NNS	_	12	acl:relcl
18	and	and	CC	_	17	cc
19	have	have	VBP	_	17	conj
20	narrow	narrow	JJ	_	22	amod
21	therapeutic	therapeutic	JJ	_	22	amod
22	range	range	NN	_	19	dobj
23	,	,	,	_	22	punct
24	including	include	VBG	_	26	case
25	some	some	DT	_	26	det
26	agents	agent	NNS	_	22	nmod
27	used	use	VBN	_	26	acl
28	during	during	IN	_	30	case
29	general	general	JJ	_	30	amod
30	anesthesia	anesthesia	NN	_	27	nmod
31	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	vancomycin	vancomycin	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	anesthetic	anesthetic	JJ	_	7	amod
7	agents	agent	NNS	_	4	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	associated	associate	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	erythema	erythema	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	histamine	histamine	NN	_	12	conj
15	-	-	:	_	12	punct
16	like	like	IN	_	17	case
17	flushing	flushing	NN	_	12	nmod
18	and	and	CC	_	17	cc
19	anaphylactoid	anaphylactoid	JJ	_	20	amod
20	reactions	reaction	NNS	_	17	conj
21	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	9	amod
2	and	and	CC	_	1	cc
3	/	/	:	_	6	punct
4	or	or	CC	_	6	cc
5	sequential	sequential	JJ	_	6	amod
6	systemic	systemic	JJ	_	1	conj
7	or	or	CC	_	6	cc
8	topical	topical	JJ	_	6	conj
9	use	use	NN	_	0	ROOT
10	of	of	IN	_	9	dep
11	other	other	JJ	_	10	dep
12	potentially	potentially	RB	_	13	advmod
13	neurotoxic	neurotoxic	JJ	_	42	nsubj
14	and	and	CC	_	13	cc
15	/	/	:	_	18	punct
16	or	or	CC	_	18	cc
17	nephrotoxic	nephrotoxic	JJ	_	18	amod
18	drugs	drug	NNS	_	13	conj
19	,	,	,	_	18	punct
20	such	such	JJ	_	23	case
21	as	as	IN	_	20	mwe
22	amphotericin	amphotericin	NN	_	23	compound
23	B	b	NN	_	18	nmod
24	,	,	,	_	23	punct
25	aminoglycosides	aminoglycoside	NNS	_	23	conj
26	,	,	,	_	23	punct
27	bacitracin	bacitracin	NN	_	23	conj
28	,	,	,	_	23	punct
29	polymyxin	polymyxin	NN	_	30	compound
30	B	b	NN	_	23	conj
31	,	,	,	_	23	punct
32	colistin	colistin	NN	_	23	conj
33	,	,	,	_	23	punct
34	viomycin	viomycin	NN	_	23	conj
35	,	,	,	_	23	punct
36	or	or	CC	_	23	cc
37	cisplatin	cisplatin	NN	_	23	conj
38	,	,	,	_	18	punct
39	when	when	WRB	_	40	advmod
40	indicated	indicate	VBN	_	18	dep
41	,	,	,	_	13	punct
42	requires	require	VBZ	_	11	acl:relcl
43	careful	careful	JJ	_	44	amod
44	monitoring	monitoring	NN	_	42	dobj
45	.	.	.	_	9	punct

1	Potential	potential	JJ	_	11	nsubjpass
2	for	for	IN	_	5	mark
3	INVEGA	INVEGA	NNP	_	5	nsubj
4	to	to	TO	_	5	mark
5	Affect	affect	VB	_	1	advcl
6	Other	other	JJ	_	8	amod
7	Drugs	drug	NNS	_	8	compound
8	Paliperidone	paliperidone	NN	_	5	dobj
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	cause	cause	VB	_	11	xcomp
14	clinically	clinically	RB	_	15	advmod
15	important	important	JJ	_	17	amod
16	pharmacokinetic	pharmacokinetic	JJ	_	17	amod
17	interactions	interaction	NNS	_	13	dobj
18	with	with	IN	_	19	case
19	drugs	drug	NNS	_	17	nmod
20	that	that	WDT	_	22	nsubjpass
21	are	be	VBP	_	22	auxpass
22	metabolized	metabolize	VBN	_	19	acl:relcl
23	by	by	IN	_	26	case
24	cytochrome	cytochrome	NN	_	26	compound
25	P450	p450	NN	_	26	compound
26	isozymes	isozyme	NNS	_	22	nmod
27	.	.	.	_	11	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	in	in	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	that	that	IN	_	14	mark
10	paliperidone	paliperidone	NN	_	14	nsubj
11	does	do	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	substantially	substantially	RB	_	14	advmod
14	inhibit	inhibit	VB	_	8	ccomp
15	the	the	DT	_	16	det
16	metabolism	metabolism	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	metabolized	metabolize	VBN	_	18	acl
20	by	by	IN	_	23	case
21	cytochrome	cytochrome	NN	_	23	compound
22	P450	p450	NN	_	23	compound
23	isozymes	isozyme	NNS	_	19	nmod
24	,	,	,	_	23	punct
25	including	include	VBG	_	26	case
26	CYP1A2	cyp1a2	NN	_	23	nmod
27	,	,	,	_	26	punct
28	CYP2A6	cyp2a6	NN	_	26	conj
29	,	,	,	_	26	punct
30	CYP2C8	cyp2c8	NN	_	26	conj
31	/	/	:	_	26	punct
32	9	9	CD	_	26	dep
33	/	/	:	_	32	punct
34	10	10	CD	_	33	root
35	,	,	,	_	34	punct
36	CYP2D6	cyp2d6	NN	_	35	root
37	,	,	,	_	36	punct
38	CYP2E1	cyp2e1	NN	_	37	root
39	,	,	,	_	38	punct
40	CYP3A4	cyp3a4	NN	_	38	conj
41	,	,	,	_	38	punct
42	and	and	CC	_	38	cc
43	CYP3A5	cyp3a5	NN	_	38	conj
44	.	.	.	_	38	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	paliperidone	paliperidone	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	expected	expect	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	inhibit	inhibit	VB	_	6	xcomp
9	clearance	clearance	NN	_	8	dobj
10	of	of	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	that	that	WDT	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	metabolized	metabolize	VBN	_	11	acl:relcl
15	by	by	IN	_	18	case
16	these	these	DT	_	18	det
17	metabolic	metabolic	JJ	_	18	amod
18	pathways	pathway	NNS	_	14	nmod
19	in	in	IN	_	23	case
20	a	a	DT	_	23	det
21	clinically	clinically	RB	_	22	advmod
22	relevant	relevant	JJ	_	23	amod
23	manner	manner	NN	_	14	nmod
24	.	.	.	_	6	punct

1	Paliperidone	paliperidone	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	also	also	RB	_	5	advmod
4	not	not	RB	_	5	neg
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	have	have	VB	_	5	xcomp
8	enzyme	enzyme	NN	_	7	dobj
9	inducing	induce	VBG	_	8	acl
10	properties	property	NNS	_	9	dobj
11	.	.	.	_	5	punct

1	At	at	IN	_	3	case
2	therapeutic	therapeutic	JJ	_	3	amod
3	concentrations	concentration	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	paliperidone	paliperidone	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	inhibit	inhibit	VB	_	0	ROOT
9	P	p	NN	_	11	compound
10	-	-	:	_	11	punct
11	glycoprotein	glycoprotein	NN	_	8	dobj
12	.	.	.	_	8	punct

1	Paliperidone	paliperidone	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	therefore	therefore	RB	_	5	advmod
4	not	not	RB	_	5	neg
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	inhibit	inhibit	VB	_	5	xcomp
8	P	p	NN	_	10	compound
9	-	-	:	_	10	punct
10	glycoprotein	glycoprotein	NN	_	7	dobj
11	-	-	:	_	10	punct
12	mediated	mediate	VBN	_	13	amod
13	transport	transport	NN	_	10	dep
14	of	of	IN	_	16	case
15	other	other	JJ	_	16	amod
16	drugs	drug	NNS	_	13	nmod
17	in	in	IN	_	21	case
18	a	a	DT	_	21	det
19	clinically	clinically	RB	_	20	advmod
20	relevant	relevant	JJ	_	21	amod
21	manner	manner	NN	_	13	nmod
22	.	.	.	_	5	punct

1	Given	give	VBN	_	5	case
2	the	the	DT	_	5	det
3	primary	primary	JJ	_	5	amod
4	CNS	cns	NN	_	5	compound
5	effects	effect	NNS	_	12	nmod
6	of	of	IN	_	7	case
7	paliperidone	paliperidone	NN	_	5	nmod
8	,	,	,	_	12	punct
9	INVEGA	invega	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	0	ROOT
13	with	with	IN	_	14	case
14	caution	caution	NN	_	12	nmod
15	in	in	IN	_	16	case
16	combination	combination	NN	_	12	nmod
17	with	with	IN	_	21	case
18	other	other	JJ	_	21	amod
19	centrally	centrally	RB	_	20	advmod
20	acting	act	VBG	_	21	amod
21	drugs	drug	NNS	_	16	nmod
22	and	and	CC	_	21	cc
23	alcohol	alcohol	NN	_	21	conj
24	.	.	.	_	12	punct

1	Paliperidone	paliperidone	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effect	effect	NN	_	3	dobj
6	of	of	IN	_	7	case
7	levodopa	levodopa	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	11	amod
10	dopamine	dopamine	NN	_	11	compound
11	agonists	agonist	NNS	_	7	conj
12	.	.	.	_	3	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	its	its	PRP$	_	4	nmod:poss
4	potential	potential	NN	_	15	nmod
5	for	for	IN	_	6	mark
6	inducing	induce	VBG	_	4	acl
7	orthostatic	orthostatic	JJ	_	8	amod
8	hypotension	hypotension	NN	_	6	dobj
9	,	,	,	_	8	punct
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	8	appos
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	when	when	WRB	_	19	advmod
17	INVEGA	INVEGA	NNP	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	administered	administer	VBN	_	15	advcl
20	with	with	IN	_	23	case
21	other	other	JJ	_	23	amod
22	therapeutic	therapeutic	JJ	_	23	amod
23	agents	agent	NNS	_	19	nmod
24	that	that	WDT	_	25	nsubj
25	have	have	VBP	_	23	acl:relcl
26	this	this	DT	_	27	det
27	potential	potential	NN	_	25	dobj
28	.	.	.	_	15	punct

1	Potential	potential	JJ	_	12	nsubj
2	for	for	IN	_	6	mark
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	6	nsubj
5	to	to	TO	_	6	mark
6	Affect	affect	VB	_	1	advcl
7	INVEGA	INVEGA	NNP	_	8	compound
8	Paliperidone	Paliperidone	NNP	_	6	dobj
9	is	be	VBZ	_	12	cop
10	not	not	RB	_	12	neg
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	0	ROOT
13	of	of	IN	_	14	case
14	CYP1A2	cyp1a2	NN	_	12	nmod
15	,	,	,	_	14	punct
16	CYP2A6	cyp2a6	NN	_	14	conj
17	,	,	,	_	14	punct
18	CYP2C9	cyp2c9	NN	_	14	conj
19	,	,	,	_	14	punct
20	and	and	CC	_	14	cc
21	CYP2C19	cyp2c19	NN	_	14	conj
22	,	,	,	_	12	punct
23	so	so	RB	_	35	mark
24	that	that	IN	_	23	mwe
25	an	a	DT	_	26	det
26	interaction	interaction	NN	_	35	nsubj
27	with	with	IN	_	28	case
28	inhibitors	inhibitor	NNS	_	26	nmod
29	or	or	CC	_	28	cc
30	inducers	inducer	NNS	_	28	conj
31	of	of	IN	_	33	case
32	these	these	DT	_	33	det
33	isozymes	isozyme	NNS	_	28	nmod
34	is	be	VBZ	_	35	cop
35	unlikely	unlikely	JJ	_	12	advcl
36	.	.	.	_	12	punct

1	While	while	IN	_	5	mark
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	studies	study	NNS	_	5	nsubj
5	indicate	indicate	VBP	_	0	ROOT
6	that	that	IN	_	13	mark
7	CYP2D6	cyp2d6	NN	_	13	nsubjpass
8	and	and	CC	_	7	cc
9	CYP3A4	cyp3a4	NN	_	7	conj
10	may	may	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	minimally	minimally	RB	_	13	advmod
13	involved	involve	VBN	_	5	ccomp
14	in	in	IN	_	16	case
15	paliperidone	paliperidone	NN	_	16	compound
16	metabolism	metabolism	NN	_	13	nmod
17	,	,	,	_	16	punct
18	in	in	FW	_	20	amod
19	vivo	vivo	FW	_	18	dep
20	studies	study	NNS	_	23	nsubj
21	do	do	VBP	_	23	aux
22	not	not	RB	_	23	neg
23	show	show	VB	_	16	acl:relcl
24	decreased	decrease	VBN	_	25	amod
25	elimination	elimination	NN	_	23	dobj
26	by	by	IN	_	28	case
27	these	these	DT	_	28	det
28	isozymes	isozyme	NNS	_	25	nmod
29	and	and	CC	_	23	cc
30	they	they	PRP	_	31	nsubj
31	contribute	contribute	VBP	_	23	conj
32	to	to	TO	_	36	case
33	only	only	RB	_	36	advmod
34	a	a	DT	_	36	det
35	small	small	JJ	_	36	amod
36	fraction	fraction	NN	_	31	nmod
37	of	of	IN	_	40	case
38	total	total	JJ	_	40	amod
39	body	body	NN	_	40	compound
40	clearance	clearance	NN	_	36	nmod
41	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	14	nsubjpass
3	of	of	IN	_	7	case
4	CYLERT	CYLERT	NNP	_	7	compound
5	(	(	CD	_	7	nummod
6	pemoline	pemoline	NN	_	7	compound
7	)	)	NN	_	2	nmod
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	2	nmod
11	has	have	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	studied	study	VBN	_	0	ROOT
15	in	in	IN	_	16	case
16	humans	human	NNS	_	14	nmod
17	.	.	.	_	14	punct

1	Patients	patient	NNS	_	19	nsubjpass
2	who	who	WP	_	4	nsubj
3	are	be	VBP	_	4	aux
4	receiving	receive	VBG	_	1	acl:relcl
5	CYLERT	CYLERT	NNP	_	4	dobj
6	concurrently	concurrently	RB	_	4	advmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	4	nmod
10	,	,	,	_	1	punct
11	especially	especially	RB	_	12	advmod
12	drugs	drug	NNS	_	1	appos
13	with	with	IN	_	15	case
14	CNS	cns	NN	_	15	compound
15	activity	activity	NN	_	12	nmod
16	,	,	,	_	1	punct
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	monitored	monitor	VBN	_	0	ROOT
20	carefully	carefully	RB	_	19	advmod
21	.	.	.	_	19	punct

1	Decreased	decrease	VBN	_	3	amod
2	seizure	seizure	NN	_	3	compound
3	threshold	threshold	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	CYLERT	CYLERT	NNP	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	14	case
13	antiepileptic	antiepileptic	JJ	_	14	amod
14	medications	medication	NNS	_	9	nmod
15	.	.	.	_	6	punct

1	CYP	cyp	NN	_	3	compound
2	3A4	3a4	NN	_	3	compound
3	Inhibitors	inhibitor	NNS	_	4	nsubj
4	(	(	VBP	_	0	ROOT
5	e	e	LS	_	14	dep
6	.	.	.	_	5	punct
7	g	g	NN	_	10	compound
8	.	.	.	_	10	punct
9	Macrolide	Macrolide	NNP	_	10	compound
10	Antibiotics	Antibiotics	NNPS	_	14	nsubj
11	and	and	CC	_	10	cc
12	Protease	protease	NN	_	13	compound
13	Inhibitors	inhibitor	NNS	_	10	conj
14	)	)	VBP	_	4	ccomp
15	There	there	EX	_	19	expl
16	have	have	VBP	_	19	aux
17	been	be	VBN	_	19	cop
18	rare	rare	JJ	_	19	amod
19	reports	report	NNS	_	14	ccomp
20	of	of	IN	_	23	case
21	serious	serious	JJ	_	23	amod
22	adverse	adverse	JJ	_	23	amod
23	events	event	NNS	_	19	nmod
24	in	in	IN	_	25	case
25	connection	connection	NN	_	23	nmod
26	with	with	IN	_	28	case
27	the	the	DT	_	28	det
28	coadministration	coadministration	NN	_	25	nmod
29	of	of	IN	_	33	case
30	certain	certain	JJ	_	33	amod
31	ergot	ergot	NN	_	33	compound
32	alkaloid	alkaloid	NN	_	33	compound
33	drugs	drug	NNS	_	28	nmod
34	(	(	VBP	_	19	acl
35	e	e	LS	_	34	dobj
36	.	.	.	_	35	punct
37	g	g	NN	_	42	compound
38	.	.	.	_	37	punct
39	dihydroergotamine	dihydroergotamine	NN	_	37	conj
40	and	and	CC	_	37	cc
41	ergotamine	ergotamine	NN	_	37	conj
42	)	)	NN	_	35	dep
43	and	and	CC	_	42	cc
44	potent	potent	JJ	_	47	amod
45	CYP	cyp	NN	_	47	compound
46	3A4	3a4	NN	_	47	compound
47	inhibitors	inhibitor	NNS	_	42	conj
48	,	,	,	_	42	punct
49	resulting	result	VBG	_	42	acl
50	in	in	IN	_	51	case
51	vasospasm	vasospasm	NN	_	49	nmod
52	leading	lead	VBG	_	51	acl
53	to	to	TO	_	55	case
54	cerebral	cerebral	JJ	_	55	amod
55	ischemia	ischemia	NN	_	52	nmod
56	and	and	CC	_	55	cc
57	/	/	:	_	59	punct
58	or	or	CC	_	59	cc
59	ischemia	ischemia	NN	_	55	conj
60	of	of	IN	_	62	case
61	the	the	DT	_	62	det
62	extremities	extremity	NNS	_	59	nmod
63	.	.	.	_	4	punct

1	Although	although	IN	_	6	mark
2	there	there	EX	_	6	expl
3	have	have	VBP	_	6	aux
4	been	be	VBN	_	6	cop
5	no	no	DT	_	6	neg
6	reports	report	NNS	_	0	ROOT
7	of	of	IN	_	9	case
8	such	such	JJ	_	9	amod
9	interactions	interaction	NNS	_	6	nmod
10	with	with	IN	_	11	case
11	methylergonovine	methylergonovine	NN	_	9	nmod
12	alone	alone	RB	_	11	advmod
13	,	,	,	_	11	punct
14	potent	potent	JJ	_	17	amod
15	CYP	cyp	NN	_	17	compound
16	3A4	3a4	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	21	nsubjpass
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	coadministered	coadminister	VBN	_	11	acl:relcl
22	with	with	IN	_	23	case
23	methylergonovine	methylergonovine	NN	_	21	nmod
24	.	.	.	_	6	punct

1	Examples	example	NNS	_	11	nsubj
2	of	of	IN	_	3	case
3	some	some	DT	_	1	nmod
4	of	of	IN	_	10	case
5	the	the	DT	_	10	det
6	more	more	RBR	_	7	advmod
7	potent	potent	JJ	_	10	amod
8	CYP	cyp	NN	_	10	compound
9	3A4	3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	3	nmod
11	include	include	VBP	_	0	ROOT
12	macrolide	macrolide	NN	_	13	compound
13	antibiotics	antibiotic	NNS	_	14	nsubj
14	(	(	VBP	_	11	ccomp
15	e	e	LS	_	14	dobj
16	.	.	.	_	15	punct
17	g	g	NN	_	15	dep
18	.	.	.	_	17	punct
19	,	,	,	_	17	punct
20	erythromycin	erythromycin	NN	_	33	nsubj
21	,	,	,	_	20	punct
22	troleandomycin	troleandomycin	NN	_	20	conj
23	,	,	,	_	20	punct
24	clarithromycin	clarithromycin	NN	_	25	compound
25	)	)	NN	_	20	conj
26	,	,	,	_	20	punct
27	HIV	hiv	NN	_	28	compound
28	protease	protease	NN	_	20	conj
29	or	or	CC	_	20	cc
30	reverse	reverse	JJ	_	32	amod
31	transcriptase	transcriptase	NN	_	32	compound
32	inhibitors	inhibitor	NNS	_	20	conj
33	(	(	VBP	_	17	parataxis
34	e	e	LS	_	33	dobj
35	.	.	.	_	34	punct
36	g	g	NN	_	34	dep
37	.	.	.	_	36	punct
38	,	,	,	_	36	punct
39	ritonavir	ritonavir	NN	_	49	compound
40	,	,	,	_	39	punct
41	indinavir	indinavir	NN	_	39	conj
42	,	,	,	_	39	punct
43	nelfinavir	nelfinavir	NN	_	39	conj
44	,	,	,	_	39	punct
45	delavirdine	delavirdine	NN	_	46	compound
46	)	)	NN	_	39	conj
47	or	or	CC	_	39	cc
48	azole	azole	NN	_	39	conj
49	antifungals	antifungal	NNS	_	50	nsubj
50	(	(	VBP	_	36	parataxis
51	e	e	LS	_	50	dobj
52	.	.	.	_	51	punct
53	g	g	NN	_	51	dep
54	.	.	.	_	53	punct
55	,	,	,	_	53	punct
56	ketoconazole	ketoconazole	NN	_	53	appos
57	,	,	,	_	56	punct
58	itraconazole	itraconazole	NN	_	56	conj
59	,	,	,	_	56	punct
60	voriconazole	voriconazole	NN	_	61	compound
61	)	)	NN	_	56	conj
62	.	.	.	_	11	punct

1	Less	less	RBR	_	5	advmod
2	potent	potent	JJ	_	5	amod
3	CYP	cyp	NN	_	5	compound
4	3A4	3a4	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	caution	caution	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Less	less	RBR	_	3	amod
2	potent	potent	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	4	nsubj
4	include	include	VBP	_	0	ROOT
5	saquinavir	saquinavir	NN	_	4	dobj
6	,	,	,	_	5	punct
7	nefazodone	nefazodone	NN	_	5	conj
8	,	,	,	_	5	punct
9	fluconazole	fluconazole	NN	_	5	conj
10	,	,	,	_	5	punct
11	grapefruit	grapefruit	NN	_	12	compound
12	juice	juice	NN	_	5	conj
13	,	,	,	_	5	punct
14	fluoxetine	fluoxetine	NN	_	5	conj
15	,	,	,	_	5	punct
16	fluvoxamine	fluvoxamine	NN	_	5	conj
17	,	,	,	_	5	punct
18	zileuton	zileuton	NN	_	5	conj
19	,	,	,	_	5	punct
20	and	and	CC	_	5	cc
21	clotrimazole	clotrimazole	NN	_	5	conj
22	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	lists	list	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	not	not	RB	_	5	neg
5	exhaustive	exhaustive	JJ	_	0	ROOT
6	,	,	,	_	5	punct
7	and	and	CC	_	5	cc
8	the	the	DT	_	9	det
9	prescriber	prescriber	NN	_	11	nsubj
10	should	should	MD	_	11	aux
11	consider	consider	VB	_	5	conj
12	the	the	DT	_	13	det
13	effects	effect	NNS	_	11	dobj
14	on	on	IN	_	16	case
15	CYP	cyp	NN	_	16	compound
16	3A4	3a4	NN	_	13	nmod
17	of	of	IN	_	19	case
18	other	other	JJ	_	19	amod
19	agents	agent	NNS	_	16	nmod
20	being	be	VBG	_	21	auxpass
21	considered	consider	VBN	_	19	acl
22	for	for	IN	_	24	case
23	concomitant	concomitant	JJ	_	24	amod
24	use	use	NN	_	21	nmod
25	with	with	IN	_	26	case
26	methylergonovine	methylergonovine	NN	_	24	nmod
27	.	.	.	_	5	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	10	nsubjpass
4	involving	involve	VBG	_	3	acl
5	other	other	JJ	_	8	amod
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	isoenzymes	isoenzyme	NNS	_	4	dobj
9	are	be	VBP	_	10	auxpass
10	known	know	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	12	advmod
6	Methergine	Methergine	NNP	_	10	compound
7	(	(	CD	_	10	nummod
8	methylergonovine	methylergonovine	NN	_	10	compound
9	maleate	maleate	NN	_	10	compound
10	)	)	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	used	use	VBN	_	4	advcl
13	concurrently	concurrently	RB	_	12	advmod
14	with	with	IN	_	16	case
15	other	other	JJ	_	16	amod
16	vasoconstrictors	vasoconstrictor	NNS	_	12	nmod
17	or	or	CC	_	16	cc
18	ergot	ergot	NN	_	19	compound
19	alkaloids	alkaloid	NNS	_	16	conj
20	.	.	.	_	4	punct

1	To	to	TO	_	2	mark
2	minimize	minimize	VB	_	21	advcl
3	CNS	cns	NN	_	4	compound
4	depression	depression	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	possible	possible	JJ	_	7	amod
7	potentiation	potentiation	NN	_	4	conj
8	,	,	,	_	21	punct
9	barbiturates	barbiturate	NNS	_	21	nsubjpass
10	,	,	,	_	9	punct
11	antihistamines	antihistamine	NNS	_	9	conj
12	,	,	,	_	9	punct
13	narcotics	narcotic	NNS	_	9	conj
14	,	,	,	_	9	punct
15	hypotensive	hypotensive	JJ	_	16	amod
16	agents	agent	NNS	_	9	conj
17	or	or	CC	_	9	cc
18	phenothiazines	phenothiazine	NNS	_	9	conj
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	used	use	VBN	_	0	ROOT
22	with	with	IN	_	23	case
23	caution	caution	NN	_	21	nmod
24	.	.	.	_	21	punct

1	Ethyl	Ethyl	NNP	_	2	compound
2	alcohol	alcohol	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	since	since	IN	_	14	mark
8	there	there	EX	_	14	expl
9	may	may	MD	_	14	aux
10	be	be	VB	_	14	cop
11	an	a	DT	_	14	det
12	Antabuse	antabuse	JJ	_	14	amod
13	(	(	NN	_	14	compound
14	disulfiram	disulfiram	NN	_	18	dep
15	)	)	SYM	_	18	dep
16	-	-	:	_	18	punct
17	like	like	IN	_	18	case
18	reaction	reaction	NN	_	6	xcomp
19	.	.	.	_	6	punct

1	Because	because	IN	_	3	mark
2	Matulane	matulane	NN	_	3	nsubj
3	exhibits	exhibit	VBZ	_	16	advcl
4	some	some	DT	_	8	det
5	monoamine	monoamine	NN	_	8	compound
6	oxidase	oxidase	NN	_	8	compound
7	inhibitory	inhibitory	JJ	_	8	amod
8	activity	activity	NN	_	3	dobj
9	,	,	,	_	16	punct
10	sympathomimetic	sympathomimetic	JJ	_	11	amod
11	drugs	drug	NNS	_	16	nsubj
12	,	,	,	_	11	punct
13	tricyclic	tricyclic	JJ	_	15	amod
14	antidepressant	antidepressant	JJ	_	15	amod
15	drugs	drug	NNS	_	11	appos
16	(	(	VBP	_	0	ROOT
17	e	e	LS	_	52	dep
18	.	.	.	_	17	punct
19	g	g	NN	_	52	nsubjpass
20	.	.	.	_	19	punct
21	,	,	,	_	19	punct
22	amitriptyline	amitriptyline	NNP	_	23	compound
23	HCl	hcl	NN	_	19	conj
24	,	,	,	_	19	punct
25	imipramine	imipramine	NN	_	27	compound
26	HCl	hcl	NN	_	27	compound
27	)	)	NN	_	19	conj
28	and	and	CC	_	19	cc
29	other	other	JJ	_	30	amod
30	drugs	drug	NNS	_	19	conj
31	and	and	CC	_	19	cc
32	foods	food	NNS	_	19	conj
33	with	with	IN	_	37	case
34	known	known	JJ	_	37	amod
35	high	high	JJ	_	37	amod
36	tyramine	tyramine	NN	_	37	compound
37	content	content	NN	_	19	nmod
38	,	,	,	_	37	punct
39	such	such	JJ	_	41	case
40	as	as	IN	_	39	mwe
41	wine	wine	NN	_	37	nmod
42	,	,	,	_	41	punct
43	yogurt	yogurt	NN	_	41	conj
44	,	,	,	_	41	punct
45	ripe	ripe	JJ	_	46	amod
46	cheese	cheese	NN	_	41	conj
47	and	and	CC	_	41	cc
48	bananas	banana	NNS	_	41	conj
49	,	,	,	_	37	punct
50	should	should	MD	_	52	aux
51	be	be	VB	_	52	auxpass
52	avoided	avoid	VBN	_	16	ccomp
53	.	.	.	_	16	punct

1	A	a	DT	_	3	det
2	further	further	JJ	_	3	amod
3	phenomenon	phenomenon	NN	_	12	nsubj
4	of	of	IN	_	5	case
5	toxicity	toxicity	NN	_	3	nmod
6	common	common	JJ	_	5	amod
7	to	to	TO	_	10	case
8	many	many	JJ	_	10	amod
9	hydrazine	hydrazine	NN	_	10	compound
10	derivatives	derivative	NNS	_	6	nmod
11	is	be	VBZ	_	12	cop
12	hemolysis	hemolysis	NN	_	0	ROOT
13	and	and	CC	_	12	cc
14	the	the	DT	_	15	det
15	appearance	appearance	NN	_	12	conj
16	of	of	IN	_	17	case
17	Heinz	Heinz	NNP	_	15	nmod
18	-	-	:	_	17	punct
19	Ehrlich	Ehrlich	NNP	_	21	compound
20	inclusion	inclusion	NN	_	21	compound
21	bodies	body	NNS	_	17	dep
22	in	in	IN	_	23	case
23	erythrocytes	erythrocyte	NNS	_	21	nmod
24	.	.	.	_	12	punct

1	No	no	DT	_	2	neg
2	cross	cross	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	resistance	resistance	NN	_	15	nsubjpass
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	chemotherapeutic	chemotherapeutic	JJ	_	8	amod
8	agents	agent	NNS	_	4	nmod
9	,	,	,	_	8	punct
10	radiotherapy	radiotherapy	NN	_	8	conj
11	or	or	CC	_	8	cc
12	steroids	steroid	NNS	_	8	conj
13	has	have	VBZ	_	15	aux
14	been	be	VBN	_	15	auxpass
15	demonstrated	demonstrate	VBN	_	2	dep
16	.	.	.	_	2	punct

1	Phenothiazines	phenothiazine	NNS	_	3	nsubj
2	are	be	VBP	_	3	cop
3	capable	capable	JJ	_	0	ROOT
4	of	of	IN	_	5	mark
5	potentiating	potentiate	VBG	_	3	advcl
6	CNS	cns	NN	_	7	compound
7	depressants	depressant	NNS	_	5	dobj
8	(	(	VBP	_	5	dep
9	e	e	LS	_	8	dobj
10	.	.	.	_	9	punct
11	g	g	NN	_	9	dep
12	.	.	.	_	11	punct
13	,	,	,	_	11	punct
14	barbiturates	barbiturate	NNS	_	11	conj
15	,	,	,	_	11	punct
16	anesthetics	anesthetic	NNS	_	11	conj
17	,	,	,	_	11	punct
18	opiates	opiate	NNS	_	11	conj
19	,	,	,	_	11	punct
20	alcohol	alcohol	NN	_	11	conj
21	,	,	,	_	11	punct
22	etc	etc	FW	_	11	conj
23	.	.	.	_	11	punct
24	)	)	SYM	_	9	dep

1	as	as	RB	_	7	cc
2	well	well	RB	_	1	mwe
3	as	as	IN	_	1	mwe
4	atropine	atropine	NN	_	7	compound
5	and	and	CC	_	4	cc
6	phosphorous	phosphorous	JJ	_	4	conj
7	insecticides	insecticide	NNS	_	0	ROOT
8	.	.	.	_	7	punct

1	Drugs	drug	NNS	_	15	nsubjpass
2	affecting	affect	VBG	_	1	acl
3	pituitary	pituitary	JJ	_	6	amod
4	or	or	CC	_	3	cc
5	adrenocortical	adrenocortical	JJ	_	3	conj
6	function	function	NN	_	2	dobj
7	,	,	,	_	1	punct
8	including	include	VBG	_	11	case
9	all	all	DT	_	11	det
10	corticosteroid	corticosteroid	NN	_	11	compound
11	therapy	therapy	NN	_	1	nmod
12	,	,	,	_	1	punct
13	must	must	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	discontinued	discontinue	VBN	_	0	ROOT
16	prior	prior	RB	_	20	advmod
17	to	to	TO	_	20	case
18	and	and	CC	_	17	cc
19	during	during	IN	_	17	conj
20	testing	testing	NN	_	15	nmod
21	with	with	IN	_	22	case
22	Metopirone	metopirone	NN	_	20	nmod
23	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	metabolism	metabolism	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	Metopirone	Metopirone	NNP	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	accelerated	accelerate	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	phenytoin	phenytoin	NN	_	6	nmod
9	;	;	:	_	6	punct

1	therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	results	result	NNS	_	9	nsubj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	test	test	NN	_	3	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	cop
9	inaccurate	inaccurate	JJ	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	taking	take	VBG	_	11	acl
13	phenytoin	phenytoin	NN	_	12	dobj
14	within	within	IN	_	16	case
15	two	two	CD	_	16	nummod
16	weeks	week	NNS	_	12	nmod
17	before	before	RB	_	16	advmod
18	.	.	.	_	9	punct

1	Asubnormal	asubnormal	JJ	_	2	amod
2	response	response	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	occur	occur	VB	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	on	on	IN	_	9	case
8	estrogen	estrogen	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	.	.	.	_	4	punct

1	Metopirone	metopirone	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	glucuronidation	glucuronidation	NN	_	2	dobj
5	of	of	IN	_	6	case
6	acetaminophen	acetaminophen	NN	_	4	nmod
7	and	and	CC	_	2	cc
8	could	could	MD	_	10	aux
9	possibly	possibly	RB	_	10	advmod
10	potentiate	potentiate	VB	_	2	conj
11	acetaminophen	acetaminophen	NN	_	12	compound
12	toxicity	toxicity	NN	_	10	dobj
13	.	.	.	_	2	punct

1	Preliminary	preliminary	JJ	_	2	amod
2	evidence	evidence	NN	_	3	nsubj
3	suggests	suggest	VBZ	_	0	ROOT
4	that	that	IN	_	6	mark
5	cimetidine	cimetidine	NN	_	6	nsubj
6	inhibits	inhibit	VBZ	_	3	ccomp
7	mebendazole	mebendazole	JJ	_	8	amod
8	metabolism	metabolism	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	may	may	MD	_	11	aux
11	result	result	VB	_	6	conj
12	in	in	IN	_	14	case
13	an	a	DT	_	14	det
14	increase	increase	NN	_	11	nmod
15	in	in	IN	_	17	case
16	plasma	plasma	NN	_	17	compound
17	concentrations	concentration	NNS	_	14	nmod
18	of	of	IN	_	19	case
19	mebendazole	mebendazole	NN	_	17	nmod
20	.	.	.	_	3	punct

1	Pantoprazole	Pantoprazole	NNP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	through	through	IN	_	8	case
5	the	the	DT	_	8	det
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	system	system	NN	_	3	nmod
9	,	,	,	_	3	punct
10	primarily	primarily	RB	_	15	advmod
11	the	the	DT	_	15	det
12	CYP2C19	cyp2c19	NN	_	15	compound
13	and	and	CC	_	12	cc
14	CYP3A4	cyp3a4	NN	_	12	conj
15	isozymes	isozyme	NNS	_	3	dep
16	,	,	,	_	15	punct
17	and	and	CC	_	15	cc
18	subsequently	subsequently	RB	_	19	advmod
19	undergoes	undergo	VBZ	_	15	conj
20	Phase	phase	NN	_	22	compound
21	II	ii	CD	_	22	nummod
22	conjugation	conjugation	NN	_	19	dobj
23	.	.	.	_	3	punct

1	Based	base	VBN	_	3	case
2	on	on	IN	_	3	case
3	studies	study	NNS	_	17	advcl
4	evaluating	evaluate	VBG	_	3	acl
5	possible	possible	JJ	_	6	amod
6	interactions	interaction	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	pantoprazole	pantoprazole	NN	_	6	nmod
9	with	with	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	6	nmod
12	,	,	,	_	17	punct
13	no	no	DT	_	15	neg
14	dosage	dosage	NN	_	15	compound
15	adjustment	adjustment	NN	_	17	nsubjpass
16	is	be	VBZ	_	17	auxpass
17	needed	need	VBN	_	0	ROOT
18	with	with	IN	_	20	case
19	concomitant	concomitant	JJ	_	20	amod
20	use	use	NN	_	17	nmod
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	following	following	NN	_	20	nmod
24	:	:	:	_	17	punct
25	theophylline	theophylline	NN	_	17	dep
26	,	,	,	_	25	punct
27	cisapride	cisapride	NN	_	25	conj
28	,	,	,	_	25	punct
29	antipyrine	antipyrine	NN	_	25	conj
30	,	,	,	_	25	punct
31	caffeine	caffeine	NN	_	25	conj
32	,	,	,	_	25	punct
33	carbamazepine	carbamazepine	NN	_	25	conj
34	,	,	,	_	25	punct
35	diazepam	diazepam	NN	_	36	compound
36	(	(	NN	_	25	conj
37	and	and	CC	_	25	cc
38	its	its	PRP$	_	40	nmod:poss
39	active	active	JJ	_	40	amod
40	metabolite	metabolite	NN	_	25	conj
41	,	,	,	_	40	punct
42	desmethyldiazepam	desmethyldiazepam	NN	_	43	compound
43	)	)	NN	_	40	conj
44	,	,	,	_	40	punct
45	diclofenac	diclofenac	NN	_	40	conj
46	,	,	,	_	40	punct
47	naproxen	naproxen	NN	_	40	conj
48	,	,	,	_	40	punct
49	piroxicam	piroxicam	NN	_	40	conj
50	,	,	,	_	40	punct
51	digoxin	digoxin	NN	_	40	conj
52	,	,	,	_	40	punct
53	ethanol	ethanol	NN	_	40	conj
54	,	,	,	_	40	punct
55	glyburide	glyburide	NN	_	40	conj
56	,	,	,	_	40	punct
57	an	a	DT	_	61	det
58	oral	oral	JJ	_	61	amod
59	contraceptive	contraceptive	JJ	_	61	amod
60	(	(	NN	_	61	compound
61	levonorgestrel	levonorgestrel	NN	_	40	appos
62	/	/	:	_	61	punct
63	ethinyl	ethinyl	NN	_	65	compound
64	estradiol	estradiol	NN	_	65	compound
65	)	)	NN	_	61	dep
66	,	,	,	_	65	punct
67	metoprolol	metoprolol	NN	_	65	conj
68	,	,	,	_	65	punct
69	nifedipine	nifedipine	NN	_	65	conj
70	,	,	,	_	65	punct
71	phenytoin	phenytoin	NN	_	65	conj
72	,	,	,	_	65	punct
73	warfarin	warfarin	NN	_	65	conj
74	,	,	,	_	65	punct
75	midazolam	midazolam	NN	_	65	conj
76	,	,	,	_	65	punct
77	clarithromycin	clarithromycin	NN	_	65	conj
78	,	,	,	_	65	punct
79	metronidazole	metronidazole	NN	_	65	conj
80	,	,	,	_	65	punct
81	or	or	CC	_	65	cc
82	amoxicillin	amoxicillin	NNP	_	65	conj
83	.	.	.	_	17	punct

1	Clinically	clinically	RB	_	2	advmod
2	relevant	relevant	JJ	_	3	amod
3	interactions	interaction	NNS	_	16	nsubjpass
4	of	of	IN	_	5	case
5	pantoprazole	pantoprazole	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	3	nmod
9	with	with	IN	_	13	case
10	the	the	DT	_	13	det
11	same	same	JJ	_	13	amod
12	metabolic	metabolic	JJ	_	13	amod
13	pathways	pathway	NNS	_	8	nmod
14	are	be	VBP	_	16	auxpass
15	not	not	RB	_	16	neg
16	expected	expect	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	21	advmod
2	,	,	,	_	21	punct
3	when	when	WRB	_	4	advmod
4	coadministered	coadminister	VBN	_	21	advcl
5	with	with	IN	_	6	case
6	pantoprazole	pantoprazole	NN	_	4	nmod
7	,	,	,	_	21	punct
8	adjustment	adjustment	NN	_	21	nsubj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	dosage	dosage	NN	_	8	nmod
12	of	of	IN	_	13	case
13	pantoprazole	pantoprazole	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	of	of	IN	_	17	case
16	such	such	JJ	_	17	amod
17	drugs	drug	NNS	_	13	conj
18	may	may	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	cop
21	necessary	necessary	JJ	_	0	ROOT
22	.	.	.	_	21	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	also	also	RB	_	2	advmod
4	no	no	DT	_	5	neg
5	interaction	interaction	NN	_	2	nsubj
6	with	with	IN	_	9	case
7	concomitantly	concomitantly	RB	_	8	advmod
8	administered	administer	VBN	_	9	amod
9	antacids	antacid	NNS	_	5	nmod
10	.	.	.	_	2	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	aux
4	postmarketing	postmarket	VBG	_	0	ROOT
5	reports	report	NNS	_	4	dobj
6	of	of	IN	_	8	case
7	increased	increase	VBN	_	8	amod
8	INR	inr	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	prothrombin	prothrombin	NN	_	8	conj
11	time	time	NN	_	8	dep
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	8	nmod
14	receiving	receive	VBG	_	13	acl
15	proton	proton	NN	_	17	compound
16	pump	pump	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	14	dobj
18	,	,	,	_	13	punct
19	including	include	VBG	_	20	case
20	pantoprazole	pantoprazole	NN	_	13	nmod
21	,	,	,	_	13	punct
22	and	and	CC	_	13	cc
23	warfarin	warfarin	NN	_	13	conj
24	concomitantly	concomitantly	RB	_	23	advmod
25	.	.	.	_	4	punct

1	Increases	increase	NNS	_	0	ROOT
2	in	in	IN	_	3	case
3	INR	inr	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	prothrombin	prothrombin	NN	_	3	conj
6	time	time	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	lead	lead	VB	_	1	acl:relcl
9	to	to	TO	_	11	case
10	abnormal	abnormal	JJ	_	11	amod
11	bleeding	bleeding	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	even	even	RB	_	14	advmod
14	death	death	NN	_	11	conj
15	.	.	.	_	1	punct

1	Patients	patient	NNS	_	12	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	6	case
4	proton	proton	NN	_	6	compound
5	pump	pump	NN	_	6	compound
6	inhibitors	inhibitor	NNS	_	2	nmod
7	and	and	CC	_	6	cc
8	warfarin	warfarin	NN	_	6	conj
9	concomitantly	concomitantly	RB	_	12	advmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	monitored	monitor	VBN	_	0	ROOT
13	for	for	IN	_	14	case
14	increases	increase	NNS	_	12	nmod
15	in	in	IN	_	16	case
16	INR	inr	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	prothrombin	prothrombin	NN	_	19	compound
19	time	time	NN	_	16	conj
20	.	.	.	_	12	punct

1	Because	because	IN	_	7	case
2	of	of	IN	_	1	mwe
3	profound	profound	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	long	long	JJ	_	3	conj
6	lasting	lasting	JJ	_	7	amod
7	inhibition	inhibition	NN	_	15	nmod
8	of	of	IN	_	11	case
9	gastric	gastric	JJ	_	11	amod
10	acid	acid	NN	_	11	compound
11	secretion	secretion	NN	_	7	nmod
12	,	,	,	_	15	punct
13	pantoprazole	pantoprazole	NN	_	15	nsubj
14	may	may	MD	_	15	aux
15	interfere	interfere	VB	_	0	ROOT
16	with	with	IN	_	17	case
17	absorption	absorption	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drugs	drug	NNS	_	17	nmod
20	where	where	WRB	_	26	advmod
21	gastric	gastric	JJ	_	22	amod
22	pH	ph	NN	_	26	nsubj
23	is	be	VBZ	_	26	cop
24	an	a	DT	_	26	det
25	important	important	JJ	_	26	amod
26	determinant	determinant	NN	_	19	acl:relcl
27	of	of	IN	_	29	case
28	their	they	PRP$	_	29	nmod:poss
29	bioavailability	bioavailability	NN	_	26	nmod
30	(	(	CD	_	33	nummod
31	eg	eg	FW	_	33	compound
32	,	,	,	_	33	punct
33	ketoconazole	ketoconazole	NN	_	29	dep
34	,	,	,	_	17	punct
35	ampicillin	ampicillin	NN	_	36	compound
36	esters	ester	NNS	_	17	conj
37	,	,	,	_	17	punct
38	and	and	CC	_	17	cc
39	iron	iron	NN	_	40	compound
40	salts	salt	NNS	_	17	conj
41	)	)	VBP	_	15	advmod
42	.	.	.	_	15	punct

1	Laboratory	Laboratory	NNP	_	2	compound
2	Tests	Tests	NNP	_	6	nsubj
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	0	ROOT
7	of	of	IN	_	13	case
8	false	false	JJ	_	13	amod
9	-	-	:	_	13	punct
10	positive	positive	JJ	_	13	amod
11	urine	urine	NN	_	13	compound
12	screening	screening	NN	_	13	compound
13	tests	test	NNS	_	6	nmod
14	for	for	IN	_	18	case
15	tetrahydrocannabinol	tetrahydrocannabinol	NN	_	18	compound
16	(	(	CD	_	18	nummod
17	THC	thc	NN	_	18	compound
18	)	)	NN	_	13	nmod
19	in	in	IN	_	20	case
20	patients	patient	NNS	_	18	nmod
21	receiving	receive	VBG	_	20	acl
22	most	most	RBS	_	23	advmod
23	proton	proton	JJ	_	25	amod
24	pump	pump	NN	_	25	compound
25	inhibitors	inhibitor	NNS	_	21	dobj
26	,	,	,	_	20	punct
27	including	include	VBG	_	28	case
28	pantoprazole	pantoprazole	NN	_	20	nmod
29	.	.	.	_	6	punct

1	An	a	DT	_	4	det
2	alternative	alternative	JJ	_	4	amod
3	confirmatory	confirmatory	JJ	_	4	amod
4	method	method	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	considered	consider	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	verify	verify	VB	_	7	xcomp
10	positive	positive	JJ	_	11	amod
11	results	result	NNS	_	9	dobj
12	.	.	.	_	7	punct

1	Sulfoxone	sulfoxone	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	barbiturates	barbiturate	NNS	_	5	nmod
8	,	,	,	_	7	punct
9	tolbutamide	tolbutamide	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	uricosurics	uricosuric	NNS	_	7	conj
13	.	.	.	_	3	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	thiazides	thiazide	NNS	_	4	nmod
7	(	(	RB	_	8	advmod
8	increased	increase	VBD	_	10	amod
9	thrombocytopenia	thrombocytopenia	NN	_	10	compound
10	)	)	NN	_	4	dobj
11	,	,	,	_	10	punct
12	cyclosporine	cyclosporine	NN	_	13	compound
13	(	(	NN	_	14	nsubj
14	increased	increase	VBD	_	10	acl:relcl
15	nephrotoxicity	nephrotoxicity	NN	_	16	compound
16	)	)	NN	_	14	dobj
17	,	,	,	_	10	punct
18	sulfonylurea	sulfonylurea	NN	_	19	compound
19	agents	agent	NNS	_	20	nsubj
20	(	(	VBP	_	10	acl:relcl
21	increased	increase	VBN	_	24	amod
22	hypoglycemic	hypoglycemic	JJ	_	24	amod
23	response	response	NN	_	24	compound
24	)	)	NN	_	28	nsubj
25	,	,	,	_	24	punct
26	warfarin	warfarin	NN	_	27	compound
27	(	(	NN	_	24	appos
28	increased	increase	VBD	_	20	ccomp
29	anticoagulant	anticoagulant	JJ	_	31	amod
30	effect	effect	NN	_	31	compound
31	)	)	NN	_	28	dobj
32	,	,	,	_	31	punct
33	methotrexate	methotrexate	NN	_	34	compound
34	(	(	NN	_	35	nsubj
35	decreased	decrease	VBD	_	31	acl:relcl
36	renal	renal	JJ	_	37	amod
37	excretion	excretion	NN	_	35	dobj
38	of	of	IN	_	40	case
39	methotrexate	methotrexate	NN	_	40	compound
40	)	)	NN	_	37	nmod
41	,	,	,	_	40	punct
42	phenytoin	phenytoin	NN	_	43	compound
43	(	(	NN	_	40	appos
44	decreased	decrease	VBD	_	4	xcomp
45	hepatic	hepatic	JJ	_	46	amod
46	clearance	clearance	NN	_	44	dobj
47	of	of	IN	_	49	case
48	phenytoin	phenytoin	NN	_	49	compound
49	)	)	NN	_	46	nmod
50	.	.	.	_	4	punct

1	Thiabendazole	Thiabendazole	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	compete	compete	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	nmod
7	,	,	,	_	6	punct
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	theophylline	theophylline	NN	_	6	nmod
11	,	,	,	_	6	punct
12	for	for	IN	_	13	case
13	sites	site	NNS	_	6	nmod
14	of	of	IN	_	15	case
15	metabolism	metabolism	NN	_	13	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	liver	liver	NN	_	13	nmod
19	,	,	,	_	6	punct
20	thus	thus	RB	_	21	advmod
21	elevating	elevate	VBG	_	6	acl
22	the	the	DT	_	24	det
23	serum	serum	NN	_	24	compound
24	levels	level	NNS	_	21	dobj
25	of	of	IN	_	27	case
26	such	such	JJ	_	27	amod
27	compounds	compound	NNS	_	24	nmod
28	to	to	TO	_	31	case
29	potentially	potentially	RB	_	30	advmod
30	toxic	toxic	JJ	_	31	amod
31	levels	level	NNS	_	21	nmod
32	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	17	advmod
2	,	,	,	_	17	punct
3	when	when	WRB	_	12	advmod
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	12	nsubjpass
6	of	of	IN	_	7	case
7	thiabendazole	thiabendazole	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	xanthine	xanthine	NN	_	10	compound
10	derivatives	derivative	NNS	_	7	conj
11	is	be	VBZ	_	12	auxpass
12	anticipated	anticipate	VBN	_	17	advcl
13	,	,	,	_	17	punct
14	it	it	PRP	_	17	nsubj
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	cop
17	necessary	necessary	JJ	_	0	ROOT
18	to	to	TO	_	19	mark
19	monitor	monitor	VB	_	17	xcomp
20	blood	blood	NN	_	21	compound
21	levels	level	NNS	_	19	dobj
22	and	and	CC	_	21	cc
23	/	/	:	_	25	punct
24	or	or	CC	_	25	cc
25	reduce	reduce	VB	_	21	conj
26	the	the	DT	_	27	det
27	dosage	dosage	NN	_	25	dobj
28	of	of	IN	_	30	case
29	such	such	JJ	_	30	amod
30	compounds	compound	NNS	_	27	nmod
31	.	.	.	_	17	punct

1	Such	such	JJ	_	3	amod
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	administered	administer	VBN	_	0	ROOT
7	under	under	IN	_	10	case
8	careful	careful	JJ	_	10	amod
9	medical	medical	JJ	_	10	amod
10	supervision	supervision	NN	_	6	nmod
11	.	.	.	_	6	punct

1	Administration	administration	NN	_	5	nsubj
2	of	of	IN	_	4	case
3	valproic	valproic	JJ	_	4	amod
4	acid	acid	NN	_	1	nmod
5	decreases	decrease	VBZ	_	0	ROOT
6	oral	oral	JJ	_	7	amod
7	clearance	clearance	NN	_	5	dobj
8	of	of	IN	_	9	case
9	temozolomide	temozolomide	NN	_	7	nmod
10	by	by	IN	_	13	case
11	about	about	IN	_	12	advmod
12	5	5	CD	_	13	nummod
13	%	%	NN	_	5	nmod
14	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	implication	implication	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	effect	effect	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	with	with	IN	_	4	case
3	Severe	severe	JJ	_	4	amod
4	Hepatic	hepatic	JJ	_	1	nmod
5	or	or	CC	_	4	cc
6	Renal	renal	JJ	_	4	conj
7	Impairment	impairment	NN	_	8	compound
8	Caution	caution	NN	_	4	dep
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	exercised	exercise	VBN	_	0	ROOT
12	when	when	WRB	_	16	advmod
13	TEMODAR	TEMODAR	NNP	_	14	compound
14	Capsules	Capsules	NNPS	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	administered	administer	VBN	_	11	advcl
17	to	to	TO	_	18	case
18	patients	patient	NNS	_	16	nmod
19	with	with	IN	_	21	case
20	severe	severe	JJ	_	21	amod
21	hepatic	hepatic	JJ	_	18	nmod
22	or	or	CC	_	21	cc
23	renal	renal	JJ	_	24	amod
24	impairment	impairment	NN	_	21	conj
25	.	.	.	_	11	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	that	that	IN	_	6	mark
5	there	there	EX	_	6	expl
6	are	be	VBP	_	3	ccomp
7	no	no	DT	_	9	neg
8	significant	significant	JJ	_	9	amod
9	alterations	alteration	NNS	_	6	nsubj
10	in	in	IN	_	12	case
11	pharmacokinetic	pharmacokinetic	JJ	_	12	amod
12	parameters	parameter	NNS	_	9	nmod
13	of	of	IN	_	14	case
14	zidovudine	zidovudine	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	rifabutin	rifabutin	NN	_	14	conj
17	to	to	TO	_	18	mark
18	warrant	warrant	VB	_	9	acl
19	dosage	dosage	NN	_	20	compound
20	adjustment	adjustment	NN	_	18	dobj
21	when	when	WRB	_	25	advmod
22	megestrol	megestrol	JJ	_	23	amod
23	acetate	acetate	NN	_	25	nsubjpass
24	is	be	VBZ	_	25	auxpass
25	administered	administer	VBN	_	18	advcl
26	with	with	IN	_	28	case
27	these	these	DT	_	28	det
28	drugs	drug	NNS	_	25	nmod
29	.	.	.	_	3	punct

1	A	a	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	demonstrated	demonstrate	VBD	_	0	ROOT
5	that	that	IN	_	21	mark
6	coadministration	coadministration	NN	_	21	nsubj
7	of	of	IN	_	9	case
8	megestrol	megestrol	JJ	_	9	amod
9	acetate	acetate	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	indinavir	indinavir	NN	_	9	conj
12	results	result	NNS	_	9	dep
13	in	in	IN	_	16	case
14	a	a	DT	_	16	det
15	significant	significant	JJ	_	16	amod
16	decrease	decrease	NN	_	6	nmod
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	pharmacokinetic	pharmacokinetic	JJ	_	20	amod
20	parameters	parameter	NNS	_	16	nmod
21	(	(	VBP	_	4	ccomp
22	~	~	CD	_	23	compound
23	36	36	CD	_	24	nummod
24	%	%	NN	_	21	dobj
25	for	for	IN	_	26	case
26	Cmax	cmax	NN	_	21	nmod
27	and	and	CC	_	26	cc
28	~	~	NN	_	26	conj
29	28	28	CD	_	30	nummod
30	%	%	NN	_	26	dep
31	for	for	IN	_	33	case
32	AUC	auc	NN	_	33	compound
33	)	)	NN	_	21	nmod
34	of	of	IN	_	35	case
35	indinavir	indinavir	NN	_	33	nmod
36	.	.	.	_	4	punct

1	Administration	administration	NN	_	10	nsubjpass
2	of	of	IN	_	5	case
3	a	a	DT	_	5	det
4	higher	higher	JJR	_	5	amod
5	dose	dose	NN	_	1	nmod
6	of	of	IN	_	7	case
7	indinavir	indinavir	NN	_	5	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	when	when	WRB	_	12	advmod
12	coadministering	coadminister	VBG	_	10	advcl
13	with	with	IN	_	15	case
14	megestrol	megestrol	JJ	_	15	amod
15	acetate	acetate	NN	_	12	nmod
16	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	17	nsubjpass
3	of	of	IN	_	4	case
4	indinavir	indinavir	NN	_	2	nmod
5	,	,	,	_	4	punct
6	zidovudine	zidovudine	NN	_	4	conj
7	or	or	CC	_	4	cc
8	rifabutin	rifabutin	NN	_	4	conj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
12	of	of	IN	_	14	case
13	megestrol	megestrol	JJ	_	14	amod
14	acetate	acetate	NN	_	11	nmod
15	were	be	VBD	_	17	auxpass
16	not	not	RB	_	17	neg
17	studied	study	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Vasopressors	Vasopressors	NNP	_	7	nsubj
2	,	,	,	_	1	punct
3	particularly	particularly	RB	_	4	advmod
4	metaraminol	metaraminol	NN	_	1	appos
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	cause	cause	VB	_	0	ROOT
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	arrhythmias	arrhythmia	NNS	_	7	dobj
11	during	during	IN	_	13	case
12	halothane	halothane	NN	_	13	compound
13	anesthesia	anesthesia	NN	_	7	nmod
14	and	and	CC	_	7	cc
15	therefore	therefore	RB	_	18	advmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	7	conj
19	only	only	RB	_	22	advmod
20	with	with	IN	_	22	case
21	great	great	JJ	_	22	amod
22	caution	caution	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	not	not	RB	_	26	neg
25	at	at	IN	_	26	case
26	all	all	DT	_	22	conj
27	.	.	.	_	7	punct

1	MAO	MAO	NNP	_	2	compound
2	Inhibitors	inhibitor	NNS	_	0	ROOT
3	-	-	:	_	2	punct
4	The	the	DT	_	6	det
5	pressor	pressor	NN	_	6	compound
6	effect	effect	NN	_	13	nsubjpass
7	of	of	IN	_	10	case
8	sympathomimetic	sympathomimetic	JJ	_	10	amod
9	pressor	pressor	NN	_	10	compound
10	amines	amine	NNS	_	6	nmod
11	is	be	VBZ	_	13	auxpass
12	markedly	markedly	RB	_	13	advmod
13	potentiated	potentiate	VBN	_	2	dep
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	monoamine	monoamine	NN	_	19	compound
18	oxidase	oxidase	NN	_	19	compound
19	inhibitors	inhibitor	NNS	_	16	dobj
20	(	(	VBP	_	13	xcomp
21	MAOI	MAOI	NNP	_	20	dobj
22	)	)	CD	_	21	nummod
23	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	16	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	9	case
8	these	these	DT	_	9	det
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	16	punct
11	the	the	DT	_	13	det
12	initial	initial	JJ	_	13	amod
13	dose	dose	NN	_	16	nsubj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	cop
16	small	small	JJ	_	0	ROOT
17	and	and	CC	_	16	cc
18	used	use	VBN	_	16	conj
19	with	with	IN	_	21	case
20	due	due	JJ	_	21	amod
21	caution	caution	NN	_	18	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	pressor	pressor	NN	_	3	compound
3	response	response	NN	_	10	nsubjpass
4	of	of	IN	_	6	case
5	adrenergic	adrenergic	JJ	_	6	amod
6	agents	agent	NNS	_	3	nmod
7	may	may	MD	_	10	aux
8	also	also	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	potentiated	potentiate	VBN	_	0	ROOT
11	by	by	IN	_	13	case
12	tricyclic	tricyclic	JJ	_	13	amod
13	antidepressants	antidepressant	NNS	_	10	nmod
14	.	.	.	_	10	punct

1	The	the	DT	_	5	det
2	CNS	cns	NN	_	5	compound
3	-	-	:	_	5	punct
4	depressant	depressant	NN	_	5	compound
5	effect	effect	NN	_	9	nsubj
6	of	of	IN	_	7	case
7	propoxyphene	propoxyphene	NN	_	5	nmod
8	is	be	VBZ	_	9	cop
9	additive	additive	JJ	_	0	ROOT
10	with	with	IN	_	11	case
11	that	that	DT	_	9	nmod
12	of	of	IN	_	15	case
13	other	other	JJ	_	15	amod
14	CNS	cns	NN	_	15	compound
15	depressants	depressant	NNS	_	11	nmod
16	,	,	,	_	15	punct
17	including	include	VBG	_	18	case
18	alcohol	alcohol	NN	_	15	nmod
19	.	.	.	_	9	punct

1	As	as	IN	_	4	mark
2	is	be	VBZ	_	4	cop
3	the	the	DT	_	4	det
4	case	case	NN	_	12	advcl
5	with	with	IN	_	8	case
6	many	many	JJ	_	8	amod
7	medicinal	medicinal	JJ	_	8	amod
8	agents	agent	NNS	_	4	nmod
9	,	,	,	_	12	punct
10	propoxyphene	propoxyphene	NN	_	12	nsubj
11	may	may	MD	_	12	aux
12	slow	slow	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	metabolism	metabolism	NN	_	12	dobj
15	of	of	IN	_	19	case
16	a	a	DT	_	19	det
17	concomitantly	concomitantly	RB	_	18	advmod
18	administered	administer	VBN	_	19	amod
19	drug	drug	NN	_	14	nmod
20	.	.	.	_	12	punct

1	Should	should	MD	_	3	aux
2	this	this	DT	_	3	nsubj
3	occur	occur	VB	_	0	ROOT
4	,	,	,	_	3	punct
5	the	the	DT	_	8	det
6	higher	higher	JJR	_	8	amod
7	serum	serum	NN	_	8	compound
8	concentrations	concentration	NNS	_	13	nsubj
9	of	of	IN	_	11	case
10	that	that	DT	_	11	det
11	drug	drug	NN	_	8	nmod
12	may	may	MD	_	13	aux
13	result	result	VB	_	3	ccomp
14	in	in	IN	_	19	case
15	increased	increase	VBN	_	19	amod
16	pharmacologic	pharmacologic	JJ	_	19	amod
17	or	or	CC	_	16	cc
18	adverse	adverse	JJ	_	16	conj
19	effects	effect	NNS	_	13	nmod
20	of	of	IN	_	22	case
21	that	that	DT	_	22	det
22	drug	drug	NN	_	19	nmod
23	.	.	.	_	3	punct

1	Such	such	JJ	_	2	amod
2	occurrences	occurrence	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	propoxyphene	propoxyphene	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	administered	administer	VBN	_	5	advcl
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	13	case
13	antidepressants	antidepressant	NNS	_	11	nmod
14	,	,	,	_	13	punct
15	anticonvulsants	anticonvulsant	NNS	_	13	conj
16	,	,	,	_	13	punct
17	or	or	CC	_	13	cc
18	warfarin	warfarin	NN	_	13	conj
19	-	-	:	_	9	punct
20	like	like	IN	_	21	case
21	drugs	drug	NNS	_	9	nmod
22	.	.	.	_	5	punct

1	Sever	sever	VB	_	0	ROOT
2	neurologic	neurologic	JJ	_	3	amod
3	signs	sign	NNS	_	9	nsubj
4	,	,	,	_	3	punct
5	including	include	VBG	_	6	case
6	coma	coma	NN	_	3	nmod
7	,	,	,	_	3	punct
8	have	have	VBP	_	9	aux
9	occurred	occur	VBN	_	1	ccomp
10	with	with	IN	_	12	case
11	concurrent	concurrent	JJ	_	12	amod
12	use	use	NN	_	9	nmod
13	of	of	IN	_	14	case
14	carbamazepine	carbamazepine	NN	_	12	nmod
15	.	.	.	_	1	punct

1	Reduced	reduce	VBN	_	2	amod
2	absorption	absorption	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	folic	folic	JJ	_	5	amod
5	acid	acid	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	digoxin	digoxin	NN	_	5	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	when	when	WRB	_	15	advmod
12	those	those	DT	_	13	det
13	agents	agent	NNS	_	15	nsubjpass
14	were	be	VBD	_	15	auxpass
15	administered	administer	VBN	_	10	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	with	with	IN	_	18	case
18	sulfasalazine	sulfasalazine	NN	_	15	nmod
19	.	.	.	_	10	punct

1	When	when	WRB	_	16	advmod
2	daily	daily	JJ	_	3	amod
3	doses	dose	NNS	_	16	nsubjpass
4	of	of	IN	_	7	case
5	sulfasalazine	sulfasalazine	NN	_	7	compound
6	2	2	CD	_	7	nummod
7	g	g	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	weekly	weekly	JJ	_	10	amod
10	doses	dose	NNS	_	7	conj
11	of	of	IN	_	14	case
12	methotrexate	methotrexate	NN	_	14	compound
13	7.5	7.5	CD	_	14	nummod
14	mg	mg	NN	_	10	nmod
15	were	be	VBD	_	16	auxpass
16	coadministered	coadminister	VBN	_	38	advcl
17	to	to	TO	_	21	case
18	15	15	CD	_	21	nummod
19	rheumatoid	rheumatoid	JJ	_	21	amod
20	arthritis	arthritis	NN	_	21	compound
21	patients	patient	NNS	_	16	nmod
22	in	in	IN	_	28	case
23	a	a	DT	_	28	det
24	drug	drug	NN	_	28	compound
25	-	-	:	_	28	punct
26	drug	drug	NN	_	28	compound
27	interaction	interaction	NN	_	28	compound
28	study	study	NN	_	21	nmod
29	,	,	,	_	38	punct
30	the	the	DT	_	32	det
31	pharmacokinetic	pharmacokinetic	JJ	_	32	amod
32	disposition	disposition	NN	_	38	nsubjpass
33	of	of	IN	_	35	case
34	the	the	DT	_	35	det
35	drugs	drug	NNS	_	32	nmod
36	was	be	VBD	_	38	auxpass
37	not	not	RB	_	38	neg
38	altered	alter	VBN	_	0	ROOT
39	.	.	.	_	38	punct

1	Daily	Daily	NNP	_	2	compound
2	doses	dose	NNS	_	25	nsubjpass
3	of	of	IN	_	6	case
4	sulfasalazine	sulfasalazine	NN	_	6	compound
5	2	2	CD	_	6	nummod
6	g	g	NN	_	2	nmod
7	(	(	CD	_	11	nummod
8	maximum	maximum	NN	_	11	compound
9	3	3	CD	_	11	nummod
10	g	g	NN	_	11	compound
11	)	)	NN	_	6	dep
12	and	and	CC	_	6	cc
13	weekly	weekly	JJ	_	14	amod
14	doses	dose	NNS	_	6	conj
15	of	of	IN	_	23	case
16	methotrexate	methotrexate	NN	_	23	compound
17	7.5	7.5	CD	_	18	compound
18	mg	mg	NN	_	23	amod
19	(	(	NN	_	23	compound
20	maximum	maximum	NN	_	23	compound
21	15	15	CD	_	22	compound
22	mg	mg	NN	_	23	amod
23	)	)	NN	_	14	nmod
24	were	be	VBD	_	25	auxpass
25	administered	administer	VBN	_	0	ROOT
26	alone	alone	RB	_	25	advmod
27	or	or	CC	_	25	cc
28	in	in	IN	_	29	case
29	combination	combination	NN	_	25	conj
30	to	to	TO	_	34	case
31	310	310	CD	_	34	nummod
32	rheumatoid	rheumatoid	JJ	_	34	amod
33	arthritis	arthritis	NN	_	34	compound
34	patients	patient	NNS	_	29	nmod
35	in	in	IN	_	42	case
36	two	two	CD	_	42	nummod
37	controlled	controlled	JJ	_	42	amod
38	52	52	CD	_	42	nummod
39	-	-	:	_	42	punct
40	week	week	NN	_	42	compound
41	clinical	clinical	JJ	_	42	amod
42	studies	study	NNS	_	34	nmod
43	.	.	.	_	25	punct

1	The	the	DT	_	4	det
2	overall	overall	JJ	_	4	amod
3	toxicity	toxicity	NN	_	4	compound
4	profile	profile	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	combination	combination	NN	_	4	nmod
8	revealed	reveal	VBD	_	0	ROOT
9	an	a	DT	_	11	det
10	increased	increase	VBN	_	11	amod
11	incidence	incidence	NN	_	8	dobj
12	of	of	IN	_	15	case
13	gastrointestinal	gastrointestinal	JJ	_	15	amod
14	adverse	adverse	JJ	_	15	amod
15	events	event	NNS	_	11	nmod
16	,	,	,	_	15	punct
17	especially	especially	RB	_	18	advmod
18	nausea	nausea	NN	_	15	appos
19	,	,	,	_	15	punct
20	when	when	WRB	_	21	advmod
21	compared	compare	VBN	_	8	advcl
22	to	to	TO	_	24	case
23	the	the	DT	_	24	det
24	incidence	incidence	NN	_	21	nmod
25	associated	associate	VBN	_	24	acl
26	with	with	IN	_	28	case
27	either	either	CC	_	28	det
28	drug	drug	NN	_	25	nmod
29	administered	administer	VBN	_	28	acl
30	alone	alone	RB	_	29	advmod
31	.	.	.	_	8	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	The	the	DT	_	8	det
8	presence	presence	NN	_	20	nsubjpass
9	of	of	IN	_	10	case
10	sulfasalazine	sulfasalazine	NN	_	8	nmod
11	or	or	CC	_	10	cc
12	its	its	PRP$	_	13	nmod:poss
13	metabolites	metabolite	NNS	_	10	conj
14	in	in	IN	_	16	case
15	body	body	NN	_	16	compound
16	fluids	fluid	NNS	_	8	nmod
17	has	have	VBZ	_	20	aux
18	not	not	RB	_	20	neg
19	been	be	VBN	_	20	auxpass
20	reported	report	VBN	_	5	dep
21	to	to	TO	_	22	mark
22	interfere	interfere	VB	_	20	xcomp
23	with	with	IN	_	26	case
24	laboratory	laboratory	NN	_	26	compound
25	test	test	NN	_	26	compound
26	procedures	procedure	NNS	_	22	nmod
27	.	.	.	_	20	punct

1	REFERENCES	reference	NNS	_	0	ROOT
2	7	7	CD	_	1	nummod
3	.	.	.	_	1	punct
4	Farr	Farr	NNP	_	5	compound
5	M	m	NN	_	1	dep
6	,	,	,	_	5	punct
7	et	et	FW	_	8	compound
8	al	al	FW	_	5	appos
9	.	.	.	_	1	punct

1	Immunodeficiencies	immunodeficiency	NNS	_	0	ROOT
2	associated	associate	VBN	_	1	acl
3	with	with	IN	_	5	case
4	sulphasalazine	sulphasalazine	NN	_	5	compound
5	therapy	therapy	NN	_	2	nmod
6	in	in	IN	_	8	case
7	inflammatory	inflammatory	JJ	_	8	amod
8	arthritis	arthritis	NN	_	5	nmod
9	.	.	.	_	1	punct

1	British	british	JJ	_	3	amod
2	Jnl	jnl	NN	_	3	compound
3	Rheum	Rheum	NNP	_	0	ROOT
4	1991	1991	CD	_	3	nummod
5	;	;	:	_	3	punct
6	30	30	CD	_	3	nummod
7	:	:	:	_	3	punct
8	413	413	CD	_	3	dep
9	-	-	:	_	3	punct
10	417	417	CD	_	3	dep
11	.	.	.	_	3	punct

1	Digoxin	Digoxin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	4	expl
4	was	be	VBD	_	1	dep
5	a	a	DT	_	7	det
6	slight	slight	JJ	_	7	amod
7	increase	increase	NN	_	4	nsubj
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	area	area	NN	_	7	nmod
11	under	under	IN	_	15	case
12	the	the	DT	_	15	det
13	curve	curve	NN	_	15	compound
14	(	(	CD	_	15	nummod
15	AUC	auc	NN	_	7	nmod
16	,	,	,	_	7	punct
17	11	11	CD	_	18	nummod
18	%	%	NN	_	7	conj
19	)	)	CD	_	18	nummod
20	and	and	CC	_	7	cc
21	mean	mean	VB	_	7	conj
22	peak	peak	JJ	_	24	amod
23	drug	drug	NN	_	24	compound
24	concentration	concentration	NN	_	21	dobj
25	(	(	CD	_	26	nummod
26	Cmax	Cmax	NNP	_	24	dep
27	,	,	,	_	4	punct
28	18	18	CD	_	29	nummod
29	%	%	NN	_	4	nsubj
30	)	)	CD	_	29	nummod
31	of	of	IN	_	32	case
32	digoxin	digoxin	NN	_	29	nmod
33	with	with	IN	_	35	case
34	the	the	DT	_	35	det
35	co	co	NN	_	29	nmod
36	-	-	:	_	29	punct
37	administration	administration	NN	_	29	dep
38	of	of	IN	_	41	case
39	100	100	CD	_	40	compound
40	mg	mg	NN	_	41	amod
41	sitagliptin	sitagliptin	NN	_	37	nmod
42	for	for	IN	_	44	case
43	10	10	CD	_	44	nummod
44	days	day	NNS	_	37	nmod
45	.	.	.	_	1	punct

1	Patients	patient	NNS	_	6	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	digoxin	digoxin	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	appropriately	appropriately	RB	_	6	advmod
8	.	.	.	_	6	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	digoxin	digoxin	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	JANUVIA	januvia	NN	_	5	conj
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	While	while	IN	_	7	mark
2	co	co	NN	_	4	compound
3	-	-	:	_	4	punct
4	administration	administration	NN	_	7	nsubj
5	of	of	IN	_	6	case
6	ZAVESCA	zavesca	NN	_	4	nmod
7	appeared	appear	VBD	_	22	advcl
8	to	to	TO	_	9	mark
9	increase	increase	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	clearance	clearance	NN	_	9	dobj
12	of	of	IN	_	13	case
13	Cerezyme	Cerezyme	NNP	_	11	nmod
14	by	by	IN	_	16	case
15	70	70	CD	_	16	nummod
16	%	%	NN	_	9	nmod
17	,	,	,	_	22	punct
18	these	these	DT	_	19	det
19	results	result	NNS	_	22	nsubj
20	are	be	VBP	_	22	cop
21	not	not	RB	_	22	neg
22	conclusive	conclusive	JJ	_	0	ROOT
23	because	because	IN	_	27	case
24	of	of	IN	_	23	mwe
25	the	the	DT	_	27	det
26	small	small	JJ	_	27	amod
27	number	number	NN	_	22	nmod
28	of	of	IN	_	29	case
29	subjects	subject	NNS	_	27	nmod
30	studied	study	VBN	_	29	acl
31	and	and	CC	_	22	cc
32	because	because	IN	_	34	mark
33	patients	patient	NNS	_	34	nsubj
34	took	take	VBD	_	22	conj
35	variable	variable	JJ	_	36	amod
36	doses	dose	NNS	_	34	dobj
37	of	of	IN	_	38	case
38	Cerezyme	Cerezyme	NNP	_	36	nmod
39	.	.	.	_	22	punct

1	Combination	combination	NN	_	2	compound
2	therapy	therapy	NN	_	12	nsubjpass
3	with	with	IN	_	7	case
4	Cerezyme	Cerezyme	NNP	_	7	compound
5	(	(	CD	_	7	nummod
6	imiglucerase	imiglucerase	NN	_	7	compound
7	)	)	NN	_	2	nmod
8	and	and	CC	_	7	cc
9	ZAVESCA	zavesca	NN	_	7	conj
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	indicated	indicate	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Methysergide	Methysergide	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	reverse	reverse	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	analgesic	analgesic	JJ	_	6	amod
6	activity	activity	NN	_	3	dobj
7	of	of	IN	_	9	case
8	narcotic	narcotic	JJ	_	9	amod
9	analgesics	analgesic	NNS	_	6	nmod
10	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	0	ROOT
3	with	with	IN	_	5	case
4	vasoconstrictor	vasoconstrictor	NN	_	5	compound
5	agents	agent	NNS	_	2	nmod
6	including	include	VBG	_	8	case
7	ergot	ergot	NN	_	8	compound
8	alkaloids	alkaloid	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	sumatriptan	sumatriptan	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	nicotine	nicotine	NN	_	14	compound
14	(	(	NN	_	8	conj
15	e	e	LS	_	20	dep
16	.	.	.	_	15	punct
17	g	g	NN	_	20	compound
18	.	.	.	_	20	punct
19	smoking	smoking	NN	_	20	compound
20	)	)	NN	_	22	nsubj
21	may	may	MD	_	22	aux
22	result	result	VB	_	2	acl:relcl
23	in	in	IN	_	25	case
24	enhanced	enhance	VBN	_	25	amod
25	vasoconstriction	vasoconstriction	NN	_	22	nmod
26	.	.	.	_	2	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	7	case
3	Vitamin	vitamin	NN	_	7	compound
4	B1	b1	NN	_	7	compound
5	(	(	CD	_	7	nummod
6	Thiamine	thiamine	NN	_	7	compound
7	)	)	NN	_	1	nmod
8	:	:	:	_	1	punct
9	Loop	Loop	NNP	_	10	compound
10	Diuretics	Diuretics	NNP	_	1	dep
11	,	,	,	_	10	punct
12	Oral	Oral	NNP	_	13	compound
13	Contraceptives	Contraceptives	NNP	_	10	conj
14	,	,	,	_	10	punct
15	Stavudine	Stavudine	NNP	_	10	conj
16	,	,	,	_	10	punct
17	Tricyclic	tricyclic	JJ	_	18	amod
18	Antidepressants	antidepressant	NNS	_	10	appos

1	Interactions	interaction	NNS	_	11	nsubj
2	for	for	IN	_	4	case
3	Vitamin	vitamin	NN	_	4	compound
4	B2	b2	NN	_	1	nmod
5	(	(	CD	_	6	nummod
6	Riboflavin	Riboflavin	NNP	_	4	dep
7	)	)	CD	_	6	nummod
8	:	:	:	_	6	punct
9	Alcohol	alcohol	NN	_	6	dep
10	-	-	:	_	6	punct
11	impairs	impair	VBZ	_	0	ROOT
12	the	the	DT	_	14	det
13	intestinal	intestinal	JJ	_	14	amod
14	absorption	absorption	NN	_	11	dobj
15	of	of	IN	_	16	case
16	riboflavin	riboflavin	NN	_	14	nmod

1	Probenecid	Probenecid	NNP	_	4	compound
2	-	-	:	_	4	punct
3	concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	5	nsubj
5	decreases	decrease	VBZ	_	0	ROOT
6	gastrointestinal	gastrointestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	riboflavin	riboflavin	NN	_	7	nmod
10	;	;	:	_	5	punct

1	requirements	requirement	NNS	_	6	nsubjpass
2	for	for	IN	_	3	case
3	riboflavin	riboflavin	NN	_	1	nmod
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	probenecid	probenecid	NN	_	9	dobj
11	.	.	.	_	6	punct

1	Mequitazine	Mequitazine	NNP	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	CNS	cns	NN	_	6	compound
6	depressant	depressant	NN	_	3	nmod
7	,	,	,	_	6	punct
8	antichlolinergic	antichlolinergic	JJ	_	6	conj
9	,	,	,	_	6	punct
10	TCA	TCA	NNP	_	6	conj
11	,	,	,	_	6	punct
12	MAOIs	maoi	NNS	_	6	conj
13	,	,	,	_	6	punct
14	and	and	CC	_	6	cc
15	alcohol	alcohol	NN	_	6	conj
16	.	.	.	_	3	punct

1	Antacids	antacid	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Absorption	absorption	NN	_	11	nsubjpass
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	single	single	JJ	_	7	amod
7	dose	dose	NN	_	3	nmod
8	of	of	IN	_	9	case
9	Myfortic	Myfortic	NNP	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	decreased	decrease	VBN	_	1	appos
12	when	when	WRB	_	13	advmod
13	administered	administer	VBN	_	11	advcl
14	to	to	TO	_	19	case
15	12	12	CD	_	19	nummod
16	stable	stable	JJ	_	19	amod
17	renal	renal	JJ	_	19	amod
18	transplant	transplant	NN	_	19	compound
19	patients	patient	NNS	_	13	nmod
20	also	also	RB	_	21	advmod
21	taking	take	VBG	_	13	xcomp
22	magnesium	magnesium	NN	_	27	dep
23	-	-	:	_	27	punct
24	aluminum	aluminum	NN	_	27	nsubj
25	containing	contain	VBG	_	24	acl
26	antacids	antacid	NNS	_	25	dobj
27	(	(	VBP	_	21	dobj
28	30	30	CD	_	29	nummod
29	mL	ml	NN	_	27	dobj
30	)	)	CD	_	29	nummod
31	:	:	:	_	27	punct
32	the	the	DT	_	34	det
33	mean	mean	NN	_	34	compound
34	Cmax	cmax	NN	_	47	nsubj
35	and	and	CC	_	34	cc
36	AUC	auc	NN	_	34	conj
37	(	(	CD	_	38	compound
38	0	0	CD	_	36	nummod
39	-	-	:	_	36	punct
40	t	t	NN	_	42	compound
41	)	)	NN	_	42	compound
42	values	value	NNS	_	36	conj
43	for	for	IN	_	44	case
44	MPA	MPA	NNP	_	42	nmod
45	were	be	VBD	_	47	cop
46	25	25	CD	_	47	nummod
47	%	%	NN	_	27	parataxis
48	and	and	CC	_	47	cc
49	37	37	CD	_	50	nummod
50	%	%	NN	_	47	conj
51	lower	lower	JJR	_	47	advmod
52	,	,	,	_	47	punct
53	respectively	respectively	RB	_	47	advmod
54	,	,	,	_	47	punct
55	than	than	IN	_	59	mark
56	when	when	WRB	_	59	advmod
57	Myfortic	Myfortic	NNP	_	59	nsubjpass
58	was	be	VBD	_	59	auxpass
59	administered	administer	VBN	_	47	advcl
60	alone	alone	RB	_	59	advmod
61	under	under	IN	_	63	case
62	fasting	fasting	NN	_	63	compound
63	conditions	condition	NNS	_	59	nmod
64	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	10	mark
5	Myfortic	myfortic	JJ	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	antacids	antacid	NNS	_	5	conj
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	3	ccomp
11	simultaneously	simultaneously	RB	_	10	advmod
12	.	.	.	_	3	punct

1	Cyclosporine	cyclosporine	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	4	advmod
4	studied	study	VBN	_	19	advcl
5	in	in	IN	_	9	case
6	stable	stable	JJ	_	9	amod
7	renal	renal	JJ	_	9	amod
8	transplant	transplant	NN	_	9	compound
9	patients	patient	NNS	_	4	nmod
10	,	,	,	_	9	punct
11	cyclosporine	cyclosporine	NN	_	9	conj
12	,	,	,	_	9	punct
13	USP	usp	NN	_	17	compound
14	(	(	CD	_	13	nummod
15	MODIFIED	modify	VBN	_	17	amod
16	)	)	CD	_	17	nummod
17	pharmacokinetics	pharmacokinetic	NNS	_	9	conj
18	were	be	VBD	_	19	aux
19	unaffected	unaffected	JJ	_	1	dep
20	by	by	IN	_	23	case
21	steady	steady	JJ	_	23	amod
22	state	state	NN	_	23	compound
23	dosing	dosing	NN	_	19	nmod
24	of	of	IN	_	25	case
25	Myfortic	myfortic	JJ	_	23	nmod
26	.	.	.	_	1	punct

1	Acyclovir	acyclovir	NN	_	3	compound
2	/	/	:	_	3	punct
3	Ganciclovir	Ganciclovir	NNP	_	0	ROOT
4	:	:	:	_	3	punct
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	taken	take	VBN	_	3	dep
8	with	with	IN	_	9	case
9	Myfortic	myfortic	JJ	_	7	nmod
10	;	;	:	_	3	punct

1	however	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	during	during	IN	_	5	case
4	the	the	DT	_	5	det
5	period	period	NN	_	11	nmod
6	of	of	IN	_	7	case
7	treatment	treatment	NN	_	5	nmod
8	,	,	,	_	11	punct
9	physicians	physician	NNS	_	11	nsubj
10	should	should	MD	_	11	aux
11	monitor	monitor	VB	_	0	ROOT
12	blood	blood	NN	_	14	compound
13	cell	cell	NN	_	14	compound
14	counts	count	NNS	_	11	dobj
15	.	.	.	_	11	punct

1	Both	both	DT	_	2	cc:preconj
2	acyclovir	acyclovir	NN	_	0	ROOT
3	/	/	:	_	2	punct
4	ganciclovir	ganciclovir	NN	_	7	compound
5	and	and	CC	_	4	cc
6	MPAG	mpag	NN	_	4	conj
7	concentrations	concentration	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	increased	increase	VBN	_	2	dep
10	in	in	IN	_	15	case
11	the	the	DT	_	15	dep
12	presence	presence	NN	_	15	dep
13	of	of	IN	_	15	case
14	renal	renal	JJ	_	15	amod
15	impairment	impairment	NN	_	9	nmod
16	,	,	,	_	9	punct
17	their	they	PRP$	_	18	nmod:poss
18	coexistence	coexistence	NN	_	20	nsubj
19	may	may	MD	_	20	aux
20	compete	compete	VB	_	9	parataxis
21	for	for	IN	_	23	case
22	tubular	tubular	JJ	_	23	amod
23	secretion	secretion	NN	_	20	nmod
24	and	and	CC	_	20	cc
25	further	further	JJ	_	26	amod
26	increase	increase	NN	_	20	conj
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	concentrations	concentration	NNS	_	26	nmod
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	two	two	CD	_	29	nmod
33	.	.	.	_	2	punct

1	Azathioprine	Azathioprine	NNP	_	4	compound
2	/	/	:	_	4	punct
3	Mycophenolate	Mycophenolate	NNP	_	4	compound
4	Mofetil	Mofetil	NNP	_	0	ROOT
5	:	:	:	_	4	punct
6	Given	give	VBN	_	12	mark
7	that	that	IN	_	12	mark
8	azathioprine	azathioprine	NN	_	12	nsubj
9	and	and	CC	_	8	cc
10	mycophenolate	mycophenolate	JJ	_	8	conj
11	mofetil	mofetil	NN	_	8	dep
12	inhibit	inhibit	VBP	_	18	advcl
13	purine	purine	NN	_	14	compound
14	metabolism	metabolism	NN	_	12	dobj
15	,	,	,	_	18	punct
16	it	it	PRP	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	recommended	recommend	VBN	_	4	dep
19	that	that	IN	_	23	mark
20	Myfortic	Myfortic	NNP	_	23	nsubjpass
21	not	not	RB	_	23	neg
22	be	be	VB	_	23	auxpass
23	administered	administer	VBN	_	18	ccomp
24	concomitantly	concomitantly	RB	_	23	advmod
25	with	with	IN	_	26	case
26	azathioprine	azathioprine	NN	_	23	nmod
27	or	or	CC	_	26	cc
28	mycophenolate	mycophenolate	JJ	_	29	amod
29	mofetil	mofetil	NN	_	26	conj
30	.	.	.	_	4	punct

1	Cholestyramine	cholestyramine	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Drugs	drug	NNS	_	1	conj
4	that	that	WDT	_	5	nsubj
5	Bind	bind	VB	_	1	acl:relcl
6	Bile	Bile	NNP	_	7	compound
7	Acids	Acids	NNPS	_	5	dobj
8	:	:	:	_	1	punct
9	These	these	DT	_	10	det
10	drugs	drug	NNS	_	11	nsubj
11	interrupt	interrupt	VBP	_	1	dep
12	enterohepatic	enterohepatic	JJ	_	13	amod
13	recirculation	recirculation	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	reduce	reduce	VB	_	11	conj
16	MPA	MPA	NNP	_	17	compound
17	exposure	exposure	NN	_	15	dobj
18	when	when	WRB	_	19	advmod
19	coadministered	coadminister	VBN	_	11	advcl
20	with	with	IN	_	22	case
21	mycophenolate	mycophenolate	JJ	_	22	amod
22	mofetil	mofetil	NN	_	19	nmod
23	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	administer	administer	VB	_	0	ROOT
6	Myfortic	myfortic	JJ	_	5	dobj
7	with	with	IN	_	8	case
8	cholestyramine	cholestyramine	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	other	other	JJ	_	11	amod
11	agents	agent	NNS	_	8	conj
12	that	that	WDT	_	14	nsubj
13	may	may	MD	_	14	aux
14	interfere	interfere	VB	_	6	acl:relcl
15	with	with	IN	_	17	case
16	enterohepatic	enterohepatic	JJ	_	17	amod
17	recirculation	recirculation	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	drugs	drug	NNS	_	17	conj
20	that	that	WDT	_	22	nsubj
21	may	may	MD	_	22	aux
22	bind	bind	VB	_	17	acl:relcl
23	bile	bile	NN	_	24	compound
24	acids	acid	NNS	_	22	dobj
25	,	,	,	_	14	punct
26	for	for	IN	_	30	case
27	example	example	NN	_	30	compound
28	bile	bile	NN	_	30	compound
29	acid	acid	NN	_	30	compound
30	sequestrates	sequestrate	NNS	_	14	nmod
31	or	or	CC	_	30	cc
32	oral	oral	JJ	_	34	amod
33	activated	activate	VBN	_	34	amod
34	charcoal	charcoal	NN	_	30	conj
35	,	,	,	_	14	punct
36	because	because	IN	_	39	case
37	of	of	IN	_	36	mwe
38	the	the	DT	_	39	det
39	potential	potential	JJ	_	14	nmod
40	to	to	TO	_	41	mark
41	reduce	reduce	VB	_	39	acl
42	the	the	DT	_	43	det
43	efficacy	efficacy	NN	_	41	dobj
44	of	of	IN	_	45	case
45	Myfortic	myfortic	JJ	_	43	nmod
46	.	.	.	_	5	punct

1	Oral	oral	JJ	_	2	amod
2	Contraceptives	contraceptive	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Given	give	VBN	_	7	case
5	the	the	DT	_	7	det
6	different	different	JJ	_	7	amod
7	metabolism	metabolism	NN	_	24	nsubjpass
8	of	of	IN	_	12	case
9	Myfortic	myfortic	JJ	_	12	amod
10	and	and	CC	_	9	cc
11	oral	oral	JJ	_	9	conj
12	contraceptives	contraceptive	NNS	_	7	nmod
13	,	,	,	_	7	punct
14	no	no	DT	_	16	neg
15	drug	drug	NN	_	16	compound
16	interaction	interaction	NN	_	7	appos
17	between	between	IN	_	20	case
18	these	these	DT	_	20	det
19	two	two	CD	_	20	nummod
20	classes	class	NNS	_	16	nmod
21	of	of	IN	_	22	case
22	drug	drug	NN	_	20	nmod
23	is	be	VBZ	_	24	auxpass
24	expected	expect	VBN	_	2	dep
25	.	.	.	_	2	punct

1	However	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	in	in	IN	_	9	case
4	a	a	DT	_	9	det
5	drug	drug	NN	_	9	compound
6	-	-	:	_	9	punct
7	drug	drug	NN	_	9	compound
8	interaction	interaction	NN	_	9	compound
9	study	study	NN	_	11	nmod
10	,	,	,	_	11	punct
11	mean	mean	VB	_	0	ROOT
12	levonorgesterol	levonorgesterol	NN	_	13	compound
13	AUC	auc	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	decreased	decrease	VBN	_	11	ccomp
16	by	by	IN	_	18	case
17	15	15	CD	_	18	nummod
18	%	%	NN	_	15	nmod
19	when	when	WRB	_	20	advmod
20	coadministered	coadminister	VBN	_	15	advcl
21	with	with	IN	_	23	case
22	mycophenolate	mycophenolate	JJ	_	23	amod
23	mofetil	mofetil	NN	_	20	nmod
24	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	that	that	IN	_	10	mark
7	oral	oral	JJ	_	8	amod
8	contraceptives	contraceptive	NNS	_	10	nsubj
9	are	be	VBP	_	10	cop
10	co	co	SYM	_	5	ccomp
11	-	-	:	_	10	punct
12	administered	administer	VBN	_	23	csubjpass
13	with	with	IN	_	14	case
14	Myfortic	myfortic	JJ	_	12	nmod
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	additional	additional	JJ	_	21	amod
19	birth	birth	NN	_	21	compound
20	control	control	NN	_	21	compound
21	methods	method	NNS	_	16	conj
22	be	be	VB	_	23	auxpass
23	considered	consider	VBN	_	10	parataxis
24	.	.	.	_	5	punct

1	Live	live	VB	_	0	ROOT
2	Vaccines	vaccine	NNS	_	1	dobj
3	:	:	:	_	1	punct
4	During	during	IN	_	5	case
5	treatment	treatment	NN	_	1	nmod
6	with	with	IN	_	7	case
7	Myfortic	myfortic	JJ	_	5	nmod
8	,	,	,	_	5	punct
9	the	the	DT	_	10	det
10	use	use	NN	_	17	nsubjpass
11	of	of	IN	_	14	case
12	live	live	JJ	_	14	amod
13	attenuated	attenuate	VBN	_	14	amod
14	vaccines	vaccine	NNS	_	10	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	avoided	avoid	VBN	_	5	acl:relcl
18	and	and	CC	_	17	cc
19	patients	patient	NNS	_	22	nsubjpass
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	advised	advise	VBN	_	17	conj
23	that	that	IN	_	28	mark
24	vaccinations	vaccination	NNS	_	28	nsubj
25	may	may	MD	_	28	aux
26	be	be	VB	_	28	cop
27	less	less	RBR	_	28	advmod
28	effective	effective	JJ	_	17	ccomp
29	.	.	.	_	1	punct

1	Influenza	influenza	NN	_	2	compound
2	vaccination	vaccination	NN	_	6	nsubj
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	of	of	IN	_	6	case
6	value	value	NN	_	0	ROOT
7	.	.	.	_	6	punct

1	Prescribers	prescriber	NNS	_	3	nsubj
2	should	should	MD	_	3	aux
3	refer	refer	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	national	national	JJ	_	6	amod
6	guidelines	guideline	NNS	_	3	nmod
7	for	for	IN	_	9	case
8	influenza	influenza	NN	_	9	compound
9	vaccination	vaccination	NN	_	6	nmod
10	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	8	nsubj
2	that	that	WDT	_	3	nsubj
3	alter	alter	VBP	_	1	acl:relcl
4	the	the	DT	_	6	det
5	gastrointestinal	gastrointestinal	JJ	_	6	amod
6	flora	flora	NN	_	3	dobj
7	may	may	MD	_	8	aux
8	interact	interact	VB	_	0	ROOT
9	with	with	IN	_	10	case
10	Myfortic	myfortic	JJ	_	8	nmod
11	by	by	IN	_	12	mark
12	disrupting	disrupt	VBG	_	8	advcl
13	enterohepatic	enterohepatic	JJ	_	14	amod
14	recirculation	recirculation	NN	_	12	dobj
15	.	.	.	_	8	punct

1	Interference	interference	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	MPAG	mpag	NN	_	4	compound
4	hydrolysis	hydrolysis	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	lead	lead	VB	_	0	ROOT
7	to	to	TO	_	9	case
8	less	less	JJR	_	9	amod
9	MPA	mpa	NN	_	6	nmod
10	available	available	JJ	_	9	amod
11	for	for	IN	_	12	case
12	absorption	absorption	NN	_	10	nmod
13	.	.	.	_	6	punct

1	SPIRIVA	SPIRIVA	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	commonly	commonly	RB	_	10	advmod
10	used	use	VBN	_	8	acl
11	in	in	IN	_	12	case
12	COPD	copd	NN	_	10	nmod
13	without	without	IN	_	14	case
14	increases	increase	NNS	_	10	nmod
15	in	in	IN	_	18	case
16	adverse	adverse	JJ	_	18	amod
17	drug	drug	NN	_	18	compound
18	reactions	reaction	NNS	_	14	nmod
19	.	.	.	_	4	punct

1	These	these	DT	_	2	nsubj
2	include	include	VBP	_	0	ROOT
3	sympathomimetic	sympathomimetic	JJ	_	4	amod
4	bronchodilators	bronchodilator	NNS	_	2	dobj
5	,	,	,	_	4	punct
6	methylxanthines	methylxanthine	NNS	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	oral	oral	JJ	_	12	amod
10	and	and	CC	_	9	cc
11	inhaled	inhale	VBD	_	9	conj
12	steroids	steroid	NNS	_	4	conj
13	.	.	.	_	2	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	5	det
4	co	co	NN	_	5	compound
5	administration	administration	NN	_	2	root
6	of	of	IN	_	7	case
7	SPIRIVA	spiriva	NN	_	5	nmod
8	with	with	IN	_	5	acl
9	other	other	JJ	_	8	advmod
10	anticholinergic	anticholinergic	JJ	_	9	dep
11	containing	contain	VBG	_	10	dep
12	drugs	drug	NNS	_	11	dobj
13	(	(	CD	_	12	nummod
14	e	e	LS	_	24	dep
15	.	.	.	_	14	punct
16	g	g	NN	_	24	dep
17	.	.	.	_	16	punct
18	,	,	,	_	24	punct
19	ipratropium	ipratropium	NN	_	20	compound
20	)	)	NN	_	24	nsubjpass
21	has	have	VBZ	_	24	aux
22	not	not	RB	_	24	neg
23	been	be	VBN	_	24	auxpass
24	studied	study	VBN	_	12	dep
25	and	and	CC	_	24	cc
26	is	be	VBZ	_	29	auxpass
27	therefore	therefore	RB	_	29	advmod
28	not	not	RB	_	29	neg
29	recommended	recommend	VBN	_	24	conj
30	.	.	.	_	5	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	7	case
3	Other	other	JJ	_	7	amod
4	Central	Central	NNP	_	7	compound
5	Nervous	Nervous	NNP	_	7	compound
6	System	System	NNP	_	7	compound
7	Depressants	Depressants	NNPS	_	1	nmod
8	:	:	:	_	1	punct
9	MEPERIDINE	MEPERIDINE	NNP	_	11	nsubj
10	SHOULD	should	MD	_	11	aux
11	BE	be	VB	_	1	parataxis
12	USED	USED	NNP	_	11	dobj
13	WITH	with	IN	_	15	case
14	GREAT	great	JJ	_	15	amod
15	CAUTION	caution	NN	_	12	nmod
16	AND	and	CC	_	12	cc
17	IN	in	IN	_	19	case
18	REDUCED	REDUCED	NNP	_	19	compound
19	DOSAGE	DOSAGE	NNP	_	12	conj
20	IN	in	IN	_	21	case
21	PATIENTS	patient	NNS	_	19	nmod
22	WHO	who	WP	_	25	nsubj
23	ARE	be	VBP	_	25	aux
24	CONCURRENTLY	concurrently	RB	_	25	advmod
25	RECEIVING	receive	VBG	_	21	acl:relcl
26	OTHER	other	JJ	_	28	amod
27	NARCOTIC	narcotic	NN	_	28	compound
28	ANALGESICS	analgesics	NN	_	25	dobj
29	,	,	,	_	11	punct
30	GENERAL	GENERAL	NNP	_	31	compound
31	ANESTHETICS	ANESTHETICS	NNP	_	11	dep
32	,	,	,	_	31	punct
33	PHENOTHIAZINES	PHENOTHIAZINES	NNP	_	31	conj
34	,	,	,	_	31	punct
35	OTHER	OTHER	NNP	_	36	compound
36	TRANQUILIZERS	TRANQUILIZERS	NNP	_	31	conj
37	,	,	,	_	31	punct
38	SEDATIVE	SEDATIVE	NNP	_	31	appos
39	-	-	:	_	31	punct
40	HYPNOTICS	hypnotics	NN	_	43	compound
41	(	(	CD	_	43	nummod
42	INCLUDING	INCLUDING	NNP	_	43	compound
43	BARBITURATES	BARBITURATES	NNP	_	52	nsubj
44	)	)	CD	_	43	nummod
45	,	,	,	_	43	punct
46	TRICYCLIC	tricyclic	JJ	_	47	amod
47	ANTIDEPRESSANTS	antidepressant	NNS	_	43	appos
48	AND	and	CC	_	47	cc
49	OTHER	other	NN	_	51	compound
50	CNS	cns	NN	_	51	compound
51	DEPRESSANTS	depressant	NNS	_	47	conj
52	(	(	VBP	_	31	acl:relcl
53	INCLUDING	include	VBG	_	52	xcomp
54	ALCOHOL	ALCOHOL	NNP	_	53	dobj
55	)	)	CD	_	54	nummod
56	.	.	.	_	1	punct

1	RESPIRATORY	respiratory	JJ	_	2	amod
2	DEPRESSION	depression	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	HYPOTENSION	hypotension	NN	_	2	conj
5	,	,	,	_	2	punct
6	AND	and	CC	_	2	cc
7	PROFOUND	profound	JJ	_	12	amod
8	SEDATION	sedation	NN	_	12	compound
9	OR	or	NN	_	12	compound
10	COMA	COMA	NNP	_	12	compound
11	MAY	MAY	NNP	_	12	compound
12	RESULT	RESULT	NNP	_	2	conj
13	.	.	.	_	2	punct

1	Drug	drug	NN	_	4	compound
2	-	-	:	_	4	punct
3	Drug	drug	NN	_	4	compound
4	Interactions	interaction	NNS	_	0	ROOT
5	:	:	:	_	4	punct
6	The	the	DT	_	10	det
7	pharmacokinetic	pharmacokinetic	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	pharmacodynamic	pharmacodynamic	JJ	_	7	conj
10	interactions	interaction	NNS	_	24	nsubjpass
11	between	between	IN	_	13	case
12	FLOMAX	FLOMAX	NNP	_	13	compound
13	capsules	capsule	NNS	_	10	nmod
14	and	and	CC	_	13	cc
15	other	other	JJ	_	20	amod
16	alpha	alpha	NN	_	20	compound
17	-	-	:	_	20	punct
18	adrenergic	adrenergic	JJ	_	20	amod
19	blocking	block	VBG	_	20	compound
20	agents	agent	NNS	_	13	conj
21	have	have	VBP	_	24	aux
22	not	not	RB	_	24	neg
23	been	be	VBN	_	24	auxpass
24	determined	determine	VBN	_	4	dep
25	.	.	.	_	24	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	interactions	interaction	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	expected	expect	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	FLOMAX	FLOMAX	NNP	_	9	compound
9	capsules	capsule	NNS	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	NOT	not	RB	_	13	advmod
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	6	conj
14	in	in	IN	_	15	case
15	combination	combination	NN	_	13	nmod
16	with	with	IN	_	22	case
17	other	other	JJ	_	22	amod
18	alpha	alpha	NN	_	22	compound
19	-	-	:	_	22	punct
20	adrenergic	adrenergic	JJ	_	22	amod
21	blocking	block	VBG	_	22	amod
22	agents	agent	NNS	_	15	nmod
23	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	10	nsubjpass
4	between	between	IN	_	5	case
5	cimetidine	cimetidine	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	FLOMAX	flomax	NN	_	8	compound
8	capsules	capsule	NNS	_	5	conj
9	was	be	VBD	_	10	auxpass
10	investigated	investigate	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	significant	significant	JJ	_	5	amod
5	changes	change	NNS	_	3	dobj
6	in	in	IN	_	9	case
7	tamsulosin	tamsulosin	NN	_	9	compound
8	HCI	hci	NN	_	9	compound
9	clearance	clearance	NN	_	5	nmod
10	(	(	CD	_	11	compound
11	26	26	CD	_	12	dep
12	%	%	NN	_	13	dep
13	decrease	decrease	NN	_	9	dep
14	)	)	NN	_	13	dep
15	and	and	CC	_	14	cc
16	AUC	auc	NN	_	21	compound
17	(	(	CD	_	18	compound
18	44	44	CD	_	19	dep
19	%	%	NN	_	21	dep
20	increase	increase	NN	_	21	compound
21	)	)	NN	_	14	conj
22	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	FLOMAX	FLOMAX	NNP	_	4	compound
4	capsules	capsule	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	caution	caution	NN	_	7	nmod
10	in	in	IN	_	11	case
11	combination	combination	NN	_	7	nmod
12	with	with	IN	_	13	case
13	cimetidine	cimetidine	NN	_	11	nmod
14	,	,	,	_	7	punct
15	particularly	particularly	RB	_	17	advmod
16	at	at	IN	_	17	case
17	doses	dose	NNS	_	7	nmod
18	higher	higher	JJR	_	17	amod
19	than	than	IN	_	21	case
20	0.4	0.4	CD	_	21	nummod
21	mg	mg	NN	_	18	nmod
22	.	.	.	_	7	punct

1	Results	result	NNS	_	20	nsubj
2	from	from	IN	_	13	case
3	limited	limit	VBN	_	13	dep
4	in	in	FW	_	5	compound
5	vitro	vitro	FW	_	6	advmod
6	and	and	CC	_	13	cc
7	in	in	FW	_	9	amod
8	vivo	vivo	FW	_	7	dep
9	drug	drug	NN	_	13	conj
10	-	-	:	_	13	punct
11	drug	drug	NN	_	13	compound
12	interaction	interaction	NN	_	13	compound
13	studies	study	NNS	_	1	nmod
14	between	between	IN	_	16	case
15	tamsulosin	tamsulosin	NN	_	16	compound
16	HCI	hci	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	warfarin	warfarin	NN	_	16	conj
19	are	be	VBP	_	20	cop
20	inconclusive	inconclusive	JJ	_	0	ROOT
21	.	.	.	_	20	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	warfarin	warfarin	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	FLOMAX	flomax	NN	_	14	compound
14	capsules	capsule	NNS	_	11	conj
15	.	.	.	_	6	punct

1	Catecholamine	catecholamine	NN	_	4	compound
2	-	-	:	_	4	punct
3	depleting	deplete	VBG	_	4	amod
4	drugs	drug	NNS	_	6	nsubj
5	(	(	CD	_	4	nummod
6	e	e	LS	_	0	ROOT
7	.	.	.	_	6	punct
8	g	g	NN	_	14	dep
9	.	.	.	_	8	punct
10	,	,	,	_	14	punct
11	reserpine	reserpine	NN	_	12	compound
12	)	)	NN	_	14	nsubj
13	may	may	MD	_	14	aux
14	have	have	VB	_	6	parataxis
15	an	a	DT	_	17	det
16	additive	additive	JJ	_	17	amod
17	effect	effect	NN	_	14	dobj
18	when	when	WRB	_	19	advmod
19	given	give	VBN	_	14	advcl
20	with	with	IN	_	21	case
21	beta	beta	NN	_	19	nmod
22	-	-	:	_	14	punct
23	blocking	block	VBG	_	14	xcomp
24	agents	agent	NNS	_	23	dobj
25	.	.	.	_	6	punct

1	Patients	patient	NNS	_	16	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	7	case
4	extended	extended	JJ	_	7	amod
5	release	release	NN	_	7	compound
6	metoprolol	metoprolol	NN	_	7	compound
7	succinate	succinate	NN	_	2	nmod
8	plus	plus	CC	_	7	cc
9	a	a	DT	_	11	det
10	catecholamine	catecholamine	NN	_	11	compound
11	depletor	depletor	NN	_	7	conj
12	should	should	MD	_	16	aux
13	therefore	therefore	RB	_	16	advmod
14	be	be	VB	_	16	auxpass
15	closely	closely	RB	_	16	advmod
16	observed	observe	VBN	_	0	ROOT
17	for	for	IN	_	18	case
18	evidence	evidence	NN	_	16	nmod
19	of	of	IN	_	20	case
20	hypotension	hypotension	NN	_	18	nmod
21	or	or	CC	_	20	cc
22	marked	marked	JJ	_	23	amod
23	bradycardia	bradycardia	NN	_	20	conj
24	,	,	,	_	18	punct
25	which	which	WDT	_	27	nsubj
26	may	may	MD	_	27	aux
27	produce	produce	VB	_	18	acl:relcl
28	vertigo	vertigo	NN	_	27	dobj
29	,	,	,	_	28	punct
30	syncope	syncope	NN	_	28	conj
31	,	,	,	_	28	punct
32	or	or	CC	_	28	cc
33	postural	postural	JJ	_	34	amod
34	hypotension	hypotension	NN	_	28	conj
35	.	.	.	_	16	punct

1	Concomitant	concomitant	JJ	_	3	amod
2	administration	administration	NN	_	3	compound
3	contra	contra	NN	_	5	nsubj
4	-	-	:	_	5	punct
5	indicated	indicate	VBD	_	0	ROOT
6	:	:	:	_	5	punct
7	-	-	:	_	5	punct
8	Vasoconstrictive	vasoconstrictive	JJ	_	10	amod
9	ergot	ergot	NN	_	10	compound
10	alkaloids	alkaloid	NNS	_	5	dobj
11	.	.	.	_	5	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administrations	administration	NNS	_	0	ROOT
3	not	not	RB	_	4	neg
4	recommended	recommend	VBN	_	2	acl
5	:	:	:	_	2	punct
6	-	-	:	_	2	punct
7	Terfenadine	terfenadine	NN	_	2	dep
8	and	and	CC	_	7	cc
9	astemizole	astemizole	NN	_	7	conj
10	:	:	:	_	2	punct
11	Certain	certain	JJ	_	12	amod
12	macrolides	macrolide	NNS	_	13	nsubj
13	interact	interact	VBP	_	2	dep
14	with	with	IN	_	15	case
15	terfenadine	terfenadine	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	astemizole	astemizole	NN	_	15	conj
18	leading	lead	VBG	_	15	acl
19	to	to	TO	_	22	case
20	increased	increase	VBN	_	22	amod
21	serum	serum	NN	_	22	compound
22	concentrations	concentration	NNS	_	18	nmod
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	latter	latter	JJ	_	22	nmod
26	.	.	.	_	2	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	result	result	VB	_	0	ROOT
4	in	in	IN	_	7	case
5	severe	severe	JJ	_	7	amod
6	ventricular	ventricular	JJ	_	7	amod
7	arrhythmia	arrhythmia	NN	_	3	nmod
8	,	,	,	_	7	punct
9	typically	typically	RB	_	12	advmod
10	torsades	torsades	FW	_	12	compound
11	de	de	FW	_	12	compound
12	pointe	pointe	FW	_	7	appos
13	.	.	.	_	3	punct

1	Although	although	IN	_	8	mark
2	such	such	PDT	_	4	det:predet
3	a	a	DT	_	4	det
4	reaction	reaction	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	demonstrated	demonstrate	VBN	_	22	advcl
9	with	with	IN	_	10	case
10	roxithromycin	roxithromycin	NN	_	8	nmod
11	,	,	,	_	22	punct
12	concomitant	concomitant	JJ	_	13	amod
13	administration	administration	NN	_	22	nsubjpass
14	of	of	IN	_	15	case
15	roxithromycin	roxithromycin	NN	_	13	nmod
16	with	with	IN	_	17	case
17	terfenadine	terfenadine	NN	_	13	nmod
18	or	or	CC	_	17	cc
19	astemizole	astemizole	NN	_	17	conj
20	is	be	VBZ	_	22	auxpass
21	not	not	RB	_	22	neg
22	recommended	recommend	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	-	-	:	_	0	ROOT
2	Cisapride	cisapride	NN	_	1	root
3	,	,	,	_	2	punct
4	pimozide	pimozide	NN	_	3	root
5	:	:	:	_	4	punct
6	Other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	23	nsubjpass
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	cisapride	cisapride	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	pimozide	pimozide	NN	_	10	conj
13	,	,	,	_	7	punct
14	which	which	WDT	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	metabolised	metabolise	VBN	_	7	acl:relcl
17	by	by	IN	_	20	case
18	hepatic	hepatic	JJ	_	20	amod
19	CYP3A	cyp3a	NN	_	20	compound
20	isozymes	isozyme	NNS	_	16	nmod
21	have	have	VBP	_	23	aux
22	been	be	VBN	_	23	auxpass
23	associated	associate	VBN	_	4	dep
24	with	with	IN	_	27	case
25	QT	qt	NN	_	27	compound
26	interval	interval	NN	_	27	compound
27	prolongation	prolongation	NN	_	23	nmod
28	and	and	CC	_	27	cc
29	/	/	:	_	32	punct
30	or	or	CC	_	32	cc
31	cardiac	cardiac	JJ	_	32	amod
32	arrythmias	arrythmia	NNS	_	27	conj
33	(	(	VBP	_	23	xcomp
34	typically	typically	RB	_	35	advmod
35	torsades	torsade	NNS	_	33	dobj
36	de	de	IN	_	38	amod
37	pointe	pointe	FW	_	38	compound
38	)	)	FW	_	35	dobj
39	as	as	IN	_	41	case
40	a	a	DT	_	41	det
41	result	result	NN	_	35	nmod
42	of	of	IN	_	43	case
43	increase	increase	NN	_	41	nmod
44	in	in	IN	_	47	case
45	their	they	PRP$	_	47	nmod:poss
46	serum	serum	NN	_	47	compound
47	level	level	NN	_	43	nmod
48	subsequent	subsequent	JJ	_	43	amod
49	to	to	TO	_	50	case
50	interaction	interaction	NN	_	48	nmod
51	with	with	IN	_	53	case
52	significant	significant	JJ	_	53	amod
53	inhibitors	inhibitor	NNS	_	50	nmod
54	of	of	IN	_	56	case
55	the	the	DT	_	56	det
56	isozyme	isozyme	NN	_	53	nmod
57	,	,	,	_	53	punct
58	including	include	VBG	_	61	case
59	some	some	DT	_	61	det
60	macrolide	macrolide	NN	_	61	compound
61	antibacterials	antibacterial	NNS	_	53	nmod
62	.	.	.	_	4	punct

1	Although	although	IN	_	7	mark
2	such	such	PDT	_	4	det:predet
3	a	a	DT	_	4	det
4	risk	risk	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	verified	verify	VBN	_	19	advcl
8	for	for	IN	_	9	case
9	roxithromycin	roxithromycin	NN	_	7	nmod
10	,	,	,	_	19	punct
11	combination	combination	NN	_	19	nsubjpass
12	of	of	IN	_	13	case
13	roxithromycin	roxithromycin	NN	_	11	nmod
14	with	with	IN	_	16	case
15	such	such	JJ	_	16	amod
16	drugs	drug	NNS	_	11	nmod
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	recommended	recommend	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Cimetidine	Cimetidine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effects	effect	NNS	_	16	nsubjpass
5	of	of	IN	_	8	case
6	chronic	chronic	JJ	_	8	amod
7	cimetidine	cimetidine	NN	_	8	compound
8	use	use	NN	_	4	nmod
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	4	nmod
12	of	of	IN	_	13	case
13	rimantadine	rimantadine	NN	_	11	nmod
14	are	be	VBP	_	16	auxpass
15	not	not	RB	_	16	neg
16	known	know	VBN	_	1	appos
17	.	.	.	_	1	punct

1	When	when	WRB	_	11	advmod
2	a	a	DT	_	6	det
3	single	single	JJ	_	6	amod
4	100	100	CD	_	5	compound
5	mg	mg	NN	_	6	amod
6	dose	dose	NN	_	11	nsubjpass
7	of	of	IN	_	9	case
8	rimantadine	rimantadine	NN	_	9	compound
9	HCl	hcl	NN	_	6	nmod
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	42	advcl
12	one	one	CD	_	13	nummod
13	hour	hour	NN	_	11	nmod
14	after	after	IN	_	13	case
15	the	the	DT	_	16	det
16	initiation	initiation	NN	_	13	dep
17	of	of	IN	_	18	case
18	Cimetidine	Cimetidine	NNP	_	16	nmod
19	(	(	CD	_	20	compound
20	300	300	CD	_	21	nummod
21	mg	mg	NN	_	18	dep
22	four	four	CD	_	23	nummod
23	times	time	NNS	_	26	nmod:npmod
24	a	a	DT	_	25	det
25	day	day	NN	_	23	nmod:npmod
26	)	)	CD	_	21	nummod
27	,	,	,	_	42	punct
28	the	the	DT	_	32	det
29	apparent	apparent	JJ	_	32	amod
30	total	total	JJ	_	32	amod
31	rimantadine	rimantadine	NN	_	32	compound
32	clearance	clearance	NN	_	42	nsubjpass
33	of	of	IN	_	36	case
34	this	this	DT	_	36	det
35	single	single	JJ	_	36	amod
36	dose	dose	NN	_	32	nmod
37	in	in	IN	_	40	case
38	normal	normal	JJ	_	40	amod
39	healthy	healthy	JJ	_	40	amod
40	adults	adult	NNS	_	32	nmod
41	was	be	VBD	_	42	auxpass
42	reduced	reduce	VBN	_	0	ROOT
43	by	by	IN	_	45	case
44	18	18	CD	_	45	nummod
45	%	%	NN	_	42	nmod
46	(	(	CD	_	45	nummod
47	compared	compare	VBN	_	53	case
48	to	to	TO	_	53	case
49	the	the	DT	_	53	det
50	apparent	apparent	JJ	_	53	amod
51	total	total	JJ	_	53	amod
52	rimantadine	rimantadine	NN	_	53	compound
53	clearance	clearance	NN	_	42	advcl
54	in	in	IN	_	57	case
55	the	the	DT	_	57	det
56	same	same	JJ	_	57	amod
57	subjects	subject	NNS	_	53	nmod
58	in	in	IN	_	60	case
59	the	the	DT	_	60	det
60	absence	absence	NN	_	53	nmod
61	of	of	IN	_	63	case
62	cimetidine	cimetidine	NN	_	63	compound
63	)	)	NN	_	60	nmod
64	.	.	.	_	42	punct

1	Acetaminophen	acetaminophen	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Rimantadine	Rimantadine	NNP	_	4	compound
4	HCl	hcl	NN	_	10	nsubjpass
5	,	,	,	_	4	punct
6	100	100	CD	_	7	nummod
7	mg	mg	NN	_	4	appos
8	,	,	,	_	4	punct
9	was	be	VBD	_	10	auxpass
10	given	give	VBN	_	1	dep
11	twice	twice	RB	_	12	advmod
12	daily	daily	RB	_	10	advmod
13	for	for	IN	_	15	case
14	13	13	CD	_	15	nummod
15	days	day	NNS	_	10	nmod
16	to	to	TO	_	19	case
17	12	12	CD	_	19	nummod
18	healthy	healthy	JJ	_	19	amod
19	volunteers	volunteer	NNS	_	10	nmod
20	.	.	.	_	1	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	14	nmod
3	11	11	CD	_	2	nummod
4	,	,	,	_	14	punct
5	acetaminophen	acetaminophen	NN	_	8	compound
6	(	(	NN	_	8	compound
7	650	650	CD	_	8	nummod
8	mg	mg	NN	_	12	dep
9	four	four	CD	_	10	compound
10	times	time	NNS	_	12	nummod
11	daily	daily	JJ	_	12	amod
12	)	)	NN	_	14	nsubjpass
13	was	be	VBD	_	14	auxpass
14	started	start	VBN	_	0	ROOT
15	and	and	CC	_	14	cc
16	continued	continue	VBN	_	14	conj
17	for	for	IN	_	19	case
18	8	8	CD	_	19	nummod
19	days	day	NNS	_	16	nmod
20	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	rimantadine	rimantadine	NN	_	2	nmod
5	were	be	VBD	_	6	auxpass
6	assessed	assess	VBN	_	0	ROOT
7	on	on	IN	_	8	case
8	days	day	NNS	_	6	nmod
9	11	11	CD	_	8	dep
10	and	and	CC	_	9	cc
11	13	13	CD	_	9	conj
12	.	.	.	_	6	punct

1	Coadministration	coadministration	NN	_	4	nsubj
2	with	with	IN	_	3	case
3	acetaminophen	acetaminophen	NN	_	1	nmod
4	reduced	reduce	VBD	_	0	ROOT
5	the	the	DT	_	7	det
6	peak	peak	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	and	and	CC	_	7	cc
9	AUC	auc	NN	_	10	compound
10	values	value	NNS	_	7	conj
11	for	for	IN	_	12	case
12	rimantadine	rimantadine	NN	_	7	nmod
13	by	by	IN	_	16	case
14	approximately	approximately	RB	_	15	advmod
15	11	11	CD	_	16	nummod
16	%	%	NN	_	4	nmod
17	.	.	.	_	4	punct

1	Aspirin	aspirin	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Rimantadine	Rimantadine	NNP	_	4	compound
4	HCl	hcl	NN	_	10	nsubjpass
5	,	,	,	_	4	punct
6	100	100	CD	_	7	nummod
7	mg	mg	NN	_	4	appos
8	,	,	,	_	4	punct
9	was	be	VBD	_	10	auxpass
10	given	give	VBN	_	1	dep
11	twice	twice	RB	_	13	advmod
12	daily	daily	JJ	_	13	amod
13	fro	fro	NN	_	10	dobj
14	13	13	CD	_	15	nummod
15	days	day	NNS	_	13	nmod:npmod
16	to	to	TO	_	15	dep
17	12	12	CD	_	19	nummod
18	healthy	healthy	JJ	_	19	amod
19	volunteers	volunteer	NNS	_	15	dep
20	.	.	.	_	1	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	15	nmod
3	11	11	CD	_	2	nummod
4	,	,	,	_	15	punct
5	aspirin	aspirin	NN	_	8	compound
6	(	(	NN	_	8	compound
7	650	650	CD	_	8	nummod
8	mg	mg	NN	_	15	nsubjpass
9	,	,	,	_	8	punct
10	four	four	CD	_	11	compound
11	times	time	NNS	_	13	nummod
12	daily	daily	JJ	_	13	amod
13	)	)	NN	_	8	appos
14	was	be	VBD	_	15	auxpass
15	started	start	VBN	_	0	ROOT
16	and	and	CC	_	15	cc
17	continued	continue	VBN	_	15	conj
18	for	for	IN	_	20	case
19	8	8	CD	_	20	nummod
20	days	day	NNS	_	17	nmod
21	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	rimantadine	rimantadine	NN	_	2	nmod
5	were	be	VBD	_	6	auxpass
6	assessed	assess	VBN	_	0	ROOT
7	on	on	IN	_	8	case
8	days	day	NNS	_	6	nmod
9	11	11	CD	_	8	dep
10	and	and	CC	_	9	cc
11	13	13	CD	_	9	conj
12	.	.	.	_	6	punct

1	Peak	peak	JJ	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	9	nsubjpass
4	and	and	CC	_	3	cc
5	AUC	auc	NN	_	3	conj
6	of	of	IN	_	7	case
7	rimantadine	rimantadine	NN	_	5	nmod
8	were	be	VBD	_	9	auxpass
9	reduced	reduce	VBN	_	0	ROOT
10	approximately	approximately	RB	_	11	advmod
11	10	10	CD	_	12	nummod
12	%	%	NN	_	9	dobj
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	presence	presence	NN	_	9	nmod
16	of	of	IN	_	17	case
17	aspirin	aspirin	NN	_	15	nmod
18	.	.	.	_	9	punct

1	Because	because	IN	_	5	mark
2	tetracyclines	tetracycline	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	shown	show	VBN	_	19	advcl
6	to	to	TO	_	7	mark
7	depress	depress	VB	_	5	xcomp
8	plasma	plasma	NN	_	10	compound
9	prothrombin	prothrombin	NN	_	10	compound
10	activity	activity	NN	_	7	dobj
11	,	,	,	_	19	punct
12	patients	patient	NNS	_	19	nsubj
13	who	who	WP	_	17	nsubj
14	are	be	VBP	_	17	cop
15	on	on	IN	_	17	case
16	anticoagulant	anticoagulant	JJ	_	17	amod
17	therapy	therapy	NN	_	12	acl:relcl
18	may	may	MD	_	19	aux
19	require	require	VB	_	0	ROOT
20	downward	downward	JJ	_	21	amod
21	adjustment	adjustment	NN	_	19	dobj
22	of	of	IN	_	25	case
23	their	they	PRP$	_	25	nmod:poss
24	anticoagulant	anticoagulant	JJ	_	25	amod
25	dosage	dosage	NN	_	21	nmod
26	.	.	.	_	19	punct

1	Since	since	IN	_	5	mark
2	bacteriostatic	bacteriostatic	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	interfere	interfere	VB	_	15	advcl
6	with	with	IN	_	9	case
7	the	the	DT	_	9	det
8	bactericidal	bactericidal	JJ	_	9	amod
9	action	action	NN	_	5	nmod
10	of	of	IN	_	11	case
11	penicillin	penicillin	NN	_	9	nmod
12	,	,	,	_	15	punct
13	it	it	PRP	_	15	nsubj
14	is	be	VBZ	_	15	cop
15	advisable	advisable	JJ	_	0	ROOT
16	to	to	TO	_	17	mark
17	avoid	avoid	VB	_	15	xcomp
18	giving	give	VBG	_	17	xcomp
19	tetracycline	tetracycline	NN	_	21	compound
20	class	class	NN	_	21	compound
21	drugs	drug	NNS	_	18	dobj
22	in	in	IN	_	23	case
23	conjunction	conjunction	NN	_	18	nmod
24	with	with	IN	_	25	case
25	penicillin	penicillin	NN	_	23	nmod
26	.	.	.	_	15	punct

1	Absorption	absorption	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	tetracyclines	tetracycline	NNS	_	1	nmod
4	is	be	VBZ	_	5	auxpass
5	impaired	impair	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	antacids	antacid	NNS	_	5	nmod
8	containing	contain	VBG	_	7	acl
9	aluminum	aluminum	NN	_	8	dobj
10	,	,	,	_	9	punct
11	calcium	calcium	NN	_	9	conj
12	or	or	CC	_	9	cc
13	magnesium	magnesium	NN	_	9	conj
14	,	,	,	_	5	punct
15	and	and	CC	_	5	cc
16	iron	iron	NN	_	5	conj
17	-	-	:	_	16	punct
18	containing	contain	VBG	_	16	acl
19	preparations	preparation	NNS	_	18	dobj
20	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	tetracycline	tetracycline	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	methoxyflurane	methoxyflurane	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	result	result	VB	_	10	xcomp
13	in	in	IN	_	16	case
14	fatal	fatal	JJ	_	16	amod
15	renal	renal	JJ	_	16	amod
16	toxicity	toxicity	NN	_	12	nmod
17	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	tetracyclines	tetracycline	NNS	_	2	nmod
5	with	with	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	contraceptives	contraceptive	NNS	_	2	nmod
8	may	may	MD	_	9	aux
9	render	render	VB	_	0	ROOT
10	oral	oral	JJ	_	11	amod
11	contraceptives	contraceptive	NNS	_	13	nsubj
12	less	less	RBR	_	13	advmod
13	effective	effective	JJ	_	9	xcomp
14	.	.	.	_	9	punct

1	There	there	EX	_	8	expl
2	have	have	VBP	_	8	aux
3	been	be	VBN	_	8	cop
4	no	no	DT	_	8	neg
5	formal	formal	JJ	_	8	amod
6	drug	drug	NN	_	8	compound
7	interaction	interaction	NN	_	8	compound
8	studies	study	NNS	_	0	ROOT
9	performed	perform	VBN	_	8	acl
10	with	with	IN	_	11	case
11	HERCEPTIN	herceptin	NN	_	9	nmod
12	in	in	IN	_	13	case
13	humans	human	NNS	_	11	nmod
14	.	.	.	_	8	punct

1	Administration	administration	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	paclitaxel	paclitaxel	NN	_	1	nmod
4	in	in	IN	_	5	case
5	combination	combination	NN	_	1	nmod
6	with	with	IN	_	7	case
7	HERCEPTIN	herceptin	NN	_	5	nmod
8	resulted	result	VBD	_	0	ROOT
9	in	in	IN	_	14	case
10	a	a	DT	_	14	det
11	two	two	CD	_	14	nummod
12	-	-	:	_	14	punct
13	fold	fold	JJ	_	14	amod
14	decrease	decrease	NN	_	8	nmod
15	in	in	IN	_	17	case
16	HERCEPTIN	herceptin	NN	_	17	compound
17	clearance	clearance	NN	_	14	nmod
18	in	in	IN	_	24	case
19	a	a	DT	_	24	det
20	non	non	JJ	_	24	amod
21	-	-	:	_	24	punct
22	human	human	JJ	_	24	amod
23	primate	primate	JJ	_	24	amod
24	study	study	NN	_	14	nmod
25	and	and	CC	_	14	cc
26	in	in	IN	_	31	case
27	a	a	DT	_	31	det
28	1.5	1.5	CD	_	31	nummod
29	-	-	:	_	31	punct
30	fold	fold	JJ	_	31	amod
31	increase	increase	NN	_	14	conj
32	in	in	IN	_	35	case
33	HERCEPTIN	herceptin	NN	_	35	compound
34	serum	serum	NN	_	35	compound
35	levels	level	NNS	_	31	nmod
36	in	in	IN	_	38	case
37	clinical	clinical	JJ	_	38	amod
38	studies	study	NNS	_	31	nmod
39	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	23	nsubj
4	of	of	IN	_	5	case
5	Sanctura	sanctura	NN	_	3	nmod
6	with	with	IN	_	9	case
7	other	other	JJ	_	9	amod
8	anticholinergic	anticholinergic	JJ	_	9	amod
9	agents	agent	NNS	_	3	nmod
10	that	that	WDT	_	11	nsubj
11	produce	produce	VBP	_	9	acl:relcl
12	dry	dry	JJ	_	13	amod
13	mouth	mouth	NN	_	11	dobj
14	,	,	,	_	13	punct
15	constipation	constipation	NN	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	other	other	JJ	_	21	amod
19	anticholinergic	anticholinergic	JJ	_	21	amod
20	pharmacological	pharmacological	JJ	_	21	amod
21	effects	effect	NNS	_	13	conj
22	may	may	MD	_	23	aux
23	increase	increase	VB	_	0	ROOT
24	the	the	DT	_	25	det
25	frequency	frequency	NN	_	23	dobj
26	and	and	CC	_	25	cc
27	/	/	:	_	29	punct
28	or	or	CC	_	29	cc
29	severity	severity	NN	_	25	conj
30	of	of	IN	_	32	case
31	such	such	JJ	_	32	amod
32	effects	effect	NNS	_	29	nmod
33	.	.	.	_	23	punct

1	Anticholinergic	anticholinergic	JJ	_	2	amod
2	agents	agent	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	potentially	potentially	RB	_	5	advmod
5	alter	alter	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	12	case
9	some	some	DT	_	12	det
10	concomitantly	concomitantly	RB	_	11	advmod
11	administered	administer	VBN	_	12	amod
12	drugs	drug	NNS	_	7	nmod
13	due	due	JJ	_	7	amod
14	to	to	TO	_	16	case
15	anticholinergic	anticholinergic	JJ	_	16	amod
16	effects	effect	NNS	_	13	nmod
17	on	on	IN	_	19	case
18	gastrointestinal	gastrointestinal	JJ	_	19	amod
19	motility	motility	NN	_	16	nmod
20	.	.	.	_	5	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Eliminated	eliminate	VBN	_	1	acl
3	by	by	IN	_	6	case
4	Active	active	JJ	_	6	amod
5	Tubular	tubular	JJ	_	6	amod
6	Secretion	secretion	NN	_	2	nmod
7	:	:	:	_	1	punct
8	Although	although	IN	_	21	mark
9	studies	study	NNS	_	21	nsubjpass
10	to	to	TO	_	11	mark
11	assess	assess	VB	_	9	acl
12	drug	drug	NN	_	15	compound
13	-	-	:	_	15	punct
14	drug	drug	NN	_	15	compound
15	interactions	interaction	NNS	_	11	dobj
16	with	with	IN	_	17	case
17	Sanctura	Sanctura	NNP	_	15	nmod
18	have	have	VBP	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	conducted	conduct	VBN	_	24	advcl
22	,	,	,	_	24	punct
23	Sanctura	Sanctura	NNP	_	24	nsubj
24	has	have	VBZ	_	1	dep
25	the	the	DT	_	26	det
26	potential	potential	NN	_	24	dobj
27	for	for	IN	_	29	case
28	pharmacokinetic	pharmacokinetic	JJ	_	29	amod
29	interactions	interaction	NNS	_	26	nmod
30	with	with	IN	_	32	case
31	other	other	JJ	_	32	amod
32	drugs	drug	NNS	_	29	nmod
33	that	that	WDT	_	35	nsubjpass
34	are	be	VBP	_	35	auxpass
35	eliminated	eliminate	VBN	_	32	acl:relcl
36	by	by	IN	_	40	case
37	active	active	JJ	_	40	amod
38	tubular	tubular	JJ	_	40	amod
39	secretion	secretion	NN	_	40	compound
40	(	(	NN	_	35	nmod
41	e	e	LS	_	26	dep
42	.	.	.	_	41	punct
43	g	g	NN	_	45	compound
44	.	.	.	_	45	punct
45	digoxin	digoxin	NN	_	41	dep
46	,	,	,	_	45	punct
47	procainamide	procainamide	NN	_	45	conj
48	,	,	,	_	45	punct
49	pancuronium	pancuronium	NN	_	45	conj
50	,	,	,	_	45	punct
51	morphine	morphine	NN	_	45	conj
52	,	,	,	_	45	punct
53	vancomycin	vancomycin	NN	_	45	conj
54	,	,	,	_	45	punct
55	metformin	metformin	NN	_	45	conj
56	and	and	CC	_	45	cc
57	tenofovir	tenofovir	NN	_	58	compound
58	)	)	NN	_	45	conj
59	.	.	.	_	1	punct

1	Coadministration	Coadministration	NNP	_	15	nsubj
2	of	of	IN	_	3	case
3	Sanctura	Sanctura	NNP	_	1	nmod
4	with	with	IN	_	5	case
5	drugs	drug	NNS	_	1	nmod
6	that	that	WDT	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	eliminated	eliminate	VBN	_	5	acl:relcl
9	by	by	IN	_	13	case
10	active	active	JJ	_	13	amod
11	renal	renal	JJ	_	13	amod
12	tubular	tubular	JJ	_	13	amod
13	secretion	secretion	NN	_	8	nmod
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	18	det
17	serum	serum	NN	_	18	compound
18	concentration	concentration	NN	_	15	dobj
19	of	of	IN	_	20	case
20	Sanctura	Sanctura	NNP	_	18	nmod
21	and	and	CC	_	15	cc
22	/	/	:	_	26	punct
23	or	or	CC	_	26	cc
24	the	the	DT	_	26	det
25	coadministered	coadminister	VBN	_	26	amod
26	drug	drug	NN	_	15	conj
27	due	due	JJ	_	29	case
28	to	to	TO	_	27	mwe
29	competition	competition	NN	_	26	nmod
30	for	for	IN	_	33	case
31	this	this	DT	_	33	det
32	elimination	elimination	NN	_	33	compound
33	pathway	pathway	NN	_	29	nmod
34	.	.	.	_	15	punct

1	Careful	careful	JJ	_	3	amod
2	patient	patient	NN	_	3	compound
3	monitoring	monitoring	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	such	such	JJ	_	10	amod
10	drugs	drug	NNS	_	8	dobj
11	.	.	.	_	5	punct

1	Drug	drug	NN	_	3	compound
2	-	-	:	_	3	punct
3	Laboratory	laboratory	NN	_	0	ROOT
4	-	-	:	_	3	punct
5	Test	test	NN	_	7	compound
6	Interactions	interaction	NNS	_	7	compound
7	Interactions	interaction	NNS	_	16	nsubjpass
8	between	between	IN	_	9	case
9	Sanctura	Sanctura	NNP	_	7	nmod
10	and	and	CC	_	9	cc
11	laboratory	laboratory	NN	_	12	compound
12	tests	test	NNS	_	9	conj
13	have	have	VBP	_	16	aux
14	not	not	RB	_	16	neg
15	been	be	VBN	_	16	auxpass
16	studied	study	VBN	_	3	dep
17	.	.	.	_	3	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	in	in	IN	_	6	mark
6	administering	administer	VBG	_	4	advcl
7	DEMSER	demser	NN	_	6	dobj
8	to	to	TO	_	9	case
9	patients	patient	NNS	_	6	nmod
10	receiving	receive	VBG	_	9	acl
11	phenothiazines	phenothiazine	NNS	_	10	dobj
12	or	or	CC	_	11	cc
13	haloperidol	haloperidol	NN	_	11	conj
14	because	because	IN	_	23	mark
15	the	the	DT	_	17	det
16	extrapyramidal	extrapyramidal	JJ	_	17	amod
17	effects	effect	NNS	_	23	nsubjpass
18	of	of	IN	_	20	case
19	these	these	DT	_	20	det
20	drugs	drug	NNS	_	17	nmod
21	can	can	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	expected	expect	VBN	_	4	advcl
24	to	to	TO	_	26	mark
25	be	be	VB	_	26	auxpass
26	potentiated	potentiate	VBN	_	23	xcomp
27	by	by	IN	_	28	case
28	inhibition	inhibition	NN	_	26	nmod
29	of	of	IN	_	31	case
30	catecholamine	catecholamine	NN	_	31	compound
31	synthesis	synthesis	NN	_	28	nmod
32	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	12	nsubj
3	of	of	IN	_	4	case
4	DEMSER	demser	NN	_	2	nmod
5	with	with	IN	_	6	case
6	alcohol	alcohol	NN	_	2	nmod
7	or	or	CC	_	6	cc
8	other	other	JJ	_	10	amod
9	CNS	cns	NN	_	10	compound
10	depressants	depressant	NNS	_	6	conj
11	can	can	MD	_	12	aux
12	increase	increase	VB	_	0	ROOT
13	their	they	PRP$	_	15	nmod:poss
14	sedative	sedative	JJ	_	15	amod
15	effects	effect	NNS	_	12	dobj
16	.	.	.	_	12	punct

1	You	you	PRP	_	2	nsubj
2	cannot	cannot	VBP	_	0	ROOT
3	take	take	VB	_	2	ccomp
4	mazindol	mazindol	NN	_	3	dobj
5	if	if	IN	_	8	mark
6	you	you	PRP	_	8	nsubj
7	have	have	VBP	_	8	aux
8	taken	take	VBN	_	3	advcl
9	a	a	DT	_	14	det
10	monoamine	monoamine	NN	_	14	compound
11	oxidase	oxidase	NN	_	14	compound
12	inhibitor	inhibitor	NN	_	14	compound
13	(	(	NN	_	14	compound
14	MAOI	MAOI	NNP	_	8	dobj
15	)	)	CD	_	14	nummod
16	such	such	JJ	_	21	case
17	as	as	IN	_	16	mwe
18	isocarboxazid	isocarboxazid	NN	_	21	compound
19	(	(	CD	_	21	nummod
20	Marplan	Marplan	NNP	_	21	compound
21	)	)	NN	_	14	nmod
22	,	,	,	_	21	punct
23	tranylcypromine	tranylcypromine	NN	_	26	compound
24	(	(	CD	_	26	nummod
25	Parnate	Parnate	NNP	_	26	compound
26	)	)	NN	_	21	conj
27	,	,	,	_	21	punct
28	or	or	CC	_	21	cc
29	phenelzine	phenelzine	NN	_	32	compound
30	(	(	CD	_	32	nummod
31	Nardil	nardil	NN	_	32	compound
32	)	)	NN	_	21	conj
33	in	in	IN	_	37	case
34	the	the	DT	_	37	det
35	last	last	JJ	_	37	amod
36	14	14	CD	_	37	nummod
37	days	day	NNS	_	8	nmod
38	.	.	.	_	2	punct

1	Changes	change	NNS	_	11	nsubj
2	in	in	IN	_	3	case
3	insulin	insulin	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	8	amod
6	diabetes	diabetes	NN	_	8	compound
7	drug	drug	NN	_	8	compound
8	therapies	therapy	NNS	_	3	conj
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	necessary	necessary	JJ	_	0	ROOT
12	during	during	IN	_	13	case
13	treatment	treatment	NN	_	11	nmod
14	with	with	IN	_	15	case
15	mazindol	mazindol	NN	_	13	nmod
16	.	.	.	_	11	punct

1	Mazindol	Mazindol	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	reduce	reduce	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	10	case
7	guanethidine	guanethidine	NN	_	10	compound
8	(	(	CD	_	10	nummod
9	Ismelin	Ismelin	NNP	_	10	compound
10	)	)	NN	_	5	nmod
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	an	a	DT	_	6	det
6	increase	increase	NN	_	3	nmod
7	in	in	IN	_	9	case
8	blood	blood	NN	_	9	compound
9	pressure	pressure	NN	_	6	nmod
10	.	.	.	_	3	punct

1	Tell	tell	VB	_	0	ROOT
2	your	you	PRP$	_	3	nmod:poss
3	doctor	doctor	NN	_	1	dobj
4	if	if	IN	_	7	mark
5	you	you	PRP	_	7	nsubj
6	are	be	VBP	_	7	aux
7	taking	take	VBG	_	1	advcl
8	guanethidine	guanethidine	NN	_	7	dobj
9	.	.	.	_	1	punct

1	Before	before	IN	_	2	mark
2	taking	take	VBG	_	6	advcl
3	this	this	DT	_	4	det
4	medication	medication	NN	_	2	dobj
5	,	,	,	_	6	punct
6	tell	tell	VB	_	0	ROOT
7	your	you	PRP$	_	8	nmod:poss
8	doctor	doctor	NN	_	6	dobj
9	if	if	IN	_	12	mark
10	you	you	PRP	_	12	nsubj
11	are	be	VBP	_	12	aux
12	taking	take	VBG	_	6	advcl
13	a	a	DT	_	15	det
14	tricyclic	tricyclic	JJ	_	15	amod
15	antidepressant	antidepressant	JJ	_	12	dobj
16	such	such	JJ	_	21	case
17	as	as	IN	_	16	mwe
18	amitriptyline	amitriptyline	NNP	_	21	compound
19	(	(	NNP	_	21	compound
20	Elavil	Elavil	NNP	_	21	compound
21	)	)	NN	_	15	nmod
22	,	,	,	_	21	punct
23	amoxapine	amoxapine	NN	_	26	compound
24	(	(	CD	_	26	nummod
25	Asendin	asendin	NN	_	26	compound
26	)	)	NN	_	21	conj
27	,	,	,	_	21	punct
28	doxepin	doxepin	NN	_	31	compound
29	(	(	CD	_	31	nummod
30	Sinequan	sinequan	JJ	_	31	amod
31	)	)	NN	_	21	conj
32	,	,	,	_	21	punct
33	nortriptyline	nortriptyline	NN	_	36	compound
34	(	(	CD	_	36	nummod
35	Pamelor	Pamelor	NNP	_	36	compound
36	)	)	NN	_	21	conj
37	,	,	,	_	21	punct
38	imipramine	imipramine	NN	_	41	compound
39	(	(	CD	_	41	nummod
40	Tofranil	Tofranil	NNP	_	41	compound
41	)	)	NN	_	21	conj
42	,	,	,	_	21	punct
43	clomipramine	clomipramine	NN	_	46	compound
44	(	(	CD	_	46	nummod
45	Anafranil	Anafranil	NNP	_	46	compound
46	)	)	NN	_	21	conj
47	,	,	,	_	21	punct
48	protriptyline	protriptyline	NN	_	51	compound
49	(	(	CD	_	51	nummod
50	Vivactil	Vivactil	NNP	_	51	compound
51	)	)	NN	_	21	conj
52	,	,	,	_	21	punct
53	or	or	CC	_	21	cc
54	desipramine	desipramine	NN	_	57	compound
55	(	(	CD	_	57	nummod
56	Norpramin	norpramin	JJ	_	57	amod
57	)	)	NN	_	21	conj
58	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	mazindol	mazindol	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Mitotane	Mitotane	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	accelerate	accelerate	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	6	dobj
9	of	of	IN	_	10	case
10	warfarin	warfarin	NN	_	8	nmod
11	by	by	IN	_	13	case
12	the	the	DT	_	13	det
13	mechanism	mechanism	NN	_	6	nmod
14	of	of	IN	_	18	case
15	hepatic	hepatic	JJ	_	18	amod
16	microsomal	microsomal	JJ	_	18	amod
17	enzyme	enzyme	NN	_	18	compound
18	induction	induction	NN	_	13	nmod
19	,	,	,	_	6	punct
20	leading	lead	VBG	_	6	advcl
21	to	to	TO	_	23	case
22	an	a	DT	_	23	det
23	increase	increase	NN	_	20	nmod
24	in	in	IN	_	26	case
25	dosage	dosage	NN	_	26	compound
26	requirements	requirement	NNS	_	23	nmod
27	for	for	IN	_	28	case
28	warfarin	warfarin	NN	_	26	nmod
29	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	physicians	physician	NNS	_	6	nsubj
4	should	should	MD	_	6	aux
5	closely	closely	RB	_	6	advmod
6	monitor	monitor	VB	_	0	ROOT
7	patients	patient	NNS	_	6	dobj
8	for	for	IN	_	10	case
9	a	a	DT	_	10	det
10	change	change	NN	_	7	nmod
11	in	in	IN	_	14	case
12	anticoagulant	anticoagulant	JJ	_	14	amod
13	dosage	dosage	NN	_	14	compound
14	requirements	requirement	NNS	_	10	nmod
15	when	when	WRB	_	16	advmod
16	administering	administer	VBG	_	6	advcl
17	Mitotane	Mitotane	NNP	_	16	dobj
18	to	to	TO	_	19	case
19	patients	patient	NNS	_	16	nmod
20	on	on	IN	_	24	case
21	coumarin	coumarin	NN	_	24	compound
22	-	-	:	_	24	punct
23	type	type	NN	_	24	compound
24	anticoagulants	anticoagulant	NNS	_	19	nmod
25	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	Mitotane	mitotane	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	given	give	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	caution	caution	NN	_	7	nmod
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	receiving	receive	VBG	_	11	acl
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	15	nsubj
15	susceptible	susceptible	JJ	_	12	xcomp
16	to	to	TO	_	18	case
17	the	the	DT	_	18	det
18	influence	influence	NN	_	15	nmod
19	of	of	IN	_	22	case
20	hepatic	hepatic	JJ	_	22	amod
21	enzyme	enzyme	NN	_	22	compound
22	induction	induction	NN	_	18	nmod
23	.	.	.	_	7	punct

1	Ergot	Ergot	NNP	_	7	nsubjpass
2	-	-	:	_	7	punct
3	containing	contain	VBG	_	7	csubjpass
4	drugs	drug	NNS	_	3	dobj
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	cause	cause	VB	_	7	xcomp
10	prolonged	prolonged	JJ	_	12	amod
11	vasospastic	vasospastic	JJ	_	12	amod
12	reactions	reaction	NNS	_	9	dobj
13	.	.	.	_	7	punct

1	Because	because	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	0	ROOT
4	a	a	DT	_	6	det
5	theoretical	theoretical	JJ	_	6	amod
6	basis	basis	NN	_	3	nsubj
7	that	that	IN	_	12	mark
8	these	these	DT	_	9	det
9	effects	effect	NNS	_	12	nsubj
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	additive	additive	JJ	_	6	ccomp
13	,	,	,	_	12	punct
14	use	use	NN	_	12	dep
15	of	of	IN	_	16	case
16	ergotamine	ergotamine	NN	_	14	nmod
17	-	-	:	_	14	punct
18	containing	contain	VBG	_	14	dep
19	or	or	CC	_	18	cc
20	ergot	ergot	NN	_	18	conj
21	-	-	:	_	12	punct
22	type	type	NN	_	23	compound
23	medications	medication	NNS	_	24	nsubj
24	(	(	VBP	_	12	parataxis
25	like	like	IN	_	26	case
26	dihydroergotamine	dihydroergotamine	NN	_	24	nmod
27	or	or	CC	_	26	cc
28	methysergide	methysergide	NN	_	29	compound
29	)	)	NN	_	26	conj
30	and	and	CC	_	26	cc
31	sumatriptan	sumatriptan	NN	_	26	conj
32	within	within	IN	_	34	case
33	24	24	CD	_	34	nummod
34	hours	hour	NNS	_	24	nmod
35	of	of	IN	_	37	case
36	each	each	DT	_	37	det
37	other	other	JJ	_	34	nmod
38	should	should	MD	_	40	aux
39	be	be	VB	_	40	auxpass
40	avoided	avoid	VBN	_	12	dep
41	.	.	.	_	3	punct

1	MAO	mao	SYM	_	5	dep
2	-	-	:	_	5	punct
3	A	a	NN	_	4	compound
4	inhibitors	inhibitor	NNS	_	5	nsubj
5	reduce	reduce	VB	_	0	ROOT
6	sumatriptan	sumatriptan	NN	_	7	compound
7	clearance	clearance	NN	_	5	dobj
8	,	,	,	_	5	punct
9	significantly	significantly	RB	_	10	advmod
10	increasing	increase	VBG	_	5	advcl
11	systemic	systemic	JJ	_	12	amod
12	exposure	exposure	NN	_	10	dobj
13	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	17	advmod
2	,	,	,	_	17	punct
3	the	the	DT	_	4	det
4	use	use	NN	_	17	nsubjpass
5	of	of	IN	_	8	case
6	sumatriptan	sumatriptan	NN	_	8	compound
7	succinate	succinate	JJ	_	8	amod
8	tablets	tablet	NNS	_	4	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	4	nmod
11	receiving	receive	VBG	_	10	acl
12	MAO	MAO	NNP	_	15	compound
13	-	-	:	_	15	punct
14	A	a	NN	_	15	compound
15	inhibitors	inhibitor	NNS	_	11	dobj
16	is	be	VBZ	_	17	auxpass
17	contraindicated	contraindicate	VBN	_	0	ROOT
18	.	.	.	_	17	punct
19	Selective	selective	JJ	_	22	amod
20	serotonin	serotonin	NN	_	22	compound
21	reuptake	reuptake	NN	_	22	compound
22	inhibitors	inhibitor	NNS	_	17	dobj
23	(	(	VBN	_	24	amod
24	SSRIs	ssri	NNS	_	25	nsubj
25	)	)	VBP	_	22	acl:relcl
26	(	(	CD	_	29	nummod
27	e	e	LS	_	29	dep
28	.	.	.	_	27	punct
29	g	g	NN	_	25	dobj
30	.	.	.	_	17	punct
31	,	,	,	_	17	punct
32	fluoxetine	fluoxetine	NN	_	42	nsubjpass
33	,	,	,	_	32	punct
34	fluvoxamine	fluvoxamine	NN	_	32	conj
35	,	,	,	_	32	punct
36	paroxetine	paroxetine	NN	_	32	conj
37	,	,	,	_	32	punct
38	sertraline	sertraline	NN	_	39	compound
39	)	)	NN	_	32	conj
40	have	have	VBP	_	42	aux
41	been	be	VBN	_	42	auxpass
42	reported	report	VBN	_	17	parataxis
43	,	,	,	_	42	punct
44	rarely	rarely	RB	_	42	advmod
45	,	,	,	_	42	punct
46	to	to	TO	_	47	mark
47	cause	cause	VB	_	42	xcomp
48	weakness	weakness	NN	_	47	dobj
49	,	,	,	_	48	punct
50	hyperreflexia	hyperreflexia	NN	_	48	conj
51	,	,	,	_	48	punct
52	and	and	CC	_	48	cc
53	incoordination	incoordination	NN	_	48	conj
54	when	when	WRB	_	55	advmod
55	coadministered	coadminister	VBN	_	47	advcl
56	with	with	IN	_	57	case
57	sumatriptan	sumatriptan	NN	_	55	nmod
58	.	.	.	_	17	punct

1	If	if	IN	_	11	mark
2	concomitant	concomitant	JJ	_	3	amod
3	treatment	treatment	NN	_	11	nsubjpass
4	with	with	IN	_	5	case
5	sumatriptan	sumatriptan	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	an	a	DT	_	8	det
8	SSRI	SSRI	NNP	_	5	conj
9	is	be	VBZ	_	11	auxpass
10	clinically	clinically	RB	_	11	advmod
11	warranted	warrant	VBN	_	19	advcl
12	,	,	,	_	19	punct
13	appropriate	appropriate	JJ	_	14	amod
14	observation	observation	NN	_	19	nsubjpass
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	patient	patient	NN	_	14	nmod
18	is	be	VBZ	_	19	auxpass
19	advised	advise	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	SKELID	SKELID	NNP	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	80	80	CD	_	8	nummod
8	%	%	NN	_	6	dobj
9	by	by	IN	_	10	case
10	calcium	calcium	NN	_	6	nmod
11	,	,	,	_	10	punct
12	when	when	WRB	_	17	advmod
13	calcium	calcium	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	SKELID	skelid	NNS	_	13	conj
16	are	be	VBP	_	17	auxpass
17	administered	administer	VBN	_	10	acl:relcl
18	at	at	IN	_	21	case
19	the	the	DT	_	21	det
20	same	same	JJ	_	21	amod
21	time	time	NN	_	17	nmod
22	,	,	,	_	10	punct
23	and	and	CC	_	10	cc
24	60	60	CD	_	25	nummod
25	%	%	NN	_	10	conj
26	by	by	IN	_	28	case
27	some	some	DT	_	28	det
28	aluminum	aluminum	NN	_	6	nmod
29	-	-	:	_	28	punct
30	or	or	CC	_	28	cc
31	magnesium	magnesium	NN	_	28	conj
32	-	-	:	_	28	punct
33	containing	contain	VBG	_	28	acl
34	antacids	antacid	NNS	_	33	dobj
35	,	,	,	_	28	punct
36	when	when	WRB	_	37	advmod
37	administered	administer	VBN	_	28	acl:relcl
38	1	1	CD	_	39	nummod
39	hour	hour	NN	_	37	nmod
40	before	before	IN	_	39	case
41	SKELID	skelid	NNS	_	39	dep
42	.	.	.	_	6	punct

1	Aspirin	aspirin	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	bioavailability	bioavailability	NN	_	3	dobj
5	of	of	IN	_	6	case
6	SKELID	skelid	NNS	_	4	nmod
7	by	by	IN	_	11	case
8	up	up	RB	_	10	dep
9	to	to	TO	_	8	mwe
10	50	50	CD	_	11	nummod
11	%	%	NN	_	3	nmod
12	when	when	WRB	_	13	advmod
13	taken	take	VBN	_	3	advcl
14	2	2	CD	_	15	nummod
15	hours	hour	NNS	_	13	nmod
16	after	after	IN	_	15	case
17	SKELID	skelid	NNS	_	15	dep
18	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	SKELID	SKELID	NNP	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	2	2	LS	_	6	dep
8	-	-	:	_	7	punct
9	4	4	CD	_	10	nummod
10	fold	fold	NN	_	7	dep
11	by	by	IN	_	12	case
12	indomethacin	indomethacin	NN	_	10	nmod
13	but	but	CC	_	10	cc
14	is	be	VBZ	_	17	auxpass
15	not	not	RB	_	17	neg
16	significantly	significantly	RB	_	17	advmod
17	altered	alter	VBN	_	10	conj
18	by	by	IN	_	19	case
19	coadministration	coadministration	NN	_	17	nmod
20	of	of	IN	_	21	case
21	diclofenac	diclofenac	NN	_	19	nmod
22	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	parameters	parameter	NNS	_	9	nsubjpass
4	of	of	IN	_	5	case
5	digoxin	digoxin	NN	_	3	nmod
6	are	be	VBP	_	9	auxpass
7	not	not	RB	_	9	neg
8	significantly	significantly	RB	_	9	advmod
9	modified	modify	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	SKELID	skelid	NN	_	12	compound
12	coadministration	coadministration	NN	_	9	nmod
13	.	.	.	_	9	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	show	show	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	tiludronate	tiludronate	NN	_	9	nsubj
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	displace	displace	VB	_	4	ccomp
10	warfarin	warfarin	NN	_	9	dobj
11	from	from	IN	_	14	case
12	its	its	PRP$	_	14	nmod:poss
13	binding	binding	NN	_	14	amod
14	site	site	NN	_	9	nmod
15	on	on	IN	_	16	case
16	protein	protein	NN	_	14	nmod
17	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	usually	usually	RB	_	2	advmod
4	complete	complete	JJ	_	5	amod
5	cross	cross	NN	_	2	nsubj
6	-	-	:	_	5	punct
7	resistance	resistance	NN	_	5	dep
8	between	between	IN	_	12	case
9	PURINETHOL	PURINETHOL	NNP	_	12	compound
10	(	(	CD	_	12	nummod
11	mercaptopurine	mercaptopurine	NN	_	12	compound
12	)	)	NN	_	7	nmod
13	and	and	CC	_	12	cc
14	TABLOID	tabloid	NN	_	16	compound
15	brand	brand	NN	_	16	compound
16	Thioguanine	thioguanine	NN	_	12	conj
17	.	.	.	_	2	punct

1	As	as	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	0	ROOT
4	in	in	FW	_	6	amod
5	vitro	vitro	FW	_	4	dep
6	evidence	evidence	NN	_	3	nsubj
7	that	that	IN	_	10	mark
8	aminosalicylate	aminosalicylate	NN	_	9	compound
9	derivatives	derivative	NNS	_	10	nsubj
10	(	(	VBP	_	6	ccomp
11	e	e	LS	_	10	dobj
12	.	.	.	_	11	punct
13	g	g	NN	_	11	dep
14	.	.	.	_	13	punct
15	,	,	,	_	13	punct
16	olsalazine	olsalazine	NN	_	23	nsubj
17	,	,	,	_	16	punct
18	mesalazine	mesalazine	NN	_	16	conj
19	,	,	,	_	16	punct
20	or	or	CC	_	16	cc
21	sulphasalazine	sulphasalazine	NN	_	16	conj
22	)	)	CD	_	21	nummod
23	inhibit	inhibit	VBP	_	13	dep
24	the	the	DT	_	26	det
25	TPMT	tpmt	NN	_	26	compound
26	enzyme	enzyme	NN	_	23	dobj
27	,	,	,	_	23	punct
28	they	they	PRP	_	31	nsubjpass
29	should	should	MD	_	31	aux
30	be	be	VB	_	31	auxpass
31	administered	administer	VBN	_	23	parataxis
32	with	with	IN	_	33	case
33	caution	caution	NN	_	31	nmod
34	to	to	TO	_	35	case
35	patients	patient	NNS	_	33	nmod
36	receiving	receive	VBG	_	35	acl
37	concurrent	concurrent	JJ	_	39	amod
38	thioguanine	thioguanine	NN	_	39	compound
39	therapy	therapy	NN	_	36	dobj
40	.	.	.	_	3	punct

1	Other	other	JJ	_	3	amod
2	eye	eye	NN	_	3	compound
3	drops	drop	NNS	_	22	nsubj
4	or	or	CC	_	3	cc
5	medications	medication	NNS	_	3	conj
6	such	such	JJ	_	12	case
7	as	as	IN	_	6	mwe
8	acetylcholine	acetylcholine	NN	_	12	compound
9	chloride	chloride	NN	_	12	compound
10	(	(	CD	_	12	nummod
11	Miochol	Miochol	NNP	_	12	compound
12	)	)	NN	_	5	nmod
13	and	and	CC	_	12	cc
14	carbachol	carbachol	NN	_	16	compound
15	(	(	CD	_	16	nummod
16	Carboptic	Carboptic	NNP	_	12	conj
17	,	,	,	_	3	punct
18	Isopto	Isopto	NNP	_	20	compound
19	Carbachol	Carbachol	NNP	_	20	compound
20	)	)	NN	_	3	appos
21	may	may	MD	_	22	aux
22	decrease	decrease	VB	_	0	ROOT
23	the	the	DT	_	24	det
24	effects	effect	NNS	_	22	dobj
25	of	of	IN	_	27	case
26	suprofen	suprofen	JJ	_	27	amod
27	ophthalmic	ophthalmic	JJ	_	24	nmod
28	.	.	.	_	22	punct

1	Vasopressors	Vasopressors	NNP	_	7	nsubj
2	,	,	,	_	1	punct
3	particularly	particularly	RB	_	4	advmod
4	metaraminol	metaraminol	NN	_	1	appos
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	cause	cause	VB	_	0	ROOT
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	arrhythmias	arrhythmia	NNS	_	7	dobj
11	during	during	IN	_	13	case
12	halothane	halothane	NN	_	13	compound
13	anesthesia	anesthesia	NN	_	7	nmod
14	and	and	CC	_	7	cc
15	therefore	therefore	RB	_	18	advmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	7	conj
19	only	only	RB	_	22	advmod
20	with	with	IN	_	22	case
21	great	great	JJ	_	22	amod
22	caution	caution	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	not	not	RB	_	26	neg
25	at	at	IN	_	26	case
26	all	all	DT	_	22	conj
27	.	.	.	_	7	punct

1	MAO	MAO	NNP	_	2	compound
2	Inhibitors	inhibitor	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	6	det
5	pressor	pressor	NN	_	6	compound
6	effect	effect	NN	_	13	nsubjpass
7	of	of	IN	_	10	case
8	sympathomimetic	sympathomimetic	JJ	_	10	amod
9	pressor	pressor	NN	_	10	compound
10	amines	amine	NNS	_	6	nmod
11	is	be	VBZ	_	13	auxpass
12	markedly	markedly	RB	_	13	advmod
13	potentiated	potentiate	VBN	_	2	dep
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	monoamine	monoamine	NN	_	19	compound
18	oxidase	oxidase	NN	_	19	compound
19	inhibitors	inhibitor	NNS	_	16	dobj
20	(	(	VBP	_	13	xcomp
21	MAOI	MAOI	NNP	_	20	dobj
22	)	)	CD	_	21	nummod
23	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	16	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	9	case
8	these	these	DT	_	9	det
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	16	punct
11	the	the	DT	_	13	det
12	initial	initial	JJ	_	13	amod
13	dose	dose	NN	_	16	nsubj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	cop
16	small	small	JJ	_	0	ROOT
17	and	and	CC	_	16	cc
18	used	use	VBN	_	16	conj
19	with	with	IN	_	21	case
20	due	due	JJ	_	21	amod
21	caution	caution	NN	_	18	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	pressor	pressor	NN	_	3	compound
3	response	response	NN	_	10	nsubjpass
4	of	of	IN	_	6	case
5	adrenergic	adrenergic	JJ	_	6	amod
6	agents	agent	NNS	_	3	nmod
7	may	may	MD	_	10	aux
8	also	also	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	potentiated	potentiate	VBN	_	0	ROOT
11	by	by	IN	_	13	case
12	tricyclic	tricyclic	JJ	_	13	amod
13	antidepressants	antidepressant	NNS	_	10	nmod
14	.	.	.	_	10	punct

1	Paricalcitol	Paricalcitol	NNP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	expected	expect	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	inhibit	inhibit	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	metabolized	metabolize	VBN	_	10	acl
12	by	by	IN	_	16	case
13	cytochrome	cytochrome	NN	_	16	compound
14	P450	p450	NN	_	16	compound
15	enzymes	enzyme	NNS	_	16	compound
16	CYP1A2	cyp1a2	NN	_	11	nmod
17	,	,	,	_	16	punct
18	CYP2A6	cyp2a6	NN	_	16	conj
19	,	,	,	_	16	punct
20	CYP2B6	cyp2b6	NN	_	16	conj
21	,	,	,	_	16	punct
22	CYP2C8	cyp2c8	NN	_	16	conj
23	,	,	,	_	16	punct
24	CYP2C9	cyp2c9	NN	_	16	conj
25	,	,	,	_	16	punct
26	CYP2C19	cyp2c19	NN	_	16	conj
27	,	,	,	_	16	punct
28	CYP2D6	cyp2d6	NN	_	29	compound
29	CYP2E1	cyp2e1	NN	_	16	conj
30	or	or	CC	_	16	cc
31	CYP3A	cyp3a	NN	_	16	conj
32	nor	nor	CC	_	6	cc
33	induce	induce	VB	_	6	conj
34	the	the	DT	_	35	det
35	clearance	clearance	NN	_	33	dobj
36	of	of	IN	_	37	case
37	drugs	drug	NNS	_	35	nmod
38	metabolized	metabolize	VBN	_	37	acl
39	by	by	IN	_	40	case
40	CYP2B6	cyp2b6	NN	_	38	nmod
41	,	,	,	_	40	punct
42	CYP2C9	cyp2c9	NN	_	40	conj
43	or	or	CC	_	40	cc
44	CYP3A	cyp3a	NN	_	40	conj
45	.	.	.	_	4	punct

1	A	a	DT	_	4	det
2	multiple	multiple	JJ	_	4	amod
3	dose	dose	NN	_	4	compound
4	drug	drug	NN	_	9	nsubj
5	-	-	:	_	4	punct
6	drug	drug	NN	_	8	compound
7	interaction	interaction	NN	_	8	compound
8	study	study	NN	_	4	dep
9	demonstrated	demonstrate	VBD	_	0	ROOT
10	that	that	IN	_	13	mark
11	ketoconazole	ketoconazole	NN	_	13	nsubj
12	approximately	approximately	RB	_	13	advmod
13	doubled	double	VBD	_	9	ccomp
14	paricalcitol	paricalcitol	NN	_	15	compound
15	AUC0	auc0	NN	_	13	dobj
16	-	-	:	_	13	punct
17	.	.	.	_	13	punct
18	Since	since	IN	_	22	mark
19	paricalcitol	paricalcitol	NN	_	22	nsubjpass
20	is	be	VBZ	_	22	auxpass
21	partially	partially	RB	_	22	advmod
22	metabolized	metabolize	VBN	_	29	advcl
23	by	by	IN	_	24	case
24	CYP3A	cyp3a	NN	_	22	nmod
25	and	and	CC	_	24	cc
26	ketoconazole	ketoconazole	NN	_	24	conj
27	le	le	DT	_	24	dep
28	is	be	VBZ	_	29	auxpass
29	known	know	VBN	_	13	parataxis
30	to	to	TO	_	34	mark
31	be	be	VB	_	34	cop
32	a	a	DT	_	34	det
33	strong	strong	JJ	_	34	amod
34	inhibitor	inhibitor	NN	_	29	xcomp
35	of	of	IN	_	39	case
36	cytochrome	cytochrome	NN	_	39	compound
37	P450	p450	NN	_	39	compound
38	3A	3a	NN	_	39	compound
39	enzyme	enzyme	NN	_	34	nmod
40	,	,	,	_	34	punct
41	care	care	NN	_	44	nsubjpass
42	should	should	MD	_	44	aux
43	be	be	VB	_	44	auxpass
44	taken	take	VBN	_	34	parataxis
45	while	while	IN	_	44	xcomp
46	dosing	dosing	NN	_	47	compound
47	paricalcitol	paricalcitol	NN	_	45	dep
48	with	with	IN	_	49	case
49	ketoconazole	ketoconazole	NN	_	47	nmod
50	and	and	CC	_	49	cc
51	other	other	JJ	_	55	amod
52	strong	strong	JJ	_	55	amod
53	P450	p450	NN	_	55	compound
54	3A	3a	NN	_	55	compound
55	inhibitors	inhibitor	NNS	_	49	conj
56	including	include	VBG	_	57	case
57	atazanavir	atazanavir	NN	_	55	nmod
58	,	,	,	_	57	punct
59	clarithromycin	clarithromycin	NN	_	57	conj
60	,	,	,	_	57	punct
61	indinavir	indinavir	NN	_	57	conj
62	,	,	,	_	57	punct
63	itraconazole	itraconazole	NN	_	57	conj
64	,	,	,	_	57	punct
65	nefazodone	nefazodone	NN	_	57	conj
66	,	,	,	_	57	punct
67	nelfinavir	nelfinavir	NN	_	57	conj
68	,	,	,	_	57	punct
69	ritonavir	ritonavir	NN	_	57	conj
70	,	,	,	_	57	punct
71	saquinavir	saquinavir	NN	_	57	conj
72	,	,	,	_	57	punct
73	telithromycin	telithromycin	NN	_	57	conj
74	or	or	CC	_	57	cc
75	voriconazole	voriconazole	NN	_	57	conj
76	.	.	.	_	9	punct

1	Dose	dose	NN	_	2	compound
2	adjustment	adjustment	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	Zemplar	Zemplar	NNP	_	5	compound
5	Capsules	Capsules	NNPS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	required	require	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	and	and	CC	_	8	cc
11	iPTH	ipth	NN	_	15	compound
12	and	and	CC	_	11	cc
13	serum	serum	NN	_	11	conj
14	calcium	calcium	NN	_	15	compound
15	concentrations	concentration	NNS	_	19	nsubjpass
16	should	should	MD	_	19	aux
17	be	be	VB	_	19	auxpass
18	closely	closely	RB	_	19	advmod
19	monitored	monitor	VBN	_	8	conj
20	if	if	IN	_	23	mark
21	a	a	DT	_	22	det
22	patient	patient	NN	_	23	nsubj
23	initiates	initiate	VBZ	_	19	advcl
24	or	or	CC	_	23	cc
25	discontinues	discontinue	VBZ	_	23	conj
26	therapy	therapy	NN	_	23	dobj
27	with	with	IN	_	31	case
28	a	a	DT	_	31	det
29	strong	strong	JJ	_	31	amod
30	CYP3A4	cyp3a4	NN	_	31	compound
31	inhibitor	inhibitor	NN	_	26	nmod
32	such	such	JJ	_	34	case
33	as	as	IN	_	32	mwe
34	ketoconazole	ketoconazole	NN	_	31	nmod
35	.	.	.	_	8	punct

1	Drugs	drug	NNS	_	17	nsubj
2	that	that	WDT	_	3	nsubj
3	impair	impair	VBP	_	1	acl:relcl
4	intestinal	intestinal	JJ	_	5	amod
5	absorption	absorption	NN	_	3	dobj
6	of	of	IN	_	10	case
7	fat	fat	NN	_	10	compound
8	-	-	:	_	10	punct
9	soluble	soluble	JJ	_	10	amod
10	vitamins	vitamin	NNS	_	5	nmod
11	,	,	,	_	5	punct
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	cholestyramine	cholestyramine	NN	_	5	nmod
15	,	,	,	_	17	punct
16	may	may	MD	_	17	aux
17	interfere	interfere	VB	_	0	ROOT
18	with	with	IN	_	20	case
19	the	the	DT	_	20	det
20	absorption	absorption	NN	_	17	nmod
21	of	of	IN	_	23	case
22	Zemplar	Zemplar	NNP	_	23	compound
23	Capsules	Capsules	NNPS	_	20	nmod
24	.	.	.	_	17	punct

1	Zidovudine	Zidovudine	NNP	_	3	nsubj
2	competitively	competitively	RB	_	3	advmod
3	inhibits	inhibit	VBZ	_	0	ROOT
4	the	the	DT	_	6	det
5	intracellular	intracellular	JJ	_	6	amod
6	phosphorylation	phosphorylation	NN	_	3	dobj
7	of	of	IN	_	8	case
8	stavudine	stavudine	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	use	use	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	zidovudine	zidovudine	NN	_	3	nmod
6	in	in	IN	_	7	case
7	combination	combination	NN	_	3	nmod
8	with	with	IN	_	9	case
9	ZERIT	zerit	NN	_	7	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	12	mark
6	the	the	DT	_	7	det
7	phosphorylation	phosphorylation	NN	_	12	nsubjpass
8	of	of	IN	_	9	case
9	stavudine	stavudine	NN	_	7	nmod
10	is	be	VBZ	_	12	auxpass
11	also	also	RB	_	12	advmod
12	inhibited	inhibit	VBN	_	4	ccomp
13	at	at	IN	_	15	case
14	relevant	relevant	JJ	_	15	amod
15	concentrations	concentration	NNS	_	12	nmod
16	by	by	IN	_	17	case
17	doxorubicin	doxorubicin	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	ribavirin	ribavirin	NNP	_	17	conj
20	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	10	nsubj
4	of	of	IN	_	8	case
5	these	these	DT	_	8	det
6	in	in	FW	_	8	amod
7	vitro	vitro	FW	_	6	dep
8	interactions	interaction	NNS	_	3	nmod
9	is	be	VBZ	_	10	cop
10	unknown	unknown	JJ	_	0	ROOT
11	;	;	:	_	10	punct

1	therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	14	nsubjpass
5	of	of	IN	_	6	case
6	stavudine	stavudine	NN	_	4	nmod
7	with	with	IN	_	8	case
8	either	either	DT	_	4	nmod
9	of	of	IN	_	11	case
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	undertaken	undertake	VBN	_	0	ROOT
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	.	.	.	_	14	punct

1	No	no	DT	_	4	neg
2	specific	specific	JJ	_	4	amod
3	cytochrome	cytochrome	NN	_	4	compound
4	P450	p450	NN	_	0	ROOT
5	-	-	:	_	4	punct
6	based	base	VBN	_	9	amod
7	drug	drug	NN	_	9	compound
8	interaction	interaction	NN	_	9	compound
9	studies	study	NNS	_	12	nsubjpass
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	conducted	conduct	VBN	_	4	dep
13	.	.	.	_	4	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	0	ROOT
4	between	between	IN	_	6	case
5	85	85	CD	_	6	nummod
6	mg	mg	NN	_	3	nmod
7	/	/	:	_	6	punct
8	m2	m2	NN	_	9	compound
9	ELOXATIN	eloxatin	NN	_	6	dep
10	and	and	CC	_	6	cc
11	infusional	infusional	JJ	_	17	dep
12	5	5	LS	_	17	dep
13	-	-	:	_	12	punct
14	FU	FU	NNP	_	17	nsubjpass
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	observed	observe	VBN	_	6	conj
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	treated	treat	VBN	_	19	acl
21	every	every	DT	_	23	det
22	2	2	CD	_	23	nummod
23	weeks	week	NNS	_	20	nmod:tmod
24	.	.	.	_	3	punct

1	Increases	increase	NNS	_	14	nsubjpass
2	of	of	IN	_	7	case
3	5	5	CD	_	7	nummod
4	-	-	:	_	7	punct
5	FU	FU	NNP	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	1	nmod
8	by	by	IN	_	11	case
9	approximately	approximately	RB	_	10	advmod
10	20	20	CD	_	11	nummod
11	%	%	NN	_	1	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	with	with	IN	_	16	case
16	doses	dose	NNS	_	14	nmod
17	of	of	IN	_	19	case
18	130	130	CD	_	19	nummod
19	mg	mg	NN	_	16	nmod
20	/	/	:	_	19	punct
21	m2	m2	NN	_	22	compound
22	ELOXATIN	eloxatin	NN	_	19	dep
23	dosed	dose	VBD	_	14	dep
24	every	every	DT	_	26	det
25	3	3	CD	_	26	nummod
26	weeks	week	NNS	_	23	nmod:tmod
27	.	.	.	_	14	punct

1	Since	since	IN	_	6	mark
2	platinum	platinum	NN	_	6	nsubjpass
3	containing	contain	VBG	_	2	acl
4	species	species	NNS	_	3	dobj
5	are	be	VBP	_	6	auxpass
6	eliminated	eliminate	VBN	_	18	advcl
7	primarily	primarily	RB	_	6	advmod
8	through	through	IN	_	10	case
9	the	the	DT	_	10	det
10	kidney	kidney	NN	_	6	nmod
11	,	,	,	_	18	punct
12	clearance	clearance	NN	_	18	nsubjpass
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	products	product	NNS	_	12	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	decreased	decrease	VBN	_	0	ROOT
19	by	by	IN	_	20	case
20	coadministration	coadministration	NN	_	18	nmod
21	of	of	IN	_	24	case
22	potentially	potentially	RB	_	23	advmod
23	nephrotoxic	nephrotoxic	JJ	_	24	amod
24	compounds	compound	NNS	_	20	nmod
25	;	;	:	_	18	punct

1	although	although	IN	_	8	mark
2	,	,	,	_	8	punct
3	this	this	DT	_	8	nsubjpass
4	has	have	VBZ	_	8	aux
5	not	not	RB	_	8	neg
6	been	be	VBN	_	8	auxpass
7	specifically	specifically	RB	_	8	advmod
8	studied	study	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	CHEMET	CHEMET	NNP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	interact	interact	VB	_	4	xcomp
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	including	include	VBG	_	12	case
11	iron	iron	NN	_	12	compound
12	supplements	supplement	NNS	_	9	nmod
13	;	;	:	_	4	punct

1	interactions	interaction	NNS	_	6	nsubjpass
2	have	have	VBP	_	6	aux
3	not	not	RB	_	6	neg
4	been	be	VBN	_	6	auxpass
5	systematically	systematically	RB	_	6	advmod
6	studied	study	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	17	nsubjpass
3	of	of	IN	_	4	case
4	CHEMET	chemet	NN	_	2	nmod
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	chelation	chelation	NN	_	8	compound
8	therapy	therapy	NN	_	2	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	14	case
11	as	as	IN	_	10	mwe
12	CaNa	cana	NN	_	14	compound
13	2	2	CD	_	14	nummod
14	EDTA	edta	NN	_	8	nmod
15	is	be	VBZ	_	17	auxpass
16	not	not	RB	_	17	neg
17	recommended	recommend	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Tests	Tests	NNP	_	5	compound
5	Interaction	interaction	NN	_	0	ROOT
6	:	:	:	_	5	punct
7	Succimer	Succimer	NNP	_	9	nsubj
8	may	may	MD	_	9	aux
9	interfere	interfere	VB	_	5	parataxis
10	with	with	IN	_	11	case
11	serum	serum	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	urinary	urinary	JJ	_	15	amod
14	laboratory	laboratory	NN	_	15	compound
15	tests	test	NNS	_	11	conj
16	.	.	.	_	5	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	succimer	succimer	NN	_	5	dobj
7	to	to	TO	_	8	mark
8	cause	cause	VB	_	6	acl
9	false	false	JJ	_	11	amod
10	positive	positive	JJ	_	11	amod
11	results	result	NNS	_	8	dobj
12	for	for	IN	_	13	case
13	ketones	ketone	NNS	_	11	nmod
14	in	in	IN	_	15	case
15	urine	urine	NN	_	13	nmod
16	using	use	VBG	_	8	xcomp
17	nitroprusside	nitroprusside	NN	_	18	compound
18	reagents	reagent	NNS	_	16	dobj
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	Ketostix	Ketostix	NNP	_	18	nmod
22	and	and	CC	_	5	cc
23	falsely	falsely	RB	_	24	advmod
24	decreased	decrease	VBD	_	25	amod
25	measurements	measurement	NNS	_	5	conj
26	of	of	IN	_	29	case
27	serum	serum	NN	_	29	compound
28	uric	uric	JJ	_	29	amod
29	acid	acid	NN	_	25	nmod
30	and	and	CC	_	29	cc
31	CPK	cpk	NN	_	29	conj
32	.	.	.	_	5	punct

1	Thiazide	Thiazide	NNP	_	2	compound
2	diuretics	diuretic	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	accentuate	accentuate	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	orthostatic	orthostatic	JJ	_	7	amod
7	hypotension	hypotension	NN	_	4	dobj
8	that	that	WDT	_	10	nsubj
9	may	may	MD	_	10	aux
10	occur	occur	VB	_	7	acl:relcl
11	with	with	IN	_	12	case
12	phenothiazines	phenothiazine	NNS	_	10	nmod
13	.	.	.	_	4	punct

1	Antihypertensive	antihypertensive	JJ	_	2	amod
2	effects	effect	NNS	_	10	nsubjpass
3	of	of	IN	_	4	case
4	guanethidine	guanethidine	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	related	related	JJ	_	7	amod
7	compounds	compound	NNS	_	4	conj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	counteracted	counteract	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	phenothiazines	phenothiazine	NNS	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	used	use	VBN	_	10	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	.	.	.	_	10	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	propranolol	propranolol	NN	_	2	nmod
5	with	with	IN	_	6	case
6	phenothiazines	phenothiazine	NNS	_	2	nmod
7	results	result	VBZ	_	0	ROOT
8	in	in	IN	_	11	case
9	increased	increase	VBN	_	11	amod
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	7	nmod
12	of	of	IN	_	14	case
13	both	both	DT	_	14	det
14	drugs	drug	NNS	_	11	nmod
15	.	.	.	_	7	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	11	11	CD	_	6	nummod
5	clinical	clinical	JJ	_	6	amod
6	drug	drug	NN	_	2	nmod
7	-	-	:	_	6	punct
8	drug	drug	NN	_	10	compound
9	interaction	interaction	NN	_	10	compound
10	studies	study	NNS	_	12	nsubjpass
11	were	be	VBD	_	12	auxpass
12	conducted	conduct	VBN	_	6	acl:relcl
13	in	in	IN	_	15	case
14	healthy	healthy	JJ	_	15	amod
15	volunteers	volunteer	NNS	_	12	nmod
16	to	to	TO	_	17	mark
17	evaluate	evaluate	VB	_	12	xcomp
18	the	the	DT	_	19	det
19	potential	potential	NN	_	17	dobj
20	for	for	IN	_	21	case
21	interaction	interaction	NN	_	19	nmod
22	between	between	IN	_	23	case
23	MYCAMINE	MYCAMINE	NNP	_	21	nmod
24	and	and	CC	_	23	cc
25	mycophenolate	mycophenolate	JJ	_	26	amod
26	mofetil	mofetil	NN	_	23	conj
27	,	,	,	_	26	punct
28	cyclosporine	cyclosporine	NN	_	26	conj
29	,	,	,	_	26	punct
30	tacrolimus	tacrolimus	NN	_	26	conj
31	,	,	,	_	26	punct
32	prednisolone	prednisolone	NN	_	26	conj
33	,	,	,	_	26	punct
34	sirolimus	sirolimus	NN	_	26	conj
35	,	,	,	_	26	punct
36	nifedipine	nifedipine	NN	_	26	conj
37	,	,	,	_	26	punct
38	fluconazole	fluconazole	NN	_	26	conj
39	,	,	,	_	26	punct
40	ritonavir	ritonavir	NN	_	26	conj
41	,	,	,	_	26	punct
42	and	and	CC	_	26	cc
43	rifampin	rifampin	NN	_	26	conj
44	.	.	.	_	2	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	studies	study	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	no	no	DT	_	6	neg
6	interaction	interaction	NN	_	14	nsubjpass
7	that	that	WDT	_	8	nsubj
8	altered	alter	VBD	_	6	acl:relcl
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	micafungin	micafungin	NN	_	10	nmod
13	was	be	VBD	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	of	of	IN	_	8	case
6	a	a	DT	_	8	det
7	single	single	JJ	_	8	amod
8	dose	dose	NN	_	4	nmod
9	or	or	CC	_	8	cc
10	multiple	multiple	JJ	_	11	amod
11	doses	dose	NNS	_	8	conj
12	of	of	IN	_	13	case
13	MYCAMINE	mycamine	NN	_	8	nmod
14	on	on	IN	_	16	case
15	mycophenolate	mycophenolate	JJ	_	16	amod
16	mofetil	mofetil	NN	_	4	nmod
17	,	,	,	_	16	punct
18	cyclosporine	cyclosporine	NN	_	16	conj
19	,	,	,	_	16	punct
20	tacrolimus	tacrolimus	NN	_	16	conj
21	,	,	,	_	16	punct
22	prednisolone	prednisolone	NN	_	16	conj
23	,	,	,	_	16	punct
24	and	and	CC	_	16	cc
25	fluconazole	fluconazole	NN	_	26	compound
26	pharmacokinetics	pharmacokinetic	NNS	_	16	conj
27	.	.	.	_	2	punct

1	Sirolimus	Sirolimus	NNP	_	2	compound
2	AUC	auc	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	increased	increase	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	21	21	CD	_	7	nummod
7	%	%	NN	_	4	nmod
8	with	with	IN	_	10	case
9	no	no	DT	_	10	neg
10	effect	effect	NN	_	4	nmod
11	on	on	IN	_	12	case
12	Cmax	Cmax	NNP	_	10	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	presence	presence	NN	_	10	nmod
16	of	of	IN	_	20	case
17	steady	steady	JJ	_	20	amod
18	-	-	:	_	20	punct
19	state	state	NN	_	20	compound
20	MYCAMINE	mycamine	NN	_	15	nmod
21	compared	compare	VBN	_	23	case
22	with	with	IN	_	23	case
23	sirolimus	sirolimus	NN	_	4	advcl
24	alone	alone	RB	_	23	advmod
25	.	.	.	_	4	punct

1	Nifedipine	Nifedipine	NNP	_	2	compound
2	AUC	auc	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	Cmax	cmax	NN	_	2	conj
5	were	be	VBD	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	18	18	CD	_	9	nummod
9	%	%	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	42	42	CD	_	12	nummod
12	%	%	NN	_	9	conj
13	,	,	,	_	6	punct
14	respectively	respectively	RB	_	6	advmod
15	,	,	,	_	6	punct
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	presence	presence	NN	_	6	nmod
19	of	of	IN	_	23	case
20	steady	steady	JJ	_	23	amod
21	-	-	:	_	23	punct
22	state	state	NN	_	23	compound
23	MYCAMINE	mycamine	NN	_	18	nmod
24	compared	compare	VBN	_	26	case
25	with	with	IN	_	26	case
26	nifedipine	nifedipine	NN	_	18	nmod
27	alone	alone	RB	_	26	advmod
28	.	.	.	_	6	punct

1	Patients	patient	NNS	_	12	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	sirolimus	sirolimus	NN	_	2	dobj
4	or	or	CC	_	3	cc
5	nifedipine	nifedipine	NN	_	3	conj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	2	nmod
8	with	with	IN	_	9	case
9	MYCAMINE	mycamine	NN	_	7	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	monitored	monitor	VBN	_	0	ROOT
13	for	for	IN	_	14	case
14	sirolimus	sirolimus	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	nifedipine	nifedipine	NN	_	17	compound
17	toxicity	toxicity	NN	_	14	conj
18	and	and	CC	_	14	cc
19	sirolimus	sirolimus	NN	_	22	compound
20	or	or	CC	_	19	cc
21	nifedipine	nifedipine	NN	_	19	conj
22	dosage	dosage	NN	_	14	conj
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	reduced	reduce	VBN	_	12	ccomp
26	if	if	IN	_	27	mark
27	necessary	necessary	JJ	_	25	advcl
28	.	.	.	_	12	punct

1	Micafungin	Micafungin	NNP	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	not	not	RB	_	5	neg
4	an	a	DT	_	5	det
5	inhibitor	inhibitor	NN	_	0	ROOT
6	of	of	IN	_	7	case
7	P	p	NN	_	5	nmod
8	-	-	:	_	7	punct
9	glycoprotein	glycoprotein	NN	_	7	dep
10	and	and	CC	_	7	cc
11	,	,	,	_	7	punct
12	therefore	therefore	RB	_	7	advmod
13	,	,	,	_	7	punct
14	would	would	MD	_	17	aux
15	not	not	RB	_	17	neg
16	be	be	VB	_	17	auxpass
17	expected	expect	VBN	_	7	dep
18	to	to	TO	_	19	mark
19	alter	alter	VB	_	17	xcomp
20	P	p	NN	_	22	compound
21	-	-	:	_	22	punct
22	glycoprotein	glycoprotein	NN	_	19	dobj
23	-	-	:	_	22	punct
24	mediated	mediate	VBN	_	27	amod
25	drug	drug	NN	_	27	compound
26	transport	transport	NN	_	27	compound
27	activity	activity	NN	_	22	dep
28	.	.	.	_	5	punct

1	Hypokalemia	hypokalemia	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	sensitize	sensitize	VB	_	0	ROOT
4	or	or	CC	_	3	cc
5	exaggerate	exaggerate	VB	_	3	conj
6	the	the	DT	_	7	det
7	response	response	NN	_	3	dobj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	heart	heart	NN	_	7	nmod
11	to	to	TO	_	14	case
12	the	the	DT	_	14	det
13	toxic	toxic	JJ	_	14	amod
14	effects	effect	NNS	_	7	nmod
15	of	of	IN	_	16	case
16	digitalis	digitalis	NN	_	14	nmod
17	(	(	CD	_	16	nummod
18	e	e	LS	_	20	dep
19	.	.	.	_	18	punct
20	g	g	NN	_	14	dep
21	.	.	.	_	20	punct
22	,	,	,	_	3	punct
23	increased	increase	VBD	_	26	amod
24	ventricular	ventricular	JJ	_	26	amod
25	irritability	irritability	NN	_	26	compound
26	)	)	NN	_	3	dobj
27	.	.	.	_	3	punct

1	Hypokalemia	hypokalemia	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	develop	develop	VB	_	0	ROOT
4	during	during	IN	_	6	case
5	concomitant	concomitant	JJ	_	6	amod
6	use	use	NN	_	3	nmod
7	of	of	IN	_	8	case
8	steroids	steroid	NNS	_	6	nmod
9	or	or	CC	_	8	cc
10	ACTH	acth	NN	_	8	conj
11	.	.	.	_	3	punct

1	Insulin	insulin	NN	_	2	compound
2	requirements	requirement	NNS	_	8	nsubjpass
3	in	in	IN	_	5	case
4	diabetic	diabetic	JJ	_	5	amod
5	patients	patient	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	increased	increase	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	decreased	decrease	VBN	_	8	conj
11	,	,	,	_	8	punct
12	or	or	CC	_	8	cc
13	unchanged	unchanged	JJ	_	8	conj
14	.	.	.	_	8	punct

1	Thiazides	thiazide	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	arterial	arterial	JJ	_	5	amod
5	responsiveness	responsiveness	NN	_	3	dobj
6	to	to	TO	_	7	case
7	norepinephrine	norepinephrine	NN	_	5	nmod
8	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	diminution	diminution	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	sufficient	sufficient	JJ	_	0	ROOT
6	to	to	TO	_	7	mark
7	preclude	preclude	VB	_	5	xcomp
8	effectiveness	effectiveness	NN	_	7	dobj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	pressor	pressor	NN	_	12	compound
12	agent	agent	NN	_	8	nmod
13	for	for	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	use	use	NN	_	7	nmod
16	.	.	.	_	5	punct

1	Thiazide	thiazide	JJ	_	2	amod
2	drugs	drug	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	responsiveness	responsiveness	NN	_	4	dobj
7	of	of	IN	_	8	case
8	tubocurarine	tubocurarine	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Lithium	lithium	NN	_	3	compound
2	renal	renal	JJ	_	3	amod
3	clearance	clearance	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	reduced	reduce	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	thiazides	thiazide	NNS	_	5	nmod
8	,	,	,	_	5	punct
9	increasing	increase	VBG	_	5	xcomp
10	the	the	DT	_	11	det
11	risk	risk	NN	_	9	dobj
12	of	of	IN	_	14	case
13	lithium	lithium	NN	_	14	compound
14	toxicity	toxicity	NN	_	11	nmod
15	.	.	.	_	5	punct

1	Thiazides	thiazide	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	add	add	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	or	or	CC	_	4	cc
6	potentiate	potentiate	VB	_	4	conj
7	the	the	DT	_	8	det
8	action	action	NN	_	3	nmod
9	of	of	IN	_	12	case
10	other	other	JJ	_	12	amod
11	antihypertensive	antihypertensive	JJ	_	12	amod
12	drugs	drug	NNS	_	8	nmod
13	.	.	.	_	3	punct

1	Potentiation	potentiation	NN	_	2	nsubj
2	occurs	occur	VBZ	_	0	ROOT
3	with	with	IN	_	9	case
4	ganglionic	ganglionic	JJ	_	9	amod
5	or	or	CC	_	4	cc
6	peripheral	peripheral	JJ	_	4	conj
7	adrenergic	adrenergic	JJ	_	9	amod
8	blocking	blocking	NN	_	9	compound
9	drugs	drug	NNS	_	2	nmod
10	.	.	.	_	2	punct

1	Carbidopa	carbidopa	NN	_	3	compound
2	/	/	:	_	3	punct
3	Levodopa	Levodopa	NNP	_	0	ROOT
4	:	:	:	_	3	punct
5	Carbidopa	carbidopa	NN	_	7	compound
6	/	/	:	_	7	punct
7	Levodopa	levodopa	NN	_	10	nsubj
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	influence	influence	VB	_	3	parataxis
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	10	dobj
13	of	of	IN	_	14	case
14	pramipexole	pramipexole	NN	_	12	nmod
15	in	in	IN	_	17	case
16	healthy	healthy	JJ	_	17	amod
17	volunteers	volunteer	NNS	_	10	nmod
18	(	(	VBP	_	10	dep
19	N	n	NN	_	20	nsubj
20	=	=	JJ	_	18	ccomp
21	10	10	CD	_	22	nummod
22	)	)	NN	_	20	dobj
23	.	.	.	_	3	punct

1	5	5	CD	_	2	nummod
2	hours	hour	NNS	_	0	ROOT
3	.	.	.	_	2	punct

1	Selegiline	Selegiline	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	healthy	healthy	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	6	nmod
6	(	(	VBP	_	1	appos
7	N	n	NN	_	8	nsubj
8	=	=	JJ	_	6	ccomp
9	11	11	CD	_	10	nummod
10	)	)	NN	_	8	dobj
11	,	,	,	_	8	punct
12	selegiline	selegiline	NN	_	15	nsubj
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	influence	influence	VB	_	8	dep
16	the	the	DT	_	17	det
17	pharmacokinetics	pharmacokinetic	NNS	_	15	dobj
18	of	of	IN	_	19	case
19	pramipexole	pramipexole	NN	_	17	nmod
20	.	.	.	_	1	punct

1	Amantadine	Amantadine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Population	Population	NNP	_	5	compound
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	analysis	analysis	NN	_	6	nsubj
6	suggests	suggest	VBZ	_	1	appos
7	that	that	IN	_	10	mark
8	amantadine	amantadine	NN	_	10	nsubj
9	is	be	VBZ	_	10	cop
10	unlikely	unlikely	JJ	_	6	ccomp
11	to	to	TO	_	12	mark
12	alter	alter	VB	_	10	xcomp
13	the	the	DT	_	15	det
14	oral	oral	JJ	_	15	amod
15	clearance	clearance	NN	_	12	dobj
16	of	of	IN	_	19	case
17	pramipexole	pramipexole	NN	_	19	compound
18	(	(	CD	_	19	nummod
19	N	n	NN	_	15	nmod
20	=	=	JJ	_	15	amod
21	54	54	CD	_	22	nummod
22	)	)	NN	_	20	dep
23	.	.	.	_	1	punct

1	Cimetidine	Cimetidine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Cimetidine	Cimetidine	NNP	_	21	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	known	known	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	tubular	tubular	JJ	_	11	amod
11	secretion	secretion	NN	_	7	nmod
12	of	of	IN	_	14	case
13	organic	organic	JJ	_	14	amod
14	bases	basis	NNS	_	11	nmod
15	via	via	IN	_	19	case
16	the	the	DT	_	19	det
17	cationic	cationic	JJ	_	19	amod
18	transport	transport	NN	_	19	compound
19	system	system	NN	_	7	nmod
20	,	,	,	_	3	punct
21	caused	cause	VBD	_	1	appos
22	a	a	DT	_	25	det
23	50	50	CD	_	24	compound
24	%	%	NN	_	25	amod
25	increase	increase	NN	_	21	dobj
26	in	in	IN	_	28	case
27	pramipexole	pramipexole	NN	_	28	compound
28	AUC	auc	NN	_	25	nmod
29	and	and	CC	_	25	cc
30	a	a	DT	_	33	det
31	40	40	CD	_	32	compound
32	%	%	NN	_	33	amod
33	increase	increase	NN	_	25	conj
34	in	in	IN	_	39	case
35	half	half	NN	_	39	dep
36	-	-	:	_	39	punct
37	life	life	NN	_	39	compound
38	(	(	CD	_	39	nummod
39	N	n	NN	_	33	nmod
40	=	=	JJ	_	39	amod
41	12	12	CD	_	42	nummod
42	)	)	NN	_	40	dep
43	.	.	.	_	1	punct

1	Probenecid	Probenecid	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Probenecid	Probenecid	NNP	_	23	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	known	known	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	tubular	tubular	JJ	_	11	amod
11	secretion	secretion	NN	_	7	nmod
12	of	of	IN	_	14	case
13	organic	organic	JJ	_	14	amod
14	acids	acid	NNS	_	11	nmod
15	via	via	IN	_	18	case
16	the	the	DT	_	18	det
17	aruonic	aruonic	JJ	_	18	amod
18	transporter	transporter	NN	_	7	nmod
19	,	,	,	_	3	punct
20	did	do	VBD	_	23	aux
21	not	not	RB	_	23	neg
22	noticeably	noticeably	RB	_	23	advmod
23	influence	influence	VB	_	1	parataxis
24	pramipexole	pramipexole	NN	_	25	compound
25	pharmacokinetics	pharmacokinetic	NNS	_	26	nsubj
26	(	(	VBP	_	23	ccomp
27	N	n	NN	_	28	nsubj
28	=	=	JJ	_	26	ccomp
29	12	12	CD	_	30	nummod
30	)	)	NN	_	28	dobj
31	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	0	ROOT
3	eliminated	eliminate	VBN	_	2	acl
4	via	via	IN	_	6	case
5	renal	renal	JJ	_	6	amod
6	secretion	secretion	NN	_	3	nmod
7	:	:	:	_	2	punct
8	Population	Population	NNP	_	10	compound
9	pharmacokinetic	pharmacokinetic	JJ	_	10	amod
10	analysis	analysis	NN	_	11	nsubj
11	suggests	suggest	VBZ	_	2	dep
12	that	that	IN	_	27	mark
13	coadministration	coadministration	NN	_	27	nsubj
14	of	of	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	that	that	WDT	_	18	nsubjpass
17	are	be	VBP	_	18	auxpass
18	secreted	secrete	VBN	_	15	acl:relcl
19	by	by	IN	_	23	case
20	the	the	DT	_	23	det
21	cationic	cationic	JJ	_	23	amod
22	transport	transport	NN	_	23	compound
23	system	system	NN	_	18	nmod
24	(	(	CD	_	23	nummod
25	e	e	LS	_	27	dep
26	.	.	.	_	25	punct
27	g	g	NN	_	11	ccomp
28	.	.	.	_	11	punct
29	,	,	,	_	11	punct
30	cimetidine	cimetidine	NN	_	45	nsubj
31	,	,	,	_	30	punct
32	ranitidine	ranitidine	NN	_	30	conj
33	,	,	,	_	30	punct
34	diltiazem	diltiazem	NN	_	30	conj
35	,	,	,	_	30	punct
36	triamterene	triamterene	NN	_	30	conj
37	,	,	,	_	30	punct
38	verapamil	verapamil	NN	_	30	conj
39	,	,	,	_	30	punct
40	quinidine	quinidine	NN	_	30	conj
41	,	,	,	_	30	punct
42	and	and	CC	_	30	cc
43	quinine	quinine	NN	_	44	compound
44	)	)	NN	_	30	conj
45	decreases	decrease	VBZ	_	11	ccomp
46	the	the	DT	_	48	det
47	oral	oral	JJ	_	48	amod
48	clearance	clearance	NN	_	45	dobj
49	of	of	IN	_	50	case
50	pramipexole	pramipexole	NN	_	48	nmod
51	by	by	IN	_	54	case
52	about	about	RB	_	53	advmod
53	20	20	CD	_	54	nummod
54	%	%	NN	_	45	nmod
55	,	,	,	_	45	punct
56	while	while	IN	_	65	mark
57	those	those	DT	_	65	nsubj
58	secreted	secrete	VBN	_	57	acl
59	by	by	IN	_	63	case
60	the	the	DT	_	63	det
61	anionic	anionic	JJ	_	63	amod
62	transport	transport	NN	_	63	compound
63	system	system	NN	_	58	nmod
64	(	(	CD	_	63	nummod
65	e	e	LS	_	45	advcl
66	.	.	.	_	65	punct
67	g	g	NN	_	82	nsubj
68	.	.	.	_	67	punct
69	,	,	,	_	67	punct
70	cephalosporins	cephalosporin	NNS	_	67	conj
71	,	,	,	_	67	punct
72	penicillins	penicillin	NNS	_	67	conj
73	,	,	,	_	67	punct
74	indomethacin	indomethacin	NN	_	67	conj
75	,	,	,	_	67	punct
76	hydrochlorothiazide	hydrochlorothiazide	NN	_	67	conj
77	,	,	,	_	67	punct
78	and	and	CC	_	67	cc
79	chlorpropamide	chlorpropamide	NN	_	80	compound
80	)	)	NN	_	67	conj
81	are	be	VBP	_	82	cop
82	likely	likely	JJ	_	65	parataxis
83	to	to	TO	_	84	mark
84	have	have	VB	_	82	xcomp
85	little	little	JJ	_	86	amod
86	effect	effect	NN	_	84	dobj
87	on	on	IN	_	90	case
88	the	the	DT	_	90	det
89	oral	oral	JJ	_	90	amod
90	clearance	clearance	NN	_	84	nmod
91	of	of	IN	_	92	case
92	pramipexole	pramipexole	NN	_	90	nmod
93	.	.	.	_	2	punct

1	CYP	cyp	NN	_	2	compound
2	interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Inhibitors	inhibitor	NNS	_	12	nsubjpass
5	of	of	IN	_	8	case
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	enzymes	enzyme	NNS	_	4	nmod
9	would	would	MD	_	12	aux
10	not	not	RB	_	12	neg
11	be	be	VB	_	12	auxpass
12	expected	expect	VBN	_	2	dep
13	to	to	TO	_	14	mark
14	affect	affect	VB	_	12	xcomp
15	pramipexole	pramipexole	NN	_	16	compound
16	elimination	elimination	NN	_	14	dobj
17	because	because	IN	_	22	mark
18	pramipexole	pramipexole	NN	_	22	nsubjpass
19	is	be	VBZ	_	22	auxpass
20	not	not	RB	_	22	neg
21	appreciably	appreciably	RB	_	22	advmod
22	metabolized	metabolize	VBN	_	12	advcl
23	by	by	IN	_	25	case
24	these	these	DT	_	25	det
25	enzymes	enzyme	NNS	_	22	nmod
26	in	in	FW	_	27	compound
27	vivo	vivo	FW	_	28	advmod
28	or	or	CC	_	22	advmod
29	in	in	FW	_	30	compound
30	vitro	vitro	FW	_	28	advmod
31	.	.	.	_	2	punct

1	Pramipexole	Pramipexole	NNP	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	CYP	cyp	NN	_	7	compound
6	enzymes	enzyme	NNS	_	7	compound
7	CYPIA2	cypia2	NN	_	4	dobj
8	,	,	,	_	7	punct
9	CYP2C9	cyp2c9	NN	_	7	conj
10	,	,	,	_	7	punct
11	CYP2CI9	cyp2ci9	NN	_	7	conj
12	,	,	,	_	7	punct
13	CYP2EI	cyp2ei	NN	_	7	conj
14	,	,	,	_	7	punct
15	and	and	CC	_	7	cc
16	CYP3A4	cyp3a4	NN	_	7	conj
17	.	.	.	_	4	punct

1	Inhibition	inhibition	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	CYP2D6	cyp2d6	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	an	a	DT	_	9	det
8	apparent	apparent	JJ	_	9	amod
9	Ki	ki	NN	_	5	nmod
10	of	of	IN	_	12	case
11	30	30	CD	_	12	nummod
12	uM	um	NN	_	9	nmod
13	,	,	,	_	5	punct
14	indicating	indicate	VBG	_	5	xcomp
15	that	that	IN	_	19	mark
16	pramipexole	pramipexole	NN	_	19	nsubj
17	will	will	MD	_	19	aux
18	not	not	RB	_	19	neg
19	inhibit	inhibit	VB	_	14	ccomp
20	CYP	cyp	NN	_	21	compound
21	enzymes	enzyme	NNS	_	19	dobj
22	at	at	IN	_	24	case
23	plasma	plasma	NN	_	24	compound
24	concentrations	concentration	NNS	_	19	nmod
25	observed	observe	VBN	_	24	acl
26	following	follow	VBG	_	36	case
27	the	the	DT	_	36	det
28	highest	highest	JJS	_	36	amod
29	recommended	recommend	VBN	_	36	amod
30	clinical	clinical	JJ	_	36	amod
31	dose	dose	NN	_	36	compound
32	(	(	NN	_	36	compound
33	1.5	1.5	CD	_	34	compound
34	mg	mg	NN	_	36	amod
35	tid	tid	NN	_	36	compound
36	)	)	NN	_	25	nmod
37	.	.	.	_	5	punct

1	Dopamine	dopamine	NN	_	2	compound
2	antagonists	antagonist	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Since	since	IN	_	9	mark
5	pramipexole	pramipexole	NN	_	9	nsubj
6	is	be	VBZ	_	9	cop
7	a	a	DT	_	9	det
8	dopamine	dopamine	NN	_	9	compound
9	agonist	agonist	NN	_	13	advcl
10	,	,	,	_	13	punct
11	it	it	PRP	_	13	nsubj
12	is	be	VBZ	_	13	cop
13	possible	possible	JJ	_	2	dep
14	that	that	IN	_	22	mark
15	dopamine	dopamine	NN	_	16	compound
16	antagonists	antagonist	NNS	_	22	nsubj
17	,	,	,	_	16	punct
18	such	such	JJ	_	21	case
19	as	as	IN	_	18	mwe
20	the	the	DT	_	21	det
21	neuroleptics	neuroleptic	NNS	_	16	nmod
22	(	(	VBP	_	13	ccomp
23	phenothiazines	phenothiazine	NNS	_	27	nsubj
24	,	,	,	_	23	punct
25	butyrophenones	butyrophenone	NNS	_	23	appos
26	,	,	,	_	23	punct
27	thioxanthenes	thioxanthene	VBZ	_	22	ccomp
28	)	)	CD	_	27	dobj
29	or	or	CC	_	28	cc
30	metoclopramide	metoclopramide	NN	_	28	conj
31	,	,	,	_	27	punct
32	may	may	MD	_	33	aux
33	diminish	diminish	VB	_	27	dep
34	the	the	DT	_	35	det
35	effectiveness	effectiveness	NN	_	33	dobj
36	of	of	IN	_	37	case
37	MIRAPEX	MIRAPEX	NNP	_	35	nmod
38	.	.	.	_	2	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	There	there	EX	_	7	expl
7	are	be	VBP	_	5	acl:relcl
8	no	no	DT	_	10	neg
9	known	known	JJ	_	10	amod
10	interactions	interaction	NNS	_	7	nsubj
11	between	between	IN	_	12	case
12	MIRAPEX	MIRAPEX	NNP	_	10	nmod
13	and	and	CC	_	12	cc
14	laboratory	laboratory	NN	_	15	compound
15	tests	test	NNS	_	12	conj
16	.	.	.	_	5	punct

1	Do	do	VB	_	3	aux
2	not	not	RB	_	3	neg
3	exceed	exceed	VB	_	0	ROOT
4	a	a	DT	_	8	det
5	5	5	CD	_	6	compound
6	mg	mg	NN	_	8	amod
7	daily	daily	JJ	_	8	amod
8	dose	dose	NN	_	3	dobj
9	of	of	IN	_	10	case
10	VESIcare	vesicare	NN	_	8	nmod
11	when	when	WRB	_	12	advmod
12	administered	administer	VBN	_	3	advcl
13	with	with	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	doses	dose	NNS	_	12	nmod
16	of	of	IN	_	17	case
17	ketoconazole	ketoconazole	NN	_	15	nmod
18	or	or	CC	_	17	cc
19	other	other	JJ	_	22	amod
20	potent	potent	JJ	_	22	amod
21	CYP3A4	cyp3a4	NN	_	22	compound
22	inhibitors	inhibitor	NNS	_	17	conj
23	.	.	.	_	3	punct

1	Patients	patient	NNS	_	29	dep
2	with	with	IN	_	3	case
3	Congenital	congenital	JJ	_	1	nmod
4	or	or	CC	_	3	cc
5	Acquired	acquire	VBN	_	3	conj
6	QT	QT	NNP	_	7	compound
7	Prolongation	Prolongation	NNP	_	3	dep
8	In	in	IN	_	10	case
9	a	a	DT	_	10	det
10	study	study	NN	_	1	nmod
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	effect	effect	NN	_	10	nmod
14	of	of	IN	_	15	case
15	solifenacin	solifenacin	NN	_	13	nmod
16	on	on	IN	_	19	case
17	the	the	DT	_	19	det
18	QT	QT	NNP	_	19	compound
19	interval	interval	NN	_	13	nmod
20	in	in	IN	_	23	case
21	76	76	CD	_	23	nummod
22	healthy	healthy	JJ	_	23	amod
23	women	woman	NNS	_	13	nmod
24	,	,	,	_	29	punct
25	the	the	DT	_	28	det
26	QT	QT	NNP	_	28	compound
27	prolonging	prolong	VBG	_	28	compound
28	effect	effect	NN	_	29	nsubj
29	appeared	appear	VBD	_	0	ROOT
30	less	less	RBR	_	29	advmod
31	with	with	IN	_	34	case
32	solifenacin	solifenacin	NN	_	34	compound
33	10	10	CD	_	34	nummod
34	mg	mg	NN	_	30	nmod
35	than	than	IN	_	39	case
36	with	with	IN	_	39	case
37	30	30	CD	_	38	compound
38	mg	mg	NN	_	39	amod
39	(	(	NN	_	30	nmod
40	three	three	CD	_	41	compound
41	times	time	NNS	_	43	nummod
42	the	the	DT	_	43	det
43	maximum	maximum	NN	_	39	dep
44	recommended	recommend	VBD	_	46	amod
45	dose	dose	NN	_	46	compound
46	)	)	NN	_	43	dep
47	,	,	,	_	29	punct
48	and	and	CC	_	29	cc
49	the	the	DT	_	50	det
50	effect	effect	NN	_	57	nsubj
51	of	of	IN	_	52	case
52	solifenacin	solifenacin	NN	_	50	nmod
53	30	30	CD	_	54	nummod
54	mg	mg	NN	_	52	dep
55	did	do	VBD	_	57	aux
56	not	not	RB	_	57	neg
57	appear	appear	VB	_	29	conj
58	as	as	IN	_	59	advmod
59	large	large	JJ	_	57	xcomp
60	as	as	IN	_	61	case
61	that	that	DT	_	59	nmod
62	of	of	IN	_	66	case
63	the	the	DT	_	66	det
64	positive	positive	JJ	_	66	amod
65	control	control	NN	_	66	compound
66	moxifloxacin	moxifloxacin	NN	_	61	nmod
67	at	at	IN	_	70	case
68	its	its	PRP$	_	70	nmod:poss
69	therapeutic	therapeutic	JJ	_	70	amod
70	dose	dose	NN	_	66	nmod
71	.	.	.	_	29	punct

1	This	this	DT	_	2	det
2	observation	observation	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	clinical	clinical	JJ	_	8	amod
8	decisions	decision	NNS	_	5	nmod
9	to	to	TO	_	10	mark
10	prescribe	prescribe	VB	_	8	acl
11	VESIcare	vesicare	NN	_	10	dobj
12	for	for	IN	_	13	case
13	patients	patient	NNS	_	10	nmod
14	with	with	IN	_	17	case
15	a	a	DT	_	17	det
16	known	known	JJ	_	17	amod
17	history	history	NN	_	13	nmod
18	of	of	IN	_	20	case
19	QT	QT	NNP	_	20	compound
20	prolongation	prolongation	NN	_	17	nmod
21	or	or	CC	_	20	cc
22	patients	patient	NNS	_	20	conj
23	who	who	WP	_	25	nsubj
24	are	be	VBP	_	25	aux
25	taking	take	VBG	_	13	acl:relcl
26	medications	medication	NNS	_	25	dobj
27	known	know	VBN	_	26	acl
28	to	to	TO	_	29	mark
29	prolong	prolong	VB	_	27	xcomp
30	the	the	DT	_	32	det
31	QT	QT	NNP	_	32	compound
32	interval	interval	NN	_	29	dobj
33	.	.	.	_	5	punct

1	Montelukast	montelukast	NN	_	10	nsubj
2	at	at	IN	_	4	case
3	a	a	DT	_	4	det
4	Dose	dose	NN	_	1	nmod
5	of	of	IN	_	7	case
6	10	10	CD	_	7	nummod
7	mg	mg	NN	_	4	nmod
8	Once	once	RB	_	9	advmod
9	Daily	daily	JJ	_	10	advmod
10	Dosed	dose	VBN	_	0	ROOT
11	to	to	TO	_	14	case
12	Pharmacokinetic	pharmacokinetic	JJ	_	14	amod
13	Steady	steady	JJ	_	14	amod
14	State	state	NN	_	10	nmod
15	-	-	:	_	10	punct
16	did	do	VBD	_	18	aux
17	not	not	RB	_	18	neg
18	cause	cause	VB	_	10	parataxis
19	clinically	clinically	RB	_	20	advmod
20	significant	significant	JJ	_	21	amod
21	changes	change	NNS	_	18	dobj
22	in	in	IN	_	24	case
23	the	the	DT	_	24	det
24	kinetics	kinetics	NNS	_	21	nmod
25	of	of	IN	_	29	case
26	a	a	DT	_	29	det
27	single	single	JJ	_	29	amod
28	intravenous	intravenous	JJ	_	29	amod
29	dose	dose	NN	_	24	nmod
30	of	of	IN	_	31	case
31	theophylline	theophylline	NN	_	29	nmod
32	(	(	CD	_	31	nummod
33	predominantly	predominantly	RB	_	39	advmod
34	a	a	DT	_	39	det
35	cytochrome	cytochrome	NN	_	39	compound
36	P450	p450	NN	_	39	compound
37	1A2	1a2	NN	_	39	compound
38	substrate	substrate	NN	_	39	compound
39	)	)	NN	_	21	nmod
40	.	.	.	_	10	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	profile	profile	NN	_	4	dobj
8	of	of	IN	_	9	case
9	warfarin	warfarin	NN	_	7	nmod
10	(	(	CD	_	9	nummod
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	9	nmod:npmod
13	of	of	IN	_	16	case
14	cytochromes	cytochrome	NNS	_	16	compound
15	P450	p450	NN	_	16	compound
16	2A6	2a6	NN	_	12	nmod
17	and	and	CC	_	16	cc
18	2C9	2c9	NN	_	16	conj
19	)	)	CD	_	18	nummod
20	or	or	CC	_	4	cc
21	influence	influence	VB	_	4	conj
22	the	the	DT	_	23	det
23	effect	effect	NN	_	21	dobj
24	of	of	IN	_	31	case
25	a	a	DT	_	31	det
26	single	single	JJ	_	31	amod
27	30	30	CD	_	31	nummod
28	-	-	:	_	31	punct
29	mg	mg	NN	_	31	compound
30	oral	oral	JJ	_	31	amod
31	dose	dose	NN	_	23	nmod
32	of	of	IN	_	33	case
33	warfarin	warfarin	NN	_	31	nmod
34	on	on	IN	_	36	case
35	prothrombin	prothrombin	NN	_	36	compound
36	time	time	NN	_	23	nmod
37	or	or	CC	_	36	cc
38	the	the	DT	_	44	det
39	INR	inr	NN	_	44	compound
40	(	(	CD	_	44	nummod
41	International	International	NNP	_	44	compound
42	Normalized	Normalized	NNP	_	44	compound
43	Ratio	Ratio	NNP	_	44	compound
44	)	)	NN	_	36	conj
45	.	.	.	_	4	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	profile	profile	NN	_	4	dobj
8	or	or	CC	_	7	cc
9	urinary	urinary	JJ	_	10	amod
10	excretion	excretion	NN	_	7	conj
11	of	of	IN	_	13	case
12	immunoreactive	immunoreactive	JJ	_	13	amod
13	digoxin	digoxin	NN	_	7	nmod
14	.	.	.	_	4	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	8	det
6	plasma	plasma	NN	_	8	compound
7	concentration	concentration	NN	_	8	compound
8	profile	profile	NN	_	4	dobj
9	of	of	IN	_	10	case
10	terfenadine	terfenadine	NN	_	8	nmod
11	(	(	CD	_	10	nummod
12	a	a	DT	_	13	det
13	substrate	substrate	NN	_	10	dep
14	of	of	IN	_	17	case
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	3A4	3a4	NN	_	13	nmod
18	)	)	CD	_	17	nummod
19	or	or	CC	_	17	cc
20	fexofenadine	fexofenadine	NN	_	17	conj
21	,	,	,	_	4	punct
22	its	its	PRP$	_	24	nmod:poss
23	carboxylated	carboxylate	VBN	_	24	amod
24	metabolite	metabolite	NN	_	4	dobj
25	,	,	,	_	4	punct
26	and	and	CC	_	4	cc
27	did	do	VBD	_	29	aux
28	not	not	RB	_	29	neg
29	prolong	prolong	VB	_	4	conj
30	the	the	DT	_	32	det
31	QTc	qtc	NN	_	32	compound
32	interval	interval	NN	_	29	dobj
33	following	follow	VBG	_	36	case
34	co	co	SYM	_	36	dep
35	-	-	:	_	36	punct
36	administration	administration	NN	_	29	nmod
37	with	with	IN	_	40	case
38	terfenadine	terfenadine	NN	_	40	compound
39	60	60	CD	_	40	nummod
40	mg	mg	NN	_	36	nmod
41	twice	twice	RB	_	42	advmod
42	daily	daily	RB	_	29	advmod
43	.	.	.	_	4	punct

1	Montelukast	Montelukast	NNP	_	0	ROOT
2	at	at	IN	_	3	case
3	Doses	Doses	NNP	_	1	nmod
4	of	of	IN	_	8	case
5	100	100	CD	_	8	nummod
6	mg	mg	NN	_	8	compound
7	Daily	Daily	NNP	_	8	compound
8	Dosed	Dosed	NNP	_	3	nmod
9	to	to	TO	_	12	case
10	Pharmacokinetic	pharmacokinetic	JJ	_	12	amod
11	Steady	steady	JJ	_	12	amod
12	State	state	NN	_	1	nmod
13	:	:	:	_	1	punct
14	-	-	:	_	1	punct
15	did	do	VBD	_	18	aux
16	not	not	RB	_	18	neg
17	significantly	significantly	RB	_	18	advmod
18	alter	alter	VB	_	1	dep
19	the	the	DT	_	21	det
20	plasma	plasma	NN	_	21	compound
21	concentrations	concentration	NNS	_	18	dobj
22	of	of	IN	_	24	case
23	either	either	CC	_	24	det
24	component	component	NN	_	21	nmod
25	of	of	IN	_	28	case
26	an	a	DT	_	28	det
27	oral	oral	JJ	_	28	amod
28	contraceptive	contraceptive	NN	_	24	nmod
29	containing	contain	VBG	_	28	acl
30	norethindrone	norethindrone	NN	_	32	compound
31	1	1	CD	_	32	nummod
32	mg	mg	NN	_	29	dobj
33	/	/	:	_	32	punct
34	ethinyl	ethinyl	NN	_	35	compound
35	estradiol	estradiol	NN	_	32	dep
36	35	35	CD	_	37	nummod
37	mcg	mcg	NN	_	35	dep
38	.	.	.	_	1	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	cause	cause	VB	_	0	ROOT
5	any	any	DT	_	8	det
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	change	change	NN	_	4	dobj
9	in	in	IN	_	11	case
10	plasma	plasma	NN	_	11	compound
11	profiles	profile	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	prednisone	prednisone	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	prednisolone	prednisolone	NN	_	13	conj
16	following	follow	VBG	_	17	case
17	administration	administration	NN	_	4	nmod
18	of	of	IN	_	21	case
19	either	either	CC	_	21	cc:preconj
20	oral	oral	JJ	_	21	amod
21	prednisone	prednisone	NN	_	17	nmod
22	or	or	CC	_	21	cc
23	intravenous	intravenous	JJ	_	24	amod
24	prednisolone	prednisolone	NN	_	21	conj
25	.	.	.	_	4	punct

1	Phenobarbital	Phenobarbital	NNP	_	8	nsubj
2	,	,	,	_	1	punct
3	which	which	WDT	_	4	nsubj
4	induces	induce	VBZ	_	1	acl:relcl
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	4	dobj
7	,	,	,	_	1	punct
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	AUC	auc	NN	_	8	dobj
11	of	of	IN	_	12	case
12	montelukast	montelukast	NN	_	10	nmod
13	approximately	approximately	RB	_	14	advmod
14	40	40	CD	_	15	nummod
15	%	%	NN	_	8	nmod:npmod
16	following	follow	VBG	_	22	case
17	a	a	DT	_	22	det
18	single	single	JJ	_	22	amod
19	10	10	CD	_	22	nummod
20	-	-	:	_	22	punct
21	mg	mg	NN	_	22	compound
22	dose	dose	NN	_	8	nmod
23	of	of	IN	_	24	case
24	montelukast	montelukast	NN	_	22	nmod
25	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	7	nsubjpass
4	for	for	IN	_	5	case
5	montelukast	montelukast	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	reasonable	reasonable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	employ	employ	VB	_	3	xcomp
6	appropriate	appropriate	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	when	when	WRB	_	23	advmod
10	potent	potent	JJ	_	14	amod
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	inducers	inducer	NNS	_	23	nsubj
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	phenobarbital	phenobarbital	NN	_	14	nmod
19	or	or	CC	_	18	cc
20	rifampin	rifampin	NN	_	18	conj
21	,	,	,	_	14	punct
22	are	be	VBP	_	23	cop
23	co	co	SYM	_	5	advcl
24	-	-	:	_	23	punct
25	administered	administer	VBN	_	23	dep
26	with	with	IN	_	27	case
27	montelukast	montelukast	NN	_	25	nmod
28	.	.	.	_	3	punct

1	Montelukast	Montelukast	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	therapies	therapy	NNS	_	4	nmod
8	routinely	routinely	RB	_	9	advmod
9	used	use	VBN	_	7	acl
10	in	in	IN	_	15	case
11	the	the	DT	_	15	det
12	prophylaxis	prophylaxis	NN	_	15	amod
13	and	and	CC	_	12	cc
14	chronic	chronic	JJ	_	12	conj
15	treatment	treatment	NN	_	9	nmod
16	of	of	IN	_	17	case
17	asthma	asthma	NN	_	15	nmod
18	with	with	IN	_	21	case
19	no	no	DT	_	21	neg
20	apparent	apparent	JJ	_	21	amod
21	increase	increase	NN	_	9	nmod
22	in	in	IN	_	24	case
23	adverse	adverse	JJ	_	24	amod
24	reactions	reaction	NNS	_	21	nmod
25	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	drug	drug	NN	_	15	nmod
3	-	-	:	_	5	punct
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	15	nsubj
6	,	,	,	_	5	punct
7	the	the	DT	_	10	det
8	recommended	recommend	VBN	_	10	amod
9	clinical	clinical	JJ	_	10	amod
10	dose	dose	NN	_	5	appos
11	of	of	IN	_	12	case
12	montelukast	montelukast	NN	_	10	nmod
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	have	have	VB	_	0	ROOT
16	clinically	clinically	RB	_	17	advmod
17	important	important	JJ	_	18	amod
18	effects	effect	NNS	_	15	dobj
19	on	on	IN	_	21	case
20	the	the	DT	_	21	det
21	pharmacokinetics	pharmacokinetic	NNS	_	15	nmod
22	of	of	IN	_	25	case
23	the	the	DT	_	25	det
24	following	follow	VBG	_	25	amod
25	drugs	drug	NNS	_	21	nmod
26	:	:	:	_	21	punct
27	theophylline	theophylline	NN	_	35	nsubj
28	,	,	,	_	27	punct
29	prednisone	prednisone	NN	_	27	conj
30	,	,	,	_	27	punct
31	prednisolone	prednisolone	NN	_	27	conj
32	,	,	,	_	27	punct
33	oral	oral	JJ	_	34	amod
34	contraceptives	contraceptive	NNS	_	27	conj
35	(	(	VBP	_	21	dep
36	norethindrone	norethindrone	NN	_	38	compound
37	1	1	CD	_	38	nummod
38	mg	mg	NN	_	35	dobj
39	/	/	:	_	38	punct
40	ethinyl	ethinyl	NN	_	44	compound
41	estradiol	estradiol	NN	_	44	compound
42	35	35	CD	_	44	nummod
43	mcg	mcg	NN	_	44	compound
44	)	)	NN	_	38	dep
45	,	,	,	_	44	punct
46	terfenadine	terfenadine	NN	_	44	conj
47	,	,	,	_	44	punct
48	digoxin	digoxin	NN	_	44	conj
49	,	,	,	_	44	punct
50	and	and	CC	_	44	cc
51	warfarin	warfarin	NN	_	44	conj
52	.	.	.	_	15	punct

1	Although	although	IN	_	8	mark
2	additional	additional	JJ	_	5	amod
3	specific	specific	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	were	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	performed	perform	VBN	_	12	advcl
9	,	,	,	_	12	punct
10	montelukast	montelukast	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	used	use	VBN	_	0	ROOT
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	17	case
15	a	a	DT	_	17	det
16	wide	wide	JJ	_	17	amod
17	range	range	NN	_	12	nmod
18	of	of	IN	_	21	case
19	commonly	commonly	RB	_	20	advmod
20	prescribed	prescribe	VBN	_	21	amod
21	drugs	drug	NNS	_	17	nmod
22	in	in	IN	_	24	case
23	clinical	clinical	JJ	_	24	amod
24	studies	study	NNS	_	12	nmod
25	without	without	IN	_	26	case
26	evidence	evidence	NN	_	12	nmod
27	of	of	IN	_	30	case
28	clinical	clinical	JJ	_	30	amod
29	adverse	adverse	JJ	_	30	amod
30	interactions	interaction	NNS	_	26	nmod
31	.	.	.	_	12	punct

1	These	these	DT	_	2	det
2	medications	medication	NNS	_	3	nsubj
3	included	include	VBD	_	0	ROOT
4	thyroid	thyroid	NN	_	5	compound
5	hormones	hormone	NNS	_	3	dobj
6	,	,	,	_	5	punct
7	sedative	sedative	JJ	_	8	amod
8	hypnotics	hypnotic	NNS	_	5	conj
9	,	,	,	_	5	punct
10	non	non	JJ	_	16	amod
11	-	-	:	_	16	punct
12	steroidal	steroidal	JJ	_	16	amod
13	anti	anti	JJ	_	16	amod
14	-	-	:	_	16	punct
15	inflammatory	inflammatory	JJ	_	16	amod
16	agents	agent	NNS	_	5	conj
17	,	,	,	_	5	punct
18	benzodiazepines	benzodiazepine	NNS	_	5	conj
19	,	,	,	_	5	punct
20	and	and	CC	_	5	cc
21	decongestants	decongestant	NNS	_	5	conj
22	.	.	.	_	3	punct

1	Phenobarbital	Phenobarbital	NNP	_	8	nsubj
2	,	,	,	_	1	punct
3	which	which	WDT	_	4	nsubj
4	induces	induce	VBZ	_	1	acl:relcl
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	4	dobj
7	,	,	,	_	1	punct
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	AUC	auc	NN	_	8	dobj
11	of	of	IN	_	12	case
12	montelukast	montelukast	NN	_	10	nmod
13	approximately	approximately	RB	_	14	advmod
14	40	40	CD	_	15	nummod
15	%	%	NN	_	8	nmod:npmod
16	following	follow	VBG	_	22	case
17	a	a	DT	_	22	det
18	single	single	JJ	_	22	amod
19	10	10	CD	_	22	nummod
20	-	-	:	_	22	punct
21	mg	mg	NN	_	22	compound
22	dose	dose	NN	_	8	nmod
23	of	of	IN	_	24	case
24	montelukast	montelukast	NN	_	22	nmod
25	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	7	nsubjpass
4	for	for	IN	_	5	case
5	montelukast	montelukast	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	reasonable	reasonable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	employ	employ	VB	_	3	xcomp
6	appropriate	appropriate	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	when	when	WRB	_	23	advmod
10	potent	potent	JJ	_	14	amod
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	inducers	inducer	NNS	_	23	nsubj
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	phenobarbital	phenobarbital	NN	_	14	nmod
19	or	or	CC	_	18	cc
20	rifampin	rifampin	NN	_	18	conj
21	,	,	,	_	14	punct
22	are	be	VBP	_	23	cop
23	co	co	SYM	_	5	advcl
24	-	-	:	_	23	punct
25	administered	administer	VBN	_	23	dep
26	with	with	IN	_	27	case
27	montelukast	montelukast	NN	_	25	nmod
28	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	study	study	NN	_	26	nmod
5	of	of	IN	_	10	case
6	18	18	CD	_	10	nummod
7	chronic	chronic	JJ	_	10	amod
8	hepatitis	hepatitis	NN	_	10	compound
9	C	c	NN	_	10	compound
10	patients	patient	NNS	_	4	nmod
11	concomitantly	concomitantly	RB	_	12	advmod
12	receiving	receive	VBG	_	10	acl
13	methadone	methadone	NN	_	12	dobj
14	,	,	,	_	26	punct
15	treatment	treatment	NN	_	26	nsubjpass
16	with	with	IN	_	17	case
17	PEG	peg	NN	_	15	nmod
18	-	-	:	_	17	punct
19	Intron	intron	NN	_	17	dep
20	once	once	RB	_	21	advmod
21	weekly	weekly	JJ	_	15	amod
22	for	for	IN	_	24	case
23	4	4	CD	_	24	nummod
24	weeks	week	NNS	_	21	nmod
25	was	be	VBD	_	26	auxpass
26	associated	associate	VBN	_	0	ROOT
27	with	with	IN	_	30	case
28	a	a	DT	_	30	det
29	mean	mean	JJ	_	30	amod
30	increase	increase	NN	_	26	nmod
31	of	of	IN	_	33	case
32	16	16	CD	_	33	nummod
33	%	%	NN	_	30	nmod
34	in	in	IN	_	36	case
35	methadone	methadone	NN	_	36	compound
36	AUC	auc	NN	_	30	nmod
37	;	;	:	_	26	punct

1	in	in	IN	_	2	case
2	2	2	CD	_	10	nmod
3	out	out	IN	_	6	case
4	of	of	IN	_	6	case
5	18	18	CD	_	6	nummod
6	patients	patient	NNS	_	2	nmod
7	,	,	,	_	10	punct
8	methadone	methadone	NN	_	9	compound
9	AUC	auc	NN	_	10	nsubj
10	doubled	double	VBD	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	finding	finding	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	;	;	:	_	8	punct

1	however	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	for	for	IN	_	9	case
8	the	the	DT	_	9	det
9	signs	sign	NNS	_	6	nmod
10	and	and	CC	_	9	cc
11	symptoms	symptom	NNS	_	9	conj
12	of	of	IN	_	15	case
13	increased	increase	VBN	_	15	amod
14	narcotic	narcotic	JJ	_	15	amod
15	effect	effect	NN	_	9	nmod
16	.	.	.	_	6	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	16	nmod
5	,	,	,	_	16	punct
6	the	the	DT	_	7	det
7	potential	potential	NN	_	16	nsubj
8	for	for	IN	_	9	case
9	interaction	interaction	NN	_	7	nmod
10	by	by	IN	_	12	case
11	a	a	DT	_	12	det
12	variety	variety	NN	_	9	nmod
13	of	of	IN	_	14	case
14	mechanisms	mechanism	NNS	_	12	nmod
15	(	(	CD	_	14	nummod
16	e	e	LS	_	0	ROOT
17	.	.	.	_	16	punct
18	g	g	NN	_	16	dep
19	.	.	.	_	18	punct
20	,	,	,	_	18	punct
21	pharmacodynamic	pharmacodynamic	JJ	_	24	amod
22	,	,	,	_	21	punct
23	pharmacokinetic	pharmacokinetic	JJ	_	21	dep
24	inhibition	inhibition	NN	_	18	dep
25	or	or	CC	_	24	cc
26	enhancement	enhancement	NN	_	24	conj
27	,	,	,	_	24	punct
28	etc	etc	FW	_	24	conj
29	.	.	.	_	24	punct
30	)	)	SYM	_	18	dep

1	is	be	VBZ	_	3	cop
2	a	a	DT	_	3	det
3	possibility	possibility	NN	_	0	ROOT
4	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Affecting	affect	VBG	_	1	acl
3	Hepatic	hepatic	JJ	_	4	amod
4	Metabolism	metabolism	NN	_	2	dobj
5	The	the	DT	_	6	det
6	metabolism	metabolism	NN	_	20	nsubjpass
7	and	and	CC	_	6	cc
8	pharmacokinetics	pharmacokinetic	NNS	_	6	conj
9	of	of	IN	_	13	case
10	REMERON	remeron	NN	_	13	compound
11	SolTab	soltab	JJ	_	13	amod
12	(	(	NN	_	13	compound
13	mirtazapine	mirtazapine	NN	_	6	nmod
14	)	)	CD	_	13	nummod
15	Orally	orally	RB	_	16	advmod
16	Disintegrating	disintegrate	VBG	_	17	amod
17	Tablets	tablet	NNS	_	6	dep
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	affected	affect	VBN	_	4	acl:relcl
21	by	by	IN	_	23	case
22	the	the	DT	_	23	det
23	induction	induction	NN	_	20	nmod
24	or	or	CC	_	23	cc
25	inhibition	inhibition	NN	_	23	conj
26	of	of	IN	_	27	case
27	drug	drug	NN	_	25	nmod
28	-	-	:	_	27	punct
29	metab	metab	NN	_	27	dep
30	-	-	:	_	27	punct
31	olizing	olize	VBG	_	32	amod
32	enzymes	enzyme	NNS	_	27	dep
33	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	16	nsubjpass
2	that	that	WDT	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	Metabolized	metabolize	VBN	_	1	acl:relcl
5	by	by	IN	_	14	case
6	and	and	CC	_	5	cc
7	/	/	:	_	5	conj
8	or	or	CC	_	5	cc
9	Inhibit	inhibit	VB	_	5	conj
10	Cytochrome	cytochrome	NN	_	14	compound
11	P450	p450	NN	_	14	compound
12	Enzymes	enzyme	NNS	_	14	compound
13	Many	many	JJ	_	14	amod
14	drugs	drug	NNS	_	4	nmod
15	are	be	VBP	_	16	auxpass
16	metabolized	metabolize	VBN	_	0	ROOT
17	by	by	IN	_	25	case
18	and	and	CC	_	17	cc
19	/	/	:	_	17	conj
20	or	or	CC	_	17	cc
21	inhibit	inhibit	VBP	_	17	conj
22	various	various	JJ	_	25	amod
23	cytochrome	cytochrome	NN	_	25	compound
24	P450	p450	NN	_	25	compound
25	enzymes	enzyme	NNS	_	16	nmod
26	,	,	,	_	16	punct
27	e	e	LS	_	16	xcomp
28	.	.	.	_	27	punct
29	g	g	NN	_	27	dep
30	.	.	.	_	29	punct
31	,	,	,	_	29	punct
32	2D6	2d6	NN	_	29	appos
33	,	,	,	_	32	punct
34	1A2	1a2	NN	_	32	conj
35	,	,	,	_	32	punct
36	3A4	3a4	NN	_	32	conj
37	,	,	,	_	32	punct
38	etc	etc	FW	_	32	conj
39	.	.	.	_	16	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	10	mark
7	mirtazapine	mirtazapine	NN	_	10	nsubj
8	is	be	VBZ	_	10	cop
9	a	a	DT	_	10	det
10	substrate	substrate	NN	_	5	ccomp
11	for	for	IN	_	12	case
12	several	several	JJ	_	10	nmod
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	enzymes	enzyme	NNS	_	12	nmod
16	,	,	,	_	12	punct
17	including	include	VBG	_	18	case
18	2D6	2d6	NN	_	12	nmod
19	,	,	,	_	18	punct
20	1A2	1a2	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	3A4	3a4	NN	_	18	conj
24	.	.	.	_	5	punct

1	While	while	IN	_	6	mark
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	studies	study	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	shown	show	VBN	_	67	advcl
7	that	that	IN	_	13	mark
8	mirtazapine	mirtazapine	NN	_	13	nsubj
9	is	be	VBZ	_	13	cop
10	not	not	RB	_	13	neg
11	a	a	DT	_	13	det
12	potent	potent	JJ	_	13	amod
13	inhibitor	inhibitor	NN	_	6	ccomp
14	of	of	IN	_	15	case
15	any	any	DT	_	13	nmod
16	of	of	IN	_	18	case
17	these	these	DT	_	18	det
18	enzymes	enzyme	NNS	_	15	nmod
19	,	,	,	_	67	punct
20	an	a	DT	_	21	det
21	indication	indication	NN	_	67	ccomp
22	that	that	WDT	_	26	mark
23	mirtazapine	mirtazapine	NN	_	26	nsubj
24	is	be	VBZ	_	26	cop
25	not	not	RB	_	26	neg
26	likely	likely	JJ	_	21	ccomp
27	to	to	TO	_	28	mark
28	have	have	VB	_	26	xcomp
29	a	a	DT	_	33	det
30	clinically	clinically	RB	_	31	advmod
31	significant	significant	JJ	_	33	amod
32	inhibitory	inhibitory	JJ	_	33	amod
33	effect	effect	NN	_	28	dobj
34	on	on	IN	_	36	case
35	the	the	DT	_	36	det
36	metabolism	metabolism	NN	_	28	nmod
37	of	of	IN	_	39	case
38	other	other	JJ	_	39	amod
39	drugs	drug	NNS	_	36	nmod
40	that	that	WDT	_	42	nsubj
41	are	be	VBP	_	42	cop
42	substrates	substrate	NNS	_	39	acl:relcl
43	for	for	IN	_	47	case
44	these	these	DT	_	47	det
45	cytochrome	cytochrome	NN	_	47	compound
46	P450	p450	NN	_	47	compound
47	enzymes	enzyme	NNS	_	42	nmod
48	,	,	,	_	67	punct
49	the	the	DT	_	51	det
50	concomitant	concomitant	JJ	_	51	amod
51	use	use	NN	_	67	nsubjpass
52	of	of	IN	_	54	case
53	REMERON	remeron	NN	_	54	compound
54	SolTab	soltab	NN	_	51	nmod
55	with	with	IN	_	58	case
56	most	most	JJS	_	58	amod
57	other	other	JJ	_	58	amod
58	drugs	drug	NNS	_	51	nmod
59	metabolized	metabolize	VBN	_	58	acl
60	by	by	IN	_	62	case
61	these	these	DT	_	62	det
62	enzymes	enzyme	NNS	_	59	nmod
63	has	have	VBZ	_	67	aux
64	not	not	RB	_	67	neg
65	been	be	VBN	_	67	auxpass
66	formally	formally	RB	_	67	advmod
67	studied	study	VBN	_	0	ROOT
68	.	.	.	_	67	punct

1	Consequently	consequently	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	not	not	RB	_	6	neg
6	possible	possible	JJ	_	0	ROOT
7	to	to	TO	_	8	mark
8	make	make	VB	_	6	xcomp
9	any	any	DT	_	11	det
10	definitive	definitive	JJ	_	11	amod
11	statements	statement	NNS	_	8	dobj
12	about	about	IN	_	14	case
13	the	the	DT	_	14	det
14	risks	risk	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	coadministration	coadministration	NN	_	14	nmod
17	of	of	IN	_	19	case
18	REMERON	remeron	NN	_	19	compound
19	SolTab	soltab	NN	_	16	nmod
20	with	with	IN	_	22	case
21	such	such	JJ	_	22	amod
22	drugs	drug	NNS	_	16	nmod
23	.	.	.	_	6	punct

1	Alcohol	alcohol	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	13	nsubj
5	of	of	IN	_	6	case
6	alcohol	alcohol	NN	_	4	nmod
7	(	(	CD	_	6	nummod
8	equivalent	equivalent	JJ	_	4	amod
9	to	to	TO	_	12	case
10	60	60	CD	_	12	nummod
11	g	g	NN	_	12	compound
12	)	)	NN	_	8	nmod
13	had	have	VBD	_	1	appos
14	a	a	DT	_	16	det
15	minimal	minimal	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	on	on	IN	_	19	case
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	13	nmod
20	of	of	IN	_	21	case
21	mirtazapine	mirtazapine	NN	_	19	nmod
22	(	(	CD	_	25	nummod
23	15	15	CD	_	24	compound
24	mg	mg	NN	_	25	amod
25	)	)	NN	_	21	dep
26	in	in	IN	_	30	case
27	6	6	CD	_	30	nummod
28	healthy	healthy	JJ	_	30	amod
29	male	male	JJ	_	30	amod
30	subjects	subject	NNS	_	13	nmod
31	.	.	.	_	1	punct

1	However	however	RB	_	14	advmod
2	,	,	,	_	14	punct
3	the	the	DT	_	4	det
4	impairment	impairment	NN	_	14	nsubjpass
5	of	of	IN	_	9	case
6	cognitive	cognitive	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	motor	motor	NN	_	6	conj
9	skills	skill	NNS	_	4	nmod
10	produced	produce	VBN	_	9	acl
11	by	by	IN	_	12	case
12	REMERON	remeron	NN	_	10	nmod
13	were	be	VBD	_	14	auxpass
14	shown	show	VBN	_	0	ROOT
15	to	to	TO	_	17	mark
16	be	be	VB	_	17	cop
17	additive	additive	JJ	_	14	xcomp
18	with	with	IN	_	19	case
19	those	those	DT	_	17	nmod
20	produced	produce	VBN	_	19	acl
21	by	by	IN	_	22	case
22	alcohol	alcohol	NN	_	20	nmod
23	.	.	.	_	14	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	avoid	avoid	VB	_	6	xcomp
9	alcohol	alcohol	NN	_	8	dobj
10	while	while	IN	_	11	mark
11	taking	take	VBG	_	8	advcl
12	REMERON	REMERON	NNP	_	13	compound
13	SolTab	SolTab	NNP	_	11	dobj
14	.	.	.	_	6	punct
15	Diazepam	Diazepam	NNP	_	6	dep
16	:	:	:	_	15	punct
17	Concomitant	concomitant	JJ	_	18	amod
18	administration	administration	NN	_	25	nsubj
19	of	of	IN	_	20	case
20	diazepam	diazepam	NN	_	18	nmod
21	(	(	CD	_	22	compound
22	15	15	CD	_	23	dep
23	mg	mg	NN	_	24	dep
24	)	)	NN	_	20	dep
25	had	have	VBD	_	15	appos
26	a	a	DT	_	28	det
27	minimal	minimal	JJ	_	28	amod
28	effect	effect	NN	_	25	dobj
29	on	on	IN	_	31	case
30	plasma	plasma	NN	_	31	compound
31	levels	level	NNS	_	25	nmod
32	of	of	IN	_	33	case
33	mirtazapine	mirtazapine	NN	_	31	nmod
34	(	(	CD	_	37	nummod
35	15	15	CD	_	36	compound
36	mg	mg	NN	_	37	amod
37	)	)	NN	_	33	dep
38	in	in	IN	_	41	case
39	12	12	CD	_	41	nummod
40	healthy	healthy	JJ	_	41	amod
41	subjects	subject	NNS	_	25	nmod
42	.	.	.	_	6	punct

1	However	however	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	4	det
4	impairment	impairment	NN	_	13	nsubjpass
5	of	of	IN	_	7	case
6	motor	motor	NN	_	7	compound
7	skills	skill	NNS	_	4	nmod
8	produced	produce	VBN	_	7	acl
9	by	by	IN	_	10	case
10	REMERON	REMERON	NNP	_	8	nmod
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	shown	show	VBN	_	0	ROOT
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	cop
16	additive	additive	JJ	_	13	xcomp
17	with	with	IN	_	18	case
18	those	those	DT	_	16	nmod
19	caused	cause	VBN	_	18	acl
20	by	by	IN	_	21	case
21	diazepam	diazepam	NN	_	19	nmod
22	.	.	.	_	13	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	avoid	avoid	VB	_	6	xcomp
9	diazepam	diazepam	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	other	other	JJ	_	13	amod
12	similar	similar	JJ	_	13	amod
13	drugs	drug	NNS	_	9	conj
14	while	while	IN	_	15	mark
15	taking	take	VBG	_	8	advcl
16	REMERON	REMERON	NNP	_	17	compound
17	SolTab	SolTab	NNP	_	15	dobj
18	.	.	.	_	6	punct

1	Ketoconazole	ketoconazole	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Spontaneous	spontaneous	JJ	_	6	amod
4	adverse	adverse	JJ	_	6	amod
5	reaction	reaction	NN	_	6	compound
6	reports	report	NNS	_	17	nsubj
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	concomitant	concomitant	JJ	_	11	amod
11	ketoconazole	ketoconazole	NN	_	9	dobj
12	with	with	IN	_	14	case
13	recommended	recommend	VBN	_	14	amod
14	doses	dose	NNS	_	9	nmod
15	of	of	IN	_	16	case
16	terfenadine	terfenadine	NN	_	14	nmod
17	demonstrate	demonstrate	VBP	_	1	dep
18	QT	qt	NN	_	20	compound
19	interval	interval	NN	_	20	compound
20	prolongation	prolongation	NN	_	17	dobj
21	and	and	CC	_	20	cc
22	rare	rare	JJ	_	25	amod
23	serious	serious	JJ	_	25	amod
24	cardiac	cardiac	JJ	_	25	amod
25	events	event	NNS	_	20	conj
26	,	,	,	_	17	punct
27	e	e	LS	_	29	dep
28	.	.	.	_	27	punct
29	g	g	NN	_	17	dep
30	.	.	.	_	1	punct

1	death	death	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	cardiac	cardiac	JJ	_	4	amod
4	arrest	arrest	NN	_	1	conj
5	,	,	,	_	1	punct
6	and	and	CC	_	1	cc
7	ventricular	ventricular	JJ	_	8	amod
8	arrhythmia	arrhythmia	NN	_	1	conj
9	including	include	VBG	_	12	case
10	torsades	torsade	NNS	_	12	compound
11	de	de	IN	_	12	amod
12	pointes	pointe	NNS	_	8	nmod
13	.	.	.	_	1	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	data	datum	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	ketoconazole	ketoconazole	NN	_	7	nsubj
6	markedly	markedly	RB	_	7	advmod
7	inhibits	inhibit	VBZ	_	3	ccomp
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	11	case
11	terfenadine	terfenadine	NN	_	9	nmod
12	,	,	,	_	7	punct
13	resulting	result	VBG	_	7	advcl
14	in	in	IN	_	18	case
15	elevated	elevated	JJ	_	18	amod
16	plasma	plasma	NN	_	18	compound
17	terfenadine	terfenadine	NN	_	18	compound
18	levels	level	NNS	_	13	nmod
19	.	.	.	_	3	punct

1	Presence	presence	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	unchanged	unchanged	JJ	_	4	amod
4	terfenadine	terfenadine	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	10	case
8	statistically	statistically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	prolongation	prolongation	NN	_	6	nmod
11	of	of	IN	_	16	case
12	the	the	DT	_	16	det
13	QT	QT	NNP	_	16	compound
14	and	and	CC	_	13	cc
15	QTc	QTc	NNP	_	13	conj
16	intervals	interval	NNS	_	10	nmod
17	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	ketoconazole	ketoconazole	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	terfenadine	terfenadine	NN	_	4	conj
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Itraconazole	Itraconazole	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Torsades	Torsades	NNP	_	5	compound
4	de	de	NNP	_	5	compound
5	pointes	pointes	NNP	_	13	nsubjpass
6	and	and	CC	_	5	cc
7	elevated	elevated	JJ	_	10	amod
8	parent	parent	NN	_	10	compound
9	terfenadine	terfenadine	NN	_	10	compound
10	levels	level	NNS	_	5	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	1	appos
14	during	during	IN	_	16	case
15	concomitant	concomitant	JJ	_	16	amod
16	use	use	NN	_	13	nmod
17	of	of	IN	_	18	case
18	terfenadine	terfenadine	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	itraconazole	itraconazole	NN	_	18	conj
21	in	in	IN	_	23	case
22	clinical	clinical	JJ	_	23	amod
23	trials	trial	NNS	_	16	nmod
24	of	of	IN	_	25	case
25	itraconazole	itraconazole	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	from	from	IN	_	29	case
28	foreign	foreign	JJ	_	29	amod
29	post	post	NN	_	25	conj
30	-	-	:	_	29	punct
31	marketing	marketing	NN	_	32	compound
32	sources	source	NNS	_	29	dep
33	.	.	.	_	1	punct

1	One	one	CD	_	2	nummod
2	death	death	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	from	from	IN	_	9	case
8	foreign	foreign	JJ	_	9	amod
9	post	post	NN	_	6	nmod
10	-	-	:	_	9	punct
11	marketing	marketing	NN	_	12	compound
12	sources	source	NNS	_	9	dep
13	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	itraconazole	itraconazole	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	terfenadine	terfenadine	NN	_	4	conj
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	5	det
4	chemical	chemical	NN	_	5	compound
5	similarity	similarity	NN	_	37	nmod
6	of	of	IN	_	12	case
7	other	other	JJ	_	12	amod
8	azole	azole	NN	_	12	compound
9	-	-	:	_	12	punct
10	type	type	NN	_	12	compound
11	antifungal	antifungal	JJ	_	12	amod
12	agents	agent	NNS	_	5	nmod
13	(	(	VBP	_	5	acl
14	including	include	VBG	_	15	case
15	fluconazole	fluconazole	NN	_	13	nmod
16	,	,	,	_	15	punct
17	metronidazole	metronidazole	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	miconazole	miconazole	JJ	_	21	amod
21	)	)	NN	_	15	conj
22	to	to	TO	_	23	case
23	ketoconazole	ketoconazole	NN	_	21	nmod
24	,	,	,	_	5	punct
25	and	and	CC	_	5	cc
26	itraconazole	itraconazole	NN	_	5	conj
27	,	,	,	_	37	punct
28	concomitant	concomitant	JJ	_	29	amod
29	use	use	NN	_	37	nsubjpass
30	of	of	IN	_	32	case
31	these	these	DT	_	32	det
32	products	product	NNS	_	29	nmod
33	with	with	IN	_	34	case
34	terfenadine	terfenadine	NN	_	29	nmod
35	is	be	VBZ	_	37	auxpass
36	not	not	RB	_	37	neg
37	recommended	recommend	VBN	_	0	ROOT
38	pending	pend	VBG	_	40	case
39	full	full	JJ	_	40	amod
40	examination	examination	NN	_	37	nmod
41	of	of	IN	_	43	case
42	potential	potential	JJ	_	43	amod
43	interactions	interaction	NNS	_	40	nmod
44	.	.	.	_	37	punct

1	Macrolides	Macrolides	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	6	amod
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	7	nsubj
7	indicate	indicate	VBP	_	1	appos
8	that	that	IN	_	13	mark
9	erythromycin	erythromycin	NN	_	13	nsubj
10	and	and	CC	_	9	cc
11	clarithromycin	clarithromycin	NN	_	9	conj
12	can	can	MD	_	13	aux
13	exert	exert	VB	_	7	ccomp
14	an	a	DT	_	15	det
15	effect	effect	NN	_	13	dobj
16	on	on	IN	_	18	case
17	terfenadine	terfenadine	NN	_	18	compound
18	metabolism	metabolism	NN	_	15	nmod
19	by	by	IN	_	21	case
20	a	a	DT	_	21	det
21	mechanism	mechanism	NN	_	13	nmod
22	which	which	WDT	_	25	nsubj
23	may	may	MD	_	25	aux
24	be	be	VB	_	25	cop
25	similar	similar	JJ	_	21	acl:relcl
26	to	to	TO	_	27	case
27	that	that	DT	_	25	nmod
28	of	of	IN	_	29	case
29	ketoconazole	ketoconazole	NN	_	27	nmod
30	,	,	,	_	13	punct
31	but	but	CC	_	13	cc
32	to	to	TO	_	35	case
33	a	a	DT	_	35	det
34	lesser	lesser	JJR	_	35	amod
35	extent	extent	NN	_	13	conj
36	.	.	.	_	1	punct

1	Although	although	IN	_	4	mark
2	erythromycin	erythromycin	NN	_	4	nsubj
3	measurably	measurably	RB	_	4	advmod
4	decreases	decrease	VBZ	_	22	advcl
5	the	the	DT	_	6	det
6	clearance	clearance	NN	_	4	dobj
7	of	of	IN	_	11	case
8	the	the	DT	_	11	det
9	terfenadine	terfenadine	NN	_	11	compound
10	acid	acid	NN	_	11	compound
11	metabolite	metabolite	NN	_	6	nmod
12	,	,	,	_	22	punct
13	its	its	PRP$	_	14	nmod:poss
14	influence	influence	NN	_	22	nsubj
15	on	on	IN	_	18	case
16	terfenadine	terfenadine	NN	_	18	compound
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	14	nmod
19	is	be	VBZ	_	22	cop
20	still	still	RB	_	22	advmod
21	under	under	IN	_	22	case
22	investigation	investigation	NN	_	0	ROOT
23	.	.	.	_	22	punct

1	A	a	DT	_	4	det
2	few	few	JJ	_	4	amod
3	spontaneous	spontaneous	JJ	_	4	amod
4	accounts	account	NNS	_	19	nsubjpass
5	of	of	IN	_	8	case
6	QT	qt	NN	_	8	compound
7	interval	interval	NN	_	8	compound
8	prolongation	prolongation	NN	_	4	nmod
9	with	with	IN	_	11	case
10	ventricular	ventricular	JJ	_	11	amod
11	arrhythmia	arrhythmia	NN	_	8	nmod
12	including	include	VBG	_	15	case
13	torsades	torsade	NNS	_	15	compound
14	de	de	IN	_	15	amod
15	pointes	pointe	NNS	_	11	nmod
16	,	,	,	_	4	punct
17	have	have	VBP	_	19	aux
18	been	be	VBN	_	19	auxpass
19	reported	report	VBN	_	0	ROOT
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	receiving	receive	VBG	_	21	acl
23	erythromycin	erythromycin	NN	_	22	dobj
24	or	or	CC	_	23	cc
25	troleandomycin	troleandomycin	NN	_	23	conj
26	.	.	.	_	19	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	terfenadine	terfenadine	NN	_	2	nmod
5	with	with	IN	_	6	case
6	clarithromycin	clarithromycin	NN	_	2	nmod
7	,	,	,	_	6	punct
8	erythromycin	erythromycin	NN	_	6	conj
9	,	,	,	_	6	punct
10	or	or	CC	_	6	cc
11	troleandomycin	troleandomycin	NN	_	6	conj
12	is	be	VBZ	_	13	auxpass
13	contraindicated	contraindicate	VBN	_	0	ROOT
14	:	:	:	_	13	punct
15	Pending	pend	VBG	_	36	advcl
16	full	full	JJ	_	17	amod
17	characterization	characterization	NN	_	15	dobj
18	of	of	IN	_	20	case
19	potential	potential	JJ	_	20	amod
20	interactions	interaction	NNS	_	17	nmod
21	,	,	,	_	36	punct
22	concomitant	concomitant	JJ	_	23	amod
23	administration	administration	NN	_	36	nsubjpass
24	of	of	IN	_	25	case
25	terfenadine	terfenadine	NN	_	23	nmod
26	with	with	IN	_	29	case
27	other	other	JJ	_	29	amod
28	macrolide	macrolide	NN	_	29	compound
29	antibiotics	antibiotic	NNS	_	23	nmod
30	,	,	,	_	29	punct
31	including	include	VBG	_	32	case
32	azithromycin	azithromycin	NN	_	29	nmod
33	,	,	,	_	29	punct
34	is	be	VBZ	_	36	auxpass
35	not	not	RB	_	36	neg
36	recommended	recommend	VBN	_	13	parataxis
37	.	.	.	_	13	punct

1	Studies	study	NNS	_	12	nsubj
2	to	to	TO	_	3	mark
3	evaluate	evaluate	VB	_	1	acl
4	potential	potential	JJ	_	5	amod
5	interactions	interaction	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	terfenadine	terfenadine	NN	_	5	nmod
8	with	with	IN	_	9	case
9	azithromycin	azithromycin	NN	_	5	nmod
10	are	be	VBP	_	12	cop
11	in	in	IN	_	12	case
12	progress	progress	NN	_	0	ROOT
13	.	.	.	_	12	punct

1	Acromegalic	acromegalic	JJ	_	2	amod
2	patients	patient	NNS	_	7	nsubjpass
3	with	with	IN	_	5	case
4	diabetes	diabetes	NN	_	5	compound
5	mellitus	mellitus	NN	_	2	nmod
6	being	be	VBG	_	7	auxpass
7	treated	treat	VBN	_	17	csubj
8	with	with	IN	_	9	case
9	insulin	insulin	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	/	/	:	_	15	punct
12	or	or	CC	_	15	cc
13	oral	oral	JJ	_	15	amod
14	hypoglycemic	hypoglycemic	JJ	_	15	amod
15	agents	agent	NNS	_	9	conj
16	may	may	MD	_	17	aux
17	require	require	VB	_	0	ROOT
18	dose	dose	NN	_	19	compound
19	reductions	reduction	NNS	_	17	dobj
20	of	of	IN	_	23	case
21	these	these	DT	_	23	det
22	therapeutic	therapeutic	JJ	_	23	amod
23	agents	agent	NNS	_	19	nmod
24	after	after	IN	_	26	case
25	the	the	DT	_	26	det
26	initiation	initiation	NN	_	17	nmod
27	of	of	IN	_	28	case
28	therapy	therapy	NN	_	26	nmod
29	with	with	IN	_	30	case
30	SOMAVERT	SOMAVERT	NNP	_	28	nmod
31	.	.	.	_	17	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	patients	patient	NNS	_	9	nsubj
6	on	on	IN	_	7	case
7	opioids	opioid	NNS	_	5	nmod
8	often	often	RB	_	9	advmod
9	needed	need	VBD	_	0	ROOT
10	higher	higher	JJR	_	13	amod
11	serum	serum	NN	_	13	compound
12	pegvisomant	pegvisomant	NN	_	13	compound
13	concentrations	concentration	NNS	_	9	dobj
14	to	to	TO	_	15	mark
15	achieve	achieve	VB	_	9	advcl
16	appropriate	appropriate	JJ	_	17	amod
17	IGF	igf	NN	_	15	dobj
18	-	-	:	_	17	punct
19	I	I	PRP	_	20	nummod
20	suppression	suppression	NN	_	17	dep
21	compared	compare	VBN	_	23	case
22	with	with	IN	_	23	case
23	patients	patient	NNS	_	15	advcl
24	not	not	RB	_	25	neg
25	receiving	receive	VBG	_	23	acl
26	opioids	opioid	NNS	_	25	dobj
27	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	known	know	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	ARAMINE	aramine	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	20	csubj
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	9	case
8	digitalized	digitalized	JJ	_	9	amod
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	4	punct
11	since	since	IN	_	13	case
12	the	the	DT	_	13	det
13	combination	combination	NN	_	4	nmod
14	of	of	IN	_	15	case
15	digitalis	digitalis	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	sympathomimetic	sympathomimetic	JJ	_	18	amod
18	amines	amine	NNS	_	15	conj
19	may	may	MD	_	20	aux
20	cause	cause	VB	_	0	ROOT
21	ectopic	ectopic	JJ	_	22	amod
22	arrhythmias	arrhythmia	NNS	_	20	dobj
23	.	.	.	_	20	punct

1	Monoamine	monoamine	NN	_	3	compound
2	oxidase	oxidase	NN	_	3	compound
3	inhibitors	inhibitor	NNS	_	8	nsubj
4	or	or	CC	_	3	cc
5	tricyclic	tricyclic	JJ	_	6	amod
6	antidepressants	antidepressant	NNS	_	3	conj
7	may	may	MD	_	8	aux
8	potentiate	potentiate	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	action	action	NN	_	8	dobj
11	of	of	IN	_	13	case
12	sympathomimetic	sympathomimetic	JJ	_	13	amod
13	amines	amine	NNS	_	10	nmod
14	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	18	advmod
2	,	,	,	_	18	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	18	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	9	dobj
12	,	,	,	_	18	punct
13	the	the	DT	_	15	det
14	initial	initial	JJ	_	15	amod
15	dose	dose	NN	_	18	nsubj
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	cop
18	small	small	JJ	_	0	ROOT
19	and	and	CC	_	18	cc
20	given	give	VBN	_	22	case
21	with	with	IN	_	22	case
22	caution	caution	NN	_	18	conj
23	.	.	.	_	18	punct

1	Tetracycline	tetracycline	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	a	a	DT	_	5	det
4	bacteriostatic	bacteriostatic	JJ	_	5	amod
5	antibiotic	antibiotic	JJ	_	1	appos
6	,	,	,	_	1	punct
7	may	may	MD	_	8	aux
8	antagonize	antagonize	VB	_	22	csubjpass
9	the	the	DT	_	11	det
10	bactericidal	bactericidal	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	penicillin	penicillin	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	concurrent	concurrent	JJ	_	16	amod
16	use	use	NN	_	13	conj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	drugs	drug	NNS	_	13	nmod
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	avoided	avoid	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	alcohol	alcohol	NN	_	2	nmod
5	with	with	IN	_	7	case
6	phentermine	phentermine	NN	_	7	compound
7	hydrochloride	hydrochloride	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	result	result	VB	_	0	ROOT
10	in	in	IN	_	14	case
11	an	a	DT	_	14	det
12	adverse	adverse	JJ	_	14	amod
13	drug	drug	NN	_	14	compound
14	interaction	interaction	NN	_	9	nmod
15	.	.	.	_	9	punct

1	AGGRASTAT	AGGRASTAT	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	studied	study	VBN	_	0	ROOT
5	on	on	IN	_	7	case
6	a	a	DT	_	7	det
7	background	background	NN	_	4	nmod
8	of	of	IN	_	9	case
9	aspirin	aspirin	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	heparin	heparin	NN	_	9	conj
12	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	AGGRASTAT	AGGRASTAT	NNP	_	2	nmod
5	,	,	,	_	2	punct
6	in	in	IN	_	7	case
7	combination	combination	NN	_	2	nmod
8	with	with	IN	_	9	case
9	heparin	heparin	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	aspirin	aspirin	NN	_	9	conj
12	,	,	,	_	2	punct
13	has	have	VBZ	_	15	aux
14	been	be	VBN	_	15	auxpass
15	associated	associate	VBN	_	28	ccomp
16	with	with	IN	_	18	case
17	an	a	DT	_	18	det
18	increase	increase	NN	_	15	nmod
19	in	in	IN	_	20	case
20	bleeding	bleed	VBG	_	18	nmod
21	compared	compare	VBN	_	23	case
22	to	to	TO	_	23	case
23	heparin	heparin	NN	_	18	nmod
24	and	and	CC	_	23	cc
25	aspirin	aspirin	NN	_	23	conj
26	alone	alone	RB	_	23	advmod
27	(	(	RB	_	28	advmod
28	see	see	VB	_	0	ROOT

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Inhibitors	inhibitor	NNS	_	2	dep
5	of	of	IN	_	7	case
6	CYP3A4	cyp3a4	NN	_	7	compound
7	Isozymes	isozyme	NNS	_	4	nmod
8	:	:	:	_	4	punct
9	Caution	caution	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	advised	advise	VBN	_	4	dep
12	when	when	WRB	_	15	advmod
13	midazolam	midazolam	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	administered	administer	VBN	_	11	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	with	with	IN	_	18	case
18	drugs	drug	NNS	_	15	nmod
19	that	that	WDT	_	21	nsubjpass
20	are	be	VBP	_	21	auxpass
21	known	know	VBN	_	18	acl:relcl
22	to	to	TO	_	23	mark
23	inhibit	inhibit	VB	_	21	xcomp
24	the	the	DT	_	29	det
25	cytochrome	cytochrome	NN	_	29	compound
26	P450	p450	NN	_	29	compound
27	3A4	3a4	NN	_	29	compound
28	enzyme	enzyme	NN	_	29	compound
29	system	system	NN	_	23	dobj
30	(	(	CD	_	31	nummod
31	ie	ie	NN	_	29	dep
32	,	,	,	_	11	punct
33	some	some	DT	_	34	det
34	drugs	drug	NNS	_	11	dobj
35	in	in	IN	_	38	case
36	the	the	DT	_	38	det
37	drug	drug	NN	_	38	compound
38	classes	class	NNS	_	34	nmod
39	of	of	IN	_	41	case
40	azole	azole	NN	_	41	compound
41	antimycotics	antimycotic	NNS	_	38	nmod
42	,	,	,	_	11	punct
43	protease	protease	NN	_	44	compound
44	inhibitors	inhibitor	NNS	_	11	conj
45	,	,	,	_	11	punct
46	calcium	calcium	NN	_	48	compound
47	channel	channel	NN	_	48	compound
48	antagonists	antagonist	NNS	_	11	conj
49	,	,	,	_	11	punct
50	and	and	CC	_	11	cc
51	macrolide	macrolide	NN	_	52	compound
52	antibiotics	antibiotic	NNS	_	53	nsubj
53	)	)	VBP	_	11	conj
54	.	.	.	_	2	punct

1	Drugs	drug	NNS	_	16	nsubjpass
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	erythromycin	erythromycin	NN	_	1	nmod
5	,	,	,	_	4	punct
6	diltiazem	diltiazem	NN	_	4	conj
7	,	,	,	_	4	punct
8	verapamil	verapamil	NN	_	4	conj
9	,	,	,	_	4	punct
10	ketoconazole	ketoconazole	NN	_	4	conj
11	,	,	,	_	4	punct
12	fluconazole	fluconazole	NN	_	4	conj
13	and	and	CC	_	4	cc
14	itraconazole	itraconazole	NN	_	4	conj
15	were	be	VBD	_	16	auxpass
16	shown	show	VBN	_	0	ROOT
17	to	to	TO	_	19	mark
18	significantly	significantly	RB	_	19	advmod
19	increase	increase	VB	_	16	xcomp
20	the	the	DT	_	22	det
21	C	c	NN	_	22	compound
22	max	max	NN	_	19	dobj
23	and	and	CC	_	22	cc
24	AUC	auc	NN	_	22	conj
25	of	of	IN	_	28	case
26	orally	orally	RB	_	27	advmod
27	administered	administer	VBN	_	28	amod
28	midazolam	midazolam	NN	_	22	nmod
29	.	.	.	_	16	punct

1	These	these	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	result	result	VB	_	0	ROOT
6	in	in	IN	_	10	case
7	increased	increase	VBN	_	10	amod
8	and	and	CC	_	7	cc
9	prolonged	prolong	VBN	_	7	conj
10	sedation	sedation	NN	_	5	nmod
11	due	due	JJ	_	14	case
12	to	to	TO	_	11	mwe
13	a	a	DT	_	14	det
14	decrease	decrease	NN	_	10	nmod
15	in	in	IN	_	17	case
16	plasma	plasma	NN	_	17	compound
17	clearance	clearance	NN	_	14	nmod
18	of	of	IN	_	19	case
19	midazolam	midazolam	NN	_	17	nmod
20	.	.	.	_	5	punct

1	Although	although	IN	_	3	mark
2	not	not	RB	_	3	neg
3	studied	study	VBN	_	15	advcl
4	,	,	,	_	15	punct
5	the	the	DT	_	10	det
6	potent	potent	JJ	_	10	amod
7	cytochrome	cytochrome	NN	_	10	compound
8	P450	p450	NN	_	10	compound
9	3A4	3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	15	nsubj
11	ritonavir	ritonavir	NN	_	10	dep
12	and	and	CC	_	11	cc
13	nelfinavir	nelfinavir	NN	_	11	conj
14	may	may	MD	_	15	aux
15	cause	cause	VB	_	0	ROOT
16	intense	intense	JJ	_	19	amod
17	and	and	CC	_	16	cc
18	prolonged	prolonged	JJ	_	16	conj
19	sedation	sedation	NN	_	15	dobj
20	and	and	CC	_	19	cc
21	respiratory	respiratory	JJ	_	22	amod
22	depression	depression	NN	_	19	conj
23	due	due	JJ	_	26	case
24	to	to	TO	_	23	mwe
25	a	a	DT	_	26	det
26	decrease	decrease	NN	_	19	nmod
27	in	in	IN	_	29	case
28	plasma	plasma	NN	_	29	compound
29	clearance	clearance	NN	_	26	nmod
30	of	of	IN	_	31	case
31	midazolam	midazolam	NN	_	29	nmod
32	.	.	.	_	15	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	when	when	WRB	_	8	advmod
5	VERSED	VERSED	NNP	_	6	compound
6	Syrup	Syrup	NNP	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	used	use	VBN	_	3	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	12	case
11	these	these	DT	_	12	det
12	drugs	drug	NNS	_	8	nmod
13	.	.	.	_	3	punct

1	Dose	dose	NN	_	2	compound
2	adjustments	adjustment	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	and	and	CC	_	5	cc
7	possible	possible	JJ	_	8	amod
8	prolongation	prolongation	NN	_	15	nsubjpass
9	and	and	CC	_	8	cc
10	intensity	intensity	NN	_	8	conj
11	of	of	IN	_	12	case
12	effect	effect	NN	_	8	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	anticipated	anticipate	VBN	_	5	conj
16	.	.	.	_	5	punct

1	Inducers	inducer	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	CYP3A4	cyp3a4	NN	_	4	compound
4	Isozymes	isozyme	NNS	_	1	nmod
5	:	:	:	_	1	punct
6	Cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	inducers	inducer	NNS	_	19	nsubj
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	rifampin	rifampin	NN	_	8	nmod
13	,	,	,	_	12	punct
14	carbamazepine	carbamazepine	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	phenytoin	phenytoin	NN	_	12	conj
18	,	,	,	_	8	punct
19	induce	induce	VBP	_	1	dep
20	metabolism	metabolism	NN	_	19	dobj
21	and	and	CC	_	19	cc
22	caused	cause	VBD	_	19	conj
23	a	a	DT	_	27	det
24	markedly	markedly	RB	_	25	advmod
25	decreased	decrease	VBN	_	27	amod
26	C	c	NN	_	27	compound
27	max	max	NN	_	22	dobj
28	and	and	CC	_	27	cc
29	AUC	auc	NN	_	27	conj
30	of	of	IN	_	32	case
31	oral	oral	JJ	_	32	amod
32	midazolam	midazolam	NN	_	27	nmod
33	in	in	IN	_	35	case
34	adult	adult	JJ	_	35	amod
35	studies	study	NNS	_	27	nmod
36	.	.	.	_	1	punct

1	Although	although	IN	_	7	mark
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	7	nsubjpass
4	have	have	VBP	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	11	advcl
8	,	,	,	_	11	punct
9	phenobarbital	phenobarbital	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	have	have	VB	_	11	xcomp
14	the	the	DT	_	16	det
15	same	same	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	.	.	.	_	11	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	VERSED	VERSED	NNP	_	7	compound
7	Syrup	Syrup	NNP	_	5	dobj
8	to	to	TO	_	9	case
9	patients	patient	NNS	_	5	nmod
10	receiving	receive	VBG	_	9	acl
11	these	these	DT	_	12	det
12	medications	medication	NNS	_	10	dobj
13	and	and	CC	_	5	cc
14	if	if	IN	_	20	mark
15	necessary	necessary	JJ	_	17	amod
16	dose	dose	NN	_	17	compound
17	adjustments	adjustment	NNS	_	20	nsubjpass
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	considered	consider	VBN	_	5	conj
21	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	difficulty	difficulty	NN	_	11	nsubj
3	in	in	IN	_	4	mark
4	achieving	achieve	VBG	_	2	acl
5	adequate	adequate	JJ	_	6	amod
6	sedation	sedation	NN	_	4	dobj
7	may	may	MD	_	11	aux
8	have	have	VB	_	11	aux
9	been	be	VBN	_	11	cop
10	the	the	DT	_	11	det
11	result	result	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	decreased	decrease	VBN	_	14	amod
14	absorption	absorption	NN	_	11	nmod
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	sedatives	sedative	NNS	_	14	nmod
18	due	due	JJ	_	23	case
19	to	to	TO	_	18	mwe
20	both	both	CC	_	23	cc:preconj
21	the	the	DT	_	23	det
22	gastrointestinal	gastrointestinal	JJ	_	23	amod
23	effects	effect	NNS	_	17	nmod
24	and	and	CC	_	23	cc
25	stimulant	stimulant	NN	_	26	compound
26	effects	effect	NNS	_	23	conj
27	of	of	IN	_	28	case
28	methylphenidate	methylphenidate	NN	_	23	nmod
29	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	sedative	sedative	JJ	_	3	amod
3	effect	effect	NN	_	8	nsubjpass
4	of	of	IN	_	6	case
5	VERSED	VERSED	NNP	_	6	compound
6	Syrup	Syrup	NNP	_	3	nmod
7	is	be	VBZ	_	8	auxpass
8	accentuated	accentuate	VBN	_	0	ROOT
9	by	by	IN	_	13	case
10	any	any	DT	_	13	det
11	concomitantly	concomitantly	RB	_	12	advmod
12	administered	administer	VBN	_	13	amod
13	medication	medication	NN	_	8	nmod
14	which	which	WDT	_	15	nsubj
15	depresses	depress	VBZ	_	13	acl:relcl
16	the	the	DT	_	19	det
17	central	central	JJ	_	19	amod
18	nervous	nervous	JJ	_	19	amod
19	system	system	NN	_	15	dobj
20	,	,	,	_	13	punct
21	particularly	particularly	RB	_	22	advmod
22	narcotics	narcotic	NNS	_	13	appos
23	(	(	CD	_	26	nummod
24	eg	eg	FW	_	26	compound
25	,	,	,	_	26	punct
26	morphine	morphine	NN	_	22	dep
27	,	,	,	_	26	punct
28	meperidine	meperidine	NN	_	26	conj
29	and	and	CC	_	26	cc
30	fentanyl	fentanyl	NN	_	31	compound
31	)	)	NN	_	26	conj
32	,	,	,	_	22	punct
33	propofol	propofol	NN	_	22	conj
34	,	,	,	_	22	punct
35	ketamine	ketamine	NN	_	22	conj
36	,	,	,	_	22	punct
37	nitrous	nitrous	JJ	_	38	amod
38	oxide	oxide	NN	_	22	conj
39	,	,	,	_	22	punct
40	secobarbital	secobarbital	NN	_	22	conj
41	and	and	CC	_	22	cc
42	droperidol	droperidol	NN	_	22	conj
43	.	.	.	_	8	punct

1	Consequently	consequently	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	10	nsubjpass
5	of	of	IN	_	7	case
6	VERSED	VERSED	NNP	_	7	compound
7	Syrup	Syrup	NNP	_	4	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	adjusted	adjust	VBN	_	0	ROOT
11	according	accord	VBG	_	14	case
12	to	to	TO	_	11	mwe
13	the	the	DT	_	14	det
14	type	type	NN	_	10	nmod
15	and	and	CC	_	14	cc
16	amount	amount	NN	_	14	conj
17	of	of	IN	_	19	case
18	concomitant	concomitant	JJ	_	19	amod
19	medications	medication	NNS	_	14	nmod
20	administered	administer	VBN	_	19	acl
21	and	and	CC	_	14	cc
22	the	the	DT	_	25	det
23	desired	desire	VBN	_	25	amod
24	clinical	clinical	JJ	_	25	amod
25	response	response	NN	_	14	conj
26	.	.	.	_	10	punct

1	No	no	DT	_	4	neg
2	significant	significant	JJ	_	4	amod
3	adverse	adverse	JJ	_	4	amod
4	interactions	interaction	NNS	_	8	nsubj
5	with	with	IN	_	7	case
6	common	common	JJ	_	7	amod
7	premedications	premedication	NNS	_	4	nmod
8	(	(	VBP	_	31	csubjpass
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	atropine	atropine	NN	_	8	nmod
12	,	,	,	_	11	punct
13	scopolamine	scopolamine	NN	_	11	conj
14	,	,	,	_	11	punct
15	glycopyrrolate	glycopyrrolate	NN	_	11	conj
16	,	,	,	_	11	punct
17	diazepam	diazepam	NN	_	11	conj
18	,	,	,	_	11	punct
19	hydroxyzine	hydroxyzine	NN	_	11	conj
20	,	,	,	_	11	punct
21	and	and	CC	_	11	cc
22	other	other	JJ	_	24	amod
23	muscle	muscle	NN	_	24	compound
24	relaxants	relaxant	NNS	_	11	conj
25	)	)	CD	_	24	nummod
26	or	or	CC	_	24	cc
27	local	local	JJ	_	28	amod
28	anesthetics	anesthetic	NNS	_	24	conj
29	have	have	VBP	_	31	aux
30	been	be	VBN	_	31	auxpass
31	observed	observe	VBN	_	0	ROOT
32	.	.	.	_	31	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	36	nsubj
4	of	of	IN	_	7	case
5	other	other	JJ	_	7	amod
6	CNS	cns	NN	_	7	compound
7	depressants	depressant	NNS	_	3	nmod
8	including	include	VBG	_	9	case
9	sedatives	sedative	NNS	_	7	nmod
10	,	,	,	_	9	punct
11	hypnotics	hypnotic	NNS	_	9	conj
12	,	,	,	_	9	punct
13	tranquilizers	tranquilizer	NNS	_	9	conj
14	,	,	,	_	9	punct
15	general	general	JJ	_	16	amod
16	anesthetics	anesthetic	NNS	_	9	conj
17	,	,	,	_	9	punct
18	phenothiazines	phenothiazine	NNS	_	9	conj
19	,	,	,	_	9	punct
20	other	other	JJ	_	21	amod
21	opioids	opioid	NNS	_	9	conj
22	,	,	,	_	9	punct
23	tricyclic	tricyclic	JJ	_	24	amod
24	antidepressants	antidepressant	NNS	_	9	conj
25	,	,	,	_	9	punct
26	monoamine	monoamine	NN	_	27	compound
27	oxidase	oxidase	NN	_	31	compound
28	(	(	CD	_	31	nummod
29	MAO	MAO	NNP	_	31	compound
30	)	)	NN	_	31	compound
31	inhibitors	inhibitor	NNS	_	9	conj
32	,	,	,	_	9	punct
33	and	and	CC	_	9	cc
34	alcohol	alcohol	NN	_	9	conj
35	may	may	MD	_	36	aux
36	produce	produce	VB	_	0	ROOT
37	additive	additive	JJ	_	40	amod
38	CNS	cn	NNS	_	40	compound
39	depressant	depressant	NN	_	40	compound
40	effects	effect	NNS	_	36	dobj
41	.	.	.	_	36	punct

1	When	when	WRB	_	6	advmod
2	such	such	JJ	_	4	amod
3	combined	combined	JJ	_	4	amod
4	therapy	therapy	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	contemplated	contemplate	VBN	_	17	advcl
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	one	one	CD	_	9	nmod
12	or	or	CC	_	11	cc
13	both	both	DT	_	14	det
14	agents	agent	NNS	_	11	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Anticholinergics	anticholinergic	NNS	_	15	nsubj
2	or	or	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	medications	medication	NNS	_	1	conj
5	with	with	IN	_	7	case
6	anticholinergic	anticholinergic	JJ	_	7	amod
7	activity	activity	NN	_	1	nmod
8	when	when	WRB	_	9	advmod
9	used	use	VBN	_	1	acl:relcl
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	13	case
12	opioid	opioid	JJ	_	13	amod
13	analgesics	analgesic	NNS	_	9	nmod
14	may	may	MD	_	15	aux
15	result	result	VB	_	0	ROOT
16	in	in	IN	_	18	case
17	increased	increase	VBN	_	18	amod
18	risk	risk	NN	_	15	nmod
19	of	of	IN	_	21	case
20	urinary	urinary	JJ	_	21	amod
21	retention	retention	NN	_	18	nmod
22	and	and	CC	_	21	cc
23	/	/	:	_	26	punct
24	or	or	CC	_	26	cc
25	severe	severe	JJ	_	26	amod
26	constipation	constipation	NN	_	21	conj
27	,	,	,	_	26	punct
28	which	which	WDT	_	30	nsubj
29	may	may	MD	_	30	aux
30	lead	lead	VB	_	26	acl:relcl
31	to	to	TO	_	33	case
32	paralytic	paralytic	JJ	_	33	amod
33	ileus	ileus	NN	_	30	nmod
34	.	.	.	_	15	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	11	mark
6	the	the	DT	_	7	det
7	incidence	incidence	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	bradycardia	bradycardia	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	increased	increase	VBN	_	4	ccomp
12	when	when	WRB	_	15	advmod
13	oxymorphone	oxymorphone	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	combined	combine	VBN	_	11	advcl
16	with	with	IN	_	17	case
17	propofol	propofol	NN	_	15	nmod
18	for	for	IN	_	19	case
19	induction	induction	NN	_	17	nmod
20	of	of	IN	_	21	case
21	anesthesia	anesthesia	NN	_	19	nmod
22	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	CNS	cns	NN	_	5	compound
5	toxicity	toxicity	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	(	(	CD	_	10	nummod
10	confusion	confusion	NN	_	8	dobj
11	,	,	,	_	10	punct
12	disorientation	disorientation	NN	_	10	conj
13	,	,	,	_	10	punct
14	respiratory	respiratory	JJ	_	15	amod
15	depression	depression	NN	_	10	conj
16	,	,	,	_	10	punct
17	apnea	apnea	NN	_	10	conj
18	,	,	,	_	10	punct
19	seizures	seizure	NNS	_	10	appos
20	)	)	RB	_	21	advmod
21	following	follow	VBG	_	19	acl
22	coadministration	coadministration	NN	_	21	dobj
23	of	of	IN	_	24	case
24	cimetidine	cimetidine	NN	_	22	nmod
25	with	with	IN	_	27	case
26	opioid	opioid	JJ	_	27	amod
27	analgesics	analgesic	NNS	_	22	nmod
28	;	;	:	_	8	punct

1	no	no	DT	_	5	neg
2	clear	clear	JJ	_	5	amod
3	-	-	:	_	5	punct
4	cut	cut	NN	_	5	compound
5	cause	cause	NN	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	effect	effect	NN	_	8	compound
8	relationship	relationship	NN	_	5	conj
9	was	be	VBD	_	10	auxpass
10	established	establish	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Dosages	dosage	NNS	_	8	nsubjpass
2	of	of	IN	_	5	case
3	concomitantly	concomitantly	RB	_	4	advmod
4	administered	administer	VBN	_	5	amod
5	opioids	opioid	NNS	_	1	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	reduced	reduce	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	approximately	approximately	RB	_	11	advmod
11	half	half	RB	_	8	nmod
12	,	,	,	_	8	punct
13	because	because	IN	_	15	mark
14	levomepromazine	levomepromazine	NN	_	15	nsubj
15	amplifies	amplify	VBZ	_	8	advcl
16	the	the	DT	_	18	det
17	therapeutic	therapeutic	JJ	_	18	amod
18	actions	action	NNS	_	15	dobj
19	and	and	CC	_	18	cc
20	side	side	NN	_	22	compound
21	-	-	:	_	22	punct
22	effects	effect	NNS	_	18	conj
23	of	of	IN	_	24	case
24	opioids	opioid	NNS	_	22	nmod
25	.	.	.	_	8	punct

1	Combination	combination	NN	_	8	nsubjpass
2	with	with	IN	_	6	case
3	tramadol	tramadol	NN	_	6	compound
4	(	(	CD	_	6	nummod
5	Ultram	Ultram	NNP	_	6	compound
6	)	)	NN	_	1	nmod
7	is	be	VBZ	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	increased	increase	VBN	_	11	amod
11	risk	risk	NN	_	8	nmod
12	of	of	IN	_	13	case
13	seizures	seizure	NNS	_	11	nmod
14	.	.	.	_	8	punct

1	Additive	additive	JJ	_	3	amod
2	sedative	sedative	JJ	_	3	amod
3	effects	effect	NNS	_	8	nsubj
4	and	and	CC	_	3	cc
5	confusional	confusional	JJ	_	6	amod
6	states	state	NNS	_	3	conj
7	may	may	MD	_	8	aux
8	emerge	emerge	VB	_	0	ROOT
9	if	if	IN	_	12	mark
10	levomepromazine	levomepromazine	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	given	give	VBN	_	8	advcl
13	with	with	IN	_	14	case
14	benzodiazepines	benzodiazepine	NNS	_	12	nmod
15	or	or	CC	_	14	cc
16	barbiturates	barbiturate	NNS	_	14	conj
17	.	.	.	_	8	punct

1	This	this	DT	_	4	nsubjpass
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	avoided	avoid	VBN	_	0	ROOT
5	by	by	IN	_	6	mark
6	using	use	VBG	_	4	advcl
7	the	the	DT	_	9	det
8	lowest	lowest	JJS	_	9	amod
9	dose	dose	NN	_	6	dobj
10	possible	possible	JJ	_	9	amod
11	with	with	IN	_	13	case
12	the	the	DT	_	13	det
13	substances	substance	NNS	_	10	nmod
14	in	in	IN	_	15	case
15	question	question	NN	_	13	nmod
16	.	.	.	_	4	punct

1	Exert	exert	VB	_	11	csubj
2	particular	particular	JJ	_	3	amod
3	caution	caution	NN	_	1	dobj
4	in	in	IN	_	5	mark
5	combining	combine	VBG	_	1	advcl
6	levomepromazine	levomepromazine	NN	_	5	dobj
7	with	with	IN	_	10	case
8	other	other	JJ	_	10	amod
9	anticholinergic	anticholinergic	JJ	_	10	amod
10	drugs	drug	NNS	_	5	nmod
11	(	(	VBP	_	0	ROOT
12	tricyclic	tricyclic	JJ	_	13	amod
13	antidepressants	antidepressant	NNS	_	11	dobj
14	and	and	CC	_	13	cc
15	antiparkinsonian	antiparkinsonian	JJ	_	17	amod
16	-	-	:	_	17	punct
17	agents	agent	NNS	_	13	conj
18	)	)	CD	_	17	nummod
19	:	:	:	_	11	punct
20	Particularly	particularly	RB	_	22	advmod
21	the	the	DT	_	22	det
22	elderly	elderly	JJ	_	24	nsubj
23	may	may	MD	_	24	aux
24	develop	develop	VB	_	11	parataxis
25	delirium	delirium	NN	_	24	dobj
26	,	,	,	_	25	punct
27	high	high	JJ	_	28	amod
28	fever	fever	NN	_	25	conj
29	,	,	,	_	25	punct
30	severe	severe	JJ	_	31	amod
31	obstipation	obstipation	NN	_	25	conj
32	,	,	,	_	25	punct
33	even	even	RB	_	34	advmod
34	ileus	ileus	NN	_	25	conj
35	and	and	CC	_	25	cc
36	glaucoma	glaucoma	NN	_	25	conj
37	.	.	.	_	11	punct

1	Reduce	reduce	VB	_	0	ROOT
2	both	both	CC	_	4	cc:preconj
3	the	the	DT	_	4	det
4	dose	dose	NN	_	1	dobj
5	of	of	IN	_	6	case
6	levomepromazine	levomepromazine	NN	_	4	nmod
7	and	and	CC	_	4	cc
8	the	the	DT	_	9	det
9	dose	dose	NN	_	4	conj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	other	other	JJ	_	13	amod
13	drug	drug	NN	_	9	nmod
14	.	.	.	_	1	punct

1	If	if	IN	_	2	mark
2	possible	possible	JJ	_	4	advcl
3	,	,	,	_	4	punct
4	avoid	avoid	VB	_	0	ROOT
5	such	such	JJ	_	6	amod
6	combinations	combination	NNS	_	4	dobj
7	.	.	.	_	4	punct

1	Caffeine	caffeine	NN	_	13	nsubj
2	and	and	CC	_	1	cc
3	/	/	:	_	5	punct
4	or	or	CC	_	5	cc
5	stimulantes	stimulante	NNS	_	1	conj
6	of	of	IN	_	11	case
7	the	the	DT	_	11	det
8	ephedrine	ephedrine	NN	_	11	compound
9	/	/	:	_	11	punct
10	amphetamine	amphetamine	NN	_	11	compound
11	type	type	NN	_	5	nmod
12	may	may	MD	_	13	aux
13	counteract	counteract	VB	_	0	ROOT
14	the	the	DT	_	16	det
15	specific	specific	JJ	_	16	amod
16	actions	action	NNS	_	13	dobj
17	of	of	IN	_	18	case
18	levomepromazine	levomepromazine	NN	_	16	nmod
19	.	.	.	_	13	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	substances	substance	NNS	_	2	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	avoided	avoid	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Coffee	Coffee	NNP	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	black	black	JJ	_	4	amod
4	tea	tea	NN	_	1	conj
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	avoided	avoid	VBN	_	0	ROOT
8	because	because	IN	_	10	mark
9	they	they	PRP	_	10	nsubj
10	decrease	decrease	VBP	_	7	advcl
11	the	the	DT	_	12	det
12	absorption	absorption	NN	_	10	dobj
13	of	of	IN	_	14	case
14	levomepromazine	levomepromazine	NN	_	12	nmod
15	considerably	considerably	RB	_	10	advmod
16	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	same	same	JJ	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	true	true	JJ	_	0	ROOT
5	for	for	IN	_	6	case
6	antacids	antacid	NNS	_	4	nmod
7	;	;	:	_	4	punct

1	these	these	DT	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	given	give	VBN	_	0	ROOT
5	1	1	CD	_	7	compound
6	to	to	TO	_	7	dep
7	2	2	CD	_	8	nummod
8	hours	hour	NNS	_	4	dobj
9	before	before	IN	_	13	nmod
10	or	or	CC	_	9	cc
11	after	after	IN	_	9	conj
12	oral	oral	JJ	_	13	amod
13	administration	administration	NN	_	8	nmod
14	of	of	IN	_	15	case
15	leveomepromazine	leveomepromazine	NN	_	13	nmod
16	.	.	.	_	4	punct

1	Usage	usage	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	Alcohol	alcohol	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Due	due	JJ	_	18	advmod
6	to	to	TO	_	8	case
7	the	the	DT	_	8	det
8	potential	potential	NN	_	5	nmod
9	for	for	IN	_	13	case
10	increased	increase	VBN	_	13	amod
11	CNS	cns	NN	_	13	compound
12	depressants	depressant	NNS	_	13	compound
13	effects	effect	NNS	_	8	nmod
14	,	,	,	_	18	punct
15	alcohol	alcohol	NN	_	18	nsubjpass
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	1	dep
19	with	with	IN	_	20	case
20	caution	caution	NN	_	18	nmod
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	who	who	WP	_	26	nsubj
24	are	be	VBP	_	26	aux
25	currently	currently	RB	_	26	advmod
26	receiving	receive	VBG	_	22	acl:relcl
27	pentazocine	pentazocine	NN	_	26	dobj
28	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	CNS	cns	NN	_	4	compound
3	depressant	depressant	NN	_	4	compound
4	effects	effect	NNS	_	10	nsubj
5	of	of	IN	_	7	case
6	oxycodone	oxycodone	NN	_	7	compound
7	hydrochloride	hydrochloride	NN	_	4	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	cop
10	additive	additive	JJ	_	0	ROOT
11	with	with	IN	_	12	case
12	that	that	DT	_	10	nmod
13	of	of	IN	_	16	case
14	other	other	JJ	_	16	amod
15	CNS	cns	NN	_	16	compound
16	depressants	depressant	NNS	_	12	nmod
17	..	..	VBP	_	10	dep

1	Limited	limited	JJ	_	2	amod
2	evidence	evidence	NN	_	3	nsubj
3	suggests	suggest	VBZ	_	0	ROOT
4	that	that	IN	_	8	mark
5	ascorbic	ascorbic	JJ	_	6	amod
6	acid	acid	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	influence	influence	VB	_	3	ccomp
9	the	the	DT	_	10	det
10	intensity	intensity	NN	_	8	dobj
11	and	and	CC	_	10	cc
12	duration	duration	NN	_	10	conj
13	of	of	IN	_	14	case
14	action	action	NN	_	10	nmod
15	of	of	IN	_	16	case
16	bishydroxycoumarin	bishydroxycoumarin	NN	_	14	nmod
17	.	.	.	_	3	punct

1	Alcohol	alcohol	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	8	case
4	a	a	DT	_	8	det
5	multiple	multiple	JJ	_	8	amod
6	-	-	:	_	8	punct
7	dose	dose	NN	_	8	compound
8	study	study	NN	_	1	nmod
9	in	in	IN	_	13	case
10	30	30	CD	_	13	nummod
11	normal	normal	JJ	_	13	amod
12	weight	weight	NN	_	13	compound
13	subjects	subject	NNS	_	8	nmod
14	,	,	,	_	8	punct
15	coadministration	coadministration	NN	_	26	dep
16	of	of	IN	_	17	case
17	XENICAL	XENICAL	NNP	_	15	nmod
18	and	and	CC	_	17	cc
19	40	40	CD	_	20	nummod
20	grams	gram	NNS	_	17	conj
21	of	of	IN	_	22	case
22	alcohol	alcohol	NN	_	20	nmod
23	(	(	CD	_	22	nummod
24	e	e	LS	_	26	dep
25	.	.	.	_	24	punct
26	g	g	NN	_	8	dep
27	.	.	.	_	26	punct
28	,	,	,	_	26	punct
29	approximately	approximately	RB	_	30	advmod
30	3	3	CD	_	31	nummod
31	glasses	glass	NNS	_	37	nsubj
32	of	of	IN	_	34	case
33	wine	wine	NN	_	34	compound
34	)	)	NN	_	31	nmod
35	did	do	VBD	_	37	aux
36	not	not	RB	_	37	neg
37	result	result	VB	_	26	dep
38	in	in	IN	_	39	case
39	alteration	alteration	NN	_	37	nmod
40	of	of	IN	_	42	case
41	alcohol	alcohol	NN	_	42	compound
42	pharmacokinetics	pharmacokinetic	NNS	_	39	nmod
43	,	,	,	_	26	punct
44	orlistat	orlistat	NN	_	45	compound
45	pharmacodynamics	pharmacodynamic	NNS	_	46	nsubj
46	(	(	VBP	_	26	parataxis
47	fecal	fecal	JJ	_	50	amod
48	fat	fat	JJ	_	50	amod
49	excretion	excretion	NN	_	50	compound
50	)	)	NN	_	46	dobj
51	,	,	,	_	50	punct
52	or	or	CC	_	50	cc
53	systemic	systemic	JJ	_	54	amod
54	exposure	exposure	NN	_	50	conj
55	to	to	TO	_	56	case
56	orlistat	orlistat	NN	_	54	nmod
57	.	.	.	_	1	punct

1	Cyclosporine	cyclosporine	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Preliminary	preliminary	JJ	_	4	amod
4	data	datum	NNS	_	13	nsubj
5	from	from	IN	_	12	case
6	a	a	DT	_	12	det
7	XENICAL	xenical	NN	_	12	compound
8	and	and	CC	_	7	cc
9	cyclosporine	cyclosporine	NN	_	7	conj
10	drug	drug	NN	_	12	compound
11	interaction	interaction	NN	_	12	compound
12	study	study	NN	_	4	nmod
13	indicate	indicate	VBP	_	1	appos
14	a	a	DT	_	15	det
15	reduction	reduction	NN	_	13	dobj
16	in	in	IN	_	19	case
17	cyclosporine	cyclosporine	NN	_	19	compound
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	15	nmod
20	when	when	WRB	_	23	advmod
21	XENICAL	XENICAL	NNP	_	23	nsubjpass
22	was	be	VBD	_	23	auxpass
23	coadministered	coadminister	VBN	_	13	advcl
24	with	with	IN	_	25	case
25	cyclosporine	cyclosporine	NN	_	23	nmod
26	.	.	.	_	1	punct

1	Digoxin	Digoxin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	8	case
4	12	12	CD	_	8	nummod
5	normal	normal	JJ	_	8	amod
6	-	-	:	_	8	punct
7	weight	weight	NN	_	8	compound
8	subjects	subject	NNS	_	24	nmod
9	receiving	receive	VBG	_	8	acl
10	XENICAL	xenical	NN	_	12	compound
11	120	120	CD	_	12	nummod
12	mg	mg	NN	_	9	dobj
13	three	three	CD	_	14	nummod
14	times	time	NNS	_	9	nmod:tmod
15	a	a	DT	_	16	det
16	day	day	NN	_	14	nmod:npmod
17	for	for	IN	_	19	case
18	6	6	CD	_	19	nummod
19	days	day	NNS	_	9	nmod
20	,	,	,	_	24	punct
21	XENICAL	XENICAL	NNP	_	24	nsubj
22	did	do	VBD	_	24	aux
23	not	not	RB	_	24	neg
24	alter	alter	VB	_	1	appos
25	the	the	DT	_	26	det
26	pharmacokinetics	pharmacokinetic	NNS	_	24	dobj
27	of	of	IN	_	30	case
28	a	a	DT	_	30	det
29	single	single	JJ	_	30	amod
30	dose	dose	NN	_	26	nmod
31	of	of	IN	_	32	case
32	digoxin	digoxin	NN	_	30	nmod
33	.	.	.	_	1	punct

1	Fat	Fat	NNP	_	0	ROOT
2	-	-	:	_	1	punct
3	soluble	soluble	JJ	_	5	amod
4	Vitamin	vitamin	NN	_	5	compound
5	Supplements	supplement	NNS	_	1	dep
6	and	and	CC	_	5	cc
7	Analogues	analogue	NNS	_	5	conj
8	:	:	:	_	1	punct
9	A	a	DT	_	12	det
10	pharmacokinetic	pharmacokinetic	JJ	_	12	amod
11	interaction	interaction	NN	_	12	compound
12	study	study	NN	_	13	nsubj
13	showed	show	VBD	_	1	dep
14	a	a	DT	_	17	det
15	30	30	CD	_	16	compound
16	%	%	NN	_	17	amod
17	reduction	reduction	NN	_	13	dobj
18	in	in	IN	_	19	case
19	beta	beta	NN	_	17	nmod
20	-	-	:	_	17	punct
21	carotene	carotene	NN	_	23	compound
22	supplement	supplement	NN	_	23	compound
23	absorption	absorption	NN	_	17	dep
24	when	when	WRB	_	26	advmod
25	concomitantly	concomitantly	RB	_	26	advmod
26	administered	administer	VBN	_	23	acl:relcl
27	with	with	IN	_	28	case
28	XENICAL	xenical	NN	_	26	nmod
29	.	.	.	_	1	punct

1	XENICAL	xenical	NN	_	2	nsubj
2	inhibited	inhibit	VBD	_	0	ROOT
3	absorption	absorption	NN	_	2	dobj
4	of	of	IN	_	9	case
5	a	a	DT	_	9	det
6	vitamin	vitamin	NN	_	9	compound
7	E	e	NN	_	9	compound
8	acetate	acetate	NN	_	9	compound
9	supplement	supplement	NN	_	3	nmod
10	by	by	IN	_	13	case
11	approximately	approximately	RB	_	12	advmod
12	60	60	CD	_	13	nummod
13	%	%	NN	_	2	nmod
14	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	orlistat	orlistat	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	2	nmod
8	of	of	IN	_	11	case
9	supplemental	supplemental	JJ	_	11	amod
10	vitamin	vitamin	NN	_	11	compound
11	D	d	NN	_	7	nmod
12	,	,	,	_	11	punct
13	vitamin	vitamin	NN	_	14	compound
14	A	a	NN	_	11	conj
15	,	,	,	_	11	punct
16	and	and	CC	_	11	cc
17	nutritionally	nutritionally	RB	_	24	advmod
18	-	-	:	_	24	punct
19	derived	derive	VBN	_	21	amod
20	vitamin	vitamin	NN	_	21	compound
21	K	k	NN	_	24	nsubjpass
22	is	be	VBZ	_	24	auxpass
23	not	not	RB	_	24	neg
24	known	know	VBN	_	11	conj
25	at	at	IN	_	27	case
26	this	this	DT	_	27	det
27	time	time	NN	_	24	nmod
28	.	.	.	_	2	punct

1	Glyburide	Glyburide	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	8	case
4	12	12	CD	_	8	nummod
5	normal	normal	JJ	_	8	amod
6	-	-	:	_	8	punct
7	weight	weight	NN	_	8	compound
8	subjects	subject	NNS	_	24	nmod
9	receiving	receive	VBG	_	8	acl
10	orlistat	orlistat	NN	_	12	compound
11	80	80	CD	_	12	nummod
12	mg	mg	NN	_	9	dobj
13	three	three	CD	_	14	nummod
14	times	time	NNS	_	9	nmod:tmod
15	a	a	DT	_	16	det
16	day	day	NN	_	14	nmod:npmod
17	for	for	IN	_	19	case
18	5	5	CD	_	19	nummod
19	days	day	NNS	_	9	nmod
20	,	,	,	_	24	punct
21	orlistat	orlistat	NN	_	24	nsubj
22	did	do	VBD	_	24	aux
23	not	not	RB	_	24	neg
24	alter	alter	VB	_	1	appos
25	the	the	DT	_	26	det
26	pharmacokinetics	pharmacokinetic	NNS	_	24	dobj
27	or	or	CC	_	26	cc
28	pharmacodynamics	pharmacodynamic	NNS	_	31	compound
29	(	(	CD	_	31	nummod
30	blood	blood	NN	_	31	compound
31	glucose	glucose	NN	_	26	conj
32	-	-	:	_	24	punct
33	lowering	lower	VBG	_	24	advcl
34	)	)	NN	_	33	dobj
35	of	of	IN	_	36	case
36	glyburide	glyburide	NN	_	34	nmod
37	.	.	.	_	1	punct

1	Nifedipine	nifedipine	NN	_	2	compound
2	(	(	NN	_	3	nsubj
3	extended	extend	VBD	_	0	ROOT
4	-	-	:	_	3	punct
5	release	release	NN	_	6	compound
6	tablets	tablet	NNS	_	3	dobj
7	)	)	CD	_	6	nummod
8	:	:	:	_	6	punct
9	In	in	IN	_	14	case
10	17	17	CD	_	14	nummod
11	normal	normal	JJ	_	14	amod
12	-	-	:	_	14	punct
13	weight	weight	NN	_	14	compound
14	subjects	subject	NNS	_	30	nmod
15	receiving	receive	VBG	_	14	acl
16	XENICAL	xenical	NN	_	18	compound
17	120	120	CD	_	18	nummod
18	mg	mg	NN	_	15	dobj
19	three	three	CD	_	20	nummod
20	times	time	NNS	_	15	nmod:tmod
21	a	a	DT	_	22	det
22	day	day	NN	_	20	nmod:npmod
23	for	for	IN	_	25	case
24	6	6	CD	_	25	nummod
25	days	day	NNS	_	15	nmod
26	,	,	,	_	30	punct
27	XENICAL	XENICAL	NNP	_	30	nsubj
28	did	do	VBD	_	30	aux
29	not	not	RB	_	30	neg
30	alter	alter	VB	_	6	dep
31	the	the	DT	_	32	det
32	bioavailability	bioavailability	NN	_	30	dobj
33	of	of	IN	_	34	case
34	nifedipine	nifedipine	NN	_	32	nmod
35	(	(	CD	_	34	nummod
36	extended	extend	VBD	_	30	xcomp
37	-	-	:	_	36	punct
38	release	release	NN	_	39	compound
39	tablets	tablet	NNS	_	40	nsubj
40	)	)	VBP	_	36	ccomp
41	.	.	.	_	3	punct

1	Oral	oral	JJ	_	2	amod
2	Contraceptives	contraceptive	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	10	case
5	20	20	CD	_	10	nummod
6	normal	normal	JJ	_	10	amod
7	-	-	:	_	10	punct
8	weight	weight	NN	_	10	compound
9	female	female	JJ	_	10	amod
10	subjects	subject	NNS	_	2	nmod
11	,	,	,	_	10	punct
12	the	the	DT	_	13	det
13	treatment	treatment	NN	_	25	nsubj
14	of	of	IN	_	17	case
15	XENICAL	xenical	NN	_	17	compound
16	120	120	CD	_	17	nummod
17	mg	mg	NN	_	13	nmod
18	three	three	CD	_	19	nummod
19	times	time	NNS	_	13	nmod:tmod
20	a	a	DT	_	21	det
21	day	day	NN	_	19	nmod:npmod
22	for	for	IN	_	24	case
23	23	23	CD	_	24	nummod
24	days	day	NNS	_	13	nmod
25	resulted	result	VBD	_	10	acl:relcl
26	in	in	IN	_	28	case
27	no	no	DT	_	28	neg
28	changes	change	NNS	_	25	nmod
29	in	in	IN	_	31	case
30	the	the	DT	_	31	det
31	ovulation	ovulation	NN	_	28	nmod
32	-	-	:	_	28	punct
33	suppressing	suppress	VBG	_	28	acl
34	action	action	NN	_	33	dobj
35	of	of	IN	_	37	case
36	oral	oral	JJ	_	37	amod
37	contraceptives	contraceptive	NNS	_	34	nmod
38	.	.	.	_	2	punct

1	Phenytoin	Phenytoin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	8	case
4	12	12	CD	_	8	nummod
5	normal	normal	JJ	_	8	amod
6	-	-	:	_	8	punct
7	weight	weight	NN	_	8	compound
8	subjects	subject	NNS	_	24	nmod
9	receiving	receive	VBG	_	8	acl
10	XENICAL	xenical	NN	_	12	compound
11	120	120	CD	_	12	nummod
12	mg	mg	NN	_	9	dobj
13	three	three	CD	_	14	nummod
14	times	time	NNS	_	9	nmod:tmod
15	a	a	DT	_	16	det
16	day	day	NN	_	14	nmod:npmod
17	for	for	IN	_	19	case
18	7	7	CD	_	19	nummod
19	days	day	NNS	_	9	nmod
20	,	,	,	_	24	punct
21	XENICAL	XENICAL	NNP	_	24	nsubj
22	did	do	VBD	_	24	aux
23	not	not	RB	_	24	neg
24	alter	alter	VB	_	1	appos
25	the	the	DT	_	26	det
26	pharmacokinetics	pharmacokinetic	NNS	_	24	dobj
27	of	of	IN	_	33	case
28	a	a	DT	_	33	det
29	single	single	JJ	_	33	amod
30	300	300	CD	_	33	nummod
31	-	-	:	_	33	punct
32	mg	mg	NN	_	33	compound
33	dose	dose	NN	_	26	nmod
34	of	of	IN	_	35	case
35	phenytoin	phenytoin	NN	_	33	nmod
36	.	.	.	_	1	punct

1	Pravastatin	Pravastatin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	9	case
4	a	a	DT	_	9	det
5	2	2	LS	_	9	amod
6	-	-	:	_	9	punct
7	way	way	NN	_	9	compound
8	crossover	crossover	NN	_	9	compound
9	study	study	NN	_	34	nmod
10	of	of	IN	_	14	case
11	24	24	CD	_	14	nummod
12	normal	normal	JJ	_	14	amod
13	-	-	:	_	14	punct
14	weight	weight	NN	_	9	nmod
15	,	,	,	_	9	punct
16	mildly	mildly	RB	_	17	advmod
17	hypercholesterolemic	hypercholesterolemic	JJ	_	18	amod
18	patients	patient	NNS	_	9	appos
19	receiving	receive	VBG	_	18	acl
20	XENICAL	xenical	NN	_	22	compound
21	120	120	CD	_	22	nummod
22	mg	mg	NN	_	19	dobj
23	three	three	CD	_	24	nummod
24	times	time	NNS	_	18	dep
25	a	a	DT	_	26	det
26	day	day	NN	_	24	nmod:npmod
27	for	for	IN	_	29	case
28	6	6	CD	_	29	nummod
29	days	day	NNS	_	24	nmod
30	,	,	,	_	9	punct
31	XENICAL	XENICAL	NNP	_	34	nsubj
32	did	do	VBD	_	34	aux
33	not	not	RB	_	34	neg
34	affect	affect	VB	_	1	appos
35	the	the	DT	_	36	det
36	pharmacokinetics	pharmacokinetic	NNS	_	34	dobj
37	of	of	IN	_	38	case
38	pravastatin	pravastatin	NN	_	36	nmod
39	.	.	.	_	1	punct

1	Warfarin	Warfarin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	8	case
4	12	12	CD	_	8	nummod
5	normal	normal	JJ	_	8	amod
6	-	-	:	_	8	punct
7	weight	weight	NN	_	8	compound
8	subjects	subject	NNS	_	24	nmod
9	,	,	,	_	8	punct
10	administration	administration	NN	_	24	nsubj
11	of	of	IN	_	14	case
12	XENICAL	xenical	NN	_	14	compound
13	120	120	CD	_	14	nummod
14	mg	mg	NN	_	10	nmod
15	three	three	CD	_	16	nummod
16	times	time	NNS	_	10	nmod:tmod
17	a	a	DT	_	18	det
18	day	day	NN	_	16	nmod:npmod
19	for	for	IN	_	21	case
20	16	16	CD	_	21	nummod
21	days	day	NNS	_	10	nmod
22	did	do	VBD	_	24	aux
23	not	not	RB	_	24	neg
24	result	result	VB	_	1	dep
25	in	in	IN	_	27	case
26	any	any	DT	_	27	det
27	change	change	NN	_	24	nmod
28	in	in	IN	_	31	case
29	either	either	CC	_	31	cc:preconj
30	warfarin	warfarin	NN	_	31	compound
31	pharmacokinetics	pharmacokinetic	NNS	_	27	nmod
32	(	(	VBP	_	31	acl
33	both	both	CC	_	34	cc:preconj
34	R	r	NN	_	32	dobj
35	-	-	:	_	34	punct
36	and	and	CC	_	34	cc
37	S	s	NN	_	39	compound
38	-	-	:	_	39	punct
39	enantiomers	enantiomer	NNS	_	34	conj
40	)	)	CD	_	39	nummod
41	or	or	CC	_	39	cc
42	pharmacodynamics	pharmacodynamic	NNS	_	39	conj
43	(	(	VBP	_	24	ccomp
44	prothrombin	prothrombin	NN	_	45	compound
45	time	time	NN	_	43	dobj
46	and	and	CC	_	45	cc
47	serum	serum	NN	_	49	compound
48	Factor	factor	NN	_	49	compound
49	VII	vii	NN	_	45	conj
50	)	)	CD	_	49	nummod
51	.	.	.	_	1	punct

1	Although	although	IN	_	14	mark
2	undercarboxylated	undercarboxylated	JJ	_	3	amod
3	osteocalcin	osteocalcin	NN	_	14	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	6	det
6	marker	marker	NN	_	3	appos
7	of	of	IN	_	11	case
8	vitamin	vitamin	NN	_	11	compound
9	K	k	NN	_	11	compound
10	nutritional	nutritional	JJ	_	11	amod
11	status	status	NN	_	6	nmod
12	,	,	,	_	3	punct
13	was	be	VBD	_	14	cop
14	unaltered	unaltered	JJ	_	22	advcl
15	with	with	IN	_	17	case
16	XENICAL	XENICAL	NNP	_	17	compound
17	administration	administration	NN	_	14	nmod
18	,	,	,	_	22	punct
19	vitamin	vitamin	NN	_	21	compound
20	K	k	NN	_	21	compound
21	levels	level	NNS	_	22	nsubj
22	tended	tend	VBD	_	0	ROOT
23	to	to	TO	_	24	mark
24	decline	decline	VB	_	22	xcomp
25	in	in	IN	_	26	case
26	subjects	subject	NNS	_	24	nmod
27	taking	take	VBG	_	26	acl
28	XENICAL	XENICAL	NNP	_	27	dobj
29	.	.	.	_	22	punct

1	Therefore	therefore	RB	_	26	advmod
2	,	,	,	_	26	punct
3	as	as	IN	_	9	mark
4	vitamin	vitamin	NN	_	6	compound
5	K	k	NN	_	6	compound
6	absorption	absorption	NN	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	decreased	decrease	VBN	_	26	advcl
10	with	with	IN	_	11	case
11	XENICAL	xenical	NN	_	9	nmod
12	,	,	,	_	26	punct
13	patients	patient	NNS	_	26	nsubjpass
14	on	on	IN	_	17	case
15	chronic	chronic	JJ	_	17	amod
16	stable	stable	JJ	_	17	amod
17	doses	dose	NNS	_	13	nmod
18	of	of	IN	_	19	case
19	warfarin	warfarin	NN	_	17	nmod
20	who	who	WP	_	22	nsubjpass
21	are	be	VBP	_	22	auxpass
22	prescribed	prescribe	VBN	_	17	acl:relcl
23	XENICAL	XENICAL	NNP	_	22	dobj
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	monitored	monitor	VBN	_	0	ROOT
27	closely	closely	RB	_	26	advmod
28	for	for	IN	_	29	case
29	changes	change	NNS	_	26	nmod
30	in	in	IN	_	32	case
31	coagulation	coagulation	NN	_	32	compound
32	parameters	parameter	NNS	_	29	nmod
33	.	.	.	_	26	punct

1	Probenecid	Probenecid	NNP	_	2	nsubj
2	competes	compete	VBZ	_	0	ROOT
3	with	with	IN	_	4	case
4	meropenem	meropenem	NN	_	2	nmod
5	for	for	IN	_	8	case
6	active	active	JJ	_	8	amod
7	tubular	tubular	JJ	_	8	amod
8	secretion	secretion	NN	_	2	nmod
9	and	and	CC	_	2	cc
10	thus	thus	RB	_	11	advmod
11	inhibits	inhibit	VBZ	_	2	conj
12	the	the	DT	_	14	det
13	renal	renal	JJ	_	14	amod
14	excretion	excretion	NN	_	11	dobj
15	of	of	IN	_	16	case
16	meropenem	meropenem	NN	_	14	nmod
17	.	.	.	_	2	punct

1	This	this	DT	_	2	nsubj
2	led	lead	VBD	_	0	ROOT
3	to	to	TO	_	6	case
4	statistically	statistically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	increases	increase	NNS	_	2	nmod
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	elimination	elimination	NN	_	10	compound
10	half	half	NN	_	6	nmod
11	-	-	:	_	10	punct
12	life	life	NN	_	10	dep
13	(	(	CD	_	14	compound
14	38	38	CD	_	15	nummod
15	%	%	NN	_	12	dep
16	)	)	CD	_	15	nummod
17	and	and	CC	_	15	cc
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	extent	extent	NN	_	15	conj
21	of	of	IN	_	24	case
22	systemic	systemic	JJ	_	24	amod
23	exposure	exposure	NN	_	24	compound
24	(	(	NN	_	20	nmod
25	56	56	CD	_	26	nummod
26	%	%	NN	_	24	dep
27	)	)	CD	_	26	nummod
28	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	4	det
4	coadministration	coadministration	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	probenecid	probenecid	NN	_	4	nmod
7	with	with	IN	_	8	case
8	meropenem	meropenem	NN	_	4	nmod
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	evidence	evidence	NN	_	16	nsubj
4	that	that	IN	_	7	mark
5	meropenem	meropenem	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	reduce	reduce	VB	_	3	ccomp
8	serum	serum	NN	_	9	compound
9	levels	level	NNS	_	7	dobj
10	of	of	IN	_	12	case
11	valproic	valproic	JJ	_	12	amod
12	acid	acid	NN	_	9	nmod
13	to	to	TO	_	15	case
14	subtherapeutic	subtherapeutic	JJ	_	15	amod
15	levels	level	NNS	_	7	nmod
16	(	(	VBP	_	2	ccomp
17	therapeutic	therapeutic	JJ	_	18	amod
18	range	range	NN	_	16	dobj
19	considered	consider	VBN	_	18	acl
20	to	to	TO	_	25	mark
21	be	be	VB	_	25	cop
22	50	50	CD	_	24	compound
23	to	to	TO	_	24	dep
24	100	100	CD	_	25	nummod
25	g	g	NN	_	19	xcomp
26	/	/	:	_	25	punct
27	mL	ml	NN	_	30	compound
28	total	total	JJ	_	30	amod
29	valproate	valproate	NN	_	30	compound
30	)	)	NN	_	25	dep
31	.	.	.	_	2	punct

1	Ondansetron	ondansetron	NN	_	5	nsubj
2	does	do	VBZ	_	5	aux
3	not	not	RB	_	5	neg
4	itself	itself	PRP	_	5	nsubj
5	appear	appear	VB	_	0	ROOT
6	to	to	TO	_	7	mark
7	induce	induce	VB	_	5	xcomp
8	or	or	CC	_	7	cc
9	inhibit	inhibit	VB	_	7	conj
10	the	the	DT	_	12	det
11	cytochrome	cytochrome	NN	_	12	compound
12	P	p	NN	_	7	dobj
13	-	-	:	_	12	punct
14	450	450	CD	_	15	nummod
15	drug	drug	NN	_	12	dep
16	-	-	:	_	12	punct
17	metabolizing	metabolize	VBG	_	19	amod
18	enzyme	enzyme	NN	_	19	compound
19	system	system	NN	_	12	dep
20	of	of	IN	_	22	case
21	the	the	DT	_	22	det
22	liver	liver	NN	_	19	nmod
23	.	.	.	_	5	punct

1	Because	because	IN	_	4	mark
2	ondansetron	ondansetron	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	0	ROOT
5	by	by	IN	_	8	case
6	hepatic	hepatic	JJ	_	8	amod
7	cytochrome	cytochrome	NN	_	8	compound
8	P	p	NN	_	4	nmod
9	-	-	:	_	8	punct
10	450	450	CD	_	11	nummod
11	drug	drug	NN	_	8	dep
12	-	-	:	_	8	punct
13	metabolizing	metabolize	VBG	_	14	amod
14	enzymes	enzyme	NNS	_	15	nsubj
15	(	(	VBP	_	8	dep
16	CYP3A4	cyp3a4	NN	_	15	dobj
17	,	,	,	_	16	punct
18	CYP2D6	cyp2d6	NN	_	16	conj
19	,	,	,	_	16	punct
20	CYP1A2	cyp1a2	NN	_	21	compound
21	)	)	NN	_	16	conj
22	,	,	,	_	16	punct
23	inducers	inducer	NNS	_	16	conj
24	or	or	CC	_	16	cc
25	inhibitors	inhibitor	NNS	_	16	conj
26	of	of	IN	_	28	case
27	these	these	DT	_	28	det
28	enzymes	enzyme	NNS	_	16	nmod
29	may	may	MD	_	30	aux
30	change	change	VB	_	15	dep
31	the	the	DT	_	32	det
32	clearance	clearance	NN	_	30	dobj
33	and	and	CC	_	30	cc
34	,	,	,	_	30	punct
35	hence	hence	RB	_	30	advmod
36	,	,	,	_	30	punct
37	the	the	DT	_	38	det
38	half	half	NN	_	30	dobj
39	-	-	:	_	38	punct
40	life	life	NN	_	38	dep
41	of	of	IN	_	42	case
42	ondansetron	ondansetron	NN	_	40	nmod
43	.	.	.	_	4	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	basis	basis	NN	_	13	nmod
4	of	of	IN	_	7	case
5	limited	limited	JJ	_	7	amod
6	available	available	JJ	_	7	amod
7	data	datum	NNS	_	3	nmod
8	,	,	,	_	13	punct
9	no	no	DT	_	11	neg
10	dosage	dosage	NN	_	11	compound
11	adjustment	adjustment	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	for	for	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	on	on	IN	_	18	case
17	these	these	DT	_	18	det
18	drugs	drug	NNS	_	15	nmod
19	.	.	.	_	13	punct

1	Phenytoin	Phenytoin	NNP	_	0	ROOT
2	,	,	,	_	1	punct
3	Carbamazepine	Carbamazepine	NNP	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	Rifampicin	Rifampicin	NNP	_	1	conj
7	:	:	:	_	1	punct
8	In	in	IN	_	9	case
9	patients	patient	NNS	_	1	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	13	case
12	potent	potent	JJ	_	13	amod
13	inducers	inducer	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	CYP3A4	cyp3a4	NN	_	13	nmod
16	(	(	CD	_	15	nummod
17	i	i	LS	_	9	dep
18	.	.	.	_	17	punct
19	e	e	LS	_	17	dep
20	.	.	.	_	19	punct
21	,	,	,	_	19	punct
22	phenytoin	phenytoin	NN	_	36	nsubjpass
23	,	,	,	_	22	punct
24	carbamazepine	carbamazepine	NN	_	22	conj
25	,	,	,	_	22	punct
26	and	and	CC	_	22	cc
27	rifampicin	rifampicin	NN	_	28	compound
28	)	)	NN	_	22	conj
29	,	,	,	_	22	punct
30	the	the	DT	_	31	det
31	clearance	clearance	NN	_	22	appos
32	of	of	IN	_	33	case
33	ondansetron	ondansetron	NN	_	31	nmod
34	was	be	VBD	_	36	auxpass
35	significantly	significantly	RB	_	36	advmod
36	increased	increase	VBN	_	19	parataxis
37	and	and	CC	_	36	cc
38	ondansetron	ondansetron	VBN	_	40	amod
39	blood	blood	NN	_	40	compound
40	concentrations	concentration	NNS	_	42	nsubjpass
41	were	be	VBD	_	42	auxpass
42	decreased	decrease	VBN	_	36	conj
43	.	.	.	_	1	punct

1	However	however	RB	_	16	advmod
2	,	,	,	_	16	punct
3	on	on	IN	_	5	case
4	the	the	DT	_	5	det
5	basis	basis	NN	_	16	nmod
6	of	of	IN	_	8	case
7	available	available	JJ	_	8	amod
8	data	datum	NNS	_	5	nmod
9	,	,	,	_	16	punct
10	no	no	DT	_	12	neg
11	dosage	dosage	NN	_	12	compound
12	adjustment	adjustment	NN	_	16	nsubjpass
13	for	for	IN	_	14	case
14	ondansetron	ondansetron	NN	_	12	nmod
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	for	for	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	on	on	IN	_	21	case
20	these	these	DT	_	21	det
21	drugs	drug	NNS	_	18	nmod
22	.	.	.	_	16	punct
23	1,3	1,3	CD	_	24	nummod
24	Tramadol	Tramadol	NNP	_	16	dep
25	:	:	:	_	24	punct
26	Although	although	IN	_	37	mark
27	no	no	DT	_	30	neg
28	pharmacokinetic	pharmacokinetic	JJ	_	30	amod
29	drug	drug	NN	_	30	compound
30	interaction	interaction	NN	_	37	nsubjpass
31	between	between	IN	_	32	case
32	ondansetron	ondansetron	NN	_	30	nmod
33	and	and	CC	_	32	cc
34	tramadol	tramadol	NN	_	32	conj
35	has	have	VBZ	_	37	aux
36	been	be	VBN	_	37	auxpass
37	observed	observe	VBN	_	44	advcl
38	,	,	,	_	44	punct
39	data	datum	NNS	_	44	nsubj
40	from	from	IN	_	43	case
41	2	2	CD	_	43	nummod
42	small	small	JJ	_	43	amod
43	studies	study	NNS	_	39	nmod
44	indicate	indicate	VBP	_	24	dep
45	that	that	IN	_	49	mark
46	ondansetron	ondansetron	NN	_	49	nsubjpass
47	may	may	MD	_	49	aux
48	be	be	VB	_	49	auxpass
49	associated	associate	VBN	_	44	ccomp
50	with	with	IN	_	52	case
51	an	a	DT	_	52	det
52	increase	increase	NN	_	49	nmod
53	in	in	IN	_	56	case
54	patient	patient	NN	_	56	compound
55	controlled	controlled	JJ	_	56	amod
56	administration	administration	NN	_	52	nmod
57	of	of	IN	_	58	case
58	tramadol	tramadol	NN	_	56	nmod
59	.	.	.	_	44	punct
60	4,5	4,5	CD	_	61	nummod
61	Chemotherapy	Chemotherapy	NNP	_	44	dep
62	:	:	:	_	61	punct
63	Tumor	tumor	NN	_	64	compound
64	response	response	NN	_	76	nsubjpass
65	to	to	TO	_	66	case
66	chemotherapy	chemotherapy	NN	_	64	nmod
67	in	in	IN	_	73	case
68	the	the	DT	_	73	det
69	P	p	NN	_	73	compound
70	388	388	CD	_	73	nummod
71	mouse	mouse	NN	_	73	compound
72	leukemia	leukemia	NN	_	73	compound
73	model	model	NN	_	66	nmod
74	is	be	VBZ	_	76	auxpass
75	not	not	RB	_	76	neg
76	affected	affect	VBN	_	61	dep
77	by	by	IN	_	78	case
78	ondansetron	ondansetron	NN	_	76	nmod
79	.	.	.	_	16	punct

1	In	in	IN	_	2	case
2	humans	human	NNS	_	12	nmod
3	,	,	,	_	12	punct
4	carmustine	carmustine	NN	_	12	nsubj
5	,	,	,	_	4	punct
6	etoposide	etoposide	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	cisplatin	cisplatin	NN	_	4	conj
10	do	do	VBP	_	12	aux
11	not	not	RB	_	12	neg
12	affect	affect	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
15	of	of	IN	_	16	case
16	ondansetron	ondansetron	NN	_	14	nmod
17	.	.	.	_	12	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	crossover	crossover	NN	_	4	compound
4	study	study	NN	_	12	nmod
5	in	in	IN	_	8	case
6	76	76	CD	_	8	nummod
7	pediatric	pediatric	JJ	_	8	amod
8	patients	patient	NNS	_	4	nmod
9	,	,	,	_	12	punct
10	I	I	PRP	_	12	dep
11	.	.	.	_	12	punct
12	V	V	NNP	_	0	ROOT
13	.	.	.	_	12	punct

1	ondansetron	ondansetron	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	increase	increase	VB	_	0	ROOT
5	blood	blood	NN	_	6	compound
6	levels	level	NNS	_	4	dobj
7	of	of	IN	_	11	case
8	high	high	JJ	_	11	amod
9	-	-	:	_	11	punct
10	dose	dose	NN	_	11	compound
11	methotrexate	methotrexate	NN	_	6	nmod
12	.	.	.	_	4	punct

1	CYP3A4	cyp3a4	NN	_	2	compound
2	Inhibitors	inhibitor	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Ketoconazole	Ketoconazole	NNP	_	29	nsubj
5	,	,	,	_	4	punct
6	an	a	DT	_	7	det
7	inhibitor	inhibitor	NN	_	4	appos
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	drug	drug	NN	_	7	nmod
11	metabolizing	metabolize	VBG	_	10	acl
12	enzyme	enzyme	NN	_	13	compound
13	CYP3A4	cyp3a4	NN	_	11	dobj
14	,	,	,	_	4	punct
15	significantly	significantly	RB	_	16	advmod
16	increased	increase	VBN	_	18	amod
17	plasma	plasma	NN	_	18	compound
18	concentrations	concentration	NNS	_	4	appos
19	of	of	IN	_	20	case
20	tolterodine	tolterodine	NN	_	18	nmod
21	when	when	WRB	_	22	advmod
22	coadministered	coadminister	VBN	_	18	acl:relcl
23	to	to	TO	_	24	case
24	subjects	subject	NNS	_	22	nmod
25	who	who	WP	_	28	nsubj
26	were	be	VBD	_	28	cop
27	poor	poor	JJ	_	28	amod
28	metabolizers	metabolizer	NNS	_	24	acl:relcl
29	(	(	VBP	_	2	appos
30	see	see	VB	_	29	xcomp
31	CLINICAL	CLINICAL	NNP	_	32	compound
32	PHARMACOLOGY	PHARMACOLOGY	NNP	_	30	dobj
33	,	,	,	_	32	punct
34	Variability	variability	NN	_	32	appos
35	in	in	IN	_	36	case
36	Metabolism	metabolism	NN	_	34	nmod
37	and	and	CC	_	36	cc
38	Drug	drug	NN	_	36	conj
39	-	-	:	_	32	punct
40	Drug	drug	NN	_	41	compound
41	Interactions	interaction	NNS	_	42	nsubj
42	)	)	VBP	_	32	dep
43	.	.	.	_	2	punct

1	For	for	IN	_	2	case
2	patients	patient	NNS	_	15	nmod
3	receiving	receive	VBG	_	2	acl
4	ketoconazole	ketoconazole	NN	_	3	dobj
5	or	or	CC	_	4	cc
6	other	other	JJ	_	9	amod
7	potent	potent	JJ	_	9	amod
8	CYP3A4	cyp3a4	NN	_	9	compound
9	inhibitors	inhibitor	NNS	_	4	conj
10	such	such	JJ	_	14	case
11	as	as	IN	_	10	mwe
12	other	other	JJ	_	14	amod
13	azole	azole	NN	_	14	compound
14	antifungals	antifungal	NNS	_	2	nmod
15	(	(	VBP	_	0	ROOT
16	eg	eg	FW	_	24	compound
17	,	,	,	_	16	punct
18	itraconazole	itraconazole	NN	_	16	conj
19	,	,	,	_	16	punct
20	miconazole	miconazole	NN	_	16	conj
21	)	)	CD	_	20	nummod
22	or	or	CC	_	16	cc
23	macrolide	macrolide	NN	_	16	conj
24	antibiotics	antibiotic	NNS	_	25	nsubj
25	(	(	VBP	_	15	ccomp
26	eg	eg	FW	_	25	dobj
27	,	,	,	_	26	punct
28	erythromycin	erythromycin	NN	_	26	conj
29	,	,	,	_	26	punct
30	clarithromycin	clarithromycin	NN	_	26	conj
31	)	)	CD	_	30	nummod
32	or	or	CC	_	26	cc
33	cyclosporine	cyclosporine	NN	_	26	conj
34	or	or	CC	_	33	cc
35	vinblastine	vinblastine	NN	_	33	conj
36	,	,	,	_	26	punct
37	the	the	DT	_	39	det
38	recommended	recommend	VBN	_	39	amod
39	dose	dose	NN	_	45	nsubj
40	of	of	IN	_	42	case
41	DETROL	DETROL	NNP	_	42	compound
42	LA	LA	NNP	_	39	nmod
43	is	be	VBZ	_	45	cop
44	2	2	CD	_	45	nummod
45	mg	mg	NN	_	26	ccomp
46	daily	daily	RB	_	45	advmod
47	.	.	.	_	15	punct

1	Drug	drug	NN	_	3	compound
2	-	-	:	_	3	punct
3	Laboratory	laboratory	NN	_	0	ROOT
4	-	-	:	_	3	punct
5	Test	test	NN	_	7	compound
6	Interactions	interaction	NNS	_	7	compound
7	Interactions	interaction	NNS	_	16	nsubjpass
8	between	between	IN	_	9	case
9	tolterodine	tolterodine	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	laboratory	laboratory	NN	_	12	compound
12	tests	test	NNS	_	9	conj
13	have	have	VBP	_	16	aux
14	not	not	RB	_	16	neg
15	been	be	VBN	_	16	auxpass
16	studied	study	VBN	_	3	dep
17	.	.	.	_	3	punct

1	Since	since	IN	_	4	mark
2	trimetrexate	trimetrexate	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	22	advcl
5	by	by	IN	_	9	case
6	a	a	DT	_	9	det
7	P450	p450	NN	_	9	compound
8	enzyme	enzyme	NN	_	9	compound
9	system	system	NN	_	4	nmod
10	,	,	,	_	22	punct
11	drugs	drug	NNS	_	22	nsubj
12	that	that	WDT	_	13	nsubj
13	induce	induce	VBP	_	11	acl:relcl
14	or	or	CC	_	13	cc
15	inhibit	inhibit	VBP	_	13	conj
16	this	this	DT	_	17	det
17	drug	drug	NN	_	20	compound
18	metabolizing	metabolize	VBG	_	20	amod
19	enzyme	enzyme	NN	_	20	compound
20	system	system	NN	_	13	dobj
21	may	may	MD	_	22	aux
22	elicit	elicit	VB	_	0	ROOT
23	important	important	JJ	_	24	amod
24	drug	drug	NN	_	22	dobj
25	-	-	:	_	24	punct
26	drug	drug	NN	_	27	compound
27	interactions	interaction	NNS	_	24	dep
28	that	that	WDT	_	30	nsubj
29	may	may	MD	_	30	aux
30	alter	alter	VB	_	27	acl:relcl
31	trimetrexate	trimetrexate	NN	_	33	compound
32	plasma	plasma	NN	_	33	compound
33	concentrations	concentration	NNS	_	30	dobj
34	.	.	.	_	22	punct

1	Agents	agent	NNS	_	19	nsubj
2	that	that	WDT	_	5	nsubjpass
3	might	might	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	1	acl:relcl
6	with	with	IN	_	7	case
7	trimetrexate	trimetrexate	NN	_	5	nmod
8	in	in	IN	_	10	case
9	AIDS	aids	NN	_	10	compound
10	patients	patient	NNS	_	7	nmod
11	for	for	IN	_	13	case
12	other	other	JJ	_	13	amod
13	indications	indication	NNS	_	10	nmod
14	that	that	WDT	_	16	nsubj
15	could	could	MD	_	16	aux
16	elicit	elicit	VB	_	13	acl:relcl
17	this	this	DT	_	18	det
18	activity	activity	NN	_	16	dobj
19	include	include	VBP	_	0	ROOT
20	erythromycin	erythromycin	NN	_	19	dobj
21	,	,	,	_	20	punct
22	rifampin	rifampin	NN	_	20	conj
23	,	,	,	_	20	punct
24	rifabutin	rifabutin	NN	_	20	conj
25	,	,	,	_	20	punct
26	ketoconazole	ketoconazole	NN	_	20	conj
27	,	,	,	_	20	punct
28	and	and	CC	_	20	cc
29	fluconazole	fluconazole	NN	_	20	conj
30	.	.	.	_	19	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	perfusion	perfusion	NN	_	9	nsubj
4	of	of	IN	_	7	case
5	isolated	isolate	VBN	_	7	amod
6	rat	rat	NN	_	7	compound
7	liver	liver	NN	_	3	nmod
8	has	have	VBZ	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	that	that	IN	_	12	mark
11	cimetidine	cimetidine	NN	_	12	nsubj
12	caused	cause	VBD	_	9	ccomp
13	a	a	DT	_	15	det
14	significant	significant	JJ	_	15	amod
15	reduction	reduction	NN	_	12	dobj
16	in	in	IN	_	18	case
17	trimetrexate	trimetrexate	NN	_	18	compound
18	metabolism	metabolism	NN	_	15	nmod
19	and	and	CC	_	12	cc
20	that	that	IN	_	22	mark
21	acetaminophen	acetaminophen	NN	_	22	nsubj
22	altered	alter	VBD	_	12	conj
23	the	the	DT	_	25	det
24	relative	relative	JJ	_	25	amod
25	concentration	concentration	NN	_	22	dobj
26	of	of	IN	_	28	case
27	trimetrexate	trimetrexate	NN	_	28	compound
28	metabolites	metabolite	NNS	_	25	nmod
29	possibly	possibly	RB	_	31	advmod
30	by	by	IN	_	31	mark
31	competing	compete	VBG	_	22	advcl
32	for	for	IN	_	34	case
33	sulfate	sulfate	NN	_	34	compound
34	metabolites	metabolite	NNS	_	31	nmod
35	.	.	.	_	9	punct

1	Based	base	VBN	_	8	case
2	on	on	IN	_	8	case
3	an	a	DT	_	8	det
4	in	in	FW	_	8	amod
5	vitro	vitro	FW	_	4	dep
6	rat	rat	NN	_	8	compound
7	liver	liver	NN	_	8	compound
8	model	model	NN	_	14	advcl
9	,	,	,	_	14	punct
10	nitrogen	nitrogen	NN	_	13	compound
11	substituted	substitute	VBN	_	13	amod
12	imidazole	imidazole	NN	_	13	compound
13	drugs	drug	NNS	_	14	nsubj
14	(	(	VBP	_	0	ROOT
15	clotrimazole	clotrimazole	NN	_	22	nsubj
16	,	,	,	_	15	punct
17	ketoconazole	ketoconazole	NN	_	15	conj
18	,	,	,	_	15	punct
19	miconazole	miconazole	NN	_	20	compound
20	)	)	NN	_	15	conj
21	were	be	VBD	_	22	cop
22	potent	potent	JJ	_	14	ccomp
23	,	,	,	_	22	punct
24	non	non	JJ	_	22	dep
25	-	-	:	_	22	punct
26	competitive	competitive	JJ	_	27	amod
27	inhibitors	inhibitor	NNS	_	22	dep
28	of	of	IN	_	30	case
29	trimetrexate	trimetrexate	NN	_	30	compound
30	metabolism	metabolism	NN	_	27	nmod
31	.	.	.	_	14	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	medicated	medicate	VBN	_	1	acl
3	with	with	IN	_	5	case
4	these	these	DT	_	5	det
5	drugs	drug	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	trimetrexate	trimetrexate	NN	_	5	conj
8	should	should	MD	_	11	aux
9	be	be	VB	_	11	auxpass
10	carefully	carefully	RB	_	11	advmod
11	monitored	monitor	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Coumarin	Coumarin	NNP	_	0	ROOT
2	-	-	:	_	1	punct
3	Derivative	derivative	JJ	_	4	amod
4	Anticoagulants	Anticoagulants	NNPS	_	1	dep
5	:	:	:	_	1	punct
6	Prolongation	prolongation	NN	_	21	nsubjpass
7	of	of	IN	_	9	case
8	prothrombin	prothrombin	NN	_	9	compound
9	time	time	NN	_	6	nmod
10	(	(	CD	_	12	nummod
11	PT	pt	NN	_	12	compound
12	)	)	NN	_	9	dep
13	and	and	CC	_	12	cc
14	International	International	NNP	_	18	compound
15	Normalized	Normalized	NNP	_	18	compound
16	Ratio	Ratio	NNP	_	18	compound
17	(	(	CD	_	18	nummod
18	INR	INR	NNP	_	12	conj
19	)	)	CD	_	18	nummod
20	were	be	VBD	_	21	auxpass
21	observed	observe	VBN	_	1	dep
22	in	in	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	receiving	receive	VBG	_	23	acl
25	ZOLINZA	ZOLINZA	NNP	_	24	dobj
26	concomitantly	concomitantly	RB	_	28	advmod
27	with	with	IN	_	28	case
28	coumarin	coumarin	NN	_	24	nmod
29	-	-	:	_	28	punct
30	derivative	derivative	JJ	_	31	amod
31	anticoagulants	anticoagulant	NNS	_	28	dep
32	.	.	.	_	1	punct

1	Physicians	Physicians	NNP	_	4	nsubj
2	should	should	MD	_	4	aux
3	carefully	carefully	RB	_	4	advmod
4	monitor	monitor	VB	_	0	ROOT
5	PT	pt	NN	_	4	dobj
6	and	and	CC	_	5	cc
7	INR	inr	NN	_	5	conj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	4	nmod
10	concurrently	concurrently	RB	_	11	advmod
11	administered	administer	VBN	_	15	amod
12	ZOLINZA	zolinza	NN	_	15	compound
13	and	and	CC	_	12	cc
14	coumarin	coumarin	NN	_	12	conj
15	derivatives	derivative	NNS	_	9	dep
16	.	.	.	_	4	punct

1	Other	other	JJ	_	3	amod
2	HDAC	hdac	NN	_	3	compound
3	Inhibitors	inhibitor	NNS	_	11	nsubjpass
4	Severe	severe	JJ	_	5	amod
5	thrombocytopenia	thrombocytopenia	NN	_	3	dep
6	and	and	CC	_	5	cc
7	gastrointestinal	gastrointestinal	JJ	_	8	amod
8	bleeding	bleeding	NN	_	5	conj
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	with	with	IN	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	use	use	NN	_	11	nmod
15	of	of	IN	_	16	case
16	ZOLINZA	zolinza	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	other	other	JJ	_	20	amod
19	HDAC	hdac	NN	_	20	compound
20	inhibitors	inhibitor	NNS	_	16	conj
21	(	(	VBP	_	11	dep
22	e	e	LS	_	21	dobj
23	.	.	.	_	22	punct
24	g	g	NN	_	22	dep
25	.	.	.	_	24	punct
26	,	,	,	_	24	punct
27	valproic	valproic	JJ	_	29	amod
28	acid	acid	NN	_	29	compound
29	)	)	NN	_	24	appos
30	.	.	.	_	11	punct

1	Monitor	Monitor	NNP	_	3	compound
2	platelet	platelet	NN	_	3	compound
3	count	count	NN	_	0	ROOT
4	every	every	DT	_	6	det
5	2	2	CD	_	6	nummod
6	weeks	week	NNS	_	3	nmod:tmod
7	for	for	IN	_	11	case
8	the	the	DT	_	11	det
9	first	first	JJ	_	11	amod
10	2	2	CD	_	11	nummod
11	months	month	NNS	_	3	nmod
12	.	.	.	_	3	punct

1	Nasal	nasal	JJ	_	2	amod
2	Spray	spray	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Formal	formal	JJ	_	5	amod
5	studies	study	NNS	_	19	nsubjpass
6	designed	design	VBN	_	5	acl
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	8	dobj
11	with	with	IN	_	14	case
12	Calcitonin	calcitonin	NN	_	14	compound
13	(	(	CD	_	14	nummod
14	salmon	salmon	NN	_	10	nmod
15	)	)	CD	_	14	nummod
16	have	have	VBP	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	done	do	VBN	_	2	dep
20	.	.	.	_	2	punct

1	No	no	DT	_	4	neg
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	with	with	IN	_	15	case
9	Calcitonin	calcitonin	NN	_	15	compound
10	(	(	CD	_	15	nummod
11	salmon	salmon	NN	_	15	compound
12	)	)	CD	_	15	nummod
13	nasal	nasal	JJ	_	15	amod
14	spray	spray	NN	_	15	compound
15	ingredients	ingredient	NNS	_	7	nmod
16	.	.	.	_	7	punct

1	Currently	currently	RB	_	13	advmod
2	,	,	,	_	13	punct
3	no	no	DT	_	5	neg
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	13	nsubjpass
6	with	with	IN	_	10	case
7	Calcitonin	calcitonin	NN	_	10	compound
8	(	(	CD	_	10	nummod
9	salmon	salmon	NN	_	10	compound
10	)	)	NN	_	5	nmod
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	15	nsubjpass
3	of	of	IN	_	5	case
4	prior	prior	JJ	_	5	amod
5	use	use	NN	_	2	nmod
6	of	of	IN	_	7	case
7	diphosphonates	diphosphonate	NNS	_	5	nmod
8	in	in	IN	_	11	case
9	postmenopausal	postmenopausal	JJ	_	11	amod
10	osteoporosis	osteoporosis	NN	_	11	compound
11	patients	patient	NNS	_	2	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	assessed	assess	VBN	_	0	ROOT
16	;	;	:	_	15	punct

1	however	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	12	nmod
5	with	with	IN	_	6	case
6	Paget	paget	NN	_	4	nmod
7	'	'	''	_	12	punct
8	s	be	VBZ	_	12	compound
9	Disease	Disease	NNP	_	12	compound
10	prior	prior	RB	_	12	advmod
11	diphosphonate	diphosphonate	NN	_	12	compound
12	use	use	NN	_	0	ROOT
13	appears	appear	VBZ	_	12	acl
14	to	to	TO	_	15	mark
15	reduce	reduce	VB	_	13	xcomp
16	the	the	DT	_	20	det
17	anti	anti	JJ	_	20	amod
18	-	-	:	_	20	punct
19	resorptive	resorptive	JJ	_	20	amod
20	response	response	NN	_	15	dobj
21	to	to	TO	_	27	case
22	Calcitonin	calcitonin	NN	_	27	compound
23	(	(	NN	_	27	compound
24	salmon	salmon	NN	_	27	compound
25	)	)	CD	_	27	nummod
26	nasal	nasal	JJ	_	27	amod
27	spray	spray	NN	_	20	nmod
28	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	absorption	absorption	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	medications	medication	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	decreased	decrease	VBN	_	0	ROOT
9	during	during	IN	_	12	case
10	the	the	DT	_	12	det
11	concurrent	concurrent	JJ	_	12	amod
12	use	use	NN	_	8	nmod
13	of	of	IN	_	14	case
14	scopolamine	scopolamine	NN	_	12	nmod
15	because	because	IN	_	19	case
16	of	of	IN	_	15	mwe
17	decreased	decrease	VBN	_	19	amod
18	gastric	gastric	JJ	_	19	amod
19	motility	motility	NN	_	8	nmod
20	and	and	CC	_	19	cc
21	delayed	delay	VBN	_	23	amod
22	gastric	gastric	JJ	_	23	amod
23	emptying	emptying	NN	_	19	conj
24	.	.	.	_	8	punct

1	Scopolamine	scopolamine	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	care	care	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	4	nmod
9	taking	take	VBG	_	8	acl
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	9	dobj
12	that	that	WDT	_	14	nsubj
13	are	be	VBP	_	14	cop
14	capable	capable	JJ	_	11	acl:relcl
15	of	of	IN	_	16	mark
16	causing	cause	VBG	_	14	advcl
17	CNS	cns	NN	_	18	compound
18	effects	effect	NNS	_	16	dobj
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	sedatives	sedative	NNS	_	18	nmod
22	,	,	,	_	21	punct
23	tranquilizers	tranquilizer	NNS	_	21	conj
24	,	,	,	_	21	punct
25	or	or	CC	_	21	cc
26	alcohol	alcohol	NN	_	21	conj
27	.	.	.	_	4	punct

1	Special	special	JJ	_	2	amod
2	attention	attention	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	paid	pay	VBN	_	0	ROOT
6	to	to	TO	_	8	case
7	potential	potential	JJ	_	8	amod
8	interactions	interaction	NNS	_	5	nmod
9	with	with	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	having	have	VBG	_	10	acl
12	anticholinergic	anticholinergic	JJ	_	13	amod
13	properties	property	NNS	_	11	dobj
14	;	;	:	_	5	punct

1	e	e	LS	_	0	ROOT
2	.	.	.	_	1	punct
3	g	g	NN	_	1	dep
4	.	.	.	_	3	punct
5	,	,	,	_	3	punct
6	other	other	JJ	_	8	amod
7	belladonna	belladonna	NN	_	8	compound
8	alkaloids	alkaloid	NNS	_	3	conj
9	,	,	,	_	3	punct
10	antihistamines	antihistamine	NNS	_	11	compound
11	(	(	VBP	_	3	appos
12	including	include	VBG	_	14	case
13	meclizine	meclizine	NN	_	14	compound
14	)	)	NN	_	11	nmod
15	,	,	,	_	14	punct
16	tricyclic	tricyclic	JJ	_	17	amod
17	antidepressants	antidepressant	NNS	_	14	conj
18	,	,	,	_	14	punct
19	and	and	CC	_	14	cc
20	muscle	muscle	NN	_	21	compound
21	relaxants	relaxant	NNS	_	14	conj
22	.	.	.	_	1	punct

1	Laboratory	Laboratory	NNP	_	4	compound
2	Test	Test	NNP	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	Scopolamine	Scopolamine	NNP	_	6	nsubj
5	will	will	MD	_	6	aux
6	interfere	interfere	VB	_	0	ROOT
7	with	with	IN	_	11	case
8	the	the	DT	_	11	det
9	gastric	gastric	JJ	_	11	amod
10	secretion	secretion	NN	_	11	compound
11	test	test	NN	_	6	nmod
12	.	.	.	_	6	punct

1	Formal	formal	JJ	_	3	amod
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	12	nsubjpass
4	of	of	IN	_	5	case
5	TNKase	tnkase	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	performed	perform	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	studied	study	VBN	_	1	acl
3	in	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	TNKase	tnkase	NN	_	5	nmod
8	were	be	VBD	_	10	auxpass
9	routinely	routinely	RB	_	10	advmod
10	treated	treat	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	heparin	heparin	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	aspirin	aspirin	NN	_	12	conj
15	.	.	.	_	10	punct

1	Anticoagulants	Anticoagulants	NNPS	_	2	nsubj
2	(	(	VBP	_	0	ROOT
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	heparin	heparin	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	vitamin	vitamin	NN	_	9	compound
8	K	k	NN	_	9	compound
9	antagonists	antagonist	NNS	_	5	conj
10	)	)	CD	_	9	nummod
11	and	and	CC	_	5	cc
12	drugs	drug	NNS	_	5	conj
13	that	that	WDT	_	14	nsubj
14	alter	alter	VBP	_	5	acl:relcl
15	platelet	platelet	NN	_	16	compound
16	function	function	NN	_	14	dobj
17	(	(	CD	_	16	dep
18	such	such	JJ	_	21	case
19	as	as	IN	_	18	mwe
20	acetylsalicylic	acetylsalicylic	JJ	_	21	amod
21	acid	acid	NN	_	17	nmod
22	,	,	,	_	21	punct
23	dipyridamole	dipyridamole	NN	_	21	conj
24	,	,	,	_	21	punct
25	and	and	CC	_	21	cc
26	GP	gp	NN	_	27	compound
27	IIb	iib	NN	_	21	conj
28	/	/	:	_	2	punct
29	IIIa	iiia	NN	_	30	compound
30	inhibitors	inhibitor	NNS	_	2	dobj
31	)	)	NN	_	33	nsubj
32	may	may	MD	_	33	aux
33	increase	increase	VB	_	30	acl:relcl
34	the	the	DT	_	35	det
35	risk	risk	NN	_	33	dobj
36	of	of	IN	_	37	case
37	bleeding	bleed	VBG	_	35	nmod
38	if	if	IN	_	39	mark
39	administered	administer	VBN	_	33	advcl
40	prior	prior	RB	_	39	advmod
41	to	to	TO	_	48	nmod
42	,	,	,	_	48	punct
43	during	during	IN	_	48	conj
44	,	,	,	_	48	punct
45	or	or	CC	_	48	cc
46	after	after	IN	_	48	conj
47	TNKase	tnkase	NN	_	48	compound
48	therapy	therapy	NN	_	39	nmod
49	.	.	.	_	2	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	23	nsubj
6	During	during	IN	_	8	case
7	TNKase	tnkase	NN	_	8	compound
8	therapy	therapy	NN	_	5	nmod
9	,	,	,	_	5	punct
10	results	result	NNS	_	5	appos
11	of	of	IN	_	13	case
12	coagulation	coagulation	NN	_	13	compound
13	tests	test	NNS	_	10	nmod
14	and	and	CC	_	13	cc
15	/	/	:	_	17	punct
16	or	or	CC	_	17	cc
17	measures	measure	NNS	_	13	conj
18	of	of	IN	_	20	case
19	fibrinolytic	fibrinolytic	JJ	_	20	amod
20	activity	activity	NN	_	17	nmod
21	may	may	MD	_	23	aux
22	be	be	VB	_	23	cop
23	unreliable	unreliable	JJ	_	0	ROOT
24	unless	unless	IN	_	28	mark
25	specific	specific	JJ	_	26	amod
26	precautions	precaution	NNS	_	28	nsubjpass
27	are	be	VBP	_	28	auxpass
28	taken	take	VBN	_	23	advcl
29	to	to	TO	_	30	mark
30	prevent	prevent	VB	_	28	xcomp
31	in	in	FW	_	33	amod
32	vitro	vitro	FW	_	31	dep
33	artifacts	artifact	NNS	_	30	dobj
34	.	.	.	_	23	punct

1	Tenecteplase	tenecteplase	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	an	a	DT	_	4	det
4	enzyme	enzyme	NN	_	0	ROOT
5	that	that	IN	_	15	nsubj
6	,	,	,	_	15	punct
7	when	when	WRB	_	8	advmod
8	present	present	JJ	_	15	dep
9	in	in	IN	_	10	case
10	blood	blood	NN	_	8	nmod
11	in	in	IN	_	13	case
12	pharmacologic	pharmacologic	JJ	_	13	amod
13	concentrations	concentration	NNS	_	8	nmod
14	,	,	,	_	15	punct
15	remains	remain	VBZ	_	4	acl:relcl
16	active	active	JJ	_	15	xcomp
17	under	under	IN	_	20	case
18	in	in	FW	_	20	amod
19	vitro	vitro	FW	_	18	dep
20	conditions	condition	NNS	_	16	nmod
21	.	.	.	_	4	punct

1	This	this	DT	_	3	nsubj
2	can	can	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	5	case
5	degradation	degradation	NN	_	3	nmod
6	of	of	IN	_	7	case
7	fibrinogen	fibrinogen	NN	_	5	nmod
8	in	in	IN	_	10	case
9	blood	blood	NN	_	10	compound
10	samples	sample	NNS	_	5	nmod
11	removed	remove	VBD	_	3	xcomp
12	for	for	IN	_	13	case
13	analysis	analysis	NN	_	11	nmod
14	.	.	.	_	3	punct

1	Trilostane	trilostane	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	aminoglutethimide	aminoglutethimide	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	mitotane	mitotane	NN	_	5	conj
8	(	(	CD	_	7	nummod
9	causing	cause	VBG	_	3	xcomp
10	too	too	RB	_	11	advmod
11	great	great	JJ	_	13	amod
12	a	a	DT	_	13	det
13	decrease	decrease	NN	_	9	dobj
14	in	in	IN	_	17	case
15	adrenal	adrenal	JJ	_	17	amod
16	function	function	NN	_	17	compound
17	)	)	NN	_	13	nmod
18	.	.	.	_	3	punct

1	Although	although	IN	_	3	mark
2	MIVACRON	MIVACRON	NNP	_	3	nsubj
3	(	(	VBD	_	17	advcl
4	a	a	DT	_	5	det
5	mixture	mixture	NN	_	12	nsubjpass
6	of	of	IN	_	9	case
7	three	three	CD	_	9	nummod
8	stereoisomers	stereoisomer	NNS	_	9	compound
9	)	)	NN	_	5	nmod
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	administered	administer	VBN	_	3	ccomp
13	safely	safely	RB	_	12	advmod
14	following	follow	VBG	_	15	case
15	succinylcholine	succinylcholine	NN	_	12	nmod
16	-	-	:	_	17	punct
17	facilitated	facilitate	VBD	_	0	ROOT
18	tracheal	tracheal	JJ	_	19	amod
19	intubation	intubation	NN	_	31	nsubjpass
20	,	,	,	_	19	punct
21	the	the	DT	_	22	det
22	interaction	interaction	NN	_	19	appos
23	between	between	IN	_	24	case
24	MIVACRON	MIVACRON	NNP	_	22	nmod
25	and	and	CC	_	24	cc
26	succinylcholine	succinylcholine	NN	_	24	conj
27	has	have	VBZ	_	31	aux
28	not	not	RB	_	31	neg
29	been	be	VBN	_	31	auxpass
30	systematically	systematically	RB	_	31	advmod
31	studied	study	VBN	_	17	ccomp
32	.	.	.	_	17	punct

1	Prior	prior	RB	_	6	advmod
2	administration	administration	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	succinylcholine	succinylcholine	NN	_	2	nmod
5	can	can	MD	_	6	aux
6	potentiate	potentiate	VB	_	0	ROOT
7	the	the	DT	_	10	det
8	neuromuscular	neuromuscular	JJ	_	10	amod
9	blocking	blocking	NN	_	10	compound
10	effects	effect	NNS	_	6	dobj
11	of	of	IN	_	13	case
12	nondepolarizing	nondepolarizing	JJ	_	13	amod
13	agents	agent	NNS	_	10	nmod
14	.	.	.	_	6	punct

1	Evidence	evidence	NN	_	9	nsubjpass
2	of	of	IN	_	4	case
3	spontaneous	spontaneous	JJ	_	4	amod
4	recovery	recovery	NN	_	1	nmod
5	from	from	IN	_	6	case
6	succinylcholine	succinylcholine	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	before	before	IN	_	12	case
11	the	the	DT	_	12	det
12	administration	administration	NN	_	9	nmod
13	of	of	IN	_	14	case
14	MIVACRON	MIVACRON	NNP	_	12	nmod
15	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	19	nsubjpass
3	of	of	IN	_	4	case
4	MIVACRON	MIVACRON	NNP	_	2	nmod
5	before	before	IN	_	6	case
6	succinylcholine	succinylcholine	NN	_	2	nmod
7	to	to	TO	_	8	mark
8	attenuate	attenuate	VB	_	2	acl
9	some	some	DT	_	8	dobj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	side	side	JJ	_	13	amod
13	effects	effect	NNS	_	9	nmod
14	of	of	IN	_	15	case
15	succinylcholine	succinylcholine	NN	_	13	nmod
16	has	have	VBZ	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	studied	study	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	5	neg
4	clinical	clinical	JJ	_	5	amod
5	data	datum	NNS	_	2	nsubj
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	use	use	NN	_	5	nmod
9	of	of	IN	_	10	case
10	MIVACRON	mivacron	NN	_	8	nmod
11	with	with	IN	_	16	case
12	other	other	JJ	_	16	amod
13	nondepolarizing	nondepolarizing	JJ	_	16	amod
14	neuromuscular	neuromuscular	JJ	_	16	amod
15	blocking	block	VBG	_	16	amod
16	agents	agent	NNS	_	8	nmod
17	.	.	.	_	2	punct

1	Isoflurane	isoflurane	NN	_	4	compound
2	and	and	CC	_	1	cc
3	enflurane	enflurane	NN	_	1	conj
4	(	(	NN	_	0	ROOT
5	administered	administer	VBN	_	4	acl
6	with	with	IN	_	8	case
7	nitrous	nitrous	JJ	_	8	amod
8	oxide	oxide	NN	_	5	nmod
9	/	/	:	_	4	punct
10	oxygen	oxygen	NN	_	4	dep
11	to	to	TO	_	12	mark
12	achieve	achieve	VB	_	10	acl
13	1.25	1.25	CD	_	14	nummod
14	M	m	NN	_	12	dobj
15	.	.	.	_	4	punct
16	C	c	NN	_	4	dep
17	.	.	.	_	4	punct

1	decrease	decrease	VB	_	13	csubj
2	the	the	DT	_	3	det
3	ED50	ed50	NN	_	1	dobj
4	of	of	IN	_	5	case
5	MIVACRON	MIVACRON	NNP	_	3	nmod
6	by	by	IN	_	11	case
7	as	as	RB	_	10	advmod
8	much	much	JJ	_	10	advmod
9	as	as	IN	_	10	advmod
10	25	25	CD	_	11	nummod
11	%	%	NN	_	1	nmod
12	(	(	CD	_	11	nummod
13	see	see	VBP	_	0	ROOT
14	CLINICAL	CLINICAL	NNP	_	15	compound
15	PHARMACOLOGY	PHARMACOLOGY	NNP	_	13	dobj
16	:	:	:	_	15	punct
17	Pharmacodynamics	pharmacodynamic	NNS	_	15	dep
18	and	and	CC	_	17	cc
19	Individualization	individualization	NN	_	17	conj
20	of	of	IN	_	21	case
21	Dosages	dosage	NNS	_	17	nmod
22	)	)	CD	_	21	nummod
23	.	.	.	_	13	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	also	also	RB	_	5	advmod
5	prolong	prolong	VB	_	0	ROOT
6	the	the	DT	_	9	det
7	clinically	clinically	RB	_	8	advmod
8	effective	effective	JJ	_	9	amod
9	duration	duration	NN	_	5	dobj
10	of	of	IN	_	11	case
11	action	action	NN	_	9	nmod
12	and	and	CC	_	5	cc
13	decrease	decrease	VB	_	5	conj
14	the	the	DT	_	17	det
15	average	average	JJ	_	17	amod
16	infusion	infusion	NN	_	17	compound
17	requirement	requirement	NN	_	13	dobj
18	of	of	IN	_	19	case
19	MIVACRON	MIVACRON	NNP	_	17	nmod
20	by	by	IN	_	25	case
21	as	as	RB	_	24	advmod
22	much	much	JJ	_	24	advmod
23	as	as	IN	_	24	advmod
24	35	35	CD	_	25	nummod
25	%	%	NN	_	13	nmod
26	to	to	TO	_	28	case
27	40	40	CD	_	28	nummod
28	%	%	NN	_	13	nmod
29	.	.	.	_	5	punct

1	A	a	DT	_	3	det
2	greater	greater	JJR	_	3	amod
3	potentiation	potentiation	NN	_	13	nsubjpass
4	of	of	IN	_	8	case
5	the	the	DT	_	8	det
6	neuromuscular	neuromuscular	JJ	_	8	amod
7	blocking	blocking	NN	_	8	compound
8	effects	effect	NNS	_	3	nmod
9	of	of	IN	_	10	case
10	MIVACRON	MIVACRON	NNP	_	8	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	expected	expect	VBN	_	0	ROOT
14	with	with	IN	_	16	case
15	higher	higher	JJR	_	16	amod
16	concentrations	concentration	NNS	_	13	nmod
17	of	of	IN	_	18	case
18	enflurane	enflurane	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	isoflurane	isoflurane	NN	_	18	conj
21	.	.	.	_	13	punct

1	Halothane	Halothane	NNP	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	little	little	JJ	_	2	dobj
4	or	or	CC	_	3	cc
5	no	no	DT	_	3	conj
6	effect	effect	NN	_	3	dep
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	ED50	ed50	NN	_	2	nmod
10	,	,	,	_	2	punct
11	but	but	CC	_	2	cc
12	may	may	MD	_	13	aux
13	prolong	prolong	VB	_	2	conj
14	the	the	DT	_	15	det
15	duration	duration	NN	_	13	dobj
16	of	of	IN	_	17	case
17	action	action	NN	_	15	nmod
18	and	and	CC	_	13	cc
19	decrease	decrease	VB	_	13	conj
20	the	the	DT	_	23	det
21	average	average	JJ	_	23	amod
22	infusion	infusion	NN	_	23	compound
23	requirement	requirement	NN	_	19	dobj
24	by	by	IN	_	29	case
25	as	as	RB	_	28	advmod
26	much	much	JJ	_	28	advmod
27	as	as	IN	_	28	advmod
28	20	20	CD	_	29	nummod
29	%	%	NN	_	19	nmod
30	.	.	.	_	2	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	16	nsubj
3	which	which	WDT	_	5	nsubj
4	may	may	MD	_	5	aux
5	enhance	enhance	VB	_	2	acl:relcl
6	the	the	DT	_	9	det
7	neuromuscular	neuromuscular	JJ	_	9	amod
8	blocking	block	VBG	_	9	amod
9	action	action	NN	_	5	dobj
10	of	of	IN	_	12	case
11	nondepolarizing	nondepolarizing	JJ	_	12	amod
12	agents	agent	NNS	_	9	nmod
13	such	such	JJ	_	15	case
14	as	as	IN	_	13	mwe
15	MIVACRON	MIVACRON	NNP	_	12	nmod
16	include	include	VBP	_	0	ROOT
17	certain	certain	JJ	_	18	amod
18	antibiotics	antibiotic	NNS	_	19	nsubj
19	(	(	VBP	_	16	ccomp
20	e	e	LS	_	19	dobj
21	.	.	.	_	20	punct
22	g	g	NN	_	20	dep
23	.	.	.	_	22	punct
24	,	,	,	_	22	punct
25	aminoglycosides	aminoglycoside	NNS	_	22	conj
26	,	,	,	_	22	punct
27	tetracyclines	tetracycline	NNS	_	22	conj
28	,	,	,	_	22	punct
29	bacitracin	bacitracin	NN	_	22	conj
30	,	,	,	_	22	punct
31	polymyxins	polymyxin	NNS	_	22	conj
32	,	,	,	_	22	punct
33	lincomycin	lincomycin	NN	_	22	conj
34	,	,	,	_	22	punct
35	clindamycin	clindamycin	NN	_	22	conj
36	,	,	,	_	22	punct
37	colistin	colistin	NN	_	22	conj
38	,	,	,	_	22	punct
39	and	and	CC	_	22	cc
40	sodium	sodium	NN	_	42	compound
41	colistimethate	colistimethate	NN	_	42	compound
42	)	)	NN	_	22	conj
43	,	,	,	_	22	punct
44	magnesium	magnesium	NN	_	45	compound
45	salts	salt	NNS	_	22	conj
46	,	,	,	_	22	punct
47	lithium	lithium	NN	_	22	conj
48	,	,	,	_	22	punct
49	local	local	JJ	_	50	amod
50	anesthetics	anesthetic	NNS	_	22	conj
51	,	,	,	_	22	punct
52	procainamide	procainamide	NN	_	22	conj
53	,	,	,	_	22	punct
54	and	and	CC	_	22	cc
55	quinidine	quinidine	NN	_	22	conj
56	.	.	.	_	16	punct

1	The	the	DT	_	4	det
2	neuromuscular	neuromuscular	JJ	_	4	amod
3	blocking	blocking	NN	_	4	compound
4	effect	effect	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	MIVACRON	MIVACRON	NNP	_	4	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	enhanced	enhance	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	that	that	WDT	_	13	nsubj
13	reduce	reduce	VBP	_	11	acl:relcl
14	plasma	plasma	NN	_	16	compound
15	cholinesterase	cholinesterase	NN	_	16	compound
16	activity	activity	NN	_	13	dobj
17	(	(	CD	_	20	nummod
18	e	e	LS	_	20	dep
19	.	.	.	_	18	punct
20	g	g	NN	_	13	dep
21	.	.	.	_	9	punct
22	,	,	,	_	9	punct
23	chronically	chronically	RB	_	24	advmod
24	administered	administer	VBN	_	26	amod
25	oral	oral	JJ	_	26	amod
26	contraceptives	contraceptive	NNS	_	9	dobj
27	,	,	,	_	26	punct
28	glucocorticoids	glucocorticoid	NNS	_	26	conj
29	,	,	,	_	26	punct
30	or	or	CC	_	26	cc
31	certain	certain	JJ	_	34	amod
32	monoamine	monoamine	NN	_	34	compound
33	oxidase	oxidase	NN	_	34	compound
34	inhibitors	inhibitor	NNS	_	26	conj
35	)	)	CD	_	34	nummod
36	or	or	CC	_	26	cc
37	by	by	IN	_	38	case
38	drugs	drug	NNS	_	26	conj
39	that	that	WDT	_	41	nsubj
40	irreversibly	irreversibly	RB	_	41	advmod
41	inhibit	inhibit	VBP	_	38	acl:relcl
42	plasma	plasma	NN	_	43	compound
43	cholinesterase	cholinesterase	NN	_	41	dobj
44	.	.	.	_	26	punct
45	Resistance	resistance	NN	_	58	nsubjpass
46	to	to	TO	_	50	case
47	the	the	DT	_	50	det
48	neuromuscular	neuromuscular	JJ	_	50	amod
49	blocking	block	VBG	_	50	amod
50	action	action	NN	_	45	nmod
51	of	of	IN	_	55	case
52	nondepolarizing	nondepolarizing	JJ	_	55	amod
53	neuromuscular	neuromuscular	JJ	_	55	amod
54	blocking	block	VBG	_	55	amod
55	agents	agent	NNS	_	50	nmod
56	has	have	VBZ	_	58	aux
57	been	be	VBN	_	58	auxpass
58	demonstrated	demonstrate	VBN	_	26	acl:relcl
59	in	in	IN	_	60	case
60	patients	patient	NNS	_	58	nmod
61	chronically	chronically	RB	_	62	advmod
62	administered	administer	VBN	_	60	acl
63	phenytoin	phenytoin	NN	_	62	dobj
64	or	or	CC	_	63	cc
65	carbamazepine	carbamazepine	NN	_	63	conj
66	.	.	.	_	9	punct

1	While	while	IN	_	16	mark
2	the	the	DT	_	3	det
3	effects	effect	NNS	_	16	nsubj
4	of	of	IN	_	6	case
5	chronic	chronic	JJ	_	6	amod
6	phenytoin	phenytoin	NN	_	3	nmod
7	or	or	CC	_	6	cc
8	carbamazepine	carbamazepine	NN	_	9	compound
9	therapy	therapy	NN	_	6	conj
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	action	action	NN	_	3	nmod
13	of	of	IN	_	14	case
14	MIVACRON	MIVACRON	NNP	_	12	nmod
15	are	be	VBP	_	16	cop
16	unknown	unknown	JJ	_	20	advcl
17	,	,	,	_	20	punct
18	slightly	slightly	RB	_	19	advmod
19	shorter	shorter	JJR	_	20	amod
20	durations	duration	NNS	_	33	nmod
21	of	of	IN	_	23	case
22	neuromuscular	neuromuscular	JJ	_	23	amod
23	block	block	NN	_	20	nmod
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	anticipated	anticipate	VBN	_	33	csubj
27	and	and	CC	_	26	cc
28	infusion	infusion	NN	_	30	compound
29	rate	rate	NN	_	30	compound
30	requirements	requirement	NNS	_	26	conj
31	may	may	MD	_	33	aux
32	be	be	VB	_	33	cop
33	higher	higher	JJR	_	0	ROOT
34	.	.	.	_	33	punct

1	Some	some	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	9	nsubj
4	are	be	VBP	_	9	cop
5	:	:	:	_	9	punct
6	-	-	:	_	9	punct
7	birth	birth	NN	_	9	compound
8	control	control	NN	_	9	compound
9	pills	pill	NNS	_	0	ROOT
10	-	-	:	_	9	punct
11	corticosteroids	corticosteroid	NNS	_	13	compound
12	-	-	:	_	13	punct
13	medicines	medicine	NNS	_	9	dep
14	for	for	IN	_	15	case
15	angina	angina	NN	_	13	nmod
16	or	or	CC	_	15	cc
17	high	high	JJ	_	19	amod
18	blood	blood	NN	_	19	compound
19	pressure	pressure	NN	_	15	conj
20	-	-	:	_	13	punct
21	medicines	medicine	NNS	_	13	dep
22	for	for	IN	_	23	case
23	pain	pain	NN	_	21	nmod
24	-	-	:	_	13	punct
25	medicines	medicine	NNS	_	13	dep
26	to	to	TO	_	27	mark
27	control	control	VB	_	25	acl
28	seizures	seizure	NNS	_	27	dobj
29	such	such	JJ	_	31	case
30	as	as	IN	_	29	mwe
31	phenytoin	phenytoin	NN	_	28	nmod
32	or	or	CC	_	31	cc
33	carbamazepine	carbamazepine	NN	_	31	conj
34	-	-	:	_	13	punct
35	certain	certain	JJ	_	36	amod
36	antibiotics	antibiotic	NNS	_	13	dep
37	given	give	VBN	_	36	acl
38	by	by	IN	_	39	case
39	injection	injection	NN	_	37	nmod
40	-	-	:	_	39	punct
41	cisplatin	cisplatin	NN	_	39	dep
42	-	-	:	_	39	punct
43	edrophonium	edrophonium	NN	_	39	dep
44	-	-	:	_	39	punct
45	neostigmine	neostigmine	NN	_	48	compound
46	-	-	:	_	48	punct
47	polymyxin	polymyxin	NN	_	48	compound
48	B	b	NN	_	39	dep
49	or	or	CC	_	48	cc
50	bacitracin	bacitracin	NN	_	48	conj
51	-	-	:	_	39	punct
52	local	local	JJ	_	53	amod
53	anesthetics	anesthetic	NNS	_	39	dep
54	such	such	JJ	_	56	case
55	as	as	IN	_	54	mwe
56	procaine	procaine	NN	_	53	nmod
57	-	-	:	_	56	punct
58	general	general	JJ	_	59	amod
59	anesthetics	anesthetic	NNS	_	56	dep
60	-	-	:	_	59	punct
61	succinylcholine	succinylcholine	NN	_	59	dep
62	or	or	CC	_	61	cc
63	other	other	JJ	_	65	amod
64	muscle	muscle	NN	_	65	compound
65	relaxants	relaxant	NNS	_	61	conj

1	Clinically	clinically	RB	_	4	advmod
2	or	or	CC	_	1	cc
3	potentially	potentially	RB	_	1	conj
4	significant	significant	JJ	_	6	amod
5	drug	drug	NN	_	6	compound
6	interactions	interaction	NNS	_	17	nsubjpass
7	between	between	IN	_	8	case
8	DIFLUCAN	DIFLUCAN	NNP	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	12	det
11	following	follow	VBG	_	12	amod
12	agents	agent	NNS	_	8	conj
13	/	/	:	_	14	punct
14	classes	class	NNS	_	17	nsubjpass
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	observed	observe	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	These	these	DT	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	described	describe	VBN	_	0	ROOT
4	in	in	IN	_	6	case
5	greater	greater	JJR	_	6	amod
6	detail	detail	NN	_	3	nmod
7	below	below	IN	_	6	advmod
8	:	:	:	_	3	punct
9	DIFLUCAN	DIFLUCAN	NNP	_	15	compound
10	and	and	CC	_	9	cc
11	the	the	DT	_	13	det
12	following	follow	VBG	_	13	amod
13	agents	agent	NNS	_	9	conj
14	/	/	:	_	15	punct
15	classes	class	NNS	_	18	nsubjpass
16	have	have	VBP	_	18	aux
17	been	be	VBN	_	18	auxpass
18	observed	observe	VBN	_	3	parataxis
19	.	.	.	_	3	punct

1	These	these	DT	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	described	describe	VBN	_	0	ROOT
4	in	in	IN	_	6	case
5	greater	greater	JJR	_	6	amod
6	detail	detail	NN	_	3	nmod
7	below	below	IN	_	6	advmod
8	:	:	:	_	3	punct
9	Oral	oral	JJ	_	10	amod
10	hypoglycemics	hypoglycemic	NNS	_	3	dep
11	,	,	,	_	10	punct
12	Coumarin	Coumarin	NNP	_	15	compound
13	-	-	:	_	15	punct
14	type	type	NN	_	15	compound
15	anticoagulants	anticoagulant	NNS	_	10	conj
16	,	,	,	_	10	punct
17	Phenytoin	Phenytoin	NNP	_	10	conj
18	,	,	,	_	10	punct
19	Cyclosporine	Cyclosporine	NNP	_	10	conj
20	,	,	,	_	10	punct
21	Rifampin	Rifampin	NNP	_	10	conj
22	,	,	,	_	10	punct
23	Theophylline	Theophylline	NNP	_	10	conj
24	,	,	,	_	10	punct
25	Terfenadine	Terfenadine	NNP	_	10	conj
26	,	,	,	_	10	punct
27	Cisapride	Cisapride	NNP	_	10	conj
28	,	,	,	_	10	punct
29	Astemizole	Astemizole	NNP	_	10	conj
30	,	,	,	_	10	punct
31	Rifabutin	Rifabutin	NNP	_	10	conj
32	,	,	,	_	10	punct
33	Tacrolimus	Tacrolimus	NNP	_	10	conj
34	,	,	,	_	10	punct
35	Short	Short	NNP	_	38	compound
36	-	-	:	_	38	punct
37	acting	act	VBG	_	38	amod
38	benzodiazepines	benzodiazepine	NNS	_	10	conj
39	,	,	,	_	10	punct
40	Oral	oral	JJ	_	41	amod
41	hypoglycemics	hypoglycemic	NNS	_	10	conj
42	:	:	:	_	10	punct
43	Clinically	clinically	RB	_	45	advmod
44	significant	significant	JJ	_	45	amod
45	hypoglycemia	hypoglycemia	NN	_	48	nsubjpass
46	may	may	MD	_	48	aux
47	be	be	VB	_	48	auxpass
48	precipitated	precipitate	VBN	_	10	dep
49	by	by	IN	_	51	case
50	the	the	DT	_	51	det
51	use	use	NN	_	48	nmod
52	of	of	IN	_	53	case
53	DIFLUCAN	DIFLUCAN	NNP	_	51	nmod
54	with	with	IN	_	57	case
55	oral	oral	JJ	_	57	amod
56	hypoglycemic	hypoglycemic	JJ	_	57	amod
57	agents	agent	NNS	_	51	nmod
58	;	;	:	_	48	punct

1	one	one	CD	_	2	nummod
2	fatality	fatality	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	from	from	IN	_	7	case
7	hypoglycemia	hypoglycemia	NN	_	5	nmod
8	in	in	IN	_	9	case
9	association	association	NN	_	5	nmod
10	with	with	IN	_	12	case
11	combined	combined	JJ	_	12	amod
12	DIFLUCAN	DIFLUCAN	NNP	_	9	nmod
13	and	and	CC	_	12	cc
14	glyburide	glyburide	NN	_	15	compound
15	use	use	NN	_	12	conj
16	.	.	.	_	5	punct

1	DIFLUCAN	DIFLUCAN	NNP	_	2	nsubj
2	reduces	reduce	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	metabolism	metabolism	NN	_	2	dobj
5	of	of	IN	_	6	case
6	tolbutamide	tolbutamide	NN	_	4	nmod
7	,	,	,	_	6	punct
8	glyburide	glyburide	NN	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	glipizide	glipizide	NN	_	6	conj
12	and	and	CC	_	2	cc
13	increases	increase	VBZ	_	2	conj
14	the	the	DT	_	16	det
15	plasma	plasma	NN	_	16	compound
16	concentration	concentration	NN	_	13	dobj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	agents	agent	NNS	_	16	nmod
20	.	.	.	_	2	punct

1	When	when	WRB	_	4	advmod
2	DIFLUCAN	DIFLUCAN	NNP	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	used	use	VBN	_	21	advcl
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	7	case
7	these	these	DT	_	4	nmod
8	or	or	CC	_	7	cc
9	other	other	JJ	_	13	amod
10	sulfonylurea	sulfonylurea	NN	_	13	compound
11	oral	oral	JJ	_	13	amod
12	hypoglycemic	hypoglycemic	JJ	_	13	amod
13	agents	agent	NNS	_	7	conj
14	,	,	,	_	13	punct
15	blood	blood	NN	_	17	compound
16	glucose	glucose	NN	_	17	compound
17	concentrations	concentration	NNS	_	13	appos
18	should	should	MD	_	21	aux
19	be	be	VB	_	21	auxpass
20	carefully	carefully	RB	_	21	advmod
21	monitored	monitor	VBN	_	0	ROOT
22	and	and	CC	_	21	cc
23	the	the	DT	_	24	det
24	dose	dose	NN	_	30	nsubjpass
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	sulfonylurea	sulfonylurea	NN	_	24	nmod
28	should	should	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	adjusted	adjust	VBN	_	21	conj
31	as	as	RB	_	32	advmod
32	necessary	necessary	JJ	_	30	xcomp
33	.	.	.	_	21	punct

1	Coumarin	Coumarin	NNP	_	4	compound
2	-	-	:	_	4	punct
3	type	type	NN	_	4	compound
4	anticoagulants	anticoagulant	NNS	_	0	ROOT
5	:	:	:	_	4	punct
6	Prothrombin	Prothrombin	NNP	_	7	compound
7	time	time	NN	_	10	nsubjpass
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	increased	increase	VBN	_	4	parataxis
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	concomitant	concomitant	JJ	_	15	amod
15	DIFLUCAN	DIFLUCAN	NNP	_	13	dobj
16	and	and	CC	_	15	cc
17	coumarin	coumarin	NN	_	20	compound
18	-	-	:	_	20	punct
19	type	type	NN	_	20	compound
20	anticoagulants	anticoagulant	NNS	_	15	conj
21	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	post	post	NN	_	5	nmod
3	-	-	:	_	5	punct
4	marketing	marketing	NN	_	5	compound
5	experience	experience	NN	_	0	ROOT
6	,	,	,	_	5	punct
7	as	as	IN	_	11	case
8	with	with	IN	_	11	case
9	other	other	JJ	_	11	amod
10	azole	azole	NN	_	11	compound
11	antifungals	antifungal	NNS	_	30	nmod
12	,	,	,	_	11	punct
13	bleeding	bleed	VBG	_	11	acl
14	events	event	NNS	_	13	dobj
15	(	(	JJ	_	16	amod
16	bruising	bruise	VBG	_	14	acl
17	,	,	,	_	16	punct
18	epistaxis	epistaxis	NN	_	16	conj
19	,	,	,	_	16	punct
20	gastrointestinal	gastrointestinal	JJ	_	21	amod
21	bleeding	bleeding	NN	_	16	conj
22	,	,	,	_	16	punct
23	hematuria	hematuria	NN	_	16	conj
24	,	,	,	_	16	punct
25	and	and	CC	_	16	cc
26	melena	melena	NN	_	16	conj
27	)	)	CD	_	26	nummod
28	have	have	VBP	_	30	aux
29	been	be	VBN	_	30	auxpass
30	reported	report	VBN	_	5	acl:relcl
31	in	in	IN	_	32	case
32	association	association	NN	_	30	nmod
33	with	with	IN	_	34	case
34	increases	increase	NNS	_	32	nmod
35	in	in	IN	_	37	case
36	prothrombin	prothrombin	NN	_	37	compound
37	time	time	NN	_	34	nmod
38	in	in	IN	_	39	case
39	patients	patient	NNS	_	37	nmod
40	receiving	receive	VBG	_	39	acl
41	fluconazole	fluconazole	NN	_	40	dobj
42	concurrently	concurrently	RB	_	40	advmod
43	with	with	IN	_	44	case
44	warfarin	warfarin	NN	_	40	nmod
45	.	.	.	_	5	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	16	nsubjpass
3	of	of	IN	_	5	case
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	2	nmod
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	DIFLUCAN	DIFLUCAN	NNP	_	8	dobj
10	and	and	CC	_	9	cc
11	coumarin	coumarin	NN	_	9	conj
12	-	-	:	_	14	punct
13	type	type	NN	_	14	compound
14	anticoagulants	anticoagulant	NNS	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	(	(	NN	_	2	nsubj
2	See	see	VB	_	0	ROOT
3	&lt	&lt	VBN	_	2	xcomp
4	;	;	:	_	2	punct
5	a	a	DT	_	6	det
6	href	href	NN	_	2	dep
7	=	=	JJ	_	6	amod
8	&quot	&quot	NN	_	7	dep
9	;	;	:	_	6	punct
10	flucon	flucon	NN	_	12	compound
11	_	_	CD	_	12	nummod
12	cp	cp	NN	_	6	dep
13	.	.	.	_	12	punct
14	htm	htm	NN	_	16	compound
15	#	#	#	_	16	compound
16	CP&quot	cp&quot	NN	_	12	conj
17	;	;	:	_	12	punct
18	>CLINICAL	>CLINICAL	NNP	_	19	compound
19	PHARMACOLOGY	PHARMACOLOGY	NNP	_	12	dep
20	:	:	:	_	19	punct
21	Drug	Drug	NNP	_	23	compound
22	Interaction	interaction	NN	_	23	compound
23	Studies	study	NNS	_	19	dep
24	.	.	.	_	6	punct
25	)	)	SYM	_	2	dep

1	Phenytoin	Phenytoin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	DIFLUCAN	DIFLUCAN	NNP	_	4	nsubj
4	increases	increase	VBZ	_	1	appos
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	phenytoin	phenytoin	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	phenytoin	phenytoin	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	nmod
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	DIFLUCAN	DIFLUCAN	NNP	_	8	dobj
10	and	and	CC	_	9	cc
11	phenytoin	phenytoin	NN	_	9	conj
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	(	(	NN	_	2	nsubj
2	See	see	VB	_	0	ROOT
3	&lt	&lt	VBN	_	2	xcomp
4	;	;	:	_	2	punct
5	a	a	DT	_	6	det
6	href	href	NN	_	2	dep
7	=	=	JJ	_	6	amod
8	&quot	&quot	NN	_	7	dep
9	;	;	:	_	6	punct
10	flucon	flucon	NN	_	12	compound
11	_	_	CD	_	12	nummod
12	cp	cp	NN	_	6	dep
13	.	.	.	_	12	punct
14	htm	htm	NN	_	16	compound
15	#	#	#	_	16	compound
16	CP&quot	cp&quot	NN	_	12	conj
17	;	;	:	_	12	punct
18	>CLINICAL	>CLINICAL	NNP	_	19	compound
19	PHARMACOLOGY	PHARMACOLOGY	NNP	_	12	dep
20	:	:	:	_	19	punct
21	Drug	Drug	NNP	_	23	compound
22	Interaction	interaction	NN	_	23	compound
23	Studies	study	NNS	_	19	dep
24	.	.	.	_	6	punct
25	)	)	SYM	_	2	dep

1	Cyclosporine	cyclosporine	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	DIFLUCAN	DIFLUCAN	NNP	_	6	nsubj
4	may	may	MD	_	6	aux
5	significantly	significantly	RB	_	6	advmod
6	increase	increase	VB	_	1	dep
7	cyclosporine	cyclosporine	NN	_	8	compound
8	levels	level	NNS	_	6	dobj
9	in	in	IN	_	12	case
10	renal	renal	JJ	_	12	amod
11	transplant	transplant	NN	_	12	compound
12	patients	patient	NNS	_	6	nmod
13	with	with	IN	_	17	nmod
14	or	or	CC	_	13	cc
15	without	without	IN	_	13	conj
16	renal	renal	JJ	_	17	amod
17	impairment	impairment	NN	_	12	nmod
18	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	cyclosporine	cyclosporine	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	serum	serum	NN	_	8	compound
8	creatinine	creatinine	NN	_	5	conj
9	is	be	VBZ	_	10	auxpass
10	recommended	recommend	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	DIFLUCAN	DIFLUCAN	NNP	_	13	dobj
15	and	and	CC	_	14	cc
16	cyclosporine	cyclosporine	NN	_	14	conj
17	.	.	.	_	10	punct

1	(	(	NN	_	2	nsubj
2	See	see	VB	_	0	ROOT
3	CLINICAL	CLINICAL	NNP	_	4	compound
4	PHARMACOLOGY	PHARMACOLOGY	NNP	_	2	dobj
5	:	:	:	_	4	punct
6	Drug	Drug	NNP	_	8	compound
7	Interaction	interaction	NN	_	8	compound
8	Studies	study	NNS	_	4	dep
9	.	.	.	_	2	punct
10	)	)	SYM	_	2	punct

1	Rifampin	Rifampin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Rifampin	Rifampin	NNP	_	4	nsubj
4	enhances	enhance	VBZ	_	1	appos
5	the	the	DT	_	6	det
6	metabolism	metabolism	NN	_	4	dobj
7	of	of	IN	_	10	case
8	concurrently	concurrently	RB	_	9	advmod
9	administered	administer	VBN	_	10	amod
10	DIFLUCAN	DIFLUCAN	NNP	_	6	nmod
11	.	.	.	_	1	punct

1	Depending	depend	VBG	_	4	case
2	on	on	IN	_	4	case
3	clinical	clinical	JJ	_	4	amod
4	circumstances	circumstance	NNS	_	9	advcl
5	,	,	,	_	9	punct
6	consideration	consideration	NN	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	given	give	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	increasing	increase	VBG	_	9	advcl
12	the	the	DT	_	13	det
13	dose	dose	NN	_	11	dobj
14	of	of	IN	_	15	case
15	DIFLUCAN	DIFLUCAN	NNP	_	13	nmod
16	when	when	WRB	_	19	advmod
17	it	it	PRP	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	administered	administer	VBN	_	11	advcl
20	with	with	IN	_	21	case
21	rifampin	rifampin	NN	_	19	nmod
22	.	.	.	_	9	punct

1	Theophylline	Theophylline	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	DIFLUCAN	DIFLUCAN	NNP	_	4	nsubj
4	increases	increase	VBZ	_	1	appos
5	the	the	DT	_	7	det
6	serum	serum	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	theophylline	theophylline	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	14	nsubjpass
3	of	of	IN	_	6	case
4	serum	serum	NN	_	6	compound
5	theophylline	theophylline	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	DIFLUCAN	DIFLUCAN	NNP	_	9	dobj
11	and	and	CC	_	10	cc
12	theophylline	theophylline	NN	_	10	conj
13	is	be	VBZ	_	14	auxpass
14	recommended	recommend	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Terfenadine	Terfenadine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Because	because	IN	_	6	case
4	of	of	IN	_	3	mwe
5	the	the	DT	_	6	det
6	occurrence	occurrence	NN	_	32	nmod
7	of	of	IN	_	10	case
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	dysrhythmias	dysrhythmia	NNS	_	6	nmod
11	secondary	secondary	JJ	_	10	amod
12	to	to	TO	_	13	case
13	prolongation	prolongation	NN	_	11	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	QTc	qtc	NN	_	17	compound
17	interval	interval	NN	_	13	nmod
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	receiving	receive	VBG	_	19	acl
21	azole	azole	NN	_	22	compound
22	antifungals	antifungal	NNS	_	20	dobj
23	in	in	IN	_	24	case
24	conjunction	conjunction	NN	_	20	nmod
25	with	with	IN	_	26	case
26	terfenadine	terfenadine	NN	_	24	nmod
27	,	,	,	_	32	punct
28	interaction	interaction	NN	_	29	compound
29	studies	study	NNS	_	32	nsubjpass
30	have	have	VBP	_	32	aux
31	been	be	VBN	_	32	auxpass
32	performed	perform	VBN	_	1	appos
33	.	.	.	_	1	punct

1	One	one	CD	_	2	nummod
2	study	study	NN	_	0	ROOT
3	at	at	IN	_	7	case
4	a	a	DT	_	7	det
5	200	200	CD	_	7	nummod
6	-	-	:	_	7	punct
7	mg	mg	NN	_	2	nmod
8	daily	daily	RB	_	9	advmod
9	dose	dose	NN	_	12	nsubj
10	of	of	IN	_	11	case
11	fluconazole	fluconazole	NN	_	9	nmod
12	failed	fail	VBD	_	7	acl:relcl
13	to	to	TO	_	14	mark
14	demonstrate	demonstrate	VB	_	12	xcomp
15	a	a	DT	_	16	det
16	prolongation	prolongation	NN	_	14	dobj
17	in	in	IN	_	19	case
18	QTc	qtc	NN	_	19	compound
19	interval	interval	NN	_	16	nmod
20	.	.	.	_	2	punct

1	Another	another	DT	_	2	det
2	study	study	NN	_	16	nsubj
3	at	at	IN	_	13	case
4	a	a	DT	_	13	det
5	400	400	CD	_	13	dep
6	-	-	:	_	5	punct
7	mg	mg	NN	_	5	dep
8	and	and	CC	_	7	cc
9	800	800	CD	_	7	conj
10	-	-	:	_	5	punct
11	mg	mg	NN	_	13	compound
12	daily	daily	RB	_	13	advmod
13	dose	dose	NN	_	2	nmod
14	of	of	IN	_	15	case
15	fluconazole	fluconazole	NN	_	13	nmod
16	demonstrated	demonstrate	VBD	_	0	ROOT
17	that	that	IN	_	19	mark
18	DIFLUCAN	DIFLUCAN	NNP	_	19	nsubj
19	taken	take	VBN	_	16	ccomp
20	in	in	IN	_	21	case
21	doses	dose	NNS	_	19	nmod
22	of	of	IN	_	24	case
23	400	400	CD	_	24	nummod
24	mg	mg	NN	_	21	nmod
25	per	per	IN	_	26	case
26	day	day	NN	_	24	nmod
27	or	or	CC	_	24	cc
28	greater	greater	JJR	_	30	dep
29	significantly	significantly	RB	_	30	advmod
30	increases	increase	VBZ	_	24	conj
31	plasma	plasma	NN	_	32	compound
32	levels	level	NNS	_	30	dobj
33	of	of	IN	_	34	case
34	terfenadine	terfenadine	NN	_	32	nmod
35	when	when	WRB	_	36	advmod
36	taken	take	VBN	_	19	advcl
37	concomitantly	concomitantly	RB	_	36	advmod
38	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	combined	combine	VBN	_	3	amod
3	use	use	NN	_	16	nsubjpass
4	of	of	IN	_	5	case
5	fluconazole	fluconazole	NN	_	3	nmod
6	at	at	IN	_	7	case
7	doses	dose	NNS	_	3	nmod
8	of	of	IN	_	10	case
9	400	400	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	greater	greater	JJR	_	10	conj
13	with	with	IN	_	14	case
14	terfenadine	terfenadine	NN	_	3	nmod
15	is	be	VBZ	_	16	auxpass
16	contraindicated	contraindicate	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	coadministration	coadministration	NN	_	18	nsubjpass
3	of	of	IN	_	4	case
4	fluconazole	fluconazole	NN	_	2	nmod
5	at	at	IN	_	6	case
6	doses	dose	NNS	_	2	nmod
7	lower	lower	JJR	_	6	amod
8	than	than	IN	_	10	case
9	400	400	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	/	/	:	_	2	punct
12	day	day	NN	_	18	nsubjpass
13	with	with	IN	_	14	case
14	terfenadine	terfenadine	NN	_	12	nmod
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	carefully	carefully	RB	_	18	advmod
18	monitored	monitor	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	Cisapride	Cisapride	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	appos
7	of	of	IN	_	9	case
8	cardiac	cardiac	JJ	_	9	amod
9	events	event	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	including	include	VBG	_	14	case
12	torsade	torsade	NN	_	14	compound
13	de	de	IN	_	14	amod
14	pointes	pointe	NNS	_	9	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	to	to	TO	_	18	case
18	whom	whom	WP	_	23	nmod
19	fluconazole	fluconazole	NN	_	23	nsubjpass
20	and	and	CC	_	19	cc
21	cisapride	cisapride	NN	_	19	conj
22	were	be	VBD	_	23	auxpass
23	coadministered	coadminister	VBN	_	16	acl:relcl
24	.	.	.	_	1	punct

1	A	a	DT	_	3	det
2	controlled	controlled	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	found	find	VBD	_	0	ROOT
5	that	that	IN	_	20	mark
6	concomitant	concomitant	JJ	_	9	amod
7	fluconazole	fluconazole	NN	_	9	compound
8	200	200	CD	_	9	nummod
9	mg	mg	NN	_	20	nsubj
10	once	once	RB	_	11	advmod
11	daily	daily	JJ	_	9	amod
12	and	and	CC	_	11	cc
13	cisapride	cisapride	NN	_	15	compound
14	20	20	CD	_	15	nummod
15	mg	mg	NN	_	11	conj
16	four	four	CD	_	17	nummod
17	times	time	NNS	_	11	nmod:tmod
18	a	a	DT	_	19	det
19	day	day	NN	_	17	nmod:npmod
20	yielded	yield	VBD	_	4	ccomp
21	a	a	DT	_	23	det
22	significant	significant	JJ	_	23	amod
23	increase	increase	NN	_	20	dobj
24	in	in	IN	_	27	case
25	cisapride	cisapride	NN	_	27	compound
26	plasma	plasma	NN	_	27	compound
27	levels	level	NNS	_	23	nmod
28	and	and	CC	_	23	cc
29	prolongation	prolongation	NN	_	23	conj
30	of	of	IN	_	32	case
31	QTc	qtc	NN	_	32	compound
32	interval	interval	NN	_	29	nmod
33	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	combined	combine	VBN	_	3	amod
3	use	use	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	fluconazole	fluconazole	NN	_	3	nmod
6	with	with	IN	_	7	case
7	cisapride	cisapride	NN	_	3	nmod
8	is	be	VBZ	_	9	auxpass
9	contraindicated	contraindicate	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Astemizole	Astemizole	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	use	use	NN	_	23	nsubjpass
5	of	of	IN	_	6	case
6	fluconazole	fluconazole	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	4	nmod
9	concurrently	concurrently	RB	_	10	advmod
10	taking	take	VBG	_	8	acl
11	astemizole	astemizole	NN	_	10	dobj
12	or	or	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	conj
15	metabolized	metabolize	VBN	_	11	acl
16	by	by	IN	_	20	case
17	the	the	DT	_	20	det
18	cytochrome	cytochrome	NN	_	20	compound
19	P450	p450	NN	_	20	compound
20	system	system	NN	_	15	nmod
21	may	may	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	associated	associate	VBN	_	1	appos
24	with	with	IN	_	25	case
25	elevations	elevation	NNS	_	23	nmod
26	in	in	IN	_	28	case
27	serum	serum	NN	_	28	compound
28	levels	level	NNS	_	25	nmod
29	of	of	IN	_	31	case
30	these	these	DT	_	31	det
31	drugs	drug	NNS	_	28	nmod
32	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	absence	absence	NN	_	11	nmod
4	of	of	IN	_	6	case
5	definitive	definitive	JJ	_	6	amod
6	information	information	NN	_	3	nmod
7	,	,	,	_	11	punct
8	caution	caution	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	used	use	VBN	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	coadministering	coadminister	VBG	_	11	advcl
14	fluconazole	fluconazole	NN	_	13	dobj
15	.	.	.	_	11	punct

1	Patients	patient	NNS	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	be	be	VB	_	5	auxpass
4	carefully	carefully	RB	_	5	advmod
5	monitored	monitor	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	Rifabutin	Rifabutin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	dep
7	of	of	IN	_	8	case
8	uveitis	uveitis	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	6	nmod
11	to	to	TO	_	12	case
12	whom	whom	WP	_	17	nmod
13	fluconazole	fluconazole	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	rifabutin	rifabutin	NN	_	13	conj
16	were	be	VBD	_	17	auxpass
17	coadministered	coadminister	VBN	_	10	acl:relcl
18	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	rifabutin	rifabutin	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	fluconazole	fluconazole	NN	_	3	conj
6	concomitantly	concomitantly	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Tacrolimus	tacrolimus	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	dep
7	of	of	IN	_	8	case
8	nephrotoxicity	nephrotoxicity	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	6	nmod
11	to	to	TO	_	12	case
12	whom	whom	WP	_	17	nmod
13	fluconazole	fluconazole	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	tacrolimus	tacrolimus	NN	_	13	conj
16	were	be	VBD	_	17	auxpass
17	coadministered	coadminister	VBN	_	10	acl:relcl
18	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	tacrolimus	tacrolimus	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	fluconazole	fluconazole	NN	_	3	conj
6	concomitantly	concomitantly	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Short	short	JJ	_	4	amod
2	-	-	:	_	4	punct
3	acting	act	VBG	_	4	amod
4	Benzodiazepines	Benzodiazepines	NNPS	_	0	ROOT
5	:	:	:	_	4	punct
6	Following	follow	VBG	_	8	case
7	oral	oral	JJ	_	8	amod
8	administration	administration	NN	_	13	nmod
9	of	of	IN	_	10	case
10	midazolam	midazolam	NN	_	8	nmod
11	,	,	,	_	13	punct
12	fluconazole	fluconazole	NN	_	13	nsubj
13	resulted	result	VBD	_	4	dep
14	in	in	IN	_	16	case
15	substantial	substantial	JJ	_	16	amod
16	increases	increase	NNS	_	13	nmod
17	in	in	IN	_	19	case
18	midazolam	midazolam	NN	_	19	compound
19	concentrations	concentration	NNS	_	16	nmod
20	and	and	CC	_	19	cc
21	psychomotor	psychomotor	JJ	_	22	amod
22	effects	effect	NNS	_	19	conj
23	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubj
3	on	on	IN	_	4	case
4	midazolam	midazolam	NN	_	2	nmod
5	appears	appear	VBZ	_	0	ROOT
6	to	to	TO	_	9	mark
7	be	be	VB	_	9	cop
8	more	more	RBR	_	9	advmod
9	pronounced	pronounced	JJ	_	5	xcomp
10	following	follow	VBG	_	12	case
11	oral	oral	JJ	_	12	amod
12	administration	administration	NN	_	9	nmod
13	of	of	IN	_	14	case
14	fluconazole	fluconazole	NN	_	12	nmod
15	than	than	IN	_	17	case
16	with	with	IN	_	17	case
17	fluconazole	fluconazole	NN	_	9	nmod
18	administered	administer	VBN	_	17	acl
19	intravenously	intravenously	RB	_	18	advmod
20	.	.	.	_	5	punct

1	If	if	IN	_	18	mark
2	short	short	JJ	_	5	amod
3	-	-	:	_	5	punct
4	acting	act	VBG	_	5	amod
5	benzodiazepines	benzodiazepine	NNS	_	18	nsubjpass
6	,	,	,	_	5	punct
7	which	which	WDT	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	metabolized	metabolize	VBN	_	5	acl:relcl
10	by	by	IN	_	14	case
11	the	the	DT	_	14	det
12	cytochrome	cytochrome	NN	_	14	compound
13	P450	p450	NN	_	14	compound
14	system	system	NN	_	9	nmod
15	,	,	,	_	5	punct
16	are	be	VBP	_	18	auxpass
17	concomitantly	concomitantly	RB	_	18	advmod
18	administered	administer	VBN	_	25	advcl
19	with	with	IN	_	20	case
20	fluconazole	fluconazole	NN	_	18	nmod
21	,	,	,	_	25	punct
22	consideration	consideration	NN	_	25	nsubjpass
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	given	give	VBN	_	0	ROOT
26	to	to	TO	_	27	mark
27	decreasing	decrease	VBG	_	25	advcl
28	the	the	DT	_	30	det
29	benzodiazepine	benzodiazepine	NN	_	30	compound
30	dosage	dosage	NN	_	27	dobj
31	,	,	,	_	25	punct
32	and	and	CC	_	25	cc
33	the	the	DT	_	34	det
34	patients	patient	NNS	_	38	nsubjpass
35	should	should	MD	_	38	aux
36	be	be	VB	_	38	auxpass
37	appropriately	appropriately	RB	_	38	advmod
38	monitored	monitor	VBN	_	25	conj
39	.	.	.	_	25	punct

1	Fluconazole	Fluconazole	NNP	_	2	compound
2	tablets	tablet	NNS	_	14	nsubj
3	coadministered	coadminister	VBN	_	2	acl
4	with	with	IN	_	6	case
5	ethinyl	ethinyl	NN	_	6	compound
6	estradiol	estradiol	NN	_	3	nmod
7	-	-	:	_	2	punct
8	and	and	CC	_	2	cc
9	levonorgestrel	levonorgestrel	NN	_	2	conj
10	-	-	:	_	9	punct
11	containing	contain	VBG	_	9	acl
12	oral	oral	JJ	_	13	amod
13	contraceptives	contraceptive	NNS	_	11	dobj
14	produced	produce	VBD	_	0	ROOT
15	an	a	DT	_	18	det
16	overall	overall	JJ	_	18	amod
17	mean	mean	JJ	_	18	amod
18	increase	increase	NN	_	14	dobj
19	in	in	IN	_	21	case
20	ethinyl	ethinyl	NN	_	21	compound
21	estradiol	estradiol	NN	_	18	nmod
22	and	and	CC	_	21	cc
23	levonorgestrel	levonorgestrel	NN	_	24	compound
24	levels	level	NNS	_	21	conj
25	;	;	:	_	14	punct

1	however	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	in	in	IN	_	5	case
4	some	some	DT	_	5	det
5	patients	patient	NNS	_	8	nmod
6	there	there	EX	_	8	expl
7	were	be	VBD	_	8	auxpass
8	decreases	decrease	VBZ	_	0	ROOT
9	up	up	RP	_	11	dep
10	to	to	TO	_	9	mwe
11	47	47	CD	_	12	nummod
12	%	%	NN	_	8	dobj
13	and	and	CC	_	12	cc
14	33	33	CD	_	15	nummod
15	%	%	NN	_	12	conj
16	of	of	IN	_	18	case
17	ethinyl	ethinyl	NN	_	18	compound
18	estradiol	estradiol	NN	_	12	nmod
19	and	and	CC	_	18	cc
20	levonorgestrel	levonorgestrel	NN	_	21	compound
21	levels	level	NNS	_	18	conj
22	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	5	nsubj
3	presently	presently	RB	_	4	advmod
4	available	available	JJ	_	2	amod
5	indicate	indicate	VBP	_	0	ROOT
6	that	that	IN	_	22	mark
7	the	the	DT	_	8	det
8	decreases	decrease	NNS	_	22	nsubj
9	in	in	IN	_	13	case
10	some	some	DT	_	13	det
11	individual	individual	JJ	_	13	amod
12	ethinyl	ethinyl	NN	_	13	compound
13	estradiol	estradiol	NN	_	8	nmod
14	and	and	CC	_	13	cc
15	levonorgestrel	levonorgestrel	NN	_	17	compound
16	AUC	auc	NN	_	17	compound
17	values	value	NNS	_	13	conj
18	with	with	IN	_	20	case
19	fluconazole	fluconazole	NN	_	20	compound
20	treatment	treatment	NN	_	8	nmod
21	are	be	VBP	_	22	cop
22	likely	likely	JJ	_	5	ccomp
23	the	the	DT	_	24	det
24	result	result	NN	_	22	dobj
25	of	of	IN	_	27	case
26	random	random	JJ	_	27	amod
27	variation	variation	NN	_	24	nmod
28	.	.	.	_	5	punct

1	While	while	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	18	advcl
4	evidence	evidence	NN	_	3	nsubj
5	that	that	IN	_	8	mark
6	fluconazole	fluconazole	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	inhibit	inhibit	VB	_	4	ccomp
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	13	case
12	ethinyl	ethinyl	NN	_	13	compound
13	estradiol	estradiol	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	levonorgestrel	levonorgestrel	NN	_	13	conj
16	,	,	,	_	18	punct
17	there	there	EX	_	18	expl
18	is	be	VBZ	_	0	ROOT
19	no	no	DT	_	20	neg
20	evidence	evidence	NN	_	18	nsubj
21	that	that	IN	_	26	mark
22	fluconazole	fluconazole	NN	_	26	nsubj
23	is	be	VBZ	_	26	cop
24	a	a	DT	_	26	det
25	net	net	JJ	_	26	amod
26	inducer	inducer	NN	_	20	ccomp
27	of	of	IN	_	29	case
28	ethinyl	ethinyl	NN	_	29	compound
29	estradiol	estradiol	NN	_	26	nmod
30	or	or	CC	_	29	cc
31	levonorgestrel	levonorgestrel	NN	_	32	compound
32	metabolism	metabolism	NN	_	29	conj
33	.	.	.	_	18	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	effects	effect	NNS	_	3	nmod
7	is	be	VBZ	_	9	cop
8	presently	presently	RB	_	9	advmod
9	unknown	unknown	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Physicians	Physicians	NNP	_	4	nsubj
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	cop
4	aware	aware	JJ	_	0	ROOT
5	that	that	IN	_	4	dep
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	5	dep
8	with	with	IN	_	9	case
9	medications	medication	NNS	_	7	nmod
10	other	other	JJ	_	9	amod
11	than	than	IN	_	12	case
12	those	those	DT	_	10	nmod
13	listed	list	VBN	_	12	acl
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	&lt	&lt	NN	_	13	nmod
17	;	;	:	_	7	punct
18	a	a	DT	_	29	det
19	href	href	NN	_	29	dep
20	=	=	JJ	_	19	amod
21	&quot	&quot	NN	_	20	dep
22	;	;	:	_	19	punct
23	flucon	flucon	NN	_	25	compound
24	_	_	CD	_	25	nummod
25	cp	cp	NN	_	19	dep
26	.	.	.	_	19	punct
27	htm	htm	NN	_	29	compound
28	#	#	#	_	29	compound
29	CP&quot	cp&quot	NN	_	7	dep
30	;	;	:	_	29	punct
31	&gt	&gt	NN	_	29	conj
32	;	;	:	_	29	punct
33	CLINICAL	CLINICAL	NNP	_	35	compound
34	PHARMACOLOGY	PHARMACOLOGY	NNP	_	35	compound
35	section	section	NN	_	39	nsubjpass
36	have	have	VBP	_	39	aux
37	not	not	RB	_	39	neg
38	been	be	VBN	_	39	auxpass
39	conducted	conduct	VBN	_	29	parataxis
40	,	,	,	_	39	punct
41	but	but	CC	_	39	cc
42	such	such	JJ	_	43	amod
43	interactions	interaction	NNS	_	45	nsubj
44	may	may	MD	_	45	aux
45	occur	occur	VB	_	39	conj
46	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	Streptase	Streptase	NNP	_	2	nmod
5	,	,	,	_	4	punct
6	Streptokinase	Streptokinase	NNP	_	4	appos
7	,	,	,	_	4	punct
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	2	nmod
11	has	have	VBZ	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	well	well	RB	_	15	advmod
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Use	use	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	Anticoagulants	Anticoagulants	NNPS	_	1	nmod
4	and	and	CC	_	3	cc
5	Antiplatelet	Antiplatelet	NNP	_	6	compound
6	Agents	Agents	NNPS	_	3	conj
7	--	--	:	_	3	punct
8	Streptase	Streptase	NNP	_	23	nsubj
9	,	,	,	_	8	punct
10	Streptokinase	Streptokinase	NNP	_	8	appos
11	,	,	,	_	8	punct
12	alone	alone	RB	_	13	advmod
13	or	or	CC	_	8	advmod
14	in	in	IN	_	15	case
15	combination	combination	NN	_	13	conj
16	with	with	IN	_	18	case
17	antiplatelet	antiplatelet	JJ	_	18	amod
18	agents	agent	NNS	_	15	nmod
19	and	and	CC	_	18	cc
20	anticoagulants	anticoagulant	NNS	_	18	conj
21	,	,	,	_	8	punct
22	may	may	MD	_	23	aux
23	cause	cause	VB	_	3	acl:relcl
24	bleeding	bleeding	JJ	_	25	amod
25	complications	complication	NNS	_	23	dobj
26	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	careful	careful	JJ	_	4	amod
4	monitoring	monitoring	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	treatment	treatment	NN	_	17	nmod
4	of	of	IN	_	6	case
5	acute	acute	JJ	_	6	amod
6	MI	MI	NNP	_	3	nmod
7	,	,	,	_	6	punct
8	aspirin	aspirin	NN	_	6	appos
9	,	,	,	_	6	punct
10	when	when	WRB	_	13	advmod
11	not	not	RB	_	13	neg
12	otherwise	otherwise	RB	_	13	advmod
13	contraindicated	contraindicate	VBN	_	17	dep
14	,	,	,	_	17	punct
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	administered	administer	VBN	_	0	ROOT
18	with	with	IN	_	19	case
19	Streptokinase	Streptokinase	NNP	_	17	nmod
20	(	(	CD	_	19	nummod
21	see	see	VB	_	17	dep
22	below	below	IN	_	23	case
23	)	)	CD	_	21	nmod
24	.	.	.	_	17	punct

1	Anticoagulation	anticoagulation	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Antiplatelets	Antiplatelets	NNPS	_	1	conj
4	After	after	IN	_	5	case
5	Treatment	treatment	NN	_	1	nmod
6	for	for	IN	_	8	case
7	Myocardial	myocardial	JJ	_	8	amod
8	Infarction	infarction	NN	_	5	nmod
9	--	--	:	_	12	punct
10	In	in	IN	_	12	case
11	the	the	DT	_	12	det
12	treatment	treatment	NN	_	1	nmod
13	of	of	IN	_	16	case
14	acute	acute	JJ	_	16	amod
15	myocardial	myocardial	JJ	_	16	amod
16	infarction	infarction	NN	_	12	nmod
17	,	,	,	_	12	punct
18	the	the	DT	_	19	det
19	use	use	NN	_	24	nsubjpass
20	of	of	IN	_	21	case
21	aspirin	aspirin	NN	_	19	nmod
22	has	have	VBZ	_	24	aux
23	been	be	VBN	_	24	auxpass
24	shown	show	VBN	_	12	acl:relcl
25	to	to	TO	_	26	mark
26	reduce	reduce	VB	_	24	xcomp
27	the	the	DT	_	28	det
28	incidence	incidence	NN	_	26	dobj
29	of	of	IN	_	30	case
30	reinfarction	reinfarction	NN	_	28	nmod
31	and	and	CC	_	30	cc
32	stroke	stroke	NN	_	30	conj
33	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	aspirin	aspirin	NN	_	2	nmod
5	to	to	TO	_	6	case
6	Streptokinase	Streptokinase	NNP	_	2	nmod
7	causes	cause	VBZ	_	0	ROOT
8	a	a	DT	_	10	det
9	minimal	minimal	JJ	_	10	amod
10	increase	increase	NN	_	7	dobj
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	17	case
15	minor	minor	JJ	_	17	amod
16	bleeding	bleeding	JJ	_	17	amod
17	(	(	NN	_	13	nmod
18	3.9	3.9	CD	_	19	nummod
19	%	%	NN	_	17	dep
20	vs	vs	CC	_	19	advmod
21	.	.	.	_	7	punct
22	3.1	3.1	CD	_	23	nummod
23	%	%	NN	_	38	nsubj
24	)	)	CD	_	23	nummod
25	,	,	,	_	23	punct
26	but	but	CC	_	23	cc
27	does	do	VBZ	_	29	aux
28	not	not	RB	_	29	neg
29	appear	appear	VB	_	23	conj
30	to	to	TO	_	31	mark
31	increase	increase	VB	_	29	xcomp
32	the	the	DT	_	33	det
33	incidence	incidence	NN	_	31	dobj
34	of	of	IN	_	37	case
35	major	major	JJ	_	37	amod
36	bleeding	bleeding	JJ	_	37	amod
37	(	(	NN	_	33	nmod
38	see	see	VB	_	7	parataxis

1	When	when	WRB	_	4	advmod
2	methyldopa	methyldopa	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	used	use	VBN	_	15	advcl
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	antihypertensive	antihypertensive	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	,	,	,	_	15	punct
10	potentiation	potentiation	NN	_	15	nsubj
11	of	of	IN	_	13	case
12	antihypertensive	antihypertensive	JJ	_	13	amod
13	effect	effect	NN	_	10	nmod
14	may	may	MD	_	15	aux
15	occur	occur	VB	_	0	ROOT
16	.	.	.	_	15	punct

1	Patients	patient	NNS	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	followed	follow	VBN	_	0	ROOT
5	carefully	carefully	RB	_	4	advmod
6	to	to	TO	_	7	mark
7	detect	detect	VB	_	4	xcomp
8	side	side	JJ	_	9	amod
9	reactions	reaction	NNS	_	7	dobj
10	or	or	CC	_	9	cc
11	unusual	unusual	JJ	_	12	amod
12	manifestations	manifestation	NNS	_	9	conj
13	of	of	IN	_	15	case
14	drug	drug	NN	_	15	compound
15	idiosyncrasy	idiosyncrasy	NN	_	12	nmod
16	.	.	.	_	4	punct

1	Patients	patient	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	require	require	VB	_	0	ROOT
4	reduced	reduced	JJ	_	5	amod
5	doses	dose	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	anesthetics	anesthetic	NNS	_	5	nmod
8	when	when	WRB	_	10	advmod
9	on	on	IN	_	10	case
10	methyldopa	methyldopa	NN	_	3	advcl
11	.	.	.	_	3	punct

1	If	if	IN	_	4	mark
2	hypotension	hypotension	NN	_	4	nsubj
3	does	do	VBZ	_	4	aux
4	occur	occur	VB	_	12	advcl
5	during	during	IN	_	6	case
6	anesthesia	anesthesia	NN	_	4	nmod
7	,	,	,	_	12	punct
8	it	it	PRP	_	12	nsubjpass
9	usually	usually	RB	_	12	advmod
10	can	can	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	controlled	control	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	vasopressors	vasopressor	NNS	_	12	nmod
15	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	adrenergic	adrenergic	JJ	_	3	amod
3	receptors	receptor	NNS	_	4	nsubj
4	remain	remain	VBP	_	0	ROOT
5	sensitive	sensitive	JJ	_	4	xcomp
6	during	during	IN	_	7	case
7	treatment	treatment	NN	_	4	nmod
8	with	with	IN	_	9	case
9	methyldopa	methyldopa	NN	_	7	nmod
10	.	.	.	_	4	punct

1	When	when	WRB	_	6	advmod
2	methyldopa	methyldopa	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	lithium	lithium	NN	_	2	conj
5	are	be	VBP	_	6	auxpass
6	given	give	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	13	advmod
8	the	the	DT	_	9	det
9	patient	patient	NN	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	carefully	carefully	RB	_	13	advmod
13	monitored	monitor	VBN	_	6	ccomp
14	for	for	IN	_	15	case
15	symptoms	symptom	NNS	_	13	nmod
16	of	of	IN	_	18	case
17	lithium	lithium	NN	_	18	compound
18	toxicity	toxicity	NN	_	15	nmod
19	.	.	.	_	6	punct

1	Read	read	VB	_	0	ROOT
2	the	the	DT	_	3	det
3	circular	circular	JJ	_	1	dobj
4	for	for	IN	_	6	case
5	lithium	lithium	NN	_	6	compound
6	preparations	preparation	NNS	_	3	nmod
7	.	.	.	_	1	punct

1	Several	several	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	demonstrate	demonstrate	VBP	_	0	ROOT
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	3	dobj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	bioavailability	bioavailability	NN	_	5	nmod
9	of	of	IN	_	10	case
10	methyldopa	methyldopa	NN	_	8	nmod
11	when	when	WRB	_	14	advmod
12	it	it	PRP	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	ingested	ingest	VBN	_	3	advcl
15	with	with	IN	_	17	case
16	ferrous	ferrous	JJ	_	17	amod
17	sulfate	sulfate	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	ferrous	ferrous	JJ	_	20	amod
20	gluconate	gluconate	NN	_	17	conj
21	.	.	.	_	3	punct

1	This	this	DT	_	4	nsubj
2	may	may	MD	_	4	aux
3	adversely	adversely	RB	_	4	advmod
4	affect	affect	VB	_	0	ROOT
5	blood	blood	NN	_	7	compound
6	pressure	pressure	NN	_	7	compound
7	control	control	NN	_	4	dobj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	12	case
12	methyldopa	methyldopa	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	12	nsubjpass
2	of	of	IN	_	3	case
3	methyldopa	methyldopa	NN	_	1	nmod
4	with	with	IN	_	6	case
5	ferrous	ferrous	JJ	_	6	amod
6	sulfate	sulfate	NN	_	1	nmod
7	or	or	CC	_	6	cc
8	ferrous	ferrous	JJ	_	9	amod
9	gluconate	gluconate	NN	_	6	conj
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	recommended	recommend	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Monoamine	monoamine	NN	_	2	compound
2	oxidase	oxidase	NN	_	0	ROOT
3	(	(	CD	_	6	nummod
4	MAO	MAO	NNP	_	6	compound
5	)	)	NN	_	6	compound
6	inhibitors	inhibitor	NNS	_	2	dep
7	:	:	:	_	2	punct
8	See	see	VB	_	2	dep
9	CONTRAINDICATIONS	contraindication	NNS	_	8	dobj
10	.	.	.	_	2	punct

1	Drug	drug	NN	_	6	compound
2	/	/	:	_	6	punct
3	Laboratory	Laboratory	NNP	_	6	compound
4	Test	Test	NNP	_	6	compound
5	Interactions	interaction	NNS	_	6	compound
6	Methyldopa	methyldopa	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	interfere	interfere	VB	_	0	ROOT
9	with	with	IN	_	10	case
10	measurement	measurement	NN	_	8	nmod
11	of	of	IN	_	15	case
12	:	:	:	_	15	punct
13	urinary	urinary	JJ	_	15	amod
14	uric	uric	JJ	_	15	amod
15	acid	acid	NN	_	10	nmod
16	by	by	IN	_	19	case
17	the	the	DT	_	19	det
18	phosphotungstate	phosphotungstate	NN	_	19	compound
19	method	method	NN	_	8	nmod
20	,	,	,	_	19	punct
21	serum	serum	NN	_	22	compound
22	creatinine	creatinine	NN	_	19	conj
23	by	by	IN	_	27	case
24	the	the	DT	_	27	det
25	alkaline	alkaline	NN	_	27	compound
26	picrate	picrate	NN	_	27	compound
27	method	method	NN	_	22	nmod
28	,	,	,	_	19	punct
29	and	and	CC	_	19	cc
30	SGOT	sgot	NN	_	19	conj
31	by	by	IN	_	33	case
32	colorimetric	colorimetric	JJ	_	33	amod
33	methods	method	NNS	_	30	nmod
34	.	.	.	_	8	punct

1	Interference	interference	NN	_	11	nsubjpass
2	with	with	IN	_	4	case
3	spectrophotometric	spectrophotometric	JJ	_	4	amod
4	methods	method	NNS	_	1	nmod
5	for	for	IN	_	7	case
6	SGOT	sgot	NN	_	7	compound
7	analysis	analysis	NN	_	4	nmod
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Since	since	IN	_	3	mark
2	methyldopa	methyldopa	NN	_	3	nsubj
3	causes	cause	VBZ	_	24	advcl
4	fluorescence	fluorescence	NN	_	3	dobj
5	in	in	IN	_	7	case
6	urine	urine	NN	_	7	compound
7	samples	sample	NNS	_	4	nmod
8	at	at	IN	_	12	case
9	the	the	DT	_	12	det
10	same	same	JJ	_	12	amod
11	wave	wave	NN	_	12	compound
12	lengths	length	NNS	_	3	nmod
13	as	as	IN	_	14	case
14	catecholamines	catecholamine	NNS	_	12	nmod
15	,	,	,	_	24	punct
16	falsely	falsely	RB	_	17	advmod
17	high	high	JJ	_	18	amod
18	levels	level	NNS	_	24	nsubjpass
19	of	of	IN	_	21	case
20	urinary	urinary	JJ	_	21	amod
21	catecholamines	catecholamine	NNS	_	18	nmod
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	reported	report	VBN	_	0	ROOT
25	.	.	.	_	24	punct

1	This	this	DT	_	3	nsubj
2	will	will	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	diagnosis	diagnosis	NN	_	3	nmod
7	of	of	IN	_	8	case
8	pheochromocytoma	pheochromocytoma	NN	_	6	nmod
9	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	important	important	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	recognize	recognize	VB	_	3	xcomp
6	this	this	DT	_	7	det
7	phenomenon	phenomenon	NN	_	5	dobj
8	before	before	IN	_	10	case
9	a	a	DT	_	10	det
10	patient	patient	NN	_	5	nmod
11	with	with	IN	_	14	case
12	a	a	DT	_	14	det
13	possible	possible	JJ	_	14	amod
14	pheochromocytoma	pheochromocytoma	NN	_	10	nmod
15	is	be	VBZ	_	16	auxpass
16	subjected	subject	VBN	_	3	dep
17	to	to	TO	_	18	case
18	surgery	surgery	NN	_	16	nmod
19	.	.	.	_	3	punct

1	Methyldopa	methyldopa	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	measurement	measurement	NN	_	4	nmod
7	of	of	IN	_	12	case
8	VMA	VMA	NNP	_	12	compound
9	(	(	CD	_	12	nummod
10	vanillylmandelic	vanillylmandelic	JJ	_	12	amod
11	acid	acid	NN	_	12	compound
12	)	)	NN	_	6	nmod
13	,	,	,	_	12	punct
14	a	a	DT	_	15	det
15	test	test	NN	_	12	appos
16	for	for	IN	_	17	case
17	pheochromocytoma	pheochromocytoma	NN	_	15	nmod
18	,	,	,	_	12	punct
19	by	by	IN	_	21	case
20	those	those	DT	_	21	det
21	methods	method	NNS	_	6	nmod
22	which	which	WDT	_	23	nsubj
23	convert	convert	VBP	_	21	acl:relcl
24	VMA	VMA	NNP	_	23	dobj
25	to	to	TO	_	26	case
26	vanillin	vanillin	NN	_	23	nmod
27	.	.	.	_	4	punct

1	Methyldopa	methyldopa	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	recommended	recommend	VBN	_	0	ROOT
5	for	for	IN	_	7	case
6	the	the	DT	_	7	det
7	treatment	treatment	NN	_	4	nmod
8	of	of	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	with	with	IN	_	11	case
11	pheochromocytoma	pheochromocytoma	NN	_	9	nmod
12	.	.	.	_	4	punct

1	Rarely	rarely	RB	_	14	advmod
2	,	,	,	_	14	punct
3	when	when	WRB	_	6	advmod
4	urine	urine	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	exposed	expose	VBN	_	14	advcl
7	to	to	TO	_	8	case
8	air	air	NN	_	6	nmod
9	after	after	IN	_	10	mark
10	voiding	void	VBG	_	6	advcl
11	,	,	,	_	14	punct
12	it	it	PRP	_	14	nsubj
13	may	may	MD	_	14	aux
14	darken	darken	VB	_	0	ROOT
15	because	because	IN	_	17	case
16	of	of	IN	_	15	mwe
17	breakdown	breakdown	NN	_	14	nmod
18	of	of	IN	_	19	case
19	methyldopa	methyldopa	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	its	its	PRP$	_	22	nmod:poss
22	metabolites	metabolite	NNS	_	19	conj
23	.	.	.	_	14	punct

1	Anticholinesterases	Anticholinesterases	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	12	nsubj
5	of	of	IN	_	7	case
6	procaine	procaine	NN	_	7	compound
7	hydrochloride	hydrochloride	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	anticholinesterase	anticholinesterase	JJ	_	10	amod
10	agents	agent	NNS	_	7	conj
11	may	may	MD	_	12	aux
12	result	result	VB	_	1	dep
13	in	in	IN	_	16	case
14	increased	increase	VBN	_	16	amod
15	systemic	systemic	JJ	_	16	amod
16	toxicity	toxicity	NN	_	12	nmod
17	since	since	IN	_	19	mark
18	anticholinesterases	anticholinesterase	NNS	_	19	nsubj
19	inhibit	inhibit	VBP	_	12	advcl
20	the	the	DT	_	21	det
21	breakdown	breakdown	NN	_	19	dobj
22	of	of	IN	_	24	case
23	procaine	procaine	NN	_	24	compound
24	hydrochloride	hydrochloride	NN	_	21	nmod
25	.	.	.	_	1	punct

1	Antimyasthenics	Antimyasthenics	NNP	_	3	compound
2	Concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	10	nsubj
4	of	of	IN	_	6	case
5	procaine	procaine	NN	_	6	compound
6	hydrochloride	hydrochloride	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	antimyasthenics	antimyasthenic	NNS	_	6	conj
9	may	may	MD	_	10	aux
10	result	result	VB	_	0	ROOT
11	in	in	IN	_	12	case
12	loss	loss	NN	_	10	nmod
13	of	of	IN	_	14	case
14	control	control	NN	_	12	nmod
15	of	of	IN	_	16	case
16	symptoms	symptom	NNS	_	14	nmod
17	of	of	IN	_	19	case
18	myasthenia	myasthenia	NN	_	19	compound
19	gravis	gravis	NN	_	16	nmod
20	due	due	JJ	_	22	case
21	to	to	TO	_	20	mwe
22	antagonism	antagonism	NN	_	12	nmod
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	effects	effect	NNS	_	22	nmod
26	of	of	IN	_	27	case
27	antimyasthenics	antimyasthenic	NNS	_	25	nmod
28	on	on	IN	_	30	case
29	skeletal	skeletal	JJ	_	30	amod
30	muscle	muscle	NN	_	25	nmod
31	.	.	.	_	10	punct

1	Temporary	temporary	JJ	_	3	amod
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	antimyasthenics	antimyasthenic	NNS	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	required	require	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Also	also	RB	_	4	advmod
2	antimyasthenics	antimyasthenic	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	have	have	VB	_	0	ROOT
5	anticholinesterase	anticholinesterase	JJ	_	6	amod
6	activity	activity	NN	_	4	dobj
7	.	.	.	_	4	punct

1	CNS	cns	NN	_	3	compound
2	depressant	depressant	NN	_	3	compound
3	medications	medication	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Concurrent	concurrent	JJ	_	6	amod
6	use	use	NN	_	15	nsubj
7	of	of	IN	_	9	case
8	procaine	procaine	NN	_	9	compound
9	hydrochloride	hydrochloride	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	CNS	cns	NN	_	13	compound
12	depressant	depressant	NN	_	13	compound
13	medications	medication	NNS	_	9	conj
14	may	may	MD	_	15	aux
15	result	result	VB	_	3	dep
16	in	in	IN	_	19	case
17	additive	additive	JJ	_	19	amod
18	depressant	depressant	NN	_	19	compound
19	effects	effect	NNS	_	15	nmod
20	.	.	.	_	3	punct

1	Hyaluronidase	Hyaluronidase	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Hyaluronidase	hyaluronidase	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	1	dep
6	the	the	DT	_	8	det
7	diffusion	diffusion	NN	_	8	compound
8	rate	rate	NN	_	5	dobj
9	of	of	IN	_	11	case
10	procaine	procaine	NN	_	11	compound
11	hydrochloride	hydrochloride	NN	_	8	nmod
12	,	,	,	_	5	punct
13	resulting	result	VBG	_	5	advcl
14	in	in	IN	_	17	case
15	a	a	DT	_	17	det
16	decreased	decrease	VBN	_	17	amod
17	time	time	NN	_	13	nmod
18	of	of	IN	_	19	case
19	onset	onset	NN	_	17	nmod
20	,	,	,	_	5	punct
21	but	but	CC	_	5	cc
22	an	a	DT	_	23	det
23	increase	increase	NN	_	5	conj
24	in	in	IN	_	26	case
25	systemic	systemic	JJ	_	26	amod
26	toxicity	toxicity	NN	_	23	nmod
27	.	.	.	_	1	punct

1	Neuromuscular	neuromuscular	JJ	_	0	ROOT
2	blocking	block	VBG	_	1	dep
3	agents	agent	NNS	_	2	dobj
4	(	(	CD	_	3	dep
5	such	such	JJ	_	8	case
6	as	as	IN	_	5	mwe
7	suxamethonium	suxamethonium	NN	_	8	compound
8	chloride	chloride	NN	_	4	nmod
9	)	)	CD	_	8	nummod
10	:	:	:	_	1	punct
11	Concurrent	concurrent	JJ	_	12	amod
12	use	use	NN	_	21	nsubj
13	of	of	IN	_	15	case
14	procaine	procaine	NN	_	15	compound
15	hydrochloride	hydrochloride	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	neuromuscular	neuromuscular	JJ	_	19	amod
18	blocking	block	VBG	_	19	amod
19	agents	agent	NNS	_	15	conj
20	may	may	MD	_	21	aux
21	result	result	VB	_	1	parataxis
22	in	in	IN	_	23	case
23	prolongation	prolongation	NN	_	21	nmod
24	or	or	CC	_	23	cc
25	enhancement	enhancement	NN	_	23	conj
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	neuromuscular	neuromuscular	JJ	_	29	amod
29	blockade	blockade	NN	_	23	nmod
30	.	.	.	_	1	punct

1	Sulfonamides	Sulfonamides	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	11	nsubj
5	of	of	IN	_	7	case
6	procaine	procaine	NN	_	7	compound
7	hydrochloride	hydrochloride	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	sulfonamides	sulfonamide	NNS	_	7	conj
10	may	may	MD	_	11	aux
11	result	result	VB	_	1	dep
12	in	in	IN	_	14	case
13	a	a	DT	_	14	det
14	reduction	reduction	NN	_	11	nmod
15	of	of	IN	_	18	case
16	the	the	DT	_	18	det
17	antibacterial	antibacterial	JJ	_	18	amod
18	action	action	NN	_	14	nmod
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	sulfonamide	sulfonamide	NN	_	18	nmod
22	.	.	.	_	1	punct

1	Acetazolamide	Acetazolamide	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	11	nsubj
5	of	of	IN	_	6	case
6	acetazolamide	acetazolamide	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	procaine	procaine	NN	_	9	compound
9	hydrochloride	hydrochloride	NN	_	6	conj
10	may	may	MD	_	11	aux
11	extend	extend	VB	_	1	appos
12	the	the	DT	_	14	det
13	plasma	plasma	NN	_	14	compound
14	half	half	NN	_	11	dobj
15	-	-	:	_	14	punct
16	life	life	NN	_	14	dep
17	of	of	IN	_	18	case
18	procaine	procaine	NN	_	16	nmod
19	.	.	.	_	1	punct

1	Diuretics	diuretic	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Patients	patient	NNS	_	15	nsubj
4	on	on	IN	_	5	case
5	diuretics	diuretic	NNS	_	3	nmod
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	especially	especially	RB	_	9	advmod
9	those	those	DT	_	3	conj
10	started	start	VBN	_	9	acl
11	recently	recently	RB	_	10	advmod
12	,	,	,	_	3	punct
13	may	may	MD	_	15	aux
14	occasionally	occasionally	RB	_	15	advmod
15	experience	experience	VB	_	1	dep
16	an	a	DT	_	18	det
17	excessive	excessive	JJ	_	18	amod
18	reduction	reduction	NN	_	15	dobj
19	of	of	IN	_	21	case
20	blood	blood	NN	_	21	compound
21	pressure	pressure	NN	_	18	nmod
22	after	after	IN	_	23	case
23	initiation	initiation	NN	_	15	nmod
24	of	of	IN	_	27	case
25	ACEON	ACEON	NNP	_	27	compound
26	Tablets	Tablets	NNPS	_	27	compound
27	therapy	therapy	NN	_	23	nmod
28	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	can	can	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	minimized	minimize	VBN	_	0	ROOT
9	by	by	IN	_	11	mark
10	either	either	CC	_	11	cc:preconj
11	discontinuing	discontinue	VBG	_	8	advcl
12	the	the	DT	_	13	det
13	diuretic	diuretic	JJ	_	11	dobj
14	or	or	CC	_	11	cc
15	increasing	increase	VBG	_	11	conj
16	the	the	DT	_	18	det
17	salt	salt	NN	_	18	compound
18	intake	intake	NN	_	15	dobj
19	prior	prior	RB	_	15	advmod
20	to	to	TO	_	21	case
21	initiation	initiation	NN	_	19	nmod
22	of	of	IN	_	23	case
23	treatment	treatment	NN	_	21	nmod
24	with	with	IN	_	25	case
25	perindopril	perindopril	NN	_	23	nmod
26	.	.	.	_	8	punct

1	If	if	IN	_	3	mark
2	diuretics	diuretic	NNS	_	3	nsubj
3	cannot	cannot	VBP	_	5	advcl
4	be	be	VB	_	5	auxpass
5	interrupted	interrupt	VBN	_	0	ROOT
6	,	,	,	_	5	punct
7	close	close	JJ	_	9	amod
8	medical	medical	JJ	_	9	amod
9	supervision	supervision	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	provided	provide	VBN	_	5	ccomp
13	with	with	IN	_	16	case
14	the	the	DT	_	16	det
15	first	first	JJ	_	16	amod
16	dose	dose	NN	_	12	nmod
17	of	of	IN	_	19	case
18	ACEON	ACEON	NNP	_	19	compound
19	Tablets	Tablets	NNPS	_	16	nmod
20	,	,	,	_	16	punct
21	for	for	IN	_	25	case
22	at	at	IN	_	23	case
23	least	least	JJS	_	24	nmod:npmod
24	two	two	CD	_	25	nummod
25	hours	hour	NNS	_	16	conj
26	and	and	CC	_	16	cc
27	until	until	IN	_	31	mark
28	blood	blood	NN	_	29	compound
29	pressure	pressure	NN	_	31	nsubj
30	has	have	VBZ	_	31	aux
31	stabilized	stabilize	VBN	_	16	conj
32	for	for	IN	_	34	case
33	another	another	DT	_	34	det
34	hour	hour	NN	_	31	nmod
35	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	rate	rate	NN	_	12	nsubjpass
3	and	and	CC	_	2	cc
4	extent	extent	NN	_	2	conj
5	of	of	IN	_	7	case
6	perindopril	perindopril	NN	_	7	compound
7	absorption	absorption	NN	_	2	nmod
8	and	and	CC	_	7	cc
9	elimination	elimination	NN	_	7	conj
10	are	be	VBP	_	12	auxpass
11	not	not	RB	_	12	neg
12	affected	affect	VBN	_	0	ROOT
13	by	by	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	diuretics	diuretic	NNS	_	12	nmod
16	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	perindoprilat	perindoprilat	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	reduced	reduce	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	diuretics	diuretic	NNS	_	6	nmod
9	,	,	,	_	6	punct
10	however	however	RB	_	6	advmod
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	this	this	DT	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	associated	associate	VBN	_	6	conj
16	with	with	IN	_	18	case
17	a	a	DT	_	18	det
18	decrease	decrease	NN	_	15	nmod
19	in	in	IN	_	22	case
20	plasma	plasma	NN	_	22	compound
21	ACE	ace	NN	_	22	compound
22	inhibition	inhibition	NN	_	18	nmod
23	.	.	.	_	6	punct

1	Potassium	potassium	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	Potassium	potassium	NN	_	2	conj
5	-	-	:	_	2	punct
6	Sparing	spare	VBG	_	7	amod
7	Diuretics	diuretic	NNS	_	2	dep
8	:	:	:	_	2	punct
9	ACEON	ACEON	NNP	_	10	compound
10	Tablets	Tablets	NNPS	_	12	nsubj
11	may	may	MD	_	12	aux
12	increase	increase	VB	_	2	dep
13	serum	serum	NN	_	14	compound
14	potassium	potassium	NN	_	12	dobj
15	because	because	IN	_	18	case
16	of	of	IN	_	15	mwe
17	its	its	PRP$	_	18	nmod:poss
18	potential	potential	JJ	_	12	nmod
19	to	to	TO	_	20	mark
20	decrease	decrease	VB	_	18	acl
21	aldosterone	aldosterone	NN	_	22	compound
22	production	production	NN	_	20	dobj
23	.	.	.	_	2	punct

1	Use	use	NN	_	35	nsubj
2	of	of	IN	_	3	case
3	potassium	potassium	NN	_	1	nmod
4	-	-	:	_	1	punct
5	sparing	spare	VBG	_	1	acl
6	diuretics	diuretic	NNS	_	8	compound
7	(	(	CD	_	8	nummod
8	spironolactone	spironolactone	NN	_	5	dobj
9	,	,	,	_	8	punct
10	amiloride	amiloride	NN	_	8	conj
11	,	,	,	_	8	punct
12	triamterene	triamterene	NN	_	8	conj
13	and	and	CC	_	8	cc
14	others	other	NNS	_	8	conj
15	)	)	RB	_	5	advmod
16	,	,	,	_	5	punct
17	potassium	potassium	NN	_	18	compound
18	supplements	supplement	NNS	_	5	dobj
19	or	or	CC	_	18	cc
20	other	other	JJ	_	21	amod
21	drugs	drug	NNS	_	18	conj
22	capable	capable	JJ	_	18	amod
23	of	of	IN	_	24	mark
24	increasing	increase	VBG	_	22	advcl
25	serum	serum	NN	_	26	compound
26	potassium	potassium	NN	_	24	dobj
27	(	(	CD	_	28	nummod
28	indomethacin	indomethacin	NN	_	26	dep
29	,	,	,	_	26	punct
30	heparin	heparin	NN	_	26	conj
31	,	,	,	_	26	punct
32	cyclosporine	cyclosporine	NN	_	26	conj
33	and	and	CC	_	26	cc
34	others	other	NNS	_	26	conj
35	)	)	VBP	_	0	ROOT
36	can	can	MD	_	37	aux
37	increase	increase	VB	_	35	ccomp
38	the	the	DT	_	39	det
39	risk	risk	NN	_	37	dobj
40	of	of	IN	_	41	case
41	hyperkalemia	hyperkalemia	NN	_	39	nmod
42	.	.	.	_	35	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	the	the	DT	_	20	det
20	patient	patient	NN	_	24	nmod:poss
21	'	'	POS	_	20	case
22	s	s	NNS	_	24	compound
23	serum	serum	NN	_	24	compound
24	potassium	potassium	NN	_	17	conj
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	monitored	monitor	VBN	_	15	dep
28	frequently	frequently	RB	_	27	advmod
29	.	.	.	_	15	punct

1	Lithium	lithium	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	5	amod
4	serum	serum	NN	_	5	compound
5	lithium	lithium	NN	_	13	nsubjpass
6	and	and	CC	_	5	cc
7	symptoms	symptom	NNS	_	5	conj
8	of	of	IN	_	10	case
9	lithium	lithium	NN	_	10	compound
10	toxicity	toxicity	NN	_	7	nmod
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	1	dep
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	concomitant	concomitant	JJ	_	18	amod
18	lithium	lithium	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	ACE	ace	NN	_	22	compound
21	inhibitor	inhibitor	NN	_	22	compound
22	therapy	therapy	NN	_	18	conj
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	16	csubjpass
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	frequent	frequent	JJ	_	10	amod
10	monitoring	monitoring	NN	_	7	conj
11	of	of	IN	_	14	case
12	serum	serum	NN	_	14	compound
13	lithium	lithium	NN	_	14	compound
14	concentration	concentration	NN	_	10	nmod
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Use	use	NN	_	7	nsubj
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	diuretic	diuretic	JJ	_	1	nmod
5	may	may	MD	_	7	aux
6	further	further	RB	_	7	advmod
7	increase	increase	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	risk	risk	NN	_	7	dobj
10	of	of	IN	_	12	case
11	lithium	lithium	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	.	.	.	_	7	punct

1	Digoxin	digoxin	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	6	det
4	controlled	controlled	JJ	_	6	amod
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	8	nsubj
7	has	have	VBZ	_	8	aux
8	shown	show	VBN	_	1	dep
9	no	no	DT	_	10	neg
10	effect	effect	NN	_	8	dobj
11	on	on	IN	_	14	case
12	plasma	plasma	NN	_	14	compound
13	digoxin	digoxin	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	nmod
15	when	when	WRB	_	16	advmod
16	coadministered	coadminister	VBN	_	8	advcl
17	with	with	IN	_	19	case
18	ACEON	ACEON	NNP	_	19	compound
19	Tablets	Tablets	NNPS	_	16	nmod
20	,	,	,	_	8	punct
21	but	but	CC	_	8	cc
22	an	a	DT	_	23	det
23	effect	effect	NN	_	8	conj
24	of	of	IN	_	25	case
25	digoxin	digoxin	NN	_	23	nmod
26	on	on	IN	_	29	case
27	the	the	DT	_	29	det
28	plasma	plasma	NN	_	29	compound
29	concentration	concentration	NN	_	23	nmod
30	of	of	IN	_	31	case
31	perindopril	perindopril	NN	_	29	nmod
32	/	/	:	_	23	punct
33	perindoprilat	perindoprilat	NN	_	37	nsubjpass
34	has	have	VBZ	_	37	aux
35	not	not	RB	_	37	neg
36	been	be	VBN	_	37	auxpass
37	excluded	exclude	VBN	_	23	acl:relcl
38	.	.	.	_	1	punct

1	Gentamicin	Gentamicin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Animal	Animal	NNP	_	4	compound
4	data	datum	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	suggested	suggest	VBN	_	1	appos
7	the	the	DT	_	8	det
8	possibility	possibility	NN	_	6	dobj
9	of	of	IN	_	10	case
10	interaction	interaction	NN	_	8	nmod
11	between	between	IN	_	12	case
12	perindopril	perindopril	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	gentamicin	gentamicin	NN	_	12	conj
15	.	.	.	_	1	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	this	this	DT	_	7	nsubjpass
4	has	have	VBZ	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	investigated	investigate	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	human	human	JJ	_	10	amod
10	studies	study	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	Coadministration	Coadministration	NNP	_	6	nsubj
2	of	of	IN	_	4	case
3	both	both	DT	_	4	det
4	drugs	drug	NNS	_	1	nmod
5	should	should	MD	_	6	aux
6	proceed	proceed	VB	_	0	ROOT
7	with	with	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	.	.	.	_	6	punct

1	Food	Food	NNP	_	2	compound
2	Interaction	interaction	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Oral	oral	JJ	_	5	amod
5	administration	administration	NN	_	14	nsubj
6	of	of	IN	_	8	case
7	ACEON	ACEON	NNP	_	8	compound
8	Tablets	Tablets	NNPS	_	5	nmod
9	with	with	IN	_	10	case
10	food	food	NN	_	5	nmod
11	does	do	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	significantly	significantly	RB	_	14	advmod
14	lower	lower	JJR	_	2	dep
15	the	the	DT	_	16	det
16	rate	rate	NN	_	14	dobj
17	or	or	CC	_	16	cc
18	extent	extent	NN	_	16	conj
19	of	of	IN	_	21	case
20	perindopril	perindopril	NN	_	21	compound
21	absorption	absorption	NN	_	16	nmod
22	relative	relative	JJ	_	16	amod
23	to	to	TO	_	26	case
24	the	the	DT	_	26	det
25	fasted	fasted	JJ	_	26	amod
26	state	state	NN	_	22	nmod
27	.	.	.	_	2	punct

1	However	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	the	the	DT	_	4	det
4	extent	extent	NN	_	17	nsubjpass
5	of	of	IN	_	6	case
6	biotransformation	biotransformation	NN	_	4	nmod
7	of	of	IN	_	8	case
8	perindopril	perindopril	NN	_	6	nmod
9	to	to	TO	_	12	case
10	the	the	DT	_	12	det
11	active	active	JJ	_	12	amod
12	metabolite	metabolite	NN	_	4	nmod
13	,	,	,	_	12	punct
14	perindoprilat	perindoprilat	NN	_	12	appos
15	,	,	,	_	12	punct
16	is	be	VBZ	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	approximately	approximately	RB	_	19	advmod
19	43	43	CD	_	20	nummod
20	%	%	NN	_	17	dobj
21	,	,	,	_	17	punct
22	resulting	result	VBG	_	17	advcl
23	in	in	IN	_	25	case
24	a	a	DT	_	25	det
25	reduction	reduction	NN	_	22	nmod
26	in	in	IN	_	31	case
27	the	the	DT	_	31	det
28	plasma	plasma	NN	_	31	compound
29	ACE	ace	NN	_	31	compound
30	inhibition	inhibition	NN	_	31	compound
31	curve	curve	NN	_	25	nmod
32	of	of	IN	_	35	case
33	approximately	approximately	RB	_	34	advmod
34	20	20	CD	_	35	nummod
35	%	%	NN	_	31	nmod
36	,	,	,	_	17	punct
37	probably	probably	RB	_	39	advmod
38	clinically	clinically	RB	_	39	advmod
39	insignificant	insignificant	JJ	_	17	dep
40	.	.	.	_	17	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	perindopril	perindopril	NN	_	8	nsubjpass
6	was	be	VBD	_	8	auxpass
7	generally	generally	RB	_	8	advmod
8	administered	administer	VBN	_	0	ROOT
9	in	in	IN	_	14	case
10	a	a	DT	_	14	det
11	non	non	JJ	_	14	amod
12	-	-	:	_	14	punct
13	fasting	fasting	JJ	_	14	amod
14	state	state	NN	_	8	nmod
15	.	.	.	_	8	punct

1	Vindesine	Vindesine	NNP	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	following	follow	VBG	_	10	amod
10	categories	category	NNS	_	6	nmod
11	:	:	:	_	3	punct
12	-	-	:	_	3	punct
13	Blood	blood	NN	_	14	compound
14	dyscrasia	dyscrasia	NN	_	26	nsubj
15	:	:	:	_	14	punct
16	can	can	MD	_	17	aux
17	cause	cause	VB	_	14	dep
18	unpredictable	unpredictable	JJ	_	19	amod
19	myelotoxicity	myelotoxicity	NN	_	17	dobj
20	-	-	:	_	19	punct
21	Bone	bone	NN	_	23	compound
22	marrow	marrow	NN	_	23	compound
23	depressants	depressant	NNS	_	19	dep
24	:	:	:	_	14	punct
25	can	can	MD	_	26	aux
26	cause	cause	VB	_	3	parataxis
27	a	a	DT	_	29	det
28	predictable	predictable	JJ	_	29	amod
29	dose	dose	NN	_	26	dobj
30	-	-	:	_	29	punct
31	related	related	JJ	_	32	amod
32	myelotoxicity	myelotoxicity	NN	_	29	dep
33	-	-	:	_	32	punct
34	Radiation	Radiation	NNP	_	35	compound
35	therapy	therapy	NN	_	32	dep
36	:	:	:	_	26	punct
37	may	may	MD	_	38	aux
38	cause	cause	VB	_	26	dep
39	marrow	marrow	NN	_	40	compound
40	depression	depression	NN	_	38	dobj
41	-	-	:	_	40	punct
42	Neurotoxic	neurotoxic	JJ	_	43	amod
43	medications	medication	NNS	_	40	dep
44	:	:	:	_	38	punct
45	can	can	MD	_	46	aux
46	cause	cause	VB	_	53	csubj
47	neurologic	neurologic	JJ	_	48	amod
48	toxicity	toxicity	NN	_	46	dobj
49	-	-	:	_	48	punct
50	Phenytoin	Phenytoin	NNP	_	48	dep
51	:	:	:	_	48	punct
52	can	can	MD	_	53	aux
53	increase	increase	VB	_	38	parataxis
54	seizure	seizure	NN	_	55	compound
55	activity	activity	NN	_	53	dobj
56	-	-	:	_	55	punct
57	Live	live	JJ	_	59	amod
58	virus	virus	NN	_	59	compound
59	vaccines	vaccine	NNS	_	55	dep
60	:	:	:	_	26	punct
61	may	may	MD	_	62	aux
62	potentiate	potentiate	VB	_	26	dep
63	the	the	DT	_	64	det
64	replication	replication	NN	_	62	dobj
65	of	of	IN	_	68	case
66	the	the	DT	_	68	det
67	vaccine	vaccine	NN	_	68	compound
68	virus	virus	NN	_	64	nmod
69	,	,	,	_	62	punct
70	may	may	MD	_	71	aux
71	increase	increase	VB	_	62	conj
72	the	the	DT	_	74	det
73	side	side	JJ	_	74	amod
74	effects	effect	NNS	_	71	dobj
75	of	of	IN	_	77	case
76	the	the	DT	_	77	det
77	vaccination	vaccination	NN	_	74	nmod
78	,	,	,	_	62	punct
79	and	and	CC	_	62	cc
80	decrease	decrease	VB	_	62	conj
81	patient	patient	NN	_	84	compound
82	'	'	''	_	84	punct
83	s	s	NNS	_	84	compound
84	response	response	NN	_	80	dobj
85	to	to	TO	_	87	case
86	the	the	DT	_	87	det
87	vaccine	vaccine	NN	_	84	nmod
88	-	-	:	_	87	punct
89	Mitomycin	mitomycin	NN	_	87	dep
90	-	-	:	_	87	punct
91	C	c	NN	_	87	dep
92	:	:	:	_	26	punct
93	may	may	MD	_	94	aux
94	cause	cause	VB	_	26	dep
95	shortness	shortness	NN	_	94	dobj
96	of	of	IN	_	97	case
97	breath	breath	NN	_	95	nmod
98	and	and	CC	_	97	cc
99	bronchospasm	bronchospasm	NN	_	97	conj
100	-	-	:	_	94	punct
101	Killed	kill	VBN	_	103	amod
102	virus	virus	NN	_	103	compound
103	vaccines	vaccine	NNS	_	94	dobj
104	:	:	:	_	94	punct
105	may	may	MD	_	106	aux
106	decrease	decrease	VB	_	94	parataxis
107	patient	patient	NN	_	110	compound
108	'	'	''	_	110	punct
109	s	s	NNS	_	110	compound
110	response	response	NN	_	106	dobj
111	to	to	TO	_	113	case
112	the	the	DT	_	113	det
113	vaccine	vaccine	NN	_	110	nmod

1	Posicor	Posicor	NNP	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	some	some	DT	_	2	dobj
4	of	of	IN	_	9	case
5	the	the	DT	_	6	det
6	liver	liver	NN	_	9	nmod:poss
7	'	'	POS	_	6	case
8	s	s	NNS	_	9	compound
9	ability	ability	NN	_	3	nmod
10	to	to	TO	_	11	mark
11	metabolize	metabolize	VB	_	9	acl
12	some	some	DT	_	14	det
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	dobj
15	-	-	:	_	14	punct
16	terfenadine	terfenadine	NN	_	14	dep
17	,	,	,	_	16	punct
18	astemizole	astemizole	NN	_	16	conj
19	,	,	,	_	16	punct
20	cisapride	cisapride	NN	_	16	conj
21	,	,	,	_	16	punct
22	cyclosporine	cyclosporine	NN	_	16	conj
23	,	,	,	_	16	punct
24	and	and	CC	_	16	cc
25	tricyclic	tricyclic	JJ	_	26	amod
26	antidepressants	antidepressant	NNS	_	16	conj
27	.	.	.	_	2	punct

1	Thus	thus	RB	_	8	advmod
2	the	the	DT	_	3	det
3	concentrations	concentration	NNS	_	8	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	would	would	MD	_	8	aux
8	increase	increase	VB	_	14	csubjpass
9	meaning	mean	VBG	_	8	xcomp
10	side	side	JJ	_	11	amod
11	effects	effect	NNS	_	9	dobj
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	seen	see	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	required	require	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	35	nsubj
4	of	of	IN	_	5	case
5	oxybutynin	oxybutynin	NN	_	3	nmod
6	with	with	IN	_	9	case
7	other	other	JJ	_	9	amod
8	anticholinergic	anticholinergic	JJ	_	9	amod
9	drugs	drug	NNS	_	3	nmod
10	or	or	CC	_	9	cc
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	agents	agent	NNS	_	9	conj
14	which	which	WDT	_	15	nsubj
15	produce	produce	VBP	_	13	acl:relcl
16	dry	dry	JJ	_	17	amod
17	mouth	mouth	NN	_	15	dobj
18	,	,	,	_	17	punct
19	constipation	constipation	NN	_	17	conj
20	,	,	,	_	17	punct
21	somnolence	somnolence	NN	_	24	compound
22	(	(	CD	_	24	nummod
23	drowsiness	drowsiness	NN	_	24	compound
24	)	)	NN	_	17	conj
25	,	,	,	_	17	punct
26	and	and	CC	_	17	cc
27	/	/	:	_	30	punct
28	or	or	CC	_	30	cc
29	other	other	JJ	_	30	conj
30	anticholinergic	anticholinergic	JJ	_	17	conj
31	-	-	:	_	30	punct
32	like	like	IN	_	33	case
33	effects	effect	NNS	_	30	nmod
34	may	may	MD	_	35	aux
35	increase	increase	VB	_	0	ROOT
36	the	the	DT	_	37	det
37	frequency	frequency	NN	_	35	dobj
38	and	and	CC	_	37	cc
39	/	/	:	_	41	punct
40	or	or	CC	_	41	cc
41	severity	severity	NN	_	37	conj
42	of	of	IN	_	44	case
43	such	such	JJ	_	44	amod
44	effects	effect	NNS	_	41	nmod
45	.	.	.	_	35	punct

1	Anticholinergic	anticholinergic	JJ	_	2	amod
2	agents	agent	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	potentially	potentially	RB	_	5	advmod
5	alter	alter	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	12	case
9	some	some	DT	_	12	det
10	concomitantly	concomitantly	RB	_	11	advmod
11	administered	administer	VBN	_	12	amod
12	drugs	drug	NNS	_	7	nmod
13	due	due	JJ	_	7	amod
14	to	to	TO	_	16	case
15	anticholinergic	anticholinergic	JJ	_	16	amod
16	effects	effect	NNS	_	13	nmod
17	on	on	IN	_	19	case
18	gastrointestinal	gastrointestinal	JJ	_	19	amod
19	motility	motility	NN	_	16	nmod
20	.	.	.	_	5	punct

1	This	this	DT	_	5	nsubj
2	may	may	MD	_	5	aux
3	be	be	VB	_	5	cop
4	of	of	IN	_	5	case
5	concern	concern	NN	_	0	ROOT
6	for	for	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	with	with	IN	_	12	case
9	a	a	DT	_	12	det
10	narrow	narrow	JJ	_	12	amod
11	therapeutic	therapeutic	JJ	_	12	amod
12	index	index	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Mean	mean	NN	_	5	compound
2	oxybutynin	oxybutynin	NN	_	5	compound
3	chloride	chloride	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	10	nsubj
6	were	be	VBD	_	10	cop
7	approximately	approximately	RB	_	8	advmod
8	2	2	CD	_	9	nummod
9	fold	fold	NN	_	10	nmod:npmod
10	higher	higher	JJR	_	0	ROOT
11	when	when	WRB	_	15	advmod
12	DITROPAN	DITROPAN	NNP	_	13	compound
13	XL	XL	NNP	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	administered	administer	VBN	_	10	advcl
16	with	with	IN	_	17	case
17	ketoconazole	ketoconazole	NN	_	15	nmod
18	,	,	,	_	17	punct
19	a	a	DT	_	22	det
20	potent	potent	JJ	_	22	amod
21	CYP3A4	cyp3a4	NN	_	22	compound
22	inhibitor	inhibitor	NN	_	17	appos
23	.	.	.	_	10	punct

1	Other	other	JJ	_	2	amod
2	inhibitors	inhibitor	NNS	_	15	nsubj
3	of	of	IN	_	9	case
4	the	the	DT	_	9	det
5	cytochrome	cytochrome	NN	_	9	compound
6	P450	p450	NN	_	9	compound
7	3A4	3a4	NN	_	9	compound
8	enzyme	enzyme	NN	_	9	compound
9	system	system	NN	_	2	nmod
10	,	,	,	_	2	punct
11	such	such	JJ	_	14	case
12	as	as	IN	_	11	mwe
13	antimycotic	antimycotic	JJ	_	14	amod
14	agents	agent	NNS	_	2	nmod
15	(	(	VBP	_	0	ROOT
16	e	e	LS	_	28	dep
17	.	.	.	_	16	punct
18	g	g	NN	_	27	compound
19	.	.	.	_	18	punct
20	,	,	,	_	18	punct
21	itraconazole	itraconazole	NN	_	18	conj
22	and	and	CC	_	18	cc
23	miconazole	miconazole	NN	_	18	conj
24	)	)	CD	_	23	nummod
25	or	or	CC	_	23	cc
26	macrolide	macrolide	NN	_	23	conj
27	antibiotics	antibiotic	NNS	_	28	nsubj
28	(	(	VBP	_	15	ccomp
29	e	e	LS	_	40	dep
30	.	.	.	_	29	punct
31	g	g	NN	_	37	compound
32	.	.	.	_	31	punct
33	,	,	,	_	31	punct
34	erythromycin	erythromycin	NN	_	31	conj
35	and	and	CC	_	31	cc
36	clarithromycin	clarithromycin	NN	_	31	conj
37	)	)	NN	_	40	nsubj
38	,	,	,	_	40	punct
39	may	may	MD	_	40	aux
40	alter	alter	VB	_	28	ccomp
41	oxybutynin	oxybutynin	NN	_	42	nsubj
42	mean	mean	VB	_	40	ccomp
43	pharmacokinetic	pharmacokinetic	JJ	_	44	amod
44	parameters	parameter	NNS	_	45	nsubj
45	(	(	VBP	_	42	ccomp
46	i	i	LS	_	54	dep
47	.	.	.	_	46	punct
48	e	e	LS	_	54	dep
49	.	.	.	_	48	punct
50	,	,	,	_	48	punct
51	Cmax	cmax	NN	_	54	compound
52	and	and	CC	_	51	cc
53	AUC	auc	NN	_	51	conj
54	)	)	NN	_	45	dobj
55	.	.	.	_	15	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	10	nsubjpass
4	of	of	IN	_	7	case
5	such	such	JJ	_	7	amod
6	potential	potential	JJ	_	7	amod
7	interactions	interaction	NNS	_	3	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	9	advmod
6	such	such	JJ	_	7	amod
7	drugs	drug	NNS	_	9	nsubj
8	are	be	VBP	_	9	cop
9	co	co	SYM	_	4	advcl
10	-	-	:	_	9	punct
11	administered	administer	VBN	_	9	dep
12	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	ingestion	ingestion	NN	_	23	nsubj
3	of	of	IN	_	4	case
4	antacid	antacid	NN	_	2	nmod
5	(	(	CD	_	6	compound
6	20	20	CD	_	4	nummod
7	mL	ml	NN	_	4	dep
8	of	of	IN	_	9	case
9	antacid	antacid	NN	_	4	nmod
10	containing	contain	VBG	_	9	acl
11	aluminum	aluminum	NN	_	12	compound
12	hydroxide	hydroxide	NN	_	10	dobj
13	,	,	,	_	12	punct
14	magnesium	magnesium	NN	_	15	compound
15	hydroxide	hydroxide	NN	_	12	conj
16	,	,	,	_	12	punct
17	and	and	CC	_	12	cc
18	simethicone	simethicone	NN	_	19	compound
19	)	)	NN	_	12	conj
20	did	do	VBD	_	23	aux
21	not	not	RB	_	23	neg
22	significantly	significantly	RB	_	23	advmod
23	affect	affect	VB	_	0	ROOT
24	the	the	DT	_	25	det
25	exposure	exposure	NN	_	23	dobj
26	of	of	IN	_	27	case
27	oxybutynin	oxybutynin	NN	_	25	nmod
28	or	or	CC	_	27	cc
29	desethyloxybutynin	desethyloxybutynin	NN	_	27	conj
30	.	.	.	_	23	punct

